

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057460 A2(51) International Patent Classification⁷: C12N 15/55,
9/16, 15/63, 5/10, C07K 16/40, C12P 21/00, A61K 38/46,
C12Q 1/68, 1/42, G06F 19/00, 17/50

(21) International Application Number: PCT/US01/50459

(22) International Filing Date:
20 December 2001 (20.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/256,868 20 December 2000 (20.12.2000) US
60/280,186 30 March 2001 (30.03.2001) US
60/287,735 1 May 2001 (01.05.2001) US
60/295,848 5 June 2001 (05.06.2001) US
60/300,465 25 June 2001 (25.06.2001) US(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; P.O. BOX 4000, ROUTE 206 and PROVINCE-
LINE ROAD, PRINCETON, NJ 08543-4000 (US).(72) Inventors: JACKSON, Donald, G.; 2641 Main St. Apt.
1, Lawrenceville, NJ 08648 (US). FEDER, John; 277Dutchtown Zion Road, Belle Mead, NJ 08502 (US).
NELSON, Thomas; 12 Azalea Court, Lawrenceville,
NJ 08648 (US). MINTIER, Gabe; 318 Morrison Ave.,
Hightstown, NJ 08520 (US). RAMANATHAN, Chandra;
41 Alison Avenue, Wallingford, CT 06492 (US). LEE,
Liana; 8 Petunia Drive Apt. 1J, North Brunswick, NJ
08902 (US). SIEMERS, Nathan; 171 East Delaware
Ave., Pennington, NJ 08534 (US). BOL, David; 1467
Franklin Road, Langhorne, PA 19047 (US). SCHIEVEN,
Gary; 519 Bergen Street, Lawrenceville, NJ 08648 (US).
FINGER, Joshua; 222 Woodland Parkway, Apt. 254, San
Marcos, CA 92069 (US). TODDERUD, C. Gordon.; 56
Autumn Drive, Newtown, PA 18940 (US). BASSOLINO,
Donna; 9 Hidden Hollow Dr., Hamilton, NJ 08620 (US).
KRYSTEK, Stanley; 15 Back Brook Road, Ringoes,
NJ 08551 (US). MCATEE, Patrick; 416 Hale Street,
Pennington, NH 08534 (US). SUCHARD, Susan; 621
Foulkstone Rd., Wilmington, DE 19803 (US). BANAS,
Dana; 2465 Sylvan Avenue, Hamilton, NJ 08610 (US).(74) Agents: D'AMICO, Stephen et al.; Bristol-Myers Squibb
Company, P.O. Box 4000, Route 206 and Provinceline
Road, Princeton, NJ 08543-4000 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

[Continued on next page]

(54) Title: POLYNUCLEOTIDES ENCODING NOVEL HUMAN PHOSPHATASES

1 CTAGTTTACT TCTACAATTT CGGATGGAAG GATTATGGTG TAGCGTCTCT TACTACTATC 60
1 L V Y F Y N F G W K D Y G V A S L T T I 2061 CTAGATATGG TGAAGGTGAT GACATTTGCC TTACAGGAAG GAAAAGTAGC TATCCATTGT 120
21 L D M V K V M T F A L Q E G K V A I H C 40121 CATGCAGGGC TTGGTCGAAC AGGT 144
41 H A G L G R T G 48

BMY_HPP1_B

1 GATGTCTTCT GGGCCCTCCT GTGGAACACA GTT 33
1 D V F W A L L W N T V 11

(57) Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

WO 02/057460 A2



CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

5

POLYNUCLEOTIDES ENCODING NOVEL HUMAN PHOSPHATASES

This application claims benefit to provisional application U.S. Serial No. 60/256,868, filed December 20, 2000; to provisional application U.S. Serial No. 60/280,186, filed March 30, 2001; to provisional application U.S. Serial No. 60/287,735, filed May 01, 2001, to provisional application U.S. Serial No. 60/295,848, filed June 05, 2001, and to provisional application U.S. Serial No. 60/300,465, filed June 25, 2001.

15

FIELD OF THE INVENTION

The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

25

BACKGROUND OF THE INVENTION

Phosphorylation of proteins is a fundamental mechanism for regulating diverse cellular processes. While the majority of protein phosphorylation occurs at serine and threonine residues, phosphorylation at tyrosine residues is attracting a great deal of interest since the discovery that many oncogene products and growth factor receptors possess intrinsic protein tyrosine kinase activity. The importance of protein tyrosine phosphorylation in growth factor signal transduction, cell cycle progression and neoplastic transformation is now well established (Hunter et al., Ann. Rev. Biochem. 54:987-930 (1985), Ullrich et al., Cell 61:203-212 (1990), Nurse, Nature 344:503-508 (1990), Cantley et al, Cell 64:281-302 (1991)).

Biochemical studies have shown that phosphorylation on tyrosine residues of a variety of cellular proteins is a dynamic process involving competing phosphorylation

5 and dephosphorylation reactions. The regulation of protein tyrosine phosphorylation is mediated by the reciprocal actions of protein tyrosine kinases (PTKases) and protein tyrosine phosphatases (PTPases). The tyrosine phosphorylation reactions are catalyzed by PTKases. Tyrosine phosphorylated proteins can be specifically dephosphorylated through the action of PTPases. The level of protein tyrosine phosphorylation of intracellular substances is determined by the balance of PTKase and PTPase activities. (Hunter, T., Cell 58:1013-1016 (1989)).

The protein tyrosine kinases (PTKases) are a large family of proteins that includes many growth factor receptors and potential oncogenes. (Hanks et al., Science 241:42-52 (1988)). Many PTKases have been linked to initial signals required for induction of the cell cycle (Weaver et al., Mol. Cell. Biol. 11, 9:4415-4422 (1991)). PTKases comprise a discrete family of enzymes having common ancestry with, but major differences from, serine/threonine-specific protein kinases (Hanks et al., supra). The mechanisms leading to changes in activity of PTKases are best understood in the case of receptor-type PTKases having a transmembrane topology (Ullrich et al. (1990) supra). The binding of specific ligands to the extracellular domain of members of receptor-type PTKases is thought to induce their oligomerization leading to an increase in tyrosine kinase activity and activation of the signal transduction pathways (Ullrich et al., (1990) supra). Deregulation of kinase activity through mutation or overexpression is a well established mechanism for cell transformation (Hunter et al., (1985) supra; Ullrich et al., (1990) supra).

The protein phosphatases are composed of at least two separate and distinct families (Hunter, T. (1989) supra) the protein serine/threonine phosphatases and the protein tyrosine phosphatases (PTPases).

The protein tyrosine phosphatases (PTPases) are a family of proteins that have been classified into two subgroups. The first subgroup is made up of the low molecular weight, intracellular enzymes that contain a single conserved catalytic phosphatase domain. All known intracellular type PTPases contain a single conserved catalytic phosphatase domain. Examples of the first group of PTPases include (1) placental PTPase 1B (Charbonneau et al., Proc. Natl. Acad. Sci. USA 86:5252-5256 (1989); Chernoff et al., Proc. Natl. Acad. Sci. USA 87:2735-2789 (1989)), (2) T-cell PTPase (Cool et al., Proc. Natl. Acad. Sci. USA 86:5257-5261 (1989)), (3) rat brain

5 PTPase (Guan et al., Proc. Natl. Acad. Sci. USA 87:1501-1502 (1990)), (4) neuronal phosphatase (STEP) (Lombroso et al., Proc. Natl. Acad. Sci. USA 88:7242-7246 (1991)), and (5) cytoplasmic phosphatases that contain a region of homology to cytoskeletal proteins (Gu et al., Proc. Natl. Acad. Sci. USA 88:5867-57871 (1991); Yang et al., Proc. Natl. Acad. Sci. USA 88:5949-5953 (1991)).

10 Enzymes of this class are characterized by an active site motif of CX₅R. Within this motif the Cysteine sulfur acts as a nucleophile which cleaves the P-O bond and releases the phosphate; the Arginine interacts with the phosphate and facilitates nucleophilic attack. In many cases the Cysteine is preceded by a Histidine and the Arginine is followed by a Serine or Threonine. In addition, an Aspartate residue
15 located 20 or more amino acids N terminal to the Cysteine acts as a general acid during cleavage [Fauman, 1996].

The second subgroup of protein tyrosine phosphatases is made up of the high molecular weight, receptor-linked PTPases, termed R-PTPases. R-PTPases consist of
20 a) an intracellular catalytic region, b) a single transmembrane segment, and c) a putative ligand-binding extracellular domain (Gebbink et al., supra).

The structures and sizes of the c) putative ligand-binding extracellular "receptor" domains of R-PTPases are quite divergent. In contrast, the a) intracellular catalytic regions of R-PTPases are highly homologous. All RPTPases have two tandemly duplicated catalytic phosphatase homology domains, with the prominent
25 exception of an R-PTPase termed HPTP.beta., which has "only one catalytic phosphatase domain. (Tsai et al., J. Biol. Chem... 266(16):10534-10543 (1991)).

One example of R-PTPases are the leukocyte common antigens (LCA) (Ralph, S. J., EMBO J. 6:1251-1257 (1987)). LCA is a family of high molecular weight glycoproteins expressed on the surface of all leukocytes and their hemopoietic
30 progenitors (Thomas, Ann. Rev. Immunol. 7:339-369 (1989)). A remarkable degree of similarity is detected with the sequence of LCA from several species (Charbonneau et al., Proc. Natl. Acad. Sci. USA 85:7182-7186 (1988)). LCA is referred to in the literature by different names, including T200 (Trowbridge et al., Eur. J. Immunol. 6:557-562 (1962)), B220 for the B cell form (Coffman et al., Nature 289:681-683
35 (1981)), the mouse allotypic marker Ly-5 (Komuro et al., Immunogenetics 1:452-456

- 5 (1975)), and more recently CD45 (Cobbold et al., *Leucocyte Typing III*, ed. A. J. McMichael et al., pp. 788-803 (1987)).

Several studies suggest that CD45 plays a critical role in T cell activation. These studies are reviewed in Weiss A., *Ann. Rev. Genet.* 25:487-510 (1991). In one study, T-cell clones that were mutagenized by NSG and selected for their failure to
10 express CD45 had impaired responses to T-cell receptor stimuli (Weaver et al., (1991) supra). These T-cell clones were functionally defective in their responses to signals transmitted through the T cell antigen receptor, including cytolysis of appropriate targets, proliferation, and lymphokine production (Weaver et al., (1991) supra).

Other studies indicate that the PTPase activity of CD45 plays a role in the
15 activation of pp56.sup.lck, a lymphocyte-specific PTKase (Mustelin et al., *Proc. Natl. Acad. Sci. USA* 86:6302-6306 (1989); Ostergaard et al., *Proc. Natl. Acad. Sci. USA* 86:8959-8963 (1989)). These authors hypothesized that the phosphatase activity of CD45 activates pp56.sup.lck by dephosphorylation of a C-terminal tyrosine residue, which may, in turn, be related to T-cell activation.

20 Another example of R-PTPases is the leukocyte common antigen related molecule (LAR) (Streuli et al., *J. Exp. Med.* 168:1523-1530 (1988)). LAR was initially identified as a homologue of LCA (Streuli et al., supra). Although the a) intracellular catalytic region of the LAR molecule contains two catalytic phosphatase homology domains (domain I and domain II), mutational analyses suggest that only
25 domain I has catalytic phosphatase activity, whereas domain II is enzymatically inactive (Streuli et al., *EMBO J.* 9(8):2399-2407 (1990)). Chemically induced LAR mutants having tyrosine at amino acid position 1379 changed to a phenylalanine are temperature-sensitive (Tsai et al., *J. Biol. Chem.*... 266(16):10534-10543 (1991)).

A new mouse R-PTP, designated mRPTP.mu., has been cloned which has a)
30 an extracellular domain that shares some structural motifs with LAR. (Gebblink et al., (1991) supra). In addition, these authors have cloned the human homologue of RPTP.mu. and localized the gene on human chromosome 18.

Two *Drosophila* PTPases, termed DLAR and DPTP, have been predicted based on the sequences of cDNA clones (Streuli et al., *Proc. Natl. Acad. Sci. USA*
35 86:8698-8702 (1989)). cDNAs coding for another *Drosophila* R-PTPase, termed

- 5 DPTP 99A, have been cloned and characterized (Hariharan et al., Proc. Natl. Acad. Sci. USA 88:11266-11270 (1991)).

Other examples of R-PTPases include R-PTPase-.alpha., .beta., .gamma., and .zeta. (Krueger et al., EMBO J. 9:3241-3252 (1990), Sap et al., Proc. Natl. Acad. Sci. USA 87:6112-6116 (1990), Kaplan et al., Proc. Natl. Acad. Sci. USA 87:7000-7004
10 (1990), Jirik et al., FEBS Lett. 273:239-242 (1990); Mathews et al., Proc. Natl. Acad. Sci. USA 87:4444-4448 (1990), Ohagi et al., Nucl. Acids Res. 18:7159 (1990)). Published application W092/01050 discloses human R-PTPase-.alpha., .beta. and .gamma., and reports on the nature of the structural homologies found among the conserved domains of these three R-PTPases and other members of this protein
15 family. The murine R-PTPase-.alpha. has 794 amino acids, whereas the human R-PTPase-.alpha. has 802 amino acids. R-PTPase-.alpha. has an intracellular domain homologous to the catalytic domains of other tyrosine phosphatases. The 142 amino acid extracellular domain (including signal peptide of RPTPase-.alpha.) has a high serine and threonine content (32%) and 8 potential N-glycosylation sites. cDNA
20 clones have been produced that code for the R-PTPase-.alpha., and R-PTPase-.alpha. has been expressed from eukaryotic hosts. Northern analysis has been used to identify the natural expression of R-PTPase-.alpha. in various cells and tissues. A polyclonal antibody to R-PTPase-.alpha. has been produced by immunization with a synthetic peptide of R-PTPase-.alpha., which identifies a 130 kDa protein in cells transfected
25 with a cDNA clone encoding a portion of R-PTPase-.alpha..

Another example of R-PTPases is HePTP. (Jirik et al, FASEB J. 4:82082 (1990) Abstract 2253). Jirik et al. screened a cDNA library derived from a hepatoblastoma cell line, HepG2, with a probe encoding the two PTPase domains of LCA, and discovered a cDNA clone encoding a new RPTPase, named HePTP. The
30 HePTP gene appeared to be expressed in a variety of human and murine cell lines and tissues.

Since the initial purification, sequencing, and cloning of a PTPase, additional potential PTPases have been identified at a rapid pace. The number of different PTPases that have been identified is increasing steadily, leading to speculations that
35 this family may be as large as the PTKase family (Hunter (1989) supra).

5 Conserved amino acid sequences in the catalytic domains of known PTPases have been identified and defined (Krueger et al., EMBO J. 9:3241-3252 (1990) and Yi et al., Mol. Cell. Biol. 12:836-846 (1992), which are incorporated herein by reference.) These amino acid sequences are designated "consensus sequences" herein.

Yi et al. aligned the catalytic phosphatase domain sequences of the following
10 PTPases: LCA, PTP1B, TCPTP, LAR, DLAR, and HPTP.alpha., HPTP.beta., and HPTP.gamma.. This alignment includes the following "consensus sequences" (Yi et al., supra, FIG. 2(A), lines 1 and 2): DYINAS/N (SEQ ID NO:77), CXXYWP (SEQ ID NO:78), and I/VVMXXXXXE (SEQ ID NO:79).

Krueger et al., aligned the catalytic phosphatase domain sequences of PTP1B,
15 TCPTP, LAR, LCA, HPTP.alpha., .beta., .gamma., .GAMMA., .delta., .epsilon. and .zeta. and DLAR and DPTP. This alignment includes the following "consensus sequences: (Krueger et al., supra, FIG. 7, lines 1 and 2): D/NYINAS/N (SEQ ID NO:80), CXXYWP (SEQ ID NO:81), and I/VVMXXXXXE (SEQ ID NO:82).

It is becoming clear that dephosphorylation of tyrosine residues can by itself
20 function as an important regulatory mechanism. Dephosphorylation of a C-terminal tyrosine residue has been shown to activate tyrosine kinase activity in the case of the src family of tyrosine kinases (Hunter, T. Cell 49:1-4 (1987)). Tyrosine dephosphorylation has been suggested to be an obligatory step in the mitotic activation of the maturation-promoting factor (MPF) kinase (Morla et al., Cell
25 58:193-203 (1989)). These observations point out the need in the art for understanding the mechanisms that regulate tyrosine phosphatase activity.

Modulators (inhibitors or activators) of human phosphatase expression or activity could be used to treat a subject with a disorder characterized by aberrant phosphatase expression or activity or by decreased phosphorylation of a phosphatase
30 substrate protein. Examples of such disorders include but are not limited to: an immune, anti-proliferative, proliferative (e.g. cancer), metabolic (e.g. diabetes or obesity), bone (e.g., osteoporosis), neural, and/or cardiovascular diseases and/or disorders, in addition to, viral pathogenesis.

It is clear that further analysis of structure-function relationships among
35 PTPases are needed to gain important understanding of the mechanisms of signal transduction, cell cycle progression and cell growth, and neoplastic transformation.

5 The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant vectors, as well as to methods of making such vectors and host cells, in addition to their use in the production of human phosphatase polypeptides or peptides using recombinant techniques. Synthetic methods for producing the polypeptides and polynucleotides of the present invention are provided. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the human phosphatase polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

15

BRIEF SUMMARY OF THE INVENTION

 The present invention provides isolated nucleic acid molecules, that comprise, or alternatively consist of, a polynucleotide encoding the human BMY_HPP1 phosphatase protein having the amino acid sequence shown as SEQ ID NO:150, or the amino acid sequence encoded by the cDNA clone, BMY_HPP1, deposited as ATCC Deposit Number XXXXXXXX on XXXXXXXX.

 The present invention provides isolated nucleic acid molecules, that comprise, or alternatively consist of, a polynucleotide encoding the human BMY_HPP2 phosphatase protein having the amino acid sequence shown as SEQ ID NO:152, or the amino acid sequence encoded by the cDNA clone, BMY_HPP2, deposited as ATCC Deposit Number XXXXXXXX on XXXXXXXX.

 The present invention provides isolated nucleic acid molecules, that comprise, or alternatively consist of, a polynucleotide encoding the human BMY_HPP5 phosphatase protein having the amino acid sequence shown as SEQ ID NO:42, or the amino acid sequence encoded by the cDNA clone, BMY_HPP5 (also referred to as 7IC-5-E2), deposited as ATCC Deposit Number PTA-2966 on January 24th, 2001.

 The present invention provides isolated nucleic acid molecules, that comprise, or alternatively consist of, a polynucleotide encoding the human RET31 phosphatase protein having the amino acid sequence shown as SEQ ID NO:109, or the amino acid sequence encoded by the cDNA clone, RET31 (also referred to as 1hrTNF031, and/or Clone 31), deposited as ATCC Deposit Number PTA-3434 on June 7, 2001.

5 The present invention provides isolated nucleic acid molecules, that comprise, or alternatively consist of, a polynucleotide encoding the mouse RET31 phosphatase protein having the amino acid sequence shown as SEQ ID NO:114, or the amino acid sequence encoded by the cDNA clone, mRET31, deposited as ATCC Deposit Number XXXXXX on XXXXXX.

10 The present invention provides isolated nucleic acid molecules, that comprise, or alternatively consist of, a polynucleotide encoding the human BMY_HPP1 phosphatase protein having the amino acid sequence shown as SEQ ID NO:150, or the amino acid sequence encoded by the cDNA clone, BMY_HPP1, deposited as ATCC Deposit Number XXXXXX on XXXXX.

15 The present invention provides isolated nucleic acid molecules, that comprise, or alternatively consist of, a polynucleotide encoding the BMY_HPP2 phosphatase protein having the amino acid sequence shown as SEQ ID NO:152, or the amino acid sequence encoded by the cDNA clone, BMY_HPP2, deposited as ATCC Deposit Number XXXXXX on XXXXXX.

20 The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant vectors, as well as to methods of making such vectors and host cells, in addition to their use in the production of human phosphatase polypeptides or peptides using recombinant techniques. Synthetic methods for producing the polypeptides and polynucleotides of the present invention are provided. Also provided
25 are diagnostic methods for detecting diseases, disorders, and/or conditions related to the human phosphatase polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

30 The invention further provides an isolated BMY_HPP1 human phosphatase polypeptide having an amino acid sequence encoded by a polynucleotide described herein.

 The invention further provides an isolated BMY_HPP2 human phosphatase polypeptide having an amino acid sequence encoded by a polynucleotide described
35 herein.

5 The invention further provides an isolated BMY_HPP5 human phosphatase polypeptide having an amino acid sequence encoded by a polynucleotide described herein.

 The invention further provides an isolated RET31 human phosphatase polypeptide having an amino acid sequence encoded by a polynucleotide described
10 herein.

 The invention further provides an isolated RET31 mouse phosphatase polypeptide having an amino acid sequence encoded by a polynucleotide described herein.

 The invention further relates to a polynucleotide encoding a polypeptide
15 fragment of SEQ ID NO:150, 152, 8, 10, 42, or 109, or a polypeptide fragment encoded by the cDNA sequence included in the deposited clone, which is hybridizable to SEQ ID NO:149, 151, 7, 9, 41, or 108.

 The invention further relates to a polynucleotide encoding a polypeptide domain of SEQ ID NO:150, 152, 8, 10, 42, or 109 or a polypeptide domain encoded
20 by the cDNA sequence included in the deposited clone, which is hybridizable to SEQ ID NO:149, 151, 7, 9, 41, or 108.

 The invention further relates to a polynucleotide encoding a polypeptide epitope of SEQ ID NO:150, 152, 8, 10, 42, or 109 or a polypeptide epitope encoded
25 by the cDNA sequence included in the deposited clone, which is hybridizable to SEQ ID NO:149, 151, 7, 9, 41, or 108.

 The invention further relates to a polynucleotide encoding a polypeptide of SEQ ID NO:150, 152, 8, 10, 42, or 109 or the cDNA sequence included in the deposited clone, which is hybridizable to SEQ ID NO:149, 151, 7, 9, 41, or 108, having biological activity.

30 The invention further relates to a polynucleotide which is a variant of SEQ ID NO:149, 151, 7, 9, 41, or 108.

 The invention further relates to a polynucleotide which is an allelic variant of SEQ ID NO:149, 151, 7, 9, 41, or 108.

 The invention further relates to a polynucleotide which encodes a species
35 homologue of the SEQ ID NO:150, 152, 8, 10, 42, or 109.

5 The invention further relates to a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:149, 151, 7, 9, 41, or 108.

 The invention further relates to a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified herein, wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid
10 molecule having a nucleotide sequence of only A residues or of only T residues.

 The invention further relates to an isolated nucleic acid molecule of SEQ ID NO:150, 152, 8, 10, 42, or 109, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a human phosphatase protein.

 The invention further relates to an isolated nucleic acid molecule of SEQ ID
15 NO: 149, 151, 7, 9, 41, or 108 wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:150, 152, 8, 10, 42, or 109 or the polypeptide encoded by the cDNA sequence included in the deposited clone, which is hybridizable to SEQ ID NO:149, 151, 7, 9, 41, or 108.

 The invention further relates to an isolated nucleic acid molecule of of SEQ ID
20 NO: 149, 151, 7, 9, 41, or 108; wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:149, 151, 7, 9, 41, or 108 or the cDNA sequence included in the deposited clone, which is hybridizable to SEQ ID NO:149, 151, 7, 9, 41, or 108.

 The invention further relates to an isolated nucleic acid molecule of SEQ ID
25 NO:1, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

 The invention further relates to an isolated polypeptide comprising an amino acid sequence that comprises a polypeptide fragment of SEQ ID NO:150, 152, 8, 10, 42, or 109 or the encoded sequence included in the deposited clone.

30 The invention further relates to a polypeptide fragment of SEQ ID NO:150, 152, 8, 10, 42, or 109 or the encoded sequence included in the deposited clone, having biological activity.

 The invention further relates to a polypeptide domain of SEQ ID NO:150, 152, 8, 10, 42, or 109 or the encoded sequence included in the deposited clone.

35 The invention further relates to a polypeptide epitope of SEQ ID NO:150, 152, 8, 10, 42, or 109 or the encoded sequence included in the deposited clone.

5 The invention further relates to a full length protein of SEQ ID NO:150, 152, 8, 10, 42, or 109 or the encoded sequence included in the deposited clone.

 The invention further relates to a variant of SEQ ID NO:150, 152, 8, 10, 42, or 109.

 The invention further relates to an allelic variant of SEQ ID NO:150, 152, 8,
10 10, 42, or 109. The invention further relates to a species homologue of SEQ ID NO:150, 152, 8, 10, 42, or 109.

 The invention further relates to the isolated polypeptide of of SEQ ID NO:150, 152, 8, 10, 42, or 109, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

15 The invention further relates to an isolated antibody that binds specifically to the isolated polypeptide of SEQ ID NO:150, 152, 8, 10, 42, or 109.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of SEQ ID NO:150, 152, 8, 10,
20 42, or 109 or the polynucleotide of SEQ ID NO:149, 151, 7, 9, 41, or 108.

 The invention further relates to a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising the steps of (a) determining the presence or absence of a mutation in the polynucleotide of SEQ ID NO:149, 151, 7, 9, 41, or 108; and (b) diagnosing a pathological condition or
25 a susceptibility to a pathological condition based on the presence or absence of said mutation.

 The invention further relates to a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising the steps of (a) determining the presence or amount of expression of the polypeptide of of
30 SEQ ID NO:150, 152, 8, 10, 42, or 109 in a biological sample; and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

 The invention further relates to a method for identifying a binding partner to the polypeptide of SEQ ID NO:150, 152, 8, 10, 42, or 109 comprising the steps of (a)
35 contacting the polypeptide of SEQ ID NO:150, 152, 8, 10, 42, or 109 with a binding

- 5 partner; and (b) determining whether the binding partner effects an activity of the polypeptide.

The invention further relates to a gene corresponding to the cDNA sequence of SEQ ID NO:149, 151, 7, 9, 41, or 108.

- 10 The invention further relates to a method of identifying an activity in a biological assay, wherein the method comprises the steps of expressing SEQ ID NO:149, 151, 7, 9, 41, or 108 in a cell, (b) isolating the supernatant; (c) detecting an activity in a biological assay; and (d) identifying the protein in the supernatant having the activity.

- The invention further relates to a process for making polynucleotide sequences encoding gene products having altered activity selected from the group consisting of
15 SEQ ID NO:150, 152, 8, 10, 42, or 109 activity comprising the steps of (a) shuffling a nucleotide sequence of SEQ ID NO:149, 151, 7, 9, 41, or 108, (b) expressing the resulting shuffled nucleotide sequences and, (c) selecting for altered activity selected from the group consisting of SEQ ID NO:150, 152, 8, 10, 42, or 109 activity as
20 compared to the activity selected from the group consisting of SEQ ID NO:150, 152, 8, 10, 42, or 109 activity of the gene product of said unmodified nucleotide sequence.

- The invention further relates to a shuffled polynucleotide sequence produced by a shuffling process, wherein said shuffled DNA molecule encodes a gene product having enhanced tolerance to an inhibitor of any one of the activities selected from the
25 group consisting of SEQ ID NO:150, 152, 8, 10, 42, or 109 activity.

The invention further relates to a method for preventing, treating, or ameliorating a medical condition with the polypeptide provided as SEQ ID NO:150, 152, 8, 10, 42, or 109, in addition to, its encoding nucleic acid, wherein the medical condition is a condition related to aberrant phosphatase activity.

- 30 The invention further relates to a method of identifying a compound that modulates the biological activity of a phosphatase, comprising the steps of, (a) combining a candidate modulator compound with a phosphatase having the sequence set forth in one or more of SEQ ID NO:150, 152, 8, 10, 42, or 109; and measuring an effect of the candidate modulator compound on the activity of a phosphatase.

- 35 The invention further relates to a method of identifying a compound that modulates the biological activity of a phosphatase, comprising the steps of, (a)

- 5 combining a candidate modulator compound with a host cell expressing a phosphatase having the sequence as set forth in SEQ ID NO:150, 152, 8, 10, 42, or 109; and , (b) measuring an effect of the candidate modulator compound on the activity of the expressed a phosphatase.

The invention further relates to a method of identifying a compound that
10 modulates the biological activity of a phosphatase, comprising the steps of, (a) combining a candidate modulator compound with a host cell containing a vector described herein, wherein a phosphatase is expressed by the cell; and, (b) measuring an effect of the candidate modulator compound on the activity of the expressed a phosphatase.

- 15 The invention further relates to a method of screening for a compound that is capable of modulating the biological activity of a phosphatase, comprising the steps of: (a) providing a host cell described herein; (b) determining the biological activity of a phosphatase in the absence of a modulator compound; (c) contacting the cell with the modulator compound; and (d) determining the biological activity of a
20 phosphatase in the presence of the modulator compound; wherein a difference between the activity of a phosphatase in the presence of the modulator compound and in the absence of the modulator compound indicates a modulating effect of the compound.

The invention further relates to a compound that modulates the biological
25 activity of human a phosphatase as identified by the methods described herein.

The invention also relates to *in silico* screening methods including *in silico* docking and methods of structure based drug design which utilize the three dimensional coordinates of BMY_HPP1 (Figure 28, Table VIII). Also provided are methods of identifying modulators of BMY_HPP1 that include modulator building or
30 searching utilizing computer programs and algorithms. In an embodiment of the invention a method is provided for designing potential modulators of BMY_HPP1 comprising any combination of steps which utilize said three dimensional structure to design or select potential modulators.

The present invention also provides structure coordinates of the homology
35 model of BMY_HPP1. The complete coordinates are listed in Table VIII and visualized in Figure 28.. The model present in this invention further provides a basis

- 5 for designing stimulators and inhibitors or antagonists of one or more of the biological functions of BMY_HPP1, or of mutants with altered specificity.

The invention also relates to *in silico* screening methods including *in silico* docking and methods of structure based drug design which utilize the three dimensional coordinates of BMY_HPP2 (Figure 32, Table IX). Also provided are
10 methods of identifying modulators of BMY_HPP2 that include modulator building or searching utilizing computer programs and algorithms. In an embodiment of the invention a method is provided for designing potential modulators of BMY_HPP2 comprising any combination of steps which utilize said three dimensional structure to design or select potential modulators.

- 15 The present invention also provides structure coordinates of the homology model of BMY_HPP2. The complete coordinates are listed in Table IX and visualized in Figure 32. The model present in this invention further provides a basis for designing stimulators and inhibitors or antagonists of one or more of the biological functions of BMY_HPP2, or of mutants with altered specificity.

20 The invention also relates to *in silico* screening methods including *in silico* docking and methods of structure based drug design which utilize the three dimensional coordinates of BMY_HPP5 (Figure 38, Table X). Also provided are methods of identifying modulators of BMY_HPP5 that include modulator building or searching utilizing computer programs and algorithms. In an embodiment of the
25 invention a method is provided for designing potential modulators of BMY_HPP5 comprising any combination of steps which utilize said three dimensional structure to design or select potential modulators.

The present invention also provides structure coordinates of the homology model of BMY_HPP5. The complete coordinates are listed in Table X and visualized
30 in Figure 38. The model present in this invention further provides a basis for designing stimulators and inhibitors or antagonists of one or more of the biological functions of BMY_HPP5, or of mutants with altered specificity.

The invention also provides a machine readable storage medium which comprises the structure coordinates of BMY_HPP1, including all or any parts
35 conserved active site regions. Such storage medium encoded with these data are capable of displaying on a computer screen or similar viewing device, a three-

5 dimensional graphical representation of a molecule or molecular complex which comprises said regions or similarly shaped homologous regions.

The invention also provides methods for designing, evaluating and identifying compounds which bind to all or parts of the aforementioned regions. The methods include three dimensional model building (homology modeling) and methods of
10 computer assisted-drug design which can be used to identify compounds which bind or modulate the forementioned regions of the BMY_HPP1 polypeptide. Such compounds are potential inhibitors of BMY_HPP1 or its homologues.

The invention also provides a machine readable storage medium which comprises the structure coordinates of BMY_HPP2, including all or any parts
15 conserved active site regions. Such storage medium encoded with these data are capable of displaying on a computer screen or similar viewing device, a three-dimensional graphical representation of a molecule or molecular complex which comprises said regions or similarly shaped homologous regions.

The invention also provides methods for designing, evaluating and identifying
20 compounds which bind to all or parts of the aforementioned regions. The methods include three dimensional model building (homology modeling) and methods of computer assisted-drug design which can be used to identify compounds which bind or modulate the forementioned regions of the BMY_HPP2 polypeptide. Such compounds are potential inhibitors of BMY_HPP2 or its homologues.

25 The invention also provides a machine readable storage medium which comprises the structure coordinates of BMY_HPP5, including all or any parts conserved active site regions. Such storage medium encoded with these data are capable of displaying on a computer screen or similar viewing device, a three-dimensional graphical representation of a molecule or molecular complex which
30 comprises said regions or similarly shaped homologous regions.

The invention also provides methods for designing, evaluating and identifying compounds which bind to all or parts of the aforementioned regions. The methods include three dimensional model building (homology modeling) and methods of
35 computer assisted-drug design which can be used to identify compounds which bind or modulate the forementioned regions of the BMY_HPP5 polypeptide. Such compounds are potential inhibitors of BMY_HPP5 or its homologues.

5 The invention also provides a computer for producing a three-dimensional representation of a molecule or molecular complex, wherein said molecule or molecular complex comprises the structural coordinates of the model BMY_HPP1 in accordance with Table VIII, or a three-dimensional representation of a homologue of said molecule or molecular complex, wherein said homologue comprises backbone
10 atoms that have a root mean square deviation from the backbone atoms of not more than 3.5 angstroms. wherein said computer comprises:

 The invention also provides a machine-readable data storage medium, comprising a data storage material encoded with machine readable data, wherein the data is defined by the set of structure coordinates of the model BMY_HPP1 according
15 to Table VIII, or a homologue of said model, wherein said homologue comprises backbone atoms that have a root mean square deviation from the backbone atoms of not more than 3.5 Å; a working memory for storing instructions for processing said machine-readable data; a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine readable
20 data into said three-dimensional representation; and a display coupled to said central-processing unit for displaying said three-dimensional representation. The invention also provides said computer wherein the machine-readable data storage medium is defined by the set of structure coordinates of the model for BMY_HPP1 according to Table VIII, or a homologue of said molecule, said homologue having a root mean
25 square deviation from the backbone atoms of not more than 3.0 Å.

 The invention also provides a model comprising all or any part of the model defined by structure coordinates of BMY_HPP1 according to Table VIII, or a mutant or homologue of said molecule or molecular complex.

 The invention also provides a method for identifying a mutant of BMY_HPP1
30 with altered biological properties, function, or reactivity, the method comprising the step selected from the group consisting of: Using the BMY_HPP1 model or a homologue of said model according to Table VIII, for the design of protein mutants with altered biological function or properties.

 The invention also provides a method for identifying structural and chemical
35 features of BMY_HPP1 using the structural coordinates set forth in Table VIII, comprising any steps or combination of steps consisting of: employing identified

5 structural or chemical features to design or select compounds as potential
BMY_HPP1 modulators; employing the three-dimensional structural model to design
or select compounds as potential BMY_HPP1 modulators; synthesizing the potential
BMY_HPP1 modulators; and screening the potential BMY_HPP1 modulators in an
assay characterized by binding of a protein to the BMY_HPP1. The invention further
10 provides said method wherein the potential BMY_HPP1 modulator is selected from a
database. The invention further provides said method wherein the potential
BMY_HPP1 modulator is designed de novo. The invention further provides said
method wherein the potential BMY_HPP1 modulator is designed from a known
modulator of activity.

15 The invention also provides a method for identifying a compound that
modulates BMY_HPP1 activity, the method comprising any combination of steps of:
Modeling test compounds that fit spatially into or near the active site region defined
by residues D161-Y162 and H189-C190-G193-R196 of BMY_HPP1 as defined by
structure coordinates according to Table VIII, or modeling test compounds that fit
20 spatially into a three-dimensional structural model of the catalytic domain of
BMY_HPP1, mutant homologue or portion thereof; using said structure coordinates
or said active site region as set forth in prior claims to identify structural and chemical
features; employing identified structural or chemical features to design or select
compounds as potential BMY_HPP1 modulators including substrates, antagonists and
25 agonists; employing the three-dimensional structural model or the catalytic domain of
BMY_HPP1 to design or select compounds as potential BMY_HPP1 inhibitors;
screening the potential BMY_HPP1 inhibitors in an assay characterized by binding of
a test compound to BMY_HPP1; and/or modifying or replacing one or more amino
acids from BMY_HPP1 including but not limited to the residues corresponding to the
30 active site region as set forth in prior claims of BMY_HPP1 according to Table VIII.

The invention also provides a computer for producing a three-dimensional
representation of a molecule or molecular complex, wherein said molecule or
molecular complex comprises the structural coordinates of the model BMY_HPP2 in
accordance with Table IX, or a three-dimensional representation of a homologue of
35 said molecule or molecular complex, wherein said homologue comprises backbone

5 atoms that have a root mean square deviation from the backbone atoms of not more than 3.5 angstroms. wherein said computer comprises:

The invention also provides a machine-readable data storage medium, comprising a data storage material encoded with machine readable data, wherein the data is defined by the set of structure coordinates of the model BMY_HPP2 according to Table IX, or a homologue of said model, wherein said homologue comprises backbone atoms that have a root mean square deviation from the backbone atoms of not more than 3.5Å; a working memory for storing instructions for processing said machine-readable data; a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine readable data into said three-dimensional representation; and a display coupled to said central-processing unit for displaying said three-dimensional representation. The invention also provides said computer wherein the machine-readable data storage medium is defined by the set of structure coordinates of the model for BMY_HPP2 according to Table IX, or a homologue of said molecule, said homologue having a root mean square deviation from the backbone atoms of not more than 3.0 Å.

The invention also provides a model comprising all or any part of the model defined by structure coordinates of BMY_HPP2 according to Table IX, or a mutant or homologue of said molecule or molecular complex.

The invention also provides a method for identifying a mutant of BMY_HPP2 with altered biological properties, function, or reactivity, the method comprising the step selected from the group consisting of: Using the BMY_HPP2 model or a homologue of said model according to Table IX, for the design of protein mutants with altered biological function or properties.

The invention also provides a method for identifying structural and chemical features of BMY_HPP2 using the structural coordinates set forth in Table IX, comprising any steps or combination of steps consisting of: employing identified structural or chemical features to design or select compounds as potential BMY_HPP2 modulators; employing the three-dimensional structural model to design or select compounds as potential BMY_HPP2 modulators; synthesizing the potential BMY_HPP2 modulators; and screening the potential BMY_HPP2 modulators in an assay characterized by binding of a protein to the BMY_HPP2. The invention further

5 provides said method wherein the potential BMY_HPP2 modulator is selected from a database. The invention further provides said method wherein the potential BMY_HPP2 modulator is designed de novo. The invention further provides said method wherein the potential BMY_HPP2 modulator is designed from a known modulator of activity.

10 The invention also provides a method for identifying a compound that modulates BMY_HPP2 activity, the method comprising any combination of steps of: Modeling test compounds that fit spatially into or near the active site region defined by residues residues D65, H94-C95, G98, and R101 of BMY_HPP2 as defined by structure coordinates according to Table IX, or modeling test compounds that fit
15 spatially into a three-dimensional structural model of the catalytic domain of BMY_HPP2, mutant homologue or portion thereof; using said structure coordinates or said active site region as set forth in prior claims to identify structural and chemical features; employing identified structural or chemical features to design or select compounds as potential BMY_HPP2 modulators including substrates, antagonists and
20 agonists; employing the three-dimensional structural model or the catalytic domain of BMY_HPP2 to design or select compounds as potential BMY_HPP2 inhibitors; screening the potential BMY_HPP2 inhibitors in an assay characterized by binding of a test compound to BMY_HPP2; and/or modifying or replacing one or more amino acids from BMY_HPP2 including but not limited to the residues corresponding to the
25 active site region as set forth in prior claims of BMY_HPP2 according to Table IX.

The invention also provides a computer for producing a three-dimensional representation of a molecule or molecular complex, wherein said molecule or molecular complex comprises the structural coordinates of the model BMY_HPP5 in accordance with Table X, or a three-dimensional representation of a homologue of
30 said molecule or molecular complex, wherein said homologue comprises backbone atoms that have a root mean square deviation from the backbone atoms of not more than 3.5 angstroms. wherein said computer comprises:

The invention also provides a machine-readable data storage medium, comprising a data storage material encoded with machine readable data, wherein the
35 data is defined by the set of structure coordinates of the model BMY_HPP5 according to Table X, or a homologue of said model, wherein said homologue comprises

5 backbone atoms that have a root mean square deviation from the backbone atoms of not more than 3.5 Å; a working memory for storing instructions for processing said machine-readable data; a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine readable data into said three-dimensional representation; and a display coupled to said central-
10 processing unit for displaying said three-dimensional representation. The invention also provides said computer wherein the machine-readable data storage medium is defined by the set of structure coordinates of the model for BMY_HPP5 according to Table X, or a homologue of said molecule, said homologue having a root mean square deviation from the backbone atoms of not more than 3.0 Å.

15 The invention also provides a model comprising all or any part of the model defined by structure coordinates of BMY_HPP5 according to Table X, or a mutant or homologue of said molecule or molecular complex.

The invention also provides a method for identifying a mutant of BMY_HPP5 with altered biological properties, function, or reactivity, the method comprising the
20 step selected from the group consisting of: Using the BMY_HPP5 model or a homologue of said model according to Table X, for the design of protein mutants with altered biological function or properties.

The invention also provides a method for identifying structural and chemical features of BMY_HPP5 using the structural coordinates set forth in Table X,
25 comprising any steps or combination of steps consisting of: employing identified structural or chemical features to design or select compounds as potential BMY_HPP5 modulators; employing the three-dimensional structural model to design or select compounds as potential BMY_HPP5 modulators; synthesizing the potential BMY_HPP5 modulators; and screening the potential BMY_HPP5 modulators in an
30 assay characterized by binding of a protein to the BMY_HPP5. The invention further provides said method wherein the potential BMY_HPP5 modulator is selected from a database. The invention further provides said method wherein the potential BMY_HPP5 modulator is designed de novo. The invention further provides said method wherein the potential BMY_HPP5 modulator is designed from a known
35 modulator of activity.

5 The invention also provides a method for identifying a compound that modulates BMY_HPP5 activity, the method comprising any combination of steps of: Modeling test compounds that fit spatially into or near the active site region defined by residues D213, H243, C244, and R250 of BMY_HPP5 as defined by structure coordinates according to Table X, or modeling test compounds that fit
10 spatially into a three-dimensional structural model of the catalytic domain of BMY_HPP5, mutant homologue or portion thereof; using said structure coordinates or said active site region as set forth in prior claims to identify structural and chemical features; employing identified structural or chemical features to design or select compounds as potential BMY_HPP5 modulators including substrates, antagonists and
15 agonists; employing the three-dimensional structural model or the catalytic domain of BMY_HPP5 to design or select compounds as potential BMY_HPP5 inhibitors; screening the potential BMY_HPP5 inhibitors in an assay characterized by binding of a test compound to BMY_HPP5; and/or modifying or replacing one or more amino acids from BMY_HPP5 including but not limited to the residues corresponding to the
20 active site region as set forth in prior claims of BMY_HPP5 according to Table X.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is a renal condition.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is an inflammatory
25 disease.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is an inflammatory disease where dual-specificity phosphatases, either directly or indirectly, are involved in disease progression.

30 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is a cancer.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is a neural disorder.

 The invention further relates to a method for preventing, treating, or
35 ameliorating a medical condition, wherein the medical condition is a reproductive disorder.

5 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is an immunological disorder.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is a musculo-
10 degenerative disorder.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is a muscle disorder.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is a hepatic disorder.

15 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is an endocrine disorder.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is a pulmonary
20 disorder.

 The invention further relates to a method for preventing, treating, or ameliorating a medical condition, wherein the medical condition is a disorder associated, either directly or indirectly, with TNF-alpha.

 The invention further relates to a method for preventing, treating, or
25 ameliorating a medical condition, wherein the medical condition is a disorder associated, either directly or indirectly, with IL-1.

5

BRIEF DESCRIPTION OF THE FIGURES/DRAWINGS

Figure 1 shows the polynucleotide sequences (SEQ ID NO: 1 and 3) and deduced amino acid sequence (SEQ ID NO:2 and 4) of gene fragments A and B, respectfully,
10 of the novel human phosphatase, **BMY_HPP1**, of the present invention. The standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of fragment A contains a sequence of 144 nucleotides (SEQ ID NO:1), encoding a polypeptide of 48 amino acids (SEQ ID NO:2), while the polynucleotide sequence of fragment B contains a sequence of 33
15 nucleotides (SEQ ID NO:3), encoding a polypeptide of 11 amino acids (SEQ ID NO:4).

Figure 2 shows the polynucleotide sequence (SEQ ID NO: 5) and deduced amino acid sequence (SEQ ID NO:6) of a gene fragment of the novel human phosphatase,
20 **BMY_HPP2**, of the present invention. The standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of this fragment contains a sequence of 746 nucleotides (SEQ ID NO:5), encoding 248 amino acids (SEQ ID NO:6) of the full-length **BMY_HPP2** polypeptide, and/or translated portions of the 5' and/or 3' UTR of clone **BMY_HPP2**.
25 The asterisks ("*") may represent any amino acid.

Figure 3 shows the polynucleotide sequence (SEQ ID NO: 7) and deduced amino acid sequence (SEQ ID NO:8) of a gene fragment of the novel human phosphatase,
BMY_HPP3, of the present invention. The standard one-letter abbreviation for amino
30 acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of this fragment contains a sequence of 511 nucleotides (SEQ ID NO:5), encoding 170 amino acids (SEQ ID NO:8) of the full-length **BMY_HPP3** polypeptide, and/or translated portions of the 5' and/or 3' UTR of clone **BMY_HPP3**. The asterisks ("*") may represent any amino acid.

35

5 **Figures 4A-B** show the polynucleotide sequence (SEQ ID NO: 9) and deduced amino acid sequence (SEQ ID NO:10) of a gene fragment of the novel human phosphatase, BMY_HPP4, of the present invention. The standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of this fragment contains a sequence of 1710 nucleotides (SEQ ID NO:9), encoding 570
 10 amino acids (SEQ ID NO:10) of the full-length BMY_HPP3 polypeptide, and/or translated portions of the 5' and/or 3' UTR of clone BMY_HPP4. The asterisks ("*") may represent any amino acid.

Figures 5A-E show the polynucleotide sequence (SEQ ID NO: 41) and deduced
 15 amino acid sequence (SEQ ID NO:42) of the novel full-length human phosphatase, BMY_HPP5, of the present invention. The standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of this protein contains a sequence of 5111 nucleotides (SEQ ID NO:41), encoding 665 amino acids (SEQ ID NO:42) of the full-length BMY_HPP5
 20 polypeptide.

Figures 6A-D show the regions of identity between the encoded full-length human phosphatase protein BMY_HPP1 (BMY_HPP1_FL; SEQ ID NO:150), and fragments A and B of BMY_HPP1 (BMY_HPP1_A and BMY_HPP1_B; SEQ ID NO:2 and 4, respectively), to other phosphatase proteins, specifically, the Schizosacchomyces
 25 Pombe protein tyrosine phosphatase PYP3 protein (PYP3_SP; Genbank Accession No:gi| P32587; SEQ ID NO:Y7); the mouse protein tyrosine phosphatase, receptor type, O, protein (MM_RPTPO; Genbank Accession No:gi| NP_035346; SEQ ID NO:Y8); and the human protein tyrosine phosphatase, receptor type, O, protein
 30 (HS_RPTPO; Genbank Accession No:gi| NP_002839; SEQ ID NO:Y9). The alignment was performed using the CLUSTALW algorithm. The darkly shaded amino acids represent regions of matching identity. The lightly shaded amino acids represent regions of matching similarity. Dots ("•") between residues indicate gapped regions of non-identity for the aligned polypeptides. Catalytic residues are indicated in bold.

35

5 **Figures 7A-B** show the regions of identity between the encoded full-length human phosphatase protein BMY_HPP2 (BMY_HPP2.FL; SEQ ID NO:152), and the fragment of BMY_HPP2 (BMY_HPP2.partial; SEQ ID NO:6) to other phosphatase proteins, specifically, the human CDC14 (also known as the cell division cycle 14, *S. cerevisiae* Gene A protein) homologue A (HS_CDC14A; Genbank Accession No:gi|

10 NP_003663; SEQ ID NO:30); the human *S. cerevisiae* CDC14 homolog, gene B (HS_CDC14B; Genbank Accession No:gi| NP_003662; SEQ ID NO:31); and the yeast soluble tyrosine-specific protein phosphatase Cdc14p protein (SC_CDC14; Genbank Accession No:gi| NP_002839; SEQ ID NO:32). The alignment was performed using the CLUSTALW algorithm. The darkly shaded amino acids

15 represent regions of matching identity. The lightly shaded amino acids represent regions of matching similarity. Dots ("•") between residues indicate gapped regions of non-identity for the aligned polypeptides. Catalytic residues are indicated in bold.

Figure 8 shows the regions of identity between the encoded human phosphatase protein fragment of BMY_HPP3 (SEQ ID NO:8) to other phosphatase proteins, specifically, the human protein tyrosine phosphatase PTPCAAX1 PROTEIN (HS_PTPCAAX1; Genbank Accession No:gi| AAB40597; SEQ ID NO:33); the human protein tyrosine phosphatase PTPCAAX2 (HS_PTPCAAX2; Genbank Accession No:gi| AAB40598; SEQ ID NO:34); the mouse prenylated protein tyrosine

25 phosphatase (MM_PTPCAAX; Genbank Accession No:gi| JC5981; SEQ ID NO:35); and the *Drosophila* PRL-1 protein (DM_PRL1; Genbank Accession No:gi| AAF53506; SEQ ID NO:36). The alignment was performed using the CLUSTALW algorithm. The darkly shaded amino acids represent regions of matching identity. The lightly shaded amino acids represent regions of matching similarity. Dots ("•")

30 between residues indicate gapped regions of non-identity for the aligned polypeptides. Catalytic residues are indicated in bold.

Figures 9A-B show the regions of identity between the encoded human phosphatase protein fragment of BMY_HPP4 (SEQ ID NO:10) to other phosphatase proteins, specifically, the mouse osteotesticular protein tyrosine phosphatase (MM_OST-PTP; Genbank Accession No:gi| AAG28768; SEQ ID NO:37); and the rat protein-tyrosine-

35

5 phosphatase (RN_PTP-OST; Genbank Accession No:gi| A55148; SEQ ID NO:38). The alignment was performed using the CLUSTALW algorithm. The darkly shaded amino acids represent regions of matching identity. The lightly shaded amino acids represent regions of matching similarity. Dots ("•") between residues indicate gapped regions of non-identity for the aligned polypeptides. Catalytic residues are indicated
10 in bold.

Figures 10A-B shows the regions of identity between the encoded human phosphatase protein fragment of BMY_HPP5 (SEQ ID NO:42) to other phosphatase proteins, specifically, the human dual specificity phosphatase 8 (hs_dspp8; Genbank
15 Accession No:gi| NP_004411; SEQ ID NO:39); and the mouse neuronal tyrosine/threonine phosphatase 1 (r mm_npp1; Genbank Accession No:gi| NP_032774; SEQ ID NO:40). The alignment was performed using the CLUSTALW algorithm. The darkly shaded amino acids represent regions of matching identity. The lightly shaded amino acids represent regions of matching similarity. Dots ("•")
20 between residues indicate gapped regions of non-identity for the aligned polypeptides. Catalytic residues are indicated in bold.

Figure 11 shows an expression profile of the novel human phosphatase protein BMY_HPP5. The figure illustrates the relative expression level of BMY_HPP5
25 amongst various mRNA tissue sources. As shown, the BMY_HPP5 polypeptide was expressed to a significant extent, in the testis and spinal cord, and to a lesser extent, in bone marrow, brain, liver, and thymus. Expression data was obtained by measuring the steady state BMY_HPP5 mRNA levels by quantitative PCR using the PCR primer pair provided as SEQ ID NO:67 and 68 as described herein.

30
Figure 12 shows a table illustrating the percent identity and percent similarity between the BMY_HPP5 (SEQ ID NO:42), the human RET31 (SEQ ID NO:109), and the mouse RET31 (SEQ ID NO:114) polypeptides of the present invention with other phosphatase proteins. The percent identity and percent similarity values were
35 determined based upon the GAP algorithm (GCG suite of programs; and Henikoff, S.

- 5 and Henikoff, J. G., Proc. Natl. Acad. Sci. USA 89: 10915-10919(1992)) using the following parameters: gap weight = 8, and length weight = 2.

Figures 13A-F show the polynucleotide sequence (SEQ ID NO: 108) and deduced amino acid sequence (SEQ ID NO:109) of the novel full-length human phosphatase, RET31, of the present invention. The standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of this protein contains a sequence of 5450 nucleotides (SEQ ID NO:108), encoding 665 amino acids (SEQ ID NO:109) of the full-length RET31 polypeptide. An analysis of the RET31 polypeptide determined that it comprised the following features: a dual specificity phosphatase catalytic domain located from about amino acid 158 to about amino acid 297 (SEQ ID NO:134) of SEQ ID NO:109 represented by double underlining; and a catalytic cysteine amino acid residue located at amino acid 244 of SEQ ID NO:109 represented by shading.

Figures 14A-C show the regions of identity between the encoded human phosphatase protein of RET31 (SEQ ID NO:109) to other phosphatase proteins, specifically, the human protein-tyrosine phosphatase DUS8 protein, also referred to as hVH-5 (DUS8; Genbank Accession No:gi|U27193; SEQ ID NO:110); the human dual specificity MAP kinase DUSP6 protein (DUSP6; Genbank Accession No:gi|AB013382; SEQ ID NO:111); the human map kinase phosphatase MKP-5 protein (MKP-5; Genbank Accession No:gi|AB026436; SEQ ID NO:112); and the mouse RET31 protein of the present invention (mRET31; SEQ ID NO:114). The alignment was performed using the CLUSTALW algorithm. The darkly shaded amino acids represent regions of matching identity. The lightly shaded amino acids represent regions of matching similarity. Dots ("•") between residues indicate gapped regions of non-identity for the aligned polypeptides.

Figure 15 shows the results of a northern hybridization illustrating the expression profile of the novel human phosphatase protein RET31. The figure illustrates the relative expression level of RET31 amongst various mRNA tissue sources. As shown, the RET31 polypeptide was expressed predominately in adrenal gland, testis, and

5 skeletal muscle; to a significant extent, in the liver, prostate ovary, and to a lesser extent, in placenta, pancreas, thymus, small intestine, thyroid, heart, kidney and liver. Expression data was obtained by the hybridization of a 408bp P³²-labeled RET31 polynucleotide fragment corresponding to SEQ ID NO:108 (specifically the RsaI fragment of SEQ ID NO:115) to several multiple tissue northern mRNA blots as
10 described herein.

Figures 16A-C show the polynucleotide sequence (SEQ ID NO: 113) and deduced amino acid sequence (SEQ ID NO:114) of the novel full-length mouse phosphatase, mRET31, of the present invention. The standard one-letter abbreviation for amino
15 acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of this protein contains a sequence of 2756 nucleotides (SEQ ID NO:113), encoding 660 amino acids (SEQ ID NO:114) of the full-length mRET31 polypeptide. An analysis of the mRET31 polypeptide determined that it comprised the following features: a dual specificity phosphatase catalytic domain located from about amino
20 acid 158 to about amino acid 297 (SEQ ID NO:135) of SEQ ID NO:114 represented by double underlining.

Figure 17 shows the regions of identity between the dual specificity phosphatase catalytic (DSPc) domain of the encoded human phosphatase protein of RET31 (SEQ
25 ID NO:109) to the dual specificity phosphatase catalytic (DSPc) domain of other phosphatase proteins, specifically, the DSPc domain of the human protein-tyrosine phosphatase DUS8 protein, also referred to as hVH-5 (DUS8_DSPc; Genbank Accession No:gi|U27193; SEQ ID NO:110); the DSPc domain of the human dual specificity MAP kinase DUSP6 protein (DUSP6_DSPc; Genbank Accession
30 No:gi|AB013382; SEQ ID NO:111); and the DSPc domain of the human map kinase phosphatase MKP-5 protein (MKP-5_DSPc; Genbank Accession No:gi|AB026436; SEQ ID NO:112. Red boxes indicate conservation among all four DSPc domains, blue boxes indicate conservation among three DSPc domains, and green boxes indicate conservation between RET31 and one of the other protein domains. Dots
35 ("•") between residues indicate gapped regions of non-identity for the aligned polypeptides.

5

Figure 18 shows the results of a northern hybridization illustrating the expression profile of the novel human phosphatase protein RET31 in human lung microvascular endothelial cells (HMCEC) after the administration of TNF- α for 0, 1, 6, and 24 hours. As shown, the RET31 polypeptide is up-regulated by TNF- α , reaching a peak of expression of about 6 hours. Expression data was obtained by the hybridization of a 408bp P³²-labeled RET31 polynucleotide fragment corresponding to SEQ ID NO:108 (specifically the RsaI fragment of SEQ ID NO:115) to northern blots containing the isolated HMVEC mRNA for each indicated sample as described herein.

Figures 19A-F show the predicted polynucleotide sequence (SEQ ID NO: 147) and deduced amino acid sequence (SEQ ID NO:148) of the novel full-length human phosphatase, RET31, of the present invention. The standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of this protein contains a sequence of 5450 nucleotides (SEQ ID NO:147), encoding 665 amino acids (SEQ ID NO:148) of the full-length RET31 polypeptide. A portion of the sequence was determined based upon the sequence provided from the Incyte gene cluster 1026659.7 using bioinformatic methods.

Figures 20A-D show the predicted polynucleotide sequence (SEQ ID NO:149) and deduced amino acid sequence (SEQ ID NO:150) of the novel full-length human phosphatase, BMY_HPP1, of the present invention. The standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of this protein contains a sequence of 4393 nucleotides (SEQ ID NO:149), encoding 607 amino acids (SEQ ID NO:150) of the full-length BMY_HPP1 polypeptide. An analysis of the BMY_HPP1 polypeptide determined that it comprised the following features: a predicted dual specificity phosphatase catalytic domain located from about amino acid 41 to about amino acid 49 of SEQ ID NO:150 represented by shading; and conserved phosphatase catalytic residues at amino acid 14, at amino acid 42, and at amino acid 48 of SEQ ID NO:150 (Figures 20A-D).

35

5 **Figure 21** shows the polynucleotide sequence (SEQ ID NO:151) and deduced amino acid sequence (SEQ ID NO:152) of the novel full-length human phosphatase, BMY_HPP2, of the present invention. The standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. The polynucleotide sequence of this protein contains a sequence of 878 nucleotides (SEQ ID NO:151),
10 encoding 150 amino acids (SEQ ID NO:152) of the full-length BMY_HPP2 polypeptide. An analysis of the BMY_HPP2 polypeptide determined that it comprised the following features: a predicted dual specificity phosphatase catalytic domain located from about amino acid 93 and 94, and from about amino acid 100 and 101 of SEQ ID NO:152 represented by shading; and conserved phosphatase catalytic residues
15 located at amino acid 65, 94, and 100 of SEQ ID NO: 152 represented in bold.

Figure 22 shows an expression profile of the novel full-length human phosphatase protein BMY_HPP1. The figure illustrates the relative expression level of BMY_HPP1 amongst various mRNA tissue sources. As shown, the BMY_HPP1
20 polypeptide was expressed predominately in testis; to a significant extent, in the spinal cord, and to a lesser extent, in pancreas, brain, pituitary, heart, and lung. Expression data was obtained by measuring the steady state BMY_HPP1 mRNA levels by quantitative PCR using the PCR primer pair provided as SEQ ID NO:154 and 155 as described herein.

25

Figure 23 shows an expression profile of the novel full-length human phosphatase protein BMY_HPP2. The figure illustrates the relative expression level of BMY_HPP2 amongst various mRNA tissue sources. As shown, the BMY_HPP2 polypeptide was expressed predominately in liver and kidney; to a significant extent,
30 in the spleen, and to a lesser extent, in lung, testis, heart, intestine, pancreas, lymph node, spinal cord, and prostate. Expression data was obtained by measuring the steady state BMY_HPP2 mRNA levels by quantitative PCR using the PCR primer pair provided as SEQ ID NO:156 and 157 as described herein.

35 **Figure 24** shows a table illustrating the percent identity and percent similarity between the full-length BMY_HPP1 polypeptide (SEQ ID NO:150), and the full-

5 length BMY_HPP2 polypeptide (SEQ ID NO:152) of the present invention with other phosphatase proteins. The percent identity and percent similarity values were determined based upon the GAP algorithm (GCG suite of programs; and Henikoff, and Henikoff, J. G., Proc. Natl. Acad. Sci. USA 89: 10915-10919(1992)) using the following parameters: gap weight = 8, and length weight = 2.

10

Figure 25 shows a table illustrating the percent identity and percent similarity between the full-length RET31 polypeptide (SEQ ID NO:109) of the present invention with other phosphatase proteins. The percent identity and percent similarity values were determined based upon the GAP algorithm (GCG suite of programs; and
15 Henikoff, and Henikoff, J. G., Proc. Natl. Acad. Sci. USA 89: 10915-10919(1992)) using the following parameters: gap weight = 8, and length weight = 2.

Figure 26 shows an expanded expression profile of the novel full-length human phosphatase protein BMY_HPP1. The figure illustrates the relative expression level
20 of BMY_HPP1 amongst various mRNA tissue sources. As shown, the BMY_HPP1 polypeptide was expressed predominately in brain subregions and other central nervous system tissues, in particular the caudate, hippocampus and nucleus accumbens of the brain. Significant expression was observed in the in the adrenal, pineal and pituitary glands, the atrium of the heart, in the testis, and to a lesser extent
25 in a number of other tissues as shown. Expression data was obtained by measuring the steady state BMY_HPP1 mRNA levels by quantitative PCR using the PCR primer pair provided as SEQ ID NO:194 and 195, and Taqman probe (SEQ ID NO:196) as described in Example 59 herein.

30 **Figure 27** shows the regions of identity between amino acid residues M1 to E301 of the BMY_HPP1 polypeptide (amino acids M1 to E301 of SEQ ID NO:150) to amino acid residues D11 to N321 of the human tyrosine specific phosphatase 1aax (Protein Data Bank, PDB entry 1aax chain A; Genbank Accession No. gi|2981942; SEQ ID NO:206) which was used as the basis for building the BMY_HPP1 homology model
35 as represented in Table VIII and visualized in Figure 28. Amino acids defining active

- 5 site residues are highlighted with asterisks ("*"). The alignment was created using the FASTA algorithm (Pearson, *et. al.* 1990).

Figure 28 shows a three-dimensional homology model of amino acid residues M1 to E301 of the BMY_HPP1 polypeptide based upon the homologous structure of amino acid residues D11 to N321 of the human tyrosine specific phosphatase 1aax (Protein Data Bank, PDB entry 1aax chain A; Genbank Accession No. gi|2981942; SEQ ID NO:206). The structural coordinates of the BMY_HPP1 polypeptide are provided in Table VIII herein. The homology model of BMY_HPP1 was derived from generating a sequence alignment with the the human tyrosine specific phosphatase 1aax (Protein Data Bank, PDB entry 1aax chain A; Genbank Accession No. gi|2981942; SEQ ID NO:206) using the INSIGHTII (Accelrys Inc., San Diego, CA) version 2000 as described herein.

Figure 29 shows an energy graph for the BMY_HPP1 model of the present invention (dotted line) and the tyrosine specific phosphatase 1aax template (solid line) from which the model was generated. The energy distribution for each protein fold is displayed on the y-axis, while the amino acid residue position of the protein fold is displayed on the x-axis. As shown, the BMY_HPP1 model has slightly higher energies in the C-terminal region while the N-terminal region of the structural model appears to represent a "native-like" conformation of the BMY_HPP1 polypeptide. This graph supports the motif and sequence alignments in confirming that the three dimensional structure coordinates of BMY_HPP1 are an accurate and useful representation of the structure of the BMY_HPP1 polypeptide.

Figure 30 shows an expanded expression profile of the novel full-length human phosphatase protein BMY_HPP2. The figure illustrates the relative expression level of BMY_HPP2 amongst various mRNA tissue sources. As shown, the BMY_HPP2 polypeptide was expressed predominately in adrenal gland; significantly in the pineal and pituitary gland, lung parenchyma, bronchi, kidney, liver, blood vessels from the choroid plexus, coronary artery, pulmonary artery, the nucleus accumbens of the brain, and to a lesser extent in the trachea, breast and uterus and in other tissues as

- 5 shown. Expression data was obtained by measuring the steady state BMY_HPP2 mRNA levels by quantitative PCR using the PCR primer pair provided as SEQ ID NO:197 and 198, and Taqman probe (SEQ ID NO:199) as described in Example 59 herein.
- 10 **Figure 31** shows the regions of identity between amino acid residues M1 to K150 of the BMY_HPP2 polypeptide (amino acids M1 to K150 of SEQ ID NO:152) to amino acid residues N31 to K179 of the N-terminus of the human dual specificity phosphatase, 1vhr (vaccinia H1-related phosphatase VN1) (residues N31-K179; Protein Data Bank, PDB entry 1vhr chain A; Genbank Accession No. gi|1633321; SEQ ID NO:207) which was used as the basis for building the BMY_HPP2 homology model as represented in Table IX and visualized in Figure 32. Amino acids defining active site residues are highlighted in bold. The alignment was created using the FASTA algorithm (Pearson, *et. al.* 1990).
- 20 **Figure 32** shows a three-dimensional homology model of amino acid residues M1 to K150 of the BMY_HPP2 polypeptide based upon the homologous structure of amino acid residues N31 to K179 of the N-terminus of the human dual specificity phosphatase, 1vhr (vaccinia H1-related phosphatase VN1) (residues N31-K179; Protein Data Bank, PDB entry 1vhr chain A; Genbank Accession No. gi|1633321; SEQ ID NO:207). The structural coordinates of the BMY_HPP2 polypeptide are provided in Table IX herein. The homology model of BMY_HPP2 was derived from generating a sequence alignment with the human dual specificity phosphatase, 1vhr (vaccinia H1-related phosphatase VN1) (residues N31-K179; Protein Data Bank, PDB entry 1vhr chain A; Genbank Accession No. gi|1633321; SEQ ID NO:207) using the
- 30 INSIGHTII (Accelrys Inc., San Diego, CA) version 2000 as described herein.
- Figure 33** shows an energy graph for the BMY_HPP2 model of the present invention (dotted line) and the phosphatase VHR template (PDB code 1vhr) (solid line) from which the model was generated. The energy distribution for each protein fold is displayed on the y-axis, while the amino acid residue position of the protein fold is displayed on the x-axis. As shown, the BMY_HPP2 model and 1vhr template have
- 35

5 similar energies over the aligned region, suggesting that the structural model of
BMY_HPP2 represents a “native-like” conformation of the BMY_HPP2 polypeptide.
This graph supports the motif and sequence alignments in confirming that the three
dimensional structure coordinates of BMY_HPP2 are an accurate and useful
representation of the structure of the BMY_HPP1 polypeptide.

10

Figure 34 shows an expanded expression profile of the novel full-length human
phosphatase protein BMY_HPP4. The figure illustrates the relative expression level
of BMY_HPP4 amongst various mRNA tissue sources. As shown, the BMY_HPP4
polypeptide was expressed predominately in cerebellum; significantly in other
15 subregions of the brain, and in the pineal and pituitary glands. Expression data was
obtained by measuring the steady state BMY_HPP4 mRNA levels by quantitative
PCR using the PCR primer pair provided as SEQ ID NO:200 and 201, and Taqman
probe (SEQ ID NO:202) as described in Example 59 herein.

20 **Figure 35** shows an expanded expression profile of the novel full-length human
phosphatase protein BMY_HPP5. The figure illustrates the relative expression level
of BMY_HPP5 amongst various mRNA tissue sources. As shown, the BMY_HPP5
polypeptide was expressed predominately in the adrenal, pineal and pituitary glands;
significantly in the cerebellum, prostate, testis, and to a lesser extent in other tissues
25 as shown. Expression data was obtained by measuring the steady state BMY_HPP5
mRNA levels by quantitative PCR using the PCR primer pair provided as SEQ ID
NO:203 and 204, and Taqman probe (SEQ ID NO:205) as described in Example 59
herein.

30 **Figure 36** shows the results of para-nitrophenylphosphate (pNPP) phosphatase
activity assays of the purified RET31-GST full length (FL), and M1 to T302 RET31
C-terminal deletion mutant (trunc) fusion proteins, as compared to purified GST
alone. The bars represent the average of triplicate determinations, and the standard
deviations are as shown. Each protein preparation was assayed in the absence and
35 presence of 2 mM orthovanadate (“-van”). As shown, both the full-length RET31 and
M1 to T302 RET31 C-terminal deletion mutant demonstrated phosphatase activity via

5 cleavage of the NPP substrate which was blocked by the phosphatase-specific inhibitor, vanadate. Of particular significance is the unexpected five fold increase in phosphatase activity of the M1 to T302 RET31 C-terminal deletion mutant relative to the full-length RET31 polypeptide. The phosphatase assays were performed as described in Example 57 herein. The full length and truncated versions clearly
10 demonstrated phosphatase activity compared to the GST protein.

Figure 37 shows the regions of identity between amino acid residues N157 to I300 of the BMY_HPP5 polypeptide (amino acids N157 to I300 of SEQ ID NO:42) to amino acid residues A204 to L347 of the human dual specificity phosphatase MAP Kinase
15 phosphatase 3, also called PYST1, 1mkp (residues A204-L347; Protein Data Bank, PDB entry 1mkp chain A; Genbank Accession No. gi|5822131; SEQ ID NO:208) which was used as the basis for building the BMY_HPP5 homology model as represented in Table X and visualized in Figure 38. Amino acids defining active site residues are highlighted in bold. The alignment was created using the FASTA
20 algorithm (Pearson, *et. al.* 1990).

Figure 38 shows a three-dimensional homology model of amino acid residues N157 to I300 of the BMY_HPP5 polypeptide based upon the homologous structure of amino acid residues A204 to L347 of the human dual specificity phosphatase MAP
25 Kinase phosphatase 3, also called PYST1, 1mkp (residues A204-L347; Protein Data Bank, PDB entry 1mkp chain A; Genbank Accession No. gi|5822131; SEQ ID NO:208). The structural coordinates of the BMY_HPP2 polypeptide are provided in Table IX herein. The homology model of BMY_HPP2 was derived from generating a sequence alignment with the human dual specificity phosphatase MAP Kinase
30 phosphatase 3, also called PYST1, 1mkp (residues A204-L347; Protein Data Bank, PDB entry 1mkp chain A; Genbank Accession No. gi|5822131; SEQ ID NO:208) using the INSIGHTII (Accelrys Inc., San Diego, CA) version 2000 as described herein.

35 **Figure 39** shows an energy graph for the BMY_HPP5 model of the present invention (dotted line) and the phosphatase VHR template (PDB code 1vhr) (solid line) from

- 5 which the model was generated. The energy distribution for each protein fold is displayed on the y-axis, while the amino acid residue position of the protein fold is displayed on the x-axis. As shown, the BMY_HPP5 model and 1vhr template have similar energies over the aligned region, suggesting that the structural model of BMY_HPP5 represents a "native-like" conformation of the BMY_HPP5 polypeptide.
- 10 This graph supports the motif and sequence alignments in confirming that the three dimensional structure coordinates of BMY_HPP5 are an accurate and useful representation of the structure of the BMY_HPP5 polypeptide.

15 **Table I** provides a summary of the novel polypeptides and their encoding polynucleotides of the present invention.

Table II illustrates the preferred hybridization conditions for the polynucleotides of the present invention. Other hybridization conditions may be known in the art or are described elsewhere herein.

20

Table III provides the amino acid sequences of known phosphatases that were used to identify the novel human phosphatases of the present invention using the BLAST algorithm as described herein.

25 **Table IV** provides the PFAM motifs that were used in Hidden Markov Model (HMM) searches to identify the novel human phosphatases of the present invention as described herein.

30 **Table V** provides the predicted exon structure of the BMY_HPP4 gene. The 'Start' and 'End' designations refer to the respective nucleotide positions of the BMY_HPP4 as they appear for the corresponding genomic sequence in BAC AL 354751. The numbering begins at the start of BAC AL354751; nucleotide 71352 in the BAC is equivalent to nucleotide 1 of the BMY_HPP4 transcript (SEQ ID NO:9; Figure 4).

35 **Table VI** provides representative primers for sequencing and/or cloning any one of the human phosphatases of the present invention in conjunction with the teachings

5 described herein. 'Left Cloning Primer', and 'Right Cloning Primer' represent the forward and reverse sequencing primers, while the 'Internal RevComp Cloning Primer' and/or 'Internal Cloning Primer' represent antisense cloning primers as described in the Examples herein.

10 **Table VII** provides a summary of various conservative substitutions encompassed by the present invention.

Table VIII provides the structural coordinates of the homology model of the BMY_HPP1 polypeptide provided in Figure 28. A description of the headings are as follows: "Atom No" refers to the atom number within the BMY_HPP1 homology
15 model; "Atom name" refers to the element whose coordinates are measured, the first letter in the column defines the element; "Residue" refers to the amino acid of the BMY_HPP1 polypeptide within which the atom resides; "Residue No" refers to the amino acid position in which the atom resides, "X Coord", "Y Coord", and "Z Coord"
20 structurally define the atomic position of the element measured in three dimensions.

Table IX provides the structural coordinates of the homology model of the BMY_HPP2 polypeptide provided in Figure 32. A description of the headings are as follows: "Atom No" refers to the atom number within the BMY_HPP2 homology
25 model; "Atom name" refers to the element whose coordinates are measured, the first letter in the column defines the element; "Residue" refers to the amino acid of the BMY_HPP2 polypeptide within which the atom resides; "Residue No" refers to the amino acid position in which the atom resides, "X Coord", "Y Coord", and "Z Coord" structurally define the atomic position of the element measured in three dimensions.

30 **Table X** provides the structural coordinates of the homology model of the BMY_HPP5 polypeptide provided in Figure 38. A description of the headings are as follows: "Atom No" refers to the atom number within the BMY_HPP5 homology model; "Atom name" refers to the element whose coordinates are measured, the first
35 letter in the column defines the element; "Residue" refers to the amino acid of the BMY_HPP5 polypeptide within which the atom resides; "Residue No" refers to the

- 5 amino acid position in which the atom resides, "X Coord", "Y Coord", and "Z Coord" structurally define the atomic position of the element measured in three dimensions.

DETAILED DESCRIPTION OF THE INVENTION

The present invention may be understood more readily by reference to the
10 following detailed description of the preferred embodiments of the invention and the Examples included herein. All references to "phosphatase" and/or "human phosphatases" shall be construed to apply to BMY_HPP1, BMY_HPP2, BMY_HPP3, BMY_HPP4, BMY_HPP5, RET31, mouse RET31, and/or fragments thereof unless otherwise specified herein. Moreover, since BMY_HPP5 is believed to represent a
15 splice variant of the RET31 polypeptide, all references to "BMY_HPP5" shall be construed to apply to RET31, and all references to "RET31" shall be construed to apply to "BMY_HPP5".

The invention provides human polynucleotide sequences encoding novel human phosphatases with substantial homology to the class of phosphatases known as
20 phosphotyrosine or dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases. Members of this class of phosphatases have been implicated in a number of diseases and/or disorders, which include, but are not limited to, bone disorders, (Yoon, HK., Baylink, DJ., Lau, KH, Am. J. Nephrol., 20(2):153-62, (2000)), disease resistance to pathogens, reproductive disorders (Gloria, Bottini, F., Nicotra, M., Lucarini, N.,
25 Borgiani, P., La, Torre, M., Amante, A., Gimelfarb, A., Bottini, E, Dis. Markers., 12(4):261-9, (1996)), neural disorders (Shimohama, S., Fujimoto, S., Taniguchi, T., Kameyama, M., Kimura, J. Ann, Neurol., 33(6):616-21, (1993)), prostate cancer (Nguyen, L., Chapdelaine, A., and Chevalier, S., Clin. Chem. 36(8 Pt 1): 1450-5 (1990)), immune disorders, particularly those relating to haematopoietic cell
30 development, apoptosis, activation, and nonresponsiveness (Frearson, JA., Alexander, DR, Bioessays., 19(5): 417-27 (1997)), etc.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated
35 polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of

5 matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing
10 features of the polynucleotide/sequences of the present invention.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment,
15 polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain
20 the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:7, 9, 41, 108, 149, 151 or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can
25 contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without a signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the
30 polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO: 7, 9, 41, 108, 149, 151 was often generated by overlapping sequences contained in one or more clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture
35 Collection ("ATCC"). As shown in Table I, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801

5 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure. The deposited clone is inserted in the pSport plasmid (Life Technologies) using SalI and NotI restriction sites as described herein.

10 Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined above. Therefore, as is known
15 in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely
20 determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different
25 from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

Using the information provided herein, such as the nucleotide sequence provided as SEQ ID NO: 7, 9, 41, 108, 149, 151, a nucleic acid molecule of the present invention encoding a human phosphatase polypeptide may be obtained using
30 standard cloning and screening procedures, such as those for cloning cDNAs using mRNA as starting material.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within
35 the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC

5 (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.
10 Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl;
15 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

20 Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking
25 reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA⁺ sequences (such as any 3' terminal polyA⁺ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of
30 "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or
35 DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-

5 stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A
10 polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

15 The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well
20 known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in
25 a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation,
30 ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation,
35 gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing,

- 5 phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences are identified by an integer specified in Table I.

- 15 "A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar
- 20 to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

- 25 The term "organism" as referred to herein is meant to encompass any organism referenced herein, though preferably to eukaryotic organisms, more preferably to mammals, and most preferably to humans.

- The present invention encompasses the identification of proteins, nucleic acids, or other molecules, that bind to polypeptides and polynucleotides of the present
- 30 invention (for example, in a receptor-ligand interaction). The polynucleotides of the present invention can also be used in interaction trap assays (such as, for example, that described by Ozenberger and Young (Mol Endocrinol., 9(10):1321-9, (1995); and Ann. N. Y. Acad. Sci., 7;766:279-81, (1995)).

- The polynucleotide and polypeptides of the present invention are useful as
- 35 probes for the identification and isolation of full-length cDNAs and/or genomic DNA which correspond to the polynucleotides of the present invention, as probes to

5 hybridize and discover novel, related DNA sequences; as probes for positional cloning of this or a related sequence, as probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides, as probes to quantify gene expression, and as probes for microarrays.

In addition, polynucleotides and polypeptides of the present invention may
10 comprise one, two, three, four, five, six, seven, eight, or more membrane domains.

Also, in preferred embodiments the present invention provides methods for further refining the biological function of the polynucleotides and/or polypeptides of the present invention.

Specifically, the invention provides methods for using the polynucleotides and
15 polypeptides of the invention to identify orthologs, homologs, paralogs, variants, and/or allelic variants of the invention. Also provided are methods of using the polynucleotides and polypeptides of the invention to identify the entire coding region of the invention, non-coding regions of the invention, regulatory sequences of the invention, and secreted, mature, pro-, prepro-, forms of the invention (as applicable).

20 In preferred embodiments, the invention provides methods for identifying the glycosylation sites inherent in the polynucleotides and polypeptides of the invention, and the subsequent alteration, deletion, and/or addition of said sites for a number of desirable characteristics which include, but are not limited to, augmentation of protein folding, inhibition of protein aggregation, regulation of intracellular trafficking to
25 organelles, increasing resistance to proteolysis, modulation of protein antigenicity, and mediation of intercellular adhesion.

In further preferred embodiments, methods are provided for evolving the polynucleotides and polypeptides of the present invention using molecular evolution techniques in an effort to create and identify novel variants with desired structural,
30 functional, and/or physical characteristics.

The present invention further provides for other experimental methods and procedures currently available to derive functional assignments. These procedures include but are not limited to spotting of clones on arrays, micro-array technology, PCR based methods (e.g., quantitative PCR), anti-sense methodology, gene knockout
35 experiments, and other procedures that could use sequence information from clones to build a primer or a hybrid partner.

- 5 As used herein the terms "modulate or modulates" refer to an increase or decrease in the amount, quality or effect of a particular activity, DNA, RNA, or protein.

5

Polynucleotides and Polypeptides of the Invention

Features of the Polypeptide Encoded by Gene No:1

Polypeptide fragments A and B corresponding to this gene provided as SEQ ID NO:2 and 4 (Figure 1), encoded by the polynucleotide sequence according to SEQ ID NO:1 and 3 (Figure 1), the predicted full-length polypeptide sequence corresponding to this gene provided as SEQ ID NO:150 (Figures 20A-D), encoded by the full-length polynucleotide sequence according to SEQ ID NO:149 (Figures 20A-D), and/or encoded by the polynucleotide contained within the deposited clone, BMY_HPP1, has significant homology at the nucleotide and amino acid level to a number of phosphatases, which include, for example, the Schizosaccharomyces Pombe protein tyrosine phosphatase PYP3 protein (PYP3_SP; Genbank Accession No:gi|P32587; SEQ ID NO:Y7); the mouse protein tyrosine phosphatase, receptor type, O, protein (MM_RPTPO; Genbank Accession No:gi|NP_035346; SEQ ID NO:Y8); and the human protein tyrosine phosphatase, receptor type, O, protein (HS_RPTPO; Genbank Accession No:gi|NP_002839; SEQ ID NO:Y9); as determined by BLASTP. An alignment of the human phosphatase polypeptide with these proteins is provided in Figures 6A-D. The conserved catalytic residues are noted.

BMY_HPP1 is a novel phosphoprotein phosphatase encoded by a human genomic BAC clone, Genbank accession AL360020. Aside from the predicted full-length BMY_HPP1 polypeptide sequence, two separate homologous regions in BAC AL360020 have been identified. Fragment A of BMY_HPP1 includes key conserved phosphatase catalytic residues: an Aspartate ("D") at amino acid 11 of SEQ ID NO:2 (Figure 1), a Cysteine ("C") at amino acid 40 of SEQ ID NO:2 (Figure 1), and an Arginine ("R") at amino acid 46 of SEQ ID NO:2 (Figure 1). Fragment B of BMY_HPP1 represents a more N-terminal fragment and is not predicted to include any catalytic residues. The predicted conserved phosphatase catalytic residues for the predicted full-length BMY_HPP1 polypeptide are as follows: conserved phosphatase catalytic residues: an Aspartate ("D") at amino acid 14 of SEQ ID NO:150 (Figures 20A-D), a Cysteine ("C") at amino acid 42 of SEQ ID NO:150 (Figures 20A-D), and an Arginine ("R") at amino acid 48 of SEQ ID NO:150 (Figures 20A-D).

5 An alignment of the BMY_HPP1 polypeptide fragments and predicted full-length polypeptide with other phosphatase proteins (Figures 6A-D) illustrates the conserved phosphatase catalytic residues.

 Based upon the strong homology to members of the phosphatase proteins, the polypeptide encoded by the human BMY_HPP1 phosphatase of the present invention
10 is expected to share at least some biological activity with phosphatase proteins, preferably with members of the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases, particularly the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases referenced herein.

 The present invention encompasses the use of BMY_HPP1 inhibitors and/or
15 activators of BMY_HPP1 activity for the treatment, detection, amelioration, or prevention of phosphatase associated disorders, including but not limited to metabolic diseases such as diabetes, in addition to neural and/or cardiovascular diseases and disorders. The present invention also encompasses the use of BMY_HPP1 inhibitors and/or activators of BMY_HPP1 activity as immunosuppressive agents, anti-
20 inflammatory agents, and/or anti-tumor agents

 The present invention encompasses the use of BMY_HPP1 phosphatase inhibitors, including, antagonists such as antisense nucleic acids, in addition to other antagonists, as described herein, in a therapeutic regimen to diagnose, prognose, treat, ameliorate, and/or prevent diseases where a kinase activity is insufficient. One, non-
25 limiting example of a disease which may occur due to insufficient kinase activity are certain types of diabetes, where one or more kinases involved in the insulin receptor signal pathway may have insufficient activity or insufficient expression, for example.

 Moreover, the present invention encompasses the use of BMY_HPP1 phosphatase activators, and/or the use of the BMY_HPP1 phosphatase gene or protein
30 in a gene therapy regimen, as described herein, for the diagnoses, prognoses, treatment, amelioration, and/or prevention of diseases and/or disorders where a kinase activity is overly high, such as a cancer where a kinase oncogene product has excessive activity or excessive expression.

 The present invention also encompasses the use of catalytically inactive
35 variants of BMY_HPP1 proteins, including fragments thereof, such as a protein therapeutic, or the use of the encoding polynucleotide sequence or as gene therapy,

5 for example, in the diagnoses, prognosis, treatment, amelioration, and/or prevention of diseases or disorders where phosphatase activity is overly high.

The present invention encompasses the use of antibodies directed against the BMY_HPP1 polypeptides, including fragment and/or variants thereof, of the present invention in diagnostics, as a biomarkers, and/or as a therapeutic agents.

10 The present invention encompasses the use of an inactive, non-catalytic, mutant of the BMY_HPP1 phosphatase as a substrate trapping mutant to bind cellular phosphoproteins or a library of phosphopeptides to identify substrates of the BMY_HPP1 polypeptides.

The present invention encompasses the use of the BMY_HPP1 polypeptides, to identify inhibitors or activators of the BMY_HPP1 phosphatase activity using either in vitro or 'virtual' (in silico) screening methods.

One embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of the BMY_HPP1 phosphatase comprising the steps of: i.) contacting a BMY_HPP1 phosphatase inhibitor or activator labeled with an analytically detectable reagent with the BMY_HPP1 phosphatase under conditions sufficient to form a complex with the inhibitor or activator; ii.) contacting said complex with a sample containing a compound to be identified; iii) and identifying the compound as an inhibitor or activator by detecting the ability of the test compound to alter the amount of labeled known BMY_HPP1 phosphatase inhibitor or activator in the complex.

Another embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of a BMY_HPP1 phosphatase comprising the steps of: i.) contacting the BMY_HPP1 phosphatase with a compound to be identified; and ii.) and measuring the ability of the BMY_HPP1 phosphatase to remove phosphate from a substrate.

The present invention also encompasses a method for identifying a ligand for the BMY_HPP1 phosphatase comprising the steps of: i.) contacting the BMY_HPP1 phosphatase with a series of compounds under conditions to permit binding; and ii.) detecting the presence of any ligand-bound protein.

35 Preferably, the above referenced methods comprise the BMY_HPP1 phosphatase in a form selected from the group consisting of whole cells, cytosolic cell

5 fractions, membrane cell fractions, purified or partially purified forms. The invention also relates to recombinantly expressed BMY_HPP1 phosphatase in a purified, substantially purified, or unpurified state. The invention further relates to BMY_HPP1 phosphatase fused or conjugated to a protein, peptide, or other molecule or compound known in the art, or referenced herein.

10 The present invention also encompasses pharmaceutical composition of the BMY_HPP1 phosphatase polypeptide comprising a compound identified by above referenced methods and a pharmaceutically acceptable carrier.

Expression profiling designed to measure the steady state mRNA levels encoding the BMY_HPP1 polypeptide showed predominately high expression levels
15 in testis; to a significant extent, in the spinal cord, and to a lesser extent, in pancreas, brain, pituitary, heart, and lung (as shown in Figure 22).

Moreover, additional expression profiling of the BMY_HPP1 polypeptide in normal tissues showed strong expression in a number of brain subregions and other central nervous system tissues, in particular the caudate, hippocampus and nucleus
20 accumbens of the brain (as shown in Figure 26). These regions are known to be involved in a number of neurological disorders such as depression, bipolar disorder, schizophrenia, dementia, cognitive disorders and obesity. This data suggests a role for modulators of BMY_HPP1 activity in the treatment of neural disorders. In addition, BMY_HPP1 is strongly expressed in the adrenal, pineal and pituitary glands,
25 suggesting a role for modulators of BMY_HPP1 activity in the treatment of endocrine disorders; in the atrium of the heart, suggesting a role for modulators of BMY_HPP1 activity in the treatment of cardiac failure or other diseases of the heart; and in the testis, suggesting a role for modulators of BMY_HPP1 activity in the treatment of male infertility caused by defective or insufficient spermatogenesis, as a contraceptive agent, or in the treatment of testicular cancer. In addition, BMY_HPP1 was expressed
30 at lower levels across a number of tissues as well.

The strong homology to dual specificity phosphatases, combined with the predominate localized expression in testis tissue emphasizes the potential utility for BMY_HPP1 polynucleotides and polypeptides in treating, diagnosing, prognosing,
35 and/or preventing testicular, in addition to reproductive disorders.

5 In preferred embodiments, BMY_HPP1 polynucleotides and polypeptides including agonists and fragments thereof, have uses which include treating, diagnosing, prognosing, and/or preventing the following, non-limiting, diseases or disorders of the testis: spermatogenesis, infertility, Klinefelter's syndrome, XX male, epididymitis, genital warts, germinal cell aplasia, cryptorchidism, varicocele, 10 immotile cilia syndrome, and viral orchitis. The BMY_HPP1 polynucleotides and polypeptides including agonists and fragments thereof, may also have uses related to modulating testicular development, embryogenesis, reproduction, and in ameliorating, treating, and/or preventing testicular proliferative disorders (e.g., cancers, which include, for example, choriocarcinoma, Nonseminoma, seminoma, and testicular germ 15 cell tumors).

Likewise, the predominate localized expression in testis tissue also emphasizes the potential utility for BMY_HPP1 polynucleotides and polypeptides in treating, diagnosing, prognosing, and/or preventing metabolic diseases and disorders which include the following, not limiting examples: premature puberty, incomplete puberty, 20 Kallman syndrome, Cushing's syndrome, hyperprolactinemia, hemochromatosis, congenital adrenal hyperplasia, FSH deficiency, and granulomatous disease, for example.

This gene product may also be useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. The testes 25 are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

30 The strong homology to dual specificity phosphatase proteins, combined with the localized expression in spinal cord, brain subregions, and other central nervous system tissues, suggests the BMY_HPP1 polynucleotides and polypeptides may be useful in treating, diagnosing, prognosing, and/or preventing neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses 35 are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in the Examples, and elsewhere herein. Briefly, the uses include, but are not

5 limited to the detection, treatment, and/or prevention of Alzheimer's Disease,
Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,
encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma,
congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms,
hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive
10 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism,
and altered behaviors, including disorders in feeding, sleep patterns, balance, and
perception. In addition, elevated expression of this gene product in regions of the
brain indicates it plays a role in normal neural function. Potentially, this gene product
is involved in synapse formation, neurotransmission, learning, cognition, homeostasis,
15 or neuronal differentiation or survival. Furthermore, the protein may also be used to
determine biological activity, to raise antibodies, as tissue markers, to isolate cognate
ligands or receptors, to identify agents that modulate their interactions, in addition to
its use as a nutritional supplement. Protein, as well as, antibodies directed against the
protein may show utility as a tumor marker and/or immunotherapy targets for the
20 above listed tissues.

The BMY_HPP1 polypeptide has been shown to comprise one glycosylation
sites according to the Motif algorithm (Genetics Computer Group, Inc.). As discussed
more specifically herein, protein glycosylation is thought to serve a variety of
functions including: augmentation of protein folding, inhibition of protein
25 aggregation, regulation of intracellular trafficking to organelles, increasing resistance
to proteolysis, modulation of protein antigenicity, and mediation of intercellular
adhesion.

Asparagine glycosylation sites have the following consensus pattern, N-{P}-
[ST]-{P}, wherein N represents the glycosylation site. However, it is well known that
30 that potential N-glycosylation sites are specific to the consensus sequence Asn-Xaa-
Ser/Thr. However, the presence of the consensus tripeptide is not sufficient to
conclude that an asparagine residue is glycosylated, due to the fact that the folding of
the protein plays an important role in the regulation of N-glycosylation. It has been
shown that the presence of proline between Asn and Ser/Thr will inhibit N-
35 glycosylation; this has been confirmed by a recent statistical analysis of glycosylation
sites, which also shows that about 50% of the sites that have a proline C-terminal to

5 Ser/Thr are not glycosylated. Additional information relating to asparagine glycosylation may be found in reference to the following publications, which are hereby incorporated by reference herein: Marshall R.D., *Annu. Rev. Biochem.* 41:673-702(1972); Pless D.D., Lennarz W.J., *Proc. Natl. Acad. Sci. U.S.A.* 74:134-138(1977); Bause E., *Biochem. J.* 209:331-336(1983); Gavel Y., von Heijne G.,
10 *Protein Eng.* 3:433-442(1990); and Miletich J.P., Broze G.J. Jr., *J. Biol. Chem.*... 265:11397-11404(1990).

In preferred embodiments, the following asparagine glycosylation site polypeptide is encompassed by the present invention: LTPLRNISCCDPKA (SEQ ID NO:158). Polynucleotides encoding this polypeptide are also provided. The present
15 invention also encompasses the use of this BMY_HPP1 asparagine glycosylation site polypeptide as an immunogenic and/or antigenic epitope as described elsewhere herein.

The BMY_HPP1 polypeptides of the present invention were determined to comprise several phosphorylation sites based upon the Motif algorithm (Genetics
20 Computer Group, Inc.). The phosphorylation of such sites may regulate some biological activity of the BMY_HPP1 polypeptide. For example, phosphorylation at specific sites may be involved in regulating the proteins ability to associate or bind to other molecules (e.g., proteins, ligands, substrates, DNA, etc.). In the present case, phosphorylation may modulate the ability of the BMY_HPP1 polypeptide to associate
25 with other potassium channel alpha subunits, beta subunits, or its ability to modulate potassium channel function.

The BMY_HPP1 polypeptide was predicted to comprise four PKC phosphorylation sites using the Motif algorithm (Genetics Computer Group, Inc.). In vivo, protein kinase C exhibits a preference for the phosphorylation of serine or
30 threonine residues. The PKC phosphorylation sites have the following consensus pattern: [ST]-x-[RK], where S or T represents the site of phosphorylation and 'x' an intervening amino acid residue. Additional information regarding PKC phosphorylation sites can be found in Woodget J.R., Gould K.L., Hunter T., *Eur. J. Biochem.* 161:177-184(1986), and Kishimoto A., Nishiyama K., Nakanishi H.,
35 Uratsuji Y., Nomura H., Takeyama Y., Nishizuka Y., *J. Biol. Chem.*... 260:12492-12499(1985); which are hereby incorporated by reference herein.

5 In preferred embodiments, the following PKC phosphorylation site polypeptides are encompassed by the present invention: TLSFWSQKFGGLE (SEQ ID NO:159), VQNSRTPRSPLDC (SEQ ID NO:160), PLDCGSSKAQFLV (SEQ ID NO:161), and/or PTVYNTKKIFKHT (SEQ ID NO:162). Polynucleotides encoding these polypeptides are also provided. The present invention also encompasses the use
10 of these BMY_HPP1 PKC phosphorylation site polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In further confirmation of the human BMY_HPP1 polypeptide representing a novel human phosphatase polypeptide, the BMY_HPP1 polypeptide has been shown to comprise a tyrosine specific protein phosphatase active site domain according to
15 the Motif algorithm (Genetics Computer Group, Inc.).

Tyrosine specific protein phosphatases (EC 3.1.3.48) (PTPase) are enzymes that catalyze the removal of a phosphate group attached to a tyrosine residue. These enzymes are very important in the control of cell growth, proliferation, differentiation and transformation. Multiple forms of PTPase have been characterized and can be
20 classified into two categories: soluble PTPases and transmembrane receptor proteins that contain PTPase domain(s).

The currently known PTPases are listed below: Soluble PTPases, PTPN1 (PTP-1B), PTPN2 (T-cell PTPase; TC-PTP), PTPN3 (H1) and PTPN4 (MEG), enzymes that contain an N-terminal band 4.1-like domain and could act at junctions
25 between the membrane and cytoskeleton, PTPN5 (STEP), PTPN6 (PTP-1C; HCP; SHP) and PTPN11 (PTP-2C; SH-PTP3; Syp), enzymes which contain two copies of the SH2 domain at its N-terminal extremity (e.g., the Drosophila protein corkscrew (gene csw) also belongs to this subgroup), PTPN7 (LC-PTP; Hematopoietic protein-tyrosine phosphatase; HePTP), PTPN8 (70Z-PEP), PTPN9 (MEG2), PTPN12 (PTP-G1; PTP-P19), Yeast PTP1, Yeast PTP2 which may be involved in the ubiquitin-mediated protein degradation pathway, Fission yeast pyp1 and pyp2 which play a role in inhibiting the onset of mitosis, Fission yeast pyp3 which contributes to the dephosphorylation of cdc2, Yeast CDC14 which may be involved in chromosome segregation, Yersinia virulence plasmid PTPases (gene yopH), Autographa californica nuclear polyhedrosis virus 19 Kd PTPase, Dual specificity PTPases,
35 DUSP1 (PTPN10; MAP kinase phosphatase-1; MKP-1); which dephosphorylates

- 5 MAP kinase on both Thr-183 and Tyr-185, DUSP2 (PAC-1), a nuclear enzyme that dephosphorylates MAP kinases ERK1 and ERK2 on both Thr and Tyr residues, DUSP3 (VHR), DUSP4 (HVH2), DUSP5 (HVH3), DUSP6 (Pyst1; MKP-3), DUSP7 (Pyst2; MKP-X), Yeast MSG5, a PTPase that dephosphorylates MAP kinase FUS3, Yeast YVH1, Vaccinia virus H1 PTPase - a dual specificity phosphatase,
- 10 Structurally, all known receptor PTPases, are made up of a variable length extracellular domain, followed by a transmembrane region and a C-terminal catalytic cytoplasmic domain. Some of the receptor PTPases contain fibronectin type III (FN-III) repeats, immunoglobulin-like domains, MAM domains or carbonic anhydrase-like domains in their extracellular region. The cytoplasmic region generally contains two
- 15 copies of the PTPase domain. The first seems to have enzymatic activity, while the second is inactive but seems to affect substrate specificity of the first. In these domains, the catalytic cysteine is generally conserved but some other, presumably important, residues are not.

PTPase domains consist of about 300 amino acids. There are two conserved

20 cysteines, the second one has been shown to be absolutely required for activity. Furthermore, a number of conserved residues in its immediate vicinity have also been shown to be important.

A consensus sequence for tyrosine specific protein phosphatases is provided as follows:

- 25 [LIVMF]-H-C-x(2)-G-x(3)-[STC]-[STAGP]-x-[LIVMFY], wherein C is the active site residue and "X" represents any amino acid.

Additional information related to tyrosine specific protein phosphatase domains and proteins may be found in reference to the following publications Fischer E.H., Charbonneau H., Tonks N.K., Science 253:401-406(1991); Charbonneau H.,

30 Tonks N.K., Annu. Rev. Cell Biol. 8:463-493(1992); Trowbridge I.S., J. Biol. Chem... 266:23517-23520(1991); Tonks N.K., Charbonneau H., Trends Biochem. Sci. 14:497-500(1989); and Hunter T., Cell 58:1013-1016(1989); which are hereby incorporated herein by reference in their entirety.

In preferred embodiments, the following tyrosine specific protein phosphatase

35 active site domain polypeptide is encompassed by the present invention: QEGKVIHCHAGLGRTGVLIAYLV (SEQ ID NO:163). Polynucleotides encoding these

5 polypeptides are also provided. The present invention also encompasses the use of this tyrosine specific protein phosphatase active site domain polypeptide as an immunogenic and/or antigenic epitope as described elsewhere herein.

In preferred embodiments, the following N-terminal BMY_HPP1 deletion polypeptides are encompassed by the present invention: M1-L607, E2-L607, A3-
10 L607, G4-L607, I5-L607, Y6-L607, F7-L607, Y8-L607, N9-L607, F10-L607, G11-L607, W12-L607, K13-L607, D14-L607, Y15-L607, G16-L607, V17-L607, A18-L607, S19-L607, L20-L607, T21-L607, T22-L607, I23-L607, L24-L607, D25-L607, M26-L607, V27-L607, K28-L607, V29-L607, M30-L607, T31-L607, F32-L607, A33-L607, L34-L607, Q35-L607, E36-L607, G37-L607, K38-L607, V39-L607, A40-
15 L607, I41-L607, H42-L607, C43-L607, H44-L607, A45-L607, G46-L607, L47-L607, G48-L607, R49-L607, T50-L607, G51-L607, V52-L607, L53-L607, I54-L607, A55-L607, C56-L607, Y57-L607, L58-L607, V59-L607, F60-L607, A61-L607, T62-L607, R63-L607, M64-L607, T65-L607, A66-L607, D67-L607, Q68-L607, A69-L607, I70-L607, I71-L607, F72-L607, V73-L607, R74-L607, A75-L607, K76-L607, R77-L607,
20 P78-L607, N79-L607, S80-L607, I81-L607, Q82-L607, T83-L607, R84-L607, G85-L607, Q86-L607, L87-L607, L88-L607, C89-L607, V90-L607, R91-L607, E92-L607, F93-L607, T94-L607, Q95-L607, F96-L607, L97-L607, T98-L607, P99-L607, L100-L607, R101-L607, N102-L607, I103-L607, F104-L607, S105-L607, C106-L607, C107-L607, D108-L607, P109-L607, K110-L607, A111-L607, H112-L607, A113-
25 L607, V114-L607, T115-L607, L116-L607, P117-L607, Q118-L607, Y119-L607, L120-L607, I121-L607, R122-L607, Q123-L607, R124-L607, H125-L607, L126-L607, L127-L607, H128-L607, G129-L607, Y130-L607, E131-L607, A132-L607, R133-L607, L134-L607, L135-L607, K136-L607, H137-L607, V138-L607, P139-L607, K140-L607, I141-L607, I142-L607, H143-L607, L144-L607, V145-L607,
30 C146-L607, K147-L607, L148-L607, L149-L607, L150-L607, D151-L607, L152-L607, A153-L607, E154-L607, N155-L607, R156-L607, P157-L607, V158-L607, M159-L607, M160-L607, K161-L607, D162-L607, V163-L607, S164-L607, E165-L607, G166-L607, P167-L607, G168-L607, L169-L607, S170-L607, A171-L607, E172-L607, I173-L607, E174-L607, K175-L607, T176-L607, M177-L607, S178-
35 L607, E179-L607, M180-L607, V181-L607, T182-L607, M183-L607, Q184-L607, L185-L607, D186-L607, K187-L607, E188-L607, L189-L607, L190-L607, R191-

- 5 L607, H192-L607, D193-L607, S194-L607, D195-L607, V196-L607, S197-L607, N198-L607, P199-L607, P200-L607, N201-L607, P202-L607, T203-L607, A204-L607, V205-L607, A206-L607, A207-L607, D208-L607, F209-L607, D210-L607, N211-L607, R212-L607, G213-L607, M214-L607, I215-L607, F216-L607, S217-L607, N218-L607, E219-L607, Q220-L607, Q221-L607, F222-L607, D223-L607,
- 10 P224-L607, L225-L607, W226-L607, K227-L607, R228-L607, R229-L607, N230-L607, V231-L607, E232-L607, C233-L607, L234-L607, Q235-L607, P236-L607, L237-L607, T238-L607, H239-L607, L240-L607, K241-L607, R242-L607, R243-L607, L244-L607, S245-L607, Y246-L607, S247-L607, D248-L607, S249-L607, D250-L607, L251-L607, K252-L607, R253-L607, A254-L607, E255-L607, N256-
- 15 L607, L257-L607, L258-L607, E259-L607, Q260-L607, G261-L607, E262-L607, T263-L607, P264-L607, Q265-L607, T266-L607, V267-L607, P268-L607, A269-L607, Q270-L607, I271-L607, L272-L607, V273-L607, G274-L607, H275-L607, K276-L607, P277-L607, R278-L607, Q279-L607, Q280-L607, K281-L607, L282-L607, I283-L607, S284-L607, H285-L607, C286-L607, Y287-L607, I288-L607,
- 20 P289-L607, Q290-L607, S291-L607, P292-L607, E293-L607, P294-L607, D295-L607, L296-L607, H297-L607, K298-L607, E299-L607, A300-L607, L301-L607, V302-L607, R303-L607, S304-L607, T305-L607, L306-L607, S307-L607, F308-L607, W309-L607, S310-L607, Q311-L607, S312-L607, K313-L607, F314-L607, G315-L607, G316-L607, L317-L607, E318-L607, G319-L607, L320-L607, K321-
- 25 L607, D322-L607, N323-L607, G324-L607, S325-L607, P326-L607, I327-L607, F328-L607, H329-L607, G330-L607, R331-L607, I332-L607, I333-L607, P334-L607, K335-L607, E336-L607, A337-L607, Q338-L607, Q339-L607, S340-L607, G341-L607, A342-L607, F343-L607, S344-L607, A345-L607, D346-L607, V347-L607, S348-L607, G349-L607, S350-L607, H351-L607, S352-L607, P353-L607,
- 30 G354-L607, E355-L607, P356-L607, V357-L607, S358-L607, P359-L607, S360-L607, F361-L607, A362-L607, N363-L607, V364-L607, H365-L607, K366-L607, D367-L607, P368-L607, N369-L607, P370-L607, A371-L607, H372-L607, Q373-L607, Q374-L607, V375-L607, S376-L607, H377-L607, C378-L607, Q379-L607, C380-L607, K381-L607, T382-L607, H383-L607, G384-L607, V385-L607, G386-
- 35 L607, S387-L607, P388-L607, G389-L607, S390-L607, V391-L607, R392-L607, Q393-L607, N394-L607, S395-L607, R396-L607, T397-L607, P398-L607, R399-

5 L607, S400-L607, P401-L607, L402-L607, D403-L607, C404-L607, G405-L607,
S406-L607, S407-L607, P408-L607, K409-L607, A410-L607, Q411-L607, F412-
L607, L413-L607, V414-L607, E415-L607, H416-L607, E417-L607, T418-L607,
Q419-L607, D420-L607, S421-L607, K422-L607, D423-L607, L424-L607, S425-
L607, E426-L607, A427-L607, A428-L607, S429-L607, H430-L607, S431-L607,
10 A432-L607, L433-L607, Q434-L607, S435-L607, E436-L607, L437-L607, S438-
L607, A439-L607, E440-L607, A441-L607, R442-L607, R443-L607, I444-L607,
L445-L607, A446-L607, A447-L607, K448-L607, A449-L607, L450-L607, A451-
L607, N452-L607, L453-L607, N454-L607, E455-L607, S456-L607, V457-L607,
E458-L607, K459-L607, E460-L607, E461-L607, L462-L607, K463-L607, R464-
15 L607, K465-L607, V466-L607, E467-L607, M468-L607, W469-L607, Q470-L607,
K471-L607, E472-L607, L473-L607, N474-L607, S475-L607, R476-L607, D477-
L607, G478-L607, A479-L607, W480-L607, E481-L607, R482-L607, I483-L607,
C484-L607, G485-L607, E486-L607, R487-L607, D488-L607, P489-L607, F490-
L607, I491-L607, L492-L607, C493-L607, S494-L607, L495-L607, M496-L607,
20 W497-L607, S498-L607, W499-L607, V500-L607, E501-L607, Q502-L607, L503-
L607, K504-L607, E505-L607, P506-L607, V507-L607, I508-L607, T509-L607,
K510-L607, E511-L607, D512-L607, V513-L607, D514-L607, M515-L607, L516-
L607, V517-L607, D518-L607, R519-L607, R520-L607, A521-L607, D522-L607,
A523-L607, A524-L607, E525-L607, A526-L607, L527-L607, F528-L607, L529-
25 L607, L530-L607, E531-L607, K532-L607, G533-L607, Q534-L607, H535-L607,
Q536-L607, T537-L607, I538-L607, L539-L607, C540-L607, V541-L607, L542-
L607, H543-L607, C544-L607, I545-L607, V546-L607, N547-L607, L548-L607,
Q549-L607, T550-L607, I551-L607, P552-L607, V553-L607, D554-L607, V555-
L607, E556-L607, E557-L607, A558-L607, F559-L607, L560-L607, A561-L607,
30 H562-L607, A563-L607, I564-L607, K565-L607, A566-L607, F567-L607, T568-
L607, K569-L607, V570-L607, N571-L607, F572-L607, D573-L607, S574-L607,
E575-L607, N576-L607, G577-L607, P578-L607, T579-L607, V580-L607, Y581-
L607, N582-L607, T583-L607, L584-L607, K585-L607, K586-L607, I587-L607,
F588-L607, K589-L607, H590-L607, T591-L607, L592-L607, E593-L607, E594-
35 L607, K595-L607, R596-L607, K597-L607, M598-L607, T599-L607, K600-L607,
and/or D601-L607 of SEQ ID NO:150. Polynucleotide sequences encoding these

5 polypeptides are also provided. The present invention also encompasses the use of these N-terminal BMY_HPP1 deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following C-terminal BMY_HPP1 deletion polypeptides are encompassed by the present invention: M1-L607, M1-G606, M1-P605, M1-K604, M1-P603, M1-G602, M1-D601, M1-K600, M1-T599, M1-M598, M1-K597, M1-R596, M1-K595, M1-E594, M1-E593, M1-L592, M1-T591, M1-H590, M1-K589, M1-F588, M1-I587, M1-K586, M1-K585, M1-L584, M1-T583, M1-N582, M1-Y581, M1-V580, M1-T579, M1-P578, M1-G577, M1-N576, M1-E575, M1-S574, M1-D573, M1-F572, M1-N571, M1-V570, M1-K569, M1-T568, M1-F567, M1-A566, M1-K565, M1-I564, M1-A563, M1-H562, M1-A561, M1-L560, M1-F559, M1-A558, M1-E557, M1-E556, M1-V555, M1-D554, M1-V553, M1-P552, M1-I551, M1-T550, M1-Q549, M1-L548, M1-N547, M1-V546, M1-I545, M1-C544, M1-H543, M1-L542, M1-V541, M1-C540, M1-L539, M1-I538, M1-T537, M1-Q536, M1-H535, M1-Q534, M1-G533, M1-K532, M1-E531, M1-L530, M1-L529, M1-F528, M1-L527, M1-A526, M1-E525, M1-A524, M1-A523, M1-D522, M1-A521, M1-R520, M1-R519, M1-D518, M1-V517, M1-L516, M1-M515, M1-D514, M1-V513, M1-D512, M1-E511, M1-K510, M1-T509, M1-I508, M1-V507, M1-P506, M1-E505, M1-K504, M1-L503, M1-Q502, M1-E501, M1-V500, M1-W499, M1-S498, M1-W497, M1-M496, M1-L495, M1-S494, M1-C493, M1-L492, M1-I491, M1-F490, M1-P489, M1-D488, M1-R487, M1-E486, M1-G485, M1-C484, M1-I483, M1-R482, M1-E481, M1-W480, M1-A479, M1-G478, M1-D477, M1-R476, M1-S475, M1-N474, M1-L473, M1-E472, M1-K471, M1-Q470, M1-W469, M1-M468, M1-E467, M1-V466, M1-K465, M1-R464, M1-K463, M1-L462, M1-E461, M1-E460, M1-K459, M1-E458, M1-V457, M1-S456, M1-E455, M1-N454, M1-L453, M1-N452, M1-A451, M1-L450, M1-A449, M1-K448, M1-A447, M1-A446, M1-L445, M1-I444, M1-R443, M1-R442, M1-A441, M1-E440, M1-A439, M1-S438, M1-L437, M1-E436, M1-S435, M1-Q434, M1-L433, M1-A432, M1-S431, M1-H430, M1-S429, M1-A428, M1-A427, M1-E426, M1-S425, M1-L424, M1-D423, M1-K422, M1-S421, M1-D420, M1-Q419, M1-T418, M1-E417, M1-H416, M1-E415, M1-V414, M1-L413, M1-F412, M1-Q411, M1-A410, M1-K409, M1-P408, M1-S407, M1-S406, M1-G405, M1-C404, M1-D403, M1-L402, M1-P401,

5 M1-S400, M1-R399, M1-P398, M1-T397, M1-R396, M1-S395, M1-N394, M1-Q393,
M1-R392, M1-V391, M1-S390, M1-G389, M1-P388, M1-S387, M1-G386, M1-
V385, M1-G384, M1-H383, M1-T382, M1-K381, M1-C380, M1-Q379, M1-C378,
M1-H377, M1-S376, M1-V375, M1-Q374, M1-Q373, M1-H372, M1-A371, M1-
P370, M1-N369, M1-P368, M1-D367, M1-K366, M1-H365, M1-V364, M1-N363,
10 M1-A362, M1-F361, M1-S360, M1-P359, M1-S358, M1-V357, M1-P356, M1-E355,
M1-G354, M1-P353, M1-S352, M1-H351, M1-S350, M1-G349, M1-S348, M1-
V347, M1-D346, M1-A345, M1-S344, M1-F343, M1-A342, M1-G341, M1-S340,
M1-Q339, M1-Q338, M1-A337, M1-E336, M1-K335, M1-P334, M1-I333, M1-I332,
M1-R331, M1-G330, M1-H329, M1-F328, M1-I327, M1-P326, M1-S325, M1-G324,
15 M1-N323, M1-D322, M1-K321, M1-L320, M1-G319, M1-E318, M1-L317, M1-
G316, M1-G315, M1-F314, M1-K313, M1-S312, M1-Q311, M1-S310, M1-W309,
M1-F308, M1-S307, M1-L306, M1-T305, M1-S304, M1-R303, M1-V302, M1-L301,
M1-A300, M1-E299, M1-K298, M1-H297, M1-L296, M1-D295, M1-P294, M1-
E293, M1-P292, M1-S291, M1-Q290, M1-P289, M1-I288, M1-Y287, M1-C286, M1-
20 H285, M1-S284, M1-I283, M1-L282, M1-K281, M1-Q280, M1-Q279, M1-R278,
M1-P277, M1-K276, M1-H275, M1-G274, M1-V273, M1-L272, M1-I271, M1-
Q270, M1-A269, M1-P268, M1-V267, M1-T266, M1-Q265, M1-P264, M1-T263,
M1-E262, M1-G261, M1-Q260, M1-E259, M1-L258, M1-L257, M1-N256, M1-
E255, M1-A254, M1-R253, M1-K252, M1-L251, M1-D250, M1-S249, M1-D248,
25 M1-S247, M1-Y246, M1-S245, M1-L244, M1-R243, M1-R242, M1-K241, M1-
L240, M1-H239, M1-T238, M1-L237, M1-P236, M1-Q235, M1-L234, M1-C233,
M1-E232, M1-V231, M1-N230, M1-R229, M1-R228, M1-K227, M1-W226, M1-
L225, M1-P224, M1-D223, M1-F222, M1-Q221, M1-Q220, M1-E219, M1-N218,
M1-S217, M1-F216, M1-I215, M1-M214, M1-G213, M1-R212, M1-N211, M1-
30 D210, M1-F209, M1-D208, M1-A207, M1-A206, M1-V205, M1-A204, M1-T203,
M1-P202, M1-N201, M1-P200, M1-P199, M1-N198, M1-S197, M1-V196, M1-
D195, M1-S194, M1-D193, M1-H192, M1-R191, M1-L190, M1-L189, M1-E188,
M1-K187, M1-D186, M1-L185, M1-Q184, M1-M183, M1-T182, M1-V181, M1-
M180, M1-E179, M1-S178, M1-M177, M1-T176, M1-K175, M1-E174, M1-I173,
35 M1-E172, M1-A171, M1-S170, M1-L169, M1-G168, M1-P167, M1-G166, M1-
E165, M1-S164, M1-V163, M1-D162, M1-K161, M1-M160, M1-M159, M1-V158,

5 M1-P157, M1-R156, M1-N155, M1-E154, M1-A153, M1-L152, M1-D151, M1-L150, M1-L149, M1-L148, M1-K147, M1-C146, M1-V145, M1-L144, M1-H143, M1-I142, M1-I141, M1-K140, M1-P139, M1-V138, M1-H137, M1-K136, M1-L135, M1-L134, M1-R133, M1-A132, M1-E131, M1-Y130, M1-G129, M1-H128, M1-L127, M1-L126, M1-H125, M1-R124, M1-Q123, M1-R122, M1-I121, M1-L120,
 10 M1-Y119, M1-Q118, M1-P117, M1-L116, M1-T115, M1-V114, M1-A113, M1-H112, M1-A111, M1-K110, M1-P109, M1-D108, M1-C107, M1-C106, M1-S105, M1-F104, M1-I103, M1-N102, M1-R101, M1-L100, M1-P99, M1-T98, M1-L97, M1-F96, M1-Q95, M1-T94, M1-F93, M1-E92, M1-R91, M1-V90, M1-C89, M1-L88, M1-L87, M1-Q86, M1-G85, M1-R84, M1-T83, M1-Q82, M1-I81, M1-S80, M1-N79,
 15 M1-P78, M1-R77, M1-K76, M1-A75, M1-R74, M1-V73, M1-F72, M1-I71, M1-I70, M1-A69, M1-Q68, M1-D67, M1-A66, M1-T65, M1-M64, M1-R63, M1-T62, M1-A61, M1-F60, M1-V59, M1-L58, M1-Y57, M1-C56, M1-A55, M1-I54, M1-L53, M1-V52, M1-G51, M1-T50, M1-R49, M1-G48, M1-L47, M1-G46, M1-A45, M1-H44, M1-C43, M1-H42, M1-I41, M1-A40, M1-V39, M1-K38, M1-G37, M1-E36,
 20 M1-Q35, M1-L34, M1-A33, M1-F32, M1-T31, M1-M30, M1-V29, M1-K28, M1-V27, M1-M26, M1-D25, M1-L24, M1-I23, M1-T22, M1-T21, M1-L20, M1-S19, M1-A18, M1-V17, M1-G16, M1-Y15, M1-D14, M1-K13, M1-W12, M1-G11, M1-F10, M1-N9, M1-Y8, and/or M1-F7 of SEQ ID NO:150. Polynucleotide sequences encoding these polypeptides are also provided. The present invention also
 25 encompasses the use of these C-terminal BMY_HPP1 deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following polypeptide is encompassed by the present invention:

MEAGIYFNFGWKDYGVASLTTIDMVKVMTFALQEGKVIHCHAGLGRTGVLI
 30 AYLVFATRMTADQAIIVRAKRPNSIQTRGQLCVREFTQFLTPLRNISCCDPKA
 HAVTLPQYIRQRHLLHGYEARLLHVPKIIHLVCKLLDAENRPVMMKDVSEG
 PLSAEIEKTMSEMVTMLDKELLRHDSVSNPNPTAVAADFDNRGMISNEQQF
 DPLWKRNRVCLQPLTHLKRRLSYSSDLKRAENLLEQGETQTVPAQILVGHKP
 RQKLISHCYIPQSPEPDHKEALVRSTLSFWSQKFGGLEGLKDNGSPIHGRIPKE
 35 AQQSGAFADVSGSHSPGEPVSPFANVHKDPNPAHQVHCQCKTHGVGSPGS
 VQNSRTPRSPLDCGSSKAQFLVEHETQDSKDSEAASHSALQSELSAARRILAA

5 KALANLNEVEKEELKRKVMWQKLNSRDGAWERICGERPFILCSLMWSWVE
(SEQ ID NO:153). Polynucleotides encoding these polypeptides are also provided.
The present invention also encompasses the use of this polypeptide as an
immunogenic and/or antigenic epitope as described elsewhere herein.

In preferred embodiments, the following BMY_HPP1 phosphatase active site
10 domain amino acid substitutions are encompassed by the present invention: wherein
M1 is substituted with either an A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or
Y; wherein E2 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S,
T, V, W, or Y; wherein A3 is substituted with either a C, D, E, F, G, H, I, K, L, M, N,
P, Q, R, S, T, V, W, or Y; wherein G4 is substituted with either an A, C, D, E, F, H, I,
15 K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein I5 is substituted with either an A, C,
D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Y6 is substituted with
either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein F7 is
substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y;
wherein N8 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T,
20 V, W, or Y; wherein F9 is substituted with either an A, C, D, E, G, H, I, K, L, M, N,
P, Q, R, S, T, V, W, or Y; wherein G10 is substituted with either an A, C, D, E, F, H,
I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein W11 is substituted with either an A,
C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; wherein K12 is substituted
with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein D13
25 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y;
wherein Y14 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R,
S, T, V, or W; wherein G15 is substituted with either an A, C, D, E, F, H, I, K, L, M,
N, P, Q, R, S, T, V, W, or Y; wherein V16 is substituted with either an A, C, D, E, F,
G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein A17 is substituted with either a
30 C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S18 is substituted
with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein L19
is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y;
wherein T20 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R,
S, V, W, or Y; wherein T21 is substituted with either an A, C, D, E, F, G, H, I, K, L,
35 M, N, P, Q, R, S, V, W, or Y; wherein I22 is substituted with either an A, C, D, E, F,
G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein D23 is substituted with either an

- 5 A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein M24 is substituted with either an A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; wherein V25 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein K26 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V27 is substituted with either an A, C, D, E, F, G, H, I, K, L,
- 10 M, N, P, Q, R, S, T, W, or Y; wherein M28 is substituted with either an A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; wherein T29 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, or Y; wherein F30 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A31 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y;
- 15 wherein L32 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein Q33 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; wherein E34 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein G35 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein K36 is substituted
- 20 with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V37 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein I38 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein H39 is substituted with either an A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein C40 is substituted with either an A, D, E, F, G,
- 25 H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein H41 is substituted with either an A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A42 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein G43 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L44 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S,
- 30 T, V, W, or Y; wherein G45 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein R46 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein T47 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, or Y; wherein G48 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V49
- 35 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein L50 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S,

5 T, V, W, or Y; wherein I51 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A52 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Y53 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein L54 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein V55
 10 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein F56 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or wherein A57 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y of SEQ ID NO:150, in addition to any combination thereof. The present invention also encompasses the use of these BMY_HPP1
 15 phosphatase active site domain amino acid substituted polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following BMY_HPP1 phosphatase active site domain conservative amino acid substitutions are encompassed by the present invention: wherein M1 is substituted with either an A, G, S, or T; wherein E2 is
 20 substituted with a D; wherein A3 is substituted with either a G, I, L, M, S, T, or V; wherein G4 is substituted with either an A, M, S, or T; wherein I5 is substituted with either an A, V, or L; wherein Y6 is either an F, or W; wherein F7 is substituted with either a W, or Y; wherein N8 is substituted with a Q; wherein F9 is substituted with either a W, or Y; wherein G10 is substituted with either an A, M, S, or T; wherein
 25 W11 is either an F, or Y; wherein K12 is substituted with either a R, or H; wherein D13 is substituted with an E; wherein Y14 is either an F, or W; wherein G15 is substituted with either an A, M, S, or T; wherein V16 is substituted with either an A, I, or L; wherein A17 is substituted with either a G, I, L, M, S, T, or V; wherein S18 is substituted with either an A, G, M, or T; wherein L19 is substituted with either an A,
 30 I, or V; wherein T20 is substituted with either an A, G, M, or S; wherein T21 is substituted with either an A, G, M, or S; wherein I22 is substituted with either an A, V, or L; wherein D23 is substituted with an E; wherein M24 is substituted with either an A, G, S, or T; wherein V25 is substituted with either an A, I, or L; wherein K26 is substituted with either a R, or H; wherein V27 is substituted with either an A, I, or L;
 35 wherein M28 is substituted with either an A, G, S, or T; wherein T29 is substituted with either an A, G, M, or S; wherein F30 is substituted with either a W, or Y;

5 wherein A31 is substituted with either a G, I, L, M, S, T, or V; wherein L32 is substituted with either an A, I, or V; wherein Q33 is substituted with a N; wherein E34 is substituted with a D; wherein G35 is substituted with either an A, M, S, or T; wherein K36 is substituted with either a R, or H; wherein V37 is substituted with either an A, I, or L; wherein I38 is substituted with either an A, V, or L; wherein H39
 10 is substituted with either a K, or R; wherein C40 is a C; wherein H41 is substituted with either a K, or R; wherein A42 is substituted with either a G, I, L, M, S, T, or V; wherein G43 is substituted with either an A, M, S, or T; wherein L44 is substituted with either an A, I, or V; wherein G45 is substituted with either an A, M, S, or T; wherein R46 is substituted with either a K, or H; wherein T47 is substituted with
 15 either an A, G, M, or S; wherein G48 is substituted with either an A, M, S, or T; wherein V49 is substituted with either an A, I, or L; wherein L50 is substituted with either an A, I, or V; wherein I51 is substituted with either an A, V, or L; wherein A52 is substituted with either a G, I, L, M, S, T, or V; wherein Y53 is either an F, or W; wherein L54 is substituted with either an A, I, or V; wherein V55 is substituted with
 20 either an A, I, or L; wherein F56 is substituted with either a W, or Y; and/or wherein A57 is substituted with either a G, I, L, M, S, T, or V of SEQ ID NO:150 in addition to any combination thereof. Other suitable substitutions within the BMY_HPP1 phosphatase active site domain are encompassed by the present invention and are referenced elsewhere herein. The present invention also encompasses the use of these
 25 BMY_HPP1 phosphatase active site domain conservative amino acid substituted polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In addition, the present invention also encompasses BMY_HPP1 polypeptides resulting from alternative initiating start codon positions of the BMY_HPP1
 30 polynucleotide (SEQ ID NO:149).

In preferred embodiments, the following polypeptide resulting from the start codon beginning at nucleotide 31 of SEQ ID NO:149 is encompassed by the present invention:

35 MQVQDATRRPSAVRFLSSFLQRRHSTSDPVLRLQQARRGSGLGSGSATKLLSSSSLQVMVAV
 SSVSHAEGNPTFPERKRNLERPTPKYTKVGERLRHVIPGHMACSMACGGRACKYENPARWSE
 QEQAIKGVYSSWVTDNILAMARPSSELLEKYHIIDQFLSHGIKTINLQRPGEHASCNGNPLEQES
 GFTYLPEAFMEAGIYFYNFVGWKDYGVASLTITLDMVKVMTFALQEGKVAIHCHAGLGRTGVL

5 IACYLVFATRMTADQAIIFVRAKRPNSIQTRGQLLCVREFTQFLTPLRNIFSCCDPKAHAVTLPQ
 YLIRQRHLLHGYEARLLKHVPKIIHLVCKLLLDLAENRPVMMKDVSEGPGLSAEIEKTMSEMV
 TMQLDKELLRHDSVSNPPNPTAVAADFDNRGMIFSNEQQFDPLWKRRNVECLQPLTHLKRR
 LSYSDDLKRAENLLEQGETPQTVPAQILVGHKPRQKQLISHCYIPQSPEPDLHKEALVRSTLSF
 WSQSKFGGLEGLKDNGSPIFHGRIPKEAQQSGAFSADVSGSHSPGEPVSPSFANVHKDPNPAH
 10 QQVSHCQCKTHGVGSPGSVRQNSRTPRSPLDCGSSPKAQFLVEHETQDSKDLSEAASHALQS
 ELSAEARRILAAKALANL NESVEKEELKRKVEMWQKELNSRDGAWERICGERDPFILCSLMW
 SWVEQLKEPVITKEDVDMLVDRRADAAEALFLEKGGHQHTILCVLHCIVNLQTPVDVEEAF
 AHAIKAFKVNFDSENGPTVYNTLKKIFKHTLEEKRKMTKDGPKPGL (SEQ ID NO:175).
 Polynucleotides encoding these polypeptides are also provided. The present invention
 15 also encompasses the use of this polypeptide as an immunogenic and/or antigenic
 epitope as described elsewhere herein.

In preferred embodiments, the following polypeptide resulting from the start
 codon beginning at nucleotide 208 of SEQ ID NO:149 is encompassed by the present
 invention:

20 MVAVSSVSHAEGNPTFPERKRNLERPTPKYTKVGERLRHVIPGHMACSMACG
 GRACKYENPARWSESEQEQAIGVYSSWVTDNILAMARPSSELLEKYHIIDQFLS
 HGIKTIINLQRPGEHASCNP LEQESGFTYLPEAFMEAGIYFYNFGWKDYGVA
 SLTTILDMVKVMTFALQEGKVAIHCHAGLGRTGVLIACYLVFATRMTADQAI
 IFVRAKRPNSIQTRGQLLCVREFTQFLTPLRNIFSCCDPKAHAVTLPQYLRQR
 25 HLLHGYEARLLKHVPKIIHLVCKLLLDLAENRPVMMKDVSEGPGLSAEIEKT
 MSEMVTMQLDKELLRHDSVSNPPNPTAVAADFDNRGMIFSNEQQFDPLWK
 RRNVECLQPLTHLKRRLSYSDDLKRAENLLEQGETPQTVPAQILVGHKPRQ
 QKLISHCYIPQSPEPDLHKEALVRSTLSFWSQSKFGGLEGLKDNGSPIFHGRIP
 KEAQQSGAFSADVSGSHSPGEPVSPSFANVHKDPNPAHQQVSHCQCKTHGVG
 30 SPGSVRQNSRTPRSPLDCGSSPKAQFLVEHETQDSKDLSEAASHALQSELSAE
 ARRILAAKALANL NESVEKEELKRKVEMWQKELNSRDGAWERICGERDPFIL
 CSLMWSWVEQLKEPVITKEDVDMLVDRRADAAEALFLEKGGHQHTILCVLH
 CIVNLQTPVDVEEAF LAHAIKAFKVNFDSENGPTVYNTLKKIFKHTLEEKRK
 MTKDGPKPGL (SEQ ID NO:176). Polynucleotides encoding these polypeptides are
 35 also provided. The present invention also encompasses the use of this polypeptide as
 an immunogenic and/or antigenic epitope as described elsewhere herein.

In preferred embodiments, the following polypeptide resulting from the start
 codon beginning at nucleotide 352 of SEQ ID NO:149 is encompassed by the present

5 invention:

MACGGRACKYENPARWSEQEQAIGVYSSWVTDNILAMARPSSELLEKYHII
DQFLSHGIKTIINLQRPGEHASCNPLEQESGFTYLPEAFMEAGIYFYNFGWK
DYGVASLTITLDMVKVMTFALQEGKVAIHCHAGLGRTGVLIACYLVFATRM
TADQAIIFVRAKRPNSIQTRGQLLCVREFTQFLTPLRNIFSCCDPKAHAVTLPQ
10 YLIRQRHLLHGYEARLLKHVPKIIHLVCKLLDLAENRPVMMKDVSEGPGLS
AEIEKTMSEMVTMQLDKELLRHDSVSNPPNPTAVAADFNRGMIFSNEQQF
DPLWKRRNVECLQPLTHLKRRLSYSDSDLKRAENLLEQGETPQTVPAQILVG
HKPRQQKLISHCYIPQSPEPDLHKEALVRSTLSFWSQSKFGGLEGLKDNGSPIF
HGRIIPKEAQQSGAFSADVSGSHSPGEPVSPSFANVHKDPNPAHQQVSHCQCK
15 THGVGSPGSVRQNSRTPRSPLDCGSSPKAQFLVEHETQDSKDLSEAASHSALQ
SELSAEARRILAAKALANL NESVEKEELKRKVEMWQKELNSRDGAWERICGE
RDPFILCSLMWSWVEQLKEPVITKEDVDMLVDRRADAAEALFLEKGQHQT
LCVLHCIVNLQTIPVDVEEAFLAHAIAKFTKVNFDSENGPTVYNTLKKIFKHTL
EEKRKMTKDGPKEPGL (SEQ ID NO:177). Polynucleotides encoding these
20 polypeptides are also provided. The present invention also encompasses the use of
this polypeptide as an immunogenic and/or antigenic epitope as described elsewhere
herein.

In preferred embodiments, the following polypeptide resulting from the start
codon beginning at nucleotide 463 of SEQ ID NO:149 is encompassed by the present

25 invention:

MARPSSELLEKYHIIDQFLSHGIKTIINLQRPGEHASCNPLEQESGFTYLPEAF
MEAGIYFYNFGWKDYGVASLTITLDMVKVMTFALQEGKVAIHCHAGLGRTG
VLIACYLVFATRM TADQAIIFVRAKRPNSIQTRGQLLCVREFTQFLTPLRNIFSC
CDPKAHAVTLPQYLIRQRHLLHGYEARLLKHVPKIIHLVCKLLDLAENRPV
30 MMKDVSEGPGLSAEIEKTMSEMVTMQLDKELLRHDSVSNPPNPTAVAADF
DNRGMIFSNEQQFDPLWKRRNVECLQPLTHLKRRLSYSDSDLKRAENLLEQG
ETPQTVPAQILVGHKPRQQKLISHCYIPQSPEPDLHKEALVRSTLSFWSQSKFG
GLEGLKDNGSPIFHGRIIPKEAQQSGAFSADVSGSHSPGEPVSPSFANVHKDPN
PAHQQVSHCQCKTHGVGSPGSVRQNSRTPRSPLDCGSSPKAQFLVEHETQDS
35 KDLSEAASHSALQSELSAEARRILAAKALANL NESVEKEELKRKVEMWQKEL
NSRDGAWERICGERDPFILCSLMWSWVEQLKEPVITKEDVDMLVDRRADAA

5 EALFLLEKGQHQTLICVLHCIVNLQTIPVDVEEAFLAHAIAKFTKVNFDSENGP
TVYNTLKKIFKHTLEEKRKMTKDGPKPGL (SEQ ID NO:178). Polynucleotides
encoding these polypeptides are also provided. The present invention also
encompasses the use of this polypeptide as an immunogenic and/or antigenic epitope
as described elsewhere herein.

10 In preferred embodiments, the present invention encompasses a
polynucleotide lacking the initiating start codon, in addition to, the resulting encoded
polypeptide of BMY_HPP1. Specifically, the present invention encompasses the
polynucleotide corresponding to nucleotides 631 thru 2448 of SEQ ID NO:149, and
the polypeptide corresponding to amino acids 2 thru 607 of SEQ ID NO:150. Also
15 encompassed are recombinant vectors comprising said encoding sequence, and host
cells comprising said vector.

The present invention also provides a three-dimensional homology model of
the BMY_HPP1 polypeptide (see Figure 28) representing amino acids M1 to E301 of
BMY_HPP1 (SEQ ID NO:150). A three-dimensional homology model can be
20 constructed on the basis of the known structure of a homologous protein (Greer et al,
1991, Lesk, et al, 1992, Cardozo, et al, 1995, Yuan, et al, 1995). The homology model
of the BMY_HPP1 polypeptide, corresponding to amino acid residues M1 to E301 of
SEQ ID NO:150, was based upon the homologous structure of laax, a Human
Protein Tyrosine Phosphatase Complex (residues D11-N321; Protein Data Bank, PDB
25 entry laax chain A; Genbank Accession No. gi|2981942; SEQ ID NO:206) and is
defined by the set of structural coordinates set forth in Table VIII herein.

Homology models are useful when there is no experimental information
available on the protein of interest. A 3-dimensional model can be constructed on the
basis of the known structure of a homologous protein (Greer *et. al.*, 1991, Lesk, *et.*
30 *al.*, 1992, Cardozo, *et. al.*, 1995, Sali, *et. al.*, 1995).

Those of skill in the art will understand that a homology model is constructed
on the basis of first identifying a template, or, protein of known structure which is
similar to the protein without known structure. This can be accomplished through
pairwise alignment of sequences using such programs as FASTA (Pearson, *et. al.*
35 1990) and BLAST (Altschul, *et. al.*, 1990). In cases where sequence similarity is high
(greater than 30 %), these pairwise comparison methods may be adequate. Likewise,

5 multiple sequence alignments or profile-based methods can be used to align a query sequence to an alignment of multiple (structurally and biochemically) related proteins. When the sequence similarity is low, more advanced techniques are used such as fold recognition (protein threading; Hendlich, *et. al.*, 1990), where the compatibility of a particular sequence with the 3-dimensional fold of a potential template protein is
10 gauged on the basis of a knowledge-based potential. Following the initial sequence alignment, the query template can be optimally aligned by manual manipulation or by incorporation of other features (motifs, secondary structure predictions, and allowed sequence conservation). Next, structurally conserved regions can be identified and are used to construct the core secondary structure (Sali, *et. al.*, 1995) elements in the three
15 dimensional model. Variable regions, called "unconserved regions" and loops can be added using knowledge-based techniques. The complete model with variable regions and loops can be refined performing forcefield calculations (Sali, *et. al.*, 1995, Cardozo, *et. al.*, 1995).

Protein threading and molecular modeling of BMY_HPP1 suggested that a
20 portion of BMY_HPP1 (residues M1 to E301) had a three dimensional fold similar to that of 1aax, a Human Protein Tyrosine Phosphatase Complex (residues D11-N321; Protein Data Bank, PDB entry 1aax chain A; Genbank Accession No. gi|2981942; SEQ ID NO:206). Based on sequence, structure and known phosphatase signature sequences, BMY_HPP1 is a novel tyrosine specific phosphatase.

25 For BMY_HPP1, the pairwise alignment method FASTA (Pearson, *et. al.* 1990) and fold recognition methods (protein threading) generated identical sequence alignments for a portion (residues M1 to E301) of BMY_HPP1 aligned with the sequence of 1aax a tyrosine specific phosphatase (residues D11-N321 ; Protein Data Bank, PDB entry 1aax chain 'A; Genbank Accession No. gi|2981942; SEQ ID
30 NO:206). The alignment of BMY_HPP1 with PDB entry 1aax is set forth in Figure 27. In this invention, the homology model of BMY_HPP1 was derived from the sequence alignment set forth in Figure 27 (residues D11-N321 of SEQ ID NO:206). An overall atomic model including plausible sidechain orientations was generated using the program LOOK (Levitt 1992). The three dimensional model for
35 BMY_HPP1 is defined by the set of structure coordinates as set forth in Table VIII and is shown in Figure 28 rendered by backbone secondary structures.

5 In order to recognize errors in three-dimensional structure, knowledge based mean fields can be used to judge the quality of protein folds (Sippl 1993). The methods can be used to recognize misfolded structures as well as faulty parts of structural models. The technique generates an energy graph where the energy distribution for a given protein fold is displayed on the y-axis and residue position in the protein fold is displayed on the x-axis. The knowledge based mean fields compose a force field derived from a set of globular protein structures taken as a subset from the Protein Data Bank (Bernstein et. al. 1977). To analyze the quality of a model the energy distribution is plotted and compared to the energy distribution of the template from which the model was generated. Figure 29 shows the energy graph for the BMY_HPP1 model (dotted line) and the template (1aax, a tyrosine specific phosphatase) from which the model was generated. It is clear that the model has slightly higher energies in the C-terminal region while the N-terminal region appears to be "native-like". This graph supports the motif and sequence alignments in confirming that the three dimensional structure coordinates of BMY_HPP1 are an accurate and useful representation for the polypeptide.

 The term "structure coordinates" refers to Cartesian coordinates generated from the building of a homology model.

 Those of skill in the art will understand that a set of structure coordinates for a protein is a relative set of points that define a shape in three dimensions. Thus, it is possible that an entirely different set of coordinates could define a similar or identical shape. Moreover, slight variations in the individual coordinates, as emanate from generation of similar homology models using different alignment templates (i.e., other than the structure coordinates of 1aax), and/or using different methods in generating the homology model, will have minor effects on the overall shape. Variations in coordinates may also be generated because of mathematical manipulations of the structure coordinates. For example, the structure coordinates set forth in Table VIII and shown in Figure 28 could be manipulated by fractionalization of the structure coordinates; integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above.

 Various computational analyses are therefore necessary to determine whether a molecule or a portion thereof is sufficiently similar to all or parts of BMY_HPP1

5 described above as to be considered the same. Such analyses may be carried out in current software applications, such as INSIGHTII (Accelrys Inc., San Diego, CA) version 2000 as described in the User's Guide, online (www.accelrys.com) or software applications available in the SYBYL software suite (Tripos Inc., St. Louis, MO).

Using the superimposition tool in the program INSIGHTII comparisons can be
10 made between different structures and different conformations of the same structure. The procedure used in INSIGHTII to compare structures is divided into four steps: 1) load the structures to be compared; 2) define the atom equivalencies in these structures; 3) perform a fitting operation; and 4) analyze the results. Each structure is identified by a name. One structure is identified as the target (i.e., the fixed structure);
15 the second structure (i.e., moving structure) is identified as the source structure. Since atom equivalency within INSIGHTII is defined by user input, for the purpose of this invention we will define equivalent atoms as protein backbone atoms (N, C α , C and O) for all conserved residues between the two structures being compared. We will also consider only rigid fitting operations. When a rigid fitting method is used, the
20 working structure is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses an algorithm that computes the optimum translation and rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atom is an absolute minimum. This number, given in angstroms, is reported by INSIGHTII. For the
25 purpose of this invention, any homology model of a BMY_HPP1 that has a root mean square deviation of conserved residue backbone atoms (N, C α , C, O) of less than 3.0 Å when superimposed on the relevant backbone atoms described by structure coordinates listed in Table VIII and shown in Figure 28 are considered identical. More preferably, the root mean square deviation is less than 2.0 Å.

30 This invention as embodied by the homology model enables the structure-based design of modulators of the biological function of BMY_HPP1, as well as mutants with altered biological function and/or specificity.

There is 18% sequence identity between catalytic domain of BMY_HPP1 and the Human Protein Tyrosine Phosphatase 1B (PTP1B; PDB code 1aax) as determined
35 using the GAP program within GCG (Genetics Computing Group, Wisconsin). The structure was used as the template to generate the three dimensional model for

5 BMY_HPP1. For BMY_HPP1, the functionally important residues are located in a cleft near the site that in other phosphatases is shown to be the active site. The active site residues are defined by : H189-C190-G193-R196 and D 161 as well as Y162. All these residues are conserved in PTP1B (denoted by the "*" in Figure 27) and other known phosphatases. In the 1aax polypeptide, the Cysteine was mutated to a Serine to
10 facilitate structural analysis (Jia, Z., et al., 1995). These active site residues play critical roles in the mechanism of catalysis and substrate specificity and binding.

In a preferred embodiment of the present invention, the molecule comprises the active site region defined by structure coordinates of BMY_HPP1 amino acids described above according to Table VIII, or a mutant of said molecule. The active
15 site is defined by residues H189-C190-G193-R196 and D 161 as well as Y162 of SEQ ID NO:150. Based on the sequence alignment disclosed in Figure 27 and the structural model disclosed in Table VIII and visualized in Figure 28, D161 is identified as a general acid, Y162 as a key determinant of substrate specificity which interacts with the phosphotyrosine substrate, C190 as the catalytic Cysteine
20 nucleophile which cleaves the phosphodiester bond, and R196 as the essential Arginine which activates the bond for cleavage as described in the literature (reviewed by Fauman and Saper, 1996).

More preferred are molecules comprising all or any part of the active site region or a mutant or homologue of said molecule or molecular complex. By mutant
25 or homologue of the molecule it is meant a molecule that has a root mean square deviation from the backbone atoms of said BMY_HPP1 amino acids of not more than 3.5 Angstroms.

More preferred are molecules comprising all or any part of the active site region defined as residues above or a mutant or homologue of said molecule or
30 molecular complex. By mutant or homologue of the molecule it is meant a molecule that has a root mean square deviation from the backbone atoms of said residues in the active site region of said BMY_HPP1 of not more than 3.5 Angstroms.

The term "root mean square deviation" means the square root of the arithmetic mean of the squares of the deviations from the mean. It is a way to express the
35 deviation or variation from a trend or object. For purposes of this invention, the "root mean square deviation" defines the variation in the backbone of a protein from the

- 5 relevant portion of the backbone of BMY_HPP1 as defined by the structure coordinates described herein.

The structure coordinates of a BMY_HPP1 homology model portion thereof are stored in a machine-readable storage medium. Such data may be used for a variety of purposes, such as drug discovery and target prioritization and validation.

- 10 Accordingly, in one embodiment of this invention is provided a machine-readable data storage medium comprising a data storage material encoded with the structure coordinates set forth in Table VIII and visualized in Figure 28.

- One embodiment utilizes System 10 as disclosed in WO 98/11134, the disclosure of which is incorporated herein by reference in its entirety. Briefly, one
15 version of these embodiments comprises a computer comprising a central processing unit ("CPU"), a working memory which may be, e.g., RAM (random-access memory) or "core" memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more cathode-ray tube ("CRT") display terminals, one or more keyboards, one or more input lines, and one or more output lines, all of which are
20 interconnected by a conventional bidirectional system bus.

- Input hardware, coupled to the computer by input lines, may be implemented in a variety of ways. Machine-readable data of this invention may be inputted via the use of a modem or modems connected by a telephone line or dedicated data line. Alternatively or additionally, the input hardware may comprise CD-ROM drives or
25 disk drives. In conjunction with a display terminal, keyboard may also be used as an input device.

- Output hardware, coupled to the computer by output lines, may similarly be implemented by conventional devices. By way of example, output hardware may include a CRT display terminal for displaying a graphical representation of a region
30 or domain of the present invention using a program such as QUANTA as described herein. Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use.

- In operation, the CPU coordinates the use of the various input and output devices, coordinates data accesses from mass storage, and accesses to and from the
35 working memory, and determines the sequence of data processing steps. A number of programs may be used to process the machine-readable data of this invention. Such

5 programs are discussed in reference to the computational methods of drug discovery as described herein. Specific references to components of the hardware system are included as appropriate throughout the following description of the data storage medium.

For the purpose of the present invention, any magnetic data storage medium
10 which can be encoded with machine-readable data would be sufficient for carrying out the storage requirements of the system. The medium could be a conventional floppy diskette or hard disk, having a suitable substrate, which may be conventional, and a suitable coating, which may be conventional, on one or both sides, containing magnetic domains whose polarity or orientation could be altered magnetically, for
15 example. The medium may also have an opening for receiving the spindle of a disk drive or other data storage device.

The magnetic domains of the coating of a medium may be polarized or oriented so as to encode in a manner which may be conventional, machine readable data such as that described herein, for execution by a system such as the system
20 described herein.

Another example of a suitable storage medium which could also be encoded with such machine-readable data, or set of instructions, which could be carried out by a system such as the system described herein, could be an optically-readable data storage medium. The medium could be a conventional compact disk read only
25 memory (CD-ROM) or a rewritable medium such as a magneto-optical disk which is optically readable and magneto-optically writable. The medium preferably has a suitable substrate, which may be conventional, and a suitable coating, which may be conventional, usually of one side of substrate.

In the case of a CD-ROM, as is well known, the coating is reflective and is
30 impressed with a plurality of pits to encode the machine-readable data. The arrangement of pits is read by reflecting laser light off the surface of the coating. A protective coating, which preferably is substantially transparent, is provided on top of the reflective coating.

In the case of a magneto-optical disk, as is well known, the coating has no pits,
35 but has a plurality of magnetic domains whose polarity or orientation can be changed magnetically when heated above a certain temperature, as by a laser. The orientation

5 of the domains can be read by measuring the polarization of laser light reflected from the coating. The arrangement of the domains encodes the data as described above.

Thus, in accordance with the present invention, data capable of displaying the three dimensional structure of the BMY_HPP1 homology model, or portions thereof and their structurally similar homologues is stored in a machine-readable storage
10 medium, which is capable of displaying a graphical three-dimensional representation of the structure. Such data may be used for a variety of purposes, such as drug discovery.

For the first time, the present invention permits the use, through homology modeling based upon the sequence of BMY_HPP1 (Figures 20A-D) of structure-
15 based or rational drug design techniques to design, select, and synthesizes chemical entities that are capable of modulating the biological function of BMY_HPP1. Comparison of the BMY_HPP1 homology model with the structures of template phosphatases enable the use of rational or structure based drug design methods to design, select or synthesize specific chemical modulators of BMY_HPP1.

20 Accordingly, the present invention is also directed to the entire sequence in Figure 20A-D or any portion thereof for the purpose of generating a homology model for the purpose of three dimensional structure-based drug designs.

For purposes of this invention, we include mutants or homologues of the sequence in Figures 20A-D or any portion thereof. In a preferred embodiment, the
25 mutants or homologues have at least 25% identity, more preferably 50% identity, more preferably 75% identity, and most preferably 90% identity to the amino acid residues in Figures 20A-D (SEQ ID NO:150).

The three-dimensional model structure of the BMY_HPP1 will also provide methods for identifying modulators of biological function. Various methods or
30 combination thereof can be used to identify these compounds.

Structure coordinates of the active site region defined above can also be used to identify structural and chemical features. Identified structural or chemical features can then be employed to design or select compounds as potential BMY_HPP1 modulators. By structural and chemical features it is meant to include, but is not
35 limited to, van der Waals interactions, hydrogen bonding interactions, charge interaction, hydrophobic interactions, and dipole interaction. Alternatively, or in

5 conjunction, the three-dimensional structural model can be employed to design or select compounds as potential BMY_HPP1 modulators. Compounds identified as potential BMY_HPP1 modulators can then be synthesized and screened in an assay characterized by binding of a test compound to the BMY_HPP1, or in characterizing BMY_HPP1 deactivation in the presence of a small molecule. Examples of assays
10 useful in screening of potential BMY_HPP1 modulators include, but are not limited to, screening in silico, *in vitro* assays and high throughput assays. Finally, these methods may also involve modifying or replacing one or more amino acids from BMY_HPP1 according to Table VIII.

However, as will be understood by those of skill in the art upon this
15 disclosure, other structure based design methods can be used. Various computational structure based design methods have been disclosed in the art.

For example, a number of computer modeling systems are available in which the sequence of the BMY_HPP1 and the BMY_HPP1 structure (i.e., atomic coordinates of BMY_HPP1 and/or the atomic coordinates of the active site region as
20 provided in Table VIII) can be input. The computer system then generates the structural details of one or more these regions in which a potential BMY_HPP1 modulator binds so that complementary structural details of the potential modulators can be determined. Design in these modeling systems is generally based upon the compound being capable of physically and structurally associating with BMY_HPP1.
25 In addition, the compound must be able to assume a conformation that allows it to associate with BMY_HPP1. Some modeling systems estimate the potential inhibitory or binding effect of a potential BMY_HPP1 modulator prior to actual synthesis and testing.

Methods for screening chemical entities or fragments for their ability to
30 associate with a given protein target are well known. Often these methods begin by visual inspection of the binding site on the computer screen. Selected fragments or chemical entities are then positioned in one or more positions and orientations within the active site region in BMY_HPP1. Molecular docking is accomplished using software such as INSIGHTII, ICM (Molsoft LLC, La Jolla, CA), and SYBYL,
35 following by energy minimization and molecular dynamics with standard molecular mechanic forcefields such as CHARMM and MMFF. Examples of computer

- 5 programs which assist in the selection of chemical fragment or chemical entities useful in the present invention include, but are not limited to, GRID (Goodford, 1985), AUTODOCK (Goodsell, 1990), and DOCK (Kuntz *et. al.* 1982).

Alternatively, compounds may be designed de novo using either an empty active site or optionally including some portion of a known inhibitor. Methods of this
10 type of design include, but are not limited to LUDI (Bohm 1992), LeapFrog (Tripos Associates, St. Louis MO) and DOCK (Kuntz *et. al.*, 1982). Programs such as DOCK (Kuntz *et. al.* 1982) can be used with the atomic coordinates from the homology model to identify potential ligands from databases or virtual databases which potentially bind the in the active site region, and which may therefore be suitable
15 candidates for synthesis and testing. The computer programs may utilize a combination of the following steps:

- (a) Selection of fragments or chemical entities from a database and then positioning the chemical entity in one or more orientations within the BMY_HPP1 active site defined by residues D161-Y162 and H189-C190-G193-R196.
20 Characterization of the structural and chemical features of the chemical entity and active site including van der Waals interactions, hydrogen bonding interactions, charge interaction, hydrophobic bonding interaction, and dipole interactions;

- (b) Search databases for molecular fragments which can be joined to or replace the docked chemical entity and spatially fit into regions defined by the said
25 BMY_HPP1 active site;

- (c) Evaluate the docked chemical entity and fragments using a combination of scoring schemes which account for van der Waals interactions, hydrogen bonding interactions, charge interaction, hydrophobic interactions; or

- (d) Databases that may be used include ACD (Molecular Designs Limited),
30 Aldrich (Aldrich Chemical Company), NCI (National Cancer Institute), Maybridge(Maybridge Chemical Company Ltd), CCDC (Cambridge Crystallographic Data Center), CAST (Chemical Abstract Service), and Derwent (Derwent Information Limited).

Upon selection of preferred chemical entities or fragments, their relationship
35 to each other and BMY_HPP1 can be visualized and then assembled into a single potential modulator. Programs useful in assembling the individual chemical entities

5 include, but are not limited to SYBYL and LeapFrog (Tripos Associates, St. Louis MO), LUDI (Bohm 1992) as well as 3D Database systems (Martin 1992).

Additionally, the three-dimensional homology model of BMY_HPP1 will aid in the design of mutants with altered biological activity. Site directed mutagenesis can be used to generate proteins with similar or varying degrees of biological activity compared to native BMY_HPP1. This invention also relates to the generation of mutants or homologues of BMY_HPP1. It is clear that molecular modeling using the three dimensional structure coordinates set forth in Table VIII and visualization of the BMY_HPP1 model, Figure 28 can be utilized to design homologues or mutant polypeptides of BMY_HPP1 that have similar or altered biological activities, function or reactivities.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:149 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides consisting of a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4379 of SEQ ID NO:149, b is an integer between 15 to 4393, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:149, and where b is greater than or equal to a+14.

Features of the Polypeptide Encoded by Gene No:2

The polypeptide fragment corresponding to this gene provided as SEQ ID NO:6 (Figure 2), encoded by the polynucleotide sequence according to SEQ ID NO:5 (Figure 2), and/or encoded by the polynucleotide contained within the deposited clone, BMY_HPP2, has significant homology at the nucleotide and amino acid level to a number of phosphatases, which include, for example, the human CDC14 (also known as the cell division cycle 14, *S. cerevisiae* Gene A protein) homologue A (HS_CDC14A; Genbank Accession No:gi| NP_003663; SEQ ID NO:30); the human *S. cerevisiae* CDC14 homolog, gene B (HS_CDC14B; Genbank Accession No:gi|

5 NP_003662; SEQ ID NO:31); and the yeast soluble tyrosine-specific protein phosphatase Cdc14p protein (SC_CDC14; Genbank Accession No:gi NP_002839; SEQ ID NO:32) as determined by BLASTP. An alignment of the human phosphatase polypeptide with these proteins is provided in Figure 7.

10 BMY_HPP2 is predicted to be a phosphoprotein phosphatase based on its homology to human CDC14B as determined by BLASTP. BMY_HPP2 shows significant homology to the catalytic domains of human CDC14A and CDC14B and to yeast CDC14 including a conserved Aspartate at AA 76, a Cysteine at AA106 and an Arginine at AA 112 of BMY_HPP2 (shown in Figure 2).

15 Polypeptide sequences corresponding to portions of the encoded BMY_HPP2 polypeptide sequence have been described as BAA91172 (Genbank Accession No:gi 7020545). However, conceptual translation of BAA91172 indicates that the phosphatase homology is in an open reading frame that begins before the 5' end of the provided polynucleotide EST sequence, in addition to regions of the polypeptide that are homologous to known phosphatases. Thus, the Genbank record, or the sequence, 20 provided for BAA91172 does not provide any suggestion that this clone partially encodes a phosphatase protein.

Based upon the strong homology to members of the phosphatase proteins, the polypeptide encoded by the human BMY_HPP2 phosphatase of the present invention is expected to share at least some biological activity with phosphatase proteins, 25 preferably with members of the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases, particularly the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases referenced herein.

The present invention encompasses the use of BMY_HPP2 inhibitors and/or activators of BMY_HPP2 activity for the treatment, detection, amelioration, or 30 prevention of phosphatase associated disorders, including but not limited to metabolic diseases such as diabetes, in addition to neural and/or cardiovascular diseases and disorders. The present invention also encompasses the use of BMY_HPP2 inhibitors and/or activators of BMY_HPP2 activity as immunosuppressive agents, anti-inflammatory agents, and/or anti-tumor agents

35 The present invention encompasses the use of BMY_HPP2 phosphatase inhibitors, including, antagonists such as antisense nucleic acids, in addition to other

5 antagonists, as described herein, in a therapeutic regimen to diagnose, prognose, treat, ameliorate, and/or prevent diseases where a kinase activity is insufficient. One, non-limiting example of a disease which may occur due to insufficient kinase activity are certain types of diabetes, where one or more kinases involved in the insulin receptor signal pathway may have insufficient activity or insufficient expression, for example.

10 Moreover, the present invention encompasses the use of BMY_HPP2 phosphatase activators, and/or the use of the BMY_HPP2 phosphatase gene or protein in a gene therapy regimen, as described herein, for the diagnoses, prognoses, treatment, amelioration, and/or prevention of diseases and/or disorders where a kinase activity is overly high, such as a cancer where a kinase oncogene product has
15 excessive activity or excessive expression.

The present invention also encompasses the use of catalytically inactive variants of BMY_HPP2 proteins, including fragments thereof, such as a protein therapeutic, or the use of the encoding polynucleotide sequence or as gene therapy, for example, in the diagnoses, prognosis, treatment, amelioration, and/or prevention
20 of diseases or disorders where phosphatase activity is overly high.

The present invention encompasses the use of antibodies directed against the BMY_HPP2 polypeptides, including fragment and/or variants thereof, of the present invention in diagnostics, as a biomarkers, and/or as a therapeutic agents.

The present invention encompasses the use of an inactive, non-catalytic,
25 mutant of the BMY_HPP2 phosphatase as a substrate trapping mutant to bind cellular phosphoproteins or a library of phosphopeptides to identify substrates of the BMY_HPP2 polypeptides.

The present invention encompasses the use of the BMY_HPP2 polypeptides, to identify inhibitors or activators of the BMY_HPP2 phosphatase activity using
30 either in vitro or 'virtual' (in silico) screening methods.

One embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of the BMY_HPP2 phosphatase comprising the steps of: i.) contacting a BMY_HPP2 phosphatase inhibitor or activator labeled with an analytically detectable reagent with the BMY_HPP2 phosphatase under conditions
35 sufficient to form a complex with the inhibitor or activator; ii.) contacting said complex with a sample containing a compound to be identified; iii) and identifying

5 the compound as an inhibitor or activator by detecting the ability of the test compound to alter the amount of labeled known BMY_HPP2 phosphatase inhibitor or activator in the complex.

Another embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of a BMY_HPP2 phosphatase comprising the
10 steps of: i.) contacting the BMY_HPP2 phosphatase with a compound to be identified; and ii.) and measuring the ability of the BMY_HPP2 phosphatase to remove phosphate from a substrate.

The present invention also encompasses a method for identifying a ligand for the BMY_HPP2 phosphatase comprising the steps of: i.) contacting the BMY_HPP2
15 phosphatase with a series of compounds under conditions to permit binding; and ii.) detecting the presence of any ligand-bound protein.

Preferably, the above referenced methods comprise the BMY_HPP2 phosphatase in a form selected from the group consisting of whole cells, cytosolic cell fractions, membrane cell fractions, purified or partially purified forms. The invention
20 also relates to recombinantly expressed BMY_HPP2 phosphatase in a purified, substantially purified, or unpurified state. The invention further relates to BMY_HPP2 phosphatase fused or conjugated to a protein, peptide, or other molecule or compound known in the art, or referenced herein.

The present invention also encompasses pharmaceutical composition of the
25 BMY_HPP2 phosphatase polypeptide comprising a compound identified by above referenced methods and a pharmaceutically acceptable carrier.

Expression profiling designed to measure the steady state mRNA levels encoding the BMY_HPP2 polypeptide showed predominately high expression levels in liver and kidney; to a significant extent, in the spleen, and to a lesser extent, in
30 lung, testis, heart, intestine, pancreas, lymph node, spinal cord, and prostate (as shown in Figure 23).

Moreover, BLAST2 searches of the LifeSeq database (Incyte Pharmaceuticals) using the full-length BMY_HPP2 polynucleotide sequence (SEQ ID NO:151) led to the determination that the BMY_HPP2 sequence is expressed
35 significantly in lung libraries which include patients with emphysema and other pulmonary diseases. The BMY_HPP2 polynucleotide was also found to be expressed

5 in aorta and endothelial cells stimulated with IL-1 and TNF-alpha. These findings suggest a potential involvement of the BMY_HPP2 polynucleotides and polypeptides in the incidence of pulmonary disease and upregulation by IL-1 and TNF-alpha.

In addition, expanded expression profiling of the BMY_HPP2 polypeptide in normal tissues showed the highest level of expression in the adrenal gland, with lower but significant expression in the pineal pituitary glands suggesting a role for modulators of BMY_HPP2 activity in the treatment of endocrine disorders (as shown in Figure 30). Consistent with the expression pattern in lung libraries from the Incyte database above, high relative levels of expression were also seen in the parenchyma and bronchi of the lung, suggesting a role for modulators of BMY_HPP2 activity in the treatment of respiratory diseases such as asthma or COPD; in the kidney, suggesting a role for modulators of BMY_HPP2 activity in the treatment of kidney disorders; in the liver, suggesting a role for modulators of BMY_HPP2 activity in the treatment of liver disorders such as hepatitis or cirrhosis; in blood vessels from the choroid plexus, coronary artery and pulmonary artery, suggesting a role for modulators of BMY_HPP2 activity in the treatment of circulatory disorders such as hypertension; and in the nucleus accumbens of the brain, suggesting a role for modulators of BMY_HPP2 activity in the treatment of affective disorders such as bipolar disorder, schizophrenia and depression. In addition, the BMY_HPP2 was highly expressed in the trachea, breast and uterus and significantly expressed in many other tissues within the human body.

The strong homology to phosphatases, particularly dual-specificity phosphatases, combined with the predominate localized expression in adrenal gland tissue suggests the human BMY_HPP2 phosphatase polynucleotides and polypeptides, including agonists, antagonists, and/or fragments thereof, may be useful for treating, diagnosing, prognosing, ameliorating, and/or preventing endocrine disorders, which include, but are not limited to adrenocortical hyperfunction, adrenocortical hypofunction, lethargy, Congenital adrenal hyperplasia, aberrant ACTH regulation, aberrant adrenaline regulation, disorders associated with defects in P450C21, P450C18, P450C17, and P450C11 hydroxylases and in 3-hydroxysteroid dehydrogenase (3-HSD), hirsutism, oligomenorrhea, acne, virilization, oligomenorrhea, female pseudohermaphroditism, disorders associated with the

5 incidence of aberrant sexual characteristics, disorders associated with aberrant cortisol secretion, hypertension, hypokalemia, hypogonadism, disorders associated with aberrant androgen secretion, adrenal virilism, Adrenal adenomas, Adrenal carcinomas, disorders associated with aberrant aldosterone secretion, aldosteronism, disorders associated with aberrant steroid biosynthesis, disorders associated with
10 aberrant steroid transport, disorders associated with aberrant steroid secretion, disorders associated with aberrant steroid excretion, Addison's syndrome, and Cushing's syndrome.

The strong homology to phosphatases, particularly dual-specificity phosphatases, combined with the significant expression in liver indicates the
15 BMY_HPP2 polynucleotides and polypeptides, in addition to, fragments and variants thereof, would be useful for the detection and treatment of liver disorders and cancers. Representative uses are described in the "Hyperproliferative Disorders", "Infectious Disease", and "Binding Activity" sections below, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, amelioration, and/or prevention of
20 hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells, cirrhosis, hepatic cysts, pyrogenic abscess, amebic abscess, hydatid cyst, cystadenocarcinoma, adenoma, focal nodular hyperplasia, hemangioma, hepatocellular carcinoma, cholangiocarcinoma, and angiosarcoma, granulomatous liver disease, liver
25 transplantation, hyperbilirubinemia, jaundice, parenchymal liver disease, portal hypertension, hepatobiliary disease, hepatic parenchyma, hepatic fibrosis, anemia, gallstones, cholestasis, carbon tetrachloride toxicity, beryllium toxicity, vinyl chloride toxicity, choledocholithiasis, hepatocellular necrosis, aberrant metabolism of amino acids, aberrant metabolism of carbohydrates, aberrant synthesis proteins, aberrant
30 synthesis of glycoproteins, aberrant degradation of proteins, aberrant degradation of glycoproteins, aberrant metabolism of drugs, aberrant metabolism of hormones, aberrant degradation of drugs, aberrant degradation of drugs, aberrant regulation of lipid metabolism, aberrant regulation of cholesterol metabolism, aberrant glycogenesis, aberrant glycogenolysis, aberrant glycolysis, aberrant gluconeogenesis,
35 hyperglycemia, glucose intolerance, hyperglycemia, decreased hepatic glucose uptake, decreased hepatic glycogen synthesis, hepatic resistance to insulin, portal-

5 systemic glucose shunting, peripheral insulin resistance, hormonal abnormalities, increased levels of systemic glucagon, decreased levels of systemic cortisol, increased levels of systemic insulin, hypoglycemia, decreased gluconeogenesis, decreased hepatic glycogen content, hepatic resistance to glucagon, elevated levels of systemic aromatic amino acids, decreased levels of systemic branched-chain amino acids, 10 hepatic encephalopathy, aberrant hepatic amino acid transamination, aberrant hepatic amino acid oxidative deamination, aberrant ammonia synthesis, aberrant albumin secretion, hypoalbuminemia, aberrant cytochromes b5 function, aberrant P450 function, aberrant glutathione S-acyltransferase function, aberrant cholesterol synthesis, and aberrant bile acid synthesis.

15 Moreover, polynucleotides and polypeptides, including fragments, agonists and/or antagonists thereof, have uses which include, directly or indirectly, treating, preventing, diagnosing, and/or prognosing the following, non-limiting, hepatic infections: liver disease caused by sepsis infection, liver disease caused by bacteremia, liver disease caused by Pneumococcal pneumonia infection, liver disease 20 caused by Toxic shock syndrome, liver disease caused by Listeriosis, liver disease caused by Legionnaires' disease, liver disease caused by Brucellosis infection, liver disease caused by Neisseria gonorrhoeae infection, liver disease caused by Yersinia infection, liver disease caused by Salmonellosis, liver disease caused by Nocardiosis, liver disease caused by Spirochete infection, liver disease caused by Treponema 25 pallidum infection, liver disease caused by Brrelia burgdorferi infection, liver disease caused by Leptospirosis, liver disease caused by Coxiella burnetii infection, liver disease caused by Rickettsia richettsii infection, liver disease caused by Chlamydia trachomatis infection, liver disease caused by Chlamydia psittaci infection, liver disease caused by hepatitis virus infection, liver disease caused by Epstein-Barr virus 30 infection in addition to any other hepatic disease and/or disorder implicated by the causative agents listed above or elsewhere herein.

The strong homology to dual specificity phosphatases, combined with the localized expression in kidney tissue suggests the BMY_HPP2 polynucleotides and polypeptides may be useful in treating, diagnosing, prognosing, and/or preventing 35 renal diseases and/or disorders, which include, but are not limited to: nephritis, renal failure, nephrotic syndrome, urinary tract infection, hematuria, proteinuria, oliguria,

5 polyuria, nocturia, edema, hypertension, electrolyte disorders, sterile pyuria, renal osteodystrophy, large kidneys, renal transport defects, nephrolithiasis, azotemia, anuria, urinary retention, slowing of urinary stream, large prostate, flank tenderness, full bladder sensation after voiding, enuresis, dysuria, bacteriuria, kidney stones, glomerulonephritis, vasculitis, hemolytic uremic syndromes, thrombotic
10 thrombocytopenic purpura, malignant hypertension, casts, tubulointerstitial kidney diseases, renal tubular acidosis, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, and/or renal colic, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome, for example.

15 The strong homology to dual specificity phosphatases, combined with the localized expression in spleen tissue, in addition to the expression in endothelial cells stimulated with IL-1 and TNF-alpha, suggests the BMY_HPP2 polynucleotides and polypeptides may be useful in treating, diagnosing, prognosing, and/or preventing immune diseases and/or disorders. Representative uses are described in the "Immune
20 Activity", "Chemotaxis", and "Infectious Disease" sections below, and elsewhere herein. Briefly, the strong expression in immune tissue indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells.

The BMY_HPP2 polypeptide may also be useful as a preventative agent for
25 immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders,
30 such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. The BMY_HPP2 polypeptide may be useful for modulating cytokine production, antigen presentation, or other processes, such as for boosting immune responses, etc.

35 Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to

5 sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissuemarkers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to
10 its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

The significant expression of BMY_HPP2 transcripts in lung libraries as observed from electronic Northern's from the Incyte LifeSeq database suggests the
15 potential utility for BMY_HPP2 polynucleotides and polypeptides in treating, diagnosing, prognosing, and/or preventing pulmonary diseases and disorders which include the following, not limiting examples: ARDS, emphysema, cystic fibrosis, interstitial lung disease, chronic obstructive pulmonary disease, bronchitis, lymphangioleiomyomatosis, pneumonitis, eosinophilic pneumonias, granulomatosis,
20 pulmonary infarction, pulmonary fibrosis, pneumoconiosis, alveolar hemorrhage, neoplasms, lung abscesses, empyema, and increased susceptibility to lung infections (e.g., immunocompromised, HIV, etc.), for example.

Moreover, polynucleotides and polypeptides, including fragments, agonists and/or antagonists thereof, have uses which include, directly or indirectly, treating,
25 preventing, diagnosing, and/or prognosing the following, non-limiting, pulmonary infections: pneumonia, bacterial pneumonia, viral pneumonia (for example, as caused by Influenza virus, Respiratory syncytial virus, Parainfluenza virus, Adenovirus, Coxsackievirus, Cytomegalovirus, Herpes simplex virus, Hantavirus, etc.), mycobacteria pneumonia (for example, as caused by Mycobacterium tuberculosis, etc.)
30 mycoplasma pneumonia, fungal pneumonia (for example, as caused by Pneumocystis carinii, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Candida sp., Cryptococcus neoformans, Aspergillus sp., Zygomycetes, etc.), Legionnaires' Disease, Chlamydia pneumonia, aspiration pneumonia, Nocordia sp. Infections, parasitic pneumonia (for example, as caused by Strongyloides, Toxoplasma gondii, etc.) necrotizing pneumonia, in addition to any other pulmonary disease and/or
35

- 5 disorder (e.g., non-pneumonia) implicated by the causative agents listed above or elsewhere herein.

Antisense oligonucleotides directed against BMY_HPP2 provided evidence suggesting its involvement in the regulation of mammalian cell cycle progression (see Example 56). Subjecting cells with an effective amount of a pool of five antisense
10 oligonucleotides resulted in a significant increase in Cyclin D expression/activity providing convincing evidence that BMY_HPP2 at least regulates the activity and/or expression of Cyclin D either directly, or indirectly. Moreover, the results suggest the physiological role of BMY_HPP2 is the negative regulation of Cyclin D activity and/or expression, either directly or indirectly.

- 15 In preferred embodiments, BMY_HPP2 polynucleotides and polypeptides, including fragments thereof, are useful for treating, diagnosing, and/or ameliorating cell cycle defects, disorders related to aberrant phosphorylation, disorders related to aberrant signal transduction, proliferating disorders, and/or cancers.

Moreover, BMY_HPP2 polynucleotides and polypeptides, including
20 fragments thereof, are useful for decreasing cellular proliferation, decreasing cellular proliferation in rapidly proliferating cells, increasing the number of cells in the G1 phase of the cell cycle, and decreasing the number of cells that progress to the S phase of the cell cycle.

- In preferred embodiments, agonists directed to BMY_HPP2 are useful for
25 decreasing cellular proliferation, decreasing cellular proliferation in rapidly proliferating cells, increasing the number of cells in the G1 phase of the cell cycle, and decreasing the number of cells that progress to the S phase of the cell cycle.

Moreover, antagonists directed against BMY_HPP2 are useful for increasing cellular proliferation, increasing cellular proliferation in rapidly proliferating cells,
30 decreasing the number of cells in the G1 phase of the cell cycle, and increasing the number of cells that progress to the S phase of the cell cycle. Such antagonists would be particularly useful for transforming normal cells into immortalized cell lines, stimulating hematopoietic cells to grow and divide, increasing recovery rates of cancer patients that have undergone chemotherapy or other therapeutic regimen, by
35 boosting their immune responses, etc.

5 The BMY_HPP2 polypeptide has been shown to comprise one glycosylation sites according to the Motif algorithm (Genetics Computer Group, Inc.). As discussed more specifically herein, protein glycosylation is thought to serve a variety of functions including: augmentation of protein folding, inhibition of protein aggregation, regulation of intracellular trafficking to organelles, increasing resistance
10 to proteolysis, modulation of protein antigenicity, and mediation of intercellular adhesion.

Asparagine glycosylation sites have the following consensus pattern, N-{P}-[ST]-{P}, wherein N represents the glycosylation site. However, it is well known that that potential N-glycosylation sites are specific to the consensus sequence Asn-Xaa-Ser/Thr. However, the presence of the consensus tripeptide is not sufficient to
15 conclude that an asparagine residue is glycosylated, due to the fact that the folding of the protein plays an important role in the regulation of N-glycosylation. It has been shown that the presence of proline between Asn and Ser/Thr will inhibit N-glycosylation; this has been confirmed by a recent statistical analysis of glycosylation sites, which also shows that about 50% of the sites that have a proline C-terminal to
20 Ser/Thr are not glycosylated. Additional information relating to asparagine glycosylation may be found in reference to the following publications, which are hereby incorporated by reference herein: Marshall R.D., Annu. Rev. Biochem. 41:673-702(1972); Pless D.D., Lennarz W.J., Proc. Natl. Acad. Sci. U.S.A. 74:134-138(1977); Bause E., Biochem. J. 209:331-336(1983); Gavel Y., von Heijne G., Protein Eng. 3:433-442(1990); and Miletich J.P., Broze G.J. Jr., J. Biol. Chem...
25 265:11397-11404(1990).

In preferred embodiments, the following asparagine glycosylation site polypeptide is encompassed by the present invention: GVQPPNFSWVLPGR (SEQ
30 ID NO:164). Polynucleotides encoding this polypeptide are also provided. The present invention also encompasses the use of this BMY_HPP2 asparagine glycosylation site polypeptide as an immunogenic and/or antigenic epitope as described elsewhere herein.

The BMY_HPP2 polypeptides of the present invention were determined to
35 comprise several phosphorylation sites based upon the Motif algorithm (Genetics Computer Group, Inc.). The phosphorylation of such sites may regulate some

5 biological activity of the BMY_HPP2 polypeptide. For example, phosphorylation at specific sites may be involved in regulating the proteins ability to associate or bind to other molecules (e.g., proteins, ligands, substrates, DNA, etc.). In the present case, phosphorylation may modulate the ability of the BMY_HPP2 polypeptide to associate with other potassium channel alpha subunits, beta subunits, or its ability to modulate
10 potassium channel function.

The BMY_HPP2 polypeptide was predicted to comprise one PKC phosphorylation site using the Motif algorithm (Genetics Computer Group, Inc.). In vivo, protein kinase C exhibits a preference for the phosphorylation of serine or threonine residues. The PKC phosphorylation sites have the following consensus
15 pattern: [ST]-x-[RK], where S or T represents the site of phosphorylation and 'x' an intervening amino acid residue. Additional information regarding PKC phosphorylation sites can be found in Woodget J.R., Gould K.L., Hunter T., Eur. J. Biochem. 161:177-184(1986), and Kishimoto A., Nishiyama K., Nakanishi H., Uratsuji Y., Nomura H., Takeyama Y., Nishizuka Y., J. Biol. Chem... 260:12492-
20 12499(1985); which are hereby incorporated by reference herein.

In preferred embodiments, the following PKC phosphorylation site polypeptide is encompassed by the present invention: HLVSLTERGPPHS (SEQ ID NO:165). Polynucleotides encoding these polypeptides are also provided. The present invention also encompasses the use of these BMY_HPP2 PKC phosphorylation site
25 polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In further confirmation of the human BMY_HPP2 polypeptide representing a novel human phosphatase polypeptide, the BMY_HPP2 polypeptide has been shown to comprise a tyrosine specific protein phosphatase active site domain according to
30 the Motif algorithm (Genetics Computer Group, Inc.).

Tyrosine specific protein phosphatases (EC 3.1.3.48) (PTPase) are enzymes that catalyze the removal of a phosphate group attached to a tyrosine residue. These enzymes are very important in the control of cell growth, proliferation, differentiation and transformation. Multiple forms of PTPase have been characterized and can be
35 classified into two categories: soluble PTPases and transmembrane receptor proteins that contain PTPase domain(s).

5 The currently known PTPases are listed below: Soluble PTPases, PTPN1 (PTP-1B), PTPN2 (T-cell PTPase; TC-PTP), PTPN3 (H1) and PTPN4 (MEG), enzymes that contain an N-terminal band 4.1-like domain and could act at junctions between the membrane and cytoskeleton, PTPN5 (STEP), PTPN6 (PTP-1C; HCP; SHP) and PTPN11 (PTP-2C; SH-PTP3; Syp), enzymes which contain two copies of
10 the SH2 domain at its N-terminal extremity (e.g., the *Drosophila* protein corkscrew (gene *csw*) also belongs to this subgroup), PTPN7 (LC-PTP; Hematopoietic protein-tyrosine phosphatase; HePTP), PTPN8 (70Z-PEP), PTPN9 (MEG2), PTPN12 (PTP-G1; PTP-P19), Yeast PTP1, Yeast PTP2 which may be involved in the ubiquitin-mediated protein degradation pathway, Fission yeast *pyp1* and *pyp2* which play a role
15 in inhibiting the onset of mitosis, Fission yeast *pyp3* which contributes to the dephosphorylation of *cdc2*, Yeast CDC14 which may be involved in chromosome segregation, *Yersinia* virulence plasmid PTPases (gene *yopH*), *Autographa californica* nuclear polyhedrosis virus 19 Kd PTPase, Dual specificity PTPases, DUSP1 (PTPN10; MAP kinase phosphatase-1; MKP-1); which dephosphorylates
20 MAP kinase on both Thr-183 and Tyr-185, DUSP2 (PAC-1), a nuclear enzyme that dephosphorylates MAP kinases ERK1 and ERK2 on both Thr and Tyr residues, DUSP3 (VHR), DUSP4 (HVH2), DUSP5 (HVH3), DUSP6 (Pyst1; MKP-3), DUSP7 (Pyst2; MKP-X), Yeast MSG5, a PTPase that dephosphorylates MAP kinase FUS3, Yeast YVH1, *Vaccinia* virus H1 PTPase - a dual specificity phosphatase,

25 Structurally, all known receptor PTPases, are made up of a variable length extracellular domain, followed by a transmembrane region and a C-terminal catalytic cytoplasmic domain. Some of the receptor PTPases contain fibronectin type III (FN-III) repeats, immunoglobulin-like domains, MAM domains or carbonic anhydrase-like domains in their extracellular region. The cytoplasmic region generally contains two
30 copies of the PTPase domain. The first seems to have enzymatic activity, while the second is inactive but seems to affect substrate specificity of the first. In these domains, the catalytic cysteine is generally conserved but some other, presumably important, residues are not.

 PTPase domains consist of about 300 amino acids. There are two conserved
35 cysteines, the second one has been shown to be absolutely required for activity.

5 Furthermore, a number of conserved residues in its immediate vicinity have also been shown to be important.

A consensus sequence for tyrosine specific protein phosphatases is provided as follows:

[LIVMF]-H-C-x(2)-G-x(3)-[STC]-[STAGP]-x-[LIVMFY], wherein C is the
10 active site residue and "X" represents any amino acid.

Additional information related to tyrosine specific protein phosphatase domains and proteins may be found in reference to the following publications Fischer E.H., Charbonneau H., Tonks N.K., Science 253:401-406(1991); Charbonneau H., Tonks N.K., Annu. Rev. Cell Biol. 8:463-493(1992); Trowbridge I.S., J. Biol. Chem...
15 266:23517-23520(1991); Tonks N.K., Charbonneau H., Trends Biochem. Sci. 14:497-500(1989); and Hunter T., Cell 58:1013-1016(1989); which are hereby incorporated herein by reference in their entirety.

In preferred embodiments, the following tyrosine specific protein phosphatase active site domain polypeptide is encompassed by the present invention:
20 GEAVGVHICALGFGRTGTMLACYL (SEQ ID NO:166). Polynucleotides encoding these polypeptides are also provided. The present invention also encompasses the use of this tyrosine specific protein phosphatase active site domain polypeptide as an immunogenic and/or antigenic epitope as described elsewhere herein.

In preferred embodiments, the following N-terminal BMY_HPP2 deletion
25 polypeptides are encompassed by the present invention: M1-K150, G2-K150, V3-K150, Q4-K150, P5-K150, P6-K150, N7-K150, F8-K150, S9-K150, W10-K150, V11-K150, L12-K150, P13-K150, G14-K150, R15-K150, L16-K150, A17-K150, G18-K150, L19-K150, A20-K150, L21-K150, P22-K150, R23-K150, L24-K150, P25-K150, A26-K150, H27-K150, Y28-K150, Q29-K150, F30-K150, L31-K150,
30 L32-K150, D33-K150, L34-K150, G35-K150, V36-K150, R37-K150, H38-K150, L39-K150, V40-K150, S41-K150, L42-K150, T43-K150, E44-K150, R45-K150, G46-K150, P47-K150, P48-K150, H49-K150, S50-K150, D51-K150, S52-K150, C53-K150, P54-K150, G55-K150, L56-K150, T57-K150, L58-K150, H59-K150, R60-K150, L61-K150, R62-K150, I63-K150, P64-K150, D65-K150, F66-K150, C67-K150, P68-K150, P69-K150, A70-K150, P71-K150, D72-K150, Q73-K150, I74-K150, D75-K150, R76-K150, F77-K150, V78-K150, Q79-K150, I80-K150, V81-K150,
35

- 5 K150, D82-K150, E83-K150, A84-K150, N85-K150, A86-K150, R87-K150, G88-K150, E89-K150, A90-K150, V91-K150, G92-K150, V93-K150, H94-K150, C95-K150, A96-K150, L97-K150, G98-K150, F99-K150, G100-K150, R101-K150, T102-K150, G103-K150, T104-K150, M105-K150, L106-K150, A107-K150, C108-K150, Y109-K150, L110-K150, V111-K150, K112-K150, E113-K150, R114-K150, G115-K150, L116-K150, A117-K150, A118-K150, G119-K150, D120-K150, A121-K150, I122-K150, A123-K150, E124-K150, I125-K150, R126-K150, R127-K150, L128-K150, R129-K150, P130-K150, G131-K150, S132-K150, I133-K150, E134-K150, T135-K150, Y136-K150, E137-K150, Q138-K150, E139-K150, K140-K150, A141-K150, V142-K150, F143-K150, and/or Q144-K150 of SEQ ID NO:152.
- 10
- 15 Polynucleotide sequences encoding these polypeptides are also provided. The present invention also encompasses the use of these N-terminal BMY_HPP2 deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following C-terminal BMY_HPP2 deletion polypeptides are encompassed by the present invention: M1-K150, M1-T149, M1-R148, M1-Q147, M1-Y146, M1-F145, M1-Q144, M1-F143, M1-V142, M1-A141, M1-K140, M1-E139, M1-Q138, M1-E137, M1-Y136, M1-T135, M1-E134, M1-I133, M1-S132, M1-G131, M1-P130, M1-R129, M1-L128, M1-R127, M1-R126, M1-I125, M1-E124, M1-A123, M1-I122, M1-A121, M1-D120, M1-G119, M1-A118, M1-A117, M1-L116, M1-G115, M1-R114, M1-E113, M1-K112, M1-V111, M1-L110, M1-Y109, M1-C108, M1-A107, M1-L106, M1-M105, M1-T104, M1-G103, M1-T102, M1-R101, M1-G100, M1-F99, M1-G98, M1-L97, M1-A96, M1-C95, M1-H94, M1-V93, M1-G92, M1-V91, M1-A90, M1-E89, M1-G88, M1-R87, M1-A86, M1-N85, M1-A84, M1-E83, M1-D82, M1-V81, M1-I80, M1-Q79, M1-V78, M1-F77, M1-R76, M1-D75, M1-I74, M1-Q73, M1-D72, M1-P71, M1-A70, M1-P69, M1-P68, M1-C67, M1-F66, M1-D65, M1-P64, M1-I63, M1-R62, M1-L61, M1-R60, M1-H59, M1-L58, M1-T57, M1-L56, M1-G55, M1-P54, M1-C53, M1-S52, M1-D51, M1-S50, M1-H49, M1-P48, M1-P47, M1-G46, M1-R45, M1-E44, M1-T43, M1-L42, M1-S41, M1-V40, M1-L39, M1-H38, M1-R37, M1-V36, M1-G35, M1-L34, M1-D33, M1-L32, M1-L31, M1-F30, M1-Q29, M1-Y28, M1-H27, M1-A26, M1-P25, M1-L24, M1-R23, M1-P22, M1-L21, M1-A20, M1-L19, M1-G18, M1-A17, M1-L16, M1-

20

25

30

35

5 R15, M1-G14, M1-P13, M1-L12, M1-V11, M1-W10, M1-S9, M1-F8, and/or M1-N7 of SEQ ID NO:152. Polynucleotide sequences encoding these polypeptides are also provided. The present invention also encompasses the use of these C-terminal BMY_HPP2 deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

10 In preferred embodiments, the following BMY_HPP2 phosphatase active site domain amino acid substitutions are encompassed by the present invention: wherein M1 is substituted with either an A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; wherein G2 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V3 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein Q4 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; wherein P5 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein P6 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein N7 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; wherein F8 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S9 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein W10 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; wherein V11 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein L12 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein P13 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein G14 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein R15 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein L16 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein A17 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein G18 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L19 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein A20 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L21 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein P22 is substituted with either an A, C, D, E, F, G,

5 H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein R23 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein L24 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein P25 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein A26 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein H27 is substituted with either an A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Y28 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein Q29 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; wherein F30 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L31 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein L32 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein D33 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L34 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein G35 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V36 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein R37 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein H38 is substituted with either an A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L39 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein V40 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein S41 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein L42 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein T43 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, or Y; wherein E44 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein R45 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein G46 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein P47 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein P48 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein H49 is substituted with either an A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W, or Y;

5 wherein S50 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein D51 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S52 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein C53 is substituted with either an A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein P54 is substituted
10 with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein G55 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L56 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein T57 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, or Y; wherein L58 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein H59 is substituted with either an
15 A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein R60 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein L61 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein R62 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein I63 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein P64 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein D65 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein F66 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein C67
25 is substituted with either an A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein P68 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein P69 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein A70 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein P71 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein D72 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Q73 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; wherein I74 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein D75 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein R76 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein F77 is substituted with either an
35

- 5 A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V78 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein Q79 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; wherein I80 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V81 is substituted with either an A, C, D, E, F, G, H, I, K, L,
- 10 M, N, P, Q, R, S, T, W, or Y; wherein D82 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein E83 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A84 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein N85 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y;
- 15 wherein A86 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein R87 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein G88 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein E89 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A90 is substituted
- 20 with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V91 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein G92 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V93 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein H94 is substituted with either an A, C, D, E, F,
- 25 G, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein C95 is substituted with either an A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A96 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L97 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein G98 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S,
- 30 T, V, W, or Y; wherein F99 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein G100 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein R101 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein T102 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, or Y; wherein
- 35 G103 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein T104 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P,

5 Q, R, S, V, W, or Y; wherein M105 is substituted with either an A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; wherein L106 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein A107 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein C108 is substituted with either an A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Y109 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein L110 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or wherein V111 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y of SEQ ID NO:152, in addition to any combination thereof. The present invention also encompasses the use of these

10

15 BMY_HPP2 phosphatase active site domain amino acid substituted polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following BMY_HPP2 phosphatase active site domain conservative amino acid substitutions are encompassed by the present invention: wherein M1 is substituted with either an A, G, S, or T; wherein G2 is substituted with either an A, M, S, or T; wherein V3 is substituted with either an A, I, or L; wherein Q4 is substituted with a N; wherein P5 is a P; wherein P6 is a P; wherein N7 is substituted with a Q; wherein F8 is substituted with either a W, or Y; wherein S9 is substituted with either an A, G, M, or T; wherein W10 is either an F, or Y; wherein V11 is substituted with either an A, I, or L; wherein L12 is substituted with either an A, I, or V; wherein P13 is a P; wherein G14 is substituted with either an A, M, S, or T; wherein R15 is substituted with either a K, or H; wherein L16 is substituted with either an A, I, or V; wherein A17 is substituted with either a G, I, L, M, S, T, or V; wherein G18 is substituted with either an A, M, S, or T; wherein L19 is substituted with either an A, I, or V; wherein A20 is substituted with either a G, I, L, M, S, T, or V; wherein L21 is substituted with either an A, I, or V; wherein P22 is a P; wherein R23 is substituted with either a K, or H; wherein L24 is substituted with either an A, I, or V; wherein P25 is a P; wherein A26 is substituted with either a G, I, L, M, S, T, or V; wherein H27 is substituted with either a K, or R; wherein Y28 is either an F, or W; wherein Q29 is substituted with a N; wherein F30 is substituted with either a W, or Y; wherein L31 is substituted with either an A, I, or V; wherein L32 is substituted with either an A, I, or V; wherein D33 is substituted with an E;

20

25

30

35

5 wherein L34 is substituted with either an A, I, or V; wherein G35 is substituted with either an A, M, S, or T; wherein V36 is substituted with either an A, I, or L; wherein R37 is substituted with either a K, or H; wherein H38 is substituted with either a K, or R; wherein L39 is substituted with either an A, I, or V; wherein V40 is substituted with either an A, I, or L; wherein S41 is substituted with either an A, G, M, or T;
10 wherein L42 is substituted with either an A, I, or V; wherein T43 is substituted with either an A, G, M, or S; wherein E44 is substituted with a D; wherein R45 is substituted with either a K, or H; wherein G46 is substituted with either an A, M, S, or T; wherein P47 is a P; wherein P48 is a P; wherein H49 is substituted with either a K, or R; wherein S50 is substituted with either an A, G, M, or T; wherein D51 is substituted with an E; wherein S52 is substituted with either an A, G, M, or T;
15 wherein C53 is a C; wherein P54 is a P; wherein G55 is substituted with either an A, M, S, or T; wherein L56 is substituted with either an A, I, or V; wherein T57 is substituted with either an A, G, M, or S; wherein L58 is substituted with either an A, I, or V; wherein H59 is substituted with either a K, or R; wherein R60 is substituted with either a K, or H; wherein L61 is substituted with either an A, I, or V; wherein R62 is substituted with either a K, or H; wherein I63 is substituted with either an A, V, or L; wherein P64 is a P; wherein D65 is substituted with an E; wherein F66 is substituted with either a W, or Y; wherein C67 is a C; wherein P68 is a P; wherein P69 is a P; wherein A70 is substituted with either a G, I, L, M, S, T, or V; wherein
25 P71 is a P; wherein D72 is substituted with an E; wherein Q73 is substituted with a N; wherein I74 is substituted with either an A, V, or L; wherein D75 is substituted with an E; wherein R76 is substituted with either a K, or H; wherein F77 is substituted with either a W, or Y; wherein V78 is substituted with either an A, I, or L; wherein Q79 is substituted with a N; wherein I80 is substituted with either an A, V, or L; wherein V81 is substituted with either an A, I, or L; wherein D82 is substituted with an E; wherein E83 is substituted with a D; wherein A84 is substituted with either a G, I, L, M, S, T, or V; wherein N85 is substituted with a Q; wherein A86 is substituted with either a G, I, L, M, S, T, or V; wherein R87 is substituted with either a K, or H; wherein G88 is substituted with either an A, M, S, or T; wherein E89 is substituted with a D; wherein A90 is substituted with either a G, I, L, M, S, T, or V; wherein V91
35 is substituted with either an A, I, or L; wherein G92 is substituted with either an A, M,

5 S, or T; wherein V93 is substituted with either an A, I, or L; wherein H94 is substituted with either a K, or R; wherein C95 is a C; wherein A96 is substituted with either a G, I, L, M, S, T, or V; wherein L97 is substituted with either an A, I, or V; wherein G98 is substituted with either an A, M, S, or T; wherein F99 is substituted with either a W, or Y; wherein G100 is substituted with either an A, M, S, or T; 10 wherein R101 is substituted with either a K, or H; wherein T102 is substituted with either an A, G, M, or S; wherein G103 is substituted with either an A, M, S, or T; wherein T104 is substituted with either an A, G, M, or S; wherein M105 is substituted with either an A, G, S, or T; wherein L106 is substituted with either an A, I, or V; wherein A107 is substituted with either a G, I, L, M, S, T, or V; wherein C108 is a C; 15 wherein Y109 is either an F, or W; wherein L110 is substituted with either an A, I, or V; and/or wherein V111 is substituted with either an A, I, or L of SEQ ID NO:152 in addition to any combination thereof. Other suitable substitutions within the BMY_HPP2 phosphatase active site domain are encompassed by the present invention and are referenced elsewhere herein. The present invention also 20 encompasses the use of these BMY_HPP2 phosphatase active site domain conservative amino acid substituted polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the present invention encompasses a polynucleotide lacking the initiating start codon, in addition to, the resulting encoded 25 polypeptide of BMY_HPP2. Specifically, the present invention encompasses the polynucleotide corresponding to nucleotides 92 thru 538 of SEQ ID NO:151, and the polypeptide corresponding to amino acids 2 thru 150 of SEQ ID NO:152. Also encompassed are recombinant vectors comprising said encoding sequence, and host cells comprising said vector.

30 The present invention also provides a three-dimensional homology model of the BMY_HPP2 polypeptide (see Figure 32) representing amino acid residues M1 to K150 of the polypeptide sequence of BMY_HPP2 (amino acid residues M1 to K150 of SEQ ID NO:152). A three-dimensional homology model can be constructed on the basis of the known structure of a homologous protein (Greer et al, 1991, Lesk, et al, 35 1992, Cardozo, et al, 1995, Yuan, et al, 1995). The homology model of the BMY_HPP2 polypeptide sequence (SEQ ID NO:152), was based upon the

5 homologous structure of 1vhr from the N-terminus of the human dual specificity phosphatase (vaccinia H1-related phosphatase VN1) (residues N31-K179; Protein Data Bank, PDB entry 1vhr chain A; Genbank Accession No. gi|1633321; SEQ ID NO:207) and is defined by the set of structural coordinates set forth in Table IX herein.

10 Homology models are useful when there is no experimental information available on the protein of interest. A 3-dimensional model can be constructed on the basis of the known structure of a homologous protein (Greer et al, 1991, Lesk, et al, 1992, Cardozo, et al, 1995, Sali, et al, 1995).

Those of skill in the art will understand that a homology model is constructed
15 on the basis of first identifying a template, or, protein of known structure which is similar to the protein without known structure. This can be accomplished by through pairwise alignment of sequences using such programs as FASTA (Pearson, et al 1990) and BLAST (Altschul, et al, 1990). In cases where sequence similarity is high (greater than 30%) these pairwise comparison methods may be adequate. Likewise,
20 multiple sequence alignments or profile-based methods can be used to align a query sequence to an alignment of multiple (structurally and biochemically) related proteins. When the sequence similarity is low, more advanced techniques are used such as fold recognition (protein threading; Hendlich, et al, 1990), where the compatibility of a particular sequence with the 3-dimensional fold of a potential template protein is
25 gauged on the basis of a knowledge-based potential. Following the initial sequence alignment, the query template can be optimally aligned by manual manipulation or by incorporation of other features (motifs, secondary structure predictions, and allowed sequence conservation). Next, structurally conserved regions can be identified and used to construct the core secondary structure (Sali, et al, 1995). Loops can be added
30 using knowledge-based techniques, and refined performing forcefield calculations (Sali, et al, 1995, Cardozo, et al, 1995).

For BMV_HPP2 the pairwise alignment method FASTA (Pearson, et al 1990) and fold recognition methods (protein threading) generated identical sequence alignments for a portion (residues M1 to K150 of SEQ ID NO:152) of BMV_HPP2
35 aligned with the sequence of 1vhr from the N-terminus of the human dual specificity phosphatase (vaccinia H1-related phosphatase VN1) (residues N31-K179; Protein

5 Data Bank, PDB entry 1vhr chain A; Genbank Accession No. gi|1633321; SEQ ID
NO:207). The alignment of BMY-HPP2 with PDB entry 1vhr is set forth in Figure 31.
In this invention, the homology model of BMY_HPP2 was derived from the sequence
alignment set forth in Figure 31, and hence an overall atomic model including
plausible sidechain orientations using the program LOOK (Levitt, 1992). The three
10 dimensional model for BMY-HPP2 is defined by the set of structure coordinates as
set forth in Table IX and visualized in Figure 32.

In order to recognize errors in three-dimensional structures knowledge based
mean fields can be used to judge the quality of protein folds (Sippl 1993). The
methods can be used to recognize misfolded structures as well as faulty parts of
15 structural models. The technique generates an energy graph where the energy
distribution for a given protein fold is displayed on the y-axis and residue position in
the protein fold is displayed on the x-axis. The knowledge based mean fields compose
a force field derived from a set of globular protein structures taken as a subset from
the Protein Data Bank (Bernstein et. al. 1977). To analyze the quality of a model the
20 energy distribution is plotted and compared to the energy distribution of the template
from which the model was generated. Figure 33 shows the energy graph for
the BMY_HPP2 model (dotted line) and the template (1vhr, a dual-specificity
phosphatase) from which the model was generated. It is clear that the model and
template have similar energies over the aligned region, suggesting that BMY_HPP2 is
25 in a "native-like" conformation. This graph supports the motif and sequence
alignments in confirming that the three dimensional structure coordinates
of BMY_HPP2 are an accurate and useful representation for the polypeptide.

The term "structure coordinates" refers to Cartesian coordinates generated
from the building of a homology model.

30 Those of skill in the art will understand that a set of structure coordinates for a
protein is a relative set of points that define a shape in three dimensions. Thus, it is
possible that an entirely different set of coordinates could define a similar or identical
shape. Moreover, slight variations in the individual coordinates, as emanate from
generation of similar homology models using different alignment templates (i.e., other
35 than the structure coordinates of 1vhr), and/or using different methods in generating
the homology model, will have minor effects on the overall shape. Variations in

5 coordinates may also be generated because of mathematical manipulations of the structure coordinates. For example, the structure coordinates set forth in Table IX and visualized in Figure 32 could be manipulated by fractionalization of the structure coordinates; integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above.

10 Various computational analyses are therefore necessary to determine whether a molecule or a portion thereof is sufficiently similar to all or parts of BMY_HPP2 described above as to be considered the same. Such analyses may be carried out in current software applications, such as INSIGHTII (Molecular Simulations Inc., San Diego, CA) version 2000 and as described in the accompanying User's Guide.

15 Using the superimposition tool in the program INSIGHTII comparisons can be made between different structures and different conformations of the same structure. The procedure used in INSIGHTII to compare structures is divided into four steps: 1) load the structures to be compared; 2) define the atom equivalencies in these structures; 3) perform a fitting operation; and 4) analyze the results. Each structure is
20 identified by a name. One structure is identified as the target (i.e., the fixed structure); the second structure (i.e., moving structure) is identified as the source structure. Since atom equivalency within INSIGHTII is defined by user input, for the purpose of this invention we will define equivalent atoms as protein backbone atoms (N, C α , C and O) for all conserved residues between the two structures being compared. We will
25 also consider only rigid fitting operations. When a rigid fitting method is used, the working structure is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses an algorithm that computes the optimum translation and rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atom is an absolute
30 minimum. This number, given in angstroms, is reported by INSIGHTII. For the purpose of this invention, any homology model of a BMY_HPP2 that has a root mean square deviation of conserved residue backbone atoms (N, C α , C, O) of less than 3.0 Å when superimposed on the relevant backbone atoms described by structure coordinates listed in Table IX and visualized in Figure 32 are considered identical.
35 More preferably, the root mean square deviation is less than 2.0 Å.

5 This invention as embodied by the homology model enables the structure-based design of modulators of the biological function of BMY_HPP2, as well as mutants with altered biological function and/or specificity.

 There is 23% sequence identity between catalytic domain of BMY_HPP2 and the human dual specificity phosphatase VHR (Yuvaniyama, J., et al., 1996; PDB
10 identifier 1vhr) which was used as the template for 3D model generation as determined by the GAP program within GCG (Genetics Computer Group, Wisconsin). For the BMY_HPP2 the functionally important residues are located in a cleft comprised of residues D65, H94-C95-X-X-G98-X-X-R101 (the 'active site'). All these residues are conserved in 1vhr (D92, H123-C124-X-X-G127-X-X-R130).
15 Based on the sequence alignment disclosed in Figure 31 and the structural model disclosed in Table IX and visualized in Figure 32, D65 is identified as a general acid, C95 as the catalytic Cysteine nucleophile which cleaves the phosphodiester bond, and R101 as the essential Arginine which activates the bond for cleavage as described in the literature (reviewed by Fauman and Saper, 1996).

20 In a preferred embodiment of the present invention, the molecule comprises the cleft region defined by structure coordinates of BMY_HPP2 amino acids described above according to Table IX, or a mutant of said molecule.

 More preferred are molecules comprising all or any part of the cleft or a mutant or homologue of said molecule or molecular complex. By mutant or
25 homologue of the molecule it is meant a molecule that has a root mean square deviation from the backbone atoms of said BMY_HPP2 amino acids of not more than 3.5 Angstroms.

 The term "root mean square deviation" means the square root of the arithmetic mean of the squares of the deviations from the mean. It is a way to express the
30 deviation or variation from a trend or object. For purposes of this invention, the "root mean square deviation" defines the variation in the backbone of a protein from the relevant portion of the backbone of BMY_HPP2 as defined by the structure coordinates described herein.

 The structure coordinates of a BMY_HPP2 homology model portions thereof
35 are stored in a machine-readable storage medium. Such data may be used for a variety of purposes, such as drug discovery.

5 Accordingly, in one embodiment of this invention is provided a machine-readable data storage medium comprising a data storage material encoded with the structure coordinates set forth in Table IX

 One embodiment utilizes System 10 as disclosed in WO 98/11134, the disclosure of which is incorporated herein by reference in its entirety. Briefly, one
10 version of these embodiments comprises a computer comprising a central processing unit ("CPU"), a working memory which may be, e.g, RAM (random-access memory) or "core" memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more cathode-ray tube ("CRT") display terminals, one or more keyboards, one or more input lines, and one or more output lines, all of which are
15 interconnected by a conventional bidirectional system bus.

 Input hardware, coupled to the computer by input lines, may be implemented in a variety of ways. Machine-readable data of this invention may be inputted via the use of a modem or modems connected by a telephone line or dedicated data line. Alternatively or additionally, the input hardware may comprise CD-ROM drives or
20 disk drives. In conjunction with a display terminal, keyboard may also be used as an input device.

 Output hardware, coupled to the computer by output lines, may similarly be implemented by conventional devices. By way of example, output hardware may include a CRT display terminal for displaying a graphical representation of a region
25 or domain of the present invention using a program such as QUANTA as described herein. Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use.

 In operation, the CPU coordinates the use of the various input and output devices, coordinates data accesses from mass storage, and accesses to and from the
30 working memory, and determines the sequence of data processing steps. A number of programs may be used to process the machine-readable data of this invention. Such programs are discussed in reference to the computational methods of drug discovery as described herein. Specific references to components of the hardware system are included as appropriate throughout the following description of the data storage
35 medium.

5 For the purpose of the present invention, any magnetic data storage medium which can be encoded with machine-readable data would be sufficient for carrying out the storage requirements of the system. The medium could be a conventional floppy diskette or hard disk, having a suitable substrate, which may be conventional, and a suitable coating, which may be conventional, on one or both sides, containing
10 magnetic domains whose polarity or orientation could be altered magnetically, for example. The medium may also have an opening for receiving the spindle of a disk drive or other data storage device.

 The magnetic domains of the coating of a medium may be polarized or oriented so as to encode in a manner which may be conventional, machine readable
15 data such as that described herein, for execution by a system such as the system described herein.

 Another example of a suitable storage medium which could also be encoded with such machine-readable data, or set of instructions, which could be carried out by a system such as the system described herein, could be an optically-readable data
20 storage medium. The medium could be a conventional compact disk read only memory (CD-ROM) or a rewritable medium such as a magneto-optical disk which is optically readable and magneto-optically writable. The medium preferably has a suitable substrate, which may be conventional, and a suitable coating, which may be conventional, usually of one side of substrate.

25 In the case of a CD-ROM, as is well known, the coating is reflective and is impressed with a plurality of pits to encode the machine-readable data. The arrangement of pits is read by reflecting laser light off the surface of the coating. A protective coating, which preferably is substantially transparent, is provided on top of the reflective coating.

30 In the case of a magneto-optical disk, as is well known, the coating has no pits, but has a plurality of magnetic domains whose polarity or orientation can be changed magnetically when heated above a certain temperature, as by a laser. The orientation of the domains can be read by measuring the polarization of laser light reflected from the coating. The arrangement of the domains encodes the data as described above.

35 Thus, in accordance with the present invention, data capable of displaying the three dimensional structure of the BMV_HPP2 homology model, or portions thereof

5 and their structurally similar homologues is stored in a machine-readable storage medium, which is capable of displaying a graphical three-dimensional representation of the structure. Such data may be used for a variety of purposes, such as drug discovery.

For the first time, the present invention permits the use, through homology
10 modeling based upon the sequence of BMY_HPP2 (Figure 21; SEQ ID NO:152) of structure-based or rational drug design techniques to design, select, and synthesize chemical entities that are capable of modulating the biological function of BMY_HPP2.

Accordingly, the present invention is also directed to the entire sequence in
15 Figure 21 or any portion thereof for the purpose of generating a homology model for the purpose of 3D structure-based drug design.

For purposes of this invention, we include mutants or homologues of the sequence in Figure 21 or any portion thereof. In a preferred embodiment, the mutants or homologues have at least 25% identity, more preferably 50% identity, more
20 preferably 75% identity, and most preferably 90% identity to the amino acid residues in Figure 21.

The three-dimensional model structure of the BMY_HPP2 will also provide methods for identifying modulators of biological function. Various methods or combination thereof can be used to identify these compounds.

25 Structure coordinates of the catalytic region defined above can also be used to identify structural and chemical features. Identified structural or chemical features can then be employed to design or select compounds as potential BMY_HPP2 modulators. By structural and chemical features it is meant to include, but is not limited to, van der Waals interactions, hydrogen bonding interactions, charge
30 interaction, hydrophobic bonding interaction, and dipole interaction. Alternatively, or in conjunction, the three-dimensional structural model can be employed to design or select compounds as potential BMY_HPP2 modulators. Compounds identified as potential BMY_HPP2 modulators can then be synthesized and screened in an assay characterized by binding of a test compound to the BMY_HPP2, or in characterizing
35 BMY_HPP2 deactivation in the presence of a small molecule. Examples of assays useful in screening of potential BMY_HPP2 modulators include, but are not limited

5 to, screening *in silico*, *in vitro* assays and high throughput assays. Finally, these methods may also involve modifying or replacing one or more amino acids from BMY_HPP2 according to Table IX.

However, as will be understood by those of skill in the art upon this disclosure, other structure based design methods can be used. Various computational
10 structure based design methods have been disclosed in the art.

For example, a number of computer modeling systems are available in which the sequence of the BMY_HPP2 and the BMY_HPP2 structure (i.e., atomic coordinates of BMY_HPP2 and/or the atomic coordinates of the active site as provided in Table IX) can be input. This computer system then generates the
15 structural details of one or more these regions in which a potential BMY_HPP2 modulator binds so that complementary structural details of the potential modulators can be determined. Design in these modeling systems is generally based upon the compound being capable of physically and structurally associating with BMY_HPP2. In addition, the compound must be able to assume a conformation that allows it to
20 associate with BMY_HPP2. Some modeling systems estimate the potential inhibitory or binding effect of a potential BMY_HPP2 modulator prior to actual synthesis and testing.

Methods for screening chemical entities or fragments for their ability to associate with a given protein target are also well known. Often these methods begin
25 by visual inspection of the binding site on the computer screen. Selected fragments or chemical entities are then positioned in one or more of the active site region in BMY_HPP2. Docking is accomplished using software such as INSIGHTII, QUANTA, and SYBYL, following by energy minimization and molecular dynamics with standard molecular mechanic forcefields such as CHARMM and AMBER.
30 Examples of computer programs which assist in the selection of chemical fragment or chemical entities useful in the present invention include, but are not limited to, GRID (Goodford, 1985), AUTODOCK (Goodsell, 1990), and DOCK (Kuntz et al. 1982).

Upon selection of preferred chemical entities or fragments, their relationship to each other and BMY_HPP2 can be visualized and then assembled into a single
35 potential modulator. Programs useful in assembling the individual chemical entities

5 include, but are not limited to SYBYL and LeapFrog (Tripos Associates, St. Louis MO), LUDI (Bohm 1992) and 3D Database systems (Martin 1992).

Alternatively, compounds may be designed de novo using either an empty active site or optionally including some portion of a known inhibitor. Methods of this type of design include, but are not limited to LUDI (Bohm 1992) and LeapFrog
10 (Tripos Associates, St. Louis MO).

In addition, BMY_HPP2 is overall well suited to modern methods including combinatorial chemistry.

Programs such as DOCK (Kuntz et al. 1982) can be used with the atomic coordinates from the homology model to identify potential ligands from databases or
15 virtual databases which potentially bind the in the metal binding region, and which may therefore be suitable candidates for synthesis and testing.

Additionally, the three-dimensional homology model of BMY_HPP2 will aid in the design of mutants with altered biological activity.

Many polynucleotide sequences, such as EST sequences, are publicly
20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:151 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
25 are one or more polynucleotides consisting of a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 864 of SEQ ID NO:151, b is an integer between 15 to 878, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:151, and where b is greater than or equal to a+14.

30

Features of the Polypeptide Encoded by Gene No:3

The polypeptide fragment corresponding to this gene provided as SEQ ID NO:8 (Figure 3), encoded by the polynucleotide sequence according to SEQ ID NO:7 (Figure 3), and/or encoded by the polynucleotide contained within the deposited
35 clone, BMY_HPP3, has significant homology at the nucleotide and amino acid level to a number of phosphatases, which include, for example, the human protein tyrosine phosphatase PTPCAAX1 protein (HS_PTPCAAX1; Genbank Accession No:gi|

5 AAB40597; SEQ ID NO:33); the human protein tyrosine phosphatase PTPCAAX2 (HS_PTPCAAX2; Genbank Accession No:gi| AAB40598; SEQ ID NO:34); the mouse prenylated protein tyrosine phosphatase (MM_PTPCAAX; Genbank Accession No:gi| JC5981; SEQ ID NO:35); and the Drosophila PRL-1 protein (DM_PRL1; Genbank Accession No:gi| AAF53506; SEQ ID NO:36) as determined
 10 by BLASTP. An alignment of the human phosphatase polypeptide with these proteins is provided in Figure 8.

BMY_HPP3 is predicted to be a prenylated phosphoprotein phosphatase based on its similarity to drosophila, mouse and human prenylated phosphotyrosine phosphatases (PTPCAAX proteins). Among the conserved catalytic residues, there is
 15 a conserved Aspartate ("D") and a conserved nucleophilic Cysteine ("C") as shown in Figure 8. At the C-terminus, a consensus prenylation site is conserved in BMY-HPP3 suggesting that the protein could be post-translationally modified by farnesylation or geranylation.

Preferred polynucleotides of the present invention comprise the following
 20 nucleic acid sequence:
 ATGGCTAGAATGAACCTCCCTGCTTCTGTGGACATTGCATACAAAAATGT
 GAGATTTCTTATTACACACAACCCAACCAATACCTACTTTAATAGATTCTT
 ACAGGAACTTAAGCAGGATGGAGTTACCACCATAGTAAGAGTATGAAAA
 GCAACTTACAACATTGCTCTTTTAGAGAAGGGAAGCATCCAGGTTCCGGA
 25 CTGGCCTTTTGATGATGGTACAGCACCATCCAGCCAGATAATTGATAACTG
 GTTAAACTTATGAAAAATAAATTTTCATGAAGATCCTGGTTGTTGTATTGC
 AATTCAGTGTGTTGTAGGTTTTGGGTGAGCTCCAGTTGCTAGTTGCCCTAG
 CTTTAATTGAAGGTGGAATGAAATATGAAAATGTAGTACAGTTCATCAGA
 TAAAAGTGACATGGAACCTTTTAACAGCAAACAACCTTTTGTATTTGGAGAA
 30 ATATTGTCTTAAAATATGCTTGCACCTCAGAAATCCCAGAAATAACTGTTT
 CCTTCAG (SEQ ID NO: 83). Polypeptides encoding by these polynucleotides are also provided.

Preferred polypeptides of the present invention comprise the following amino
 acid sequence:
 35 MARMNLPASVDIA YKNVRFLITHNPTNTYFNRFLQELKQDGVTTIVRVKATY
 NIALLEKGSIQVPDWPFDGDTAPSSQIIDNWLKLMKNKFHEDPGCCIAIHCVV

- 5 GFGELQLLVALALIEGGMKYENVVQFIRKHGTFNSKQLLYLEKYCLKICLHLR
NPRNNCFLO (SEQ ID NO:84). Polynucleotides encoding these polypeptides are
also provided.

Based upon the strong homology to members of the phosphatase proteins, the polypeptide encoded by the human BMY_HPP3 phosphatase of the present invention
10 is expected to share at least some biological activity with phosphatase proteins, preferably with members of the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases, particularly the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases referenced herein.

The present invention encompasses the use of BMY_HPP3 inhibitors and/or
15 activators of BMY_HPP3 activity for the treatment, detection, amelioration, or prevention of phosphatase associated disorders, including but not limited to metabolic diseases such as diabetes, in addition to neural and/or cardiovascular diseases and disorders. The present invention also encompasses the use of BMY_HPP3 inhibitors and/or activators of BMY_HPP3 activity as immunosuppressive agents, anti-
20 inflammatory agents, and/or anti-tumor agents

The present invention encompasses the use of BMY_HPP3 phosphatase inhibitors, including, antagonists such as antisense nucleic acids, in addition to other antagonists, as described herein, in a therapeutic regimen to diagnose, prognose, treat, ameliorate, and/or prevent diseases where a kinase activity is insufficient. One, non-
25 limiting example of a disease which may occur due to insufficient kinase activity are certain types of diabetes, where one or more kinases involved in the insulin receptor signal pathway may have insufficient activity or insufficient expression, for example.

Moreover, the present invention encompasses the use of BMY_HPP3 phosphatase activators, and/or the use of the BMY_HPP3 phosphatase gene or protein
30 in a gene therapy regimen, as described herein, for the diagnoses, prognoses, treatment, amelioration, and/or prevention of diseases and/or disorders where a kinase activity is overly high, such as a cancer where a kinase oncogene product has excessive activity or excessive expression.

The present invention also encompasses the use of catalytically inactive
35 variants of BMY_HPP3 proteins, including fragments thereof, such as a protein therapeutic, or the use of the encoding polynucleotide sequence or as gene therapy,

5 for example, in the diagnoses, prognosis, treatment, amelioration, and/or prevention of diseases or disorders where phosphatase activity is overly high.

The present invention encompasses the use of antibodies directed against the BMY_HPP3 polypeptides, including fragment and/or variants thereof, of the present invention in diagnostics, as a biomarkers, and/or as a therapeutic agents.

10 The present invention encompasses the use of an inactive, non-catalytic, mutant of the BMY_HPP3 phosphatase as a substrate trapping mutant to bind cellular phosphoproteins or a library of phosphopeptides to identify substrates of the BMY_HPP3 polypeptides.

The present invention encompasses the use of the BMY_HPP3 polypeptides, 15 to identify inhibitors or activators of the BMY_HPP3 phosphatase activity using either in vitro or 'virtual' (in silico) screening methods.

One embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of the BMY_HPP3 phosphatase comprising the steps of: i.) contacting a BMY_HPP3 phosphatase inhibitor or activator labeled with 20 an analytically detectable reagent with the BMY_HPP3 phosphatase under conditions sufficient to form a complex with the inhibitor or activator; ii.) contacting said complex with a sample containing a compound to be identified; iii) and identifying the compound as an inhibitor or activator by detecting the ability of the test compound to alter the amount of labeled known BMY_HPP3 phosphatase inhibitor or activator 25 in the complex.

Another embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of a BMY_HPP3 phosphatase comprising the steps of: i.) contacting the BMY_HPP3 phosphatase with a compound to be 30 identified; and ii.) and measuring the ability of the BMY_HPP3 phosphatase to remove phosphate from a substrate.

The present invention also encompasses a method for identifying a ligand for the BMY_HPP3 phosphatase comprising the steps of: i.) contacting the BMY_HPP3 phosphatase with a series of compounds under conditions to permit binding; and ii.) detecting the presence of any ligand-bound protein.

35 Preferably, the above referenced methods comprise the BMY_HPP3 phosphatase in a form selected from the group consisting of whole cells, cytosolic cell

5 fractions, membrane cell fractions, purified or partially purified forms. The invention also relates to recombinantly expressed BMY_HPP3 phosphatase in a purified, substantially purified, or unpurified state. The invention further relates to BMY_HPP3 phosphatase fused or conjugated to a protein, peptide, or other molecule or compound known in the art, or referenced herein.

10 The present invention also encompasses pharmaceutical composition of the BMY_HPP3 phosphatase polypeptide comprising a compound identified by above referenced methods and a pharmaceutically acceptable carrier.

Features of the Polypeptide Encoded by Gene No:4

15 The polypeptide fragment corresponding to this gene provided as SEQ ID NO:10 (Figure 4), encoded by the polynucleotide sequence according to SEQ ID NO:9 (Figure 4), and/or encoded by the polynucleotide contained within the deposited clone, BMY_HPP4, has significant homology at the nucleotide and amino acid level to a number of phosphatases, which include, for example, the mouse osteotesticular
20 protein tyrosine phosphatase (MM_OST-PTP; Genbank Accession No:gi| AAG28768; SEQ ID NO:37); and the rat protein-tyrosine-phosphatase (RN_PTP-OST; Genbank Accession No:gi| A55148; SEQ ID NO:38) as determined by BLASTP. An alignment of the human phosphatase polypeptide with these proteins is provided in Figure 9.

25 BMY_HPP4 is predicted to be a phosphoprotein phosphatase based on its homology to rat osteotesticular receptor protein-tyrosine-phosphatase precursor (Genbank ID 1083770) and to mouse receptor protein-tyrosine-phosphatase precursor (Genbank ID 11066925). The BMY_HPP4 polypeptide has been shown to comprise a conserved Aspartate ("D") at amino acid 182 of SEQ ID NO:10 (Figure 4), a catalytic
30 Cysteine ("C") at amino acid 216 of SEQ ID NO:10 (Figure 4), and a conserved Arginine ("R") at amino acid 227 of SEQ ID NO:10 (Figure 4).

The predicted exon structure of the BMY_HPP4 gene is provided in Table V. The 'Start' and 'End' designations refer to the respective nucleotide positions of the BMY_HPP4 as they appear for BAC AL 354751. The numbering begins at the start
35 of BAC AL354751; nucleotide 71352 in the BAC is equivalent to nucleotide 1 of the BMY_HPP4 transcript (SEQ ID NO:9; Figure 4).

5 Based upon the strong homology to members of the phosphatase proteins, the polypeptide encoded by the human BMY_HPP4 phosphatase of the present invention is expected to share at least some biological activity with phosphatase proteins, preferably with members of the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases, particularly the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases referenced herein.

10 The present invention encompasses the use of BMY_HPP4 inhibitors and/or activators of BMY_HPP4 activity for the treatment, detection, amelioration, or prevention of phosphatase associated disorders, including but not limited to metabolic diseases such as diabetes, in addition to neural and/or cardiovascular diseases and disorders. The present invention also encompasses the use of BMY_HPP4 inhibitors and/or activators of BMY_HPP4 activity as immunosuppressive agents, anti-inflammatory agents, and/or anti-tumor agents

15 The present invention encompasses the use of BMY_HPP4 phosphatase inhibitors, including, antagonists such as antisense nucleic acids, in addition to other antagonists, as described herein, in a therapeutic regimen to diagnose, prognose, treat, ameliorate, and/or prevent diseases where a kinase activity is insufficient. One, non-limiting example of a disease which may occur due to insufficient kinase activity are certain types of diabetes, where one or more kinases involved in the insulin receptor signal pathway may have insufficient activity or insufficient expression, for example.

20 Moreover, the present invention encompasses the use of BMY_HPP4 phosphatase activators, and/or the use of the BMY_HPP4 phosphatase gene or protein in a gene therapy regimen, as described herein, for the diagnoses, prognoses, treatment, amelioration, and/or prevention of diseases and/or disorders where a kinase activity is overly high, such as a cancer where a kinase oncogene product has excessive activity or excessive expression.

25 The present invention also encompasses the use of catalytically inactive variants of BMY_HPP4 proteins, including fragments thereof, such as a protein therapeutic, or the use of the encoding polynucleotide sequence or as gene therapy, for example, in the diagnoses, prognosis, treatment, amelioration, and/or prevention of diseases or disorders where phosphatase activity is overly high.

5 The present invention encompasses the use of antibodies directed against the BMY_HPP4 polypeptides, including fragment and/or variants thereof, of the present invention in diagnostics, as a biomarkers, and/or as a therapeutic agents.

 The present invention encompasses the use of an inactive, non-catalytic, mutant of the BMY_HPP4 phosphatase as a substrate trapping mutant to bind cellular
10 phosphoproteins or a library of phosphopeptides to identify substrates of the BMY_HPP4 polypeptides.

 The present invention encompasses the use of the BMY_HPP4 polypeptides, to identify inhibitors or activators of the BMY_HPP4 phosphatase activity using either in vitro or 'virtual' (in silico) screening methods.

15 One embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of the BMY_HPP4 phosphatase comprising the steps of: i.) contacting a BMY_HPP4 phosphatase inhibitor or activator labeled with an analytically detectable reagent with the BMY_HPP4 phosphatase under conditions sufficient to form a complex with the inhibitor or activator; ii.) contacting said
20 complex with a sample containing a compound to be identified; iii) and identifying the compound as an inhibitor or activator by detecting the ability of the test compound to alter the amount of labeled known BMY_HPP4 phosphatase inhibitor or activator in the complex.

 Another embodiment of the invention relates to a method for identifying a
25 compound as an activator or inhibitor of a BMY_HPP4 phosphatase comprising the steps of: i.) contacting the BMY_HPP4 phosphatase with a compound to be identified; and ii.) and measuring the ability of the BMY_HPP4 phosphatase to remove phosphate from a substrate.

 The present invention also encompasses a method for identifying a ligand for
30 the BMY_HPP4 phosphatase comprising the steps of: i.) contacting the BMY_HPP4 phosphatase with a series of compounds under conditions to permit binding; and ii.) detecting the presence of any ligand-bound protein.

 Preferably, the above referenced methods comprise the BMY_HPP4 phosphatase in a form selected from the group consisting of whole cells, cytosolic cell
35 fractions, membrane cell fractions, purified or partially purified forms. The invention also relates to recombinantly expressed BMY_HPP4 phosphatase in a purified,

5 substantially purified, or unpurified state. The invention further relates to BMY_HPP4 phosphatase fused or conjugated to a protein, peptide, or other molecule or compound known in the art, or referenced herein.

The present invention also encompasses pharmaceutical composition of the BMY_HPP4 phosphatase polypeptide comprising a compound identified by above
10 referenced methods and a pharmaceutically acceptable carrier.

Expression profiling of the BMY_HPP4 polypeptide in normal tissues showed that BMY_HPP4 is expressed at higher levels in the cerebellum than in any other tissue, suggesting a role for modulators of BMY_HPP4 activity in the treatment of neurological disorders such as depression, bipolar disorder, schizophrenia, dementia
15 and cognitive disorders (as shown in Figure 34). BMY_HPP4 was also expressed at lower levels in other subregions of the brain. In addition, BMY_HPP4 was expressed at significant levels in the pineal and pituitary glands, suggesting a role for modulators of BMY_HPP4 activity in endocrine disorders.

The strong homology to dual specificity phosphatases, combined with the
20 localized expression in cerebellum suggests the BMY_HPP4 polynucleotides and polypeptides may be useful in treating, diagnosing, prognosing, and/or preventing neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in the Examples, and elsewhere herein. Briefly, the uses
25 include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
30 compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning,
35 cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue

5 markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

The strong homology to dual specificity phosphatases, combined with the
10 localized expression in pineal and pituitary glands suggests the BMY_HPP4 polynucleotides and polypeptides may be useful in treating, diagnosing, prognosing, and/or preventing endocrine diseases and/or disorders, which include, but are not limited to, the following: aberrant growth hormone synthesis and/or secretion, aberrant prolactin synthesis and/or secretion, aberrant luteinizing hormone synthesis
15 and/or secretion, aberrant follicle-stimulating hormone synthesis and/or secretion, aberrant thyroid-stimulating hormone synthesis and/or secretion, aberrant adrenocorticotropin synthesis and/or secretion, aberrant vasopressin secretion, aberrant oxytocin secretion, aberrant growth, aberrant lactation, aberrant sexual characteristic development, aberrant testosterone synthesis and/or secretion, aberrant
20 estrogen synthesis and/or secretion, aberrant water homeostasis, hypogonadism, Addison's disease, hypothyroidism, Cushing's disease, agromegaly, gigantism, lethargy, osteoporosis, aberrant calcium homeostasis, aberrant potassium homeostasis, reproductive disorders, and developmental disorders.

25 **Features of the Polypeptide Encoded by Gene No:5**

The polypeptide corresponding to this gene provided as SEQ ID NO:42 (Figure 5), encoded by the polynucleotide sequence according to SEQ ID NO:41 (Figure 5), and/or encoded by the polynucleotide contained within the deposited clone, BMY_HPP5, has significant homology at the nucleotide and amino acid level
30 to a number of phosphatases, which include, for example, the human dual specificity phosphatase 8 (hs_dspp8; Genbank Accession No:gi| NP_004411; SEQ ID NO:39); and the mouse neuronal tyrosine/threonine phosphatase 1 (r mm_nppl; Genbank Accession No:gi| NP_032774; SEQ ID NO:40) as determined by BLASTP. An alignment of the human phosphatase polypeptide with these proteins is provided in
35 Figures 10A-B.

5 The determined nucleotide sequence of the BMY_HPP5 cDNA in Figures 5A-E (SEQ ID NO:41) contains an open reading frame encoding a protein of about 665 amino acid residues, with a deduced molecular weight of about 73kDa. The amino acid sequence of the predicted BMY_HPP5 polypeptide is shown in Figures 5A-E (SEQ ID NO:42). The BMY_HPP5 protein shown in Figures 5A-E was determined to
10 share significant identity and similarity to several known phosphatases, particularly, dual-specificity protein phosphatases. Specifically, the BMY_HPP5 protein shown in Figures 5A-E was determined to be about 46% identical and 58% similar to the human dual specificity phosphatase 8 (HS_DSPP8; Genbank Accession No: gi|NP_004411; SEQ ID NO:39); and about 43% identical and 56% similar to the mouse
15 neuronal tyrosine/threonine phosphatase 1 (MM_NPP1; Genbank Accession No: gi|NP_032774; SEQ ID NO:40), as shown in Figure 12.

 BMY_HPP5 is predicted to encode a phosphoprotein phosphatase based on its homology to known dual-specificity protein phosphatases including human dual-specificity protein phosphatase 8 (GI 4758212) and mouse neuronal
20 tyrosine/threonine phosphatase 1 (GI 6679156) (Figures 10A-B). The BMY_HPP5 polypeptide was determined to comprise conserved residues, which include, the catalytic Aspartate ("D") at amino acid 212, and a conserved Cysteine ("C") at amino acid 244, and Arginine ("R") at amino acid 249 of SEQ ID NO:42 (Figures 5A-E).

 Based upon the strong homology to members of the phosphatase proteins, the
25 polypeptide encoded by the human BMY_HPP5 phosphatase of the present invention is expected to share at least some biological activity with phosphatase proteins, preferably with members of the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases, particularly the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases referenced herein.

30 Expression profiling designed to measure the steady state mRNA levels encoding the human phosphatase polypeptide, BMY_HPP5, showed predominately high expression levels in the testis and spinal cord, and to a lesser extent, in bone marrow, brain, liver, and thymus. (See Figure 11).

 Moreover, expanded expression profiling of the BMY_HPP5 polypeptide in
35 normal human tissues showed the highest levels of expression in the adrenal, pineal and pituitary glands suggesting that modulators of BMY_HPP5 activity could be

5 useful in the treatment of endocrine disorders (as shown in Figure 35). BMY_HPP5
also expressed at high levels in the cerebellum, suggesting a role for modulators of
BMY_HPP5 activity in the treatment of neurological disorders such as depression,
bipolar disorder, schizophrenia, dementia and cognitive disorders; in the prostate,
suggesting a role for modulators of BMY_HPP5 activity in the treatment of prostate
10 cancer or benign prostatic hyperplasia; in the testis, suggesting a role for modulators
of BMY_HPP5 activity in the treatment of male infertility caused by defective or
insufficient spermatogenesis, as a contraceptive agent, or in the treatment of testicular
cancer. BMYBMY_HPP5 was also expressed at a lower but significant level in many
other normal human tissues.

15 The strong homology to phosphatases, particularly dual-specificity
phosphatases, combined with the predominate localized expression in adrenal gland
tissue suggests the human BMY_HPP5 phosphatase polynucleotides and
polypeptides, including antagonists, and/or fragments thereof, may be useful for
treating, diagnosing, prognosing, ameliorating, and/or preventing endocrine disorders,
20 which include, but are not limited to adrenocortical hyperfunction, adrenocortical
hypofunction, lethargy. Congenital adrenal hyperplasia, aberrant ACTH regulation,
aberrant adrenaline regulation, disorders associated with defects in P450C21,
P450C18, P450C17, and P450C11 hydroxylases and in 3-hydroxysteroid
dehydrogenase (3-HSD), hirsutism, oligomenorrhea, acne, virilization,
25 oligomenorrhea, female pseudohermaphroditism, disorders associated with the
incidence of aberrant sexual characteristics, disorders associated with aberrant
cortisol secretion, hypertension, hypokalemia, hypogonadism, disorders associated
with aberrant androgen secretion, adrenal virilism, Adrenal adenomas, Adrenal
carcinomas, disorders associated with aberrant aldosterone secretion, aldosteronism,
30 disorders associated with aberrant steroid biosynthesis, disorders associated with
aberrant steroid transport, disorders associated with aberrant steroid secretion,
disorders associated with aberrant steroid excretion, Addison's syndrome, and
Cushing's syndrome.

The strong homology to phosphatases, particularly dual-specificity
35 phosphatases, combined with the predominate localized expression in pituitary gland
tissue suggests the BMY_HPP5 polynucleotides and polypeptides may be useful in

5 treating, diagnosing, prognosing, and/or preventing endocrine diseases and/or disorders, which include, but are not limited to, the following: aberrant growth hormone synthesis and/or secretion, aberrant prolactin synthesis and/or secretion, aberrant luteinizing hormone synthesis and/or secretion, aberrant follicle-stimulating hormone synthesis and/or secretion, aberrant thyroid-stimulating hormone synthesis and/or secretion, aberrant adrenocorticotropin synthesis and/or secretion, aberrant vasopressin secretion, aberrant oxytocin secretion, aberrant growth, aberrant lactation, aberrant sexual characteristic development, aberrant testosterone synthesis and/or secretion, aberrant estrogen synthesis and/or secretion, aberrant water homeostasis, hypogonadism, Addison's disease, hypothyroidism, Cushing's disease, agromegaly, gigantism, lethargy, osteoporosis, aberrant calcium homeostasis, aberrant potassium homeostasis, reproductive disorders, developmental disorders, and depression related to low incident light levels.

The strong homology to phosphatases, particularly dual-specificity phosphatases, combined with the predominate localized expression in testis tissue suggests the human BMY_HPP5 phosphatase polynucleotides and polypeptides, including antagonists, and/or fragments thereof, may be useful for treating, diagnosing, prognosing, and/or preventing male reproductive disorders, such as, for example, male infertility, impotence, and/or testicular cancer. This gene product may also be useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. In fact, increased expression of certain phosphatases have been identified as tumor markers for testicular cancer (see, for example, Koshida, K., Nishino, A., Yamamoto, H., Uchibayashi, T., Naito, K., Hisazumi, H., Hirano, K., Hayashi, Y., Wahren, B., Andersson, L, J. Urol., 146(1):57-60, (1991); and Klein, EA, Urol. Clin. North. Am., 20(1):67-73, (1993)).

35 Alternatively, the strong homology to phosphatases, particularly dual-specificity phosphatases, combined with the significant localized expression in spinal

5 cord and brain tissue suggests the human phosphatase polynucleotides and polypeptides may be useful in treating, diagnosing, prognosing, and/or preventing neural diseases and/or disorders. Representative uses are described in the "Neurological Diseases" section below, and elsewhere herein. Briefly, the expression in neural tissue indicates a role in Alzheimer's Disease, Parkinson's Disease, 10 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal dysphida, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, 15 including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine 20 biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25 Moreover, the tissue distribution in liver indicates the protein product of this clone would be useful for the detection and treatment of liver disorders and cancers. Representative uses are described in the "Hyperproliferative Disorders", "Infectious Disease", and "Binding Activity" sections below, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of hepatoblastoma, 30 jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells. In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing diseases and/or tissue trauma.

35 Moreover, human phosphatase polynucleotides and polypeptides, including fragments and agonists thereof, may have uses which include treating, diagnosing,

5 prognosing, and/or preventing hyperproliferative disorders, particularly of the renal, neural, and reproductive systems. Such disorders may include, for example, cancers, and metastasis.

The human phosphatase polynucleotides and polypeptides, including fragments and agonists thereof, may have uses which include, either directly or
10 indirectly, for boosting immune responses.

The human phosphatase polynucleotides and polypeptides, including fragments and /or antagonists thereof, may have uses which include identification of modulators of human phosphatase function including antibodies (for detection or neutralization), naturally-occurring modulators and small molecule modulators.
15 Antibodies to domains of the human phosphatase protein could be used as diagnostic agents of cardiovascular and inflammatory conditions in patients, are useful in monitoring the activation of signal transduction pathways, and can be used as a biomarker for the involvement of phosphatases in disease states, and in the evaluation of inhibitors of phosphatases in vivo.

20 Human phosphatase polypeptides and polynucleotides have additional uses which include diagnosing diseases related to the over and/or under expression of human phosphatase by identifying mutations in the human phosphatase gene by using human phosphatase sequences as probes or by determining human phosphatase protein or mRNA expression levels. Human phosphatase polypeptides may be useful
25 for screening compounds that affect the activity of the protein. Human phosphatase peptides can also be used for the generation of specific antibodies and as bait in yeast two hybrid screens to find proteins the specifically interact with human phosphatase (described elsewhere herein).

Although it is believed the encoded polypeptide may share at least some
30 biological activities with phosphatase proteins (particularly dual specificity proteins), a number of methods of determining the exact biological function of this clone are either known in the art or are described elsewhere herein. Briefly, the function of this clone may be determined by applying microarray methodology. Nucleic acids corresponding to the human phosphatase polynucleotides, in addition to, other clones
35 of the present invention, may be arrayed on microchips for expression profiling. Depending on which polynucleotide probe is used to hybridize to the slides, a change

5 in expression of a specific gene may provide additional insight into the function of this gene based upon the conditions being studied. For example, an observed increase or decrease in expression levels when the polynucleotide probe used comes from diseased heart tissue, as compared to, normal tissue might indicate a function in modulating cardiac function, for example. In the case of human BMY_HPP5
10 phosphatase, testis, spinal cord, brain, liver, bone marrow, and thymus tissue should be used, for example, to extract RNA to prepare the probe.

In addition, the function of the protein may be assessed by applying quantitative PCR methodology, for example. Real time quantitative PCR would provide the capability of following the expression of the human phosphatase gene
15 throughout development, for example. Quantitative PCR methodology requires only a nominal amount of tissue from each developmentally important step is needed to perform such experiments. Therefore, the application of quantitative PCR methodology to refining the biological function of this polypeptide is encompassed by the present invention. In the case of human phosphatase, a disease correlation related
20 to human phosphatase may be made by comparing the mRNA expression level of human phosphatase in normal tissue, as compared to diseased tissue (particularly diseased tissue isolated from the following: testis, spinal cord, brain, liver, bone marrow, and thymus tissue). Significantly higher or lower levels of human phosphatase expression in the diseased tissue may suggest human phosphatase plays a
25 role in disease progression, and antagonists against human phosphatase polypeptides would be useful therapeutically in treating, preventing, and/or ameliorating the disease. Alternatively, significantly higher or lower levels of human phosphatase expression in the diseased tissue may suggest human phosphatase plays a defensive role against disease progression, and agonists of human phosphatase polypeptides
30 may be useful therapeutically in treating, preventing, and/or ameliorating the disease. Also encompassed by the present invention are quantitative PCR probes corresponding to the polynucleotide sequence provided as SEQ ID NO:41 (Figures 4A-D).

The function of the protein may also be assessed through complementation
35 assays in yeast. For example, in the case of the human phosphatase, transforming yeast deficient in purinergic receptor activity, for example, and assessing their ability

5 to grow would provide convincing evidence the human phosphatase polypeptide has purinergic receptor activity. Additional assay conditions and methods that may be used in assessing the function of the polynucleotides and polypeptides of the present invention are known in the art, some of which are disclosed elsewhere herein.

Alternatively, the biological function of the encoded polypeptide may be
10 determined by disrupting a homologue of this polypeptide in Mice and/or rats and observing the resulting phenotype. Such knock-out experiments are known in the art, some of which are disclosed elsewhere herein.

Moreover, the biological function of this polypeptide may be determined by the application of antisense and/or sense methodology and the resulting generation of
15 transgenic mice and/or rats. Expressing a particular gene in either sense or antisense orientation in a transgenic mouse or rat could lead to respectively higher or lower expression levels of that particular gene. Altering the endogenous expression levels of a gene can lead to the observation of a particular phenotype that can then be used to derive indications on the function of the gene. The gene can be either over-expressed
20 or under expressed in every cell of the organism at all times using a strong ubiquitous promoter, or it could be expressed in one or more discrete parts of the organism using a well characterized tissue-specific promoter (e.g., a kidney, lung, spinal cord, or testes tissue specific promoter), or it can be expressed at a specified time of development using an inducible and/or a developmentally regulated promoter.

25 In the case of human phosphatase transgenic mice or rats, if no phenotype is apparent in normal growth conditions, observing the organism under diseased conditions (renal, pulmonary, neurological, or reproductive disorders, in addition to cancers, etc.) may lead to understanding the function of the gene. Therefore, the application of antisense and/or sense methodology to the creation of transgenic mice
30 or rats to refine the biological function of the polypeptide is encompassed by the present invention.

In preferred embodiments, the following N-terminal deletion mutants are encompassed by the present invention: M1-S665, A2-S665, H3-S665, E4-S665, M5-S665, I6-S665, G7-S665, T8-S665, Q9-S665, I10-S665, V11-S665, T12-S665, E13-S665, R14-S665, L15-S665, V16-S665, A17-S665, L18-S665, L19-S665, E20-S665,
35 S21-S665, G22-S665, T23-S665, E24-S665, K25-S665, V26-S665, L27-S665, L28-

5 S665, I29-S665, D30-S665, S31-S665, R32-S665, P33-S665, F34-S665, V35-S665,
E36-S665, Y37-S665, N38-S665, T39-S665, S40-S665, H41-S665, I42-S665, L43-
S665, E44-S665, A45-S665, I46-S665, N47-S665, I48-S665, N49-S665, C50-S665,
S51-S665, K52-S665, L53-S665, M54-S665, K55-S665, R56-S665, R57-S665, L58-
S665, Q59-S665, Q60-S665, D61-S665, K62-S665, V63-S665, L64-S665, I65-S665,
10 T66-S665, E67-S665, L68-S665, I69-S665, Q70-S665, H71-S665, S72-S665, A73-
S665, K74-S665, H75-S665, K76-S665, V77-S665, D78-S665, I79-S665, D80-S665,
C81-S665, S82-S665, Q83-S665, K84-S665, V85-S665, V86-S665, V87-S665, Y88-
S665, D89-S665, Q90-S665, S91-S665, S92-S665, Q93-S665, D94-S665, V95-S665,
A96-S665, S97-S665, L98-S665, S99-S665, S100-S665, D101-S665, C102-S665,
15 F103-S665, L104-S665, T105-S665, V106-S665, L107-S665, L108-S665, G109-
S665, K110-S665, L111-S665, E112-S665, K113-S665, S114-S665, F115-S665,
N116-S665, S117-S665, V118-S665, H119-S665, L120-S665, L121-S665, A122-
S665, G123-S665, G124-S665, F125-S665, A126-S665, E127-S665, F128-S665,
S129-S665, R130-S665, C131-S665, F132-S665, P133-S665, G134-S665, L135-
20 S665, C136-S665, E137-S665, G138-S665, K139-S665, S140-S665, T141-S665,
L142-S665, V143-S665, P144-S665, T145-S665, C146-S665, I147-S665, S148-S665,
Q149-S665, P150-S665, C151-S665, L152-S665, P153-S665, V154-S665, A155-
S665, N156-S665, I157-S665, G158-S665, P159-S665, T160-S665, R161-S665,
I162-S665, L163-S665, P164-S665, N165-S665, L166-S665, Y167-S665, L168-
25 S665, G169-S665, C170-S665, Q171-S665, R172-S665, D173-S665, V174-S665,
L175-S665, N176-S665, K177-S665, E178-S665, L179-S665, M180-S665, Q181-
S665, Q182-S665, N183-S665, G184-S665, I185-S665, G186-S665, Y187-S665,
V188-S665, L189-S665, N190-S665, A191-S665, S192-S665, N193-S665, T194-
S665, C195-S665, P196-S665, K197-S665, P198-S665, D199-S665, F200-S665,
30 I201-S665, P202-S665, E203-S665, S204-S665, H205-S665, F206-S665, L207-S665,
R208-S665, V209-S665, P210-S665, V211-S665, N212-S665, D213-S665, S214-
S665, F215-S665, C216-S665, E217-S665, K218-S665, I219-S665, L220-S665,
P221-S665, W222-S665, L223-S665, D224-S665, K225-S665, S226-S665, V227-
S665, D228-S665, F229-S665, I230-S665, E231-S665, K232-S665, A233-S665,
35 K234-S665, A235-S665, S236-S665, N237-S665, G238-S665, C239-S665, V240-
S665, L241-S665, V242-S665, H243-S665, C244-S665, L245-S665, A246-S665,

5 G247-S665, I248-S665, S249-S665, R250-S665, S251-S665, A252-S665, T253-S665, I254-S665, A255-S665, I256-S665, A257-S665, Y258-S665, I259-S665, M260-S665, K261-S665, R262-S665, M263-S665, D264-S665, M265-S665, S266-S665, L267-S665, D268-S665, E269-S665, A270-S665, Y271-S665, R272-S665, F273-S665, V274-S665, K275-S665, E276-S665, K277-S665, R278-S665, P279-
10 S665, T280-S665, I281-S665, S282-S665, P283-S665, N284-S665, F285-S665, N286-S665, F287-S665, L288-S665, G289-S665, Q290-S665, L291-S665, L292-S665, A293-S665, Y294-S665, E295-S665, K296-S665, K297-S665, I298-S665, K299-S665, N300-S665, Q301-S665, T302-S665, G303-S665, A304-S665, S305-S665, G306-S665, P307-S665, K308-S665, S309-S665, K310-S665, L311-S665,
15 K312-S665, L313-S665, L314-S665, P315-S665, L316-S665, E317-S665, K318-S665, P319-S665, N320-S665, E321-S665, P322-S665, V323-S665, P324-S665, A325-S665, V326-S665, S327-S665, E328-S665, G329-S665, G330-S665, Q331-S665, K332-S665, S333-S665, E334-S665, T335-S665, P336-S665, L337-S665, S338-S665, P339-S665, P340-S665, C341-S665, A342-S665, D343-S665, S344-
20 S665, A345-S665, T346-S665, S347-S665, E348-S665, A349-S665, A350-S665, G351-S665, Q352-S665, R353-S665, P354-S665, V355-S665, H356-S665, P357-S665, A358-S665, S359-S665, V360-S665, P361-S665, S362-S665, V363-S665, P364-S665, S365-S665, V366-S665, Q367-S665, P368-S665, S369-S665, L370-S665, L371-S665, E372-S665, D373-S665, S374-S665, P375-S665, L376-S665,
25 V377-S665, Q378-S665, A379-S665, L380-S665, S381-S665, G382-S665, L383-S665, H384-S665, L385-S665, S386-S665, A387-S665, D388-S665, R389-S665, L390-S665, E391-S665, D392-S665, S393-S665, N394-S665, K395-S665, L396-S665, K397-S665, R398-S665, S399-S665, F400-S665, S401-S665, L402-S665, D403-S665, I404-S665, K405-S665, S406-S665, V407-S665, S408-S665, Y409-
30 S665, S410-S665, A411-S665, S412-S665, M413-S665, A414-S665, A415-S665, S416-S665, L417-S665, H418-S665, G419-S665, F420-S665, S421-S665, S422-S665, S423-S665, E424-S665, D425-S665, A426-S665, L427-S665, E428-S665, Y429-S665, Y430-S665, K431-S665, P432-S665, S433-S665, T434-S665, T435-S665, L436-S665, D437-S665, G438-S665, T439-S665, N440-S665, K441-S665,
35 L442-S665, C443-S665, Q444-S665, F445-S665, S446-S665, P447-S665, V448-S665, Q449-S665, E450-S665, L451-S665, S452-S665, E453-S665, Q454-S665,

5 T455-S665, P456-S665, E457-S665, T458-S665, S459-S665, P460-S665, D461-S665, K462-S665, E463-S665, E464-S665, A465-S665, S466-S665, I467-S665, P468-S665, K469-S665, K470-S665, L471-S665, Q472-S665, T473-S665, A474-S665, R475-S665, P476-S665, S477-S665, D478-S665, S479-S665, Q480-S665, S481-S665, K482-S665, R483-S665, L484-S665, H485-S665, S486-S665, V487-S665, R488-S665, T489-S665, S490-S665, S491-S665, S492-S665, G493-S665, T494-S665, A495-S665, Q496-S665, R497-S665, S498-S665, L499-S665, L500-S665, S501-S665, P502-S665, L503-S665, H504-S665, R505-S665, S506-S665, G507-S665, S508-S665, V509-S665, E510-S665, D511-S665, N512-S665, Y513-S665, H514-S665, T515-S665, S516-S665, F517-S665, L518-S665, F519-S665, G520-S665, L521-S665, S522-S665, T523-S665, S524-S665, Q525-S665, Q526-S665, H527-S665, L528-S665, T529-S665, K530-S665, S531-S665, A532-S665, G533-S665, L534-S665, G535-S665, L536-S665, K537-S665, G538-S665, W539-S665, H540-S665, S541-S665, D542-S665, I543-S665, L544-S665, A545-S665, P546-S665, Q547-S665, T548-S665, S549-S665, T550-S665, P551-S665, S552-S665, L553-S665, T554-S665, S555-S665, S556-S665, W557-S665, Y558-S665, F559-S665, A560-S665, T561-S665, E562-S665, S563-S665, S564-S665, H565-S665, F566-S665, Y567-S665, S568-S665, A569-S665, S570-S665, A571-S665, I572-S665, Y573-S665, G574-S665, G575-S665, S576-S665, A577-S665, S578-S665, Y579-S665, S580-S665, A581-S665, Y582-S665, S583-S665, C584-S665, S585-S665, Q586-S665, L587-S665, P588-S665, T589-S665, C590-S665, G591-S665, D592-S665, Q593-S665, V594-S665, Y595-S665, S596-S665, V597-S665, R598-S665, R599-S665, R600-S665, Q601-S665, K602-S665, P603-S665, S604-S665, D605-S665, R606-S665, A607-S665, D608-S665, S609-S665, R610-S665, R611-S665, S612-S665, W613-S665, H614-S665, E615-S665, E616-S665, S617-S665, P618-S665, F619-S665, E620-S665, K621-S665, Q622-S665, F623-S665, K624-S665, R625-S665, R626-S665, S627-S665, C628-S665, Q629-S665, M630-S665, E631-S665, F632-S665, G633-S665, E634-S665, S635-S665, I636-S665, M637-S665, S638-S665, E639-S665, N640-S665, R641-S665, S642-S665, R643-S665, E644-S665, E645-S665, L646-S665, G647-S665, K648-S665, V649-S665, G650-S665, S651-S665, Q652-S665, S653-S665, S654-S665, F655-S665, S656-S665, G657-S665, S658-S665, and/or M659-S665 of SEQ ID NO:42. Polynucleotide

5 sequences encoding these polypeptides are also provided. The present invention also encompasses the use of the human BMY_HPP5 phosphatase N-terminal deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following C-terminal deletion mutants are
10 encompassed by the present invention: M1-S665, M1-V664, M1-E663, M1-I662, M1-I661, M1-E660, M1-M659, M1-S658, M1-G657, M1-S656, M1-F655, M1-S654, M1-S653, M1-Q652, M1-S651, M1-G650, M1-V649, M1-K648, M1-G647, M1-L646, M1-E645, M1-E644, M1-R643, M1-S642, M1-R641, M1-N640, M1-E639, M1-S638, M1-M637, M1-I636, M1-S635, M1-E634, M1-G633, M1-F632, M1-E631, M1-
15 M630, M1-Q629, M1-C628, M1-S627, M1-R626, M1-R625, M1-K624, M1-F623, M1-Q622, M1-K621, M1-E620, M1-F619, M1-P618, M1-S617, M1-E616, M1-E615, M1-H614, M1-W613, M1-S612, M1-R611, M1-R610, M1-S609, M1-D608, M1-A607, M1-R606, M1-D605, M1-S604, M1-P603, M1-K602, M1-Q601, M1-R600, M1-R599, M1-R598, M1-V597, M1-S596, M1-Y595, M1-V594, M1-Q593, M1-
20 D592, M1-G591, M1-C590, M1-T589, M1-P588, M1-L587, M1-Q586, M1-S585, M1-C584, M1-S583, M1-Y582, M1-A581, M1-S580, M1-Y579, M1-S578, M1-A577, M1-S576, M1-G575, M1-G574, M1-Y573, M1-I572, M1-A571, M1-S570, M1-A569, M1-S568, M1-Y567, M1-F566, M1-H565, M1-S564, M1-S563, M1-E562, M1-T561, M1-A560, M1-F559, M1-Y558, M1-W557, M1-S556, M1-S555, M1-
25 T554, M1-L553, M1-S552, M1-P551, M1-T550, M1-S549, M1-T548, M1-Q547, M1-P546, M1-A545, M1-L544, M1-I543, M1-D542, M1-S541, M1-H540, M1-W539, M1-G538, M1-K537, M1-L536, M1-G535, M1-L534, M1-G533, M1-A532, M1-S531, M1-K530, M1-T529, M1-L528, M1-H527, M1-Q526, M1-Q525, M1-S524, M1-T523, M1-S522, M1-L521, M1-G520, M1-F519, M1-L518, M1-F517, M1-S516,
30 M1-T515, M1-H514, M1-Y513, M1-N512, M1-D511, M1-E510, M1-V509, M1-S508, M1-G507, M1-S506, M1-R505, M1-H504, M1-L503, M1-P502, M1-S501, M1-L500, M1-L499, M1-S498, M1-R497, M1-Q496, M1-A495, M1-T494, M1-G493, M1-S492, M1-S491, M1-S490, M1-T489, M1-R488, M1-V487, M1-S486, M1-H485, M1-L484, M1-R483, M1-K482, M1-S481, M1-Q480, M1-S479, M1-
35 D478, M1-S477, M1-P476, M1-R475, M1-A474, M1-T473, M1-Q472, M1-L471, M1-K470, M1-K469, M1-P468, M1-I467, M1-S466, M1-A465, M1-E464, M1-E463,

5 M1-K462, M1-D461, M1-P460, M1-S459, M1-T458, M1-E457, M1-P456, M1-T455,
M1-Q454, M1-E453, M1-S452, M1-L451, M1-E450, M1-Q449, M1-V448, M1-
P447, M1-S446, M1-F445, M1-Q444, M1-C443, M1-L442, M1-K441, M1-N440,
M1-T439, M1-G438, M1-D437, M1-L436, M1-T435, M1-T434, M1-S433, M1-P432,
M1-K431, M1-Y430, M1-Y429, M1-E428, M1-L427, M1-A426, M1-D425, M1-
10 E424, M1-S423, M1-S422, M1-S421, M1-F420, M1-G419, M1-H418, M1-L417,
M1-S416, M1-A415, M1-A414, M1-M413, M1-S412, M1-A411, M1-S410, M1-
Y409, M1-S408, M1-V407, M1-S406, M1-K405, M1-I404, M1-D403, M1-L402,
M1-S401, M1-F400, M1-S399, M1-R398, M1-K397, M1-L396, M1-K395, M1-
N394, M1-S393, M1-D392, M1-E391, M1-L390, M1-R389, M1-D388, M1-A387,
15 M1-S386, M1-L385, M1-H384, M1-L383, M1-G382, M1-S381, M1-L380, M1-
A379, M1-Q378, M1-V377, M1-L376, M1-P375, M1-S374, M1-D373, M1-E372,
M1-L371, M1-L370, M1-S369, M1-P368, M1-Q367, M1-V366, M1-S365, M1-P364,
M1-V363, M1-S362, M1-P361, M1-V360, M1-S359, M1-A358, M1-P357, M1-
H356, M1-V355, M1-P354, M1-R353, M1-Q352, M1-G351, M1-A350, M1-A349,
20 M1-E348, M1-S347, M1-T346, M1-A345, M1-S344, M1-D343, M1-A342, M1-
C341, M1-P340, M1-P339, M1-S338, M1-L337, M1-P336, M1-T335, M1-E334, M1-
S333, M1-K332, M1-Q331, M1-G330, M1-G329, M1-E328, M1-S327, M1-V326,
M1-A325, M1-P324, M1-V323, M1-P322, M1-E321, M1-N320, M1-P319, M1-
K318, M1-E317, M1-L316, M1-P315, M1-L314, M1-L313, M1-K312, M1-L311,
25 M1-K310, M1-S309, M1-K308, M1-P307, M1-G306, M1-S305, M1-A304, M1-
G303, M1-T302, M1-Q301, M1-N300, M1-K299, M1-I298, M1-K297, M1-K296,
M1-E295, M1-Y294, M1-A293, M1-L292, M1-L291, M1-Q290, M1-G289, M1-
L288, M1-F287, M1-N286, M1-F285, M1-N284, M1-P283, M1-S282, M1-I281, M1-
T280, M1-P279, M1-R278, M1-K277, M1-E276, M1-K275, M1-V274, M1-F273,
30 M1-R272, M1-Y271, M1-A270, M1-E269, M1-D268, M1-L267, M1-S266, M1-
M265, M1-D264, M1-M263, M1-R262, M1-K261, M1-M260, M1-I259, M1-Y258,
M1-A257, M1-I256, M1-A255, M1-I254, M1-T253, M1-A252, M1-S251, M1-R250,
M1-S249, M1-I248, M1-G247, M1-A246, M1-L245, M1-C244, M1-H243, M1-V242,
M1-L241, M1-V240, M1-C239, M1-G238, M1-N237, M1-S236, M1-A235, M1-
35 K234, M1-A233, M1-K232, M1-E231, M1-I230, M1-F229, M1-D228, M1-V227,
M1-S226, M1-K225, M1-D224, M1-L223, M1-W222, M1-P221, M1-L220, M1-I219,

- 5 M1-K218, M1-E217, M1-C216, M1-F215, M1-S214, M1-D213, M1-N212, M1-V211, M1-P210, M1-V209, M1-R208, M1-L207, M1-F206, M1-H205, M1-S204, M1-E203, M1-P202, M1-I201, M1-F200, M1-D199, M1-P198, M1-K197, M1-P196, M1-C195, M1-T194, M1-N193, M1-S192, M1-A191, M1-N190, M1-L189, M1-V188, M1-Y187, M1-G186, M1-I185, M1-G184, M1-N183, M1-Q182, M1-Q181,
- 10 M1-M180, M1-L179, M1-E178, M1-K177, M1-N176, M1-L175, M1-V174, M1-D173, M1-R172, M1-Q171, M1-C170, M1-G169, M1-L168, M1-Y167, M1-L166, M1-N165, M1-P164, M1-L163, M1-I162, M1-R161, M1-T160, M1-P159, M1-G158, M1-I157, M1-N156, M1-A155, M1-V154, M1-P153, M1-L152, M1-C151, M1-P150, M1-Q149, M1-S148, M1-I147, M1-C146, M1-T145, M1-P144, M1-V143, M1-L142,
- 15 M1-T141, M1-S140, M1-K139, M1-G138, M1-E137, M1-C136, M1-L135, M1-G134, M1-P133, M1-F132, M1-C131, M1-R130, M1-S129, M1-F128, M1-E127, M1-A126, M1-F125, M1-G124, M1-G123, M1-A122, M1-L121, M1-L120, M1-H119, M1-V118, M1-S117, M1-N116, M1-F115, M1-S114, M1-K113, M1-E112, M1-L111, M1-K110, M1-G109, M1-L108, M1-L107, M1-V106, M1-T105, M1-
- 20 L104, M1-F103, M1-C102, M1-D101, M1-S100, M1-S99, M1-L98, M1-S97, M1-A96, M1-V95, M1-D94, M1-Q93, M1-S92, M1-S91, M1-Q90, M1-D89, M1-Y88, M1-V87, M1-V86, M1-V85, M1-K84, M1-Q83, M1-S82, M1-C81, M1-D80, M1-I79, M1-D78, M1-V77, M1-K76, M1-H75, M1-K74, M1-A73, M1-S72, M1-H71, M1-Q70, M1-I69, M1-L68, M1-E67, M1-T66, M1-I65, M1-L64, M1-V63, M1-K62,
- 25 M1-D61, M1-Q60, M1-Q59, M1-L58, M1-R57, M1-R56, M1-K55, M1-M54, M1-L53, M1-K52, M1-S51, M1-C50, M1-N49, M1-I48, M1-N47, M1-I46, M1-A45, M1-E44, M1-L43, M1-I42, M1-H41, M1-S40, M1-T39, M1-N38, M1-Y37, M1-E36, M1-V35, M1-F34, M1-P33, M1-R32, M1-S31, M1-D30, M1-I29, M1-L28, M1-L27, M1-V26, M1-K25, M1-E24, M1-T23, M1-G22, M1-S21, M1-E20, M1-L19, M1-L18,
- 30 M1-A17, M1-V16, M1-L15, M1-R14, M1-E13, M1-T12, M1-V11, M1-I10, M1-Q9, M1-T8, and/or M1-G7 of SEQ ID NO:42. Polynucleotide sequences encoding these polypeptides are also provided. The present invention also encompasses the use of the human BMY_HPP5 phosphatase C-terminal deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.
- 35 The present invention also encompasses immunogenic and/or antigenic epitopes of the human BMY_HPP5 phosphatase polypeptide.

5 The human phosphatase polypeptides of the present invention were determined to comprise several phosphorylation sites based upon the Motif algorithm (Genetics Computer Group, Inc.). The phosphorylation of such sites may regulate some biological activity of the human phosphatase polypeptide. For example, phosphorylation at specific sites may be involved in regulating the proteins ability to
10 associate or bind to other molecules (e.g., proteins, ligands, substrates, DNA, etc.). In the present case, phosphorylation may modulate the ability of the human phosphatase polypeptide to associate with other polypeptides, particularly cognate ligand for human phosphatase, or its ability to modulate certain cellular signal pathways.

 Specifically, the BMY_HPP5 polypeptide was predicted to comprise one
15 tyrosine phosphorylation site using the Motif algorithm (Genetics Computer Group, Inc.). Such sites are phosphorylated at the tyrosine amino acid residue. The consensus pattern for tyrosine phosphorylation sites are as follows: [RK]-x(2)-[DE]-x(3)-Y, or [RK]-x(3)-[DE]-x(2)-Y, where Y represents the phosphorylation site and 'x' represents an intervening amino acid residue. Additional information specific to
20 tyrosine phosphorylation sites can be found in Patschinsky T., Hunter T., Esch F.S., Cooper J.A., Sefton B.M., Proc. Natl. Acad. Sci. U.S.A. 79:973-977(1982); Hunter T., J. Biol. Chem... 257:4843-4848(1982), and Cooper J.A., Esch F.S., Taylor S.S., Hunter T., J. Biol. Chem... 259:7835-7841(1984), which are hereby incorporated herein by reference.

25 In preferred embodiments, the following tyrosine phosphorylation site polypeptides are encompassed by the present invention: NGCVLVHCLAGISRSATIAIAYI (SEQ ID NO:103). Polynucleotides encoding these polypeptides are also provided. The present invention also encompasses the use of the human BMY_HPP5 tyrosine phosphorylation site polypeptides as
30 immunogenic and/or antigenic epitopes as described elsewhere herein.

 The human phosphatase polypeptide was predicted to comprise twelve PKC phosphorylation sites using the Motif algorithm (Genetics Computer Group, Inc.). In vivo, protein kinase C exhibits a preference for the phosphorylation of serine or threonine residues. The PKC phosphorylation sites have the following consensus
35 pattern: [ST]-x-[RK], where S or T represents the site of phosphorylation and 'x' an intervening amino acid residue. Additional information regarding PKC

5 phosphorylation sites can be found in Woodget J.R., Gould K.L., Hunter T., Eur. J. Biochem. 161:177-184(1986), and Kishimoto A., Nishiyama K., Nakanishi H., Uratsuji Y., Nomura H., Takeyama Y., Nishizuka Y., J. Biol. Chem... 260:12492-12499(1985); which are hereby incorporated by reference herein.

In preferred embodiments, the following PKC phosphorylation site
 10 polypeptides are encompassed by the present invention: GTQIVTERLVALL (SEQ ID NO:91),
 LLESGTEKVLLID (SEQ ID NO:92), ELIQHSAKHKVDI (SEQ ID NO:93),
 VDIDCSQKVVVYD (SEQ ID NO:94), DRLEDSENKLRSF (SEQ ID NO:95),
 TTLDTGNKLCQFS (SEQ ID NO:96), PKKLQTARPSDSQ (SEQ ID NO: 97),
 15 PSDSQSKRLHSVR (SEQ ID NO:98), SKRLHSVRTSSSG (SEQ ID NO:99),
 GDQVYSVRRRQKP (SEQ ID NO:100), RRQKPSDRADSRR (SEQ ID NO:101),
 and/or SDRADSRRSWHEE (SEQ ID NO:102). Polynucleotides encoding these
 polypeptides are also provided. The present invention also encompasses the use of the
 human BMY_HPP5 phosphatase PKC phosphorylation site polypeptides as
 20 immunogenic and/or antigenic epitopes as described elsewhere herein.

The human phosphatase polypeptide has been shown to comprise six
 glycosylation sites according to the Motif algorithm (Genetics Computer Group, Inc.).
 As discussed more specifically herein, protein glycosylation is thought to serve a
 variety of functions including: augmentation of protein folding, inhibition of protein
 25 aggregation, regulation of intracellular trafficking to organelles, increasing resistance
 to proteolysis, modulation of protein antigenicity, and mediation of intercellular
 adhesion.

Asparagine phosphorylation sites have the following consensus pattern, N-
 {P}-[ST]-{P}, wherein N represents the glycosylation site. However, it is well known
 30 that that potential N-glycosylation sites are specific to the consensus sequence Asn-
 Xaa-Ser/Thr. However, the presence of the consensus tripeptide is not sufficient to
 conclude that an asparagine residue is glycosylated, due to the fact that the folding of
 the protein plays an important role in the regulation of N-glycosylation. It has been
 shown that the presence of proline between Asn and Ser/Thr will inhibit N-
 35 glycosylation; this has been confirmed by a recent statistical analysis of glycosylation
 sites, which also shows that about 50% of the sites that have a proline C-terminal to

5 Ser/Thr are not glycosylated. Additional information relating to asparagine glycosylation may be found in reference to the following publications, which are hereby incorporated by reference herein: Marshall R.D., Annu. Rev. Biochem. 41:673-702(1972); Pless D.D., Lennarz W.J., Proc. Natl. Acad. Sci. U.S.A. 74:134-138(1977); Bause E., Biochem. J. 209:331-336(1983); Gavel Y., von Heijne G.,
10 Protein Eng. 3:433-442(1990); and Miletich J.P., Broze G.J. Jr., J. Biol. Chem... 265:11397-11404(1990).

In preferred embodiments, the following asparagine glycosylation site polypeptides are encompassed by the present invention: PFVEYNTSHILEAI (SEQ ID NO:85), EAININCSKLMKRR (SEQ ID NO:86), IGYVLNASNTCPKP (SEQ ID NO:87),
15 LRVPVNDSFCEKIL (SEQ ID NO:88), EKKIKNQTGASGPK (SEQ ID NO:89), and/or SIMSENRSREELGK (SEQ ID NO:90). Polynucleotides encoding these polypeptides are also provided. The present invention also encompasses the use of the human BMY_HPP5 phosphatase asparagine glycosylation site polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

20 The present invention encompasses the use of BMY_HPP5 inhibitors and/or activators of BMY_HPP5 activity for the treatment, detection, amelioration, or prevention of phosphatase associated disorders, including but not limited to metabolic diseases such as diabetes, in addition to neural and/or cardiovascular diseases and disorders. The present invention also encompasses the use of BMY_HPP5 inhibitors
25 and/or activators of BMY_HPP5 activity as immunosuppressive agents, anti-inflammatory agents, and/or anti-tumor agents

The present invention encompasses the use of BMY_HPP5 phosphatase inhibitors, including, antagonists such as antisense nucleic acids, in addition to other antagonists, as described herein, in a therapeutic regimen to diagnose, prognose, treat,
30 ameliorate, and/or prevent diseases where a kinase activity is insufficient. One, non-limiting example of a disease which may occur due to insufficient kinase activity are certain types of diabetes, where one or more kinases involved in the insulin receptor signal pathway may have insufficient activity or insufficient expression, for example.

Moreover, the present invention encompasses the use of BMY_HPP5
35 phosphatase activators, and/or the use of the BMY_HPP5 phosphatase gene or protein in a gene therapy regimen, as described herein, for the diagnoses, prognoses,

5 treatment, amelioration, and/or prevention of diseases and/or disorders where a kinase activity is overly high, such as a cancer where a kinase oncogene product has excessive activity or excessive expression.

The present invention also encompasses the use of catalytically inactive variants of BMY_HPP5 proteins, including fragments thereof, such as a protein
10 therapeutic, or the use of the encoding polynucleotide sequence or as gene therapy, for example, in the diagnoses, prognosis, treatment, amelioration, and/or prevention of diseases or disorders where phosphatase activity is overly high.

The present invention encompasses the use of antibodies directed against the BMY_HPP5 polypeptides, including fragment and/or variants thereof, of the present
15 invention in diagnostics, as a biomarkers, and/or as a therapeutic agents.

The present invention encompasses the use of an inactive, non-catalytic, mutant of the BMY_HPP5 phosphatase as a substrate trapping mutant to bind cellular phosphoproteins or a library of phosphopeptides to identify substrates of the BMY_HPP5 polypeptides.

20 The present invention encompasses the use of the BMY_HPP5 polypeptides, to identify inhibitors or activators of the BMY_HPP5 phosphatase activity using either in vitro or 'virtual' (in silico) screening methods.

One embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of the BMY_HPP5 phosphatase comprising the
25 steps of: i.) contacting a BMY_HPP5 phosphatase inhibitor or activator labeled with an analytically detectable reagent with the BMY_HPP5 phosphatase under conditions sufficient to form a complex with the inhibitor or activator; ii.) contacting said complex with a sample containing a compound to be identified; iii) and identifying the compound as an inhibitor or activator by detecting the ability of the test compound
30 to alter the amount of labeled known BMY_HPP5 phosphatase inhibitor or activator in the complex.

Another embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of a BMY_HPP5 phosphatase comprising the
steps of: i.) contacting the BMY_HPP5 phosphatase with a compound to be
35 identified; and ii.) and measuring the ability of the BMY_HPP5 phosphatase to remove phosphate from a substrate.

5 The present invention also encompasses a method for identifying a ligand for the BMY_HPP5 phosphatase comprising the steps of: i.) contacting the BMY_HPP5 phosphatase with a series of compounds under conditions to permit binding; and ii.) detecting the presence of any ligand-bound protein.

 Preferably, the above referenced methods comprise the BMY_HPP5
10 phosphatase in a form selected from the group consisting of whole cells, cytosolic cell fractions, membrane cell fractions, purified or partially purified forms. The invention also relates to recombinantly expressed BMY_HPP5 phosphatase in a purified, substantially purified, or unpurified state. The invention further relates to BMY_HPP5 phosphatase fused or conjugated to a protein, peptide, or other molecule or compound
15 known in the art, or referenced herein.

 The present invention also encompasses a pharmaceutical composition of the BMY_HPP5 phosphatase polypeptide comprising a compound identified by above referenced methods and a pharmaceutically acceptable carrier.

 In preferred embodiments, the present invention encompasses a
20 polynucleotide lacking the initiating start codon, in addition to, the resulting encoded polypeptide of BMY_HPP5. Specifically, the present invention encompasses the polynucleotide corresponding to nucleotides 473 thru 2464 of SEQ ID NO:41, and the polypeptide corresponding to amino acids 2 thru 665 of SEQ ID NO:42. Also encompassed are recombinant vectors comprising said encoding sequence, and host
25 cells comprising said vector.

 The present invention also provides a three-dimensional homology model of the BMY_HPP5 polypeptide (see Figure 38) representing amino acids N157 to I300 of BMY_HPP5 (SEQ ID NO:42). A three-dimensional homology model can be constructed on the basis of the known structure of a homologous protein (Greer et al,
30 1991, Lesk, et al, 1992, Cardozo, et al, 1995, Yuan, et al, 1995). The homology model of the BMY_HPP5 polypeptide, corresponding to amino acid residues N157 to I300 of SEQ ID NO:42, was based upon the homologous structure of 1vhr from the N-terminus of human dual specificity phosphatase MAP Kinase phosphatase 3 (also called PYST1) (residues A204-L347; Protein Data Bank, PDB entry 1mkp chain A
35 Genbank Accession No. gi|5822131; SEQ ID NO:208) (Stewart, A. E. , et al., 1999) and is defined by the set of structural coordinates set forth in Table X herein.

5 Homology models are useful when there is no experimental information available on the protein of interest. A 3-dimensional model can be constructed on the basis of the known structure of a homologous protein (Greer et al, 1991, Lesk, et al, 1992, Cardozo, et al, 1995, Sali, et al, 1995).

Those of skill in the art will understand that a homology model is constructed
10 on the basis of first identifying a template, or, protein of known structure which is similar to the protein without known structure. This can be accomplished by through pairwise alignment of sequences using such programs as FASTA (Pearson, et al 1990) and BLAST (Altschul, et al, 1990). In cases where sequence similarity is high (greater than 30 %) these pairwise comparison methods may be adequate. Likewise,
15 multiple sequence alignments or profile-based methods can be used to align a query sequence to an alignment of multiple (structurally and biochemically) related proteins. When the sequence similarity is low, more advanced techniques are used such as fold recognition (protein threading; Hendlich, et al, 1990), where the compatibility of a particular sequence with the 3-dimensional fold of a potential template protein is
20 gauged on the basis of a knowledge-based potential. Following the initial sequence alignment, the query template can be optimally aligned by manual manipulation or by incorporation of other features (motifs, secondary structure predictions, and allowed sequence conservation). Next, structurally conserved regions can be identified and used to construct the core secondary structure (Sali, et al, 1995). Loops can be added
25 using knowledge-based techniques, and refined performing force field calculations (Sali, et al, 1995; Cardozo, et al, 1995).

For BMY_HPP5 the pairwise alignment method FASTA (Pearson, et al 1990) and fold recognition methods (protein threading) generated identical sequence alignments for a portion (residues N157 to I300 of SEQ ID NO:42) of BMY_HPP5
30 aligned with the sequence of the human dual specificity phosphatase MAP Kinase phosphatase 3 (also called PYST1) (residues A204-L347; Protein Data Bank, PDB entry 1mkp chain A; Genbank Accession No. gi|5822131; SEQ ID NO:208) (Stewart, A. E. , et al., 1999). The alignment of BMY_HPP5 with PDB entry 1mkp is set forth in Figure 37. In this invention, the homology model of BMY_HPP5 was derived from
35 the sequence alignment set forth in Figure 37, and thence an overall atomic model including plausible sidechain orientations using the program LOOK (Levitt, 1992).

- 5 The three dimensional model for BMY_HPP5 is defined by the set of structure coordinates as set forth in Table X and visualized in Figure 38.

In order to recognize errors in three-dimensional structures knowledge based mean fields can be used to judge the quality of protein folds (Sippl 1993). The methods can be used to recognize misfolded structures as well as faulty parts of structural models. The technique generates an energy graph where the energy distribution for a given protein fold is displayed on the y-axis and residue position in the protein fold is displayed on the x-axis. The knowledge based mean fields compose a force field derived from a set of globular protein structures taken as a subset from the Protein Data Bank (Bernstein et. al. 1977). To analyze the quality of a model the energy distribution is plotted and compared to the energy distribution of the template from which the model was generated. Figure 39 shows the energy graph for the BMY_HPP5 model (dotted line) and the template (1mkp, a dual-specificity phosphatase) from which the model was generated. It is clear that the model and template have similar energies over the aligned region, suggesting that BMY_HPP5 is in a "native-like" conformation. This graph supports the motif and sequence alignments in confirming that the three dimensional structure coordinates of BMY_HPP5 are an accurate and useful representation for the polypeptide.

The term "structure coordinates" refers to Cartesian coordinates generated from the building of a homology model.

- 25 Those of skill in the art will understand that a set of structure coordinates for a protein is a relative set of points that define a shape in three dimensions. Thus, it is possible that an entirely different set of coordinates could define a similar or identical shape. Moreover, slight variations in the individual coordinates, as emanate from generation of similar homology models using different alignment templates (i.e., other than the structure coordinates of 1mkp), and/or using different methods in generating the homology model, will have minor effects on the overall shape. Variations in coordinates may also be generated because of mathematical manipulations of the structure coordinates. For example, the structure coordinates set forth in Table X and visualized in Figure 38 could be manipulated by fractionalization of the structure coordinates; integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above.

5 Various computational analyses are therefore necessary to determine whether a molecule or a portion thereof is sufficiently similar to all or parts of BMY_HPP5 described above as to be considered the same. Such analyses may be carried out in current software applications, such as INSIGHTII (Molecular Simulations Inc., San Diego, CA) version 2000 and as described in the accompanying User's Guide.

10 Using the superimposition tool in the program INSIGHTII comparisons can be made between different structures and different conformations of the same structure. The procedure used in INSIGHTII to compare structures is divided into four steps: 1) load the structures to be compared; 2) define the atom equivalencies in these structures; 3) perform a fitting operation; and 4) analyze the results. Each structure is
15 identified by a name. One structure is identified as the target (i.e., the fixed structure); the second structure (i.e., moving structure) is identified as the source structure. Since atom equivalency within INSIGHTII is defined by user input, for the purpose of this invention we will define equivalent atoms as protein backbone atoms (N, C α , C and O) for all conserved residues between the two structures being compared. We will
20 also consider only rigid fitting operations. When a rigid fitting method is used, the working structure is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses an algorithm that computes the optimum translation and rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atom is an absolute
25 minimum. This number, given in angstroms, is reported by INSIGHTII. For the purpose of this invention, any homology model of a BMY_HPP5 that has a root mean square deviation of conserved residue backbone atoms (N, C α , C, O) of less than 3.0 Å when superimposed on the relevant backbone atoms described by structure coordinates listed in Table X and visualized in Figure 38 are considered identical.
30 More preferably, the root mean square deviation is less than 2.0 Å.

 This invention as embodied by the homology model enables the structure-based design of modulators of the biological function of BMY_HPP5, as well as mutants with altered biological function and/or specificity.

 There is 40% sequence identity between catalytic domain of BMY_HPP5 and
35 1mkp which was used as the template for 3D model generation. For the BMY_HPP5 the functionally important residues are located in a cleft comprised of residues D213,

5 H243, C244, R250, and S251. All these residues are conserved in 1mkp (for structure determination studies the cysteine was mutated to a serine in 1mkp). Based on the sequence alignment disclosed in Figure 37 and the structural model disclosed in Table X and visualized in Figure 38, D213 is identified as a general acid, C244 as the catalytic Cysteine nucleophile which cleaves the phosphodiester bond, and R250 as
10 the essential Arginine which activates the bond for cleavage as described in the literature (reviewed by Fauman and .Saper, 1996). Other important residues include F287 which imparts substrate specificity onto the enzyme. All of these residues are conserved.

In a preferred embodiment of the present invention, the molecule comprises
15 the cleft region defined by structure coordinates of BMY_HPP5 amino acids described above according to Table X, or a mutant of said molecule.

More preferred are molecules comprising all or any part of the cleft or a mutant or homologue of said molecule or molecular complex. By mutant or homologue of the molecule it is meant a molecule that has a root mean square
20 deviation from the backbone atoms of said BMY_HPP5 amino acids of not more than 3.5 Angstroms.

The term "root mean square deviation" means the square root of the arithmetic mean of the squares of the deviations from the mean. It is a way to express the deviation or variation from a trend or object. For purposes of this invention, the "root
25 mean square deviation" defines the variation in the backbone of a protein from the relevant portion of the backbone of BMY_HPP5 as defined by the structure coordinates described herein.

The structure coordinates of a BMY_HPP5 homology model portions thereof are stored in a machine-readable storage medium. Such data may be used for a variety
30 of purposes, such as drug discovery.

Accordingly, in one embodiment of this invention is provided a machine-readable data storage medium comprising a data storage material encoded with the structure coordinates set forth in Table X.

One embodiment utilizes System 10 as disclosed in WO 98/11134, the
35 disclosure of which is incorporated herein by reference in its entirety. Briefly, one version of these embodiments comprises a computer comprising a central processing

5 unit ("CPU"), a working memory which may be, e.g., RAM (random-access memory) or "core" memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more cathode-ray tube ("CRT") display terminals, one or more keyboards, one or more input lines, and one or more output lines, all of which are interconnected by a conventional bidirectional system bus.

10 Input hardware, coupled to the computer by input lines, may be implemented in a variety of ways. Machine-readable data of this invention may be inputted via the use of a modem or modems connected by a telephone line or dedicated data line. Alternatively or additionally, the input hardware may comprise CD-ROM drives or disk drives. In conjunction with a display terminal, keyboard may also be used as an
15 input device.

Output hardware, coupled to the computer by output lines, may similarly be implemented by conventional devices. By way of example, output hardware may include a CRT display terminal for displaying a graphical representation of a region or domain of the present invention using a program such as QUANTA as described
20 herein. Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use.

In operation, the CPU coordinates the use of the various input and output devices, coordinates data accesses from mass storage, and accesses to and from the working memory, and determines the sequence of data processing steps. A number of
25 programs may be used to process the machine-readable data of this invention. Such programs are discussed in reference to the computational methods of drug discovery as described herein. Specific references to components of the hardware system are included as appropriate throughout the following description of the data storage medium.

30 For the purpose of the present invention, any magnetic data storage medium which can be encoded with machine-readable data would be sufficient for carrying out the storage requirements of the system. The medium could be a conventional floppy diskette or hard disk, having a suitable substrate, which may be conventional, and a suitable coating, which may be conventional, on one or both sides, containing
35 magnetic domains whose polarity or orientation could be altered magnetically, for

5 example. The medium may also have an opening for receiving the spindle of a disk drive or other data storage device.

The magnetic domains of the coating of a medium may be polarized or oriented so as to encode in a manner which may be conventional, machine readable data such as that described herein, for execution by a system such as the system
10 described herein.

Another example of a suitable storage medium which could also be encoded with such machine-readable data, or set of instructions, which could be carried out by a system such as the system described herein, could be an optically-readable data storage medium. The medium could be a conventional compact disk read only
15 memory (CD-ROM) or a rewritable medium such as a magneto-optical disk which is optically readable and magneto-optically writable. The medium preferably has a suitable substrate, which may be conventional, and a suitable coating, which may be conventional, usually of one side of substrate.

In the case of a CD-ROM, as is well known, the coating is reflective and is
20 impressed with a plurality of pits to encode the machine-readable data. The arrangement of pits is read by reflecting laser light off the surface of the coating. A protective coating, which preferably is substantially transparent, is provided on top of the reflective coating.

In the case of a magneto-optical disk, as is well known, the coating has no pits,
25 but has a plurality of magnetic domains whose polarity or orientation can be changed magnetically when heated above a certain temperature, as by a laser. The orientation of the domains can be read by measuring the polarization of laser light reflected from the coating. The arrangement of the domains encodes the data as described above.

Thus, in accordance with the present invention, data capable of displaying the
30 three dimensional structure of the BMY_HPP5 homology model, or portions thereof and their structurally similar homologues is stored in a machine-readable storage medium, which is capable of displaying a graphical three-dimensional representation of the structure. Such data may be used for a variety of purposes, such as drug discovery.

35 For the first time, the present invention permits the use, through homology modeling based upon the sequence of BMY_HPP5 (Figures 5A-D; SEQ ID NO:42) of

5 structure-based or rational drug design techniques to design, select, and synthesize chemical entities that are capable of modulating the biological function of BMY_HPP5.

Accordingly, the present invention is also directed to the entire sequence in Figures 5A-D or any portion thereof for the purpose of generating a homology model
10 for the purpose of 3D structure-based drug design.

For purposes of this invention, we include mutants or homologues of the sequence in Figures 5A-D or any portion thereof. In a preferred embodiment, the mutants or homologues have at least 25% identity, more preferably 50% identity, more preferably 75% identity, and most preferably 90% identity to the amino acid
15 residues in Figures 5A-D.

The three-dimensional model structure of the BMY_HPP5 will also provide methods for identifying modulators of biological function. Various methods or combination thereof can be used to identify these compounds.

Structure coordinates of the catalytic region defined above can also be used to
20 identify structural and chemical features. Identified structural or chemical features can then be employed to design or select compounds as potential BMY_HPP5 modulators. By structural and chemical features it is meant to include, but is not limited to, van der Waals interactions, hydrogen bonding interactions, charge interaction, hydrophobic bonding interaction, and dipole interaction. Alternatively, or
25 in conjunction, the three-dimensional structural model can be employed to design or select compounds as potential BMY_HPP5 modulators. Compounds identified as potential BMY_HPP5 modulators can then be synthesized and screened in an assay characterized by binding of a test compound to the BMY_HPP5, or in characterizing BMY_HPP5 deactivation in the presence of a small molecule. Examples of assays
30 useful in screening of potential BMY_HPP5 modulators include, but are not limited to, screening in silico, *in vitro* assays and high throughput assays. Finally, these methods may also involve modifying or replacing one or more amino acids from BMY_HPP5 according to Table X.

However, as will be understood by those of skill in the art upon this
35 disclosure, other structure based design methods can be used. Various computational structure based design methods have been disclosed in the art.

5 For example, a number of computer modeling systems are available in which the sequence of the BMY_HPP5 and the BMY_HPP5 structure (i.e., atomic coordinates of BMY_HPP5 and/or the atomic coordinates of the active site as provided in Table X) can be input. This computer system then generates the structural details of one or more these regions in which a potential BMY_HPP5 modulator binds
10 so that complementary structural details of the potential modulators can be determined. Design in these modeling systems is generally based upon the compound being capable of physically and structurally associating with BMY_HPP5. In addition, the compound must be able to assume a conformation that allows it to associate with BMY_HPP5. Some modeling systems estimate the potential inhibitory
15 or binding effect of a potential BMY_HPP5 modulator prior to actual synthesis and testing.

Methods for screening chemical entities or fragments for their ability to associate with a given protein target are also well known. Often these methods begin by visual inspection of the binding site on the computer screen. Selected fragments or
20 chemical entities are then positioned in one or more of the active site region in BMY_HPP5. Docking is accomplished using software such as INSIGHTII, QUANTA and SYBYL, following by energy minimization and molecular dynamics with standard molecular mechanic forcefields such as CHARMM and AMBER. Examples of computer programs which assist in the selection of chemical fragment or
25 chemical entities useful in the present invention include, but are not limited to, GRID (Goodford, 1985), AUTODOCK (Goodsell, 1990), and DOCK (Kuntz et al. 1982).

Upon selection of preferred chemical entities or fragments, their relationship to each other and BMY_HPP5 can be visualized and then assembled into a single potential modulator. Programs useful in assembling the individual chemical entities
30 include, but are not limited to SYBYL and LeapFrog (Tripos Associates, St. Louis MO), LUDI (Bohm 1992) and 3D Database systems (Martin 1992).

Alternatively, compounds may be designed de novo using either an empty active site or optionally including some portion of a known inhibitor. Methods of this type of design include, but are not limited to LUDI (Bohm 1992) and LeapFrog
35 (Tripos Associates, St. Louis MO).

5 In addition, BMY_HPP5 is overall well suited to modern methods including combinatorial chemistry.

Programs such as DOCK (Kuntz et al. 1982) can be used with the atomic coordinates from the homology model to identify potential ligands from databases or virtual databases which potentially bind the in the metal binding region, and which
10 may therefore be suitable candidates for synthesis and testing.

Additionally, the three-dimensional homology model of BMY_HPP5 will aid in the design of mutants with altered biological activity.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
15 related to SEQ ID NO: 41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides consisting of a nucleotide sequence described by the
20 general formula of a-b, where a is any integer between 1 to 5097 of SEQ ID NO:41, b is an integer between 15 to 5111, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a+14.

25 **Features of the Polypeptide Encoded by Gene No:6**

The development of inflammatory disease is characterized by infiltration of circulating blood cells across the endothelium into the tissue. A number of key events occur in the endothelial cells that mediate this "gateway" function. The endothelial cells express receptors and chemokines that sequentially tether the leukocytes,
30 activate them, cause them to tightly adhere, and aid in their transmigration through endothelial cell junctions. This process is initiated by the production of early inflammatory mediators such as TNF- α . The coordinated expression of receptors and chemokines is mediated by intracellular signaling molecules including kinases, scaffolding proteins, and transcription factors. These molecules thus form a signaling
35 cascade that may be a "master switch" for the development of inflammatory processes. Components of this cascade such as the transcription factor NF-kB are

5 known. However, there are many other components that have not yet been identified. The analysis of genes that are differentially expressed in TNF- α -activated endothelium may help to identify other components of this "master switch" cascade.

To this end, the RNA expressed in TNF- α -stimulated human lung microvascular endothelial cells has been analyzed to identify gene products involved
10 in regulatory events. Resting cells were stimulated for 1 h with TNF- α , and the RNA was isolated from the cells. Complementary DNA (cDNA) was created from the isolated RNA. The cDNAs that were upregulated in response to TNF α were identified using subtractive hybridization methodology.

A novel dual specificity phosphatase (DSP), RET31 (Regulated in Endothelial
15 cells treated with TNF- α clone 31) (Figures 13A-F) was identified from the TNF- α treated endothelial subtraction library. The dual specificity phosphatase catalytic (DSPc) domain for RET 31 was identified using the DSPc PFAM-HMM (PF00782). A search for homologues identified three other DSPs that contain extensive homology to RET31 (Figures 14A-C). RET31, DUS8, DUSP6 and MAP-kinase phosphatase 5
20 are shown in a multiple sequence alignment comparing the DSPc domains of these four proteins (Figure 17).

RET31 was confirmed to be up-regulated by TNF- α , reaching a peak of expression at 6 h by northern blot analysis (Figure 15). RET31 mRNA was virtually undetectable in brain, spleen, and peripheral blood leukocytes by Northern blot
25 analysis.

RET31 is believed to represent a novel splice variant of the BMY_HPP5 polypeptide of the present invention. The sequence for RET31 differs in the 5' end from that of BMY_HPP5. However, comparison of the tissue expression of RET31 and BMY_HPP5 showed significant differential expression despite their significant
30 identity. Specifically, the tissue expression of BMY_HPP5 by PCR analysis (as described elsewhere herein) suggested that there were significant levels of RET31 in the brain. The reason for such disparate expression profiles is unclear but may be related to the use of separate pools of RNA or to the use of alternate probes.

In all tissues that expressed significant levels of RET31, there was a primary
35 hybridizing band and a secondary band of lower molecular weight. It is not clear

- 5 whether this represents splice variants of the same gene or whether there is a
homologue present.

The polypeptide corresponding to this gene provided as SEQ ID NO:108 (Figure 13A-F), encoded by the polynucleotide sequence according to SEQ ID NO:109 (Figure 13A-F), and/or encoded by the polynucleotide contained within the
10 deposited clone, RET31, has significant homology at the nucleotide and amino acid level to a number of phosphatases, which include, for example, the human protein-tyrosine phosphatase DUS8 protein, also referred to as hVH-5 (DUS8; Genbank Accession No:gi|U27193; SEQ ID NO:110); the human dual specificity MAP kinase DUSP6 protein (DUSP6; Genbank Accession No:gi|AB013382; SEQ ID NO:111);
15 and the human map kinase phosphatase MKP-5 protein (MKP-5; Genbank Accession No:gi|AB026436; SEQ ID NO:112) as determined by BLASTP. An alignment of the human phosphatase polypeptide with these proteins is provided in Figures 14A-C.

The human protein-tyrosine phosphatase DUS8 protein (also referred to as hVH-5) is thought to be a member of a subset of protein tyrosine phosphatases that
20 regulate mitogen-activated protein kinase. The catalytic region of hVH-5 was expressed as a fusion protein and was shown to hydrolyze p-nitrophenylphosphate and inactivate mitogen-activated protein kinase, thus proving that hVH-5 possessed phosphatase activity. Moreover, expression of hVH-5 transcripts were induced in PC12 cells upon nerve growth factor and insulin treatment in a manner characteristic
25 of an immediate-early gene, suggesting a possible role in the signal transduction cascade (The J. Neurochem. 65 (4), 1823-1833 (1995)).

The dual specificity MAP kinase DUSP6 protein is believed to be implicated in pancreatic carcinogenesis based upon its encoding polynucleotide mapping to chromosome locus12q21, one of the regions of frequent allelic loss in pancreatic
30 cancer, in addition to, its reduced expressions amongst several pancreatic cancer cell lines (Cytogenet. Cell Genet. 82 (3-4), 156-159 (1998)).

The human map kinase phosphatase MKP-5 protein was determined to belong to a group of dual specificity protein phosphatases that negatively regulate members of the mitogen-activated protein kinase (MAPK) superfamily, which consists of three
35 major subfamilies, MAPK/extracellular signal-regulated kinase (ERK), stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK), and p38. Members

5 of this group show distinct substrate specificities for MAPKs, different tissue distribution and subcellular localization, and different modes of inducibility of their expression by extracellular stimuli. MKP-5 was shown to bind to p38 and SAPK/JNK, but not to MAPK/ERK, and inactivate p38 and SAPK/JNK, but not MAPK/ERK. p38 was determined to be the preferred substrate for MKP-5. MKP-5
10 mRNA was widely expressed in various tissues and organs, and its expression in cultured cells was inducible by stress stimuli. Thus, MKP-5 is thought to represent a type of dual specificity phosphatase specific for p38 and SAPK/JNK (J Biol Chem., 274(28):19949-56, (1999)).

The determined nucleotide sequence of the RET31 cDNA in Figures 13A-F
15 (SEQ ID NO:41) contains an open reading frame encoding a protein of about 665 amino acid residues, with a deduced molecular weight of about 73.1kDa. The amino acid sequence of the predicted RET31 polypeptide is shown in Figures 13A-F (SEQ ID NO:42). The RET31 protein shown in Figures 13A-F was determined to share significant identity and similarity to several known phosphatases, particularly, dual-
20 specificity protein phosphatases. Specifically, the RET31 protein shown in Figures 13A-F was determined to be about 50.3% identical and 56.8% similar to human protein-tyrosine phosphatase DUS8 protein (DUS8; Genbank Accession No:gi|U27193; SEQ ID NO:110); to be about 36.5% identical and 48.3% similar to the human dual specificity MAP kinase DUSP6 protein (DUSP6; Genbank Accession
25 No:gi|AB013382; SEQ ID NO:111); and to be about 34.3% identical and 47.2% similar to the human map kinase phosphatase MKP-5 protein (MKP-5; Genbank Accession No:gi|AB026436; SEQ ID NO:112), as shown in Figure 12.

Based upon the strong homology to members of the phosphatase proteins, the polypeptide encoded by the human RET31 phosphatase of the present invention is
30 expected to share at least some biological activity with phosphatase proteins, preferably with members of the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases, particularly the novel phosphotyrosine/dual-specificity (P-Tyr, P-Ser and P-Thr) phosphatases referenced herein.

The strong homology to phosphatases, particularly dual-specificity
35 phosphatases, combined with the predominant localized expression in adrenal gland tissue suggests the human RET31 phosphatase polynucleotides and polypeptides,

5 including antagonists, and/or fragments thereof, may be useful for treating, diagnosing, prognosing, ameliorating, and/or preventing endocrine disorders, which include, but are not limited to adrenocortical hyperfunction, adrenocortical hypofunction, lethargy. Congenital adrenal hyperplasia, aberrant ACTH regulation, aberrant adrenaline regulation, disorders associated with defects in P450C21,
10 P450C18, P450C17, and P450C11 hydroxylases and in 3-hydroxysteroid dehydrogenase (3-HSD), hirsutism, oligomenorrhea, acne, virilization, female pseudohermaphroditism, disorders associated with the incidence of aberrant sexual characteristics, disorders associated with aberrant cortisol secretion, hypertension, hypokalemia, hypogonadism, disorders associated with aberrant androgen secretion,
15 adrenal virilism, Adrenal adenomas, Adrenal carcinomas, disorders associated with aberrant aldosterone secretion, aldosteronism, disorders associated with aberrant steroid biosynthesis, disorders associated with aberrant steroid transport, disorders associated with aberrant steroid secretion, disorders associated with aberrant steroid excretion, Addison's syndrome, and Cushing's syndrome.

20 The strong homology to phosphatases, particularly dual-specificity phosphatases, combined with the localized expression in testis and prostate tissue suggests the human RET31 phosphatase polynucleotides and polypeptides, including antagonists, and/or fragments thereof, may be useful for treating, diagnosing, prognosing, and/or preventing male reproductive disorders, such as, for example,
25 male infertility, impotence, prostate cancer, ejaculatory disorders, and/or testicular cancer. This gene product may also be useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed
30 in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. In fact, increased expression of certain phosphatases have been identified as tumor markers for testicular cancer (see, for example, Koshida, K., Nishino, A., Yamamoto, H., Uchibayashi, T., Naito, K., Hisazumi, H., Hirano, K., Hayashi, Y., Wahren, B., Andersson, L, J. Urol.,
35 146(1):57-60, (1991); and Klein, EA, Urol. Clin. North. Am., 20(1):67-73, (1993)).

5 The strong homology to phosphatases, particularly dual-specificity phosphatases, combined with the significant localized expression in ovary and placental tissue suggests the human phosphatase polynucleotides and polypeptides may be useful in treating, diagnosing, prognosing, and/or preventing reproductive disorders.

10 In preferred embodiments, RET31 polynucleotides and polypeptides including agonists and fragments thereof, have uses which include treating, diagnosing, prognosing, and/or preventing the following, non-limiting, diseases or disorders of the uterus: dysfunctional uterine bleeding, amenorrhea, primary dysmenorrhea, sexual dysfunction, infertility, pelvic inflammatory disease, endometriosis, placental
15 aromatase deficiency, premature menopause, and placental dysfunction.

 The strong homology to phosphatases, particularly dual-specificity phosphatases, combined with the significant localized expression in skeletal tissue suggests the human phosphatase polynucleotides and polypeptides may be useful in treating, diagnosing, prognosing, and/or preventing muscle diseases and/or disorders,
20 which include but are not limited to, musculodegenerative disorders, multiple sclerosis, atrophy, ticks.

 Alternatively, the strong homology to phosphatases, particularly dual-specificity phosphatases, combined with the significant localized expression in liver tissue suggests the human phosphatase polynucleotides and polypeptides may be
25 useful in treating, diagnosing, prognosing, and/or preventing hepatic diseases and/or disorders. Representative uses are described in the "Hyperproliferative Disorders", "Infectious Disease", and "Binding Activity" sections below, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are
30 attributable to the differentiation of hepatocyte progenitor cells, cirrhosis, hepatic cysts, pyrogenic abscess, amebic abscess, hydatid cyst, cystadenocarcinoma, adenoma, focal nodular hyperplasia, hemangioma, hepatocellular carcinoma, cholangiocarcinoma, angiosarcoma, and granulomatous liver disease. In addition the protein product is useful for treating developmental abnormalities, fetal deficiencies,
35 pre-natal disorders and various would-healing diseases and/or tissue trauma.

5 Moreover, polynucleotides and polypeptides, including fragments and/or
antagonists thereof, have uses which include, directly or indirectly, treating,
preventing, diagnosing, and/or prognosing the following, non-limiting, hepatic
infections: liver disease caused by sepsis infection, liver disease caused by
bacteremia, liver disease caused by Pneumococcal pneumonia infection, liver disease
10 caused by Toxic shock syndrome, liver disease caused by Listeriosis, liver disease
caused by Legionnaires' disease, liver disease caused by Brucellosis infection, liver
disease caused by Neisseria gonorrhoeae infection, liver disease caused by Yersinia
infection, liver disease caused by Salmonellosis, liver disease caused by Nocardiosis,
liver disease caused by Spirochete infection, liver disease caused by Treponema
15 pallidum infection, liver disease caused by Brrelia burgdorferi infection, liver disease
caused by Leptospirosis, liver disease caused by Coxiella burnetii infection, liver
disease caused by Rickettsia richettsii infection, liver disease caused by Chlamydia
trachomatis infection, liver disease caused by Chlamydia psittaci infection, in addition
to any other hepatic disease and/or disorder implicated by the causative agents listed
20 above or elsewhere herein.

 The strong homology to phosphatases, particularly dual-specificity
phosphatases, combined with the significant localized expression in placental tissue
suggests the human phosphatase polynucleotides and polypeptides may be useful in
treating, diagnosing, prognosing, and/or preventing a variety of vascular disorders and
25 conditions, which include, but are not limited to microvascular disease, vascular leak
syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease,
arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to
determine biological activity, raise antibodies, as tissue markers, to isolate cognate
ligands or receptors, to identify agents that modulate their interactions, in addition to
30 its use as a nutritional supplement. Protein, as well as, antibodies directed against the
protein may show utility as a tumor marker and/or immunotherapy targets for the
above listed tissues.

 The strong homology to phosphatases, particularly dual-specificity
phosphatases, combined with the predominate localized expression in pancreas tissue
35 suggests the human RET31 phosphatase polynucleotides and polypeptides, including
antagonists, and/or fragments thereof, may be useful for treating, diagnosing,

- 5 prognosing, and/or preventing pancreatic, in addition to metabolic and gastrointestinal disorders.

In preferred embodiments, RET31 polynucleotides and polypeptides including agonists, antagonists, and fragments thereof, have uses which include treating, diagnosing, prognosing, and/or preventing the following, non-limiting, diseases or disorders of the pancreas: diabetes mellitus, diabetes, type 1 diabetes, type 2 diabetes, adult onset diabetes, indications related to islet cell transplantation, indications related to pancreatic transplantation, pancreatitis, pancreatic cancer, pancreatic exocrine insufficiency, alcohol induced pancreatitis, maldigestion of fat, maldigestion of protein, hypertriglyceridemia, vitamin b12 malabsorption, hypercalcemia, hypocalcemia, hyperglycemia, ascites, pleural effusions, abdominal pain, pancreatic necrosis, pancreatic abscess, pancreatic pseudocyst, gastrinomas, pancreatic islet cell hyperplasia, multiple endocrine neoplasia type 1 (men 1) syndrome, insulinitis, amputations, diabetic neuropathy, pancreatic auto-immune disease, genetic defects of -cell function, HNF-1 aberrations (formerly MODY3), glucokinase aberrations (formerly MODY2), HNF-4 aberrations (formerly MODY1), mitochondrial DNA aberrations, genetic defects in insulin action, type a insulin resistance, leprechaunism, Rabson-Mendenhall syndrome, lipotrophic diabetes, pancreatectomy, cystic fibrosis, hemochromatosis, fibrocalculous pancreatopathy, endocrinopathies, acromegaly, Cushing's syndrome, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma, drug- or chemical-induced diabetes such as from the following drugs: Vacor, Pentamidine, Nicotinic acid, Glucocorticoids, Thyroid hormone, Diazoxide, Adrenergic agonists, Thiazides, Dilantin, and Interferon, pancreatic infections, congenital rubella, cytomegalovirus, uncommon forms of immune-mediated diabetes, "stiff-man" syndrome, anti-insulin receptor antibodies, in addition to other genetic syndromes sometimes associated with diabetes which include, for example, Down's syndrome, Klinefelter's syndrome, Turner's syndrome, Wolfram's syndrome, Friedrich's ataxia, Huntington's chorea, Lawrence Moon Beidel syndrome, Myotonic dystrophy, Porphyria, and Prader Willi syndrome, and/or Gestational diabetes mellitus (GDM).

- 35 The strong homology to phosphatases, particularly dual-specificity phosphatases, combined with the predominate localized expression in thymus tissue

5 suggests the human RET31 phosphatase polynucleotides and polypeptides, including antagonists, and/or fragments thereof, may be useful for treating, diagnosing, prognosing, and/or preventing immune and hematopoietic disorders. Representative uses are described in the "Immune Activity", "Chemotaxis", and "Infectious Disease" sections below, and elsewhere herein. Briefly, the strong expression in immune tissue
10 indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells.

The RET31 polypeptide may also be useful as a preventative agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel
15 disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
20 disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product may be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

25 The RET31 polypeptide may be useful for modulating cytokine production, antigen presentation, or other processes, such as for boosting immune responses, etc. Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions.

Moreover, the protein may represent a secreted factor that influences the
30 differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissuemarkers, to isolate cognate
35 ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the

5 protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

The human phosphatase polynucleotides and polypeptides, including fragments and agonists thereof, may have uses which include, either directly or indirectly, for boosting immune responses.

10 The strong homology to phosphatases, particularly dual-specificity phosphatases, suggests the human phosphatase polynucleotides and polypeptides may be useful in treating, diagnosing, prognosing, and/or preventing a variety of disorders and conditions, particularly inflammatory conditions, which include, but are not limited to rheumatoid arthritis, juvenile arthritis, psoriasis, asthma, ischemia-reperfusion, multiple sclerosis, rejection of organ or tissue transplants, chronic
15 obstructive pulmonary disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, acute respiratory distress syndrome, systemic lupus erythematosus, cystic fibrosis, autoimmune diseases, cancers, tumors, and neoplasms.

The human phosphatase polynucleotides and polypeptides, including
20 fragments and /or antagonists thereof, may have uses which include identification of modulators of human phosphatase function including antibodies (for detection or neutralization), naturally-occurring modulators and small molecule modulators. Antibodies to domains of the human phosphatase protein could be used as diagnostic agents of cardiovascular and inflammatory conditions in patients, are useful in
25 monitoring the activation of signal transduction pathways, and can be used as a biomarker for the involvement of phosphatases in disease states, and in the evaluation of inhibitors of phosphatases in vivo.

Human phosphatase polypeptides and polynucleotides have additional uses which include diagnosing diseases related to the over and/or under expression of
30 human phosphatase by identifying mutations in the human phosphatase gene by using human phosphatase sequences as probes or by determining human phosphatase protein or mRNA expression levels. Human phosphatase polypeptides may be useful for screening compounds that affect the activity of the protein. Human phosphatase peptides can also be used for the generation of specific antibodies and as bait in yeast
35 two hybrid screens to find proteins that specifically interact with human phosphatase (described elsewhere herein).

5 Immunohistochemistry analysis of the protein localization of the RET31 polypeptide (see Example 58) in normal and diseased tissues determined that RET31 was strongly expressed in normal respiratory epithelial cell bodies, type I and II pneumocytes, lung neutrophils, lung mast cells, lung macrophages, in comparison to the same in asthmatic patients which showed less staining. These results suggest that
10 RET31 polypeptides and polynucleotides, including fragments thereof, may be useful for the treatment of pulmonary disorders. The decreased staining in diseased lung tissues suggests RET31 is essential for normal cell maintainance and homeostasis, and is downregulated in transformed, or rapidly proliferating cells. Thus, agonists of RET31 polypeptides and polynucleotides may be particularly useful for the treatment
15 of pulmonary disorders.

Immunohistochemistry analysis of the protein localization of the RET31 polypeptide (see Example 58) in normal and diseased tissues determined that RET31 was also strongly expressed in chondrocytes and rimming osteoblasts in degenerative arthritis, in addition to hematopoietic cell tissue. Moreover, melanocytes were
20 strongly positive, as was skin with psoriasis. These results suggest that RET31 may be involved in inflammatory responses of certain diseases and/or disorders. Thus, RET31 polypeptides and polynucleotides, including fragments thereof, may be useful for the treatment of inflammatory disorders, particularly inflammatory disorders of the skin and bone, such as, psoriasis and arthritis, for example. Moreover, antagonists of
25 RET31 polypeptides and polynucleotides may be useful for the treatment of inflammatory disorders, particularly inflammatory disorders of the skin and bone, such as, psoriasis and arthritis, for example.

Assays designed to assess the phosphatase activity of the RET31 polypeptide have been performed and prove that RET31 does indeed have phosphatase activity as
30 described in Example 57 herein (see Figure 36). The observed phosphatase activity was specific to RET31 as GST alone did not result in any observed activity. In addition, the observed phosphatase activity was specifically inhibited by the known phosphatase active site inhibitor, vanadate.

In addition to assaying the full-length RET31 polypeptide (SEQ ID NO:109),
35 a C-terminal deletion of RET31 was also assayed corresponding to amino acids M1 to

- 5 T302 of SEQ ID NO:109). The M1 to T302 deletion mutant had an unexpected five fold increase in phosphatase activity relative to the full-length protein.

A phosphatase with a sequence similar to the RET31 polypeptide has been reported as MKP7 (Masuda et al., JBC 276, 39002-39011; and Tanoue et al., JBC., 276, 26269-26639). These authors reported that the phosphatase could bind to and
10 dephosphorylate the p38 kinase and the Jnk kinase in cells, resulting in the inactivation of these kinases. Activation of p38 kinase is known to be important in the induction of apoptosis (Herlaar and Brown, Molecular Medicine Today 5, 439-447). One pathway where p38 has been reported to be important is in paclitaxel (Taxol®) induced apoptosis in tumor cells (Seidman et al., Experimental Cell Research 268, 84-
15 92). Similarly, activation of the Jnk kinase has also been reported to be important in the induction of apoptosis (Chang and Karin, Nature 410, 37-40), including in paclitaxel induced apoptosis (Lee et al., JBC., 273, 28253-28260). Therefore, inhibitors of RET31 should induce apoptosis in tumor cells by increasing the activation of p38 and Jnk kinases in the cells by preventing the dephosphorylation of
20 these kinases. This would be particularly advantageous when combined with a chemotherapeutic drug, such as paclitaxel, that activates p38 and/or Jnk kinases to help induce apoptosis. Such a use represents a novel utility of RET31 antagonists and which has not be appreciated by Masuda et al., nor by Tanoue et al. Indeed, Masuda et al. teach that MKP7 may be a tumor suppressor gene, in which case inhibition of
25 MKP7 would increase malignancies, which teaches away from our intended use for RET31 inhibitors.

In preferred embodiments, the present invention encompasses the use of inhibitors of RET31 for the treatment of cancer. Per the teachings described herein, inhibitors of RET31 may include small molecule inhibitors of RET31 activity,
30 inhibitors that prevent RET31 from binding to p38 and/or Jnk kinases, antisense oligonucleotides to RET31, and antibodies directed against RET31. Such RET31 inhibitors would be particularly useful in malignancies where RET31 was overexpressed relative to normal tissues. In addition to the use of RET31 inhibitors as single agents, inhibitors of RET31 would be of particular use in combination with
35 paclitaxel and other chemotherapeutic agents that induce Jnk and/or p38 dependent apoptosis in tumor cells for the treatment of malignancies. Other chemotherapeutic

- 5 agents that may induce the activation of Jnk and/or p38 leading to apoptosis that would be of use in combination with inhibitors of RET31 include but are not limited to RRR-alpha-tocopherol succinate, DA-125 [(8S,10S)-8-(3-aminopropanoyloxyacetyl)-10-[(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl) oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacene-dione
- 10 hydrochloride] a novel anthracycline derivative, cisplatin, tamoxifen, sulindac sulfone, sulindac, arsenic trioxide, actinomycin D, docetaxel (Taxotere), vinblastine, vincristine, nocodazole, colchicines, and other microtubule-interfering agents.

Although it is believed the encoded polypeptide may share at least some biological activities with phosphatase proteins (particularly dual specificity proteins),

15 a number of methods of determining the exact biological function of this clone are either known in the art or are described elsewhere herein. Briefly, the function of this clone may be determined by applying microarray methodology. Nucleic acids corresponding to the human phosphatase polynucleotides, in addition to, other clones of the present invention, may be arrayed on microchips for expression profiling.

20 Depending on which polynucleotide probe is used to hybridize to the slides, a change in expression of a specific gene may provide additional insight into the function of this gene based upon the conditions being studied. For example, an observed increase or decrease in expression levels when the polynucleotide probe used comes from diseased testis tissue, as compared to, normal tissue might indicate a function in

25 modulating testis function, for example. In the case of human RET31 phosphatase, adrenal gland, testis, prostate, ovary, skeletal muscle, liver, placenta, pancreas, thymus, small intestine, thyroid, heart, kidney, and/or lung tissue should be used, for example, to extract RNA to prepare the probe.

In addition, the function of the protein may be assessed by applying

30 quantitative PCR methodology, for example. Real time quantitative PCR would provide the capability of following the expression of the human phosphatase gene throughout development, for example. Quantitative PCR methodology requires only a nominal amount of tissue from each developmentally important step is needed to perform such experiments. Therefore, the application of quantitative PCR

35 methodology to refining the biological function of this polypeptide is encompassed by the present invention. In the case of human phosphatase, a disease correlation related

5 to human phosphatase may be made by comparing the mRNA expression level of human phosphatase in normal tissue, as compared to diseased tissue (particularly diseased tissue isolated from the following: adrenal gland, testis, prostate, ovary, skeletal muscle, liver, placenta, pancreas, thymus, small intestine, thyroid, heart, kidney, and/or lung tissue). Significantly higher or lower levels of human phosphatase
10 expression in the diseased tissue may suggest human phosphatase plays a role in disease progression, and antagonists against human phosphatase polypeptides would be useful therapeutically in treating, preventing, and/or ameliorating the disease. Alternatively, significantly higher or lower levels of human phosphatase expression in the diseased tissue may suggest human phosphatase plays a defensive role against
15 disease progression, and agonists of human phosphatase polypeptides may be useful therapeutically in treating, preventing, and/or ameliorating the disease. Also encompassed by the present invention are quantitative PCR probes corresponding to the polynucleotide sequence provided as SEQ ID NO:108 (Figures 13A-F).

The function of the protein may also be assessed through complementation
20 assays in yeast. For example, in the case of the human phosphatase, transforming yeast deficient in dual-specificity phosphatase activity, for example, and assessing their ability to grow would provide convincing evidence the human phosphatase polypeptide has dual-specificity phosphatase activity. Additional assay conditions and methods that may be used in assessing the function of the polynucleotides and
25 polypeptides of the present invention are known in the art, some of which are disclosed elsewhere herein.

Alternatively, the biological function of the encoded polypeptide may be determined by disrupting a homologue of this polypeptide in Mice and/or rats and observing the resulting phenotype. Such knock-out experiments are known in the art,
30 some of which are disclosed elsewhere herein.

Moreover, the biological function of this polypeptide may be determined by the application of antisense and/or sense methodology and the resulting generation of transgenic mice and/or rats. Expressing a particular gene in either sense or antisense orientation in a transgenic mouse or rat could lead to respectively higher or lower
35 expression levels of that particular gene. Altering the endogenous expression levels of a gene can lead to the observation of a particular phenotype that can then be used to

5 derive indications on the function of the gene. The gene can be either over-expressed
or under expressed in every cell of the organism at all times using a strong ubiquitous
promoter, or it could be expressed in one or more discrete parts of the organism using
a well characterized tissue-specific promoter (e.g., a adrenal gland, testis, prostate,
ovary, skeletal muscle, liver, placenta, pancreas, thymus, small intestine, thyroid,
10 heart, kidney, and/or lung tissue specific promoter), or it can be expressed at a
specified time of development using an inducible and/or a developmentally regulated
promoter.

 In the case of human phosphatase transgenic mice or rats, if no phenotype is
apparent in normal growth conditions, observing the organism under diseased
15 conditions (metabolic, reproductive, immune, hematopoietic, cardiovascular, hepatic,
or pulmonary disorders, in addition to cancers, etc.) may lead to understanding the
function of the gene. Therefore, the application of antisense and/or sense
methodology to the creation of transgenic mice or rats to refine the biological function
of the polypeptide is encompassed by the present invention.

20 In preferred embodiments, the following N-terminal RET31 deletion
polypeptides are encompassed by the present invention: M1-S665, A2-S665, H3-
S665, E4-S665, M5-S665, I6-S665, G7-S665, T8-S665, Q9-S665, I10-S665, V11-
S665, T12-S665, E13-S665, R14-S665, L15-S665, V16-S665, A17-S665, L18-S665,
L19-S665, E20-S665, S21-S665, G22-S665, T23-S665, E24-S665, K25-S665, V26-
25 S665, L27-S665, L28-S665, I29-S665, D30-S665, S31-S665, R32-S665, P33-S665,
F34-S665, V35-S665, E36-S665, Y37-S665, N38-S665, T39-S665, S40-S665, H41-
S665, I42-S665, L43-S665, E44-S665, A45-S665, I46-S665, N47-S665, I48-S665,
N49-S665, C50-S665, S51-S665, K52-S665, L53-S665, M54-S665, K55-S665, R56-
S665, R57-S665, L58-S665, Q59-S665, Q60-S665, D61-S665, K62-S665, V63-S665,
30 L64-S665, I65-S665, T66-S665, E67-S665, L68-S665, I69-S665, Q70-S665, H71-
S665, S72-S665, A73-S665, K74-S665, H75-S665, K76-S665, V77-S665, D78-S665,
I79-S665, D80-S665, C81-S665, S82-S665, Q83-S665, K84-S665, V85-S665, V86-
S665, V87-S665, Y88-S665, D89-S665, Q90-S665, S91-S665, S92-S665, Q93-S665,
D94-S665, V95-S665, A96-S665, S97-S665, L98-S665, S99-S665, S100-S665,
35 D101-S665, C102-S665, F103-S665, L104-S665, T105-S665, V106-S665, L107-
S665, L108-S665, G109-S665, K110-S665, L111-S665, E112-S665, K113-S665,

5 S665, S531-S665, A532-S665, G533-S665, L534-S665, G535-S665, L536-S665, K537-S665, G538-S665, W539-S665, H540-S665, S541-S665, D542-S665, I543-S665, L544-S665, A545-S665, P546-S665, Q547-S665, T548-S665, S549-S665, T550-S665, P551-S665, S552-S665, L553-S665, T554-S665, S555-S665, S556-S665, W557-S665, Y558-S665, F559-S665, A560-S665, T561-S665, E562-S665, S563-S665, S564-S665, H565-S665, F566-S665, Y567-S665, S568-S665, A569-S665, S570-S665, A571-S665, I572-S665, Y573-S665, G574-S665, G575-S665, S576-S665, A577-S665, S578-S665, Y579-S665, S580-S665, A581-S665, Y582-S665, S583-S665, C584-S665, S585-S665, Q586-S665, L587-S665, P588-S665, T589-S665, C590-S665, G591-S665, D592-S665, Q593-S665, V594-S665, Y595-S665, S596-S665, V597-S665, R598-S665, R599-S665, R600-S665, Q601-S665, K602-S665, P603-S665, S604-S665, D605-S665, R606-S665, A607-S665, D608-S665, S609-S665, R610-S665, R611-S665, S612-S665, W613-S665, H614-S665, E615-S665, E616-S665, S617-S665, P618-S665, F619-S665, E620-S665, K621-S665, Q622-S665, F623-S665, K624-S665, R625-S665, R626-S665, S627-S665, C628-S665, Q629-S665, M630-S665, E631-S665, F632-S665, G633-S665, E634-S665, S635-S665, I636-S665, M637-S665, S638-S665, E639-S665, N640-S665, R641-S665, S642-S665, R643-S665, E644-S665, E645-S665, L646-S665, G647-S665, K648-S665, V649-S665, G650-S665, S651-S665, Q652-S665, S653-S665, S654-S665, F655-S665, S656-S665, G657-S665, S658-S665, and/or M659-S665 of SEQ ID
 20 NO:109. Polynucleotide sequences encoding these polypeptides are also provided. The present invention also encompasses the use of these N-terminal RET31 deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following C-terminal RET31 deletion
 30 polypeptides are encompassed by the present invention: M1-S665, M1-V664, M1-E663, M1-I662, M1-I661, M1-E660, M1-M659, M1-S658, M1-G657, M1-S656, M1-F655, M1-S654, M1-S653, M1-Q652, M1-S651, M1-G650, M1-V649, M1-K648, M1-G647, M1-L646, M1-E645, M1-E644, M1-R643, M1-S642, M1-R641, M1-N640, M1-E639, M1-S638, M1-M637, M1-I636, M1-S635, M1-E634, M1-G633, M1-F632, M1-E631, M1-M630, M1-Q629, M1-C628, M1-S627, M1-R626, M1-R625, M1-K624, M1-F623, M1-Q622, M1-K621, M1-E620, M1-F619, M1-P618,

- 5 M1-S617, M1-E616, M1-E615, M1-H614, M1-W613, M1-S612, M1-R611, M1-R610, M1-S609, M1-D608, M1-A607, M1-R606, M1-D605, M1-S604, M1-P603, M1-K602, M1-Q601, M1-R600, M1-R599, M1-R598, M1-V597, M1-S596, M1-Y595, M1-V594, M1-Q593, M1-D592, M1-G591, M1-C590, M1-T589, M1-P588, M1-L587, M1-Q586, M1-S585, M1-C584, M1-S583, M1-Y582, M1-A581, M1-S580, M1-Y579, M1-S578, M1-A577, M1-S576, M1-G575, M1-G574, M1-Y573, 10 M1-I572, M1-A571, M1-S570, M1-A569, M1-S568, M1-Y567, M1-F566, M1-H565, M1-S564, M1-S563, M1-E562, M1-T561, M1-A560, M1-F559, M1-Y558, M1-W557, M1-S556, M1-S555, M1-T554, M1-L553, M1-S552, M1-P551, M1-T550, M1-S549, M1-T548, M1-Q547, M1-P546, M1-A545, M1-L544, M1-I543, M1-D542, 15 M1-S541, M1-H540, M1-W539, M1-G538, M1-K537, M1-L536, M1-G535, M1-L534, M1-G533, M1-A532, M1-S531, M1-K530, M1-T529, M1-L528, M1-H527, M1-Q526, M1-Q525, M1-S524, M1-T523, M1-S522, M1-L521, M1-G520, M1-F519, M1-L518, M1-F517, M1-S516, M1-T515, M1-H514, M1-Y513, M1-N512, M1-D511, M1-E510, M1-V509, M1-S508, M1-G507, M1-S506, M1-R505, M1-H504, 20 M1-L503, M1-P502, M1-S501, M1-L500, M1-L499, M1-S498, M1-R497, M1-Q496, M1-A495, M1-T494, M1-G493, M1-S492, M1-S491, M1-S490, M1-T489, M1-R488, M1-V487, M1-S486, M1-H485, M1-L484, M1-R483, M1-K482, M1-S481, M1-Q480, M1-S479, M1-D478, M1-S477, M1-P476, M1-R475, M1-A474, M1-T473, M1-Q472, M1-L471, M1-K470, M1-K469, M1-P468, M1-I467, M1-S466, M1-A465, 25 M1-E464, M1-E463, M1-K462, M1-D461, M1-P460, M1-S459, M1-T458, M1-E457, M1-P456, M1-T455, M1-Q454, M1-E453, M1-S452, M1-L451, M1-E450, M1-Q449, M1-V448, M1-P447, M1-S446, M1-F445, M1-Q444, M1-C443, M1-L442, M1-K441, M1-N440, M1-T439, M1-G438, M1-D437, M1-L436, M1-T435, M1-T434, M1-S433, M1-P432, M1-K431, M1-Y430, M1-Y429, M1-E428, M1-L427, M1-A426, M1-D425, M1-E424, M1-S423, M1-S422, M1-S421, M1-F420, M1-G419, 30 M1-H418, M1-L417, M1-S416, M1-A415, M1-A414, M1-M413, M1-S412, M1-A411, M1-S410, M1-Y409, M1-S408, M1-V407, M1-S406, M1-K405, M1-I404, M1-D403, M1-L402, M1-S401, M1-F400, M1-S399, M1-R398, M1-K397, M1-L396, M1-K395, M1-N394, M1-S393, M1-D392, M1-E391, M1-L390, M1-R389, M1-D388, M1-A387, M1-S386, M1-L385, M1-H384, M1-L383, M1-G382, M1-S381, 35 M1-L380, M1-A379, M1-Q378, M1-V377, M1-L376, M1-P375, M1-S374, M1-

5 D373, M1-E372, M1-L371, M1-L370, M1-S369, M1-P368, M1-Q367, M1-V366,
M1-S365, M1-P364, M1-V363, M1-S362, M1-P361, M1-V360, M1-S359, M1-A358,
M1-P357, M1-H356, M1-V355, M1-P354, M1-R353, M1-Q352, M1-G351, M1-
A350, M1-A349, M1-E348, M1-S347, M1-T346, M1-A345, M1-S344, M1-D343,
M1-A342, M1-C341, M1-P340, M1-P339, M1-S338, M1-L337, M1-P336, M1-T335,
10 M1-E334, M1-S333, M1-K332, M1-Q331, M1-G330, M1-G329, M1-E328, M1-
S327, M1-V326, M1-A325, M1-P324, M1-V323, M1-P322, M1-E321, M1-N320,
M1-P319, M1-K318, M1-E317, M1-L316, M1-H315, M1-L314, M1-L313, M1-
K312, M1-L311, M1-K310, M1-S309, M1-K308, M1-P307, M1-G306, M1-S305,
M1-A304, M1-G303, M1-T302, M1-Q301, M1-N300, M1-K299, M1-I298, M1-
15 K297, M1-K296, M1-E295, M1-Y294, M1-D293, M1-L292, M1-L291, M1-Q290,
M1-G289, M1-L288, M1-F287, M1-N286, M1-F285, M1-N284, M1-P283, M1-S282,
M1-I281, M1-T280, M1-P279, M1-R278, M1-K277, M1-E276, M1-K275, M1-V274,
M1-F273, M1-R272, M1-Y271, M1-A270, M1-E269, M1-D268, M1-L267, M1-
S266, M1-M265, M1-D264, M1-M263, M1-R262, M1-K261, M1-M260, M1-I259,
20 M1-Y258, M1-A257, M1-I256, M1-A255, M1-I254, M1-T253, M1-A252, M1-S251,
M1-R250, M1-S249, M1-I248, M1-G247, M1-A246, M1-L245, M1-C244, M1-H243,
M1-V242, M1-L241, M1-V240, M1-C239, M1-G238, M1-N237, M1-S236, M1-
A235, M1-K234, M1-A233, M1-K232, M1-E231, M1-I230, M1-F229, M1-D228,
M1-V227, M1-S226, M1-K225, M1-D224, M1-L223, M1-W222, M1-P221, M1-
25 L220, M1-I219, M1-K218, M1-E217, M1-C216, M1-F215, M1-S214, M1-D213, M1-
N212, M1-V211, M1-P210, M1-V209, M1-R208, M1-L207, M1-F206, M1-H205,
M1-S204, M1-E203, M1-P202, M1-I201, M1-F200, M1-D199, M1-P198, M1-K197,
M1-P196, M1-C195, M1-T194, M1-Y193, M1-S192, M1-A191, M1-N190, M1-
L189, M1-V188, M1-Y187, M1-G186, M1-I185, M1-G184, M1-N183, M1-Q182,
30 M1-Q181, M1-I180, M1-L179, M1-E178, M1-K177, M1-N176, M1-L175, M1-V174,
M1-D173, M1-R172, M1-Q171, M1-C170, M1-G169, M1-L168, M1-Y167, M1-
L166, M1-N165, M1-P164, M1-L163, M1-I162, M1-R161, M1-T160, M1-P159, M1-
G158, M1-I157, M1-N156, M1-A155, M1-V154, M1-P153, M1-L152, M1-C151,
M1-P150, M1-Q149, M1-S148, M1-I147, M1-C146, M1-T145, M1-P144, M1-V143,
35 M1-L142, M1-T141, M1-S140, M1-K139, M1-G138, M1-E137, M1-C136, M1-
L135, M1-G134, M1-P133, M1-F132, M1-C131, M1-R130, M1-S129, M1-F128,

5 M1-E127, M1-A126, M1-F125, M1-G124, M1-G123, M1-A122, M1-L121, M1-L120, M1-H119, M1-V118, M1-S117, M1-N116, M1-F115, M1-S114, M1-K113, M1-E112, M1-L111, M1-K110, M1-G109, M1-L108, M1-L107, M1-V106, M1-T105, M1-L104, M1-F103, M1-C102, M1-D101, M1-S100, M1-S99, M1-L98, M1-S97, M1-A96, M1-V95, M1-D94, M1-Q93, M1-S92, M1-S91, M1-Q90, M1-D89,
10 M1-Y88, M1-V87, M1-V86, M1-V85, M1-K84, M1-Q83, M1-S82, M1-C81, M1-D80, M1-I79, M1-D78, M1-V77, M1-K76, M1-H75, M1-K74, M1-A73, M1-S72, M1-H71, M1-Q70, M1-I69, M1-L68, M1-E67, M1-T66, M1-I65, M1-L64, M1-V63, M1-K62, M1-D61, M1-Q60, M1-Q59, M1-L58, M1-R57, M1-R56, M1-K55, M1-M54, M1-L53, M1-K52, M1-S51, M1-C50, M1-N49, M1-I48, M1-N47, M1-I46, M1-A45, M1-E44, M1-L43, M1-I42, M1-H41, M1-S40, M1-T39, M1-N38, M1-Y37, M1-E36, M1-V35, M1-F34, M1-P33, M1-R32, M1-S31, M1-D30, M1-I29, M1-L28, M1-L27, M1-V26, M1-K25, M1-E24, M1-T23, M1-G22, M1-S21, M1-E20, M1-L19, M1-L18, M1-A17, M1-V16, M1-L15, M1-R14, M1-E13, M1-T12, M1-V11, M1-I10, M1-Q9, M1-T8, and/or M1-G7 of SEQ ID NO:109. Polynucleotide sequences
15 encoding these polypeptides are also provided. The present invention also encompasses the use of these C-terminal RET31 deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.
20

The present invention also encompasses immunogenic and/or antigenic epitopes of the human RET31 phosphatase polypeptide.

25 The human phosphatase polypeptides of the present invention were determined to comprise several phosphorylation sites based upon the Motif algorithm (Genetics Computer Group, Inc.). The phosphorylation of such sites may regulate some biological activity of the human phosphatase polypeptide. For example, phosphorylation at specific sites may be involved in regulating the proteins ability to
30 associate or bind to other molecules (e.g., proteins, ligands, substrates, DNA, etc.). In the present case, phosphorylation may modulate the ability of the human phosphatase polypeptide to associate with other polypeptides, particularly cognate ligand for human phosphatase, or its ability to modulate certain cellular signal pathways.

The human phosphatase polypeptide was predicted to comprise twelve PKC
35 phosphorylation sites using the Motif algorithm (Genetics Computer Group, Inc.). In vivo, protein kinase C exhibits a preference for the phosphorylation of serine or

5 S114-S665, F115-S665, N116-S665, S117-S665, V118-S665, H119-S665, L120-S665, L121-S665, A122-S665, G123-S665, G124-S665, F125-S665, A126-S665, E127-S665, F128-S665, S129-S665, R130-S665, C131-S665, F132-S665, P133-S665, G134-S665, L135-S665, C136-S665, E137-S665, G138-S665, K139-S665, S140-S665, T141-S665, L142-S665, V143-S665, P144-S665, T145-S665, C146-S665, I147-S665, S148-S665, Q149-S665, P150-S665, C151-S665, L152-S665, P153-S665, V154-S665, A155-S665, N156-S665, I157-S665, G158-S665, P159-S665, T160-S665, R161-S665, I162-S665, L163-S665, P164-S665, N165-S665, L166-S665, Y167-S665, L168-S665, G169-S665, C170-S665, Q171-S665, R172-S665, D173-S665, V174-S665, L175-S665, N176-S665, K177-S665, E178-S665, L179-S665, I180-S665, Q181-S665, Q182-S665, N183-S665, G184-S665, I185-S665, G186-S665, Y187-S665, V188-S665, L189-S665, N190-S665, A191-S665, S192-S665, Y193-S665, T194-S665, C195-S665, P196-S665, K197-S665, P198-S665, D199-S665, F200-S665, I201-S665, P202-S665, E203-S665, S204-S665, H205-S665, F206-S665, L207-S665, R208-S665, V209-S665, P210-S665, V211-S665, N212-S665, D213-S665, S214-S665, F215-S665, C216-S665, E217-S665, K218-S665, I219-S665, L220-S665, P221-S665, W222-S665, L223-S665, D224-S665, K225-S665, S226-S665, V227-S665, D228-S665, F229-S665, I230-S665, E231-S665, K232-S665, A233-S665, K234-S665, A235-S665, S236-S665, N237-S665, G238-S665, C239-S665, V240-S665, L241-S665, V242-S665, H243-S665, C244-S665, L245-S665, A246-S665, G247-S665, I248-S665, S249-S665, R250-S665, S251-S665, A252-S665, T253-S665, I254-S665, A255-S665, I256-S665, A257-S665, Y258-S665, I259-S665, M260-S665, K261-S665, R262-S665, M263-S665, D264-S665, M265-S665, S266-S665, L267-S665, D268-S665, E269-S665, A270-S665, Y271-S665, R272-S665, F273-S665, V274-S665, K275-S665, E276-S665, K277-S665, R278-S665, P279-S665, T280-S665, I281-S665, S282-S665, P283-S665, N284-S665, F285-S665, N286-S665, F287-S665, L288-S665, G289-S665, Q290-S665, L291-S665, L292-S665, D293-S665, Y294-S665, E295-S665, K296-S665, K297-S665, I298-S665, K299-S665, N300-S665, Q301-S665, T302-S665, G303-S665, A304-S665, S305-S665, G306-S665, P307-S665, K308-S665, S309-S665, K310-S665, L311-S665, K312-S665, L313-S665, L314-S665, H315-S665, L316-S665, E317-S665, K318-S665, P319-S665, N320-S665, E321-S665,

WO 02/057460

- 5 P322-S665, V323-S665, P324-S665, A325-S665, V326-S665, S327-S665, E328-S665, G329-S665, G330-S665, Q331-S665, K332-S665, S333-S665, E334-S665, T335-S665, P336-S665, L337-S665, S338-S665, P339-S665, P340-S665, C341-S665, A342-S665, D343-S665, S344-S665, A345-S665, T346-S665, S347-S665, E348-S665, A349-S665, A350-S665, G351-S665, Q352-S665, R353-S665, P354-S665, 10 V355-S665, H356-S665, P357-S665, A358-S665, S359-S665, V360-S665, P361-S665, S362-S665, V363-S665, P364-S665, S365-S665, V366-S665, Q367-S665, P368-S665, S369-S665, L370-S665, L371-S665, E372-S665, D373-S665, S374-S665, P375-S665, L376-S665, V377-S665, Q378-S665, A379-S665, L380-S665, S381-S665, G382-S665, L383-S665, H384-S665, L385-S665, S386-S665, A387-S665, 15 S665, D388-S665, R389-S665, L390-S665, E391-S665, D392-S665, S393-S665, N394-S665, K395-S665, L396-S665, K397-S665, R398-S665, S399-S665, F400-S665, S401-S665, L402-S665, D403-S665, I404-S665, K405-S665, S406-S665, V407-S665, S408-S665, Y409-S665, S410-S665, A411-S665, S412-S665, M413-S665, A414-S665, A415-S665, S416-S665, L417-S665, H418-S665, G419-S665, 20 F420-S665, S421-S665, S422-S665, S423-S665, E424-S665, D425-S665, A426-S665, L427-S665, E428-S665, Y429-S665, Y430-S665, K431-S665, P432-S665, S433-S665, T434-S665, T435-S665, L436-S665, D437-S665, G438-S665, T439-S665, N440-S665, K441-S665, L442-S665, C443-S665, Q444-S665, F445-S665, S446-S665, P447-S665, V448-S665, Q449-S665, E450-S665, L451-S665, S452-S665, 25 S665, E453-S665, Q454-S665, T455-S665, P456-S665, E457-S665, T458-S665, S459-S665, P460-S665, D461-S665, K462-S665, E463-S665, E464-S665, A465-S665, S466-S665, I467-S665, P468-S665, K469-S665, K470-S665, L471-S665, Q472-S665, T473-S665, A474-S665, R475-S665, P476-S665, S477-S665, D478-S665, S479-S665, Q480-S665, S481-S665, K482-S665, R483-S665, L484-S665, 30 H485-S665, S486-S665, V487-S665, R488-S665, T489-S665, S490-S665, S491-S665, S492-S665, G493-S665, T494-S665, A495-S665, Q496-S665, R497-S665, S498-S665, L499-S665, L500-S665, S501-S665, P502-S665, L503-S665, H504-S665, R505-S665, S506-S665, G507-S665, S508-S665, V509-S665, E510-S665, D511-S665, N512-S665, Y513-S665, H514-S665, T515-S665, S516-S665, F517-S665, 35 S665, L518-S665, F519-S665, G520-S665, L521-S665, S522-S665, T523-S665, S524-S665, Q525-S665, Q526-S665, H527-S665, L528-S665, T529-S665, K530-S665

5 threonine residues. The PKC phosphorylation sites have the following consensus pattern: [ST]-x-[RK], where S or T represents the site of phosphorylation and 'x' an intervening amino acid residue. Additional information regarding PKC phosphorylation sites can be found in Woodget J.R., Gould K.L., Hunter T., Eur. J. Biochem. 161:177-184(1986), and Kishimoto A., Nishiyama K., Nakanishi H.,
 10 Uratsuji Y., Nomura H., Takeyama Y., Nishizuka Y., J. Biol. Chem... 260:12492-12499(1985); which are hereby incorporated by reference herein.

In preferred embodiments, the following PKC phosphorylation site polypeptides are encompassed by the present invention: GTQIVTERLVALL (SEQ ID NO:116), LLESGTEKVLLID (SEQ ID NO:117), ELIQHSAKHKVDI (SEQ ID NO:118), VDIDCSQKVVVYD (SEQ ID NO:119), DRLEDNKLKRSF (SEQ ID NO:120), TTLDGTNKLCQFS (SEQ ID NO:121), PKKLQTARPSDSQ (SEQ ID NO:122), PSDSQSKRLHSVR (SEQ ID NO:123), SKRLHSVRTSSSG (SEQ ID NO:124), GDQVYSVRRRQKP (SEQ ID NO:125), RRQKPSDRADSRR (SEQ ID NO:126), and/or SDRADSRRSWHEE (SEQ ID NO:127). Polynucleotides encoding
 15 these polypeptides are also provided. The present invention also encompasses the use of the human RET31 phosphatase PKC phosphorylation site polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

The human phosphatase polypeptide has been shown to comprise six glycosylation sites according to the Motif algorithm (Genetics Computer Group, Inc.).
 25 As discussed more specifically herein, protein glycosylation is thought to serve a variety of functions including: augmentation of protein folding, inhibition of protein aggregation, regulation of intracellular trafficking to organelles, increasing resistance to proteolysis, modulation of protein antigenicity, and mediation of intercellular adhesion.

30 Asparagine phosphorylation sites have the following consensus pattern, N-{P}-[ST]-{P}, wherein N represents the glycosylation site. However, it is well known that that potential N-glycosylation sites are specific to the consensus sequence Asn-Xaa-Ser/Thr. However, the presence of the consensus tripeptide is not sufficient to conclude that an asparagine residue is glycosylated, due to the fact that the folding of
 35 the protein plays an important role in the regulation of N-glycosylation. It has been shown that the presence of proline between Asn and Ser/Thr will inhibit N-

glycosylation; this has been confirmed by a recent statistical analysis of glycosylation sites, which also shows that about 50% of the sites that have a proline C-terminal to Ser/Thr are not glycosylated. Additional information relating to asparagine glycosylation may be found in reference to the following publications, which are hereby incorporated by reference herein: Marshall R.D., *Annu. Rev. Biochem.* 41:673-702(1972); Pless D.D., Lennarz W.J., *Proc. Natl. Acad. Sci. U.S.A.* 74:134-138(1977); Bause E., *Biochem. J.* 209:331-336(1983); Gavel Y., von Heijne G., *Protein Eng.* 3:433-442(1990); and Miletich J.P., Broze G.J. Jr., *J. Biol. Chem.* 265:11397-11404(1990).

In preferred embodiments, the following asparagine glycosylation site polypeptides are encompassed by the present invention: PFVEYNTSHILEAI (SEQ ID NO:128), EAININCSKLMKRR (SEQ ID NO:129), IGYVLNASYTCKPKP (SEQ ID NO:130), LRVPVNDSFCEKIL (SEQ ID NO:131), EKKIKNQTGASGPK (SEQ ID NO:132), and/or SIMSENRSREELGK (SEQ ID NO:133). Polynucleotides encoding these polypeptides are also provided. The present invention also encompasses the use of the human RET31 phosphatase asparagine glycosylation site polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In confirmation of the human RET31 representing a novel human phosphatase polypeptide, the RET31 polypeptide has been shown to comprise a dual specificity phosphatase catalytic domain as identified by the BLAST2 algorithm using the DSPc PFAM HMM (PF00782) as a query sequence.

The catalytic residue of the human RET31 polypeptide is represented by an active site cysteine located at amino acid residue 244 of SEQ ID NO:109 (Figures 13A-F).

In preferred embodiments, the following human RET31 DSPc domain polypeptide is encompassed by the present invention: GPTRILPNLYLGCQRDVLNKELIQQNGIGYVLNASYTCKPKPDFIPESHFLRPV NDSFCEKILPWLDKSVDFIEKAKASNGCVLVHCLAGISRSATIAIAYIMKRMD MSLDEAYRFVKEKRPTISPNFNFLGQLLDYEKK (SEQ ID NO:134). Polynucleotides encoding this polypeptide are also provided. The present invention

5 also encompasses the use of this human RET31 DSPc domain polypeptide as an immunogenic and/or antigenic epitope as described elsewhere herein.

In preferred embodiments, the following human RET31 DSPc domain amino acid substitutions are encompassed by the present invention: wherein G158 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein P159 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein T160 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, or Y; wherein R161 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein I162 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L163 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein P164 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein N165 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; wherein L166 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein Y167 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein L168 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein G169 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein C170 is substituted with either an A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Q171 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; wherein R172 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein D173 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V174 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein L175 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein N176 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; wherein K177 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein E178 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L179 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein I180 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Q181 is substituted with either an A, C, D, E, F, G, H, I,

5 K, L, M, N, P, R, S, T, V, W, or Y; wherein Q182 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; wherein N183 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; wherein G184 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein I185 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S,
10 T, V, W, or Y; wherein G186 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Y187 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein V188 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein L189 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein
15 N190 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; wherein A191 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S192 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein Y193 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein T194 is substituted with
20 either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, or Y; wherein C195 is substituted with either an A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein P196 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein K197 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein P198 is substituted with either an A, C, D, E, F,
25 G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein D199 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein F200 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein I201 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein P202 is substituted with either an A, C, D, E, F, G, H, I, K, L,
30 M, N, Q, R, S, T, V, W, or Y; wherein E203 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S204 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein H205 is substituted with either an A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein F206 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S,
35 T, V, W, or Y; wherein L207 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein R208 is substituted with either an A, C, D, E, F,

5 G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein V209 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein P210 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein V211 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein N212 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q,
10 R, S, T, V, W, or Y; wherein D213 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S214 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein F215 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein C216 is substituted with either an A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y;
15 wherein E217 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein K218 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein I219 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L220 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein P221 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y;
20 wherein W222 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; wherein L223 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein D224 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein K225 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S226 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein V227 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein D228 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein F229 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein I230 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein E231 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein K232 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A233 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein K234 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A235 is substituted with either a C, D, E, F, G,

- 5 H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S236 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein N237 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; wherein G238 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein C239 is substituted with either an A, D, E, F, G, H, I, K, L, M,
- 10 N, P, Q, R, S, T, V, W, or Y; wherein V240 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein L241 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein V242 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein H243 is substituted with either an A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S,
- 15 T, V, W, or Y; wherein C244 is substituted with either an A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L245 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein A246 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein G247 is substituted with either an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein I248
- 20 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S249 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein R250 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein S251 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein A252 is substituted with
- 25 either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein T253 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, or Y; wherein I254 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A255 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein I256 is substituted with either an A, C, D, E, F,
- 30 G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A257 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Y258 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein I259 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein M260 is substituted with either an A, C, D, E, F, G, H, I, K, L, N, P, Q, R,
- 35 S, T, V, W, or Y; wherein K261 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein R262 is substituted with either an A, C, D,

5 E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein M263 is substituted with either an A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; wherein D264 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein M265 is substituted with either an A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; wherein S266 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein L267 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein D268 is substituted with either an A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein E269 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein A270 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Y271 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein R272 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein F273 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein V274 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; wherein K275 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein E276 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein K277 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; wherein R278 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; wherein P279 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein T280 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, or Y; wherein I281 is substituted with either an A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein S282 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; wherein P283 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; wherein N284 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; wherein F285 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein N286 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; wherein F287 is substituted with either an A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein L288 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein G289 is substituted with either

5 an A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Q290 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; wherein L291 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein L292 is substituted with either an A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; wherein D293 is substituted with either an A, C, E, F, G,
 10 H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein Y294 is substituted with either an A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; wherein E295 is substituted with either an A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; wherein K296 is substituted with either an A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or wherein K297 is substituted with either an A, C, D, E, F, G, H, I, L, M,
 15 N, P, Q, R, S, T, V, W, or Y of SEQ ID NO:109, in addition to any combination thereof. The present invention also encompasses the use of these human RET31 DSPc domain amino acid substituted polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following human RET31 DSPc domain
 20 conservative amino acid substitutions are encompassed by the present invention: wherein G158 is substituted with either an A, M, S, or T; wherein P159 is a P; wherein T160 is substituted with either an A, G, M, or S; wherein R161 is substituted with either a K, or H; wherein I162 is substituted with either an A, V, or L; wherein L163 is substituted with either an A, I, or V; wherein P164 is a P; wherein N165 is
 25 substituted with a Q; wherein L166 is substituted with either an A, I, or V; wherein Y167 is either an F, or W; wherein L168 is substituted with either an A, I, or V; wherein G169 is substituted with either an A, M, S, or T; wherein C170 is a C; wherein Q171 is substituted with a N; wherein R172 is substituted with either a K, or H; wherein D173 is substituted with an E; wherein V174 is substituted with either an
 30 A, I, or L; wherein L175 is substituted with either an A, I, or V; wherein N176 is substituted with a Q; wherein K177 is substituted with either a R, or H; wherein E178 is substituted with a D; wherein L179 is substituted with either an A, I, or V; wherein I180 is substituted with either an A, V, or L; wherein Q181 is substituted with a N; wherein Q182 is substituted with a N; wherein N183 is substituted with a Q; wherein
 35 G184 is substituted with either an A, M, S, or T; wherein I185 is substituted with either an A, V, or L; wherein G186 is substituted with either an A, M, S, or T;

5 wherein Y187 is either an F, or W; wherein V188 is substituted with either an A, I, or L; wherein L189 is substituted with either an A, I, or V; wherein N190 is substituted with a Q; wherein A191 is substituted with either a G, I, L, M, S, T, or V; wherein S192 is substituted with either an A, G, M, or T; wherein Y193 is either an F, or W; wherein T194 is substituted with either an A, G, M, or S; wherein C195 is a C;
10 wherein P196 is a P; wherein K197 is substituted with either a R, or H; wherein P198 is a P; wherein D199 is substituted with an E; wherein F200 is substituted with either a W, or Y; wherein I201 is substituted with either an A, V, or L; wherein P202 is a P; wherein E203 is substituted with a D; wherein S204 is substituted with either an A, G, M, or T; wherein H205 is substituted with either a K, or R; wherein F206 is substituted with either a W, or Y; wherein L207 is substituted with either an A, I, or V; wherein R208 is substituted with either a K, or H; wherein V209 is substituted with either an A, I, or L; wherein P210 is a P; wherein V211 is substituted with either an A, I, or L; wherein N212 is substituted with a Q; wherein D213 is substituted with an E; wherein S214 is substituted with either an A, G, M, or T; wherein F215 is substituted with either a W, or Y; wherein C216 is a C; wherein E217 is substituted with a D; wherein K218 is substituted with either a R, or H; wherein I219 is substituted with either an A, V, or L; wherein L220 is substituted with either an A, I, or V; wherein P221 is a P; wherein W222 is either an F, or Y; wherein L223 is substituted with either an A, I, or V; wherein D224 is substituted with an E; wherein
25 K225 is substituted with either a R, or H; wherein S226 is substituted with either an A, G, M, or T; wherein V227 is substituted with either an A, I, or L; wherein D228 is substituted with an E; wherein F229 is substituted with either a W, or Y; wherein I230 is substituted with either an A, V, or L; wherein E231 is substituted with a D; wherein K232 is substituted with either a R, or H; wherein A233 is substituted with either a G, I, L, M, S, T, or V; wherein K234 is substituted with either a R, or H; wherein A235 is substituted with either a G, I, L, M, S, T, or V; wherein S236 is substituted with either an A, G, M, or T; wherein N237 is substituted with a Q; wherein G238 is substituted with either an A, M, S, or T; wherein C239 is a C; wherein V240 is substituted with either an A, I, or L; wherein L241 is substituted with either an A, I, or V; wherein V242 is substituted with either an A, I, or L; wherein H243 is substituted with either a K, or R; wherein C244 is a C; wherein L245 is substituted with either an
35

5 A, I, or V; wherein A246 is substituted with either a G, I, L, M, S, T, or V; wherein G247 is substituted with either an A, M, S, or T; wherein I248 is substituted with either an A, V, or L; wherein S249 is substituted with either an A, G, M, or T; wherein R250 is substituted with either a K, or H; wherein S251 is substituted with either an A, G, M, or T; wherein A252 is substituted with either a G, I, L, M, S, T, or V; wherein T253 is substituted with either an A, G, M, or S; wherein I254 is substituted with either an A, V, or L; wherein A255 is substituted with either a G, I, L, M, S, T, or V; wherein I256 is substituted with either an A, V, or L; wherein A257 is substituted with either a G, I, L, M, S, T, or V; wherein Y258 is either an F, or W; wherein I259 is substituted with either an A, V, or L; wherein M260 is substituted with either an A, G, S, or T; wherein K261 is substituted with either a R, or H; wherein R262 is substituted with either a K, or H; wherein M263 is substituted with either an A, G, S, or T; wherein D264 is substituted with an E; wherein M265 is substituted with either an A, G, S, or T; wherein S266 is substituted with either an A, G, M, or T; wherein L267 is substituted with either an A, I, or V; wherein D268 is substituted with an E; wherein E269 is substituted with a D; wherein A270 is substituted with either a G, I, L, M, S, T, or V; wherein Y271 is either an F, or W; wherein R272 is substituted with either a K, or H; wherein F273 is substituted with either a W, or Y; wherein V274 is substituted with either an A, I, or L; wherein K275 is substituted with either a R, or H; wherein E276 is substituted with a D; wherein K277 is substituted with either a R, or H; wherein R278 is substituted with either a K, or H; wherein P279 is a P; wherein T280 is substituted with either an A, G, M, or S; wherein I281 is substituted with either an A, V, or L; wherein S282 is substituted with either an A, G, M, or T; wherein P283 is a P; wherein N284 is substituted with a Q; wherein F285 is substituted with either a W, or Y; wherein N286 is substituted with a Q; wherein F287 is substituted with either a W, or Y; wherein L288 is substituted with either an A, I, or V; wherein G289 is substituted with either an A, M, S, or T; wherein Q290 is substituted with a N; wherein L291 is substituted with either an A, I, or V; wherein L292 is substituted with either an A, I, or V; wherein D293 is substituted with an E; wherein Y294 is either an F, or W; wherein E295 is substituted with a D; wherein K296 is substituted with either a R, or H; and/or wherein K297 is substituted with either a R, or H of SEQ ID NO:109 in addition to any combination

5 thereof. Other suitable substitutions within the human RET31 DSPc domain are encompassed by the present invention and are referenced elsewhere herein. The present invention also encompasses the use of these human RET31 DSPc domain conservative amino acid substituted polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

10 In further confirmation of the human RET31 polypeptide representing a novel human phosphatase polypeptide, the RET31 polypeptide has been shown to comprise a tyrosine specific protein phosphatase active site domain according to the Motif algorithm (Genetics Computer Group, Inc.).

15 Tyrosine specific protein phosphatases (EC 3.1.3.48) (PTPase) are enzymes that catalyze the removal of a phosphate group attached to a tyrosine residue. These enzymes are very important in the control of cell growth, proliferation, differentiation and transformation. Multiple forms of PTPase have been characterized and can be classified into two categories: soluble PTPases and transmembrane receptor proteins that contain PTPase domain(s).

20 The currently known PTPases are listed below: Soluble PTPases, PTPN1 (PTP-1B), PTPN2 (T-cell PTPase; TC-PTP), PTPN3 (H1) and PTPN4 (MEG), enzymes that contain an N-terminal band 4.1-like domain and could act at junctions between the membrane and cytoskeleton, PTPN5 (STEP), PTPN6 (PTP-1C; HCP; SHP) and PTPN11 (PTP-2C; SH-PTP3; Syp), enzymes which contain two copies of
25 the SH2 domain at its N-terminal extremity (e.g., the Drosophila protein corkscrew (gene csw) also belongs to this subgroup), PTPN7 (LC-PTP; Hematopoietic protein-tyrosine phosphatase; HePTP), PTPN8 (70Z-PEP), PTPN9 (MEG2), PTPN12 (PTP-G1; PTP-P19), Yeast PTP1, Yeast PTP2 which may be involved in the ubiquitin-mediated protein degradation pathway, Fission yeast pyp1 and pyp2 which play a role
30 in inhibiting the onset of mitosis, Fission yeast pyp3 which contributes to the dephosphorylation of cdc2, Yeast CDC14 which may be involved in chromosome segregation, Yersinia virulence plasmid PTPases (gene yopH), Autographa californica nuclear polyhedrosis virus 19 Kd PTPase, Dual specificity PTPases, DUSP1 (PTPN10; MAP kinase phosphatase-1; MKP-1); which dephosphorylates
35 MAP kinase on both Thr-183 and Tyr-185, DUSP2 (PAC-1), a nuclear enzyme that dephosphorylates MAP kinases ERK1 and ERK2 on both Thr and Tyr residues,

- 5 DUSP3 (VHR), DUSP4 (HVH2), DUSP5 (HVH3), DUSP6 (Pyst1; MKP-3), DUSP7 (Pyst2; MKP-X), Yeast MSG5, a PTPase that dephosphorylates MAP kinase FUS3, Yeast YVH1, Vaccinia virus H1 PTPase - a dual specificity phosphatase,

Structurally, all known receptor PTPases, are made up of a variable length extracellular domain, followed by a transmembrane region and a C-terminal catalytic
10 cytoplasmic domain. Some of the receptor PTPases contain fibronectin type III (FN-III) repeats, immunoglobulin-like domains, MAM domains or carbonic anhydrase-like domains in their extracellular region. The cytoplasmic region generally contains two copies of the PTPase domain. The first seems to have enzymatic activity, while the second is inactive but seems to affect substrate specificity of the first. In these
15 domains, the catalytic cysteine is generally conserved but some other, presumably important, residues are not.

PTPase domains consist of about 300 amino acids. There are two conserved cysteines, the second one has been shown to be absolutely required for activity. Furthermore, a number of conserved residues in its immediate vicinity have also been
20 shown to be important.

A consensus sequence for tyrosine specific protein phosphatases is provided as follows:

[LIVMF]-H-C-x(2)-G-x(3)-[STC]-[STAGP]-x-[LIVMFY], wherein C is the active site residue and "X" represents any amino acid.

- 25 Additional information related to tyrosine specific protein phosphatase domains and proteins may be found in reference to the following publications Fischer E.H., Charbonneau H., Tonks N.K., Science 253:401-406(1991); Charbonneau H., Tonks N.K., Annu. Rev. Cell Biol. 8:463-493(1992); Trowbridge I.S., J. Biol. Chem... 266:23517-23520(1991); Tonks N.K., Charbonneau H., Trends Biochem. Sci. 14:497-
30 500(1989); and Hunter T., Cell 58:1013-1016(1989); which are hereby incorporated herein by reference in their entirety.

In preferred embodiments, the following tyrosine specific protein phosphatase active site domain polypeptide is encompassed by the present invention: NGCVLVHCLAGISRSATIAIAYI (SEQ ID NO:144). Polynucleotides encoding
35 these polypeptides are also provided. The present invention also encompasses the use

5 of this tyrosine specific protein phosphatase active site domain polypeptide as an immunogenic and/or antigenic epitope as described elsewhere herein.

In addition to the human RET31 polynucleotide and polypeptide sequence, the present invention also relates to the isolated mouse ortholog of the RET31 polypeptide.

10 The polypeptide corresponding to the mouse RET31 gene provided as SEQ ID NO:113 (Figure 16A-C), encoded by the polynucleotide sequence according to SEQ ID NO:114 (Figure 16A-C), and/or encoded by the polynucleotide contained within the deposited clone, mRET31, has significant homology at the nucleotide and amino acid level to a number of phosphatases, which include, for example, the human
15 RET31 protein of the present invention (SEQ ID NO:109); the human DUS8 (DUS8; Genbank Accession No:gi|U27193; SEQ ID NO:110); the human DUSP6 protein(DUSP6; Genbank Accession No:gi|AB013382; SEQ ID NO:111); and the human map kinase phosphatase MKP-5 protein (MKP-5; Genbank Accession No:gi|AB026436; SEQ ID NO:112) as determined by BLASTP. An alignment of the
20 human phosphatase polypeptide with these proteins is provided in Figures 14A-C.

The determined nucleotide sequence of the mRET31 cDNA in Figures 16A-C (SEQ ID NO:114) contains an open reading frame encoding a protein of about 660 amino acid residues, with a deduced molecular weight of about 73kDa. The amino acid sequence of the predicted mRET31 polypeptide is shown in Figures 16A-C (SEQ
25 ID NO:114). The mRET31 protein shown in Figures 16A-C was determined to share significant identity and similarity to several known phosphates, particularly, dual-specificity protein phosphatases. Specifically, the mRET31 protein shown in Figures 16A-C was determined to be about 90% identical and 92% similar to the human RET31 protein of the present invention (SEQ ID NO:109); to be about 48.5%
30 identical and 55.7% similar to the human DUS8 (DUS8; Genbank Accession No:gi|U27193; SEQ ID NO:110); to be about 37.4% identical and 49.7% similar to the human DUSP6 protein(DUSP6; Genbank Accession No:gi|AB013382; SEQ ID NO:111); and to be about 35.2% identical and 46.9% similar to the human map kinase phosphatase MKP-5 protein (MKP-5; Genbank Accession No:gi|AB026436; SEQ ID
35 NO:112), as shown in Figure 12.

5 The translational start nucleotide position of the mRET31 polynucleotide has been determined to begin at nucleotide 369 of SEQ ID NO:113 (Figures 16A-C), and the transational stop nucleotide position has been determined to be at nucleotide 2348 of SEQ ID NO:113 (Figures 16A-C).

 In preferred embodiments, the following N-terminal mRET31 deletion
10 polypeptides are encompassed by the present invention: M1-S660, A2-S660, H3-S660, E4-S660, M5-S660, I6-S660, G7-S660, T8-S660, Q9-S660, I10-S660, V11-S660, T12-S660, E13-S660, S14-S660, L15-S660, V16-S660, A17-S660, L18-S660, L19-S660, E20-S660, S21-S660, G22-S660, T23-S660, E24-S660, K25-S660, V26-S660, L27-S660, L28-S660, I29-S660, D30-S660, S31-S660, R32-S660, P33-S660,
15 F34-S660, V35-S660, E36-S660, Y37-S660, N38-S660, T39-S660, S40-S660, H41-S660, I42-S660, L43-S660, E44-S660, A45-S660, I46-S660, N47-S660, I48-S660, N49-S660, C50-S660, S51-S660, K52-S660, L53-S660, M54-S660, K55-S660, R56-S660, R57-S660, L58-S660, Q59-S660, Q60-S660, D61-S660, K62-S660, V63-S660, L64-S660, I65-S660, T66-S660, E67-S660, L68-S660, I69-S660, H70-S660, Q71-S660, S72-S660, T73-S660, K74-S660, H75-S660, K76-S660, V77-S660, D78-S660, I79-S660, D80-S660, C81-S660, N82-S660, Q83-S660, R84-S660, V85-S660, V86-S660, V87-S660, Y88-S660, D89-S660, H90-S660, S91-S660, S92-S660, Q93-S660, D94-S660, V95-S660, G96-S660, S97-S660, L98-S660, S99-S660, S100-S660, D101-S660, C102-S660, F103-S660, L104-S660, T105-S660, V106-S660, L107-S660, L108-S660, G109-S660, K110-S660, L111-S660, E112-S660, R113-S660, S114-S660, F115-S660, N116-S660, S117-S660, V118-S660, H119-S660, L120-S660, L121-S660, A122-S660, G123-S660, G124-S660, F125-S660, A126-S660, E127-S660, F128-S660, S129-S660, R130-S660, C131-S660, F132-S660, P133-S660, G134-S660, L135-S660, C136-S660, E137-S660, G138-S660, K139-S660,
25 S140-S660, T141-S660, L142-S660, V143-S660, P144-S660, T145-S660, C146-S660, I147-S660, S148-S660, Q149-S660, P150-S660, C151-S660, L152-S660, P153-S660, V154-S660, A155-S660, N156-S660, I157-S660, G158-S660, P159-S660, T160-S660, R161-S660, I162-S660, L163-S660, P164-S660, N165-S660, L166-S660, Y167-S660, L168-S660, G169-S660, C170-S660, Q171-S660, R172-S660, D173-S660, V174-S660, L175-S660, N176-S660, K177-S660, D178-S660,
35 L179-S660, M180-S660, Q181-S660, Q182-S660, N183-S660, G184-S660, I185-

5 S660, G186-S660, Y187-S660, V188-S660, L189-S660, N190-S660, A191-S660,
S192-S660, N193-S660, T194-S660, C195-S660, P196-S660, K197-S660, P198-
S660, D199-S660, F200-S660, I201-S660, P202-S660, E203-S660, S204-S660,
H205-S660, F206-S660, L207-S660, R208-S660, V209-S660, P210-S660, V211-
S660, N212-S660, D213-S660, S214-S660, F215-S660, C216-S660, E217-S660,
10 K218-S660, I219-S660, L220-S660, P221-S660, W222-S660, L223-S660, D224-
S660, K225-S660, S226-S660, V227-S660, D228-S660, F229-S660, I230-S660,
E231-S660, K232-S660, A233-S660, K234-S660, A235-S660, S236-S660, N237-
S660, G238-S660, C239-S660, V240-S660, L241-S660, I242-S660, H243-S660,
C244-S660, L245-S660, A246-S660, G247-S660, I248-S660, S249-S660, R250-
15 S660, S251-S660, A252-S660, T253-S660, I254-S660, A255-S660, I256-S660,
A257-S660, Y258-S660, I259-S660, M260-S660, K261-S660, R262-S660, M263-
S660, D264-S660, M265-S660, S266-S660, L267-S660, D268-S660, E269-S660,
A270-S660, Y271-S660, R272-S660, F273-S660, V274-S660, K275-S660, E276-
S660, K277-S660, R278-S660, P279-S660, T280-S660, I281-S660, S282-S660,
20 P283-S660, N284-S660, F285-S660, N286-S660, F287-S660, M288-S660, G289-
S660, Q290-S660, L291-S660, M292-S660, D293-S660, Y294-S660, E295-S660,
K296-S660, T297-S660, I298-S660, N299-S660, N300-S660, Q301-S660, T302-
S660, G303-S660, M304-S660, S305-S660, G306-S660, P307-S660, K308-S660,
S309-S660, K310-S660, L311-S660, K312-S660, L313-S660, L314-S660, H315-
25 S660, L316-S660, D317-S660, K318-S660, P319-S660, S320-S660, E321-S660,
P322-S660, V323-S660, P324-S660, A325-S660, A326-S660, S327-S660, E328-
S660, G329-S660, G330-S660, W331-S660, K332-S660, S333-S660, A334-S660,
L335-S660, S336-S660, L337-S660, S338-S660, P339-S660, P340-S660, C341-S660,
A342-S660, N343-S660, S344-S660, T345-S660, S346-S660, E347-S660, A348-
30 S660, S349-S660, G350-S660, Q351-S660, R352-S660, L353-S660, V354-S660,
H355-S660, P356-S660, A357-S660, S358-S660, V359-S660, P360-S660, R361-
S660, L362-S660, Q363-S660, P364-S660, S365-S660, L366-S660, L367-S660,
E368-S660, D369-S660, S370-S660, P371-S660, L372-S660, V373-S660, Q374-
S660, A375-S660, L376-S660, S377-S660, G378-S660, L379-S660, Q380-S660,
35 L381-S660, S382-S660, S383-S660, E384-S660, K385-S660, L386-S660, E387-
S660, D388-S660, S389-S660, T390-S660, K391-S660, L392-S660, K393-S660,

5 R394-S660, S395-S660, F396-S660, S397-S660, L398-S660, D399-S660, I400-S660,
K401-S660, S402-S660, V403-S660, S404-S660, Y405-S660, S406-S660, A407-
S660, S408-S660, M409-S660, A410-S660, A411-S660, S412-S660, L413-S660,
H414-S660, G415-S660, F416-S660, S417-S660, S418-S660, E419-S660, E420-
S660, A421-S660, L422-S660, D423-S660, Y424-S660, C425-S660, K426-S660,
10 P427-S660, S428-S660, A429-S660, T430-S660, L431-S660, D432-S660, G433-
S660, T434-S660, N435-S660, K436-S660, L437-S660, C438-S660, Q439-S660,
F440-S660, S441-S660, P442-S660, V443-S660, Q444-S660, E445-S660, V446-
S660, S447-S660, E448-S660, Q449-S660, S450-S660, P451-S660, E452-S660,
T453-S660, S454-S660, P455-S660, D456-S660, K457-S660, E458-S660, E459-
15 S660, A460-S660, H461-S660, I462-S660, P463-S660, K464-S660, Q465-S660,
P466-S660, Q467-S660, P468-S660, P469-S660, R470-S660, P471-S660, S472-
S660, E473-S660, S474-S660, Q475-S660, V476-S660, T477-S660, R478-S660,
L479-S660, H480-S660, S481-S660, V482-S660, R483-S660, T484-S660, G485-
S660, S486-S660, S487-S660, G488-S660, S489-S660, T490-S660, Q491-S660,
20 R492-S660, P493-S660, F494-S660, F495-S660, S496-S660, P497-S660, L498-S660,
H499-S660, R500-S660, S501-S660, G502-S660, S503-S660, V504-S660, E505-
S660, D506-S660, N507-S660, Y508-S660, H509-S660, T510-S660, N511-S660,
F512-S660, L513-S660, F514-S660, G515-S660, L516-S660, S517-S660, T518-
S660, S519-S660, Q520-S660, Q521-S660, H522-S660, L523-S660, T524-S660,
25 K525-S660, S526-S660, A527-S660, G528-S660, L529-S660, G530-S660, L531-
S660, K532-S660, G533-S660, W534-S660, H535-S660, S536-S660, D537-S660,
I538-S660, L539-S660, A540-S660, P541-S660, Q542-S660, S543-S660, S544-S660,
A545-S660, P546-S660, S547-S660, L548-S660, T549-S660, S550-S660, S551-
S660, W552-S660, Y553-S660, F554-S660, A555-S660, T556-S660, E557-S660,
30 P558-S660, S559-S660, H560-S660, L561-S660, Y562-S660, S563-S660, A564-
S660, S565-S660, A566-S660, I567-S660, Y568-S660, G569-S660, G570-S660,
N571-S660, S572-S660, S573-S660, Y574-S660, S575-S660, A576-S660, Y577-
S660, S578-S660, C579-S660, G580-S660, Q581-S660, L582-S660, P583-S660,
T584-S660, C585-S660, S586-S660, D587-S660, Q588-S660, I589-S660, Y590-
35 S660, S591-S660, V592-S660, R593-S660, R594-S660, R595-S660, Q596-S660,
K597-S660, P598-S660, T599-S660, D600-S660, R601-S660, A602-S660, D603-

5 S660, S604-S660, R605-S660, R606-S660, S607-S660, W608-S660, H609-S660, E610-S660, E611-S660, S612-S660, P613-S660, F614-S660, E615-S660, K616-S660, Q617-S660, F618-S660, K619-S660, R620-S660, R621-S660, S622-S660, C623-S660, Q624-S660, M625-S660, E626-S660, F627-S660, G628-S660, E629-S660, S630-S660, I631-S660, M632-S660, S633-S660, E634-S660, N635-S660, 10 R636-S660, S637-S660, R638-S660, E639-S660, E640-S660, L641-S660, G642-S660, K643-S660, V644-S660, G645-S660, S646-S660, Q647-S660, S648-S660, S649-S660, F650-S660, S651-S660, G652-S660, S653-S660, and/or M654-S660 of SEQ ID NO:114. Polynucleotide sequences encoding these polypeptides are also provided. The present invention also encompasses the use of these N-terminal 15 mRET31 deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following C-terminal mRET31 deletion polypeptides are encompassed by the present invention: M1-S660, M1-V659, M1-E658, M1-I657, M1-I656, M1-E655, M1-M654, M1-S653, M1-G652, M1-S651, M1- 20 F650, M1-S649, M1-S648, M1-Q647, M1-S646, M1-G645, M1-V644, M1-K643, M1-G642, M1-L641, M1-E640, M1-E639, M1-R638, M1-S637, M1-R636, M1-N635, M1-E634, M1-S633, M1-M632, M1-I631, M1-S630, M1-E629, M1-G628, M1-F627, M1-E626, M1-M625, M1-Q624, M1-C623, M1-S622, M1-R621, M1-R620, M1-K619, M1-F618, M1-Q617, M1-K616, M1-E615, M1-F614, M1-P613, 25 M1-S612, M1-E611, M1-E610, M1-H609, M1-W608, M1-S607, M1-R606, M1-R605, M1-S604, M1-D603, M1-A602, M1-R601, M1-D600, M1-T599, M1-P598, M1-K597, M1-Q596, M1-R595, M1-R594, M1-R593, M1-V592, M1-S591, M1-Y590, M1-I589, M1-Q588, M1-D587, M1-S586, M1-C585, M1-T584, M1-P583, M1-L582, M1-Q581, M1-G580, M1-C579, M1-S578, M1-Y577, M1-A576, M1-S575, M1-Y574, M1-S573, M1-S572, M1-N571, M1-G570, M1-G569, M1-Y568, 30 M1-I567, M1-A566, M1-S565, M1-A564, M1-S563, M1-Y562, M1-L561, M1-H560, M1-S559, M1-P558, M1-E557, M1-T556, M1-A555, M1-F554, M1-Y553, M1-W552, M1-S551, M1-S550, M1-T549, M1-L548, M1-S547, M1-P546, M1-A545, M1-S544, M1-S543, M1-Q542, M1-P541, M1-A540, M1-L539, M1-I538, M1-D537, 35 M1-S536, M1-H535, M1-W534, M1-G533, M1-K532, M1-L531, M1-G530, M1-L529, M1-G528, M1-A527, M1-S526, M1-K525, M1-T524, M1-L523, M1-H522,

- 5 M1-Q521, M1-Q520, M1-S519, M1-T518, M1-S517, M1-L516, M1-G515, M1-F514, M1-L513, M1-F512, M1-N511, M1-T510, M1-H509, M1-Y508, M1-N507, M1-D506, M1-E505, M1-V504, M1-S503, M1-G502, M1-S501, M1-R500, M1-H499, M1-L498, M1-P497, M1-S496, M1-F495, M1-F494, M1-P493, M1-R492, M1-Q491, M1-T490, M1-S489, M1-G488, M1-S487, M1-S486, M1-G485, M1-T484, M1-R483,
- 10 M1-V482, M1-S481, M1-H480, M1-L479, M1-R478, M1-T477, M1-V476, M1-Q475, M1-S474, M1-E473, M1-S472, M1-P471, M1-R470, M1-P469, M1-P468, M1-Q467, M1-P466, M1-Q465, M1-K464, M1-P463, M1-I462, M1-H461, M1-A460, M1-E459, M1-E458, M1-K457, M1-D456, M1-P455, M1-S454, M1-T453, M1-E452, M1-P451, M1-S450, M1-Q449, M1-E448, M1-S447, M1-V446, M1-E445, M1-Q444,
- 15 M1-V443, M1-P442, M1-S441, M1-F440, M1-Q439, M1-C438, M1-L437, M1-K436, M1-N435, M1-T434, M1-G433, M1-D432, M1-L431, M1-T430, M1-A429, M1-S428, M1-P427, M1-K426, M1-C425, M1-Y424, M1-D423, M1-L422, M1-A421, M1-E420, M1-E419, M1-S418, M1-S417, M1-F416, M1-G415, M1-H414, M1-L413, M1-S412, M1-A411, M1-A410, M1-M409, M1-S408, M1-A407, M1-
- 20 S406, M1-Y405, M1-S404, M1-V403, M1-S402, M1-K401, M1-I400, M1-D399, M1-L398, M1-S397, M1-F396, M1-S395, M1-R394, M1-K393, M1-L392, M1-K391, M1-T390, M1-S389, M1-D388, M1-E387, M1-L386, M1-K385, M1-E384, M1-S383, M1-S382, M1-L381, M1-Q380, M1-L379, M1-G378, M1-S377, M1-L376, M1-A375, M1-Q374, M1-V373, M1-L372, M1-P371, M1-S370, M1-D369, M1-E368,
- 25 M1-L367, M1-L366, M1-S365, M1-P364, M1-Q363, M1-L362, M1-R361, M1-P360, M1-V359, M1-S358, M1-A357, M1-P356, M1-H355, M1-V354, M1-L353, M1-R352, M1-Q351, M1-G350, M1-S349, M1-A348, M1-E347, M1-S346, M1-T345, M1-S344, M1-N343, M1-A342, M1-C341, M1-P340, M1-P339, M1-S338, M1-L337, M1-S336, M1-L335, M1-A334, M1-S333, M1-K332, M1-W331, M1-G330, M1-
- 30 G329, M1-E328, M1-S327, M1-A326, M1-A325, M1-P324, M1-V323, M1-P322, M1-E321, M1-S320, M1-P319, M1-K318, M1-D317, M1-L316, M1-H315, M1-L314, M1-L313, M1-K312, M1-L311, M1-K310, M1-S309, M1-K308, M1-P307, M1-G306, M1-S305, M1-M304, M1-G303, M1-T302, M1-Q301, M1-N300, M1-N299, M1-I298, M1-T297, M1-K296, M1-E295, M1-Y294, M1-D293, M1-M292,
- 35 M1-L291, M1-Q290, M1-G289, M1-M288, M1-F287, M1-N286, M1-F285, M1-N284, M1-P283, M1-S282, M1-I281, M1-T280, M1-P279, M1-R278, M1-K277, M1-

5 E276, M1-K275, M1-V274, M1-F273, M1-R272, M1-Y271, M1-A270, M1-E269,
M1-D268, M1-L267, M1-S266, M1-M265, M1-D264, M1-M263, M1-R262, M1-
K261, M1-M260, M1-I259, M1-Y258, M1-A257, M1-I256, M1-A255, M1-I254, M1-
T253, M1-A252, M1-S251, M1-R250, M1-S249, M1-I248, M1-G247, M1-A246,
M1-L245, M1-C244, M1-H243, M1-I242, M1-L241, M1-V240, M1-C239, M1-G238,
10 M1-N237, M1-S236, M1-A235, M1-K234, M1-A233, M1-K232, M1-E231, M1-
I230, M1-F229, M1-D228, M1-V227, M1-S226, M1-K225, M1-D224, M1-L223,
M1-W222, M1-P221, M1-L220, M1-I219, M1-K218, M1-E217, M1-C216, M1-F215,
M1-S214, M1-D213, M1-N212, M1-V211, M1-P210, M1-V209, M1-R208, M1-
L207, M1-F206, M1-H205, M1-S204, M1-E203, M1-P202, M1-I201, M1-F200, M1-
15 D199, M1-P198, M1-K197, M1-P196, M1-C195, M1-T194, M1-N193, M1-S192,
M1-A191, M1-N190, M1-L189, M1-V188, M1-Y187, M1-G186, M1-I185, M1-
G184, M1-N183, M1-Q182, M1-Q181, M1-M180, M1-L179, M1-D178, M1-K177,
M1-N176, M1-L175, M1-V174, M1-D173, M1-R172, M1-Q171, M1-C170, M1-
G169, M1-L168, M1-Y167, M1-L166, M1-N165, M1-P164, M1-L163, M1-I162,
20 M1-R161, M1-T160, M1-P159, M1-G158, M1-I157, M1-N156, M1-A155, M1-V154,
M1-P153, M1-L152, M1-C151, M1-P150, M1-Q149, M1-S148, M1-I147, M1-C146,
M1-T145, M1-P144, M1-V143, M1-L142, M1-T141, M1-S140, M1-K139, M1-
G138, M1-E137, M1-C136, M1-L135, M1-G134, M1-P133, M1-F132, M1-C131,
M1-R130, M1-S129, M1-F128, M1-E127, M1-A126, M1-F125, M1-G124, M1-
25 G123, M1-A122, M1-L121, M1-L120, M1-H119, M1-V118, M1-S117, M1-N116,
M1-F115, M1-S114, M1-R113, M1-E112, M1-L111, M1-K110, M1-G109, M1-L108,
M1-L107, M1-V106, M1-T105, M1-L104, M1-F103, M1-C102, M1-D101, M1-S100,
M1-S99, M1-L98, M1-S97, M1-G96, M1-V95, M1-D94, M1-Q93, M1-S92, M1-S91,
M1-H90, M1-D89, M1-Y88, M1-V87, M1-V86, M1-V85, M1-R84, M1-Q83, M1-
30 N82, M1-C81, M1-D80, M1-I79, M1-D78, M1-V77, M1-K76, M1-H75, M1-K74,
M1-T73, M1-S72, M1-Q71, M1-H70, M1-I69, M1-L68, M1-E67, M1-T66, M1-I65,
M1-L64, M1-V63, M1-K62, M1-D61, M1-Q60, M1-Q59, M1-L58, M1-R57, M1-
R56, M1-K55, M1-M54, M1-L53, M1-K52, M1-S51, M1-C50, M1-N49, M1-I48,
M1-N47, M1-I46, M1-A45, M1-E44, M1-L43, M1-I42, M1-H41, M1-S40, M1-T39,
35 M1-N38, M1-Y37, M1-E36, M1-V35, M1-F34, M1-P33, M1-R32, M1-S31, M1-D30,
M1-I29, M1-L28, M1-L27, M1-V26, M1-K25, M1-E24, M1-T23, M1-G22, M1-S21,

5 M1-E20, M1-L19, M1-L18, M1-A17, M1-V16, M1-L15, M1-S14, M1-E13, M1-T12, M1-V11, M1-I10, M1-Q9, M1-T8, and/or M1-G7 of SEQ ID NO:114. Polynucleotide sequences encoding these polypeptides are also provided. The present invention also encompasses the use of these C-terminal mRET31 deletion polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

10 In confirmation of the mouse RET31 representing a novel mouse phosphatase polypeptide, the mRET31 polypeptide has been shown to comprise a dual specificity phosphatase catalytic domain as identified by the BLAST2 algorithm using the DSPc PFAM HMM (PF00782) as a query sequence.

In preferred embodiments, the following mouse RET31 DSPc domain
 15 polypeptide is encompassed by the present invention:
 GPTRILPNLYLGCQRDVLNKDLMQQNGIGYVLNASNTCPKPDFIPESHFLRVP
 VNDSFCEKILPWLDKSVDFIEKAKASNGCVLIHCLAGISRSATIAIAYIMKRMD
 MSLDEAYRFVKEKRPTISPNFNFMGQLMDYEKT (SEQ ID NO:135).
 Polynucleotides encoding this polypeptide are also provided. The present invention
 20 also encompasses the use of this mouse RET31 DSPc domain polypeptide as an immunogenic and/or antigenic epitope as described elsewhere herein.

The present invention encompasses the use of RET31 inhibitors and/or activators of RET31 activity for the treatment, detection, amelioration, or prevention of phosphatase associated disorders, including but not limited to metabolic diseases
 25 such as diabetes, in addition to neural and/or cardiovascular diseases and disorders. The present invention also encompasses the use of RET31 inhibitors and/or activators of RET31 activity as immunosuppressive agents, anti-inflammatory agents, and/or anti-tumor agents

The present invention encompasses the use of RET31 phosphatase inhibitors,
 30 including, antagonists such as antisense nucleic acids, in addition to other antagonists, as described herein, in a therapeutic regimen to diagnose, prognose, treat, ameliorate, and/or prevent diseases where a kinase activity is insufficient. One, non-limiting example of a disease which may occur due to insufficient kinase activity are certain types of diabetes, where one or more kinases involved in the insulin receptor signal
 35 pathway may have insufficient activity or insufficient expression, for example.

5 Moreover, the present invention encompasses the use of RET31 phosphatase activators, and/or the use of the RET31 phosphatase gene or protein in a gene therapy regimen, as described herein, for the diagnoses, prognoses, treatment, amelioration, and/or prevention of diseases and/or disorders where a kinase activity is overly high, such as a cancer where a kinase oncogene product has excessive activity or excessive
10 expression.

 The present invention also encompasses the use of catalytically inactive variants of RET31 proteins, including fragments thereof, such as a protein therapeutic, or the use of the encoding polynucleotide sequence or as gene therapy, for example, in the diagnoses, prognosis, treatment, amelioration, and/or prevention of diseases or
15 disorders where phosphatase activity is overly high.

 The present invention encompasses the use of antibodies directed against the RET31 polypeptides, including fragment and/or variants thereof, of the present invention in diagnostics, as a biomarkers, and/or as a therapeutic agents.

 The present invention encompasses the use of an inactive, non-catalytic,
20 mutant of the RET31 phosphatase as a substrate trapping mutant to bind cellular phosphoproteins or a library of phosphopeptides to identify substrates of the RET31 polypeptides.

 The present invention encompasses the use of the RET31 polypeptides, to identify inhibitors or activators of the RET31 phosphatase activity using either in vitro
25 or 'virtual' (in silico) screening methods.

 One embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of the RET31 phosphatase comprising the steps of: i.) contacting a RET31 phosphatase inhibitor or activator labeled with an analytically detectable reagent with the RET31 phosphatase under conditions
30 sufficient to form a complex with the inhibitor or activator; ii.) contacting said complex with a sample containing a compound to be identified; iii) and identifying the compound as an inhibitor or activator by detecting the ability of the test compound to alter the amount of labeled known RET31 phosphatase inhibitor or activator in the complex.

35 Another embodiment of the invention relates to a method for identifying a compound as an activator or inhibitor of a RET31 phosphatase comprising the steps

- 5 of: i.) contacting the RET31 phosphatase with a compound to be identified; and ii.) and measuring the ability of the RET31 phosphatase to remove phosphate from a substrate.

The present invention also encompasses a method for identifying a ligand for the RET31 phosphatase comprising the steps of: i.) contacting the RET31 phosphatase
10 with a series of compounds under conditions to permit binding; and ii.) detecting the presence of any ligand-bound protein.

Preferably, the above referenced methods comprise the RET31 phosphatase in a form selected from the group consisting of whole cells, cytosolic cell fractions, membrane cell fractions, purified or partially purified forms. The invention also
15 relates to recombinantly expressed RET31 phosphatase in a purified, substantially purified, or unpurified state. The invention further relates to RET31 phosphatase fused or conjugated to a protein, peptide, or other molecule or compound known in the art, or referenced herein.

The present invention also encompasses pharmaceutical composition of the
20 RET31 phosphatase polypeptide comprising a compound identified by above referenced methods and a pharmaceutically acceptable carrier.

In preferred embodiments, the present invention encompasses a polynucleotide lacking the initiating start codon, in addition to, the resulting encoded polypeptide of RET31. Specifically, the present invention encompasses the
25 polynucleotide corresponding to nucleotides 541 thru 2532 of SEQ ID NO:108, and the polypeptide corresponding to amino acids 2 thru 665 of SEQ ID NO:109. Also encompassed are recombinant vectors comprising said encoding sequence, and host cells comprising said vector.

Many polynucleotide sequences, such as EST sequences, are publicly
30 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 108 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
35 are one or more polynucleotides consisting of a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 5436 of SEQ ID NO:108,

- 5 b is an integer between 15 to 5450, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:108, and where b is greater than or equal to a+14.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
10 related to SEQ ID NO: 113 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides consisting of a nucleotide sequence described by the
15 general formula of a-b, where a is any integer between 1 to 2742 of SEQ ID NO:113, b is an integer between 15 to 2756, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:113, and where b is greater than or equal to a+14.

5 **Table I**

Gene No.	CDNA CloneID	ATCC Deposit No. Z and Date	Vector	NT SEQ ID. No. X	Total NT Seq of Clone	5' NT of Start Codon of ORF	3' NT of ORF	AA Seq ID No. Y	Total AA of ORF
1.	BMV_HPP1_FL	XXXXXX Xx/xx/xx		149	4393	628	2448	150	607
1.	BMV_HPP1 - Fragment A	XXXXXX Xx/xx/xx		1	144	1	144	2	48
1.	BMV_HPP1 - Fragment B	XXXXXX Xx/xx/xx		3	33	1	33	4	11
2.	BMV_HPP2_FL	XXXXXX Xx/xx/xx		151	878	89	538	152	150
2.	BMV_HPP2 - partial	XXXXXX Xx/xx/xx		5	746	2	745	6	248
3.	BMV_HPP3	XXXXXX Xx/xx/xx		7	511	1	510	8	170
4.	BMV_HPP4	XXXXXX Xx/xx/xx		9	1710	1	1710	10	570
5.	BMV_HPP5 (7IC-5-E2)	PTA-2966 01/24/01	pSport	41	5111	470	2464	42	665
6.	RET31 (also referred to as 1hrTNF031, and/or Clone 31)	PTA-3434 06/07/01	PTAdv	108	5450	538	2532	109	665

5 Table I summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table I and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous
10 sequence of high redundancy (usually several overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

 The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." "Vector" refers to the type of vector contained in the cDNA Clone ID.

15 "Total NT Seq. Of Clone" refers to the total number of nucleotides in the clone contig identified by "Gene No." The deposited clone may contain all or most of the sequence of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon of ORF."

 The translated amino acid sequence, beginning with the methionine, is
20 identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

 The total number of amino acids within the open reading frame of SEQ ID
25 NO:Y is identified as "Total AA of ORF".

 SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and
30 described further herein. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ
35 ID NO:Y may be used, for example, to generate antibodies which bind specifically to

- 5 proteins containing the polypeptides and the proteins encoded by the cDNA clones identified in Table I.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or
10 deleted nucleotides may cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

- 15 Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a cDNA of the invention deposited with the ATCC, as set
20 forth in Table I. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a
25 suitable host cell containing the deposited cDNA, collecting the protein, and determining its sequence.

- The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein.
30 Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

- Also provided in the present invention are species homologs, allelic variants, and/or orthologs. The skilled artisan could, using procedures well-known in the art,
35 obtain the polynucleotide sequence corresponding to full-length genes (including, but not limited to the full-length coding region), allelic variants, splice variants, orthologs,

5 and/or species homologues of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, relying on the sequence from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologues may be isolated and identified by making suitable probes or primers which correspond to the 5', 3', or internal regions of the sequences provided herein
10 and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides
15 produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the protein, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-
20 sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, can be substantially purified using techniques described
25 herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using protocols described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the full-length form of the protein.

30 The present invention provides a polynucleotide comprising, or alternatively consisting of, the sequence identified as SEQ ID NO:X, and/or a cDNA provided in ATCC Deposit No. Z:. The present invention also provides a polypeptide comprising, or alternatively consisting of, the sequence identified as SEQ ID NO:Y, and/or a polypeptide encoded by the cDNA provided in ATCC Deposit NO:Z. The present
35 invention also provides polynucleotides encoding a polypeptide comprising, or

- 5 alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, and/or a polypeptide sequence encoded by the cDNA contained in ATCC Deposit No:Z.

Preferably, the present invention is directed to a polynucleotide comprising, or alternatively consisting of, the sequence identified as SEQ ID NO:X, and/or a cDNA provided in ATCC Deposit No.: that is less than, or equal to, a polynucleotide
10 sequence that is 5 mega basepairs, 1 mega basepairs, 0.5 mega basepairs, 0.1 mega basepairs, 50,000 basepairs, 20,000 basepairs, or 10,000 basepairs in length.

The present invention encompasses polynucleotides with sequences complementary to those of the polynucleotides of the present invention disclosed herein. Such sequences may be complementary to the sequence disclosed as SEQ ID
15 NO:X, the sequence contained in a deposit, and/or the nucleic acid sequence encoding the sequence disclosed as SEQ ID NO:Y.

The present invention also encompasses polynucleotides capable of hybridizing, preferably under reduced stringency conditions, more preferably under stringent conditions, and most preferably under highly stringent conditions, to
20 polynucleotides described herein. Examples of stringency conditions are shown in Table II below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

25

5 **TABLE II**

Stringency Condition	Polynucleotide Hybrid\pm	Hybrid Length (bp) \ddagger	Hybridization Temperature and Buffer\dagger	Wash Temperature and Buffer \dagger
A	DNA:DNA	> or equal to 50	65°C; 1xSSC – or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
B	DNA:DNA	< 50	Tb*; 1xSSC	Tb*; 1xSSC
C	DNA:RNA	> or equal to 50	67°C; 1xSSC – or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
D	DNA:RNA	< 50	Td*; 1xSSC	Td*; 1xSSC
E	RNA:RNA	> or equal to 50	70°C; 1xSSC – or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
F	RNA:RNA	< 50	Tf*; 1xSSC	Tf*; 1xSSC
G	DNA:DNA	> or equal to 50	65°C; 4xSSC – or- 45°C; 4xSSC, 50% formamide	65°C; 1xSSC
H	DNA:DNA	< 50	Th*; 4xSSC	Th*; 4xSSC
I	DNA:RNA	> or equal to 50	67°C; 4xSSC – or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
J	DNA:RNA	< 50	Tj*; 4xSSC	Tj*; 4xSSC

Stringency Condition	Polynucleotide Hybrid \pm	Hybrid Length (bp) \ddagger	Hybridization Temperature and Buffer \dagger	Wash Temperature and Buffer \dagger
K	RNA:RNA	> or equal to 50	70°C; 4xSSC – or- 40°C; 6xSSC, 50% formamide	67°C; 1xSSC
L	RNA:RNA	< 50	Tl*; 2xSSC	Tl*; 2xSSC
M	DNA:DNA	> or equal to 50	50°C; 4xSSC – or- 40°C 6xSSC, 50% formamide	50°C; 2xSSC
N	DNA:DNA	< 50	Tn*; 6xSSC	Tn*; 6xSSC
O	DNA:RNA	> or equal to 50	55°C; 4xSSC – or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
P	DNA:RNA	< 50	Tp*; 6xSSC	Tp*; 6xSSC
Q	RNA:RNA	> or equal to 50	60°C; 4xSSC – or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
R	RNA:RNA	< 50	Tr*; 4xSSC	Tr*; 4xSSC

5

\ddagger : The "hybrid length" is the anticipated length for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide of unknown sequence, the hybrid is assumed to be that of the hybridizing polynucleotide of the present invention. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity. Methods of aligning two or more polynucleotide sequences and/or determining the percent

10

5 identity between two polynucleotide sequences are well known in the art (e.g., MegAlign program of the DNA*Star suite of programs, etc).

†: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after
10 hybridization is complete. The hybridizations and washes may additionally include 5X Denhardt's reagent, .5-1.0% SDS, 100ug/ml denatured, fragmented salmon sperm DNA, 0.5% sodium pyrophosphate, and up to 50% formamide.

*T_b – T_r: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature T_m of the
15 hybrids there T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, $T_m(^{\circ}\text{C}) = 2(\# \text{ of A} + \text{T bases}) + 4(\# \text{ of G} + \text{C bases})$. For hybrids between 18 and 49 base pairs in length, $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\% \text{G} + \text{C}) - (600/\text{N})$, where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = .165
20 M).

±: The present invention encompasses the substitution of any one, or more DNA or RNA hybrid partners with either a PNA, or a modified polynucleotide. Such modified polynucleotides are known in the art and are more particularly described elsewhere herein.

25 Additional examples of stringency conditions for polynucleotide hybridization are provided, for example, in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M., Ausubel et al., eds, John Wiley and Sons, Inc., sections 2.10 and
30 6.3-6.4, which are hereby incorporated by reference herein.

Preferably, such hybridizing polynucleotides have at least 70% sequence identity (more preferably, at least 80% identity; and most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which they hybridize, where sequence identity is determined by comparing the sequences of the
35 hybridizing polynucleotides when aligned so as to maximize overlap and identity

5 while minimizing sequence gaps. The determination of identity is well known in the art, and discussed more specifically elsewhere herein.

The invention encompasses the application of PCR methodology to the polynucleotide sequences of the present invention, the clone deposited with the ATCC, and/or the cDNA encoding the polypeptides of the present invention. PCR techniques for the amplification of nucleic acids are described in US Patent No. 4, 683, 195 and Saiki et al., Science, 239:487-491 (1988). PCR, for example, may include the following steps, of denaturation of template nucleic acid (if double-stranded), annealing of primer to target, and polymerization. The nucleic acid probed or used as a template in the amplification reaction may be genomic DNA, cDNA, RNA, or a PNA. PCR may be used to amplify specific sequences from genomic DNA, specific RNA sequence, and/or cDNA transcribed from mRNA. References for the general use of PCR techniques, including specific method parameters, include Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51:263, (1987), Ehrlich (ed), PCR Technology, Stockton Press, NY, 1989; Ehrlich et al., Science, 252:1643-1650, (1991); and "PCR Protocols, A Guide to Methods and Applications", Eds., Innis et al., Academic Press, New York, (1990).

Signal Sequences

The present invention also encompasses mature forms of the polypeptide comprising, or alternatively consisting of, the polypeptide sequence of SEQ ID NO:Y, the polypeptide encoded by the polynucleotide described as SEQ ID NO:X, and/or the polypeptide sequence encoded by a cDNA in the deposited clone. The present invention also encompasses polynucleotides encoding mature forms of the present invention, such as, for example the polynucleotide sequence of SEQ ID NO:X, and/or the polynucleotide sequence provided in a cDNA of the deposited clone.

According to the signal hypothesis, proteins secreted by eukaryotic cells have a signal or secretary leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most eukaryotic cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known

- 5 that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch,
10 Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the
15 cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

The established method for identifying the location of signal sequences, in addition, to their cleavage sites has been the SignalP program (v1.1) developed by
20 Henrik Nielsen et al., Protein Engineering 10:1-6 (1997). The program relies upon the algorithm developed by von Heinje, though provides additional parameters to increase the prediction accuracy.

More recently, a hidden Markov model has been developed (H. Neilson, et al., Ismb 1998;6:122-30), which has been incorporated into the more recent SignalP
25 (v2.0). This new method increases the ability to identify the cleavage site by discriminating between signal peptides and uncleaved signal anchors. The present invention encompasses the application of the method disclosed therein to the prediction of the signal peptide location, including the cleavage site, to any of the polypeptide sequences of the present invention.

30 As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the polypeptide of the present invention may contain a signal sequence. Polypeptides of the invention which comprise a signal sequence have an N-terminus beginning within 5 residues (i.e., + or - 5 residues, or preferably at the -5, -4, -3, -2, -
35 1, +1, +2, +3, +4, or +5 residue) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein

5 is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally
10 occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited
15 clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

20 The present invention also encompasses variants (e.g., allelic variants, orthologs, etc.) of the polynucleotide sequence disclosed herein in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in the deposited clone.

The present invention also encompasses variants of the polypeptide sequence,
25 and/or fragments therein, disclosed in SEQ ID NO:Y, a polypeptide encoded by the polynucleotide sequence in SEQ ID NO:X, and/or a polypeptide encoded by a cDNA in the deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential
30 properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

Thus, one aspect of the invention provides an isolated nucleic acid molecule comprising, or alternatively consisting of, a polynucleotide having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding a
35 human phosphatase related polypeptide having an amino acid sequence as shown in the sequence listing and described in SEQ ID NO:X or the cDNA contained in ATCC

- 5 deposit No:Z; (b) a nucleotide sequence encoding a mature human phosphatase related polypeptide having the amino acid sequence as shown in the sequence listing and described in SEQ ID NO:X or the cDNA contained in ATCC deposit No:Z; (c) a nucleotide sequence encoding a biologically active fragment of a human phosphatase related polypeptide having an amino acid sequence shown in the sequence listing and
10 described in SEQ ID NO:X or the cDNA contained in ATCC deposit No:Z; (d) a nucleotide sequence encoding an antigenic fragment of a human phosphatase related polypeptide having an amino acid sequence shown in the sequence listing and described in SEQ ID NO:X or the cDNA contained in ATCC deposit No:Z; (e) a nucleotide sequence encoding a human phosphatase related polypeptide comprising
15 the complete amino acid sequence encoded by a human cDNA plasmid contained in SEQ ID NO:X or the cDNA contained in ATCC deposit No:Z; (f) a nucleotide sequence encoding a mature human phosphatase related polypeptide having an amino acid sequence encoded by a human cDNA plasmid contained in SEQ ID NO:X or the cDNA contained in ATCC deposit No:Z; (g) a nucleotide sequence encoding a
20 biologically active fragment of a human phosphatase related polypeptide having an amino acid sequence encoded by a human cDNA plasmid contained in SEQ ID NO:X or the cDNA contained in ATCC deposit No:Z; (h) a nucleotide sequence encoding an antigenic fragment of a human phosphatase related polypeptide having an amino acid sequence encoded by a human cDNA plasmid contained in SEQ ID NO:X or the
25 cDNA contained in ATCC deposit No:Z; (I) a nucleotide sequence complimentary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), or (h), above.

The present invention is also directed to polynucleotide sequences which comprise, or alternatively consist of, a polynucleotide sequence which is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to, for
30 example, any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), or (h), above. Polynucleotides encoded by these nucleic acid molecules are also encompassed by the invention. In another embodiment, the invention encompasses nucleic acid molecules which comprise, or alternatively, consist of a polynucleotide which hybridizes under stringent conditions, or alternatively, under lower stringency conditions, to a
35 polynucleotide in (a), (b), (c), (d), (e), (f), (g), or (h), above. Polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent

5 hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polypeptides.

Another aspect of the invention provides an isolated nucleic acid molecule comprising, or alternatively, consisting of, a polynucleotide having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding a
10 human phosphatase related polypeptide having an amino acid sequence as shown in the sequence listing and described in Table I; (b) a nucleotide sequence encoding a mature human phosphatase related polypeptide having the amino acid sequence as shown in the sequence listing and described in Table I; (c) a nucleotide sequence encoding a biologically active fragment of a human phosphatase related polypeptide
15 having an amino acid sequence as shown in the sequence listing and described in Table I; (d) a nucleotide sequence encoding an antigenic fragment of a human phosphatase related polypeptide having an amino acid sequence as shown in the sequence listing and described in Table I; (e) a nucleotide sequence encoding a human phosphatase related polypeptide comprising the complete amino acid sequence encoded by a
20 human cDNA in a cDNA plasmid contained in the ATCC Deposit and described in Table I; (f) a nucleotide sequence encoding a mature human phosphatase related polypeptide having an amino acid sequence encoded by a human cDNA in a cDNA plasmid contained in the ATCC Deposit and described in Table I; (g) a nucleotide sequence encoding a biologically active fragment of a human phosphatase related
25 polypeptide having an amino acid sequence encoded by a human cDNA in a cDNA plasmid contained in the ATCC Deposit and described in Table I; (h) a nucleotide sequence encoding an antigenic fragment of a human phosphatase related polypeptide having an amino acid sequence encoded by a human cDNA in a cDNA plasmid contained in the ATCC deposit and described in Table I; (i) a nucleotide sequence
30 complimentary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), or (h) above.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively, consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to, for
35 example, any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), or (h), above.

5 The present invention encompasses polypeptide sequences which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 98%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to, the following non-limited examples, the polypeptide sequence identified as SEQ ID NO:Y, the polypeptide sequence encoded by a cDNA provided in the deposited clone, and/or
10 polypeptide fragments of any of the polypeptides provided herein. Polynucleotides encoded by these nucleic acid molecules are also encompassed by the invention. In another embodiment, the invention encompasses nucleic acid molecules which comprise, or alternatively, consist of a polynucleotide which hybridizes under stringent conditions, or alternatively, under lower stringency conditions, to a
15 polynucleotide in (a), (b), (c), (d), (e), (f), (g), or (h), above. Polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polypeptides.

 The present invention is also directed to polypeptides which comprise, or
20 alternatively consist of, an amino acid sequence which is at least 80%, 98%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the cDNA in cDNA plasmid:Z, and/or polypeptide fragments of any of these polypeptides
25 (e.g., those fragments described herein). Polynucleotides which hybridize to the complement of the nucleic acid molecules encoding these polypeptides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the present invention, as are the polypeptides encoded by these polynucleotides.

30 By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In
35 other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the

5 reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence referenced in Table I, the ORF (open reading frame), or any fragment specified as described herein.

10 As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention)
15 and a subject sequence, also referred to as a global sequence alignment, can be determined using the CLUSTALW computer program (Thompson, J.D., et al., Nucleic Acids Research, 2(22):4673-4680, (1994)), which is based on the algorithm of Higgins, D.G., et al., Computer Applications in the Biosciences (CABIOS), 8(2):189-191, (1992). In a sequence alignment the query and subject sequences are
20 both DNA sequences. An RNA sequence can be compared by converting U's to T's. However, the CLUSTALW algorithm automatically converts U's to T's when comparing RNA sequences to DNA sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a CLUSTALW alignment of DNA sequences to calculate percent identity via pairwise alignments
25 are: Matrix=IUB, k-tuple=1, Number of Top Diagonals=5, Gap Penalty=3, Gap Open Penalty 10, Gap Extension Penalty=0.1, Scoring Method=Percent, Window Size=5 or the length of the subject nucleotide sequence, whichever is shorter. For multiple alignments, the following CLUSTALW parameters are preferred: Gap Opening Penalty=10; Gap Extension Parameter=0.05; Gap Separation Penalty Range=8; End
30 Gap Separation Penalty=Off; % Identity for Alignment Delay=40%; Residue Specific Gaps:Off; Hydrophilic Residue Gap=Off; and Transition Weighting=0. The pairwise and multiple alignment parameters provided for CLUSTALW above represent the default parameters as provided with the AlignX software program (Vector NTI suite of programs, version 6.0).

35 The present invention encompasses the application of a manual correction to the percent identity results, in the instance where the subject sequence is shorter than

5 the query sequence because of 5' or 3' deletions, not because of internal deletions. If only the local pairwise percent identity is required, no manual correction is needed. However, a manual correction may be applied to determine the global percent identity from a global polynucleotide alignment. Percent identity calculations based upon global polynucleotide alignments are often preferred since they reflect the percent
10 identity between the polynucleotide molecules as a whole (i.e., including any polynucleotide overhangs, not just overlapping regions), as opposed to, only local matching polynucleotides. Manual corrections for global percent identity determinations are required since the CLUSTALW program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For
15 subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the CLUSTALW sequence alignment. This percentage is
20 then subtracted from the percent identity, calculated by the above CLUSTALW program using the specified parameters, to arrive at a final percent identity score. This corrected score may be used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the CLUSTALW alignment, which are not matched/aligned with the query sequence, are calculated for
25 the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the CLUSTALW alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent
30 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the CLUSTALW program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions
35 are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity

5 calculated by CLUSTALW is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are required for the purposes of the present invention.

10 In addition to the above method of aligning two or more polynucleotide or polypeptide sequences to arrive at a percent identity value for the aligned sequences, it may be desirable in some circumstances to use a modified version of the CLUSTALW algorithm which takes into account known structural features of the sequences to be aligned, such as for example, the SWISS-PROT designations for each sequence. The result of such a modified CLUSTALW algorithm may provide a more
15 accurate value of the percent identity for two polynucleotide or polypeptide sequences. Support for such a modified version of CLUSTALW is provided within the CLUSTALW algorithm and would be readily appreciated to one of skill in the art of bioinformatics.

20 The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or
25 added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the mRNA to those preferred by a bacterial host such as *E. coli*).

30 Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

35 Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be

5 deleted from the N-terminus or C-terminus of the protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem... 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy
10 terminus of this protein (Dobeli et al., J. Biotechnology 7:199-216 (1988)).

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem.. 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over
15 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined,
20 produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the protein will
25 likely be retained when less than the majority of the residues of the protein are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

30 Alternatively, such N-terminus or C-terminus deletions of a polypeptide of the present invention may, in fact, result in a significant increase in one or more of the biological activities of the polypeptide(s). For example, biological activity of many polypeptides are governed by the presence of regulatory domains at either one or both termini. Such regulatory domains effectively inhibit the biological activity of such
35 polypeptides in lieu of an activation event (e.g., binding to a cognate ligand or receptor, phosphorylation, proteolytic processing, etc.). Thus, by eliminating the

5 regulatory domain of a polypeptide, the polypeptide may effectively be rendered biologically active in the absence of an activation event.

Thus, the invention further includes polypeptide variants that show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little
10 effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural
15 selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid
20 substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction
25 of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which
30 amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved.

The invention encompasses polypeptides having a lower degree of identity but
35 having sufficient similarity so as to perform one or more of the same functions performed by the polypeptide of the present invention. Similarity is determined by

5 conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics (e.g., chemical properties). According to Cunningham et al above, such conservative substitutions are likely to be phenotypically silent. Additional guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et
10 al., Science 247:1306-1310 (1990).

Tolerated conservative amino acid substitutions of the present invention involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of
15 the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

In addition, the present invention also encompasses the conservative substitutions provided in Table VII below.

5

Table VII

For Amino Acid	Code	Replace with any of:
Alanine	A	D-Ala, Gly, beta-Ala, L-Cys, D-Cys
Arginine	R	D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn
Asparagine	N	D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln
Aspartic Acid	D	D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln
Cysteine	C	D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr
Glutamine	Q	D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp
Glutamic Acid	E	D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln
Glycine	G	Ala, D-Ala, Pro, D-Pro, β -Ala, Acp
Isoleucine	I	D-Ile, Val, D-Val, Leu, D-Leu, Met, D-Met
Leucine	L	D-Leu, Val, D-Val, Met, D-Met
Lysine	K	D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn
Methionine	M	D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val
Phenylalanine	F	D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or 5-phenylproline, cis-3,4, or 5-phenylproline
Proline	P	D-Pro, L-1-thioazolidine-4-carboxylic acid; D- or L-1-oxazolidine-4-carboxylic acid
Serine	S	D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L-Cys, D-Cys
Threonine	T	D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val
Tyrosine	Y	D-Tyr, Phe, D-Phe, L-Dopa, His, D-His
Valine	V	D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met

Aside from the uses described above, such amino acid substitutions may also
 10 increase protein or peptide stability. The invention encompasses amino acid
 substitutions that contain, for example, one or more non-peptide bonds (which replace
 the peptide bonds) in the protein or peptide sequence. Also included are substitutions
 that include amino acid residues other than naturally occurring L-amino acids, e.g., D-
 amino acids or non-naturally occurring or synthetic amino acids, e.g., β or γ amino
 15 acids.

Both identity and similarity can be readily calculated by reference to the
 following publications: Computational Molecular Biology, Lesk, A.M., ed., Oxford
 University Press, New York, 1988; Biocomputing: Informatics and Genome Projects,
 Smith, D.W., ed., Academic Press, New York, 1993; Informatics Computer Analysis
 20 of Sequence Data, Part 1, Griffin, A'M., and Griffin, H.G., eds., Humana Press, New
 Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic

- 5 Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991.

In addition, the present invention also encompasses substitution of amino acids based upon the probability of an amino acid substitution resulting in conservation of function. Such probabilities are determined by aligning multiple
10 genes with related function and assessing the relative penalty of each substitution to proper gene function. Such probabilities are often described in a matrix and are used by some algorithms (e.g., BLAST, CLUSTALW, GAP, etc.) in calculating percent similarity wherein similarity refers to the degree by which one amino acid may substitute for another amino acid without lose of function. An example of such a
15 matrix is the PAM250 or BLOSUM62 matrix.

Aside from the canonical chemically conservative substitutions referenced above, the invention also encompasses substitutions which are typically not classified as conservative, but that may be chemically conservative under certain circumstances. Analysis of enzymatic catalysis for proteases, for example, has shown that certain
20 amino acids within the active site of some enzymes may have highly perturbed pKa's due to the unique microenvironment of the active site. Such perturbed pKa's could enable some amino acids to substitute for other amino acids while conserving enzymatic structure and function. Examples of amino acids that are known to have amino acids with perturbed pKa's are the Glu-35 residue of Lysozyme, the Ile-16
25 residue of Chymotrypsin, the His-159 residue of Papain, etc. The conservation of function relates to either anomalous protonation or anomalous deprotonation of such amino acids, relative to their canonical, non-perturbed pKa. The pKa perturbation may enable these amino acids to actively participate in general acid-base catalysis due to the unique ionization environment within the enzyme active site. Thus, substituting
30 an amino acid capable of serving as either a general acid or general base within the microenvironment of an enzyme active site or cavity, as may be the case, in the same or similar capacity as the wild-type amino acid, would effectively serve as a conservative amino substitution.

Besides conservative amino acid substitution, variants of the present invention
35 include, but are not limited to, the following: (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or

5 may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion
10 region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins
15 with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

20 Moreover, the invention further includes polypeptide variants created through the application of molecular evolution ("DNA Shuffling") methodology to the polynucleotide disclosed as SEQ ID NO:X, the sequence of the clone submitted in a deposit, and/or the cDNA encoding the polypeptide disclosed as SEQ ID NO:Y. Such DNA Shuffling technology is known in the art and more particularly described
25 elsewhere herein (e.g., WPC, Stemmer, PNAS, 91:10747, (1994)), and in the Examples provided herein).

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50
30 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the
35 present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions,

5 substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

10 **Polynucleotide and Polypeptide Fragments**

The present invention is directed to polynucleotide fragments of the polynucleotides of the invention, in addition to polypeptides encoded therein by said polynucleotides and/or fragments.

15 In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15
20 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In
25 this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus, or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

30 Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150,
35 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850,

5 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More
10 preferably, these polynucleotides can be used as probes or primers as discussed herein. Also encompassed by the present invention are polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions, as are the polypeptides encoded by these polynucleotides.

15 In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples
20 of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes
25 the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the full-length protein. Further preferred polypeptide fragments include the full-length protein having a continuous
30 series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of the full-length polypeptide. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the full-length protein. Furthermore, any combination of the above amino and carboxy terminus
35 deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

5 Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, 10 surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

 Other preferred polypeptide fragments are biologically active fragments. 15 Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

20 In a preferred embodiment, the functional activity displayed by a polypeptide encoded by a polynucleotide fragment of the invention may be one or more biological activities typically associated with the full-length polypeptide of the invention. Illustrative of these biological activities includes the fragments ability to bind to at least one of the same antibodies which bind to the full-length protein, the fragments 25 ability to interact with at lease one of the same proteins which bind to the full-length, the fragments ability to elicit at least one of the same immune responses as the full-length protein (i.e., to cause the immune system to create antibodies specific to the same epitope, etc.), the fragments ability to bind to at least one of the same polynucleotides as the full-length protein, the fragments ability to bind to a receptor of 30 the full-length protein, the fragments ability to bind to a ligand of the full-length protein, and the fragments ability to multimerize with the full-length protein. However, the skilled artisan would appreciate that some fragments may have biological activities which are desirable and directly inapposite to the biological activity of the full-length protein. The functional activity of polypeptides of the 35 invention, including fragments, variants, derivatives, and analogs thereof can be

5 determined by numerous methods available to the skilled artisan, some of which are described elsewhere herein:

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide
10 sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the
15 invention (such as, for example, the sequence disclosed in SEQ ID NO:1), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined supra.

20 The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a
25 protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined
30 by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional
35 means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

5 In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes
10 are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic
15 epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce
20 antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides
25 comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to
30 be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g.,
35 Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free

5 peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while
10 other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two
15 weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known
20 in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins
25 (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of
30 mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked
35 dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric

5 polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of
10 non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts
15 from cells infected with the recombinant vaccinia virus are loaded onto Ni²⁺-nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling
20 (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33
25 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by
30 DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to
35 recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the

- 5 invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen
10 receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, monovalent, bispecific, heteroconjugate, multispecific,
15 human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of
20 immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. Moreover, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact
25 molecules, as well as, antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation of the animal or plant, and may have less non-specific tissue binding than an intact antibody (Wahl et al., J. Nucl. Med.. 24:316-325 (1983)). Thus, these
30 fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')₂, Fd,
35 single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody

5 fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any
10 animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human
15 immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both
20 a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

25 Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which
30 specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog,
35 or homologue of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least

5 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologues of human proteins and the corresponding epitopes thereof.

10 Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is

15 with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as

20 described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M,

25 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described

30 herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes

35 antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind

5 an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor
10 activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at
15 least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing
20 antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of
25 the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No.
30 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997);
35 Carlson et al., J. Biol. Chem... 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al.,

- 5 Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the
10 antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may
15 be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection
20 assays and effector molecules such as heterologous polypeptides, drugs, radionucleotides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent
25 attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of
30 numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable
35 method known in the art.

5 The antibodies of the present invention may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan (Harlow, et al., *Antibodies: A Laboratory Manual*, (Cold spring Harbor Laboratory Press, 2nd ed. (1988), which is hereby incorporated herein by reference in its entirety). For example, a polypeptide of the invention can be administered to various host animals
10 including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. The administration of the polypeptides of the present invention may entail one or more injections of an immunizing agent and, if desired, an adjuvant. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but
15 are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art. For the
20 purposes of the invention, "immunizing agent" may be defined as a polypeptide of the invention, including fragments, variants, and/or derivatives thereof, in addition to fusions with heterologous polypeptides and other forms of the polypeptides described herein.

Typically, the immunizing agent and/or adjuvant will be injected in the
25 mammal by multiple subcutaneous or intraperitoneal injections, though they may also be given intramuscularly, and/or through IV). The immunizing agent may include polypeptides of the present invention or a fusion protein or variants thereof. Depending upon the nature of the polypeptides (i.e., percent hydrophobicity, percent hydrophilicity, stability, net charge, isoelectric point etc.), it may be useful to
30 conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Such conjugation includes either chemical conjugation by derivitizing active chemical functional groups to both the polypeptide of the present invention and the immunogenic protein such that a covalent bond is formed, or through fusion-protein based methodology, or other methods known to the skilled
35 artisan. Examples of such immunogenic proteins include, but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean

5 trypsin inhibitor. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants
10 such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Additional examples of adjuvants which may be employed includes the MPL-TDM adjuvant (monophosphoryl lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

 The antibodies of the present invention may comprise monoclonal antibodies.
15 Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975) and U.S. Pat. No. 4,376,110, by Harlow, et al., *Antibodies: A Laboratory Manual*, (Cold spring Harbor Laboratory Press, 2nd ed. (1988), by Hammerling, et al., *Monoclonal Antibodies and T-Cell Hybridomas* (Elsevier, N.Y., (1981)), or other methods known to the artisan.
20 Other examples of methods which may be employed for producing monoclonal antibodies includes, but are not limited to, the human B-cell hybridoma technique (Kosbor et al., 1983, *Immunology Today* 4:72; Cole et al., 1983, *Proc. Natl. Acad. Sci. USA* 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, *Monoclonal Antibodies And Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Such
25 antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

 In a hybridoma method, a mouse, a humanized mouse, a mouse with a human
30 immune system, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro.

 The immunizing agent will typically include polypeptides of the present
35 invention or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node

5 cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, Academic Press, (1986), pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent,
10 bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the
15 hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines
20 are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. As inferred throughout the specification, human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001
25 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the polypeptides of the present invention. Preferably, the binding specificity of monoclonal antibodies
30 produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoadsorbant assay (ELISA). Such techniques are known in the art and within the skill of the artisan. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollart, *Anal.*
35 *Biochem.*, 107:220 (1980).

5 After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, supra). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal.

10 The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-sepharose, hydroxyapatite chromatography, gel exclusion chromatography, gel electrophoresis, dialysis, or affinity chromatography.

15 The skilled artisan would acknowledge that a variety of methods exist in the art for the production of monoclonal antibodies and thus, the invention is not limited to their sole production in hybridomas. For example, the monoclonal antibodies may be made by recombinant DNA methods, such as those described in US patent No. 4, 816, 567. In this context, the term "monoclonal antibody" refers to an antibody
20 derived from a single eukaryotic, phage, or prokaryotic clone. The DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies, or such chains from human, humanized, or other sources). The hybridoma
25 cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transformed into host cells such as Simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified,
30 for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (US Patent No. 4, 816, 567; Morrison et al, supra) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the
35 constant domains of an antibody of the invention, or can be substituted for the

- 5 variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain.

10 The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can

15 be accomplished using routine techniques known in the art. Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988);

20 Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an

25 antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples herein. In a non-limiting example, mice can be immunized with a

30 polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well-known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by

35 limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention.

- 5 Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably,
10 the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by
15 known techniques. For example, Fab and F(ab')₂ fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). F(ab')₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

20 For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire
25 or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or
30 disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene
35 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737;

- 5 WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody
10 coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using
15 methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties). Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S.
20 Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988).

For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human
25 antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al.,
30 *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol. Methods* 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a
35 framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding

5 residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al.,
10 U.S. Patent No. 5,585,089; Riechmann et al., *Nature* 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, *Molecular*
15 *Immunology* 28(4/5):489-498 (1991); Studnicka et al., *Protein Engineering* 7(6):805-814 (1994); Roguska. et al., *PNAS* 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332). Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from
20 an "import" variable domain. Humanization can be essentially performed following the methods of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Reichmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al., *Science*, 239:1534-1536 (1988), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are
25 chimeric antibodies (US Patent No. 4, 816, 567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possible some FR residues are substituted from analogous sites in rodent antibodies.

30 In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an
35 immunoglobulin constant region (Fc), typically that of a human immunoglobulin

- 5 (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature* 332:323-329 (1988)] and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody
10 libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety. The techniques of Cole et al., and Boerder et al., are also available for the preparation of human monoclonal
15 antibodies (Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R. Riss, (1985); and Boerner et al., *J. Immunol.*, 147(1):86-95, (1991)).

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain
20 immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or
25 simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The
30 transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo
35 class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of

5 this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 10 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA), Genpharm (San Jose, CA), and Medarex, Inc. (Princeton, NJ) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

15 Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and creation of an antibody repertoire. This approach is described, for example, in US patent Nos. 5,545,807; 20 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,106, and in the following scientific publications: Marks et al., *Biotechnol.*, 10:779-783 (1992); Lonberg et al., *Nature* 368:856-859 (1994); Fishwild et al., *Nature Biotechnol.*, 14:845-51 (1996); Neuberger, *Nature Biotechnol.*, 14:826 (1996); Lonberg and Huszar, *Intern. Rev. Immunol.*, 13:65-93 (1995). 25

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology* 12:899-903 (1988)). 30

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, *FASEB J.* 7(5):437-444; (1989) and Nissinoff, *J. Immunol.* 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide 35 multimerization and/or binding of a polypeptide of the invention to a ligand can be

5 used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind
10 its ligands/receptors, and thereby block its biological activity.

The antibodies of the present invention may be bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present invention, one of the binding specificities may be directed towards a polypeptide of the present
15 invention, the other may be for any other antigen, and preferably for a cell-surface protein, receptor, receptor subunit, tissue-specific antigen, virally derived protein, virally encoded envelope protein, bacterially derived protein, or bacterial surface protein, etc.

Methods for making bispecific antibodies are known in the art. Traditionally,
20 the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of
25 which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., *EMBO J.*, 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-
30 antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the
35 immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transformed into a suitable

5 host organism. For further details of generating bispecific antibodies see, for example Suresh et al., Meth. In Enzym., 121:210 (1986).

Heteroconjugate antibodies are also contemplated by the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to
10 unwanted cells (US Patent No. 4, 676, 980), and for the treatment of HIV infection (WO 91/00360; WO 92/20373; and EP03089). It is contemplated that the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioester bond.
15 Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in US Patent No. 4,676,980.

Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide
20 sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of
25 SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in
30 Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from
35 nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is

5 known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

15 Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

25 In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., *J. Mol. Biol.* 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid

35

5 substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other
10 alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes
15 from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized
20 antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain
25 antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

30 *Methods of Producing Antibodies*

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment,
35 derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an

5 expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using
10 techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example,
15 in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant
20 region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques
25 and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies,
30 vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently
35 purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the

5 invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant
10 virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells)
15 harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used
20 for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

25 In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified
30 may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.*... 24:5503-
35 5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such

5 fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

10 In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

15 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region 20 E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the 25 ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate 30 transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., 35 cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-

5 translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such
10 mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable
15 expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.
20 Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may
25 advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)),
30 hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp^rt- or ap^rt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci.
35 USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad.

5 Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215); and hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY 15 (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

20 The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will 25 also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

30 The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise 35 cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal,

5 chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the
10 purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to
15 a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino
20 acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in vitro
25 immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entirety.

30 The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant
35 region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be

5 fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known
10 in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341(1992) (said references incorporated by reference in their
15 entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides
20 corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The
25 polypeptides of the present invention fused or conjugated to an antibody having disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and
30 thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have
35 been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58

- 5 (1995); Johanson et al., J. Biol. Chem... 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA,
10 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson
15 et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment
20 regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance
25 may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase,
30 alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of
35 bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ¹¹¹In or ⁹⁹Tc.

5 Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ^{213}Bi . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include
10 etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologues thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine,
15 cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly
20 actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein
25 or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- α , TNF- β , AIM I (See, International Publication No. WO 97/33899),
30 AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi et al., Int. Immunol., 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte
35 macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

5 Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

 Techniques for conjugating such therapeutic moiety to antibodies are well
10 known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents
15 In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And
20 Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

25 An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

Uses for Antibodies directed against polypeptides of the invention

30 The antibodies of the present invention have various utilities. For example, such antibodies may be used in diagnostic assays to detect the presence or quantification of the polypeptides of the invention in a sample. Such a diagnostic assay may be comprised of at least two steps. The first, subjecting a sample with the antibody, wherein the sample is a tissue (e.g., human, animal, etc.), biological fluid
35 (e.g., blood, urine, sputum, semen, amniotic fluid, saliva, etc.), biological extract (e.g., tissue or cellular homogenate, etc.), a protein microchip (e.g., See Arenkov P, et al.,

5 Anal Biochem., 278(2):123-131 (2000)), or a chromatography column, etc. And a second step involving the quantification of antibody bound to the substrate. Alternatively, the method may additionally involve a first step of attaching the antibody, either covalently, electrostatically, or reversibly, to a solid support, and a second step of subjecting the bound antibody to the sample, as defined above and
10 elsewhere herein.

Various diagnostic assay techniques are known in the art, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogenous phases (Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc., (1987), pp147-158). The
15 antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as ^2H , ^{14}C , ^{32}P , or ^{125}I , a florescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline
20 phosphatase, beta-galactosidase, green fluorescent protein, or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); Dafvid et al., Biochem., 13:1014 (1974); Pain et al., J. Immunol. Metho., 40:219(1981); and Nygren, J. Histochem. And Cytochem., 30:407 (1982).

25 Antibodies directed against the polypeptides of the present invention are useful for the affinity purification of such polypeptides from recombinant cell culture or natural sources. In this process, the antibodies against a particular polypeptide are immobilized on a suitable support, such as a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a
30 sample containing the polypeptides to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except for the desired polypeptides, which are bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the desired polypeptide from the antibody.

35

5 *Immunophenotyping*

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or
10 maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with
15 antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison et al., Cell, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to
20 prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

Assays For Antibody Binding

25 The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions,
30 gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference
35 herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

5 Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell
10 lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art
15 would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

20 Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking
25 the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32P or 125I) diluted in blocking
30 buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994,
35 Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

5 ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be
10 conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of
15 skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

20 The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 125I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the
25 antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 125I) in the presence of
30 increasing amounts of an unlabeled second antibody.

Therapeutic Uses Of Antibodies

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal,
35 and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include,

5 but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression
10 and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions.
15 Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the
20 antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

25 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

30 The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment,
35 human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

5 It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will
10 preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.

Antibodies directed against polypeptides of the present invention are useful for inhibiting allergic reactions in animals. For example, by administering a therapeutically acceptable dose of an antibody, or antibodies, of the present invention,
20 or a cocktail of the present antibodies, or in combination with other antibodies of varying sources, the animal may not elicit an allergic response to antigens.

Likewise, one could envision cloning the gene encoding an antibody directed against a polypeptide of the present invention, said polypeptide having the potential to elicit an allergic and/or immune response in an organism, and transforming the
25 organism with said antibody gene such that it is expressed (e.g., constitutively, inducibly, etc.) in the organism. Thus, the organism would effectively become resistant to an allergic response resulting from the ingestion or presence of such an immune/allergic reactive polypeptide. Moreover, such a use of the antibodies of the present invention may have particular utility in preventing and/or ameliorating
30 autoimmune diseases and/or disorders, as such conditions are typically a result of antibodies being directed against endogenous proteins. For example, in the instance where the polypeptide of the present invention is responsible for modulating the immune response to auto-antigens, transforming the organism and/or individual with a construct comprising any of the promoters disclosed herein or otherwise known in
35 the art, in addition, to a polynucleotide encoding the antibody directed against the polypeptide of the present invention could effectively inhibit the organisms immune

- 5 system from eliciting an immune response to the auto-antigen(s). Detailed descriptions of therapeutic and/or gene therapy applications of the present invention are provided elsewhere herein.

Alternatively, antibodies of the present invention could be produced in a plant (e.g., cloning the gene of the antibody directed against a polypeptide of the present invention, and transforming a plant with a suitable vector comprising said gene for
10 constitutive expression of the antibody within the plant), and the plant subsequently ingested by an animal, thereby conferring temporary immunity to the animal for the specific antigen the antibody is directed towards (See, for example, US Patent Nos. 5,914,123 and 6,034,298).

- 15 In another embodiment, antibodies of the present invention, preferably polyclonal antibodies, more preferably monoclonal antibodies, and most preferably single-chain antibodies, can be used as a means of inhibiting gene expression of a particular gene, or genes, in a human, mammal, and/or other organism. See, for example, International Publication Number WO 00/05391, published 2/3/00, to Dow
20 Agrosiences LLC. The application of such methods for the antibodies of the present invention are known in the art, and are more particularly described elsewhere herein.

In yet another embodiment, antibodies of the present invention may be useful for multimerizing the polypeptides of the present invention. For example, certain proteins may confer enhanced biological activity when present in a multimeric state
25 (i.e., such enhanced activity may be due to the increased effective concentration of such proteins whereby more protein is available in a localized location).

Antibody-based Gene Therapy

- In a specific embodiment, nucleic acids comprising sequences encoding
30 antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded
35 protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according

5 to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217
10 (1993); May, *TIBTECH* 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990).

15 In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or
20 constitutive, and, optionally, tissue- specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, *Proc. Natl. Acad. Sci. USA*
25 86:8932-8935 (1989); Zijlstra et al., *Nature* 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case
30 the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered
35 in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing

5 them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, 10 encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem... 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand 15 complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, 20 the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can 25 be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can 30 be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human 35 Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993).

5 Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of
10 being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld
15 et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143- 155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

 Adeno-associated virus (AAV) has also been proposed for use in gene therapy
20 (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

 Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the
25 transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

 In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be
30 carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see,
35 e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92m (1985) and may be

5 used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

10 The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

15 Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor
20 cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy,
25 nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the
30 present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region,
35 such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or

5 Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

Therapeutic/Prophylactic Administration and Compositions

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem... 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal,

5 intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition,
10 it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an
15 inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after
20 surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

25 In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

30 In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974);
35 *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and

5 Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose
10 (see, e.g., Goodson, in *Medical Applications of Controlled Release*, supra, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic
15 acid encoding a protein, the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating
20 with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot et al., *Proc. Natl. Acad. Sci. USA* 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

25 The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized
30 pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred
35 carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid

5 carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering
10 agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium
15 saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the
20 mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the
25 composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the
30 composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms.
35 Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those

5 formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

10 The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

15 For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

25 The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Diagnosis and Imaging With Antibodies

35 Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect,

5 diagnose, or monitor diseases, disorders, and/or conditions associated with the
aberrant expression and/or activity of a polypeptide of the invention. The invention
provides for the detection of aberrant expression of a polypeptide of interest,
comprising (a) assaying the expression of the polypeptide of interest in cells or body
fluid of an individual using one or more antibodies specific to the polypeptide interest
10 and (b) comparing the level of gene expression with a standard gene expression level,
whereby an increase or decrease in the assayed polypeptide gene expression level
compared to the standard expression level is indicative of aberrant expression.

 The invention provides a diagnostic assay for diagnosing a disorder,
comprising (a) assaying the expression of the polypeptide of interest in cells or body
15 fluid of an individual using one or more antibodies specific to the polypeptide interest
and (b) comparing the level of gene expression with a standard gene expression level,
whereby an increase or decrease in the assayed polypeptide gene expression level
compared to the standard expression level is indicative of a particular disorder. With
respect to cancer, the presence of a relatively high amount of transcript in biopsied
20 tissue from an individual may indicate a predisposition for the development of the
disease, or may provide a means for detecting the disease prior to the appearance of
actual clinical symptoms. A more definitive diagnosis of this type may allow health
professionals to employ preventative measures or aggressive treatment earlier thereby
preventing the development or further progression of the cancer.

25 Antibodies of the invention can be used to assay protein levels in a biological
sample using classical immunohistological methods known to those of skill in the art
(e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell .
Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting
protein gene expression include immunoassays, such as the enzyme linked
30 immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody
assay labels are known in the art and include enzyme labels, such as, glucose oxidase;
radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H),
indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and
fluorescent labels, such as fluorescein and rhodamine, and biotin.

35 One aspect of the invention is the detection and diagnosis of a disease or
disorder associated with aberrant expression of a polypeptide of interest in an animal,

5 preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially
10 concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the
15 polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce
20 diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^{99m}Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of
25 Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the
30 labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by
35 repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial

5 diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patent using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control

5 antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or
10 rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may
15 also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The
20 diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled
25 monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing
30 unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by
35 incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

5 The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the
10 solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

 Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound
15 recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

Fusion Proteins

 Any polypeptide of the present invention can be used to generate fusion
20 proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because certain proteins target cellular locations based on trafficking signals, the polypeptides of the present
25 invention can be used as targeting molecules once fused to other proteins.

 Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

30 Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Peptide moieties may be added to the polypeptide
35 to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. Similarly, peptide cleavage sites can be introduced in-between such

5 peptide moieties, which could additionally be subjected to protease activity to remove said peptide(s) from the protein of the present invention. The addition of peptide moieties, including peptide cleavage sites, to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and
10 specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins
15 consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric
20 secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of the constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc
25 part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for
30 example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem... 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker
35 sequences (also referred to as "tags"). Due to the availability of antibodies specific to such "tags", purification of the fused polypeptide of the invention, and/or its

5 identification is significantly facilitated since antibodies specific to the polypeptides of the invention are not required. Such purification may be in the form of an affinity purification whereby an anti-tag antibody or another type of affinity matrix (e.g., anti-tag antibody attached to the matrix of a flow-thru column) that binds to the epitope tag is present. In preferred embodiments, the marker amino acid sequence is a hexa-
10 histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an
15 epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984)).

The skilled artisan would acknowledge the existence of other "tags" which could be readily substituted for the tags referred to supra for purification and/or identification of polypeptides of the present invention (Jones C., et al., J Chromatogr
20 A. 707(1):3-22 (1995)). For example, the c-myc tag and the 8F9, 3C7, 6E10, G4m B7 and 9E10 antibodies thereto (Evan et al., Molecular and Cellular Biology 5:3610-3616 (1985)); the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering, 3(6):547-553 (1990), the Flag-peptide - i.e., the octapeptide sequence DYKDDDDK (SEQ ID NO:75), (Hopp et al., Biotech. 6:1204-
25 1210 (1988); the KT3 epitope peptide (Martin et al., Science, 255:192-194 (1992)); a-tubulin epitope peptide (Skinner et al., J. Biol. Chem., 266:15136-15166, (1991)); the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al., Proc. Natl. Sci. USA, 87:6363-6397 (1990)), the FITC epitope (Zymed, Inc.), the GFP epitope (Zymed, Inc.), and the Rhodamine epitope (Zymed, Inc.).

30 The present invention also encompasses the attachment of up to nine codons encoding a repeating series of up to nine arginine amino acids to the coding region of a polynucleotide of the present invention. The invention also encompasses chemically derivitizing a polypeptide of the present invention with a repeating series of up to nine arginine amino acids. Such a tag, when attached to a polypeptide, has recently been
35 shown to serve as a universal pass, allowing compounds access to the interior of cells

- 5 without additional derivitization or manipulation (Wender, P., et al., unpublished data).

Protein fusions involving polypeptides of the present invention, including fragments and/or variants thereof, can be used for the following, non-limiting examples, subcellular localization of proteins, determination of protein-protein
10 interactions via immunoprecipitation, purification of proteins via affinity chromatography, functional and/or structural characterization of protein. The present invention also encompasses the application of hapten specific antibodies for any of the uses referenced above for epitope fusion proteins. For example, the polypeptides of the present invention could be chemically derivatized to attach hapten molecules
15 (e.g., DNP, (Zymed, Inc.)). Due to the availability of monoclonal antibodies specific to such haptens, the protein could be readily purified using immunoprecipitation, for example.

Polypeptides of the present invention, including fragments and/or variants thereof, in addition to, antibodies directed against such polypeptides, fragments,
20 and/or variants, may be fused to any of a number of known, and yet to be determined, toxins, such as ricin, saporin (Mashiba H, et al., Ann. N. Y. Acad. Sci. 1999;886:233-5), or HC toxin (Tonukari NJ, et al., Plant Cell. 2000 Feb;12(2):237-248), for example. Such fusions could be used to deliver the toxins to desired tissues for which a ligand or a protein capable of binding to the polypeptides of the invention exists.

25 The invention encompasses the fusion of antibodies directed against polypeptides of the present invention, including variants and fragments thereof, to said toxins for delivering the toxin to specific locations in a cell, to specific tissues, and/or to specific species. Such bifunctional antibodies are known in the art, though a review describing additional advantageous fusions, including citations for methods of
30 production, can be found in P.J. Hudson, Curr. Opp. In. Imm. 11:548-557, (1999); this publication, in addition to the references cited therein, are hereby incorporated by reference in their entirety herein. In this context, the term "toxin" may be expanded to include any heterologous protein, a small molecule, radionucleotides, cytotoxic drugs, liposomes, adhesion molecules, glycoproteins, ligands, cell or tissue-specific ligands,
35 enzymes, of bioactive agents, biological response modifiers, anti-fungal agents, hormones, steroids, vitamins, peptides, peptide analogs, anti-allergenic agents, anti-

5 tubercular agents, anti-viral agents, antibiotics, anti-protozoan agents, chelates, radioactive particles, radioactive ions, X-ray contrast agents, monoclonal antibodies, polyclonal antibodies and genetic material. In view of the present disclosure, one skilled in the art could determine whether any particular "toxin" could be used in the compounds of the present invention. Examples of suitable "toxins" listed above are
10 exemplary only and are not intended to limit the "toxins" that may be used in the present invention.

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

15 **Vectors, Host Cells, and Protein Production**

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In
20 the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the
25 vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to
30 name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or
35 UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one

5 selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells
10 (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

 Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-
15 9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available
20 from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

25 Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the
30 polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

 A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,
35 phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most

- 5 preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical
10 synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also
15 include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some
20 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A
25 main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂. Consequently, in a growth medium depending on methanol as a main
30 carbon source, the promoter region of one of the two alcohol oxidase genes (AOX1) is highly active. In the presence of methanol, alcohol oxidase produced from the AOX1 gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., et al., Mol. Cell. Biol. 5:1111-21 (1985); Koutz, P.J., et al., Yeast 5:167-77 (1989); Tschopp, J.F., et al., Nucl. Acids Res. 15:3859-76 (1987).
35 Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the AOX1

5 regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "Pichia Protocols: Methods in Molecular Biology," D.R. Higgins and
10 J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong AOX1 promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2,
15 pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG, as required.

20 In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

25 In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide
30 sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit
35 (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411,

5 published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using
10 techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid
15 analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ -Abu, ϵ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine,
20 norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoro-amino acids, designer amino acids such as β -methyl amino acids, Ca -methyl amino acids, Na -methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

25 The invention encompasses polypeptides which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not
30 limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH_4 ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-
35 terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and

5 addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein, the addition of epitope tagged peptide fragments (e.g., FLAG, HA, GST, thioredoxin, maltose binding protein, etc.), attachment of affinity tags such
10 as biotin and/or streptavidin, the covalent attachment of chemical moieties to the amino acid backbone, N- or C-terminal processing of the polypeptides ends (e.g., proteolytic processing), deletion of the N-terminal methionine residue, etc.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as
15 increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random
20 positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The invention further encompasses chemical derivitization of the polypeptides of the present invention, preferably where the chemical is a hydrophilic polymer residue. Exemplary hydrophilic polymers, including derivatives, may be those that
25 include polymers in which the repeating units contain one or more hydroxy groups (polyhydroxy polymers), including, for example, poly(vinyl alcohol); polymers in which the repeating units contain one or more amino groups (polyamine polymers), including, for example, peptides, polypeptides, proteins and lipoproteins, such as albumin and natural lipoproteins; polymers in which the repeating units contain one or
30 more carboxy groups (polycarboxy polymers), including, for example, carboxymethylcellulose, alginic acid and salts thereof, such as sodium and calcium alginate, glycosaminoglycans and salts thereof, including salts of hyaluronic acid, phosphorylated and sulfonated derivatives of carbohydrates, genetic material, such as interleukin-2 and interferon, and phosphorothioate oligomers; and polymers in which
35 the repeating units contain one or more saccharide moieties (polysaccharide polymers), including, for example, carbohydrates.

5 The molecular weight of the hydrophilic polymers may vary, and is generally about 50 to about 5,000,000, with polymers having a molecular weight of about 100 to about 50,000 being preferred. The polymers may be branched or unbranched. More preferred polymers have a molecular weight of about 150 to about 10,000, with molecular weights of 200 to about 8,000 being even more preferred.

10 For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release
15 desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

 Additional preferred polymers which may be used to derivatize polypeptides of the invention, include, for example, poly(ethylene glycol) (PEG),
20 poly(vinylpyrrolidone), polyoxomers, polysorbate and poly(vinyl alcohol), with PEG polymers being particularly preferred. Preferred among the PEG polymers are PEG polymers having a molecular weight of from about 100 to about 10,000. More preferably, the PEG polymers have a molecular weight of from about 200 to about 8,000, with PEG 2,000, PEG 5,000 and PEG 8,000, which have molecular weights of
25 2,000, 5,000 and 8,000, respectively, being even more preferred. Other suitable hydrophilic polymers, in addition to those exemplified above, will be readily apparent to one skilled in the art based on the present disclosure. Generally, the polymers used may include polymers that can be attached to the polypeptides of the invention via alkylation or acylation reactions.

30 The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting
35 pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free

5 amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used
10 as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may
15 select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this
20 moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminus) available for
25 derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As with the various polymers exemplified above, it is contemplated that the polymeric residues may contain functional groups in addition, for example, to those
30 typically involved in linking the polymeric residues to the polypeptides of the present invention. Such functionalities include, for example, carboxyl, amine, hydroxy and thiol groups. These functional groups on the polymeric residues can be further reacted, if desired, with materials that are generally reactive with such functional groups and which can assist in targeting specific tissues in the body including, for
35 example, diseased tissue. Exemplary materials which can be reacted with the

5 additional functional groups include, for example, proteins, including antibodies, carbohydrates, peptides, glycopeptides, glycolipids, lectins, and nucleosides.

In addition to residues of hydrophilic polymers, the chemical used to derivatize the polypeptides of the present invention can be a saccharide residue. Exemplary saccharides which can be derived include, for example, monosaccharides
10 or sugar alcohols, such as erythrose, threose, ribose, arabinose, xylose, lyxose, fructose, sorbitol, mannitol and sedoheptulose, with preferred monosaccharides being fructose, mannose, xylose, arabinose, mannitol and sorbitol; and disaccharides, such as lactose, sucrose, maltose and cellobiose. Other saccharides include, for example, inositol and ganglioside head groups. Other suitable saccharides, in addition to those
15 exemplified above, will be readily apparent to one skilled in the art based on the present disclosure. Generally, saccharides which may be used for derivitization include saccharides that can be attached to the polypeptides of the invention via alkylation or acylation reactions.

Moreover, the invention also encompasses derivitization of the polypeptides of
20 the present invention, for example, with lipids (including cationic, anionic, polymerized, charged, synthetic, saturated, unsaturated, and any combination of the above, etc.). stabilizing agents.

The invention encompasses derivitization of the polypeptides of the present invention, for example, with compounds that may serve a stabilizing function (e.g., to
25 increase the polypeptides half-life in solution, to make the polypeptides more water soluble, to increase the polypeptides hydrophilic or hydrophobic character, etc.). Polymers useful as stabilizing materials may be of natural, semi-synthetic (modified natural) or synthetic origin. Exemplary natural polymers include naturally occurring polysaccharides, such as, for example, arabinans, fructans, fucans, galactans, galacturonans, glucans, mannans, xylans (such as, for example, inulin), levan,
30 fucoidan, carrageenan, galatocarloose, pectic acid, pectins, including amylose, pullulan, glycogen, amylopectin, cellulose, dextran, dextrin, dextrose, glucose, polyglucose, polydextrose, pustulan, chitin, agarose, keratin, chondroitin, dermatan, hyaluronic acid, alginic acid, xanthin gum, starch and various other natural
35 homopolymer or heteropolymers, such as those containing one or more of the following aldoses, ketoses, acids or amines: erythrose, threose, ribose, arabinose,

5 xylose, lyxose, allose, altrose, glucose, dextrose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, mannitol, sorbitol, lactose, sucrose, trehalose, maltose, cellobiose, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, glucuronic acid, gluconic acid, glucaric acid, galacturonic acid, mannuronic acid, glucosamine, galactosamine, and neuraminic acid, and naturally occurring derivatives thereof. Accordingly, suitable polymers include, for example, proteins, such as albumin, polyalginates, and polylactide-coglycolide polymers. Exemplary semi-synthetic polymers include carboxymethylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, methylcellulose, and methoxycellulose. Exemplary synthetic polymers include polyphosphazenes, hydroxyapatites, fluoroapatite polymers, polyethylenes (such as, for example, polyethylene glycol (including for example, the class of compounds referred to as Pluronics.RTM., commercially available from BASF, Parsippany, N.J.), polyoxyethylene, and polyethylene terephthalate), polypropylenes (such as, for example, polypropylene glycol), polyurethanes (such as, for example, polyvinyl alcohol (PVA), polyvinyl chloride and polyvinylpyrrolidone), polyamides including nylon, polystyrene, polylactic acids, fluorinated hydrocarbon polymers, fluorinated carbon polymers (such as, for example, polytetrafluoroethylene), acrylate, methacrylate, and polymethylmethacrylate, and derivatives thereof. Methods for the preparation of derivatized polypeptides of the invention which employ polymers as stabilizing compounds will be readily apparent to one skilled in the art, in view of the present disclosure, when coupled with information known in the art, such as that described and referred to in Unger, U.S. Pat. No. 5,205,290, the disclosure of which is hereby incorporated by reference herein in its entirety.

30 Moreover, the invention encompasses additional modifications of the polypeptides of the present invention. Such additional modifications are known in the art, and are specifically provided, in addition to methods of derivitization, etc., in US Patent No. 6,028,066, which is hereby incorporated in its entirety herein.

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their

5 preparation, and compositions (preferably, Therapeutics) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As
10 used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid
15 sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing polypeptides having
20 identical or different amino acid sequences) or a homotrimer (e.g., containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or
25 more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

30 Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of
35 the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the

5 invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence
10 listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may
15 involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the
20 heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents
25 of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional
30 recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers
35 were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins.

5 Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence
10 that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those
15 that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

20 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-
25 Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent
30 Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by
35 reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the

5 polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see,
10 e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein
15 technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic
20 polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides
25 of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

In addition, the polynucleotide insert of the present invention could be
30 operatively linked to "artificial" or chimeric promoters and transcription factors. Specifically, the artificial promoter could comprise, or alternatively consist, of any combination of cis-acting DNA sequence elements that are recognized by trans-acting transcription factors. Preferably, the cis acting DNA sequence elements and trans-acting transcription factors are operable in mammals. Further, the trans-acting
35 transcription factors of such "artificial" promoters could also be "artificial" or

- 5 chimeric in design themselves and could act as activators or repressors to said
"artificial" promoter.

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as
10 reagents. The following description should be considered exemplary and utilizes
known techniques.

The polynucleotides of the present invention are useful for chromosome
identification. There exists an ongoing need to identify new chromosome markers,
since few chromosome marking reagents, based on actual sequence data (repeat
15 polymorphisms), are presently available. Each polynucleotide of the present invention
can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers
(preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be
selected using computer analysis so that primers do not span more than one predicted
20 exon in the genomic DNA. These primers are then used for PCR screening of somatic
cell hybrids containing individual human chromosomes. Only those hybrids
containing the human gene corresponding to the SEQ ID NO:X will yield an
amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the
25 polynucleotides to particular chromosomes. Three or more clones can be assigned per
day using a single thermal cycler. Moreover, sublocalization of the polynucleotides
can be achieved with panels of specific chromosome fragments. Other gene mapping
strategies that can be used include in situ hybridization, prescreening with labeled
flow-sorted chromosomes, and preselection by hybridization to construct
30 chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved
using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread.
This technique uses polynucleotides as short as 500 or 600 bases; however,
polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see
35 Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon
Press, New York (1988).

5 For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross
10 hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. Disease mapping data are known in the art. Assuming 1
15 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected organisms can be examined.
20 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected organisms, but not in normal organisms, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide
25 and the corresponding gene from several normal organisms is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected organisms as compared to unaffected organisms can be assessed using
30 polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the
35 present invention in cells or body fluid from an organism and comparing the measured gene expression level with a standard level of polynucleotide expression

5 level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

By "measuring the expression level of a polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or
10 estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard
15 being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of organisms not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

20 By "biological sample" is intended any biological sample obtained from an organism, body fluids, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as the following non-limiting examples, sputum, amniotic fluid, urine, saliva, breast milk, secretions, interstitial fluid, blood, serum, spinal fluid,
25 etc.) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from organisms are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may Preferably be applied in a diagnostic
30 method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with
35 polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying

5 disease loci for many disorders, including proliferative diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or
10 according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain
15 components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, *Science* 254, 1497 (1991); and M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and
20 tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform
25 multiplex hybridization. Smaller probes can be used than with DNA due to the stronger binding characteristics of PNA:DNA hybrids. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ($T_{sub.m}$) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge
30 groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, *J. Neurochem.* 56: 560 (1991);
35 "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al.,

5 Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix -
10 see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA
15 hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

The present invention encompasses the addition of a nuclear localization
20 signal, operably linked to the 5' end, 3' end, or any location therein, to any of the oligonucleotides, antisense oligonucleotides, triple helix oligonucleotides, ribozymes, PNA oligonucleotides, and/or polynucleotides, of the present invention. See, for example, G. Cutrona, et al., Nat. Biotech., 18:300-303, (2000); which is hereby incorporated herein by reference.

25 Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome,
30 thereby producing a new trait in the host cell. In one example, polynucleotide sequences of the present invention may be used to construct chimeric RNA/DNA oligonucleotides corresponding to said sequences, specifically designed to induce host cell mismatch repair mechanisms in an organism upon systemic injection, for example (Bartlett, R.J., et al., Nat. Biotech, 18:615-622 (2000), which is hereby incorporated
35 by reference herein in its entirety). Such RNA/DNA oligonucleotides could be designed to correct genetic defects in certain host strains, and/or to introduce desired

5 phenotypes in the host (e.g., introduction of a specific polymorphism within an endogenous gene corresponding to a polynucleotide of the present invention that may ameliorate and/or prevent a disease symptom and/or disorder, etc.). Alternatively, the polynucleotide sequence of the present invention may be used to construct duplex oligonucleotides corresponding to said sequence, specifically designed to correct
10 genetic defects in certain host strains, and/or to introduce desired phenotypes into the host (e.g., introduction of a specific polymorphism within an endogenous gene corresponding to a polynucleotide of the present invention that may ameliorate and/or prevent a disease symptom and/or disorder, etc.). Such methods of using duplex oligonucleotides are known in the art and are encompassed by the present invention
15 (see EP1007712, which is hereby incorporated by reference herein in its entirety).

The polynucleotides are also useful for identifying organisms from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more
20 restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

25 The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an organisms genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, organisms can be identified because each organism will have a unique set
30 of DNA sequences. Once an unique ID database is established for an organism, positive identification of that organism, living or dead, can be made from extremely small tissue samples. Similarly, polynucleotides of the present invention can be used as polymorphic markers, in addition to, the identification of transformed or non-transformed cells and/or tissues.

35 There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, when presented with tissue of

5 unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination. Moreover, as mentioned above, such reagents can be used to screen
10 and/or identify transformed and non-transformed cells and/or tissues.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making
15 oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

20 Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene
25 expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and
30 biotin.

In addition to assaying protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of
35 protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable

5 radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear
10 magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a
15 human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The
20 Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a
25 standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for
30 detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat, prevent,
35 and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the

5 polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand
10 (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of
15 an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as
20 molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological
25 activities.

Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to
30 the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery
35 techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

5 Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Beldegrun et al., *J. Natl. Cancer Inst.*, 85:207-216 (1993);
10 Ferrantini et al., *Cancer Research*, 53:107-1112 (1993); Ferrantini et al., *J. Immunology* 153: 4604-4615 (1994); Kaido, T., et al., *Int. J. Cancer* 60: 221-229 (1995); Ogura et al., *Cancer Research* 50: 5102-5106 (1990); Santodonato, et al., *Human Gene Therapy* 7:1-10 (1996); Santodonato, et al., *Gene Therapy* 4:1246-1255 (1997); and Zhang, et al., *Cancer Gene Therapy* 3: 31-38 (1996)), which are herein
15 incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

 As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal,
20 such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

 In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences
25 that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such
30 methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

 The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include
35 pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and

- 5 pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or
10 heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin
15 promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA
20 sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage,
25 pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing
30 muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which
35 are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells

- 5 of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked nucleic acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 10 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

- 15 The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the 20 procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

- 25 The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant 30 invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA , 35 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated

5 by reference); and purified transcription factors (Debs et al., J. Biol. Chem..., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly
10 useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl. Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials
15 using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference.
20 Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC),
25 dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC),
30 dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is
35 hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an

5 inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

10 The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass
15 tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing
20 cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are
25 prepared by a number of methods, well known in the art. Commonly used methods include Ca²⁺-EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*, 394:483 (1975); Wilson et al., *Cell*, 17:77 (1979)); ether injection (Deamer et al., *Biochim. Biophys. Acta*, 443:629 (1976); Ostro et al., *Biochem. Biophys. Res. Commun.*, 76:836 (1977); Fraley et al., *Proc. Natl. Acad. Sci. USA*, 76:3348 (1979));
30 detergent dialysis (Enoch et al., *Proc. Natl. Acad. Sci. USA*, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.*, 255:10431 (1980); Szoka et al., *Proc. Natl. Acad. Sci. USA*, 75:145 (1978); Schaefer-Ridder et al., *Science*, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about
35 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

5 U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in
10 transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, ex vivo or in vivo, using a
15 retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative
20 Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described
25 in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then
30 administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express polypeptides of the invention.

35 In certain other embodiments, cells are engineered, ex vivo or in vivo, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can

5 be manipulated such that it encodes and expresses polypeptides of the invention, and
at the same time is inactivated in terms of its ability to replicate in a normal lytic viral
life cycle. Adenovirus expression is achieved without integration of the viral DNA
into the host cell chromosome, thereby alleviating concerns about insertional
mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for
10 many years with an excellent safety profile (Schwartz et al., *Am. Rev. Respir. Dis.*,
109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been
demonstrated in a number of instances including transfer of alpha-1-antitrypsin and
CFTR to the lungs of cotton rats (Rosenfeld et al., *Science*, 252:431-434 (1991);
Rosenfeld et al., *Cell*, 68:143-155 (1992)). Furthermore, extensive studies to attempt
15 to establish adenovirus as a causative agent in human cancer were uniformly negative
(Green et al. *Proc. Natl. Acad. Sci. USA*, 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for
example, in Kozarsky and Wilson, *Curr. Opin. Genet. Devel.*, 3:499-503 (1993);
Rosenfeld et al., *Cell*, 68:143-155 (1992); Engelhardt et al., *Human Genet. Ther.*,
20 4:759-769 (1993); Yang et al., *Nature Genet.*, 7:362-369 (1994); Wilson et al., *Nature*
, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated
by reference. For example, the adenovirus vector Ad2 is useful and can be grown in
human 293 cells. These cells contain the E1 region of adenovirus and constitutively
express E1a and E1b, which complement the defective adenoviruses by providing the
25 products of the genes deleted from the vector. In addition to Ad2, other varieties of
adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication
deficient. Replication deficient adenoviruses require the aid of a helper virus and/or
packaging cell line to form infectious particles. The resulting virus is capable of
30 infecting cells and can express a polynucleotide of interest which is operably linked to
a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may
be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4,
E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, ex vivo or in vivo,
35 using an adeno-associated virus (AAV). AAVs are naturally occurring defective
viruses that require helper viruses to produce infectious particles (Muzyczka, *Curr.*

5 Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678,
10 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found
15 in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses.
20 Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either ex vivo or in vivo. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

25 Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO
30 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the
35 art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently

5 complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

10 The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the
15 amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating
20 agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous
25 recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding angiogenic proteins.
30 Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor,
35 granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention

5 contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may
10 be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle
15 accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppository solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein
20 has resulted in gene expression of the foreign gene in the rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries.
25 Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the
30 surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic
35 administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

5 Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA , 189:11277-11281 (1992), which is incorporated herein by reference). Oral
10 delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g.,
15 DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The
20 frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and
25 birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly preferred.

Biological Activities

The polynucleotides or polypeptides, or agonists or antagonists of the present
30 invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

35

5 Immune Activity

 The polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop
10 through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer or some autoimmune diseases, disorders, and/or conditions, acquired (e.g., by chemotherapy or toxins), or infectious.
15 Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

 A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders,
20 and/or conditions of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples
25 of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe
30 combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

 Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing
35 hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat or prevent blood

5 coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies, arterial thrombosis, venous thrombosis, etc.), blood platelet diseases, disorders, and/or conditions (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or
10 thrombolytic activity could be used to inhibit or dissolve clotting. Polynucleotides or polypeptides, or agonists or antagonists of the present invention are may also be useful for the detection, prognosis, treatment, and/or prevention of heart attacks (infarction), strokes, scarring, fibrinolysis, uncontrolled bleeding, uncontrolled coagulation, uncontrolled complement fixation, and/or inflammation.

15 A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating, preventing, and/or diagnosing autoimmune diseases, disorders, and/or conditions. Many autoimmune diseases, disorders, and/or conditions result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the
20 destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune diseases, disorders, and/or conditions.

25 Examples of autoimmune diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis,
30 Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

35 Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or

5 diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat, prevent, and/or diagnose organ rejection or graft-
10 versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response,
15 particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists or antagonist may inhibit the proliferation
20 and differentiation of cells involved in an inflammatory response. These molecules can be used to treat, prevent, and/or diagnose inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis,
25 cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

30 A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or
35 polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

5 For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new
10 immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or
15 agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

20 Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to: hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions,
25 paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or
30 protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

35 Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals

5 comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA
10 construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more Preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the
15 polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial
20 therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the
25 oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

30 For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the
35 present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature

5 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and
10 spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for
15 polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The
20 polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells,
25 groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By
30 "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of
35 ordinary skill in the art.

The present invention is further directed to antibody-based therapies which

5 involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may
10 be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the
15 antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

20 In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

25 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or
30 neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or
35 polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$,

5 5X10-8M, 10-8M, 5X10-9M, 10-9M, 5X10-10M, 10-10M, 5X10-11M, 10-11M,
5X10-12M, 10-12M, 5X10-13M, 10-13M, 5X10-14M, 10-14M, 5X10-15M, and 10-
15M.

Moreover, polypeptides of the present invention may be useful in inhibiting
the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in
10 combination with other polypeptides directly or indirectly, as described elsewhere
herein. In a most preferred embodiment, said anti-angiogenesis effect may be
achieved indirectly, for example, through the inhibition of hematopoietic, tumor-
specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl
Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference).
15 Antibodies directed to polypeptides or polynucleotides of the present invention may
also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,
Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by
reference)).

Polypeptides, including protein fusions, of the present invention, or fragments
20 thereof may be useful in inhibiting proliferative cells or tissues through the induction
of apoptosis. Said polypeptides may act either directly, or indirectly to induce
apoptosis of proliferative cells and tissues, for example in the activation of a death-
domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1),
TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related
25 apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et al.,
Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).
Moreover, in another preferred embodiment of the present invention, said
polypeptides may induce apoptosis through other mechanisms, such as in the
activation of other proteins which will activate apoptosis, or through stimulating the
30 expression of said proteins, either alone or in combination with small molecule drugs
or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins
(See for example, Mutat. Res. 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33
(1998), Chem. Biol. Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12
(1998), Int. J. Tissue React. 20(1):3-15 (1998), which are all hereby incorporated by
35 reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present

5 invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby
10 incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous
15 polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

20 Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to
25 enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Cardiovascular Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders,
30 and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor
35 triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome,

5 levocardia, tetralogy of fallot, transposition of great vessels, double outlet right
ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such
as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's
Syndrome, trilog of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart
10 disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac
output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac
arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea,
cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular
hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular
15 septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia,
pericardial effusion, pericarditis (including constrictive and tuberculous),
pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease,
rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular
pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and
20 cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter,
bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial
block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-
type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus
25 syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal
tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm,
atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic
junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia,
Torsades de Pointes, and ventricular tachycardia.

30 Heart valve disease include aortic valve insufficiency, aortic valve stenosis,
hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse,
mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve
insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve
insufficiency, and tricuspid valve stenosis.

35 Myocardial diseases include alcoholic cardiomyopathy, congestive
cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis,

- 5 pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary
10 vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomas, bacillary angiomas, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive
15 diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion,
20 Scimitar syndrome, superior vena cava syndrome, telangiectasia, ataxia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary
25 aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

30 Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural
35 hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia,

- 5 vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis,
10 Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome,
15 thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

20 Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or
25 topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

30 Anti-Angiogenesis Activity

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad et al., Cell 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound
35 healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally

5 delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases,
10 disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses et al., *Biotech.* 9:630-634 (1991); Folkman et al., *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach et al., *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman et al., *Science* 221:719-725
15 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or
20 conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers
25 described herein and otherwise known in the art (for a review of such disorders, see Fishman et al., *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide,
30 polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including
35 prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder,

5 thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast
10 tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a
15 catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or
20 conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia
25 (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound
30 granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising
35 the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

5 Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably
10 initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy,
15 retrolental fibroplasia and macular degeneration.

 Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic
20 retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman et al., *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner et al., *Surv. Ophthalmol.* 22:291-312 (1978).

25 Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited.
30 Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of diseases,
35 disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis

- 5 and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in
10 eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-
15 adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in
20 combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion,
25 but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization.
30 In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce
35 inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for

5 treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other
10 embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of
15 administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the
20 vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a
25 patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or
30 agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

35 Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists

5 and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft
10 rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome,
15 plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochelle minalia quintosa*), ulcers (*Helicobacter pylori*),
20 Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or
25 agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch
30 granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal
35 surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g.,

5 in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the
10 invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for
15 treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by
20 swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

25 Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that
30 the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of
35 Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d

5 group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

10 Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate
15 including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides
20 include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI)
25 oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the
30 context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of
35 matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate;

- 5 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST";
- 10 Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem... 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole;
- 15 and metalloproteinase inhibitors such as BB94.

Diseases at the Cellular Level

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or

20 polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma,

25 osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis

30 and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

35 Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or

5 agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g.,

- 5 hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

- 10 In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.
- 15 Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat
- 20 exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss
- 25 The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts,
- 30 artificial skin, allografts, autodermic graft, autoepidermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin
- 35 graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the

5 appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or
10 antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells,
15 keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a
20 cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial
25 thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the
30 underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly.
35 Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large

5 intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production
10 of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associate with the under expression of the polynucleotides of the invention.

15 Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to
20 prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also,
25 the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

30 The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins
35 known in the art).

In addition, the polynucleotides or polypeptides, and/or agonists or antagonists

5 of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or
10 polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

Neurological Diseases

Nervous system diseases, disorders, and/or conditions, which can be treated,
15 prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or
20 diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord
25 infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous
30 system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative
35 process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6)

5 lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar
10 degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating
15 disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects
20 of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this
25 embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further
30 aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in
35 promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may

5 be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or in vivo; (3) increased production of a neuron-associated molecule in culture or in vivo, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction in vivo. Such effects may be measured by any method known in
10 the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol.
15 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g.,
20 weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or
25 malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary
30 Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

Infectious Disease

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For
35 example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented,

5 and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

10 Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus,
15 Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus,
20 Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis),
25 chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts),
30 and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific
35 embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available

- 5 hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide
 10 and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia
 15 (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales,
 20 Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Meisseria meningitidis, Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g.,
 25 Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as
 30 Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g.,
 35 cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used

5 to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated,
10 prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g.,
15 Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or
20 polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Preferably, treatment or prevention using a polypeptide or polynucleotide
25 and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a
30 vaccine to raise an immune response against infectious disease.

Regeneration

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the
35 regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects,

5 trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal
10 or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example,
15 increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue
20 regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated, prevented,
25 and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized
30 neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

35 **Chemotaxis**

A polynucleotide or polypeptide and/or agonist or antagonist of the present

5 invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

10 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system disorder by increasing the number of cells targeted to a particular location in the body.

15 For example, chemotaxic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

It is also contemplated that a polynucleotide or polypeptide and/or agonist or

20 antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

25 **Binding Activity**

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples

30 of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology

35 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

- 5 of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*.
10 Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the
15 polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product
20 mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a
25 sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand
30 panning and FACS sorting (Coligan, et al., *Current Protocols in Immun.*, 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided
35 into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the

5 polypeptide of the present invention, after they have been labeled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-
10 transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and
15 exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

20 Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and
25 5,837,458, and Patten, P. A., et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding
30 polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone
35 PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments,

5 etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).
10
15

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.
20

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H]-thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.
25
30

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured.
35

5 Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase,
10 ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover
15 agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention
20 includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention
25 experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to
30 polynucleotides encoding polypeptides which comprise, or alternatively consist of, any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional
35 embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one

5 of the polypeptide sequences of the invention.

Targeted Delivery

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, Pseudomonas exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into

5 a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

10

Drug Screening

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method
15 would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any
20 of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed
25 cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present
30 invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound
35 form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

5 Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are
10 synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to
15 capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of
20 any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

The human phosphatase polypeptides and/or peptides of the present invention, or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic drugs or compounds in a variety of drug screening techniques. The
25 fragment employed in such a screening assay may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The reduction or abolition of activity of the formation of binding complexes between the ion channel protein and the agent being tested can be measured. Thus, the present invention provides a method for screening or assessing a plurality of compounds for their
30 specific binding affinity with a phosphatase polypeptide, or a bindable peptide fragment, of this invention, comprising providing a plurality of compounds, combining the phosphatase polypeptide, or a bindable peptide fragment, with each of a plurality of compounds for a time sufficient to allow binding under suitable

5 conditions and detecting binding of the phosphatase polypeptide or peptide to each of the plurality of test compounds, thereby identifying the compounds that specifically bind to the phosphatase polypeptide or peptide.

Methods of identifying compounds that modulate the activity of the novel human phosphatase polypeptides and/or peptides are provided by the present invention and comprise combining a potential or candidate compound or drug modulator of phosphatase activity with a phosphatase polypeptide or peptide, for example, the phosphatase amino acid sequence as set forth in SEQ ID NO:42, 109, 150, or 152, and measuring an effect of the candidate compound or drug modulator on the biological activity of the phosphatase polypeptide or peptide. Such measurable effects include, for example, physical binding interaction; the ability to phosphorylate a suitable calpain substrate; effects on native and cloned phosphatase-expressing cell line; and effects of modulators or other phosphatase-mediated physiological measures.

Another method of identifying compounds that modulate the biological activity of the novel phosphatase polypeptides of the present invention comprises combining a potential or candidate compound or drug modulator of a phosphatase activity with a host cell that expresses the phosphatase polypeptide and measuring an effect of the candidate compound or drug modulator on the biological activity of the phosphatase polypeptide. The host cell can also be capable of being induced to express the phosphatase polypeptide, e.g., via inducible expression. Physiological effects of a given modulator candidate on the phosphatase polypeptide can also be measured. Thus, cellular assays for particular phosphatase modulators may be either direct measurement or quantification of the physical biological activity of the phosphatase polypeptide, or they may be measurement or quantification of a physiological effect. Such methods preferably employ a phosphatase polypeptide as described herein, or an overexpressed recombinant phosphatase polypeptide in suitable host cells containing an expression vector as described herein, wherein the phosphatase polypeptide is expressed, overexpressed, or undergoes upregulated expression.

Another aspect of the present invention embraces a method of screening for a compound that is capable of modulating the biological activity of a phosphatase

5 polypeptide, comprising providing a host cell containing an expression vector harboring a nucleic acid sequence encoding a phosphatase polypeptide, or a functional peptide or portion thereof (e.g., SEQ ID NO:42, 109, 150, or 152); determining the biological activity of the expressed phosphatase polypeptide in the absence of a modulator compound; contacting the cell with the modulator compound and
10 determining the biological activity of the expressed phosphatase polypeptide in the presence of the modulator compound. In such a method, a difference between the activity of the phosphatase polypeptide in the presence of the modulator compound and in the absence of the modulator compound indicates a modulating effect of the compound.

15 Essentially any chemical compound can be employed as a potential modulator or ligand in the assays according to the present invention. Compounds tested as phosphatase modulators can be any small chemical compound, or biological entity (e.g., protein, sugar, nucleic acid, lipid). Test compounds will typically be small chemical molecules and peptides. Generally, the compounds used as potential
20 modulators can be dissolved in aqueous or organic (e.g., DMSO-based) solutions. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source. Assays are typically run in parallel, for example, in microtiter formats on microtiter plates in robotic assays. There are many suppliers of chemical compounds, including Sigma (St. Louis, MO),
25 Aldrich (St. Louis, MO), Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland), for example. Also, compounds may be synthesized by methods known in the art.

High throughput screening methodologies are particularly envisioned for the detection of modulators of the novel phosphatase polynucleotides and polypeptides
30 described herein. Such high throughput screening methods typically involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (e.g., ligand or modulator compounds). Such combinatorial chemical libraries or ligand libraries are then screened in one or more assays to identify those library members (e.g., particular chemical species or subclasses) that
35 display a desired characteristic activity. The compounds so identified can serve as

- 5 conventional lead compounds, or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated either by chemical synthesis or biological synthesis, by combining a number of chemical building blocks (i.e., reagents such as amino acids).
10 As an example, a linear combinatorial library, e.g., a polypeptide or peptide library, is formed by combining a set of chemical building blocks in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide or peptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

- 15 The preparation and screening of combinatorial chemical libraries is well known to those having skill in the pertinent art. Combinatorial libraries include, without limitation, peptide libraries (e.g. U.S. Patent No. 5,010,175; Furka, 1991, *Int. J. Pept. Prot. Res.*, 37:487-493; and Houghton et al., 1991, *Nature*, 354:84-88). Other chemistries for generating chemical diversity libraries can also be used. Nonlimiting
20 examples of chemical diversity library chemistries include, peptides (PCT Publication No. WO 91/019735), encoded peptides (PCT Publication No. WO 93/20242), random bio-oligomers (PCT Publication No. WO 92/00091), benzodiazepines (U.S. Patent No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., 1993, *Proc. Natl. Acad. Sci. USA*, 90:6909-6913), vinylogous
25 polypeptides (Hagihara et al., 1992, *J. Amer. Chem. Soc.*, 114:6568), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann et al., 1992, *J. Amer. Chem. Soc.*, 114:9217-9218), analogous organic synthesis of small compound libraries (Chen et al., 1994, *J. Amer. Chem. Soc.*, 116:2661), oligocarbamates (Cho et al., 1993, *Science*, 261:1303), and/or peptidyl phosphonates (Campbell et al., 1994, *J. Org.*
30 *Chem.*, 59:658), nucleic acid libraries (see Ausubel, Berger and Sambrook, all supra), peptide nucleic acid libraries (U.S. Patent No. 5,539,083), antibody libraries (e.g., Vaughn et al., 1996, *Nature Biotechnology*, 14(3):309-314) and PCT/US96/10287), carbohydrate libraries (e.g., Liang et al., 1996, *Science*, 274:1520-1522) and U.S. Patent No. 5,593,853), small organic molecule libraries (e.g., benzodiazepines, Baum
35 C&EN, Jan. 18, 1993, page 33; and U.S. Patent No. 5,288,514; isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No.

- 5 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; and the like).

Devices for the preparation of combinatorial libraries are commercially available (e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY; Symphony, Rainin, Woburn, MA; 433A Applied Biosystems, Foster City, CA; 9050
10 Plus, Millipore, Bedford, MA). In addition, a large number of combinatorial libraries are commercially available (e.g., ComGenex, Princeton, NJ; Asinex, Moscow, Russia; Tripos, Inc., St. Louis, MO; ChemStar, Ltd., Moscow, Russia; 3D Pharmaceuticals, Exton, PA; Martek Biosciences, Columbia, MD, and the like).

In one embodiment, the invention provides solid phase based *in vitro* assays in
15 a high throughput format, where the cell or tissue expressing an ion channel is attached to a solid phase substrate. In such high throughput assays, it is possible to screen up to several thousand different modulators or ligands in a single day. In particular, each well of a microtiter plate can be used to perform a separate assay against a selected potential modulator, or, if concentration or incubation time effects
20 are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 96 modulators. If 1536 well plates are used, then a single plate can easily assay from about 100 to about 1500 different compounds. It is possible to assay several different plates per day; thus, for example, assay screens for up to about 6,000-20,000 different compounds are possible using the
25 described integrated systems.

In another of its aspects, the present invention encompasses screening and small molecule (e.g., drug) detection assays which involve the detection or identification of small molecules that can bind to a given protein, i.e., a phosphatase polypeptide or peptide. Particularly preferred are assays suitable for high throughput
30 screening methodologies.

In such binding-based detection, identification, or screening assays, a functional assay is not typically required. All that is needed is a target protein, preferably substantially purified, and a library or panel of compounds (e.g., ligands, drugs, small molecules) or biological entities to be screened or assayed for binding to
35 the protein target. Preferably, most small molecules that bind to the target protein will

5 modulate activity in some manner, due to preferential, higher affinity binding to functional areas or sites on the protein.

An example of such an assay is the fluorescence based thermal shift assay (3-Dimensional Pharmaceuticals, Inc., 3DP, Exton, PA) as described in U.S. Patent Nos. 6,020,141 and 6,036,920 to Pantoliano et al.; see also, J. Zimmerman, 2000, *Gen. Eng. News*, 20(8)). The assay allows the detection of small molecules (e.g., drugs, ligands) that bind to expressed, and preferably purified, ion channel polypeptide based on affinity of binding determinations by analyzing thermal unfolding curves of protein-drug or ligand complexes. The drugs or binding molecules determined by this technique can be further assayed, if desired, by methods, such as those described
15 herein, to determine if the molecules affect or modulate function or activity of the target protein.

To purify a phosphatase polypeptide or peptide to measure a biological binding or ligand binding activity, the source may be a whole cell lysate that can be prepared by successive freeze-thaw cycles (e.g., one to three) in the presence of
20 standard protease inhibitors. The phosphatase polypeptide may be partially or completely purified by standard protein purification methods, e.g., affinity chromatography using specific antibody described *infra*, or by ligands specific for an epitope tag engineered into the recombinant phosphatase polypeptide molecule, also as described herein. Binding activity can then be measured as described.

25 Compounds which are identified according to the methods provided herein, and which modulate or regulate the biological activity or physiology of the phosphatase polypeptides according to the present invention are a preferred embodiment of this invention. It is contemplated that such modulatory compounds may be employed in treatment and therapeutic methods for treating a condition that is
30 mediated by the novel phosphatase polypeptides by administering to an individual in need of such treatment a therapeutically effective amount of the compound identified by the methods described herein.

In addition, the present invention provides methods for treating an individual in need of such treatment for a disease, disorder, or condition that is mediated by the
35 phosphatase polypeptides of the invention, comprising administering to the individual

- 5 a therapeutically effective amount of the phosphatase-modulating compound identified by a method provided herein.

Antisense And Ribozyme (Antagonists)

In specific embodiments, antagonists according to the present invention are
10 nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense
15 Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is
20 discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was
25 previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoR1
30 site on the 5 end and a HindIII site on the 3 end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature
35 polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is

5 designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced
10 intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.
15 Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or
20 constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980)), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence
30 "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the
35 hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be).

- 5 One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non-translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA.

15 Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six

20 nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-

25 stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., *BioTechniques*, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, *Pharm. Res.*, 5:539-549 (1988)). To this end, the

35 oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent,

5 etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

20 The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

35 Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are

5 commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

10 While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published
15 October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The
20 sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3' . The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme
25 is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed
30 of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under
35 the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to

5 destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells
10 and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular
15 cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

20 The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of
25 a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

30

Biotic Associations

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase the organisms ability, either directly or indirectly, to initiate and/or maintain biotic associations with other organisms. Such associations may be
35 symbiotic, nonsymbiotic, endosymbiotic, macrosymbiotic, and/or microsymbiotic in nature. In general, a polynucleotide or polypeptide and/or agonist or antagonist of the

5 present invention may increase the organisms ability to form biotic associations with any member of the fungal, bacterial, lichen, mycorrhizal, cyanobacterial, dinoflagellate, and/or algal, kingdom, phylums, families, classes, genuses, and/or species.

The mechanism by which a polynucleotide or polypeptide and/or agonist or
10 antagonist of the present invention may increase the host organisms ability, either directly or indirectly, to initiate and/or maintain biotic associations is variable, though may include, modulating osmolarity to desirable levels for the symbiont, modulating pH to desirable levels for the symbiont, modulating secretions of organic acids, modulating the secretion of specific proteins, phenolic compounds, nutrients, or the
15 increased expression of a protein required for host-biotic organisms interactions (e.g., a receptor, ligand, etc.). Additional mechanisms are known in the art and are encompassed by the invention (see, for example, "Microbial Signalling and Communication", eds., R. England, G. Hobbs, N. Bainton, and D. McL. Roberts, Cambridge University Press, Cambridge, (1999); which is hereby incorporated herein
20 by reference).

In an alternative embodiment, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may decrease the host organisms ability to form biotic associations with another organism, either directly or indirectly. The mechanism by which a polynucleotide or polypeptide and/or agonist or antagonist of
25 the present invention may decrease the host organisms ability, either directly or indirectly, to initiate and/or maintain biotic associations with another organism is variable, though may include, modulating osmolarity to undesirable levels, modulating pH to undesirable levels, modulating secretions of organic acids, modulating the secretion of specific proteins, phenolic compounds, nutrients, or the
30 decreased expression of a protein required for host-biotic organisms interactions (e.g., a receptor, ligand, etc.). Additional mechanisms are known in the art and are encompassed by the invention (see, for example, "Microbial Signalling and Communication", eds., R. England, G. Hobbs, N. Bainton, and D. McL. Roberts, Cambridge University Press, Cambridge, (1999); which is hereby incorporated herein
35 by reference).

5 The hosts ability to maintain biotic associations with a particular pathogen has significant implications for the overall health and fitness of the host. For example, human hosts have symbiosis with enteric bacteria in their gastrointestinal tracts, particularly in the small and large intestine. In fact, bacteria counts in feces of the distal colon often approach 10^{12} per milliliter of feces. Examples of bowel flora in the
10 gastrointestinal tract are members of the Enterobacteriaceae, Bacteriodes, in addition to a-hemolytic streptococci, E. coli, Bifobacteria, Anaerobic cocci, Eubacteria, Costridia, lactobacilli, and yeasts. Such bacteria, among other things, assist the host in the assimilation of nutrients by breaking down food stuffs not typically broken down by the hosts digestive system, particularly in the hosts bowel. Therefore, increasing
15 the hosts ability to maintain such a biotic association would help assure proper nutrition for the host.

 Aberrations in the enteric bacterial population of mammals, particularly humans, has been associated with the following disorders: diarrhea, ileus, chronic inflammatory disease, bowel obstruction, duodenal diverticula, biliary calculous
20 disease, and malnutrition. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention are useful for treating, detecting, diagnosing, prognosing, and/or ameliorating, either directly or indirectly, and of the above mentioned diseases and/or disorders associated with aberrant enteric flora population.

 The composition of the intestinal flora, for example, is based upon a variety of
25 factors, which include, but are not limited to, the age, race, diet, malnutrition, gastric acidity, bile salt excretion, gut motility, and immune mechanisms. As a result, the polynucleotides and polypeptides, including agonists, antagonists, and fragments thereof, may modulate the ability of a host to form biotic associations by affecting, directly or indirectly, at least one or more of these factors.

30 Although the predominate intestinal flora comprises anaerobic organisms, an underlying percentage represents aerobes (e.g., E. coli). This is significant as such aerobes rapidly become the predominate organisms in intraabdominal infections – effectively becoming opportunistic early in infection pathogenesis. As a result, there is an intrinsic need to control aerobe populations, particularly for immune
35 compromised individuals.

5 In a preferred embodiment, a polynucleotides and polypeptides, including agonists, antagonists, and fragments thereof, are useful for inhibiting biotic associations with specific enteric symbiont organisms in an effort to control the population of such organisms.

Biotic associations occur not only in the gastrointestinal tract, but also on an in
10 the integument. As opposed to the gastrointestinal flora, the cutaneous flora is comprised almost equally with aerobic and anaerobic organisms. Examples of cutaneous flora are members of the gram-positive cocci (e.g., *S. aureus*, coagulase-negative staphylococci, micrococcus, *M.sedentarius*), gram-positive bacilli (e.g., *Corynebacterium* species, *C. minutissimum*, *Brevibacterium* species,
15 *Propoionibacterium* species, *P.acnes*), gram-negative bacilli (e.g., *Acinebacter* species), and fungi (*Pityrosporum orbiculare*). The relatively low number of flora associated with the integument is based upon the inability of many organisms to adhere to the skin. The organisms referenced above have acquired this unique ability. Therefore, the polynucleotides and polypeptides of the present invention may have
20 uses which include modulating the population of the cutaneous flora, either directly or indirectly.

Aberrations in the cutaneous flora are associated with a number of significant diseases and/or disorders, which include, but are not limited to the following: impetigo, ecthyma, blistering distal dactulitis, pustules, folliculitis, cutaneous
25 abscesses, pitted keratolysis, trichomycosis axcillaris, dermatophytosis complex, axillary odor, erythrasma, cheesy foot odor, acne, tinea versicolor, seborrheic dermatitis, and *Pityrosporum folliculitis*, to name a few. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention are useful for treating, detecting, diagnosing, prognosing, and/or ameliorating, either directly or
30 indirectly, and of the above mentioned diseases and/or disorders associated with aberrant cutaneous flora population.

Additional biotic associations, including diseases and disorders associated with the aberrant growth of such associations, are known in the art and are encompassed by the invention. See, for example, "Infectious Disease", Second
35 Edition, Eds., S.L., Gorbach, J.G., Bartlett, and N.R., Blacklow, W.B. Saunders Company, Philadelphia, (1998); which is hereby incorporated herein by reference).

5

Pheromones

In another embodiment, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase the organisms ability to synthesize and/or release a pheromone. Such a pheromone may, for example, alter the organisms
10 behavior and/or metabolism.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may modulate the biosynthesis and/or release of pheromones, the organisms ability to respond to pheromones (e.g., behaviorally, and/or metabolically), and/or the organisms ability to detect pheromones. Preferably, any of the pheromones, and/or
15 volatiles released from the organism, or induced, by a polynucleotide or polypeptide and/or agonist or antagonist of the invention have behavioral effects the organism.

Other Activities

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as
20 thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells
25 of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs
30 in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

35 The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

5 The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

10 The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

 The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

 The polypeptide or polynucleotides and/or agonist or antagonists of the
15 present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

 The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue,
20 pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

 Polypeptide or polynucleotides and/or agonist or antagonists of the present
25 invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

30 Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

 Polypeptide or polynucleotides and/or agonist or antagonists of the present
35 invention may also be used to increase the efficacy of a pharmaceutical composition, either directly or indirectly. Such a use may be administered in simultaneous

5 conjunction with said pharmaceutical, or separately through either the same or different route of administration (e.g., intravenous for the polynucleotide or polypeptide of the present invention, and orally for the pharmaceutical, among others described herein.).

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to prepare individuals for extraterrestrial travel, low gravity environments, prolonged exposure to extraterrestrial radiation levels, low oxygen levels, reduction of metabolic activity, exposure to extraterrestrial pathogens, etc. Such a use may be administered either prior to an extraterrestrial event, during an extraterrestrial event, or both. Moreover, such a use may result in a number of beneficial changes in the recipient, such as, for example, any one of the following, non-limiting, effects: an increased level of hematopoietic cells, particularly red blood cells which would aid the recipient in coping with low oxygen levels; an increased level of B-cells, T-cells, antigen presenting cells, and/or macrophages, which would aid the recipient in coping with exposure to extraterrestrial pathogens, for example; a temporary (i.e., reversible) inhibition of hematopoietic cell production which would aid the recipient in coping with exposure to extraterrestrial radiation levels; increase and/or stability of bone mass which would aid the recipient in coping with low gravity environments; and/or decreased metabolism which would effectively facilitate the recipients ability to prolong their extraterrestrial travel by any one of the following, non-limiting means: (i) aid the recipient by decreasing their basal daily energy requirements; (ii) effectively lower the level of oxidative and/or metabolic stress in recipient (i.e., to enable recipient to cope with increased extraterrestrial radiation levels by decreasing the level of internal oxidative/metabolic damage acquired during normal basal energy requirements; and/or (iii) enabling recipient to subsist at a lower metabolic temperature (i.e., cryogenic, and/or sub-cryogenic environment).

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table I.

5 Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the "5' NT of Start Codon of ORF" and ending with the nucleotide at about the position of the "3' NT of ORF" as defined for SEQ ID NO:X in Table I.

10 Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

 Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500
15 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

 A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the "5' NT of ORF" and ending with the nucleotide at about the position of the "3' NT of ORF" as defined
20 for SEQ ID NO:X in Table I.

 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

 Also preferred is an isolated nucleic acid molecule which hybridizes under
25 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

 Also preferred is a composition of matter comprising a DNA molecule which
30 comprises a cDNA clone identified by a cDNA Clone Identifier in Table I, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table I for said cDNA Clone Identifier.

 Also preferred is an isolated nucleic acid molecule comprising a nucleotide
35 sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a cDNA clone identified by a cDNA Clone

- 5 Identifier in Table I, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table I.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said cDNA clone.

- 10 Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said cDNA clone.

- A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said cDNA clone.

- 20 A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table I; and a nucleotide sequence encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

- Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected

5 from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least
10 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table I; and a nucleotide sequence encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

15 The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

20 Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a protein identified in Table I, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50
25 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table I; and a nucleotide sequence encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

30 The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

35 Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise

- 5 a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table I; and a nucleotide sequence encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and
10 contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the
15 amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table I.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions "Total AA of the Open Reading Frame (ORF)" as set forth for SEQ ID NO:Y in Table I.

- 20 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino
25 acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

- Further preferred is an isolated polypeptide comprising an amino acid
30 sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a protein encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

Also preferred is a polypeptide wherein said sequence of contiguous amino
35 acids is included in the amino acid sequence of the protein encoded by a cDNA clone

5 identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the protein encoded by a cDNA clone identified by a cDNA
10 Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the protein encoded by a cDNA clone identified by a
15 cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the protein encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit
20 with the ATCC Deposit Number shown for said cDNA clone in Table I.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as
25 defined in Table I; and a complete amino acid sequence of a protein encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a
30 sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table I; and a complete amino acid sequence of a protein encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I;
35 which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and

- 5 determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of
10 polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table I; and a complete amino acid sequence of a protein encoded by a cDNA clone
15 identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

- 20 Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is
25 any integer as defined in Table I; and a complete amino acid sequence of a protein encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

Also preferred is the above method for identifying the species, tissue or cell
30 type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

- 35 Also preferred is a method for diagnosing a pathological condition associated with an organism with abnormal structure or expression of a gene encoding a protein

5 identified in Table I, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid
10 sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table I; and a complete amino acid sequence of a protein encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

15 In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence
20 selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table I; and a complete amino acid sequence of a protein encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

25 Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino
30 acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table I; and a complete amino acid sequence of a protein encoded by a cDNA clone identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I.

Further preferred is a method of making a recombinant vector comprising
35 inserting any of the above isolated nucleic acid molecule(s) into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a

5 method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making
10 an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is an integer set forth in Table I and said position of the "Total AA of ORF" of SEQ ID NO:Y is defined in Table I; and an amino acid sequence of a protein encoded by a cDNA clone
15 identified by a cDNA Clone Identifier in Table I and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table I. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a protein activity, which method comprises administering to such
20 an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of
25 illustration and are not intended as limiting.

References:

Altschul, S. F., T. L. Madden, et al. (1997). "Gapped BLAST and PSI-BLAST: a new
30 generation of protein database search programs." Nucleic Acids Res 25(17): 3389-402.

Bateman, A., E. Birney, et al. (2000). Nucleic Acids Res 28(1): 263-6.

35 Burge, C. and S. Karlin (1997)., J Mol Biol 268(1): 78-94.

- 5 Fauman, E. B. and M. A. Saper (1996)., Trends Biochem Sci 21(11): 413-7.
- Sonnhammer, E. L., S. R. Eddy, et al. (1997), Proteins 28(3): 405-20.
- Bernstein, FC, Koetzle, TF, Williams, GJB, Meyer, EF Jr., Brice, MD, Rodgers, JR,
10 Kennard, O, Simanouchi, T, Tasumi, M. 1977. The Protein Data Bank: A computer-based archival file for macromolecular structures. J. Mol. Biol. 112:535-542.
- Bohm H-J, LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J. Comp. Aid. Molec. Design 6:61-78 (1992)
- 15 Cabral, J. H. M., Lee, A., Cardozo T; Totrov M; Abagyan R Homology modeling by the ICM method. Proteins 23, 403-14(1995).
- Cardozo, T., Totrov, M., Abagyan, R. Homology modeling by the ICM method.
20 Proteins 23:403-14, 1995.
- Fauman, E. and Saper, M. Structure and function of the protein tyrosine phosphatases. Trends Biochem. Sci. 21:413-7 (1996).
- 25 Goodford, P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28:849-857 (1985)
- Goodsell, D.S. and Olsen, A.J. Automated docking of substrates to proteins by
30 simulated annealing. Proteins 8:195-202 (1990)
- Greer J Comparative modeling of homologous proteins. Meth. Enzymol. 202:239-52 (1991).
- 35 Hendlich M; Lackner P; Weitckus S; Floeckner H; Froschauer R; Gottsbacher K; Casari G; Sippl M J Identification of native protein folds amongst a large number of

- 5 incorrect models. The calculation of low energy conformations from potentials of mean force. J Mol. Biol. 216, 167-80 (1990).

Jia, Z., Badford, D., Flint, A. J., and Tonks, N. K.. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science
10 268:1754-8, 1995.

Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 161:269-288 (1982)

- 15 Lesk, A. M., Boswell, D. R., Homology Modeling : Inferences from Tables of Aligned Sequences. Curr. Op. Struc. Biol. 2: 242-247 (1992)

Levitt, M. Accurate modeling of protein conformation by automatic segment matching. J Mol Biol 226:507-33 (1992)

20

Martin, Y.C. 3D database searching in drug design. J. Med. Chem. 35:2145-2154 (1992)

- Novotny J; Rashin A A; Bruccoleri R E. Criteria that discriminate between native
25 proteins and incorrectly folded models. Proteins, 4:19-30 (1988).

Pearson W R Rapid and sensitive sequence comparison with FASTP and FASTA. Methods In Enzymology 183:63-98 (1990).

- Pearson, W. R. Rapid and sensitive sequence comparison with FASTP and FASTA.
30 Meth. Enzymol. 183:63-98, 1990.

Sali A; Potterton L; Yuan F; van Vlijmen H; Karplus M Evaluation of comparative protein modeling by MODELLER. Proteins 23:318-26 (1995).

- 5 Stewart, A. E., Dowd, S., Keyse, S. M. and McDonald, N. Q. Crystal structure of the
MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation.
Nat. Struct. Biol. 6:174-80 (1999).
- Yuvaniyama, J.; Denu, J. M.; Dixon, J. E. and Saper, M. A. Crystal structure of the
10 dual specificity protein phosphatase vhr. Science 272:1328-31 (1996).

5

Examples

Description of the Preferred Embodiments

10 **Example 1 – Method Of Identifying The Novel BMY_HPP Human Phosphatases Of The Present Invention.**

Polynucleotide sequences encoding the novel BMY_HPP phosphoprotein phosphatases of the present invention were identified by a combination of the following methods:

15 Homology-based searches using the TBLASTN program [Altschul, 1997] to compare known phosphoprotein phosphatases with human genomic (gDNA) and EST sequences. EST or gDNA sequences having significant homology to one or more of the known phosphatases listed in Table III (expect score less than or equal to 1×10^{-3}) were retained for further analysis.

20 Hidden Markov Model (HMM) searches using PFAM motifs (listed in Table IV) [Bateman, 2000 #9; Sonnhammer, 1997] were used to search human genomic sequence using the Genewise program. EST or gDNA sequences having a significant score (greater than or equal to 10) with any of the following motifs were retained for further analysis.

25 HMM searches using PFAM motifs (listed in Table IV) were used to search predicted protein sequences identified by GENSCAN analysis of human genomic sequence [Burge, 1997 #10]. gDNA sequences having a significant score (greater than or equal to 10) with any of the following motifs were retained for further analysis.

30 **Table IV: PFAM motifs used to identify phosphoprotein phosphatases**

Motif Name	PFAM Accession No.	Description
DSPc	PF00782	Dual specificity phosphatase, catalytic domain
ST_phosphatase	PF00149	Ser/Thr protein phosphatase
Y_phosphatase	PF00102	Protein-tyrosine phosphatase

Once a bacterial artificial chromosomes (BACs) encoding a novel phosphoprotein phosphatase was identified by any one of the methods above, additional potential exons were identified using GENSCAN analysis of all nearby
 35 BACs (identified by the Golden Path tiling map, UCSC). Intron/exon boundaries,

5 transcript cDNA sequence and protein sequence were determined using GENSCAN. The predicted protein sequence were used to identify the most closely related known phosphatase using the BLASTP program as described in herein.

In the case of BMY_HPP5, BMY_HPP5 was identified as an Incyte EST (ID 4155374) with homology to known protein phosphatases and significant expression in
10 the central nervous system. The Incyte clone sequence was used to design oligonucleotides for isolation of additional cDNAs. Such cDNAs have been recovered and sequenced and compared to a full-length Incyte template (assembly of EST sequences) (ID1026659.7). The BMY_HPP5 cDNA has significant identity to Incyte 1026659.7 but diverges at the five-prime and three-prime ends, suggesting that it may
15 be an alternatively spliced product of the same gene.

Example 2 - Cloning of the Novel Human BMY_HPP Phosphatases Of The Present Invention.

A variety of methods known in the art may be used for cloning the novel
20 BMY_HPP phosphatases of the present invention. Breifly, using the predicted or observed cDNA sequences for the BMY-HPP genes of the present invention, antisense oligonucleotides with biotin on the 5' end could be designed (the sequences of these oligos are provided in Table VI). These oligos will be used to isolate cDNA clones according to the following procedure:

25 One microliter (one hundred and fifty nanograms) of a biotinylated oligo is added to six microliters (six micrograms) of a mixture of single-stranded covalently closed circular cDNA libraries (such libraries are commercially available from Life Technologies, Rockville, Maryland, or may be created using routine methods known in the art) and seven microliters of 100% formamide in a 0.5 ml PCR tube. The cDNA
30 libraries used for specific BMY_HPP genes will be determined by the results of the expression patterns as described herein.

The mixture is heated in a thermal cycler to 95° C for 2 mins.

Fourteen microliters of 2X hybridization buffer (50% formamide, 1.5 M NaCl, 0.04 M NaPO₄, pH 7.2, 5 mM EDTA, 0.2% SDS) wis added to the heated
35 probe/cDNA library mixture and incubated at 42° C for 26 hours.

5 Hybrids between the biotinylated oligo and the circular cDNA are isolated by diluting the hybridization mixture to 220 microliters in a solution containing 1 M NaCl, 10 mM Tris-HCl pH 7.5, 1mM EDTA, pH 8.0 and adding 125 microliters of streptavidin magnetic beads. This solution is incubated at 42° C for 60 mins, mixing every 5 mins to resuspend the beads.

10 The beads are separated from the solution with a magnet and the beads washed three times in 200 microliters of 0.1 X SSPE, 0.1% SDS at 45° C.

 The single stranded cDNAs are released from the biotinylated oligo/streptavidin magnetic bead complex by adding 50 microliters of 0.1 N NaOH and incubating at room temperature for 10 mins.

15 The cDNAs are precipitated by adding six microliters of 3 M Sodium Acetate , 5 micrograms of glycogen and 120 microliters of 100% ethanol followed by centrifugation.

 The cDNAs are resuspended in 12 microliters of TE (10 mM Tris-HCl, pH 8.0), 1mM EDTA, pH 8.0).

20 The single stranded cDNAs are converted into double stranded molecules in a thermal cycler by mixing 5 microliters of the captured DNA with 1.5 microliters of a standard SP6 primer (homologous to a sequence on the cDNA cloning vector) at 10 micromolar concentration and 1.5 microliters of 10 X PCR buffer. The mixture is heated to 95° C for 20 seconds, then ramped down to 59 ° C. At this time 15
25 microliters of a repair mix preheated to 70° C is added (repair mix contains 4 microliters of 5 mM dNTPs (1.25 mM each), 1.5 microliters of 10X PCR buffer, 9.25 microliters of water, and 0.25 microliters of Taq polymerase). The solution is ramped back to 73° C and incubated for 23 mins.

 The repaired DNA was precipitated as described above and resuspended in 10
30 microliters of TE.

 Two microliters of double-stranded cDNA are used to transform E. coli DH12S cells by electroporation.

 The resulting colonies are screened by PCR, using a primer pair designed to identify the proper cDNAs (primer sequences, as provided in Table VI, may be used).

5 Those cDNA clones that are positive by PCR are then assessed to determine the inserts size. Two clones for each BMY_HPP gene are chosen for DNA sequencing using standard methods known in the art and described herein.

 The polynucleotide(s) of the present invention, the polynucleotide encoding the polypeptide of the present invention, or the polypeptide encoded by the deposited
10 clone may represent partial, or incomplete versions of the complete coding region (i.e., full-length gene). Several methods are known in the art for the identification of the 5' or 3' non-coding and/or coding portions of a gene which may not be present in the deposited clone. The methods that follow are exemplary and should not be
15 limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols that are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993)).

20 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be
25 sequenced and used to generate the full-length gene.

 This above method starts with total RNA isolated from the desired source, although poly-A⁺ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged
30 RNA that may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

 This modified RNA preparation is used as a template for first strand cDNA
35 synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific

5 to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene. Moreover, it may be advantageous to optimize the RACE protocol to increase the probability of isolating additional 5' or 3' coding or non-coding sequences. Various methods of optimizing a
10 RACE protocol are known in the art, though a detailed description summarizing these methods can be found in B.C. Schaefer, *Anal. Biochem.*, 227:255-273, (1995).

An alternative method for carrying out 5' or 3' RACE for the identification of coding or non-coding sequences is provided by Frohman, M.A., et al., *Proc. Nat'l. Acad. Sci. USA*, 85:8998-9002 (1988). Briefly, a cDNA clone missing either
15 the 5' or 3' end can be reconstructed to include the absent base pairs extending to the translational start or stop codon, respectively. In some cases, cDNAs are missing the start of translation, therefor. The following briefly describes a modification of this original 5' RACE procedure. Poly A⁺ or total RNAs reverse transcribed with Superscript II (Gibco/BRL) and an antisense or I complementary primer specific to
20 the cDNA sequence. The primer is removed from the reaction with a Microcon Concentrator (Amicon). The first-strand cDNA is then tailed with dATP and terminal deoxynucleotide transferase (Gibco/BRL). Thus, an anchor sequence is produced which is needed for PCR amplification. The second strand is synthesized from the dA-tail in PCR buffer, Taq DNA polymerase (Perkin-Elmer Cetus), an oligo-dT
25 primer containing three adjacent restriction sites (XhoI, SalI and ClaI) at the 5' end and a primer containing just these restriction sites. This double-stranded cDNA is PCR amplified for 40 cycles with the same primers as well as a nested cDNA-specific antisense primer. The PCR products are size-separated on an ethidium bromide-agarose gel and the region of gel containing cDNA products the predicted size of
30 missing protein-coding DNA is removed. cDNA is purified from the agarose with the Magic PCR Prep kit (Promega), restriction digested with XhoI or SalI, and ligated to a plasmid such as pBluescript SKII (Stratagene) at XhoI and EcoRV sites. This DNA is transformed into bacteria and the plasmid clones sequenced to identify the correct protein-coding inserts. Correct 5' ends are confirmed by comparing this sequence with
35 the putatively identified homologue and overlap with the partial cDNA clone. Similar

- 5 methods known in the art and/or commercial kits are used to amplify and recover 3' ends.

Several quality-controlled kits are commercially available for purchase. Similar reagents and methods to those above are supplied in kit form from Gibco/BRL for both 5' and 3' RACE for recovery of full length genes. A second kit is
10 available from Clontech which is a modification of a related technique, SLIC (single-stranded ligation to single-stranded cDNA), developed by Dumas et al., Nucleic Acids Res., 19:5227-32(1991). The major differences in procedure are that the RNA is alkaline hydrolyzed after reverse transcription and RNA ligase is used to join a restriction site-containing anchor primer to the first-strand cDNA. This obviates the
15 necessity for the dA-tailing reaction which results in a polyT stretch that is difficult to sequence past.

An alternative to generating 5' or 3' cDNA from RNA is to use cDNA library double-stranded DNA. An asymmetric PCR-amplified antisense cDNA strand is synthesized with an antisense cDNA-specific primer and a plasmid-anchored primer.
20 These primers are removed and a symmetric PCR reaction is performed with a nested cDNA-specific antisense primer and the plasmid-anchored primer.

RNA Ligase Protocol For Generating The 5' or 3' End Sequences To Obtain Full Length Genes

- 25 Once a gene of interest is identified, several methods are available for the identification of the 5' or 3' portions of the gene which may not be present in the original cDNA plasmid. These methods include, but are not limited to, filter probing, clone enrichment using specific probes and protocols similar and identical to 5' and 3'RACE. While the full-length gene may be present in the library and can be
30 identified by probing, a useful method for generating the 5' or 3' end is to use the existing sequence information from the original cDNA to generate the missing information. A method similar to 5'RACE is available for generating the missing 5' end of a desired full-length gene. (This method was published by Fromont-Racine et al., Nucleic Acids Res., 21(7): 1683-1684 (1993)). Briefly, a specific RNA
35 oligonucleotide is ligated to the 5' ends of a population of RNA presumably 30 containing full-length gene RNA transcript and a primer set containing a primer

5 specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest, is used to PCR amplify the 5' portion of the desired full length gene which may then be sequenced and used to generate the full length gene. This method starts with total RNA isolated from the desired source, poly A RNA may be used but is not a prerequisite for this procedure. The RNA preparation
 10 may then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase if used is then inactivated and the RNA is treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap
 15 cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase. This modified RNA preparation can then be used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction can then be used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the
 20 known sequence of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the relevant family.

Representative primers for cloning any one of the human phosphatases of the present invention are provided in Table VI herein as 'Left Cloning Primer', 'Right Cloning Primer', 'Internal RevComp Cloning Primer', and/or 'Internal Cloning
 25 Primer'. Other primers could be substituted for any of the above as would be appreciated by one skilled in the art.

In the case of the full-length BMY_HPP1, BMY_HPP1 was cloned using the polynucleotide sequences of the identified BMY_HPP1 fragments BMY_HPP1_A (SEQ ID NO:1) and BMY_HPP1_B (SEQ ID NO:3) to design the following antisense
 30 80 bp oligo with biotin on the 5' end:

Name	Sequence
Phos4-80b	5' bTGACAAATGGATAGCTACTTTTCCTTCCTGTAAGGCAAATGTCATC ACCTTCACCATATCTAGGATAGTAGTAAGAGACGC -3 (SEQ ID NO:45)

5 One microliter (one hundred and fifty nanograms) of the gel-purified
biotinylated PCR fragment was added to six microliters (six micrograms) of a single-
stranded covalently closed circular brain, fetal brain, bone marrow, prostate, spleen,
testis, and thymus cDNA libraries and seven microliters of 100% formamide in a 0.5
ml PCR tube. The mixture was heated in a thermal cycler to 95° C for 2 mins.
10 Fourteen microliters of 2X hybridization buffer (50% formamide, 1.5 M NaCl, 0.04
M NaPO₄, pH 7.2, 5 mM EDTA, 0.2% SDS) was added to the heated probe/cDNA
library mixture and incubated at 42° C for 26 hours. Hybrids between the biotinylated
oligo and the circular cDNA were isolated by diluting the hybridization mixture to
220 microliters in a solution containing 1 M NaCl, 10 mM Tris-HCl pH 7.5, 1mM
15 EDTA, pH 8.0 and adding 125 microliters of streptavidin magnetic beads. This
solution was incubated at 42° C for 60 mins, mixing every 5 mins to resuspend the
beads. The beads were separated from the solution with a magnet and the beads
washed three times in 200 microliters of 0.1 X SSPE, 0.1% SDS at 45° C.

 The single stranded cDNAs were released from the biotinlyated
20 probe/streptavidin magnetic bead complex by adding 50 microliters of 0.1 N NaOH
and incubating at room temperature for 10 mins. Six microliters of 3 M Sodium
Acetate was added along with 15 micrograms of glycogen and the solution ethanol
precipitated with 120 microliters of 100% ethanol. The DNA was resuspend in 12
microliters of TE (10 mM Tris-HCl, pH 8.0), 1mM EDTA, pH 8.0). The single
25 stranded cDNA was converted into double strands in a thermal cycler by mixing 5
microliters of the captured DNA with 1.5 microliters 10 micromolar standard SP6
primer (homologous to a sequence on the cDNA cloning vector) and 1.5 microliters of
10 X PCR buffer. The mixture was heated to 95° C for 20 seconds, then ramped down
to 59 ° C. At this time 15 microliters of a repair mix, that was preheated to 70° C
30 (Repair mix contains 4 microliters of 5 mM dNTPs (1.25 mM each), 1.5 microliters of
10X PCR buffer, 9.25 microliters of water, and 0.25 microliters of Taq polymerase).
The solution was ramped back to 73° C and incubated for 23 mins. The repaired DNA
was ethanol precipitated and resuspended in 10 microliters of TE. Two microliters
were electroporated in E. coli DH12S cells and resulting colonies were screened by
35 PCR, using the following primer pair number:

Name	Sequence
Phos2-2s	TACAATTTTCGGATGGAAGGATTAT (SEQ ID NO:154)
Phos2-2a	GCATGACAATGGATAGCTACTTT (SEQ ID NO:155)

5

The sequence of the BMY_HPP1 polynucleotide was sequenced and is provided in Figures 20A-D (SEQ ID NO:149).

In the case of the full-length BMY_HPP2, BMY_HPP1 was cloned using the polynucleotide sequences of the identified BMY_HPP2 fragment (SEQ ID NO:5) to design the following antisense 80 bp oligo with biotin on the 5' end:

10

Name	Sequence
Phos2-80b	5'bGTGCCGCACGCCCAGGTCCAACAGGAAGTGGTAGTGGGCGGGG AGCCGCGGCAGCGCCAGTCCCGCCAGCCGCCCCGGA -3 (SEQ ID NO:51)

One microliter (one hundred and fifty nanograms) of the gel-purified biotinylated PCR fragment was added to six microliters (six micrograms) of a single-stranded covalently closed circular brain, fetal brain, bone marrow, prostate, spleen, testis, and thymus cDNA libraries and seven microliters of 100% formamide in a 0.5 ml PCR tube. The mixture was heated in a thermal cycler to 95° C for 2 mins. Fourteen microliters of 2X hybridization buffer (50% formamide, 1.5 M NaCl, 0.04 M NaPO₄, pH 7.2, 5 mM EDTA, 0.2% SDS) was added to the heated probe/cDNA library mixture and incubated at 42° C for 26 hours. Hybrids between the biotinylated oligo and the circular cDNA were isolated by diluting the hybridization mixture to 220 microliters in a solution containing 1 M NaCl, 10 mM Tris-HCl pH 7.5, 1mM EDTA, pH 8.0 and adding 125 microliters of streptavidin magnetic beads. This solution was incubated at 42° C for 60 mins, mixing every 5 mins to resuspend the beads. The beads were separated from the solution with a magnet and the beads washed three times in 200 microliters of 0.1 X SSPE, 0.1% SDS at 45° C.

The single stranded cDNAs were released from the biotinylated probe/streptavidin magnetic bead complex by adding 50 microliters of 0.1 N NaOH and incubating at room temperature for 10 mins. Six microliters of 3 M Sodium Acetate was added along with 15 micrograms of glycogen and the solution ethanol

30

5 precipitated with 120 microliters of 100% ethanol. The DNA was resuspend in 12 microliters of TE (10 mM Tris-HCl, pH 8.0), 1mM EDTA, pH 8.0). The single stranded cDNA was converted into double strands in a thermal cycler by mixing 5 microliters of the captured DNA with 1.5 microliters 10 micromolar standard SP6 primer (homologous to a sequence on the cDNA cloning vector) and 1.5 microliters of
 10 10 X PCR buffer. The mixture was heated to 95° C for 20 seconds, then ramped down to 59 ° C. At this time 15 microliters of a repair mix, that was preheated to 70° C (Repair mix contains 4 microliters of 5 mM dNTPs (1.25 mM each), 1.5 microliters of 10X PCR buffer, 9.25 microliters of water, and 0.25 microliters of Taq polymerase). The solution was ramped back to 73° C and incubated for 23 mins. The repaired DNA
 15 was ethanol precipitated and resuspended in 10 microliters of TE. Two microliters were electroporated in E. coli DH12S cells and resulting colonies were screened by PCR, using the following primer pair number:

Name	Sequence
Phos2-2s	GAGAAAGCAGTCTTCCAGTTCTAC (SEQ ID NO:156)
Phos2-2a	ATGGGAGCTAGAGGGTTAATACT (SEQ ID NO:157)

20 The sequence of the BMY_HPP2 polynucleotide was sequenced and is provided in Figure 21 (SEQ ID NO:151).

In the case of BMY_HPP5, BMY_HPP5 was cloned using the sequence of Incyte clone 4155374 to design the following PCR oligos:

Oligo number	Name	Sequence
25 686	4155374-C3.s	5'-GGCCAAAGAGCAAACCTCAAG-3 (SEQ ID NO:69)
687	4155374-C3.Ba	5'-bGCATAGCTTGTGGTCCCAT-3 (SEQ ID NO:70)

A biotinylated nucleotide was included on the 5' end of oligo 687. Using the PCR primer pair, a 414bp biotinylated fragment was amplified using the Incyte clone
 30 as the template. The fragment was gel purified by agarose electrophoresis and stored at 4° C. The same PCR primer pair was used to screen cDNA libraries for the presence of homologous sequences. Positive PCR results were obtained in our HPLC-size fractionated brain and testis libraries. One microliter (one hundred and fifty nanograms) of the gel-purified biotinylated PCR fragment was added to six

5 microliters (six micrograms) of a single-stranded covalently closed circular testis cDNA library and seven microliters of 100% formamide in a 0.5 ml PCR tube. The mixture was heated in a thermal cycler to 95° C for 2 mins. Fourteen microliters of 2X hybridization buffer (50% formamide, 1.5 M NaCl, 0.04 M NaPO₄, pH 7.2, 5 mM EDTA, 0.2% SDS) was added to the heated probe/cDNA library mixture and
10 incubated at 42° C for 26 hours. Hybrids between the biotinylated oligo and the circular cDNA were isolated by diluting the hybridization mixture to 220 microliters in a solution containing 1 M NaCl, 10 mM Tris-HCl pH 7.5, 1mM EDTA, pH 8.0 and adding 125 microliters of streptavidin magnetic beads. This solution was incubated at 42° C for 60 mins, mixing every 5 mins to resuspend the beads. The beads were
15 separated from the solution with a magnet and the beads washed three times in 200 microliters of 0.1 X SSPE, 0.1% SDS at 45° C.

The single stranded cDNAs were released from the biotinylated probe/streptavidin magnetic bead complex by adding 50 microliters of 0.1 N NaOH and incubating at room temperature for 10 mins. Six microliters of 3 M Sodium
20 Acetate was added along with 15 micrograms of glycogen and the solution ethanol precipitated with 120 microliters of 100% ethanol. The DNA was resuspend in 12 microliters of TE (10 mM Tris-HCl, pH 8.0), 1mM EDTA, pH 8.0). The single stranded cDNA was converted into double strands in a thermal cycler by mixing 5 microliters of the captured DNA with 1.5 microliters 10 micromolar standard SP6
25 primer (homologous to a sequence on the cDNA cloning vector) and 1.5 microliters of 10 X PCR buffer. The mixture was heated to 95° C for 20 seconds, then ramped down to 59 ° C. At this time 15 microliters of a repair mix, that was preheated to 70° C (Repair mix contains 4 microliters of 5 mM dNTPs (1.25 mM each), 1.5 microliters of 10X PCR buffer, 9.25 microliters of water, and 0.25 microliters of Taq polymerase).
30 The solution was ramped back to 73° C and incubated for 23 mins. The repaired DNA was ethanol precipitated and resuspended in 10 microliters of TE. Two microliters were electroporated in E. coli DH12S cells and resulting colonies were screened by PCR, using the primer pair number 686/687. The sequence of the BMY_HPP5 polynucleotide was sequenced and is provided in Figures 5A-E (SEQ ID NO:41).

5

Example 3 – Expression Profiling Of The Novel Human BMY_HPP Phosphatase Polypeptides Of The Present Invention.

PCR primers designed from the predicted or observed cDNA sequences (described elsewhere herein) will be used in a real-time PCR assay to determine
10 relative steady state mRNA expression levels of BMY_HPP1, BMY_HPP2, BMY_HPP3, and BMY_HPP4 across a panel of human tissues according to the following protocol.

First strand cDNA may be synthesized from commercially available mRNA (Clontech) and subjected to real time quantitative PCR using a PE 5700 instrument
15 (Applied Biosystems, Foster City, CA) using the manufacturers recommended protocol. This instrument detects the amount of DNA amplified during each cycle by the fluorescent output of SYBR green, a DNA binding dye specific for double strands. The specificity of the primer pair for its target may be verified by performing a thermal denaturation profile at the end of the run which provides an indication of the
20 number of different DNA sequences present by determining melting T_m. Only primer pairs giving a single PCR product are considered. Contributions of contaminating genomic DNA to the assessment of tissue abundance may be controlled by performing the PCR with first strand made with and without reverse transcriptase. Only samples where the contribution of material amplified in the no reverse
25 transcriptase controls was negligible are considered.

Small variations in the amount of cDNA used in each tube can be determined by performing a parallel experiment using a primer pair for the cyclophilin gene, which is expressed in equal amounts in all tissues. The data is then used to normalize the data obtained with each primer pair. The PCR data was converted into a relative
30 assessment of the difference in transcript abundance amongst the tissues tested.

Representative primers for expression profiling analysis for each gene are provided in Table VI herein as 'EP Sense' and 'EP Anti-sense Primer', though may also include one or more of the following: 'Left Cloning Primer', 'Right Cloning Primer', 'Internal RevComp Cloning Primer', and/or 'Internal Cloning Primer'. Other
35 primers could be substituted for any of the above as would be appreciated by one skilled in the art.

5 In the case of BMY_HPP1, the following PCR primer pair was used to measure the steady state levels of BMY_HPP1 mRNA by quantitative PCR:

Sense: 5'- TACAATTCGGATGGAAGGATTAT -3' (SEQ ID NO:154)
Antisense: 5'- GCATGACAATGGATAGCTACTTT -3' (SEQ ID NO:155)

10

Briefly, first strand cDNA was made from commercially available mRNA. The relative amount of cDNA used in each assay was determined by performing a parallel experiment using a primer pair for a gene expressed in equal amounts in all tissues, cyclophilin. The cyclophilin primer pair detected small variations in the amount of cDNA in each sample and these data were used for normalization of the data obtained with the primer pair for the novel BMY_HPP1. The PCR data was converted into a relative assessment of the difference in transcript abundance amongst the tissues tested and the data is presented in Figure 22. Transcripts corresponding to BMY_HPP1 were expressed highly in testis; to a significant extent, in the spinal cord, and to a lesser extent, in pancreas, brain, pituitary, heart, and lung.

20 In the case of BMY_HPP2, the following PCR primer pair was used to measure the steady state levels of BMY_HPP2 mRNA by quantitative PCR:

Sense: 5'- GAGAAAGCAGTCTTCCAGTTCTAC -3' (SEQ ID NO:156)
25 Antisense: 5'- ATGGGAGCTAGAGGGTTTAATACT -3' (SEQ ID NO:157)

Briefly, first strand cDNA was made from commercially available mRNA. The relative amount of cDNA used in each assay was determined by performing a parallel experiment using a primer pair for a gene expressed in equal amounts in all tissues, cyclophilin. The cyclophilin primer pair detected small variations in the amount of cDNA in each sample and these data were used for normalization of the data obtained with the primer pair for the novel BMY_HPP2. The PCR data was converted into a relative assessment of the difference in transcript abundance amongst the tissues tested and the data is presented in Figure 23. Transcripts corresponding to BMY_HPP2 were expressed highly in liver and kidney; to a significant extent, in the spleen, and to a lesser extent, in lung, testis, heart, intestine, pancreas, lymph node, spinal cord, and prostate.

5 In the case of BMY_HPP5, the following PCR primer pair was used to measure the steady state levels of BMY_HPP5 mRNA by quantitative PCR:

Sense: 5'- ATGGGACCAACAAGCTATGC -3' (SEQ ID NO:67)

Antisense: 5'- TTATCAGGACTGGTTTCGGG -3' (SEQ ID NO:68)

10

Briefly, first strand cDNA was made from commercially available mRNA. The relative amount of cDNA used in each assay was determined by performing a parallel experiment using a primer pair for a gene expressed in equal amounts in all tissues, cyclophilin. The cyclophilin primer pair detected small variations in the amount of cDNA in each sample and these data were used for normalization of the data obtained with the primer pair for the novel BMY_HPP5. The PCR data was converted into a relative assessment of the difference in transcript abundance amongst the tissues tested and the data is presented in Figure 11. Transcripts corresponding to BMY_HPP5 were expressed highly in the testis, spinal cord, and to a lesser extent in bone marrow, brain, thymus, and liver.

20

Example 4 – Method of Assaying The Phosphatase Activity of the BMY_HPP Polypeptides of the present invention.

The Phosphatase Activity of the BMY_HPP Polypeptides of the present invention may be assessed through the application of various biochemical assays known in the art and described herein.

25

Hydrolysis of para-nitrophenyl phosphate

The phosphatase activity for BMY_HPP proteins may be measured by assaying the ability of the proteins to hydrolyze para-nitrophenyl phosphate, a compound known to be a substrate for phosphatases, as described in Krejsa, C. et al., J. Biol. Chem... Vol. 272, p.11541-11549, 1997 (which is hereby incorporated in its entirety herein). The proteins are incubated in 3 mg/ml para-nitrophenyl phosphate in a solution containing 60 mM MES, pH 6.0, 5% glycerol, 5 mM dithiothreitol, and 0.1% Triton X-100 for 15 min, or such other time as may be desired. The pH of the reaction may be varied to provide an optimal pH for each individual BMY_HPP

35

5 protein by those with ordinary skill in the art of enzyme assays. The phosphatase reaction is stopped by the addition of 3 N NaOH to give a final NaOH concentration of 0.7 M. The product of the reaction is measured by reading the absorbance of the solution at 405 nm.

10 *Two dimensional gel electrophoresis*

The BMY_HPP polynucleotides of the present invention may be subcloned into appropriate vectors for expression in host cells. Representative vectors are known in the art and described herein. 2-D gel electrophoresis (IEF followed by SDS-PAGE) will be used to assay BMY_HPP-dependent dephosphorylation of host cell proteins.

15 These proteins can be recovered from the gel and identified by mass spectrometric or other protein sequencing techniques known in the art.

Briefly, Methods for 2-dimensional gel analysis and labeling cells with proteins are well known in the art. Cells would be labeled with ^{32}P orthophosphate, cellular proteins would be resolved on 2D gels and their positions determined by
20 autoradiography. Proteins of interest would be identified by excising the spots and analyzing their sequence by mass spectroscopy. The following paper and the references therein describe the methods of labeling cells, analyzing the proteins on 2D gels and mass spec identification: Gerner, C. et al., J. Biol. Chem..., Vol. 275, p.39018 - 39026, 2000. Substrates affected by the phosphatase would be identified by
25 comparing wild type cells to cells where expression of the phosphatase is inhibited by deletion, anti-sense, or other means. Proteins whose phosphorylation increased would be either direct substrates or indirectly regulated by the phosphatase. Conversely, in cells where the active phosphatase was overexpressed, proteins whose phosphorylation decreased would either be direct substrates or indirectly regulated by
30 the phosphatase.

5

Example 5 – Method of Identifying The Substrate of the BMY_HPP Phosphatase Polypeptides of the present invention.

Substrate identification

10 Protein substrates for BMY_HPP polypeptides of the present invention may be identified by recovery of proteins dephosphorylated in the 2-D gel electrophoresis assay described above. Phosphopeptide substrates may also be identified as proteins whose phosphorylation increases when the activity or expression of a BMY_HPP protein is decreased (for example, by an antibody, antisense or double-stranded
15 inhibitory RNA or by a small molecule inhibitor of BMY_HPP activity). In either case, mass spectrometry can be used to identify the recovered proteins.

Phosphopeptide substrates for BMY-HPP polypeptides may also be identified by incubation of a phosphopeptide library with a catalytically inactive version of the protein, recovery of the complex, and peptide sequencing by standard methods such
20 as Edman degradation or mass spectrometry.

Phosphopeptide substrates can also be identified by expressing a substrate trapping mutant phosphatase (one that is catalytically inactive due to active site mutation) and isolating the proteins that bind preferentially to the substrate trapping phosphatase relative to the wild type phosphatase.

25

Example 6 – Method of Identifying RET31 of the Present Invention.

In an effort to identify gene products involved in regulatory events, the RNA expressed in TNF- α -stimulated human lung microvascular endothelial cells was analyzed. Resting cells were stimulated for 1 h with TNF- α , and the RNA was
30 isolated from the cells. Complementary DNA (cDNA) was created from the isolated RNA using methods known in the art. The cDNA that were upregulated in response to TNF α were identified using subtractive hybridization. A clone corresponding to a portion of the RET31 polynucleotide was identified and used to identify the full-length (SEQ ID NO:115). Additional methods are provided below.

35

HMVEC Cell culture

5 Primary cultures of human lung microvascular endothelial cells (HMVEC), from a single donor, were obtained from Clonetics (Walkersville, MD). The cells were grown in the endothelial cell growth medium-2 kit (CC-3202) with 5% Fetal Bovine Serum (Hyclone). Initially, the cells were seeded into a T-25 flask and, after reaching approximately 90% confluence, they were trypsinized and transferred into T-
10 225 flasks at 1.2×10^6 /flask in 80 mls of medium. For normal growth conditions, the medium was changed each 48 h. When the cells reached approximately 90% confluence, they were passaged again and seeded into T-225 flasks at 1.8×10^6 /ml in 80 mls of medium.

15 *HMVEC Cell Treatment for RNA isolation*

Subconfluent (90% confluent) T-225 flasks of HMVEC were adjusted to 40 ml of medium per flask by removing excess medium. HMVEC were either left untreated (time 0) or treated with 10 ng/ml TNF- α for 1, 6 or 24 h. The medium was not changed at the time of TNF- α addition.

20

RNA isolation

At the designated time points, The flasks of HMVEC were trypsinized briefly to remove cells from the flasks and trypsinization was terminated by the addition of fetal calf serum. The cells were removed from the flasks and the flasks rinsed with
25 PBS. The cells were pelleted, rinsed once in PBS and re-pelleted. The supernatant was removed and the cell pellet used for RNA isolation. Poly A+RNA was isolated directly using Fast Track 2.0™ (Invitrogen, Carlsbad, CA).

Construction of the Subtraction Library

30 The PCR-select cDNA subtraction kit™ (Clontech, Palo Alto, CA) was used to generate a subtraction library from untreated HMVEC poly A+ RNA (tester) and 1 h TNF- α -treated HMVEC poly A+ RNA (driver), according to the manufacturer's protocols. Ten secondary PCR reactions were combined and run on a 2% agarose gel. Fragments ranging from approximately 0.3kb – 10 kb were gel purified using the
35 QIAgen gel extraction kit (QIAgen Inc., Valencia, CA) and inserted into the TA cloning vector, pCR2.1 (Invitrogen). TOP10F' competent *E. coli* (Invitrogen) were

5 transformed and plated on LB plates containing 50 micrograms/ml ampicillin. Clones were isolated and grown in LB broth containing similar concentrations of ampicillin. Plasmids were sequenced using methods known in the art or described elsewhere herein.

10 As referenced above, the methods utilized for constructing the subtraction library followed the PCR-Select cDNA Subtraction Kit (Clontech; Protocol # PT1117-1; Version # PR85431) which is hereby incorporated herein by reference in its entirety. Additional references to this method may be found in Diatchenko, L., et al., PNAS 93:6025-6030 (1996), which is hereby incorporated herein by reference in its entirety.

15

Example7 – Method of Cloning RET31 of the Present Invention.

A clone containing the predicted coding sequence of RET31 was isolated from human microvascular endothelial cells (HMVECs) treated with tumor necrosis factor alpha (TNF α) for 6 hours using reverse transcription/polymerase chain reaction (RT/PCR). RNA was purified from the TNF α stimulated HMVEC cells according to
20 methods known in the art. A primer set (each at 400 nM final concentration) was used to amplify a 3 kb sequence using the following primers and conditions:

primer JNF388: CACACCACCATTACATCATCGTGGC (SEQ ID NO:145)

25 primer JNF525: TGCTGCTCTGCTACCAACCC (SEQ ID NO:146)

with 200 μ M dNTP's, 1X Advantage 2 polymerase, and 2.0 μ l DNA in 25.0 μ l reaction. The experiment was cycled 35 times through the following sequence: : 94°C for 30 sec, 68°C for 30 sec. then 72°C for 3.5 min. At the completion of the reaction,
30 6.0 μ l of loading dye was added and the entire reaction was separated by gel electrophoresis in a 1.2% agarose gel containing ethidium bromide. An ~3 kb size band was excised from the gel and purified using the QIAgen extraction kit (QIAgen, Valencia, CA). This fragment was ligated into the pTAdv cloning vector (Clontech, Palo Alto, CA) and sequenced using standard methods. The RET31 clone (SEQ ID
35 NO:108; Figures 13A-F) contains about a 3 kb sequence corresponding to nucleotides 472 to 3513 of the predicted RET31 coding sequence (SEQ ID NO:147). The

- 5 predicted RET31 coding sequence (SEQ ID NO:147) was derived from Incyte gene cluster 1026659.7.

A nucleic acid sequence corresponding to the nucleic acid sequence encoding the RET31 polypeptide was first identified in a subtraction library from TNF- α stimulated human lung microvascular endothelial cells (HMVEC). This subtraction
10 clone sequence encoded a 408bp partial cDNA sequence, as shown:

RET31 subtraction clone

ACAATGGAGTGGCTGAGCCTTTGAGCACACCACCATTACATCATCGTGGCAAATTAAAGAAGGAGGTGG
15 GAAAAGAGGACTTATTGTTGTCATGGCCCATGAGATGATTGGAACCTCAAATTGTTACTGAGAGGTTGGT
GGCTCTGCTGGAAAGTGGAAACGGAAAAAGTGTGCTAATTGATAGCCGGCCATTTGTGGAATACAATAC
ATCCACATTTTGGGAAGCCATTAATATCAACTGCTCCAAGCTTATGAAGCGAAGGTTGCAACAGGACAA
AGTGTTAATTACAGAGCTCATCCAGCATTGAGCGAAACATAAGGTTGACATTGATTGCAGTCAGAAGGT
TGTAGTTTACGATCAAAGCTCCCAAGATGTTGCCTCTCTCTCTTCAGACTGTTTTCTCACTGT (SEQ
20 ID NO:115)

Example 8 – Method of Determining the mRNA Expression Profile of RET31 Using Northern Hybridization.

Multiple tissue northern blots (MTN) were purchased from Clontech
25 Laboratories (Palo Alto, CA) and hybridized with P³²-labeled RET31. Briefly, a 408 bp RET31 fragment (RET31/RsaI) was isolated from subtraction clone 1hrTNF031 (SEQ ID NO:115) using RsaI restriction endonuclease, run on a 2.0% agarose gel, and purified using the QIAgen Gel Extraction Kit (QIAgen, Valencia, CA). Approximately 30 ng of RET31/RsaI was radiolabeled (6000Ci/mmol P³²-dCTP)
30 using the Random Primed DNA Labeling Kit (Roche, Indianapolis, IN). Unincorporated nucleotides were removed using NucTrap Probe Purification Columns (Stratgene, La Jolla, CA). Radiolabeled RET31/RsaI probe was added at a specific activity of 1.5x10⁶ cpm/ml of ExpressHyb hybridization solution (Clontech) and incubated overnight at 65°C. Blots were washed to 2.0XSSC/0.05%SDS at 50°C
35 and exposed to film for 24 and 48 h. The MTN's used were human MTN (#7760-1), human MTN II (#7759-1), human MTN III (#7767-1), and human cancer cell line MTN (#7757-1).

5 The results show the RET31 polypeptide was expressed predominately in adrenal gland, testis, and skeletal muscle; to a significant extent, in the liver, prostate ovary, and to a lesser extent, in placenta, pancreas, thymus, small intestine, thyroid, heart, kidney and liver (see Figure 15).

10 **Example 9 – Method of Assessing The Affect of TNF-alpha on RET31 mRNA Expression.**

 In an effort to confirm the the TNF-alpha dependent regulation of RET31 expression, HMVEC cells were treated with TNF-alpha over several time periods and the mRNA subsequently harvested and probed by northern hybridization. Briefly,
15 untreated HMVEC, 1h TNF- α stimulated HMVEC, 6 h TNF- α stimulated HMVEC, 24h TNF- α stimulated HMVEC poly A+RNA (2 μ g each) were run on a 1.2% agarose gel containing 3.0% formaldehyde and transferred to Hybond N+ nucleic acid transfer membrane (Amersham, Piscataway, NJ) using standard blotting techniques (see Maniatis et al. referenced herein). Membranes were auto cross-linked using
20 Stratalinker (Stratagene) and prehybridized in ExpressHyb hybridization solution for 1 h and probed in parallel with the multiple tissue northern blots.

 After hybridization, membranes were washed by continuous shaking for 30 minutes with low stringency solution (2XSSC/0.05%SDS) at room temperature with 2 changes of solution. Membranes were then washed for 30 minutes with high
25 stringency solution (0.1XSSC/0.1%SDS) at 50°C with 1 change of solution. The membranes were exposed with intensifying screens to X-ray film at -70°C for 10 days.

 The endothelial cell blot was reprobed for E-selectin and GAPDH.

 The results confirmed RET31 is up-regulated by TNF- α , reaching a peak of
30 expression at 6 h by northern blot analysis (see Figure 18).

Example 6 – Method Of Assessing The Physiological Function Of The human phosphatase Polypeptide At The Cellular Level.

 The physiological function of the human phosphatase polypeptide may be
35 assessed by expressing the sequences encoding human phosphatase at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a

5 mammalian expression vector containing a strong promoter that drives high levels of cDNA expression (examples are provided elsewhere herein). Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10, ug of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or
10 hematopoietic origin, using either liposome formulations or electroporation. 1-2ug of an additional plasmid containing sequences encoding a marker protein are cotransfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g.,
15 Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death.
20 These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with
25 specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of human phosphatase polypeptides on gene expression can be
30 assessed using highly purified populations of cells transfected with sequences encoding human phosphatase and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody
35 against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding

- 5 human phosphatase polypeptides and other genes of interest can be analyzed by northern analysis or microarray techniques.

Example 7 – Method Of Screening For Compounds That Interact With The human phosphatase Polypeptide.

- 10 The following assays are designed to identify compounds that bind to the human phosphatase polypeptide, bind to other cellular proteins that interact with the human phosphatase polypeptide, and to compounds that interfere with the interaction of the human phosphatase polypeptide with other cellular proteins.

- Such compounds can include, but are not limited to, other cellular proteins.
- 15 Specifically, such compounds can include, but are not limited to, peptides, such as, for example, soluble peptides, including, but not limited to Ig-tailed fusion peptides, comprising extracellular portions of human phosphatase polypeptide transmembrane receptors, and members of random peptide libraries (see, e.g., Lam, K. S. et al., 1991, Nature 354:82-84; Houghton, R. et al., 1991, Nature 354:84-86), made of D-and/or L-
- 20 configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate phosphopeptide libraries; see, e.g., Songyang, Z., et al., 1993, Cell 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab').sub.2 and FAb expression library fragments, and epitope-binding fragments
- 25 thereof), and small organic or inorganic molecules.

- Compounds identified via assays such as those described herein can be useful, for example, in elaborating the biological function of the human phosphatase polypeptide, and for ameliorating symptoms of tumor progression, for example. In instances, for example, whereby a tumor progression state or disorder results from a
- 30 lower overall level of human phosphatase expression, human phosphatase polypeptide, and/or human phosphatase polypeptide activity in a cell involved in the tumor progression state or disorder, compounds that interact with the human phosphatase polypeptide can include ones which accentuate or amplify the activity of the bound human phosphatase polypeptide. Such compounds would bring about an
- 35 effective increase in the level of human phosphatase polypeptide activity, thus ameliorating symptoms of the tumor progression disorder or state. In instances

5 whereby mutations within the human phosphatase polypeptide cause aberrant human phosphatase polypeptides to be made which have a deleterious effect that leads to tumor progression, compounds that bind human phosphatase polypeptide can be identified that inhibit the activity of the bound human phosphatase polypeptide. Assays for testing the effectiveness of such compounds are known in the art and
10 discussed, elsewhere herein.

Example 8 – Method Of Screening, In Vitro, Compounds That Bind To The Human Phosphatase Polypeptide.

 In vitro systems can be designed to identify compounds capable of binding the
15 human phosphatase polypeptide of the invention. Compounds identified can be useful, for example, in modulating the activity of wild type and/or mutant human phosphatase polypeptide, preferably mutant human phosphatase polypeptide, can be useful in elaborating the biological function of the human phosphatase polypeptide, can be utilized in screens for identifying compounds that disrupt normal human
20 phosphatase polypeptide interactions, or can in themselves disrupt such interactions.

 The principle of the assays used to identify compounds that bind to the human phosphatase polypeptide involves preparing a reaction mixture of the human phosphatase polypeptide and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex
25 which can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways. For example, one method to conduct such an assay would involve anchoring human phosphatase polypeptide or the test substance onto a solid phase and detecting human phosphatase polypeptide /test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a
30 method, the human phosphatase polypeptide can be anchored onto a solid surface, and the test compound, which is not anchored, can be labeled, either directly or indirectly.

 In practice, microtitre plates can conveniently be utilized as the solid phase. The anchored component can be immobilized by non-covalent or covalent attachments. Non-covalent attachment can be accomplished by simply coating the
35 solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the protein to be

- 5 immobilized can be used to anchor the protein to the solid surface. The surfaces can be prepared in advance and stored.

In order to conduct the assay, the nonimmobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any
10 complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labeled, an indirect label can be
15 used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the immobilized component (the antibody, in turn, can be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using
20 an immobilized antibody specific for human phosphatase polypeptide or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

25 **Example 9 – Method Of Identifying Compounds That Interfere With Human Phosphatase Polypeptide/Cellular Product Interaction.**

The human phosphatase polypeptide of the invention can, in vivo, interact with one or more cellular or extracellular macromolecules, such as proteins. Such macromolecules include, but are not limited to, polypeptides, particularly ligands, and
30 those products identified via screening methods described, elsewhere herein. For the purposes of this discussion, such cellular and extracellular macromolecules are referred to herein as "binding partner(s)". For the purpose of the present invention, "binding partner" may also encompass polypeptides, small molecule compounds, polysaccharides, lipids, and any other molecule or molecule type referenced herein.
35 Compounds that disrupt such interactions can be useful in regulating the activity of the human phosphatase polypeptide, especially mutant human phosphatase

5 polypeptide. Such compounds can include, but are not limited to molecules such as antibodies, peptides, and the like described in elsewhere herein.

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the human phosphatase polypeptide and its cellular or extracellular binding partner or partners involves preparing a reaction mixture containing the human phosphatase polypeptide, and the binding partner under conditions and for a time sufficient to allow the two products to interact and bind, thus forming a complex. In order to test a compound for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound can be initially included in the reaction mixture, or can be added at a time subsequent to the addition of human phosphatase polypeptide and its cellular or extracellular binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the human phosphatase polypeptide and the cellular or extracellular binding partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the human phosphatase polypeptide and the interactive binding partner. Additionally, complex formation within reaction mixtures containing the test compound and normal human phosphatase polypeptide can also be compared to complex formation within reaction mixtures containing the test compound and mutant human phosphatase polypeptide. This comparison can be important in those cases wherein it is desirable to identify compounds that disrupt interactions of mutant but not normal human phosphatase polypeptide.

The assay for compounds that interfere with the interaction of the human phosphatase polypeptide and binding partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the human phosphatase polypeptide or the binding partner onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the human phosphatase polypeptide and the binding partners, e.g.,

5 by competition, can be identified by conducting the reaction in the presence of the test substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the human phosphatase polypeptide and interactive cellular or extracellular binding partner. Alternatively, test compounds that disrupt preformed complexes, e.g. compounds with higher binding constants that displace one of the
10 components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are described briefly below.

In a heterogeneous assay system, either the human phosphatase polypeptide or the interactive cellular or extracellular binding partner, is anchored onto a solid
15 surface, while the non-anchored species is labeled, either directly or indirectly. In practice, microtitre plates are conveniently utilized. The anchored species can be immobilized by non-covalent or covalent attachments. Non-covalent attachment can be accomplished simply by coating the solid surface with a solution of the human phosphatase polypeptide or binding partner and drying. Alternatively, an immobilized
20 antibody specific for the species to be anchored can be used to anchor the species to the solid surface. The surfaces can be prepared in advance and stored.

In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes
25 formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored on the
30 surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, can be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which inhibit complex formation or which disrupt preformed complexes can be detected.

35 Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted

5 components, and complexes detected; e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test compounds which inhibit complex or which disrupt preformed complexes can be identified.

10 In an alternate embodiment of the invention, a homogeneous assay can be used. In this approach, a preformed complex of the human phosphatase polypeptide and the interactive cellular or extracellular binding partner product is prepared in which either the human phosphatase polypeptide or their binding partners are labeled, but the signal generated by the label is quenched due to complex formation (see, e.g.,
15 U.S. Pat. No. 4,109,496 by Rubenstein which utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances which disrupt human phosphatase polypeptide -cellular or extracellular binding partner interaction can be identified.

20 In a particular embodiment, the human phosphatase polypeptide can be prepared for immobilization using recombinant DNA techniques known in the art. For example, the human phosphatase polypeptide coding region can be fused to a glutathione-S-transferase (GST) gene using a fusion vector such as pGEX-5X-1, in such a manner that its binding activity is maintained in the resulting fusion product.
25 The interactive cellular or extracellular product can be purified and used to raise a monoclonal antibody, using methods routinely practiced in the art and described above. This antibody can be labeled with the radioactive isotope ¹²⁵I, for example, by methods routinely practiced in the art. In a heterogeneous assay, e.g., the GST- human phosphatase polypeptide fusion product can be anchored to glutathione-
30 agarose beads. The interactive cellular or extracellular binding partner product can then be added in the presence or absence of the test compound in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away, and the labeled monoclonal antibody can be added to the system and allowed to bind to the complexed components. The interaction between the
35 human phosphatase polypeptide and the interactive cellular or extracellular binding partner can be detected by measuring the amount of radioactivity that remains

5 associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test compound will result in a decrease in measured radioactivity.

Alternatively, the GST- human phosphatase polypeptide fusion product and the interactive cellular or extracellular binding partner product can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound can
10 be added either during or after the binding partners are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again the extent of inhibition of the binding partner interaction can be detected by adding the labeled antibody and measuring the radioactivity associated with the beads.

15 In another embodiment of the invention, these same techniques can be employed using peptide fragments that correspond to the binding domains of the human phosphatase polypeptide product and the interactive cellular or extracellular binding partner (in case where the binding partner is a product), in place of one or both of the full length products.

20 Any number of methods routinely practiced in the art can be used to identify and isolate the protein's binding site. These methods include, but are not limited to, mutagenesis of one of the genes encoding one of the products and screening for disruption of binding in a co-immunoprecipitation assay. Compensating mutations in the gene encoding the second species in the complex can be selected. Sequence
25 analysis of the genes encoding the respective products will reveal the mutations that correspond to the region of the product involved in interactive binding. Alternatively, one product can be anchored to a solid surface using methods described in this Section above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, such as trypsin. After washing, a
30 short, labeled peptide comprising the binding domain can remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the gene coding for the cellular or extracellular binding partner product is obtained, short gene segments can be engineered to express peptide fragments of the product, which can then be tested for binding activity and purified or synthesized.

35

5 **Example 10 - Isolation Of A Specific Clone From The Deposited Sample.**

 The deposited material in the sample assigned the ATCC Deposit Number cited in Table I for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each
10 cDNA clone identified in Table I. Typically, each ATCC deposit sample cited in Table I comprises a mixture of approximately equal amounts (by weight) of about 1-10 plasmid DNAs, each containing a different cDNA clone and/or partial cDNA clone; but such a deposit sample may include plasmids for more or less than 2 cDNA clones.

15 Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNA(s) cited for that clone in Table I. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

 Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized
20 using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with 32P-(-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as
25 XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for
30 bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

 Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the
35 3' NT of the clone defined in Table I) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain

5 reaction is carried out under routine conditions, for instance, in 25 ul of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation
10 at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

15 **Example 11 - Tissue Distribution Of Polypeptide.**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 10 is labeled with p32 using the rediprime™ DNA labeling
20 system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN0-100 column (Clontech Laboratories, Inc.) according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various tissues for mRNA expression.

Tissue Northern blots containing the bound mRNA of various tissues are
25 examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech according to manufacturers protocol number PT1190-1. Northern blots can be produced using various protocols well known in the art (e.g., Sambrook et al). Following hybridization and washing, the blots are mounted and exposed to film at -70C overnight, and the films developed according to standard procedures.

30

Example 12 - Chromosomal Mapping Of The Polynucleotides.

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of
35 conditions: 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C.

5 Mammalian DNA, preferably human DNA, is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions are analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

10

Example 13 - Bacterial Expression Of A Polypeptide.

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 10, to synthesize insertion fragments. The primers
15 used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Ampr), a
20 bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at
25 the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, that expresses the lacI repressor and also confers kanamycin resistance (Kanr). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and
30 confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.600) of between 0.4 and 0.6. IPTG
35 (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1

- 5 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris
10 is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., supra). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., supra).

- 15 Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl.
20 Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of
25 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

30 **Example 14 - Purification Of A Polypeptide From An Inclusion Body.**

The following alternative method can be used to purify a polypeptide expressed in E coli when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

Upon completion of the production phase of the E. coli fermentation, the cell
35 culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield

5 of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer
10 (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine
15 hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with
20 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential
filtration unit equipped with 0.16 um membrane filter with appropriate surface area
25 (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perceptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored.
30 Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perceptive Biosystems) and weak anion (Poros CM-20, Perceptive Biosystems) exchange resins. The columns are
35 equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a

- 5 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A₂₈₀ monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the
10 above refolding and purification steps. No major contaminant bands should be observed from Coomassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

15

Example 15 - Cloning And Expression Of A Polypeptide In A Baculovirus Expression System.

In this example, the plasmid shuttle vector pAc373 is used to insert a polynucleotide into a baculovirus to express a polypeptide. A typical baculovirus
20 expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites, which may include, for example BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is often used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the
25 beta-galactosidase gene from E. coli under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

30 Many other baculovirus vectors can be used in place of the vector above, such as pVL941 and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

35 A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA

5 sequence, as outlined in Example 10, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites at the 5' end of the primers in order to clone the amplified product into the expression vector. Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified elsewhere
10 herein (if applicable), is amplified using the PCR protocol described in Example 10. If the naturally occurring signal sequence is used to produce the protein, the vector used does not need a second signal peptide. Alternatively, the vector can be modified to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell
15 Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1%
20 agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

25 The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel
30 electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transformed with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGoldtm baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method
35 described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGoldtm virus DNA and 5ug of the plasmid are mixed in a sterile well of a

5 microtiter plate containing 50ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is
10 then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, supra. An agarose gel with "Blue Gal" (Life
15 Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a
20 micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

25 To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine
30 (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of 35S-methionine and 5 uCi 35S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

- 5 Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 16 - Expression Of A Polypeptide In Mammalian Cells.

- 10 The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening
15 sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

- 20 Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1,
25 Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

- Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transformation with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification
30 and isolation of the transformed cells.

- The transformed gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem... 253:1357-1370 (1978); Hamlin,
35 J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is

5 the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the
10 production of proteins.

A polynucleotide of the present invention is amplified according to the protocol outlined in herein. If the naturally occurring signal sequence is used to produce the protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to
15 include a heterologous signal sequence. (See, e.g., WO 96/34891.) The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and
20 purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. E. coli HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for
25 transformation. Five μ g of an expression plasmid is cotransformed with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., supra). The plasmid pSV2-neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are
30 trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of
35 methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same

- 5 procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 uM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 17 - Protein Fusions.

- 10 The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example described herein; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to
15 IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can
20 increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule.

- Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These
25 primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

- The naturally occurring signal sequence may be used to produce the protein (if
30 applicable). Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891 and/or US Patent No. 6,066,781, supra.)

Human IgG Fc region:

- 35 GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACC
GTGCCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCC

5 AAAACCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTACATGCG
 TGGTGGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
 GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC
 AGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG
 GACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCT
 10 CCCAACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAG
 AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAAC
 CAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGC
 CGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACG
 CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACC
 15 GTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGAT
 GCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTC
 CGGGTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:76)

Example 18 - Production Of An Antibody From A Polypeptide.

20 The antibodies of the present invention can be prepared by a variety of
 methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells
 expressing a polypeptide of the present invention are administered to an animal to
 induce the production of sera containing polyclonal antibodies. In a preferred method,
 a preparation of the protein is prepared and purified to render it substantially free of
 25 natural contaminants. Such a preparation is then introduced into an animal in order to
 produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are
 monoclonal antibodies (or protein binding fragments thereof). Such monoclonal
 antibodies can be prepared using hybridoma technology. (Köhler et al., Nature
 30 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J.
 Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell
 Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve
 immunizing an animal (preferably a mouse) with polypeptide or, more preferably,
 with a polypeptide-expressing cell. Such cells may be cultured in any suitable tissue
 35 culture medium; however, it is preferable to culture cells in Earle's modified Eagle's
 medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees

- 5 C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line
10 (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

15 Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody that binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a
20 mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones that produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further
25 protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments).
30 Alternatively, protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies
35 described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214

- 5 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Moreover, in another preferred method, the antibodies directed against the polypeptides of the present invention may be produced in plants. Specific methods are disclosed in US Patent Nos. 5,959,177, and 6,080,560, which are hereby incorporated in their entirety herein. The methods not only describe methods of expressing antibodies, but also the means of assembling foreign multimeric proteins in plants (i.e., antibodies, etc.), and the subsequent secretion of such antibodies from the plant.

15

Example 19 - Regulation of Protein Expression Via Controlled Aggregation In The Endoplasmic Reticulum.

As described more particularly herein, proteins regulate diverse cellular processes in higher organisms, ranging from rapid metabolic changes to growth and differentiation. Increased production of specific proteins could be used to prevent certain diseases and/or disease states. Thus, the ability to modulate the expression of specific proteins in an organism would provide significant benefits.

Numerous methods have been developed to date for introducing foreign genes, either under the control of an inducible, constitutively active, or endogenous promoter, into organisms. Of particular interest are the inducible promoters (see, M. Gossen, et al., Proc. Natl. Acad. Sci. USA, 89:5547 (1992); Y. Wang, et al., Proc. Natl. Acad. Sci. USA, 91:8180 (1994), D. No., et al., Proc. Natl. Acad. Sci. USA, 93:3346 (1996); and V.M. Rivera, et al., Nature Med, 2:1028 (1996); in addition to additional examples disclosed elsewhere herein). In one example, the gene for erythropoietin (Epo) was transferred into mice and primates under the control of a small molecule inducer for expression (e.g., tetracycline or rapamycin) (see, D. Bohl, et al., Blood, 92:1512, (1998); K.G. Rendahl, et al., Nat. Biotech, 16:757, (1998); V.M. Rivera, et al., Proc. Natl. Acad. Sci. USA, 96:8657 (1999); and X.Ye et al., Science, 283:88 (1999). Although such systems enable efficient induction of the gene of interest in the organism upon addition of the inducing agent (i.e., tetracycline, rapamycin, etc.), the levels of expression tend to peak at 24 hours and trail off to

- 5 background levels after 4 to 14 days. Thus, controlled transient expression is virtually impossible using these systems, though such control would be desirable.

A new alternative method of controlling gene expression levels of a protein from a transgene (i.e., includes stable and transient transformants) has recently been elucidated (V.M. Rivera., et al., Science, 287:826-830, (2000)). This method does not
10 control gene expression at the level of the mRNA like the aforementioned systems. Rather, the system controls the level of protein in an active secreted form. In the absence of the inducing agent, the protein aggregates in the ER and is not secreted. However, addition of the inducing agent results in dis-aggregation of the protein and the subsequent secretion from the ER. Such a system affords low basal secretion,
15 rapid, high level secretion in the presence of the inducing agent, and rapid cessation of secretion upon removal of the inducing agent. In fact, protein secretion reached a maximum level within 30 minutes of induction, and a rapid cessation of secretion within 1 hour of removing the inducing agent. The method is also applicable for controlling the level of production for membrane proteins.

- 20 Detailed methods are presented in V.M. Rivera., et al., Science, 287:826-830, (2000)), briefly:

Fusion protein constructs are created using polynucleotide sequences of the present invention with one or more copies (preferably at least 2, 3, 4, or more) of a conditional aggregation domain (CAD) a domain that interacts with itself in a ligand-
25 reversible manner (i.e., in the presence of an inducing agent) using molecular biology methods known in the art and discussed elsewhere herein. The CAD domain may be the mutant domain isolated from the human FKBP12 (Phe³⁶ to Met) protein (as disclosed in V.M. Rivera., et al., Science, 287:826-830, (2000)), or alternatively other proteins having domains with similar ligand-reversible, self-aggregation properties.
30 As a principle of design the fusion protein vector would contain a furin cleavage sequence operably linked between the polynucleotides of the present invention and the CAD domains. Such a cleavage site would enable the proteolytic cleavage of the CAD domains from the polypeptide of the present invention subsequent to secretion from the ER and upon entry into the trans-Golgi (J.B. Denault, et al., FEBS Lett.,
35 379:113, (1996)). Alternatively, the skilled artisan would recognize that any proteolytic cleavage sequence could be substituted for the furin sequence provided the

5 substituted sequence is cleavable either endogenously (e.g., the furin sequence) or
exogenously (e.g., post secretion, post purification, post production, etc.). The
preferred sequence of each feature of the fusion protein construct, from the 5' to 3'
direction with each feature being operably linked to the other, would be a promoter,
signal sequence, "X" number of (CAD)_x domains, the furin sequence (or other
10 proteolytic sequence), and the coding sequence of the polypeptide of the present
invention. The artisan would appreciate that the promotor and signal sequence,
independent from the other, could be either the endogenous promotor or signal
sequence of a polypeptide of the present invention, or alternatively, could be a
heterologous signal sequence and promotor.

15 The specific methods described herein for controlling protein secretion levels
through controlled ER aggregation are not meant to be limiting and would be
generally applicable to any of the polynucleotides and polypeptides of the present
invention, including variants, homologues, orthologs, and fragments therein.

20 **Example 20 - Alteration Of Protein Glycosylation Sites to Enhance Characteristics Of Polypeptides Of The Invention.**

Many eukaryotic cell surface and proteins are post-translationally processed to
incorporate N-linked and O-linked carbohydrates (Kornfeld and Kornfeld (1985)
Annu. Rev. Biochem. 54:631-64; Rademacher et al., (1988) Annu. Rev. Biochem.
25 57:785-838). Protein glycosylation is thought to serve a variety of functions
including: augmentation of protein folding, inhibition of protein aggregation,
regulation of intracellular trafficking to organelles, increasing resistance to
proteolysis, modulation of protein antigenicity, and mediation of intercellular
adhesion (Fieldler and Simons (1995) Cell, 81:309-312; Helenius (1994) Mol. Biol.
30 Of the Cell 5:253-265; Olden et al., (1978) Cell, 13:461-473; Caton et al., (1982) Cell,
37:417-427; Alexander and Elder (1984), Science, 226:1328-1330; and Flack et al.,
(1994), J. Biol. Chem., 269:14015-14020). In higher organisms, the nature and
extent of glycosylation can markedly affect the circulating half-life and bio-
availability of proteins by mechanisms involving receptor mediated uptake and
35 clearance (Ashwell and Morrell, (1974), Adv. Enzymol., 41:99-128; Ashwell and
Harford (1982), Ann. Rev. Biochem., 51:531-54). Receptor systems have been

5 identified that are thought to play a major role in the clearance of serum proteins through recognition of various carbohydrate structures on the glycoproteins (Stockert (1995), *Physiol. Rev.*, 75:591-609; Kery et al., (1992), *Arch. Biochem. Biophys.*, 298:49-55). Thus, production strategies resulting in incomplete attachment of terminal sialic acid residues might provide a means of shortening the bioavailability and half-
10 life of glycoproteins. Conversely, expression strategies resulting in saturation of terminal sialic acid attachment sites might lengthen protein bioavailability and half-life.

In the development of recombinant glycoproteins for use as pharmaceutical products, for example, it has been speculated that the pharmacodynamics of
15 recombinant proteins can be modulated by the addition or deletion of glycosylation sites from a glycoproteins primary structure (Berman and Lasky (1985a) *Trends in Biotechnol.*, 3:51-53). However, studies have reported that the deletion of N-linked glycosylation sites often impairs intracellular transport and results in the intracellular accumulation of glycosylation site variants (Machamer and Rose (1988), *J. Biol*
20 *Chem.*, 263:5955-5960; Gallagher et al., (1992), *J. Virology.*, 66:7136-7145; Collier et al., (1993), *Biochem.*, 32:7818-7823; Claffey et al., (1995) *Biochemica et Biophysica Acta*, 1246:1-9; Dube et al., (1988), *J. Biol. Chem.*... 263:17516-17521). While glycosylation site variants of proteins can be expressed intracellularly, it has proved difficult to recover useful quantities from growth conditioned cell culture
25 medium.

Moreover, it is unclear to what extent a glycosylation site in one species will be recognized by another species glycosylation machinery. Due to the importance of glycosylation in protein metabolism, particularly the secretion and/or expression of the protein, whether a glycosylation signal is recognized may profoundly determine a
30 proteins ability to be expressed, either endogenously or recombinately, in another organism (i.e., expressing a human protein in E.coli, yeast, or viral organisms; or an E.coli, yeast, or viral protein in human, etc.). Thus, it may be desirable to add, delete, or modify a glycosylation site, and possibly add a glycosylation site of one species to a protein of another species to improve the proteins functional, bioprocess
35 purification, and/or structural characteristics (e.g., a polypeptide of the present invention).

5 A number of methods may be employed to identify the location of glycosylation sites within a protein. One preferred method is to run the translated protein sequence through the PROSITE computer program (Swiss Institute of Bioinformatics). Once identified, the sites could be systematically deleted, or impaired, at the level of the DNA using mutagenesis methodology known in the art and available to the skilled artisan, Preferably using PCR-directed mutagenesis (See
10 Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982)). Similarly, glycosylation sites could be added, or modified at the level of the DNA using similar methods, preferably PCR methods (See, Maniatis, supra). The results of modifying the glycosylation sites for a particular protein (e.g.,
15 solubility, secretion potential, activity, aggregation, proteolytic resistance, etc.) could then be analyzed using methods know in the art.

 The skilled artisan would acknowledge the existence of other computer algorithms capable of predicting the location of glycosylation sites within a protein. For example, the Motif computer program (Genetics Computer Group suite of
20 programs) provides this function, as well.

Example 21 - Method Of Enhancing The Biological Activity/Functional Characteristics Of Invention Through Molecular Evolution.

 Although many of the most biologically active proteins known are highly
25 effective for their specified function in an organism, they often possess characteristics that make them undesirable for transgenic, therapeutic, and/or industrial applications. Among these traits, a short physiological half-life is the most prominent problem, and is present either at the level of the protein, or the level of the proteins mRNA. The ability to extend the half-life, for example, would be particularly important for a
30 proteins use in gene therapy, transgenic animal production, the bioprocess production and purification of the protein, and use of the protein as a chemical modulator among others. Therefore, there is a need to identify novel variants of isolated proteins possessing characteristics which enhance their application as a therapeutic for treating diseases of animal origin, in addition to the proteins applicability to common
35 industrial and pharmaceutical applications.

5 Thus, one aspect of the present invention relates to the ability to enhance specific characteristics of invention through directed molecular evolution. Such an enhancement may, in a non-limiting example, benefit the inventions utility as an essential component in a kit, the inventions physical attributes such as its solubility, structure, or codon optimization, the inventions specific biological activity, including
10 any associated enzymatic activity, the proteins enzyme kinetics, the proteins K_i , K_{cat} , K_m , V_{max} , K_d , protein-protein activity, protein-DNA binding activity, antagonist/inhibitory activity (including direct or indirect interaction), agonist activity (including direct or indirect interaction), the proteins antigenicity (e.g., where it would be desirable to either increase or decrease the antigenic potential of the protein), the
15 immunogenicity of the protein, the ability of the protein to form dimers, trimers, or multimers with either itself or other proteins, the antigenic efficacy of the invention, including its subsequent use a preventative treatment for disease or disease states, or as an effector for targeting diseased genes. Moreover, the ability to enhance specific characteristics of a protein may also be applicable to changing the characterized
20 activity of an enzyme to an activity completely unrelated to its initially characterized activity. Other desirable enhancements of the invention would be specific to each individual protein, and would thus be well known in the art and contemplated by the present invention.

For example, an engineered phosphatase may be constitutively active.
25 Alternatively, an engineered phosphatase may be constitutively active in the absence of ligand binding. In yet another example, an engineered phosphatase may be capable of being activated with less than all of the regulatory factors and/or conditions typically required for phosphatase activation (e.g., ligand binding, phosphorylation, conformational changes, etc.). Alternatively, an engineered phosphatase may have
30 altered substrate specificity. Such phosphatases would be useful in screens to identify phosphatase modulators, among other uses described herein.

Directed evolution is comprised of several steps. The first step is to establish a library of variants for the gene or protein of interest. The most important step is to then select for those variants that entail the activity you wish to identify. The design
35 of the screen is essential since your screen should be selective enough to eliminate non-useful variants, but not so stringent as to eliminate all variants. The last step is

5 then to repeat the above steps using the best variant from the previous screen. Each successive cycle, can then be tailored as necessary, such as increasing the stringency of the screen, for example.

Over the years, there have been a number of methods developed to introduce mutations into macromolecules. Some of these methods include, random mutagenesis,
10 "error-prone" PCR, chemical mutagenesis, site-directed mutagenesis, and other methods well known in the art (for a comprehensive listing of current mutagenesis methods, see Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982)). Typically, such methods have been used, for example, as tools for identifying the core functional region(s) of a protein or the
15 function of specific domains of a protein (if a multi-domain protein). However, such methods have more recently been applied to the identification of macromolecule variants with specific or enhanced characteristics.

Random mutagenesis has been the most widely recognized method to date. Typically, this has been carried out either through the use of "error-prone" PCR (as
20 described in Moore, J., et al, *Nature Biotechnology* 14:458, (1996), or through the application of randomized synthetic oligonucleotides corresponding to specific regions of interest (as described by Derbyshire, K.M. et al, *Gene*, 46:145-152, (1986), and Hill, DE, et al, *Methods Enzymol.*, 55:559-568, (1987). Both approaches have limits to the level of mutagenesis that can be obtained. However, either approach
25 enables the investigator to effectively control the rate of mutagenesis. This is particularly important considering the fact that mutations beneficial to the activity of the enzyme are fairly rare. In fact, using too high a level of mutagenesis may counter or inhibit the desired benefit of a useful mutation.

While both of the aforementioned methods are effective for creating
30 randomized pools of macromolecule variants, a third method, termed "DNA Shuffling", or "sexual PCR" (WPC, Stemmer, *PNAS*, 91:10747, (1994)) has recently been elucidated. DNA shuffling has also been referred to as "directed molecular evolution", "exon-shuffling", "directed enzyme evolution", "in vitro evolution", and "artificial evolution". Such reference terms are known in the art and are encompassed
35 by the invention. This new, preferred, method apparently overcomes the limitations of

- 5 the previous methods in that it not only propagates positive traits, but simultaneously eliminates negative traits in the resulting progeny.

DNA shuffling accomplishes this task by combining the principal of in vitro recombination, along with the method of "error-prone" PCR. In effect, you begin with a randomly digested pool of small fragments of your gene, created by Dnase I
10 digestion, and then introduce said random fragments into an "error-prone" PCR assembly reaction. During the PCR reaction, the randomly sized DNA fragments not only hybridize to their cognate strand, but also may hybridize to other DNA fragments corresponding to different regions of the polynucleotide of interest – regions not typically accessible via hybridization of the entire polynucleotide. Moreover, since the
15 PCR assembly reaction utilizes "error-prone" PCR reaction conditions, random mutations are introduced during the DNA synthesis step of the PCR reaction for all of the fragments -further diversifying the potential hybridization sites during the annealing step of the reaction.

A variety of reaction conditions could be utilized to carry-out the DNA
20 shuffling reaction. However, specific reaction conditions for DNA shuffling are provided, for example, in PNAS, 91:10747, (1994). Briefly:

Prepare the DNA substrate to be subjected to the DNA shuffling reaction. Preparation may be in the form of simply purifying the DNA from contaminating cellular material, chemicals, buffers, oligonucleotide primers, deoxynucleotides,
25 RNAs, etc., and may entail the use of DNA purification kits as those provided by Qiagen, Inc., or by the Promega, Corp., for example.

Once the DNA substrate has been purified, it would be subjected to Dnase I digestion. About 2-4ug of the DNA substrate(s) would be digested with .0015 units of Dnase I (Sigma) per ul in 100ul of 50mM Tris-HCL, pH 7.4/1mM MgCl₂ for 10-20
30 min. at room temperature. The resulting fragments of 10-50bp could then be purified by running them through a 2% low-melting point agarose gel by electrophoresis onto DE81 ion-exchange paper (Whatmann) or could be purified using Microcon concentrators (Amicon) of the appropriate molecular weight cutoff, or could use oligonucleotide purification columns (Qiagen), in addition to other methods known in
35 the art. If using DE81 ion-exchange paper, the 10-50bp fragments could be eluted from said paper using 1M NaCl, followed by ethanol precipitation.

5 The resulting purified fragments would then be subjected to a PCR assembly reaction by re-suspension in a PCR mixture containing: 2mM of each dNTP, 2.2mM MgCl₂, 50 mM KCl, 10mM Tris•HCL, pH 9.0, and 0.1% Triton X-100, at a final fragment concentration of 10-30ng/ul. No primers are added at this point. *Taq* DNA polymerase (Promega) would be used at 2.5 units per 100ul of reaction mixture. A
10 PCR program of 94 C for 60s; 94 C for 30s, 50-55 C for 30s, and 72 C for 30s using 30-45 cycles, followed by 72 C for 5min using an MJ Research (Cambridge, MA) PTC-150 thermocycler. After the assembly reaction is completed, a 1:40 dilution of the resulting primerless product would then be introduced into a PCR mixture (using the same buffer mixture used for the assembly reaction) containing 0.8um of each
15 primer and subjecting this mixture to 15 cycles of PCR (using 94 C for 30s, 50 C for 30s, and 72 C for 30s). The referred primers would be primers corresponding to the nucleic acid sequences of the polynucleotide(s) utilized in the shuffling reaction. Said primers could consist of modified nucleic acid base pairs using methods known in the art and referred to else where herein, or could contain additional sequences (i.e., for
20 adding restriction sites, mutating specific base-pairs, etc.).

 The resulting shuffled, assembled, and amplified product can be purified using methods well known in the art (e.g., Qiagen PCR purification kits) and then subsequently cloned using appropriate restriction enzymes.

 Although a number of variations of DNA shuffling have been published to
25 date, such variations would be obvious to the skilled artisan and are encompassed by the invention. The DNA shuffling method can also be tailored to the desired level of mutagenesis using the methods described by Zhao, et al. (Nucl Acid Res., 25(6):1307-1308, (1997).

 As described above, once the randomized pool has been created, it can then be
30 subjected to a specific screen to identify the variant possessing the desired characteristic(s). Once the variant has been identified, DNA corresponding to the variant could then be used as the DNA substrate for initiating another round of DNA shuffling. This cycle of shuffling, selecting the optimized variant of interest, and then re-shuffling, can be repeated until the ultimate variant is obtained. Examples of model
35 screens applied to identify variants created using DNA shuffling technology may be found in the following publications: J. C., Moore, et al., J. Mol. Biol., 272:336-347,

- 5 (1997), F.R., Cross, et al., Mol. Cell. Biol., 18:2923-2931, (1998), and A. Cramer, et al., Nat. Biotech., 15:436-438, (1997).

DNA shuffling has several advantages. First, it makes use of beneficial mutations. When combined with screening, DNA shuffling allows the discovery of the best mutational combinations and does not assume that the best combination
10 contains all the mutations in a population. Secondly, recombination occurs simultaneously with point mutagenesis. An effect of forcing DNA polymerase to synthesize full-length genes from the small fragment DNA pool is a background mutagenesis rate. In combination with a stringent selection method, enzymatic activity has been evolved up to 16000 fold increase over the wild-type form of the
15 enzyme. In essence, the background mutagenesis yielded the genetic variability on which recombination acted to enhance the activity.

A third feature of recombination is that it can be used to remove deleterious mutations. As discussed above, during the process of the randomization, for every one beneficial mutation, there may be at least one or more neutral or inhibitory mutations.
20 Such mutations can be removed by including in the assembly reaction an excess of the wild-type random-size fragments, in addition to the random-size fragments of the selected mutant from the previous selection. During the next selection, some of the most active variants of the polynucleotide/polypeptide/enzyme, should have lost the inhibitory mutations.

25 Finally, recombination enables parallel processing. This represents a significant advantage since there are likely multiple characteristics that would make a protein more desirable (e.g. solubility, activity, etc.). Since it is increasingly difficult to screen for more than one desirable trait at a time, other methods of molecular evolution tend to be inhibitory. However, using recombination, it would be possible to
30 combine the randomized fragments of the best representative variants for the various traits, and then select for multiple properties at once.

DNA shuffling can also be applied to the polynucleotides and polypeptides of the present invention to decrease their immunogenicity in a specified host. For example, a particular variant of the present invention may be created and isolated
35 using DNA shuffling technology. Such a variant may have all of the desired characteristics, though may be highly immunogenic in a host due to its novel intrinsic

5 structure. Specifically, the desired characteristic may cause the polypeptide to have a non-native structure which could no longer be recognized as a "self" molecule, but rather as a "foreign", and thus activate a host immune response directed against the novel variant. Such a limitation can be overcome, for example, by including a copy of the gene sequence for a xenobiotic ortholog of the native protein in with the gene
10 sequence of the novel variant gene in one or more cycles of DNA shuffling. The molar ratio of the ortholog and novel variant DNAs could be varied accordingly. Ideally, the resulting hybrid variant identified would contain at least some of the coding sequence which enabled the xenobiotic protein to evade the host immune system, and additionally, the coding sequence of the original novel variant that
15 provided the desired characteristics.

Likewise, the invention encompasses the application of DNA shuffling technology to the evolution of polynucleotides and polypeptides of the invention, wherein one or more cycles of DNA shuffling include, in addition to the gene template DNA, oligonucleotides coding for known allelic sequences, optimized codon
20 sequences, known variant sequences, known polynucleotide polymorphism sequences, known ortholog sequences, known homologue sequences, additional homologous sequences, additional non-homologous sequences, sequences from another species, and any number and combination of the above.

In addition to the described methods above, there are a number of related
25 methods that may also be applicable, or desirable in certain cases. Representative among these are the methods discussed in PCT applications WO 98/31700, and WO 98/32845, which are hereby incorporated by reference. Furthermore, related methods can also be applied to the polynucleotide sequences of the present invention in order to evolve invention for creating ideal variants for use in gene therapy, protein
30 engineering, evolution of whole cells containing the variant, or in the evolution of entire enzyme pathways containing polynucleotides of the invention as described in PCT applications WO 98/13485, WO 98/13487, WO 98/27230, WO 98/31837, and Cramer, A., et al., Nat. Biotech., 15:436-438, (1997), respectively.

Additional methods of applying "DNA Shuffling" technology to the
35 polynucleotides and polypeptides of the present invention, including their proposed applications, may be found in US Patent No. 5,605,793; PCT Application No. WO

- 5 95/22625; PCT Application No. WO 97/20078; PCT Application No. WO 97/35966;
and PCT Application No. WO 98/42832; PCT Application No. WO 00/09727
specifically provides methods for applying DNA shuffling to the identification of
herbicide selective crops which could be applied to the polynucleotides and
polypeptides of the present invention; additionally, PCT Application No. WO
10 00/12680 provides methods and compositions for generating, modifying, adapting,
and optimizing polynucleotide sequences that confer detectable phenotypic properties
on plant species; each of the above are hereby incorporated in their entirety herein for
all purposes.

5

Example 22 - Method Of Determining Alterations In A Gene Corresponding To A Polynucleotide.

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal

5 fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

10

Example 23 - Method Of Detecting Abnormal Levels Of A Polypeptide In A Biological Sample.

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide
15 is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with
20 specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described elsewhere herein. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample
25 containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature.
30 The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard
35 curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).

- 5 Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 24 – Formulation.

The invention also provides methods of treatment and/or prevention diseases,
10 disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type
15 (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other
20 factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this
25 will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An
30 intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or
35 transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating

5 material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered
10 orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of
15 administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention may also be suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the
20 form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al.,
25 Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped
30 Therapeutics of the invention (see, generally, Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang
35 et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos.

5 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

10 In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

15 For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
20 For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the
25 carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances
30 that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum
35 albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or

- 5 arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic will typically be formulated in such vehicles at a
10 concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2
15 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized
20 formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or
25 more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in
30 conjunction with other therapeutic compounds.

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG,
35 and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the

5 invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to,
10 vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture,
15 separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate
20 administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics,
25 steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the
30 combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in
35 combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include,

5 but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6
10 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication
15 No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

20 In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR(
25 (zidovudine/AZT), VIDEX((didanosine/ddI), HIVID((zalcitabine/ddC), ZERIT((stavudine/d4T), EPIVIR((lamivudine/3TC), and COMBIVIR((zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE((nevirapine), RESCRIPTOR((delavirdine), and
30 SUSTIVA((efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN((indinavir), NORVIR((ritonavir), INVIRASE((saquinavir), and VIRACEPT((nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or
35 protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

5 In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE(, DAPSONE(, PENTAMIDINE(, ATOVAQUONE(, ISONIAZID(, RIFAMPIN(, 10 PYRAZINAMIDE(, ETHAMBUTOL(, RIFABUTIN(, CLARITHROMYCIN(, AZITHROMYCIN(, GANCICLOVIR(, FOSCARNET(, CIDOFOVIR(, FLUCONAZOLE(, ITRACONAZOLE(, KETOCONAZOLE(, ACYCLOVIR(, FAMCICOLVIR(, PYRIMETHAMINE(, LEUCOVORIN(, NEUPOGEN((filgrastim/G-CSF), and LEUKINE((sargramostim/GM-CSF). In a specific 15 embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE(, DAPSONE(, PENTAMIDINE(, and/or ATOVAQUONE(to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID(, 20 RIFAMPIN(, PYRAZINAMIDE(, and/or ETHAMBUTOL(to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN(, CLARITHROMYCIN(, and/or AZITHROMYCIN(to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* 25 infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR(, FOSCARNET(, and/or CIDOFOVIR(to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE(, ITRACONAZOLE(, and/or 30 KETOCONAZOLE(to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR(and/or FAMCICOLVIR(to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any 35 combination with PYRIMETHAMINE(and/or LEUCOVORIN(to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific

5 embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN(and/or NEUPOGEN(to prophylactically treat or prevent an opportunistic bacterial infection.

 In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with
10 the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

 In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-
15 lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

20 Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

25 In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE((OKT3), SANDIMMUNE(/NEORAL(/SANGDYA((cyclosporin), PROGRAF((tacrolimus), CELLCEPT((mycophenolate), Azathioprine,
30 glucocorticosteroids, and RAPAMUNE((sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

 In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations.
35 Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR(, IVEEGAM(,

- 5 SANDOGLOBULIN(, GAMMAGARD S/D(, and GAMIMUNE(. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

10 In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives,
15 pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

20 In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU,
25 methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl
30 estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepe); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and
35 etoposide).

5 In a specific embodiment, formulations of the present invention may further comprise antagonists of P-glycoprotein (also referred to as the multidrug resistance protein, or PGP), including antagonists of its encoding polynucleotides (e.g., antisense oligonucleotides, ribozymes, zinc-finger proteins, etc.). P-glycoprotein is well known for decreasing the efficacy of various drug administrations due to its ability to export
10 intracellular levels of absorbed drug to the cell exterior. While this activity has been particularly pronounced in cancer cells in response to the administration of chemotherapy regimens, a variety of other cell types and the administration of other drug classes have been noted (e.g., T-cells and anti-HIV drugs). In fact, certain mutations in the PGP gene significantly reduces PGP function, making it less able to
15 force drugs out of cells. People who have two versions of the mutated gene--one inherited from each parent--have more than four times less PGP than those with two normal versions of the gene. People may also have one normal gene and one mutated one. Certain ethnic populations have increased incidence of such PGP mutations. Among individuals from Ghana, Kenya, the Sudan, as well as African Americans,
20 frequency of the normal gene ranged from 73% to 84%. In contrast, the frequency was 34% to 59% among British whites, Portuguese, Southwest Asian, Chinese, Filipino and Saudi populations. As a result, certain ethnic populations may require increased administration of PGP antagonist in the formulation of the present invention to arrive at the an efficacious dose of the therapeutic (e.g., those from African
25 descent). Conversely, certain ethnic populations, particularly those having increased frequency of the mutated PGP (e.g., of Caucasian descent, or non-African descent) may require less pharmaceutical compositions in the formulation due to an effective increase in efficacy of such compositions as a result of the increased effective absorption (e.g., less PGP activity) of said composition.

30 Moreover, in another specific embodiment, formulations of the present invention may further comprise antagonists of OATP2 (also referred to as the multidrug resistance protein, or MRP2), including antagonists of its encoding polynucleotides (e.g., antisense oligonucleotides, ribozymes, zinc-finger proteins, etc.). The invention also further comprises any additional antagonists known to inhibit
35 proteins thought to be attributable to a multidrug resistant phenotype in proliferating cells.

5 In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab
10 and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In
15 another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may
20 be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as
25 disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as
30 disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in
35 International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832;

- 5 and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic
10 growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE((SARGRAMOSTIM() and NEUPOGEN((FILGRASTIM()).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth
15 Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example,
20 radiation therapy.

Example 25 - Method Of Treating Decreased Levels Of The Polypeptide.

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising
25 administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the
30 secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily
35 dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on

5 administration and formulation, are provided herein.

Example 26 - Method Of Treating Increased Levels Of The Polypeptide.

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising
10 administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of
15 decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation
20 of the antisense polynucleotide is provided herein.

Example 27 - Method Of Treatment Using Gene Therapy-Ex Vivo.

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a
25 subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed
30 to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge.
35 The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long

5 terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set
10 forth in Example 10 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is
15 maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue
20 culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

25 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the
30 media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is
35 produced.

The engineered fibroblasts are then transplanted onto the host, either alone or

- 5 after having been grown to confluence on cytodex 3 microcarrier beads.

Example 28 - Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides Of The Invention.

Another method of gene therapy according to the present invention involves
10 operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935
15 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous
20 polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends.
25 Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested
30 with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol
35 precipitation.

In this Example, the polynucleotide constructs are administered as naked

5 polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

10 Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

15 Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 20 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3X10⁶ cells/ml. Electroporation should be performed immediately following resuspension.

25 Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one 30 non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The 35 resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

5 Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately 1.5.X10⁶ cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at
10 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

 Electroporated cells are maintained at room temperature for approximately 5
15 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

20 The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

25 **Example 29 - Method Of Treatment Using Gene Therapy - In Vivo.**

 Another aspect of the present invention is using in vivo gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide.
30 The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al.,
35 Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation

5 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or
10 aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present
15 invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are
20 preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies
25 have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder,
30 stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It
35 is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred

5 for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle
10 cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as
15 the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of
20 tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle in vivo is
25 determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

30 Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the
35 knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

5 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 μ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in
10 muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

15

Example 30 - Transgenic Animals.

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g.,
20 baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e.,
25 polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus
30 mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science
35 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated

5 gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into
10 enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their
15 cells, i.e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory
20 sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the
25 endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science
30 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may
35 be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA

5 expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR(RT-PCR).. Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies
10 specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate
15 lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to
20 produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of
25 polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

Example 31 - Knock-Out Animals.

30 Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E.g., see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide
35 of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or

5 regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in
10 inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, supra). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly
15 administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are
20 administered to a patient in vivo. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the
25 invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.
30 The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or
35 intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the

5 body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

10 When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does
15 not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds
20 effective in ameliorating such diseases, disorders, and/or conditions.

Example 32 - Production Of An Antibody.

a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of
25 methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing human phosphatase are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of human phosphatase protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to
30 produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for protein human phosphatase are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681.
35 (1981)). In general, an animal (preferably a mouse) is immunized with human phosphatase polypeptide or, more preferably, with a secreted human phosphatase

5 polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

10 The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as
15 described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the human phosphatase polypeptide.

Alternatively, additional antibodies capable of binding to human phosphatase polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies.
20 Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody that binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones
25 which produce an antibody whose ability to bind to the human phosphatase protein-specific antibody can be blocked by human phosphatase. Such antibodies comprise anti-idiotypic antibodies to the human phosphatase protein-specific antibody and are used to immunize an animal to induce formation of further human phosphatase protein-specific antibodies.

30 For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214
35 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO

- 5 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

b) Isolation Of Antibody Fragments Directed

Against human phosphatase From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a
10 library of antibody fragments which contain reactivities against human phosphatase to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage
15 displaying antibody fragments, approximately 109 E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10⁸ TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture
20 incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

25 M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated
30 for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al.,
35 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10¹³ transducing units/ml

5 (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10¹³ TU of phage is applied to the tube and incubated for 30
10 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to
15 infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-
20 washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates
25 coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal
30 transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 33 - Assays Detecting Stimulation Or Inhibition Of B Cell Proliferation And Differentiation.

35 Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may

5 impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak
10 effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective
15 ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays
20 designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the
25 polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as
30 IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

35 Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10⁵ B-cells suspended in culture medium (RPMI 1640

- 5 containing 10% FBS, 5 X 10⁻⁵M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10⁻⁵ dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.
- 10 In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the
- 15 results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes
- 20 to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of

25 ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

One skilled in the art could easily modify the exemplified studies to test the

30 activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 34 - T Cell Proliferation Assay.

A CD3-induced proliferation assay is performed on PBMCs and is measured

35 by the uptake of 3H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 (l/well of mAb to CD3 (HIT3a, Pharmingen) or isotype-

5 matched control mAb (B33.1) overnight at 4 degrees C (1 g/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5 x 10⁴/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of polypeptides of the invention (total volume 200
10 ul). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100 μ l of supernatant is removed and stored -20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 μ l of medium containing 0.5 uCi of 3H-thymidine and cultured at 37 degrees C for 18-24 hr. Wells
15 are harvested and incorporation of 3H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.

20 One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

Example 35 - Effect Of Polypeptides Of The Invention On The Expression Of MHC Class II, Costimulatory And Adhesion Molecules And Cell Differentiation Of Monocytes And Monocyte-Derived Human Dendritic Cells.

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- α , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC(RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells (10⁶/ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit(e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc

5 receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

10 FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the
15 labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or
20 activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal
25 elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA
30 fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10^6 /ml in PBS containing PI at a final
35 concentration of 5 (g/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA

5 fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of 5×10^5 cells/ml
10 with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then
15 performed using a commercially available ELISA kit(e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at 2×10^5 cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine
20 and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the
25 stimulant (200 nM PMA). The plates are incubated at 37(C for 2 hours and the reaction is stopped by adding 20 μ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H₂O₂ produced by the macrophages, a standard curve of a H₂O₂ solution of known molarity is performed for each experiment.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or
30 antagonists of polynucleotides or polypeptides of the invention.

Example 36 - Biological Effects of human phosphatase Polypeptides of the Invention.

Astrocyte and Neuronal Assays.

35 Recombinant polypeptides of the invention, expressed in Escherichia coli and purified as described above, can be tested for activity in promoting the survival,

5 neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A
10 thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons in vitro have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor
15 promotes survival of dissociated hippocampal neurons and enhances neurite extension." Proc. Natl. Acad. Sci. USA 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are
20 expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

25 Fibroblast and endothelial cell assays.

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at
30 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by
35 reading in a CytoFluor fluorescence reader. For the PGE2 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a

5 medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1(for 24 hours. The supernatants are collected and assayed for PGE2 by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays; the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are
10 incubated with FGF-2 or with or without polypeptides of the invention IL-1(for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess
15 effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency
20 of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP+) and
25 released. Subsequently, MPP+ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP+ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

30 It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and
35 Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated

5 to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival in vitro and it can also be tested in vivo for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined in vitro in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by
10 dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days in vitro and are processed
15 for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14,
20 a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving in vitro. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be
25 involved in Parkinson's Disease.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

30 **Example 37 - The Effect Of The human phosphatase Polypeptides Of The Invention On The Growth Of Vascular Endothelial Cells.**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at 2-5x10⁴ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements
35 (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ

- 5 ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

- 10 One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 38 - Stimulatory Effect Of Polypeptides Of The Invention On The Proliferation Of Vascular Endothelial Cells.

- For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF165 or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak et al. In Vitro Cell. Dev. Biol. 30A:512-518 (1994).

- 25 One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 39 - Inhibition Of PDGF-Induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect.

- HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with

5 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted
10 for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J.
15 Biol. Chem... 6:271(36):21985-21992 (1996).

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

20 **Example 40 - Stimulation Of Endothelial Migration.**

This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J.
25 Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 ul of the final dilution is placed in the
30 lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber, 2.5×10^5 cells suspended in 50 ul M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a
35 humidified chamber with 5% CO₂ to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated

5 cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.


One skilled in the art could easily modify the exemplified studies to test the
10 activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 41 - Stimulation Of Nitric Oxide Production By Endothelial Cells.

Nitric oxide released by the vascular endothelium is believed to be a mediator
15 of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various
20 levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-
25 specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of
30 KNO_2 (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and H_2SO_4 . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-
35 Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is

- 5 inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per 1×10^6 endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak et al.
- 10 Biochem. and Biophys. Res. Comm. 217:96-105 (1995).

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

15 **Example 42 - Effect Of human phosphatase Polypeptides Of The Invention On Cord Formation In Angiogenesis.**

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured in vitro.

- 20 CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the in vitro angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 μ l/well) for 30 min. at 37°C.
- 25 CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 μ g Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the
- 30 Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

- One skilled in the art could easily modify the exemplified studies to test the
- 35 activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

Example 43 - Angiogenic Effect On Chick Chorioallantoic Membrane.

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in
10 CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

15 On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-
20 drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

25 One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 44 - Angiogenesis Assay Using A Matrigel Implant In Mouse.

30 In vivo angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for
35 the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

5 When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical
10 dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the
15 presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

 One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

20

Example 45 - Rescue Of Ischemia In Rabbit Lower Limb Model.

 To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita et al., Am J. Pathol
25 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita et al. Am J. Pathol 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development
30 of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen et al. Hum Gene Ther. 4:749-758 (1993); Leclerc et al. J. Clin.
35 Invest. 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is

- 5 delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated
10 condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of
15 collateral capillaries determined in light microscopic sections taken from hindlimbs.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

20 **Example 46 - Effect Of Polypeptides Of The Invention On Vasodilation.**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14
25 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as $p < 0.05$ vs. the response to buffer alone.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or
30 antagonists of polynucleotides or polypeptides of the invention.

Example 47 - Rat Ischemic Skin Flap Model.

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction.
35 Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

5 The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

10 The experimental protocol includes:

a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).

b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).

15 c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.

d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

20 One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 48 - Peripheral Arterial Disease Model.

25 Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.

30 b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.

c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

35

- 5 One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 49 - Ischemic Myocardial Disease Model.

- 10 A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

- a) The heart is exposed through a left-side thoracotomy in the rat.
15 Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

- 20 c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

25

Example 50 - Rat Corneal Wound Healing Model.

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the
30 stromal layer.

b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.

c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).

- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention,
35 within the pocket.

e) Treatment with a polypeptide of the invention can also be applied

- 5 topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

10

Example 51 - Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models.

A. Diabetic db+/db+ Mouse Model.

- To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. et al., J. Surg. Res. 52:389 (1992); Greenhalgh, D.G. et al., Am. J. Pathol. 136:1235 (1990)).
- 15
20

- The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman et al. Proc. Natl. Acad. Sci. USA 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel et al., J. Immunol. 120:1375 (1978); Debray-Sachs, M. et al., Clin. Exp. Immunol. 51(1):1-7 (1983); Leiter et al., Am. J. of Pathol. 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. et al., Exp. Neurol. 83(2):221-232 (1984); Robertson et al., Diabetes 29(1):60-67 (1980); Giacomelli et al., Lab Invest. 40(4):460-473 (1979); Coleman, D.L., Diabetes 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel et al., J. Immunol. 120:1375-1377 (1978)).
- 25
30
35

5 The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, et al., Am. J. of Pathol. 136:1235-1246 (1990)).

 Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The
10 animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Bristol-Myers Squibb Company's Institutional Animal Care and Use Committee and the Guidelines for the Care and
15 Use of Laboratory Animals.

 Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., J. Exp. Med. 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized
20 water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the
25 experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

 Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily
30 measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

 A polypeptide of the invention is administered using at a range different doses,
35 from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

5 Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

 Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are
10 evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

 Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the
15 dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

 Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-
20 sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. et al., Am.
25 J. Pathol. 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

 Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control.
30 Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

 Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain
35 tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG.

- 5 Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

10 B. Steroid Impaired Rat Model

The inhibition of wound healing by steroids has been well documented in various in vitro and in vivo systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet al., J. Immunol. 115: 476-481 (1975); Werb et al., J. Exp. Med. 147:1684-
15 1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert et al., An. Intern. Med. 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck et al., Growth Factors. 5: 295-304 (1991); Haynes et al., J. Clin. Invest. 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes et al., J. Clin. Invest. 61: 703-
20 797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck et al., Growth Factors. 5: 295-304 (1991); Haynes et al., J. Clin. Invest. 61: 703-797 (1978); Wahl, "Glucocorticoids and wound
25 healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce et al., Proc. Natl. Acad. Sci. USA 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full
30 thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is
35 impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and

5 received food and water ad libitum. All manipulations are performed using aseptic techniques. This study would be conducted according to the rules and guidelines of Bristol-Myers Squibb Corporations Guidelines for the Care and Use of Laboratory Animals.

10 The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment.

15 Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

25 The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

35 Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by

- 5 establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

- Specimens are fixed in 10% buffered formalin and paraffin embedded blocks
10 are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens
15 micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

- One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or
20 antagonists of polynucleotides or polypeptides of the invention.

Example 52 - Lymphedema Animal Model.

- The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of
25 the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4
30 weeks.

- Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing.
35 Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal

- 5 paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats
10 are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2
15 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ
20 Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which
25 typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control
30 and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are
35 averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized

5 with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is
10 dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca^{2+} comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for
15 tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel,
20 dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or
25 antagonists of polynucleotides or polypeptides of the invention.

Example 53 - Suppression Of TNF Alpha-Induced Adhesion Molecule Expression By A Polypeptide Of The Invention.

The recruitment of lymphocytes to areas of inflammation and angiogenesis
30 involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on
35 endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local

5 vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF- α), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide
10 variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- α induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- α treated ECs when co-stimulated with a member of the FGF
15 family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂.
20 HUVECs are seeded in 96-well plates at concentrations of 1×10^4 cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the
25 cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 μ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μ l volumes). Plates are incubated at
30 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca⁺⁺ and Mg⁺⁺) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with
35 PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 μ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-

5 VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 µg/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with
10 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 (100) > 10-0.5 > 10-1 > 10-1.5. 5 µl of each dilution is added to triplicate wells and the resulting AP
15 content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the
20 concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

Example 54 – Method of Creating N- and C-terminal Deletion Mutants Corresponding to the Human Phosphatase Polypeptides of the Present Invention.

25 As described elsewhere herein, the present invention encompasses the creation of N- and C-terminal deletion mutants, in addition to any combination of N- and C-terminal deletions thereof, corresponding to the human phosphatase polypeptides of the present invention. A number of methods are available to one skilled in the art for creating such mutants. Such methods may include a combination of PCR
30 amplification and gene cloning methodology. Although one of skill in the art of molecular biology, through the use of the teachings provided or referenced herein, and/or otherwise known in the art as standard methods, could readily create each deletion mutant of the present invention, exemplary methods are described below using specific BMY_HPP1, BMY_HPP2, BMY_HPP5 and human RET31 deletions
35 as examples.

5 Briefly, using the isolated cDNA clone encoding the full-length human
 BMY_HPP1, BMY_HPP2, BMY_HPP5 or RET31 phosphatase polypeptide sequence
 (as described elsewhere herein, for example), appropriate primers of about 15-25
 nucleotides derived from the desired 5' and 3' positions of SEQ ID NO:41, SEQ ID
 NO:108, SEQ ID NO:149, or SEQ ID NO:151 may be designed to PCR amplify, and
 10 subsequently clone, the intended N- and/or C-terminal deletion mutant. Such primers
 could comprise, for example, an initiation and stop codon for the 5' and 3' primer,
 respectively. Such primers may also comprise restriction sites to facilitate cloning of
 the deletion mutant post amplification. Moreover, the primers may comprise
 additional sequences, such as, for example, flag-tag sequences, kozac sequences, or
 15 other sequences discussed and/or referenced herein.

For example, in the case of the N9 to L606 BMY_HPP1 N-terminal deletion
 mutant, the following primers could be used to amplify a cDNA fragment
 corresponding to this deletion mutant:

5' Primer	5'-GCAGCA <u>GCGGCCGC</u> AATTTCGGATGGAAGGATTATGGTG -3' (SEQ ID NO:167) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> GAGGCCAGGCTTAGGGCCATC -3' (SEQ ID NO:168) <i>Sall</i>

20 For example, in the case of the M1 to E500 BMY_HPP1 C-terminal deletion
 mutant, the following primers could be used to amplify a cDNA fragment
 corresponding to this deletion mutant:

5' Primer	5'- GCAGCA <u>GCGGCCGC</u> ATGGAGGCTGGCATTACTTCTAC -3' (SEQ ID NO:169) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> CACCCAAGACCACATCAAGCTGC -3' (SEQ ID NO:170) <i>Sall</i>

25 For example, in the case of the L31 to K150 BMY_HPP2 N-terminal deletion
 mutant, the following primers could be used to amplify a cDNA fragment
 corresponding to this deletion mutant:

5

5' Primer	5'-GCAGCA <u>GCGGCCGC</u> CTGTTGGACCTGGGCGTGCGGCACC -3' (SEQ ID NO:171) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> TTTCGTTCTGCTGGTAGAACTGGAAG -3' (SEQ ID NO:172) <i>Sall</i>

For example, in the case of the M1 to V111 BMY_HPP2 C-terminal deletion mutant, the following primers could be used to amplify a cDNA fragment corresponding to this deletion mutant:

5' Primer	5'- GCAGCA <u>GCGGCCGC</u> ATGGGCGTGCAGCCCCCAACTTC -3' (SEQ ID NO:173) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> CACCAGGTAACAGGCCAGCATGGTG -3' (SEQ ID NO:174) <i>Sall</i>

For example, in the case of the I256 to S665 BMY_HPP5 N-terminal deletion mutant, the following primers could be used to amplify a cDNA fragment corresponding to this deletion mutant:

5' Primer	5'-GCAGCA <u>GCGGCCGC</u> ATCGCCTACATCATGAAGAGGATGG -3' (SEQ ID NO:104) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> GGAGACCTCAATGATTCCATGCTG -3' (SEQ ID NO:105) <i>Sall</i>

For example, in the case of the M1 to Q367 BMY_HPP5 C-terminal deletion mutant, the following primers could be used to amplify a cDNA fragment corresponding to this deletion mutant:

5' Primer	5'- GCAGCA <u>GCGGCCGC</u> ATGGCCCATGAGATGATTGGAATC -3' (SEQ ID NO:106) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> CTGCACGCTGGGCACGCTGGGCACG -3' (SEQ ID NO:107) <i>Sall</i>

- 5 For example, in the case of the I157 to S665 RET31 N-terminal deletion mutant, the following primers could be used to amplify a cDNA fragment corresponding to this deletion mutant:

5' Primer	5'-GCAGCA <u>GCGGCCGC</u> ATTGGGCCAACCCGAATTCTTCCC -3' (SEQ ID NO:136) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> GGAGACCTCAATGATTTCATGCTG -3' (SEQ ID NO:137) <i>SalI</i>

- 10 For example, in the case of the M1 to K297 RET31 C-terminal deletion mutant, the following primers could be used to amplify a cDNA fragment corresponding to this deletion mutant:

5' Primer	5'- GCAGCA <u>GCGGCCGC</u> ATGGCCCATGAGATGATTGGAAGTC -3' (SEQ ID NO:138) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> CTTCTTCTCATAGTCCAGGAGTTGG -3' (SEQ ID NO:139) <i>SalI</i>

- 15 For example, in the case of the I157 to S660 mRET31 N-terminal deletion mutant, the following primers could be used to amplify a cDNA fragment corresponding to this deletion mutant:

5' Primer	5'-GCAGCA <u>GCGGCCGC</u> ATTGGGCCAACTCGAATTCTTCCC -3' (SEQ ID NO:140) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> AGAGACCTCGATGATCTCCATGCTG -3' (SEQ ID NO:141) <i>SalI</i>

- 20 For example, in the case of the M1 to T297 mRET31 C-terminal deletion mutant, the following primers could be used to amplify a cDNA fragment corresponding to this deletion mutant:

5

5' Primer	5'- GCAGCA <u>GCGGCCGC</u> ATGGCCCATGAGATGATTGGAAGTC -3' (SEQ ID NO:142) <i>NotI</i>
3' Primer	5'- GCAGCA <u>GTCGAC</u> CGTCTTCTCATAGTCCATGAGTTGG -3' (SEQ ID NO:143) <i>SalI</i>

Representative PCR amplification conditions are provided below, although the skilled artisan would appreciate that other conditions may be required for efficient amplification. A 100 ul PCR reaction mixture may be prepared using 10ng of the template DNA (cDNA clone of Human phosphatase polypeptides), 200 uM 4dNTPs, 1uM primers, 0.25U Taq DNA polymerase (PE), and standard Taq DNA polymerase buffer. Typical PCR cycling condition are as follows:

20-25 cycles: 45 sec, 93 degrees
2 min, 50 degrees
2 min, 72 degrees
1 cycle: 10 min, 72 degrees

After the final extension step of PCR, 5U Klenow Fragment may be added and incubated for 15 min at 30 degrees.

Upon digestion of the fragment with the NotI and SalI restriction enzymes, the fragment could be cloned into an appropriate expression and/or cloning vector which has been similarly digested (e.g., pSport1, among others). The skilled artisan would appreciate that other plasmids could be equally substituted, and may be desirable in certain circumstances. The digested fragment and vector are then ligated using a DNA ligase, and then used to transform competent E.coli cells using methods provided herein and/or otherwise known in the art.

The 5' primer sequence for amplifying any additional N-terminal deletion mutants may be determined by reference to the following formula:

$(S+(X * 3))$ to $((S+(X * 3))+25)$, wherein 'S' is equal to the nucleotide position of the initiating start codon of the human BMY_HPP1, BMY_HPP2,

5 BMY_HPP5 or RET31 phosphatase gene (SEQ ID NO:41, SEQ ID NO:149, SEQ ID NO:151, or SEQ ID NO:108, respectively), and 'X' is equal to the most N-terminal amino acid of the intended N-terminal deletion mutant. The first term will provide the start 5' nucleotide position of the 5' primer, while the second term will provide the end 3' nucleotide position of the 5' primer corresponding to sense strand SEQ ID
 10 NO:41, SEQ ID NO:149, SEQ ID NO:151, or SEQ ID NO:108, respectively. Once the corresponding nucleotide positions of the primer are determined, the final nucleotide sequence may be created by the addition of applicable restriction site sequences to the 5' end of the sequence, for example. As referenced herein, the addition of other sequences to the 5' primer may be desired in certain circumstances
 15 (e.g., kozac sequences, etc.).

The 3' primer sequence for amplifying any additional N-terminal deletion mutants may be determined by reference to the following formula:

(S+(X * 3)) to ((S+(X * 3))-25), wherein 'S' is equal to the nucleotide position of the initiating start codon of the human BMY_HPP1, BMY_HPP2, BMY_HPP5 or
 20 RET31 phosphatase genes (SEQ ID NO:41, SEQ ID NO:149, SEQ ID NO:151, or SEQ ID NO:108, respectively), and 'X' is equal to the most C-terminal amino acid of the intended N-terminal deletion mutant. The first term will provide the start 5' nucleotide position of the 3' primer, while the second term will provide the end 3' nucleotide position of the 3' primer corresponding to the anti-sense strand of SEQ
 25 SEQ ID NO:41, SEQ ID NO:149, SEQ ID NO:151, or SEQ ID NO:108, respectively. Once the corresponding nucleotide positions of the primer are determined, the final nucleotide sequence may be created by the addition of applicable restriction site sequences to the 5' end of the sequence, for example. As referenced herein, the addition of other sequences to the 3' primer may be desired in certain circumstances
 30 (e.g., stop codon sequences, etc.). The skilled artisan would appreciate that modifications of the above nucleotide positions may be necessary for optimizing PCR amplification.

The same general formulas provided above may be used in identifying the 5' and 3' primer sequences for amplifying any C-terminal deletion mutant of the present
 35 invention. Moreover, the same general formulas provided above may be used in identifying the 5' and 3' primer sequences for amplifying any combination of N-

5 terminal and C-terminal deletion mutant of the present invention. The skilled artisan would appreciate that modifications of the above nucleotide positions may be necessary for optimizing PCR amplification.

As mentioned above, the same methodology described for BMY_HPP1, BMY_HPP2, BMY_HPP5 or RET31 N- and C-terminal deletion mutants could be
10 applied to creating N- and C-terminal deletion mutants corresponding to HPP_BMY1, HPP_BMY2, HPP_BMY3, HPP_BMY4, HPP_BMY5, RET31, and/or mRET31 as would be appreciated by the skilled artisan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or
15 antagonists of polynucleotides or polypeptides of the invention.

Example 55 – Method of Mutating The Human Phosphatases Of The Present Invention Using Site Directed/Site-Specific Mutagenesis.

In vitro site-directed mutagenesis is an invaluable technique for studying
20 protein structure-function relationships and gene expression, for example, as well as for vector modification. Approaches utilizing single stranded DNA (ssDNA) as the template have been reported (e.g., T.A. Kunkel et al., 1985, *Proc. Natl. Acad. Sci. USA*), 82:488-492; M.A. Vandeyar et al., 1988, *Gene*, 65(1):129-133; M. Sugimoto et al., 1989, *Anal. Biochem.*, 179(2):309-311; and J.W. Taylor et al., 1985, *Nuc. Acids.*
25 *Res.*, 13(24):8765-8785).

The use of PCR in site-directed mutagenesis accomplishes strand separation by using a denaturing step to separate the complementary strands and to allow efficient polymerization of the PCR primers. PCR site-directed mutagenesis methods thus permit site specific mutations to be incorporated in virtually any double stranded
30 plasmid, thus eliminating the need for re-subcloning into M13-based bacteriophage vectors or single-stranded rescue. (M.P. Weiner et al., 1995, *Molecular Biology: Current Innovations and Future Trends*, Eds. A.M. Griffin and H.G. Griffin, Horizon Scientific Press, Norfolk, UK; and C. Papworth et al., 1996, *Strategies*, 9(3):3-4).

A protocol for performing site-directed mutagenesis, particularly employing
35 the QuikChange™ site-directed mutagenesis kit (Stratagene, La Jolla, CA; U.S. Patent Nos. 5,789,166 and 5,923,419) is provided for making point mutations, to switch or

- 5 substitute amino acids, and to delete or insert single or multiple amino acids in the RATL1d6 amino acid sequence of this invention.

Primer Design

For primer design using this protocol, the mutagenic oligonucleotide primers are designed individually according to the desired mutation. The following
10 considerations should be made for designing mutagenic primers: 1) Both of the mutagenic primers must contain the desired mutation and anneal to the same sequence on opposite strands of the plasmid; 2) Primers should be between 25 and 45 bases in length, and the melting temperature (T_m) of the primers should be greater than, or equal to, 78°C. The following formula is commonly used for estimating the T_m of
15 primers: $T = 81.5 + 0.41 (\%GC) - 675/N - \%mismatch$. For calculating T_m , N is the primer length in bases; and values for %GC and % mismatch are whole numbers. For calculating T_m for primers intended to introduce insertions or deletions, a modified version of the above formula is employed: $T = 81.5 + 0.41 (\%GC) - 675/N$, where N does not include the bases which are being inserted or deleted; 3) The desired
20 mutation (deletion or insertion) should be in the middle of the primer with approximately 10-15 bases of correct sequence on both sides; 4) The primers optimally should have a minimum GC content of 40%, and should terminate in one or more C or G bases; 5) Primers need not be 5'-phosphorylated, but must be purified either by fast polynucleotide liquid chromatography (FPLC) or by polyacrylamide gel
25 electrophoresis (PAGE). Failure to purify the primers results in a significant decrease in mutation efficiency; and 6) It is important that primer concentration is in excess. It is suggested to vary the amount of template while keeping the concentration of the primers constantly in excess (QuikChange™ Site-Directed Mutagenesis Kit, Stratagene, La Jolla, CA).

Protocol for Setting Up the Reactions

Using the above-described primer design, two complimentary oligonucleotides containing the desired mutation, flanked by unmodified nucleic acid sequence, are synthesized. The resulting oligonucleotide primers are purified.

5 A control reaction is prepared using 5 μ l 10x reaction buffer (100mM KCl; 100mM (NH₄)₂SO₄; 200mM Tris-HCl, pH 8.8; 20mM MgSO₄; 1% Triton® X-100; 1 mg/ml nuclease-free bovine serum albumin, BSA); 2 μ l (10ng) of pWhitescript™, 4.5-kb control plasmid (5 ng/ μ l); 1.25 μ l (125 ng) of oligonucleotide control primer #1 (34-mer, 100 ng/ μ l); 1.25 μ l (125 ng) of oligonucleotide control primer #2 (34-mer, 100 ng/ μ l); 1 μ l of dNTP mix; double distilled H₂O; to a final volume of 50 μ l. Thereafter, 1 μ l of DNA polymerase (*PfuTurbo*® DNA Polymerase, Stratagene), (2.5U/ μ l) is added. *PfuTurbo*® DNA Polymerase is stated to have 6-fold higher fidelity in DNA synthesis than does *Taq* polymerase. To maximize temperature cycling performance, use of thin-walled test tubes is suggested to ensure optimum
15 contact with the heating blocks of the temperature cyclers.

The sample reaction is prepared by combining 5 μ l of 10x reaction buffer; x μ l (5-50 ng) of dsDNA template; x μ l (125 ng) of oligonucleotide primer #1; x μ l (5-50 ng) of dsDNA template; x μ l (125 ng) of oligonucleotide primer #2; 1 μ l of dNTP mix; and ddH₂O to a final volume of 50 μ l. Thereafter, 1 μ l of DNA polymerase (*PfuTurbo* DNA Polymerase, Stratagene), (2.5U/ μ l) is added.
20

It is suggested that if the thermal cyclers does not have a hot-top assembly, each reaction should be overlaid with approximately 30 μ l of mineral oil.

Cycling the Reactions

Each reaction is cycled using the following cycling parameters:

25	<u>Segment</u>	<u>Cycles</u>	<u>Temperature</u>	<u>Time</u>
	1	1	95°C	30 seconds
	2	12-18	95°C	30 seconds
			55°C	1 minute
			68°C	2 minutes/kb of
30				plasmid length

For the control reaction, a 12-minute extension time is used and the reaction is run for 12 cycles. Segment 2 of the above cycling parameters is adjusted in accordance with

- 5 the type of mutation desired. For example, for point mutations, 12 cycles are used; for single amino acid changes, 16 cycles are used; and for multiple amino acid deletions or insertions, 18 cycles are used. Following the temperature cycling, the reaction is placed on ice for 2 minutes to cool the reaction to $\leq 37^{\circ}\text{C}$.

Digesting the Products and Transforming Competent Cells

- 10 One μl of the *DpnI* restriction enzyme (10U/ μl) is added directly (below mineral oil overlay) to each amplification reaction using a small, pointed pipette tip. The reaction mixture is gently and thoroughly mixed by pipetting the solution up and down several times. The reaction mixture is then centrifuged for 1 minute in a microcentrifuge. Immediately thereafter, each reaction is incubated at 37°C for 1 hour
15 to digest the parental (i.e., the non-mutated) supercoiled dsDNA.

- Competent cells (i.e., XL1-Blue supercompetent cells, Stratagene) are thawed gently on ice. For each control and sample reaction to be transformed, 50 μl of the supercompetent cells are aliquotted to a prechilled test tube (Falcon 2059 polypropylene). Next, 1 μl of the *DpnI*-digested DNA is transferred from the control
20 and the sample reactions to separate aliquots of the supercompetent cells. The transformation reactions are gently swirled to mix and incubated for 30 minutes on ice. Thereafter, the transformation reactions are heat-pulsed for 45 seconds at 42°C for 2 minutes.

- 0.5 ml of NZY+ broth, preheated to 42°C is added to the transformation
25 reactions which are then incubated at 37°C for 1 hour with shaking at 225-250 rpm. An aliquot of each transformation reaction is plated on agar plates containing the appropriate antibiotic for the vector. For the mutagenesis and transformation controls, cells are spread on LB-ampicillin agar plates containing 80 $\mu\text{g}/\text{ml}$ of X-gal and 20mM MIPTG. Transformation plates are incubated for >16 hours at 37°C .

30

Example 56 - Complementary Polynucleotides Of The BMY_HPP2 Phosphatase Of The Present Invention.

Antisense molecules or nucleic acid sequences complementary to the BMY_HPP2 protein-encoding sequence, or any part thereof, is used to decrease or to

5 inhibit the expression of naturally occurring BMY_HPP2. Although the use of antisense or complementary oligonucleotides comprising about 15 to 35 base-pairs is described, essentially the same procedure is used with smaller or larger nucleic acid sequence fragments. An oligonucleotide based on the coding sequence of BMY_HPP2 protein, as shown in Figure 21, or as depicted in SEQ ID NO:151, for example, is used to inhibit expression of naturally occurring BMY_HPP2. The complementary oligonucleotide is typically designed from the most unique 5' sequence and is used either to inhibit transcription by preventing promoter binding to the coding sequence, or to inhibit translation by preventing the ribosome from binding to the BMY_HPP2 protein-encoding transcript. However, other regions may also be targeted.

Using an appropriate portion of the signal and/or 5' sequence of SEQ ID NO:151, an effective antisense oligonucleotide includes any of about 15-35 nucleotides spanning the region which translates into the signal or 5' coding sequence, among other regions, of the polypeptide as shown in Figure 21 (SEQ ID NO:152). Appropriate oligonucleotides are designed using OLIGO 4.06 software and the BMY_HPP2 protein coding sequence (SEQ ID NO:151). Preferred oligonucleotides are dideoxy based and are provided below. The oligonucleotides were synthesized using chemistry essentially as described in U.S. Patent No. 5,849,902; which is hereby incorporated herein by reference in its entirety.

25

ID#	Sequence
13600	GGAUAUCACUACUGCAUUGCCUGGA (SEQ ID NO:179)
13601	UACAGCAGAUCUGUGCAGGCCAGGU (SEQ ID NO:180)
13602	UGAUCACACAGUAGCGGAAGAUGCU (SEQ ID NO:181)
13603	AGGAGUAGCAGAAUGGUUAGCCUUC (SEQ ID NO:182)
13604	UGAAAGCAGGCGAGAUUCGAUCCGA (SEQ ID NO:183)

The BMY_HPP2 polypeptide has been shown to be involved in the regulation of the mammalian cell cycle. Subjecting cells with an effective amount of a pool of all five of the above antisense oligonucleotides resulted in a significant increase in Cyclin D expression/activity providing convincing evidence that BMY_HPP2 at least regulates the activity and/or expression of Cyclin D either directly, or indirectly. Moreover, the results suggest the physiological role of BMY_HPP2 is the negative

- 5 regulation of Cyclin D activity and/or expression, either directly or indirectly. The Cyclin D assay used is described below and was based upon the analysis of Cyclin D activity as a downstream marker for proliferative signal transduction events.

10 *Transfection of post-quiescent A549 cells With AntiSense Oligonucleotides.*

Materials needed:

- A549 cells maintained in DMEM with high glucose (Gibco-BRL) supplemented with 10% Fetal Bovine Serum, 2mM L-Glutamine, and 1X penicillin/streptomycin.
- 15 • Opti-MEM (Gibco-BRL)
- Lipofectamine 2000 (Invitrogen)
- Antisense oligomers (Sequitur)
- Polystyrene tubes.
- Tissue culture treated plates.

20

Quiescent cells were prepared as follows:

Day 0: 300, 000 A549 cells were seeded in a T75 tissue culture flask in 10 ml of
25 A549 media, and incubated in at 37°C, 5% CO₂ in a humidified incubator for 48 hours.

Day 2: The T75 flasks were rocked to remove any loosely adherent cells, and the A549 growth media removed and replenished with 10 ml of fresh A549 media. The cells were cultured for six days without changing the media to
30 create a quiescent cell population.

Day 8: Quiescent cells were plated in multi-well format and transfected with antisense oligonucleotides.

A549 cells were transfected according to the following:

- 35 1. Trypsinize T75 flask containing quiescent population of A549 cells.
2. Count the cells and seed 24-well plates with 60K quiescent A549 cells per well.

- 5 3. Allow the cells to adhere to the tissue culture plate (approximately 4 hours).
4. Transfect the cells with antisense and control oligonucleotides according to the following:
- 10 a. A 10X stock of lipofectamine 2000 (10 ug/ml is 10X) was prepared, and diluted lipid was allowed to stand at RT for 15 minutes.
 Stock solution of lipofectamine 2000 was 1 mg/ml.
 10 X solution for transfection was 10 ug/ml.
 To prepare 10X solution, dilute 10 ul of lipofectamine 2000 stock per 1 ml of Opti-MEM (serum free media).
- 15 b. A 10X stock of each oligomer was prepared to be used in the transfection.
 Stock solutions of oligomers were at 100 uM in 20 mM HEPES, pH 7.5.
 10X concentration of oligomer was 0.25 uM.
20 To prepare the 10X solutions, dilute 2.5 ul of oligomer per 1 ml of Opti-MEM.
- c. Equal volumes of the 10X lipofectamine 2000 stock and the 10X oligomer solutions were mixed well, and incubated for 15 minutes at RT to allow complexation of the oligomer and lipid. The resulting
25 mixture was 5X.
- d. After the 15 minute complexation, 4 volumes of full growth media was added to the oligomer/lipid complexes (solution was 1X).
- e. The media was aspirated from the cells, and 0.5 ml of the 1X oligomer/lipid complexes added to each well.
- 30 f. The cells were incubated for 16-24 hours at 37°C in a humidified CO₂ incubator.
- g. Cell pellets were harvested for RNA isolation and TaqMan analysis of downstream marker genes.

35 *TaqMan Reactions*

- 5 Quantitative RT-PCR analysis was performed on total RNA preps that had been treated with DNaseI or poly A selected RNA. The Dnase treatment may be performed using methods known in the art, though preferably using a Qiagen Rneasy kit to purify the RNA samples, wherein DNase I treatment is performed on the column.
- 10 Briefly, a master mix of reagents was prepared according to the following table:

Dnase I Treatment

<u>Reagent</u>	<u>Per rxn (in uL)</u>
10x Buffer	2.5
Dnase I (1 unit/ul @1 unit per ug sample)	2
DEPC H ₂ O	0.5
RNA sample @ 0.1 ug/ul (2-3 ug total)	20
Total	25

- Next, 5 ul of master mix was aliquoted per well of a 96-well PCR reaction plate (PE part # N801-0560). RNA samples were adjusted to 0.1 ug/ul with DEPC treated H₂O (if necessary), and 20 ul was added to the aliquoted master mix for a final reaction volume of 25 ul.

- The wells were capped using strip well caps (PE part # N801-0935), placed in a plate, and briefly spun in a centrifuge to collect all volume in the bottom of the tubes. Generally, a short spin up to 500rpm in a Sorvall RT is sufficient

The plates were incubated at 37°C for 30 mins. Then, an equal volume of 0.1mM EDTA in 10mM Tris was added to each well, and heat inactivated at 70°C for 5 min. The plates were stored at -80°C upon completion.

25 *RT reaction*

A master mix of reagents was prepared according to the following table:

5

RT reaction

<u>Reagent</u>	<u>RT</u> <u>Per Rx'n (in ul)</u>	<u>No RT</u> <u>Per Rx'n (in ul)</u>
10x RT buffer	5	2.5
MgCl ₂	11	5.5
DNTP mixture	10	5
Random Hexamers	2.5	1.25
Rnase inhibitors	1.25	0.625
RT enzyme	1.25	-
Total RNA 500ng (100ng no RT)	19.0 max	10.125 max
DEPC H ₂ O	-	-
Total	50uL	25uL

Samples were adjusted to a concentration so that 500ng of RNA was added to each RT rx'n (100ng for the no RT). A maximum of 19 ul can be added to the RT rx'n mixture (10.125 ul for the no RT.) Any remaining volume up to the maximum values was filled with DEPC treated H₂O, so that the total reaction volume was 50 ul (RT) or 25 ul (no RT).

On a 96-well PCR reaction plate (PE part # N801-0560), 37.5 ul of master mix was aliquoted (22.5 ul of no RT master mix), and the RNA sample added for a total reaction volume of 50ul (25 ul, no RT). Control samples were loaded into two or even three different wells in order to have enough template for generation of a standard curve.

The wells were capped using strip well caps (PE part # N801-0935), placed in a plate, and spin briefly in a centrifuge to collect all volume in the bottom of the tubes. Generally, a short spin up to 500rpm in a Sorvall RT is sufficient.

For the RT-PCR reaction, the following thermal profile was used:

- 25°C for 10 min
- 48°C for 30 min
- 95°C for 5 min
- 4°C hold (for 1 hour)
- Store plate @-20°C or lower upon completion.

TaqMan reaction (Template comes from RT plate.)

5 A master mix was prepared according to the following table:

<u>TaqMan reaction (per well)</u>	
<u>Reagent</u>	<u>Per Rx'n (in ul)</u>
TaqMan Master Mix	4.17
100 uM Probe (SEQ ID NO:186)	.025
100 uM Forward primer (SEQ ID NO:184)	.05
100 uM Reverse primer (SEQ ID NO:185)	.05
Template	-
DEPC H ₂ O	18.21
Total	22.5

The primers used for the RT-PCR reaction is as follows:

10 Cyclin D primer and probes:

Forward Primer: ACTACCGCCTCACACGCTTC (SEQ ID NO:184)

Reverse Primer: CTTGACTCCAGCAGGGCTTC (SEQ ID NO:185)

15 TaqMan Probe: ATCAAGTGTGACCCAGACTGCCTCCG (SEQ ID NO:186)

Using a Gilson P-10 repeat pipetter, 22.5 ul of master mix was aliquouted per well of a 96-well optical plate. Then, using P-10 pipetter, 2.5 ul of sample was added
20 to individual wells. Generally, RT samples are run in triplicate with each primer/probe set used, and no RT samples are run once and only with one primer/probe set, often gapdh (or other internal control).

A standard curve is then constructed and loaded onto the plate. The curve has five points plus one no template control (NTC, =DEPC treated H₂O). The curve was
25 made with a high point of 50 ng of sample (twice the amount of RNA in unknowns), and successive samples of 25, 10, 5, and 1 ng. The curve was made from a control sample(s) (see above).

5 The wells were capped using optical strip well caps (PE part # N801-0935), placed in a plate, and spun in a centrifuge to collect all volume in the bottom of the tubes. Generally, a short spin up to 500rpm in a Sorvall RT is sufficient.

 Plates were loaded onto a PE 5700 sequence detector making sure the plate is aligned properly with the notch in the upper right hand corner. The lid was tightened
10 down and run using the 5700 and 5700 quantitation programmes and the SYBR probe using the following thermal profile:

- 50°C for 2 min
- 95°C for 10 min
- 15 • and the following for 40 cycles:
 - 95°C for 15 sec
 - 60°C for 1 min
- Change the reaction volume to 25ul.

20 Once the reaction was complete, a manual threshold of around 0.1 was set to minimize the background signal. Additional information relative to operation of the GeneAmp 5700 machine may be found in reference to the following manuals: "GeneAmp 5700 Sequence Detection System Operator Training CD"; and the "User's Manual for 5700 Sequence Detection System"; available from Perkin-Elmer and
25 hereby incorporated by reference herein in their entirety.

 Cyclin D1 is a critical regulator of the process of cell division. It has been identified as an early modulator of the G1 phase of the cell cycle, and cyclin D1 expression increases as cells enter that phase of the cell cycle. It has long been thought that an ability to pharmacologically block cancerous cells in any part of the
30 cell cycle will have a negative impact on the tumor and be beneficial for managing the disease. Support for this rationale comes from the observation that effective drugs such as Taxol block the cell cycle in G2 phase. Importantly, the rapidly dividing cells found in the cancerous state require abundant levels of cyclin D1 to maintain an accelerated rate of proliferation and proceed to S-phase. Most notably,
35 overexpression of cyclinD1 is a hallmark of several types of human tumors, especially breast tumors (J Mammary Gland Biol Neoplasia 1996 Apr;1(2):153-62). As such, it

5 is thought that drugs that affect cyclin D1, directly or indirectly, would block cancer cells from dividing and have a beneficial effect for patients. Such drug targets could lie within the signal transduction pathway between the oncogene ras and the nucleus, where cell cycle modulators control DNA synthesis (J. Biol Chem 2000, Oct 20;275 (42):32649-57). Even more evidence exists suggesting that the Wnt pathway,
10 mediated by the tumor suppressor betacatenin, regulates the cell cycle via transcriptional control of cyclinD1 (Oncogene 2001 Aug 23;20(37):5093-9; PNAS 2000 Apr11;97(8):4262-6). Thus targets influencing beta catenin/TCF4 function could also affect cyclin D1 transcript levels. As mutations in oncogenes such as ras, and tumor suppressors such as beta catenin are common to many cancers, it is obvious
15 that cyclinD1 levels are indicative of the condition of the cell and its preparedness to proliferate, and affecting cyclinD1 levels and activity could be achieved by numerous mechanisms embodied in multiple pathways.

Antisense inhibition of the HPP_BMY2 phosphatase levels provokes a response in A549 cells that indicates the regulatory pathways controlling cyclinD1
20 levels are affected. This implicates HPP_BMY2 in pathways important for maintenance of the proliferative state and progression through the cell cycle. As stated above, there are numerous pathways that could have either indirect or direct effects on the transcriptional levels of cyclin D1. Importantly, a major part of the pathways implicated involve the regulation of protein activity through phosphorylation. In as
25 much as HPP_BMY2 is a phosphatase enzyme, it is readily conceivable that dephosphorylation of proteins, the counter activity to the kinases in the signal transduction cascades, contributes to the signals determining cell cycle regulation and proliferation, including regulating cyclin D1 levels. Additionally, the complexity of the interactions between proteins in the pathways described also allow for effects on
30 the pathway eliciting compensatory responses. That is, inhibition of one pathway affecting cyclinD1 activity could provoke a more potent response and signal from another pathway of the same end, resulting in upregulation of cyclin D1. Thus, the effect of inhibition of HPP_BMY2 resulting in slight increases in cyclin D1 levels could indicate that one pathway important to cancer is effected in a way to implicate
35 HPP_BMY2 as a potential target for pharmacologic inhibition for cancer treatment,

- 5 yet a parallel pathway in the context of the experiment would replace HPP_BMY2 and propagate dysregulation of Cyclin D1.

Example 57 – Method of Creating RET31 and Truncated RET31 Fusion Protein Constructs And Methods of Expression and Purification Of The Same.

- 10 The GST fusion proteins were designed to contain the full-length RET31 protein sequence (SEQ ID NO:109), as well as a C-terminal deletion mutant of the RET31 protein sequence corresponding to amino acids M1 to T302 of SEQ ID NO:109 which was truncated after the phosphatase homology domain ending at about amino acid residue 297 of SEQ ID NO:109.

- 15 In order to generate the RET31 fusion proteins, three PCR primers were designed and received from Life Technologies (Gaithersburg, MD). The oligos were:

<u>Oligo number</u>	<u>Name</u>	<u>Sequence</u>
S5972B08	RET31for	5'-CATATGGGATCCATGGCCCATGAGATTG (SEQ ID NO:187)
S5972B09	RET31rev	5'-GGTACCCCTCGAGTCAGGAGACCTCAATGAT (SEQ ID NO:188)
20 S6311A01	RET31rev2-2	5'-GGTACCCCTCGAGTCAAGTCTGGTCTTAAT (SEQ ID NO:189)

- Clones containing the original gene sequence of the full-length RET 31 polynucleotide (SEQ ID NO:108) were used as a template for the subsequent PCR. The clone was linearized using a restriction enzyme prior to PCR. PCR was performed using random hexamers and the Expand High Fidelity PCR System (ROCHE). Amplification was achieved using RET31 forward primer (SEQ ID NO:187) paired with either RET31 Rev (SEQ ID NO:188) or Rev2-2 (SEQ ID NO:189), for the full-length cDNA or truncated cDNA respectively. The thermocycler settings were 94°C for 30 sec, 55°C for 30 sec and 72°C for 60 seconds for 25 cycles.
- 30 The amplimers were gel purified by the QIAgen Extraction kit (QIAgen, Valencia, CA) and ligated, using T4 DNA ligase, into the pGEX 4T3 Vector (Amersham Pharmacia Biotech) and sequenced using standard methods.

- Appropriate clones were chosen based upon the sequencing data, and were used for subsequent steps. Protein expression was induced with 0.1mM IPTG over a 5-hour period. The fusion protein was isolated following the methods outlined in Ausubel, et al., 1992, Short Protocols in Molecular Biology, John Wiley and Sons, Inc., pp.16-28 to 16-31., using GST beads (Pierce) and reduced Glutathione (Sigma). The predicted proteins were approximately 100kD for the full-length protein and 60

- 5 kD for the truncated protein. To confirm that GST fusion protein was present, the proteins, along with appropriate markers, were run on a 4-12% NuPage BIS TRIS Gel with Mops buffer and transferred to a PVD membrane at 4°C. The membrane was blocked with 5% nonfat dry milk in TBS, and probed with a rabbit anti-GST antibody (developed in house). A goat anti-rabbit conjugated to HRP secondary antibody
10 (Biorad) was used and the blot was developed with ECL reagent (Amersham Pharmacia Biotech) – data not shown.

Example 57 – Method of Assaying the Phosphatase Activity Of The RET31 Polypeptide.

- 15 The phosphatase activity for the full-length RET31 and the M1 to T302 C-terminal RET31 GST fusion proteins were measured by assaying the ability of the proteins to hydrolyze para-nitrophenylphosphate, a compound known to be a substrate for phosphatases, as described in Krejsa, C. et al., J. Biol. Chem.. Vol. 272, p.11541-11549, 1997 (which is hereby incorporated in its entirety herein). The proteins are
20 incubated with para-nitrophenylphosphate in a solution containing 10 mM imidazole, pH 7.0, 1 mM EDTA, 2 mM dithiothreitol, and 5 µg/ml BSA for 2 hours with and without sodium orthovanadate (Fisher) prepared in distilled water. The progress of the phosphatase reaction in a 96-well format was monitored by the OD405 nm on a plate reader (Molecular Devices) at 10-minute intervals in the kinetic mode.

- 25 The RET31-GST full length (FL), M1 to T302 C-terminal RET31-GST (trunc), or GST alone were purified and assayed for cleavage of para-nitrophenylphosphate (pNPP). The bars represent the average of triplicate determinations, and the standard deviations are as shown. Each protein preparation was assayed in the absence and presence of 2 mM of the phosphatase inhibitor
30 orthovanadate. The full length and truncated versions clearly demonstrated activity compared to the GST protein as shown in Figure 36. In addition, the full length and truncated protein phosphatase activity was blocked by the phosphatase inhibitor vanadate, as shown.

- Of particular significance is the unexpected five fold increase in phosphatase
35 activity of the M1 to T302 C-terminal RET31-GST (trunc) fusion protein relative to the RET31-GST full length (FL) fusion protein.

5 While the described phosphatase assay elucidated the phosphatase activity of the full-length RET31 (SEQ ID NO:109) and M1 to T302 RET31 C-terminal deletion mutant (amino acids 1 to 302 of SEQ ID NO:109), subsequent sequencing of the RET31-GST full length (FL) and M1 to T302 C-terminal RET31-GST (trunc) fusion protein constructs determined that several amino acid mutations were unintentionally
 10 introduced during their construction. The sequences of the RET31 portions of both fusion proteins are provided below. Since the location of these mutations are not within the conserved phosphatase domain nor near any active site residues, it is not believed they would have any effect on the phosphatase activity of either construct. Rather, the observed phosphatase activity is believed to be representative of the wild
 15 type RET31 polypeptide sequence (SEQ ID NO:109) for the RET31-GST full length (FL), while the observed phosphatase activity of the M1 to T302 C-terminal RET31-GST (trunc) fusion protein is believed to be representative of the wild type M1 to T302 C-terminal RET31 C-terminal deletion (amino acids M1 to T302 of SEQ ID NO:109). One skilled in the art of molecular biology could easily correct the
 20 mutations of both constructs using known methods in conjunction with the information and teachings described herein. Nonetheless, the polypeptide sequences of the RET31 portion of both fusion proteins are encompassed by the present invention.

In preferred embodiments, the following RET31 polypeptide is encompassed by
 25 the present invention:

MAHEIGTQIVTERLVALLESGTEKVLLIDSRPFVEYNTSHILEAININCSKLMKR
 RLQQDKVLITELIQHS AKHKVDIDCSQKV VVDQSSQDVASLSSDCFLT VLLG
 KLEKSFNSVHLLAGGFAEF SRCFPGLCEGKSTLVPTCISQPCLPVANIGPTRILP
 NLYLGCQRDVLNKELMQQNGIGYVLNASNTCPKPDFIPESHFLRVPVND SFCE
 30 KILPWLDKSVD FIEKAKASNGCVLVHCLAGISR SATIAIAYIMKRMDMSLDEA
 YRFVKEKRPTISPSFNFLGQLLDYEKKIKNQAGASGPKSKLKLHLEKPNEPVP
 AVSEGGQKSETPLSPPCADSATSEAAGQRPVHPASVPSVPSVQPSLLED SPLVQ
 ALSGLHLSADRLED SNKLKRSFSLDIKSVSYSASMAASLHGFSSED ALEYK
 PSTTLDGTNKL CQFSPVQELSEQTPETSPDKEEASIPKKLQTARPSDSQSKRLH
 35 SVRTSSSGTAQRSLLSPLHRSGSVEDNYHTSFLFGLSTSQQHLTKSAGLGLKG
 WHSDILAPQTSTPSLTSSWYFATESSHFYASAIYGGASYSAYSRSQLPTCGD

- 5 QVYSVRRRQKPSDRADSRRSWHEESPFEKQFKRRSCQMEFGESIMSENRSREE
LGKVGSSQSSFSGSMEIIEVS (SEQ ID NO:190). Polynucleotides encoding this
polypeptide are also provided.

In preferred embodiments, the following M1 to T302 RET31 polypeptide is
encompassed by the present invention:

- 10 MAHEIVGTQIVTERLVALLESQTEKVLIDSRPFVEYNTSHILEAINNCSKLMKRRLQQDKVLI
TELIQHSAAHKVDIDCSQKVVVYDQSSQDVASLSSDCFLT VLLGKLEKSFNSVHLLAGGFAEF
SRCFPGLCEGKSTLVPTCISQPCLPVANIGPTRILPNLYLGCQRDVLNKELMQQNGIGYVLNAS
NTCPKPDFIPESHFLRVPVNDSEKILPWLKSVDFIEKAKASNGCVLVHCLAGISRSATIAIA
YIMKRMDMSLDEAYRFVKEKRPTISPSFNLGQLLDYEKKIKNQT (SEQ ID NO:191).
15 Polynucleotides encoding this polypeptide are also provided.

The present invention encompasses the application of this phosphatase activity
assay to the other phosphatases of the present invention.

20 **Example 58 – Method Of Assessing The Expression Profile Of The RET31
Phosphatase Polypeptides Of The Present Invention At The Level Of The
Protein Using Immunohistochemistry**

Peptide Selection and Antibody Production

- The sequence for the RET31 polypeptide (SEQ ID NO:109) was analyzed by
25 the algorithm of Hopp and Woods to determine potential peptides for synthesis and
antibody production. The peptides were then BLASTed against the SWISS-PROT
database to determine the uniqueness of the identified peptide and to help predict the
specificity of the resulting antibodies. The following RET31 polypeptide fragments
were selected according to the methods above for peptide synthesis:
30 KNQTGASGPKSKKLKLLHLE (SEQ ID NO:192); and
CKKLQTARPSDSQSKRLHS (SEQ ID NO:193). Rabbit polyclonal antisera was
generated for both synthesized RET31 peptides. In order to allow for peptide
conjugation to the carrier protein, a cysteine residue was added to the N-terminus of
the SEQ ID NO:193 peptide. The third bleeds were subjected to peptide affinity
35 purification, and the resulting antisera were then used as primary antibodies in
immunohistochemistry experiments. The antisera for the SEQ ID NO:192 peptide was
labeled RET31 antibody 299, while the antisera for the SEQ ID NO:193 peptide was
labeled RET31 antibody 469 antibody.

5

Antibody Titration Protocol and Positive Control Study Results

Antibody titration experiments were conducted with RET31 antibodies 299 and 469 (both rabbit polyclonals) to establish concentrations that would result in minimal background and maximal detection of signal. Serial dilutions were performed at 1:50, 1:100, 1:250, 1:500, and 1:1000. The serial dilution study demonstrated the highest signal-to-noise ratios at dilutions 1:250 and 1:400, on paraffin-embedded, formalin-fixed tissues for both antibodies. These concentrations were used for the study. RET31 antibodies 299 and 469 were used as primary antibodies, and the principal detection system consisted of a Vector anti-rabbit secondary (BA-1000; DAKO Corp.), a Vector ABC-AP Kit (AK-5000; DAKO Corp.) with a Vector Red substrate kit (SK-5100; DAKO Corp.), which was used to produce a fuchsia-colored deposit. Tissues were also stained with a positive control antibody (CD31) to ensure that the tissue antigens were preserved and accessible for immunohistochemical analysis. Only tissues that stained positive for CD31 were chosen for the remainder of the study. The negative control consisted of performing the entire immunohistochemistry procedure on adjacent sections in the absence of primary antibody. Slides were imaged using a DVC 1310C digital camera coupled to a Nikon microscope. Images were stored as TIFF files using Adobe PhotoShop.

Immunohistochemistry Procedure

Slides containing paraffin sections (LifeSpan BioSciences, Inc.; Seattle, WA) were deparaffinized through xylene and alcohol, rehydrated, and then subjected to the steam method of target retrieval (#S1700; DAKO Corp.; Carpinteria, CA). Immunohistochemical assay techniques are commonly known in the art and are described briefly herein. Immunocytochemical (ICC) experiments were performed on a DAKO autostainer following the procedures and reagents developed by DAKO. Specifically, the slides were blocked with avidin, rinsed, blocked with biotin, rinsed, protein blocked with DAKO universal protein block, machine blown dry, primary antibody, incubated, and the slides rinsed. Biotinylated secondary antibody was applied using the manufacturer's instructions (1 drop/10 ml, or approximately 0.75 µg/mL), incubated, rinsed slides, and applied Vectastain ABC-AP reagent for 30

- 5 minutes. Vector Red was used as substrate and prepared according to the manufacturer's instructions just prior to use.

Immunohistochemistry Results

The immunohistochemistry results were consistent with the Northern Blot and RT-PCR expression profiles described elsewhere herein for the RET31 polypeptide. Specifically, moderate to strong staining was observed in normal respiratory epithelial cell bodies and cilia. Types I and II pneumocytes were also moderately positive, as were neutrophils, mast cells, and macrophages in normal lung. In asthmatic patients, respiratory epithelial cell bodies stained less intensely, but cilia continued to stain strongly. Pneumocytes also stained less intensely than normal tissue. Inflammatory cell staining did not differ from normal tissue. Bronchial smooth muscle stained faintly in normal and asthmatic lungs. Cytoplasmic, diffuse nucleoplasmic, and nucleolar staining was observed in several cell types, including vascular endothelial and respiratory epithelial cells.

Moderate to strong staining was seen in chondrocytes and rimming osteoblasts in degenerative arthritis. In contrast, osteocytes were negative, as was the osteoid matrix. Hematopoietic tissue showed strongly positive cytoplasm and nucleus in myeloid series cells at all stages of maturation. Megakaryocytic and erythroid cells were negative.

Schwann cells and vascular endothelial cells were moderately to strongly positive in normal colon, in contrast to epithelial cells and ganglion cells, which were negative. Inflammatory cells, such as neutrophils, eosinophils, macrophages, and mast cells were strongly positive. Plasma cells showed blush to faint staining. Lymphocytes in normal colon showed strong punctate nuclear and nucleolar staining. In contrast to normal colon, the colon sections with ulcerative colitis showed less prominent nucleolar staining in lymphocytes. Neuroendocrine cells in the epithelium were faintly positive.

Normal lung showed strong cilia staining in the respiratory epithelial cells, with only blush, diffuse, nuclear staining in the cell body of these cells. Pneumocytes were faintly to moderately positive, as were alveolar macrophages and vascular endothelium. Asthmatic lungs continued to show strong cilia staining, but showed

5 bluish positivity in normal lung, and were predominately negative in diseased lung. Pneumocyte staining varied from bluish to moderately positive in asthmatic lungs. Pneumocyte staining was unchanged from normal lung. Inflammatory cell staining was similar to normal tissue.

Moderate staining was seen in the stratum granulosum in normal skin, whereas
10 the other layers were negative or showed bluish positivity. Melanocytes were moderately to strongly positive, as were hair follicles and eccrine and sebaceous glands. Skin with psoriasis showed strong staining in the stratum granulosum, increased from normal skin. In contrast to normal skin, melanocytes in skin were negative. In the psoriasisform dermatitis sample, the staining pattern was similar to
15 that observed in normal skin.

In synovium, the reactive synoviocytes in one sample of rheumatoid arthritis were faintly to moderately positive, in contrast to normal synoviocytes, which were negative or showed bluish staining. In the second sample of rheumatoid arthritis, the difference in synoviocyte staining was smaller than in the first sample.

20 Interesting observations in this study included the very prominent staining of the nucleolus of lymphocytes and other cell types. In inflammatory bowel disease, the lymphocytes did not show nucleolar staining as prominently as in normal colon. Skin with psoriasis had very prominent staining of the stratum granulosum, in comparison to normal skin or to the psoriasisform dermatitis sample.

25 The present invention encompasses the application of this phosphatase activity assay to the other phosphatases of the present invention.

Example 59 – Method Of Assessing The Expression Profile Of The Novel Phosphatases of Polypeptides Of The Present Invention Using Expanded mRNA Tissue and Cell Sources

30

Total RNA from tissues was isolated using the TriZol protocol (Invitrogen) and quantified by determining its absorbance at 260nm. An assessment of the 18s and 28s ribosomal RNA bands was made by denaturing gel electrophoresis to determine RNA integrity.

35 The specific sequence to be measured was aligned with related genes found in GenBank to identify regions of significant sequence divergence to maximize primer

- 5 and probe specificity. Gene-specific primers and probes were designed using the ABI primer express software to amplify small amplicons (150 base pairs or less) to maximize the likelihood that the primers function at 100% efficiency. All primer/probe sequences were searched against Public Genbank databases to ensure target specificity. Primers and probes were obtained from ABI.

10

For BMY_HPP1, the primer probe sequences were as follows

Forward Primer 5'-TCAGAGAATGGGCCAACAAGA-3' (SEQ ID NO:194)

Reverse Primer 5'-CGAAAACGCTCGAGGAATGA-3' (SEQ ID NO:195)

- 15 TaqMan Probe 5'-CAGGCCTAGGTTCTCTCTCGGAAA-3' (SEQ ID NO:196)

For BMY_HPP2, the primer probe sequences were as follows

- 20 Forward Primer 5'-TCAGAGAATGGGCCAACAAGA-3' (SEQ ID NO:197)

Reverse Primer 5'-CGAAAACGCTCGAGGAATGA-3' (SEQ ID NO:198)

TaqMan Probe 5'-CAGGCCTAGGTTCTCTCTCGGAAA-3' (SEQ ID NO:199)

- 25 For BMY_HPP4, the primer probe sequences were as follows

Forward Primer 5'-TCAGAGAATGGGCCAACAAGA-3' (SEQ ID NO:200)

Reverse Primer 5'-CGAAAACGCTCGAGGAATGA-3' (SEQ ID NO:201)

TaqMan Probe 5'-CAGGCCTAGGTTCTCTCTCGGAAA-3' (SEQ ID NO:202)

30

For BMY_HPP5 (RET31), the primer probe sequences were as follows

Forward Primer 5'-TCAGAGAATGGGCCAACAAGA-3' (SEQ ID NO:203)

- 35 Reverse Primer 5'-CGAAAACGCTCGAGGAATGA-3' (SEQ ID NO:204)

TaqMan Probe 5'-CAGGCCTAGGTTCTCTCTCGGAAA-3' (SEQ ID NO:205)

5

The same BMY_HPP5 primer probe sequences hybridize to the RET31 mRNA sequences as well. Therefore, the expression profiling for BMY_HPP5 is also representative of the RET31 expression profile as well.

10 *DNA contamination*

To access the level of contaminating genomic DNA in the RNA, the RNA was divided into 2 aliquots and one half was treated with Rnase-free Dnase (Invitrogen). Samples from both the Dnase-treated and non-treated were then subjected to reverse transcription reactions with (RT+) and without (RT-) the presence of reverse transcriptase. TaqMan assays were carried out with gene-specific primers (see above) and the contribution of genomic DNA to the signal detected was evaluated by comparing the threshold cycles obtained with the RT+/RT- non-Dnase treated RNA to that on the RT+/RT- Dnase treated RNA. The amount of signal contributed by genomic DNA in the Dnased RT- RNA must be less than 10% of that obtained with Dnased RT+ RNA. If not the RNA was not used in actual experiments.

Reverse Transcription reaction and Sequence Detection

100ng of Dnase-treated total RNA was annealed to 2.5 μ M of the respective gene-specific reverse primer in the presence of 5.5 mM Magnesium Chloride by heating the sample to 72°C for 2 min and then cooling to 55° C for 30 min. 1.25 U/ μ l of MuLv reverse transcriptase and 500 μ M of each dNTP was added to the reaction and the tube was incubated at 37° C for 30 min. The sample was then heated to 90°C for 5 min to denature enzyme.

Quantitative sequence detection was carried out on an ABI PRISM 7700 by adding to the reverse transcribed reaction 2.5 μ M forward and reverse primers, 500 μ M of each dNTP, buffer and 5U AmpliTaq Gold™. The PCR reaction was then held at 94°C for 12 min, followed by 40 cycles of 94° C for 15 sec and 60° C for 30 sec.

Data handling

The threshold cycle (Ct) of the lowest expressing tissue (the highest Ct value) was used as the baseline of expression and all other tissues were expressed as the

- 5 relative abundance to that tissue by calculating the difference in Ct value between the baseline and the other tissues and using it as the exponent in $2^{(\Delta Ct)}$

mRNA levels were assayed in samples from three individual donors for each tissue for each human phosphatase polypeptide. Values presented represent the average abundance of each human phosphatase polypeptide for each tissue divided by
10 the average abundance of said polypeptide in the tissue with the lowest level of expression. For example, the lowest expression level detected for each polypeptide is as follows: BMY_HPP1 = blood mononuclear cells; BMY_HPP2 = umbilical cord; BMY_HPP4 = blood mononuclear cells; and BMY_HPP5 (RET31) = umbilical cord.

The expanded expression profile of BMY_HPP1, BMY_HPP2, BMY_HPP4,
15 and BMY_HPP5 (RET31), are provided in Figures 26, 30, 34, and 35 and are described elsewhere herein.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above
20 teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence
25 listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

5 CLAIMS

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:
 - (a) a polynucleotide fragment of SEQ ID NO:1 or a polynucleotide fragment
10 of the cDNA sequence included in ATCC Deposit No: PTA-2966, which is hybridizable to SEQ ID NO:41;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:42 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No: PTA-2966, which is hybridizable to SEQ ID NO:41;
 - 15 (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:42 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No: PTA-2966, which is hybridizable to SEQ ID NO:41;
 - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:42 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:
20 PTA-2966, which is hybridizable to SEQ ID NO:41;
 - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:42 or the cDNA sequence included in ATCC Deposit No: PTA-2966, which is hybridizable to SEQ ID NO:41, having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:41;
 - 25 (g) a polynucleotide which is an allelic variant of SEQ ID NO:41;
 - (h) an isolated polynucleotide comprising nucleotides 473 to 2464 of SEQ ID NO:41, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 665 of SEQ ID NO:42 minus the start codon;
 - (i) an isolated polynucleotide comprising nucleotides 470 to 2464 of SEQ ID
30 NO:41, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 665 of SEQ ID NO:109 including the start codon;
 - (j) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:41;
 - (k) a polynucleotide fragment of SEQ ID NO:108 or a polynucleotide
35 fragment of the cDNA sequence included in ATCC Deposit No: PTA-3434, which is hybridizable to SEQ ID NO:108;

- 5 (l) (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:109 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No: PTA-3434, which is hybridizable to SEQ ID NO:108;
- (m) a polynucleotide encoding a polypeptide domain of SEQ ID NO:109 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:
- 10 PTA-3434, which is hybridizable to SEQ ID NO:108;
- (n) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:109 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No: PTA-3434, which is hybridizable to SEQ ID NO:108;
- (o) a polynucleotide encoding a polypeptide of SEQ ID NO:109 or the cDNA
- 15 sequence included in ATCC Deposit No: PTA-3434, which is hybridizable to SEQ ID NO:108, having biological activity;
- (p) a polynucleotide which is a variant of SEQ ID NO:108;
- (q) a polynucleotide which is an allelic variant of SEQ ID NO:108;
- (r) an isolated polynucleotide comprising nucleotides 541 to 2532 of SEQ ID
- 20 NO:108, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 665 of SEQ ID NO:109 minus the start codon;
- (s) an isolated polynucleotide comprising nucleotides 538 to 2532 of SEQ ID NO:108, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 665 of SEQ ID NO:109 including the start codon;
- 25 (t) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:108;
- (u) an isolated polynucleotide comprising nucleotides 541 to 1443 of SEQ ID NO:108, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 302 of SEQ ID NO:109 minus the start codon;
- 30 (v) an isolated polynucleotide comprising nucleotides 538 to 1443 of SEQ ID NO:108, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 302 of SEQ ID NO:109 including the start codon;
- (w) a polynucleotide fragment of SEQ ID NO:149 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: XXXXXX, which is
- 35 hybridizable to SEQ ID NO:149;

- 5 (x) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:150 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No: PTA-XXXXXX, which is hybridizable to SEQ ID NO:149;
- (y) a polynucleotide encoding a polypeptide domain of SEQ ID NO:150 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:
- 10 PTA-XXXXXX, which is hybridizable to SEQ ID NO:149;
- (z) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:150 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No: PTA-XXXXXX, which is hybridizable to SEQ ID NO:149;
- (aa) a polynucleotide encoding a polypeptide of SEQ ID NO:150 or the
- 15 cDNA sequence included in ATCC Deposit No: XXXXXX, which is hybridizable to SEQ ID NO:149, having biological activity;
- (bb) a polynucleotide which is a variant of SEQ ID NO:149;
- (cc) a polynucleotide which is an allelic variant of SEQ ID NO:149;
- (dd) an isolated polynucleotide comprising nucleotides 631 to 2448 of SEQ
- 20 ID NO:149, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 607 of SEQ ID NO:150 minus the start codon; .
- (ee) an isolated polynucleotide comprising nucleotides 628 to 2448 of SEQ ID NO:149, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 607 of SEQ ID NO:150 including the start codon;
- 25 (ff) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:149;
- (gg) a polynucleotide fragment of SEQ ID NO:151 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: XXXXXX, which is hybridizable to SEQ ID NO:151;
- 30 (hh) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:152 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No: XXXXXX, which is hybridizable to SEQ ID NO:151;
- (ii) a polynucleotide encoding a polypeptide domain of SEQ ID NO:152 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:
- 35 XXXXXX, which is hybridizable to SEQ ID NO:151;

- 5 (jj) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:152 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No: XXXXXX, which is hybridizable to SEQ ID NO:151;
- (kk) a polynucleotide encoding a polypeptide of SEQ ID NO:152 or the cDNA sequence included in ATCC Deposit No: XXXXXX, which is hybridizable to
- 10 SEQ ID NO:151, having biological activity;
- (ll) a polynucleotide which is a variant of SEQ ID NO:151;
- (mm) a polynucleotide which is an allelic variant of SEQ ID NO:151;
- (nn) an isolated polynucleotide comprising nucleotides 92 to 538 of SEQ ID NO:151, wherein said nucleotides encode a polypeptide corresponding to amino acids
- 15 2 to 150 of SEQ ID NO:152 minus the start codon;
- (oo) an isolated polynucleotide comprising nucleotides 89 to 538 of SEQ ID NO:151, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 150 of SEQ ID NO:152 including the start codon;
- (pp) a polynucleotide which represents the complimentary sequence
- 20 (antisense) of SEQ ID NO:151; and
- (qq) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(pp), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
- 25 2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a human phosphatase protein.
3. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 30 4. The recombinant host cell of claim 3 comprising vector sequences.
5. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:42 or the encoded sequence included in ATCC Deposit No: PTA-2966;
- 35 (b) a polypeptide fragment of SEQ ID NO:42 or the encoded sequence included in ATCC Deposit No: PTA-2966, having biological activity;

- 5 (c) a polypeptide domain of SEQ ID NO:42 or the encoded sequence included in ATCC Deposit No: PTA-2966;
- (d) a polypeptide epitope of SEQ ID NO:42 or the encoded sequence included in ATCC Deposit No: PTA-2966;
- (e) a full length protein of SEQ ID NO:42 or the encoded sequence included in
10 ATCC Deposit No: PTA-2966;
- (f) a variant of SEQ ID NO:42;
- (g) an allelic variant of SEQ ID NO:42;
- (h) a species homologue of SEQ ID NO:42;
- (i) a polypeptide comprising amino acids 2 to 665 of SEQ ID NO:42, wherein
15 said amino acids 2 to 665 comprise a polypeptide of SEQ ID NO:42 minus the start methionine;
- (j) a polypeptide comprising amino acids 1 to 665 of SEQ ID NO:42; and
- (k) a polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-2966;
- 20 (l) a polypeptide fragment of SEQ ID NO:109 or the encoded sequence included in ATCC Deposit No: PTA-3434;
- (m) a polypeptide fragment of SEQ ID NO:109 or the encoded sequence included in ATCC Deposit No: PTA-3434, having biological activity;
- (n) a polypeptide domain of SEQ ID NO:109 or the encoded sequence
25 included in ATCC Deposit No: PTA-3434;
- (o) a polypeptide epitope of SEQ ID NO:109 or the encoded sequence included in ATCC Deposit No: PTA-3434;
- (p) a full length protein of SEQ ID NO:109 or the encoded sequence included in ATCC Deposit No: PTA-3434;
- 30 (q) a variant of SEQ ID NO:109;
- (r) an allelic variant of SEQ ID NO:109;
- (s) a species homologue of SEQ ID NO:109;
- (t) a polypeptide comprising amino acids 2 to 665 of SEQ ID NO:109, wherein said amino acids 2 to 665 comprise a polypeptide of SEQ ID NO:109 minus
35 the start methionine;
- (u) a polypeptide comprising amino acids 1 to 665 of SEQ ID NO:109;

- 5 (v) a polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-3434;
- (w) a polypeptide fragment of SEQ ID NO:150 or the encoded sequence included in ATCC Deposit No: XXXXX;
- (x) a polypeptide fragment of SEQ ID NO:150 or the encoded sequence
10 included in ATCC Deposit No: XXXXX, having biological activity;
- (y) a polypeptide domain of SEQ ID NO:150 or the encoded sequence included in ATCC Deposit No: XXXXX;
- (z) a polypeptide epitope of SEQ ID NO:150 or the encoded sequence included in ATCC Deposit No: XXXXX;
- 15 (aa) a full length protein of SEQ ID NO:150 or the encoded sequence included in ATCC Deposit No: XXXXX;
- (bb) a variant of SEQ ID NO:150;
- (cc) an allelic variant of SEQ ID NO:150;
- (dd) a species homologue of SEQ ID NO:150;
- 20 (ee) a polypeptide comprising amino acids 2 to 607 of SEQ ID NO:150, wherein said amino acids 2 to 607 comprise a polypeptide of SEQ ID NO:150 minus the start methionine;
- (ff) a polypeptide comprising amino acids 1 to 607 of SEQ ID NO:150;
- (gg) a polypeptide encoded by the cDNA contained in ATCC Deposit No.
25 XXXX;
- (hh) a polypeptide fragment of SEQ ID NO:152 or the encoded sequence included in ATCC Deposit No: XXXXX;
- (ii) a polypeptide fragment of SEQ ID NO:152 or the encoded sequence included in ATCC Deposit No: XXXXX, having biological activity;
- 30 (jj) a polypeptide domain of SEQ ID NO:152 or the encoded sequence included in ATCC Deposit No: XXXXX;
- (kk) a polypeptide epitope of SEQ ID NO:152 or the encoded sequence included in ATCC Deposit No: XXXXX;
- (ll) a full length protein of SEQ ID NO:152 or the encoded sequence included
35 in ATCC Deposit No: XXXXX;
- (mm) a variant of SEQ ID NO:152;

- 5 (nn) an allelic variant of SEQ ID NO:152;
(oo) a species homologue of SEQ ID NO:152;
(pp) a polypeptide comprising amino acids 2 to 150 of SEQ ID NO:152,
wherein said amino acids 2 to 150 comprise a polypeptide of SEQ ID NO:152 minus
the start methionine;
- 10 (qq) a polypeptide comprising amino acids 1 to 150 of SEQ ID NO:152;
and
(rr) a polypeptide encoded by the cDNA contained in ATCC Deposit No.
XXXX.
6. The isolated polypeptide of claim 5, wherein the full length protein
15 comprises sequential amino acid deletions from either the C-terminus or the N-
terminus.
7. An isolated antibody that binds specifically to the isolated polypeptide
of claim 5.
8. A recombinant host cell that expresses the isolated polypeptide of
20 claim 15
9. A method of making an isolated polypeptide comprising:
(a) culturing the recombinant host cell of claim 8 under conditions such that
said polypeptide is expressed; and
(b) recovering said polypeptide.
- 25 10. The polypeptide produced by claim 9.
11. A method for preventing, treating, or ameliorating a medical condition,
comprising administering to a mammalian subject a therapeutically effective amount
of the polypeptide of claim 5 or the polynucleotide of claim 1.
12. A method of diagnosing a pathological condition or a susceptibility to
30 a pathological condition in a subject comprising:
(a) determining the presence or absence of a mutation in the polynucleotide of
claim 1; and
(b) diagnosing a pathological condition or a susceptibility to a pathological
condition based on the presence or absence of said mutation.
- 35 13. A method of diagnosing a pathological condition or a susceptibility to
a pathological condition in a subject comprising:

- 5 (a) determining the presence or amount of expression of the polypeptide of claim 5 in a biological sample; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
14. A process for making polynucleotide sequences encoding a gene
10 product having altered phosphatase activity comprising,
- a) shuffling a nucleotide sequence of claim 1,
 - b) expressing the resulting shuffled nucleotide sequences and,
 - c) selecting for altered phosphatase activity as compared to the phosphatase activity of the gene product of said unmodified nucleotide sequence.
- 15 15. A shuffled polynucleotide sequence produced from the process of claim 14.
16. An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:
- (a) a polynucleotide encoding a polypeptide of SEQ ID NO:42;
 - 20 (b) an isolated polynucleotide comprising nucleotides 473 to 2464 of SEQ ID NO:41, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 665 of SEQ ID NO:42 minus the start codon;
 - (c) an isolated polynucleotide comprising nucleotides 473 to 2464 of SEQ ID NO:41, wherein said nucleotides encode a polypeptide corresponding to
25 amino acids 2 to 665 of SEQ ID NO:42 including the start codon;
 - (d) a polynucleotide encoding the BMY_HPP5 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. PTA-2966;
 - (e) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:41;
 - 30 (f) a polynucleotide encoding a polypeptide of SEQ ID NO:109;
 - (g) an isolated polynucleotide comprising nucleotides 473 to 2464 of SEQ ID NO:41, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 665 of SEQ ID NO:42 minus the start codon;
 - (h) an isolated polynucleotide comprising nucleotides 473 to 2464 of
35 SEQ ID NO:41, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 665 of SEQ ID NO:42 including the start codon;

- 5 (i) a polynucleotide encoding the RET31 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. PTA-3434;
- (j) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:109;
- (k) an isolated polynucleotide comprising nucleotides 541 to 1443 of
10 SEQ ID NO:108, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 302 of SEQ ID NO:109 minus the start codon;
- (l) an isolated polynucleotide comprising nucleotides 538 to 1443 of SEQ ID NO:108, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 302 of SEQ ID NO:109 including the start codon;
- 15 (m) a polynucleotide encoding a polypeptide of SEQ ID NO:150;
- (n) an isolated polynucleotide comprising nucleotides 631 to 2448 of SEQ ID NO:149, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 607 of SEQ ID NO:150 minus the start codon;
- (o) an isolated polynucleotide comprising nucleotides 628 to 2448 of
20 SEQ ID NO:149, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 607 of SEQ ID NO:150 including the start codon;
- (p) a polynucleotide encoding the BMY_HPP5 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. XXXXX;
- (q) a polynucleotide which represents the complimentary sequence
25 (antisense) of SEQ ID NO:149;
- (r) a polynucleotide encoding a polypeptide of SEQ ID NO:152;
- (s) an isolated polynucleotide comprising nucleotides 92 to 538 of SEQ ID NO:151, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 150 of SEQ ID NO:152 minus the start codon;
- 30 (t) an isolated polynucleotide comprising nucleotides 89 to 538 of SEQ ID NO:151, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 150 of SEQ ID NO:152 including the start codon;
- (u) a polynucleotide encoding the BMY_HPP5 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. XXXXX; and
- 35 (v) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:151.

- 5 17. The isolated nucleic acid molecule of claim 16, wherein the polynucleotide comprises a nucleotide sequence encoding a human phosphatase protein.
18. A recombinant vector comprising the isolated nucleic acid molecule of claim 16.
- 10 19. A recombinant host cell comprising the recombinant vector of claim 18.
20. An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
- (a). a polypeptide fragment of SEQ ID NO:42 having phosphatase activity;
- 15 (b). a polypeptide domain of SEQ ID NO:42 having phosphatase activity;
- (c). a full length protein of SEQ ID NO:42;
- (d). a polypeptide corresponding to amino acids 2 to 665 of SEQ ID NO:42, wherein said amino acids 2 to 665 comprise a polypeptide of SEQ ID NO:42 minus the start methionine;
- 20 (e). a polypeptide corresponding to amino acids 1 to 665 of SEQ ID NO:42;
- (f). a polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-2966;
- (g). a polypeptide fragment of SEQ ID NO:109 having phosphatase
- 25 activity;
- (h). a polypeptide domain of SEQ ID NO:109 having phosphatase activity;
- (i). a full length protein of SEQ ID NO:109;
- (j). a polypeptide corresponding to amino acids 2 to 665 of SEQ ID NO:109, wherein said amino acids 2 to 665 comprise a polypeptide of SEQ ID
- 30 NO:109 minus the start methionine;
- (k). a polypeptide corresponding to amino acids 1 to 665 of SEQ ID NO:109;
- (l). a polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-3434;

- 5 (m) a polypeptide corresponding to amino acids 2 to 302 of SEQ ID NO:109, wherein said amino acids 2 to 302 comprise a polypeptide of SEQ ID NO:109 minus the start methionine;
- (n) a polypeptide corresponding to amino acids 1 to 302 of SEQ ID NO:109;
- (o) a polypeptide fragment of SEQ ID NO:150 having phosphatase activity;
- 10 (p) a polypeptide domain of SEQ ID NO:150 having phosphatase activity;
- (q) a full length protein of SEQ ID NO:150;
- (r) a polypeptide corresponding to amino acids 2 to 607 of SEQ ID NO:150, wherein said amino acids 2 to 607 comprise a polypeptide of SEQ ID NO:150 minus the start methionine;
- 15 (s) a polypeptide corresponding to amino acids 1 to 607 of SEQ ID NO:150;
- (t) a polypeptide encoded by the cDNA contained in ATCC Deposit No. XXXXX;
- (u) a polypeptide fragment of SEQ ID NO:152 having phosphatase activity;
- (v) a polypeptide domain of SEQ ID NO:152 having phosphatase activity;
- 20 (w) a full length protein of SEQ ID NO:152;
- (x) a polypeptide corresponding to amino acids 2 to 150 of SEQ ID NO:152, wherein said amino acids 2 to 150 comprise a polypeptide of SEQ ID NO:152 minus the start methionine;
- (y) a polypeptide corresponding to amino acids 1 to 150 of SEQ ID NO:152;
- 25 and
- (z) a polypeptide encoded by the cDNA contained in ATCC Deposit No. XXXX.

21. A method of phosphorylating a protein comprising the step of
- 30 incubating said protein with the isolated polypeptide of claim 5.
22. The method for preventing, treating, or ameliorating a medical condition of claim 21, wherein the medical condition is a proliferative disorder.
23. A computer for producing a three-dimensional representation of a molecule or molecular complex, wherein said molecule or molecular complex
- 35 comprises the structural coordinates of a member of the group consisting of
- (a) BMY_HPP1 model provided in Figure 28 in accordance with Table VIII

- 5 (b) BMY_HPP2 model provided in Figure 32 in accordance with Table IX;
and
(c) BMY_HPP5 model provided in Figure 38 in accordance with Table X,
wherein said computer comprises:
- 10 (a) A machine-readable data storage medium, comprising a data storage
material encoded with machine readable data, wherein the data is defined by the set of
structure coordinates of the model;
(b) a working memory for storing instructions for processing said machine-
readable data;
- 15 (c) a central-processing unit coupled to said working memory and to said
machine-readable data storage medium for processing said machine readable data into
said three-dimensional representation; and
(d) a display coupled to said central-processing unit for displaying said three-
dimensional representation.

20

24. A method for identifying a mutant with altered biological properties,
function, or activity of a member of the group consisting of:

- (a) BMY_HPP1;
(b) BMY_HPP2; and
25 (c) BMY_HPP5,
Wherein said method comprises the steps of:
(a) using a model of said polypeptide according to the structural coordinates
of said model to identify amino acids to mutate; and
(b) mutating said amino acids to create a mutant protein with altered
30 biological function or properties.

25. A method for designing or selecting compounds as potential
modulators of a member of the group consisting of:

- (a) BMY_HPP1;
35 (b) BMY_HPP2; and
(c) BMY_HPP5,

5

Wherein said method comprises the steps of:

(a) identifying a structural or chemical feature of said member using the structural coordinates of said member; and

(b) rationally designing compounds that bind to said feature.

10

Figure 1**BMV_HPP1_A**

```
1 CTAGTTTACT TCTACAATTT CGGATGGAAG GATTATGGTG TAGCGTCTCT TACTACTATC 60
1 L V Y F Y N F G W K D Y G V A S L T T I 20

61 CTAGATATGG TGAAGGTGAT GACATTGACC TTACAGGAAG GAAAAGTAGC TATCCATTGT 120
21 L D M V K V M T F A L Q E G K V A I H C 40

121 CATGCAGGGC TTGGTCGAAC AGGT 144
41 H A G L G R T G 48
```

BMV_HPP1_B

```
1 GATGTCTTCT GGGCCCTCCT GTGGAACACA GTT 33
1 D V F W A L L W N T V 11
```

Figure 2

1	GTGGCCCGGGAGGCCGCGAGGCCAGGTAGGTGCGATGGGCGTGCAGCCCCCAACTTCTC	60
1	W P G R R R G Q V G A M G V Q P P N F S	20
61	CTGGGTGCTTCCGGGCGGCTGGCGGGACTGGCGCTGCCGCGGCTCCCCGCCCCTACCA	120
21	W V L P G R L A G L A L P R L P A H Y Q	40
121	GTTCTGTGTTGGACCTGGGCGTGCGGCACCTGGTGTCCCTGACGGAGCGCGGGCCCCCTCA	180
41	F L L D L G V R H L V S L T E R G P P H	60
181	CAGCGACAGCTGCCCCGGCCTCACCTGCACCGCCTGCGCATCCCCGACTTCTGCCCGCC	240
61	S D S C P G L T L H R L R I P D F C P P	80
241	GGCCCCCGACCAGATCGACCGCTTCGTGCAGATCGTGGACGAGGCCAACGCACGGGGAGA	300
81	A P D Q I D R F V Q I V D E A N A R G E	100
301	GGCTGTGGGAGTGCACCTGTGCTCTGGGCTTTGGCCGCACTGGCACCATGCTGGCCTGTTA	360
101	A V G V H C A L G F G R T G T M L A C Y	120
361	CCTGGTGAAGGAGCGGGGCTTGGCTGCAGGAGATGCCATTGCTGAAATCCGACGACTACG	420
121	L V K E R G L A A G D A I A E I R R L R	140
421	ACCCGGCCCCATCGAGACCTATGAGCAGGAGAAAGCAGTCTTCCAGTTCTACCAGCGAAC	480
141	P G P I E T Y E Q E K A V F Q F Y Q R T	160
481	GAAATAAGGGGCCTTAGTACCCTTCTACCAGGCCCTCACTCCCCTTCCCCATGTTGTCGA	540
161	K * G A L V P F Y Q A L T P L P H V V D	180
541	TGGGGCCAGAGATGAAGGGAAGTGGACTAAAGTATTAAACCCTCTAGCTCCCATTGGCTG	600
181	G A R D E G K W T K V L N P L A P I G *	200
601	AAGACACTGAAGTAGCCACCCCTGCAGGCAGGTCTTGATTGAAGGGGAGGCTTGTA CTG	660
201	R H * S S P P L Q A G P D * R G G L Y C	220
661	CTTTGTTGAATAAATGAGTTTTACGAACCAGGGAAAAAAAAAAAAAAAAAAGAAAAA	720
221	F V E * M S F T N Q G K K K K K K R K K	240
721	AAAAAAAAAAAAAAAAAAAAAGAA	746
241	K K K K K K K R	248

Figure 3

1 ATGGCTAGAA TGAACCTCCC TGCTTCTGTG GACATTGCAT ACAAAAATGT GAGATTCTT 60
1 M A R M N L P A S V D I A Y K N V R F L 20

61 ATTACACACA ACCCAACCAA TACCTACTTT AATAGATTCT TACAGGAACT TAAGCAGGAT 120
21 I T H N P T N T Y F N R F L Q E L K Q D 40

121 GGAGTTACCA CCATAGTAAG AGTATGAAAA GCAACTTACA ACATTGCTCT TTTAGAGAAG 180
41 G V T T I V R V * K A T Y N I A L L E K 60

181 GGAAGCATCC AGGTTCCGGA CTGGCCTTTT GATGATGGTA CAGCACCATC CAGCCAGATA 240
61 G S I Q V P D W P F D D G T A P S S Q I 80

241 ATTGATAACT GGTAAAACT TATGAAAAAT AAATTTTCATG AAGATCCTGG TTGTTGTATT 300
81 I D N W L K L M K N K F H E D P G C C I 100

301 GCAATTCAC TGTGTGTAGG TTTTGGGTGA GCTCCAGTTG CTAGTTGCCC TAGCTTTAAT 360
101 A I H C V V G F G * A P V A S C P S F N 120

361 TGAAGGTGGA ATGAAATATG AAAATGTAGT ACAGTTCATC AGATAAAAGT GACATGGAAC 420
121 * R W N E I * K C S T V H Q I K V T W N 140

421 TTTTAACAGC AAACAACCTT TGTATTTGGA GAAATATTGT CTTAAATAT GCTTGCACCT 480
141 F * Q Q T T F V F G E I L S * N M L A P 160

481 CAGAAATCCC AGAAATAACT GTTTCCTTCA G 511
161 Q K S Q K * L F P S 171

Figure 4A

1 CTCAGGCAGA ACTATGAGGC CAAGAGTGCT CATGCGCACC AGGCTTTCTT TTTGAAATTC 60
 1 L R Q N Y E A K S A H A H Q A F F L K F 20

61 GAGGAGCTGA AGGAGGTGAG CAAGGAGCAG CCCAGACTGG AGGCTGAGTA CCCTGCCAAC 120
 21 E E L K E V S K E Q P R L E A E Y P A N 40

121 ACCACCAAGA ACTGTTAACC ACATGTGCTA CCCTATGACC ACTCCAGGGT CAGGCTGACC 180
 41 T T K N C * P H V L P Y D H S R V R L T 60

181 CAGCTGGAGG GAGAGCCTCA TTCTGACTAC ATCAATGCCA ACTTGGTCCC AGGCTACACC 240
 61 Q L E G E P H S D Y I N A N L V P G Y T 80

241 CGCCACAGG AGTTCATTGC CTCTCAGGGG CCTCTCAAGA AAACACTGGA GAACTTCTGG 300
 81 R P Q E F I A S Q G P L K K T L E N F W 100

301 CGGCTGGTGC GGGAGCAGCA GGTCCGCATC ATCATCATGC CGACCATCAG CATGGAGAAC 360
 101 R L V R E Q Q V R I I I M P T I S M E N 120

361 GGGAGGGTGC TGTGTGAGCA TTACTGGCTG ACCGACTCTA CCCCAGACAC CCATGGTCAC 420
 121 G R V L C E H Y W L T D S T P D T H G H 140

421 ATCACCATCC ACCTCCTAGC TGAGGAGCCT GAGGATGAGT GGACCAAGCG GGAATTCAG 480
 141 I T I H L L A E E P E D E W T K R E F Q 160

481 CTGCAGCAGC TTGTCCAGCA ACATCAACGG AGGGTGGAGC AACTGCAGTT CACCACCTGA 540
 161 L Q H V V Q Q H Q R R V E Q L Q F T T * 180

541 TCCGACCACA GCATCCTTGA GGCTCCCAGC TCCCTGCTCG CCTTTATGGA GCTGGTACAG 600
 181 S D H S I L E A P S S L L A F M E L V Q 200

601 TAGCAGGCAA GGGCCACCCA GGGCGTGGGA CCCATCCTGG TGCAGTGCAG GGGCTGTCCC 660
 201 * Q A R A T Q G V G P I L V H C R G C P 220

661 TCGGGTGTGG GCATGGGCGG GACAGGCACC TTCGTGGCCC TGTCGAGGCT GCTGCAGCAG 720
 221 C G V G M G R T G T F V A L S R L L Q Q 240

721 CTGGAGGAGG AGCAGATGGT AGACGTGTTT CATGCTGTGT ATGCACTCCG GATGCACCAG 780
 241 L E E E Q M V D V F H A V Y A L R M H Q 260

781 CCCCTCATGA TCCAGACCCT GAGCCAGTAC GTCTTCCTGC ACAGCTGCCT ACTGAACAAG 840
 261 P L M I Q T L S Q Y V F L H S C L L N K 280

841 ATTCTGGAAG GACCCTTCAA CATCTCTGAG TCTTGGCCCA TCTCTGTGAC GGACCTCCCG 900
 281 I L E G P F N I S E S W P I S V T D L P 300

901 CAGGCGTGTG CCAAGAGGGC AGCCAGTGCC AATGCTGGCT TCTTGAAGGA GTACGAGGCC 960
 301 Q A C A K R A A S A N A G F L K E Y E A 320

961 ATCAAGGACG AGGCTGGCTT TTCCGCACCC CCGCCTGGCT ATGAGCAGGA CAGCCCCGTC 1020
 321 I K D E A G F S A P P P G Y E Q D S P V 340

1021 TCCTATGACC GTTCTCAGGG GCAGTTTCTT CCGGTGGAGG AGAGCCCCC TGACGACATG 1080
 341 S Y D R S Q G Q F S P V E E S P P D D M 360

1081 CCTCTCTGGA AGCCAATGAT CTGTGCTCTG CAGGGTGGGC CCTCTGGCCG TGATCATACG 1140
 361 P L W K P M I C A L Q G G P S G R D H T 380

Figure 4B

1141 GTGCTGACTG GCCCCGCAGG GCCAAAGGAG CTCTGGGAGC TGGTGTGGCA GCACAGGGCT 1200
381 V L T G P A G P K E L W E L V W Q H R A 400

1201 CATGTGCTTG TCTCTCTTG CCCACCCAAT GTCATGGAGA AGGAATTCTG GCCAACGGAG 1260
401 H V L V S L C P P N V M E K E F W P T E 420

1261 ATGCAGCCCG TAGTCACAGA CATGGTGACG GTGCACTGGG TGGCTGAGAG CAGCACAGCA 1320
421 M Q P V V T D M V T V H W V A E S S T A 440

1321 GGCTGGTTCT GTACCCTCCT CAGGGTCACA CATGGGGAGA GCAGGAAGGA AAGGGAGGTG 1380
441 G W F C T L L R V T H G E S R K E R E V 460

1381 CAGAGACTGC AATTTCATA CCTGGAGCCT GGGCATGAGC TGCCCGCCAC CACCCTGCTG 1440
461 Q R L Q F P Y L E P G H E L P A T T L L 480

1441 CCCTTCCTGG CTGCTGTGGG CCAGTGCTGC TCTCGGGGCA ACAACAAGAA GCCGGGCACA 1500
481 P F L A A V G Q C C S R G N N K K P G T 500

1501 CTGCTCAGCC ACTCCAACAA GGGTGCAACC CAGCTGGGCA CCTTCCTGGC CATGGAGCAG 1560
501 L L S H S N K G A T Q L G T F L A M E Q 520

1561 CTGCTGCAGC AGGCAGGGTC TGAGTGCACC GTGGATATCT TTAACGTGGC CCTGCAGCAG 1620
521 L L Q Q A G S E C T V D I F N V A L Q Q 540

1621 TCTCAGGCCT GTGGCCTTAT GACCCCAACA CTGAAGCAGT ATGTCTACCT CTACAAGTGT 1680
541 S Q A C G L M T P T L K Q Y V Y L Y N C 560

1681 CTGAACAGCG CGCTGGCAGA CGGGCTGCCC 1710
561 L N S A L A D G L P 570

Figure 5A

1 ATGTTTCATTTTAAAAAACTTCAGGATGGGCACAAACACACAGAAGTGGGAAATGAATAAA 60
61 AGAGTATTGATAAATTTTTGAAAATTGTTGAAGCTGAGTAATGGGCTTTCAGTCCAGTGT 120
121 AAAGCTGTTGGAGCGCGGGAGCAAAGGTAAAGAATGATGTAATGCGCTGGCTGCTCCAAA 180
181 GCATCTTTTGTGTGGAATGGTTATTCCAGTCATCTCTTTATGAATCAAATGTGAGGGGC 240
241 TGCTTTGTGGACGGAGTCCTTTGCAAGAGCACATCAACGGGAAAGAGAAAGAGACATTCA 300
301 CTTGGAGGGCTCTTGCTGAAAATGGGTTTAACTCTCCTTTTGCCAGTCACCACCAGCCTG 360
361 ACCTCATACACTTTTAGTACAATGGAGTGGCTGAGCCTTTGAGCACACCACCATTACATC 420
421 ATCGTGGCAAATTAAAGAAGGAGGTGGGAAAAGAGGACTTATTGTTGTCATGGCCCATGA 480
1 M A H E 4
481 GATGATTGGAACCTCAAATTGTTACTGAGAGGTTGGTGGCTCTGCTGGAAAGTGGAAACGGA 540
5 M I G T Q I V T E R L V A L L E S G T E 24
541 AAAAGTGCTGCTAATTGATAGCCGCCCATTTGTGGAATACAATACATCCCACATTTTGA 600
25 K V L L I D S R P F V E Y N T S H I L E 44
601 AGCCATTAATATCAACTGCTCCAAGCTTATGAAGCGAAGGTTGCAACAGGACAAAGTGT 660
45 A I N I N C S K L M K R R L Q Q D K V L 64
661 AATTACAGAGCTCATCCAGCATTAGCGAAACATAAGGTTGACATTGATTGCAGTCAGAA 720
65 I T E L I Q H S A K H K V D I D C S Q K 84
721 GGTTGTAGTTTACGATCAAAGCTCCCAAGATGTTGCCTCTCTCTCTCAGACTGTTTCT 780
85 V V V Y D Q S S Q D V A S L S S D C F L 104
781 CACTGTACTTCTGGGTAAACTGGAGAAGAGCTTCAACTCTGTTACCTGCTTGCAGGTGG 840
105 T V L L G K L E K S F N S V H L L A G G 124
841 GTTTGCTGAGTTCTCTCGTTGTTTCCCTGGCCTCTGTGAAGGAAAATCCACTCTAGTCCC 900
125 F A E F S R C F P G L C E G K S T L V P 144
901 TACCTGCATTTCTCAGCCTTGCTTACCTGTTGCCAACATTGGGCCAACCCGAATTCTTCC 960
145 T C I S Q P C L P V A N I G P T R I L P 164

Figure 5B

961	CAATCTTTATCTTGGCTGCCAGCGAGATGTCCTCAACAAGGAGCTGATGCAGCAGAATGG	1020
165	N L Y L G C Q R D V L N K E L M Q Q N G	184
1021	GATTGGTTATGTGTTAAATGCCAGCAATACCTGTCCAAAGCCTGACTTTATCCCCGAGTC	1080
185	I G Y V L N A S N T C P K P D F I P E S	204
1081	TCATTTCCCTGCGTGTGCCTGTGAATGACAGCTTTTGTGAGAAAATTTTGCCGTGGTTGGA	1140
205	H F L R V P V N D S F C E K I L P W L D	224
1141	CAAATCAGTAGATTTCATTGAGAAAGCAAAGCCTCCAATGGATGTGTTCTAGTGCAGCTG	1200
225	K S V D F I E K A K A S N G C V L V H C	244
1201	TTTAGCTGGGATCTCCCGCTCCGCCACCATCGCTATCGCCTACATCATGAAGAGGATGGA	1260
245	L A G I S R S A T I A I A Y I M K R M D	264
1261	CATGTCTTTAGATGAAGCTTACAGATTTGTGAAAGAAAAAGACCTACTATATCTCCAAA	1320
265	M S L D E A Y R F V K E K R P T I S P N	284
1321	CTTCAATTTTCTGGGCCAACTCCTGGCCTATGAGAAGAAGATTAAGAACCAGACTGGAGC	1380
285	F N F L G Q L L A Y E K K I K N Q T G A	304
1381	ATCAGGGCCAAAGAGCAAACCTCAAGCTGCTGCCCCTGGAGAAGCCAAATGAACCTGTCCC	1440
305	S G P K S K L K L L P L E K P N E P V P	324
1441	TGCTGTCTCAGAGGGTGGACAGAAAAGCGAGACGCCCCTCAGTCCACCCTGTGCCGACTC	1500
325	A V S E G G Q K S E T P L S P P C A D S	344
1501	TGCTACCTCAGAGGCAGCAGGACAAAGGCCCGTGCATCCCGCCAGCGTGCCCAGCGTGCC	1560
345	A T S E A A G Q R P V H P A S V P S V P	364
1561	CAGCGTGCAGCCGTCGCTGTTAGAGGACAGCCCGCTGGTACAGGCGCTCAGTGGGCTGCA	1620
365	S V Q P S L L E D S P L V Q A L S G L H	384
1621	CCTGTCCGCAGACAGGCTGGAAGACAGCAATAAGCTCAAGCGTTCCTTCTCTCTGGATAT	1680
385	L S A D R L E D S N K L K R S F S L D I	404
1681	CAAATCAGTTTCATATTCAGCCAGCATGGCAGCATCCTTACATGGCTTCTCCTCATCAGA	1740
405	K S V S Y S A S M A A S L H G F S S S E	424
1741	AGATGCTTTGGAATACTACAAACCTTCCACTACTCTGGATGGGACCAACAAGCTATGCCA	1800
425	D A L E Y Y K P S T T L D G T N K L C Q	444
1801	GTTCTCCCTGTTCAGGAAGTATCGGAGCAGACTCCCGAAACCAGTCCTGATAAGGAGGA	1860
445	F S P V Q E L S E Q T P E T S P D K E E	464

Figure 5C

1861	AGCCAGCATCCCCAAGAAGCTGCAGACCGCCAGGCCTTCAGACAGCCAGAGCAAGCGATT	1920
465	A S I P K K L Q T A R P S D S Q S K R L	484
1921	GCATTTCGGTCAGAACCAGCAGCAGTGGCACCGCCAGAGGTCCCTTTTATCTCCACTGCA	1980
485	H S V R T S S S G T A Q R S L L S P L H	504
1981	TCGAAGTGGGAGCGTGGAGGACAATTACCACACCAGCTTCCTTTTCGGCCTTCCACCAG	2040
505	R S G S V E D N Y H T S F L F G L S T S	524
2041	CCAGCAGCACCTCACGAAGTCTGCTGGCCTGGGCCTTAAGGGCTGGCACTCGGATATCTT	2100
525	Q Q H L T K S A G L G L K G W H S D I L	544
2101	GGCCCCCAGACCTCTACCCCTTCCCTGACCAGCAGCTGGTATTTTGCCACAGAGTCCTC	2160
545	A P Q T S T P S L T S S W Y F A T E S S	564
2161	ACACTTCTACTCTGCCTCAGCCATCTACGGAGGCAGTGCCAGTTACTCTGCCTACAGCTG	2220
565	H F Y S A S A I Y G G S A S Y S A Y S C	584
2221	CAGCCAGCTGCCCCTTGCGGAGACCAAGTCTATTCTGTGCGCAGGCGGCAGAAGCCAAG	2280
585	S Q L P T C G D Q V Y S V R R R Q K P S	604
2281	TGACAGAGCTGACTCGCGGCGGAGCTGGCATGAAGAGAGCCCCTTTGAAAAGCAGTTTAA	2340
605	D R A D S R R S W H E E S P F E K Q F K	624
2341	ACGCAGAAGCTGCCAAATGGAATTTGGAGAGAGCATCATGTCAGAGAACAGGTCACGGGA	2400
625	R R S C Q M E F G E S I M S E N R S R E	644
2401	AGAGCTGGGGAAAGTGGGCAGTCACTCTAGCTTTTCGGGCAGCATGGAAATCATTGAGGT	2460
645	E L G K V G S Q S S F S G S M E I I E V	664
2461	CTCCTGAGAAGAAAGACACTTGTGACTTCTATAGACAATTTTTTTTTCTTGTTCACAAAA	2520
665	S	665
2521	AAATTCCTGGGAATCTGAAATATGTATGTGGGCATACATATATATTTTTGGAAAATGGA	2580
2581	GCTATGGTGTAAGCAACAGGTGGATCAACCCAGTTGTTACTCTCTTAACATCTGCATT	2640
2641	TCAGAGATCAGCTAATACTTGCTCTCAACAAAAATGGAAGGGCAGATGCTAGAATCCCCC	2700
2701	CTAGACGGAGGAAAACCATTTTATTCACTGAATTACACATCCTCTTGTCTTAAAAAAGC	2760
2761	AAGTGTCTTTGGTGTGGAGGACAAAATCCCCTACCATTTTCACGTTGTGCTACTAAGAG	2820

Figure 5D

2821 ATCTCAAATATTAGTCTTTGTCCGGACCCTTCCATAGTACACCTTAGCGCTGAGACTGAG 2880
2881 CCAGCTTGGGGGTCAGGTAGGTAGACCCTGTTAGGGACAGAGCCTAGTGGTAAATCCAAG 2940
2941 AGAAATGATCCTATCCAAAGCTGATTACAAACCCACGCTCACCTGACAGCCGAGGGACA 3000
3001 CGAGCATCACTCTGCTGGACGGACCATTAGGGGCCTTGCCAAGGTCTACCTTAGAGCAAA 3060
3061 CCCAGTACCTCAGACAGGAAAGTCGGGGCTTTGACCACTACCATATCTGGTAGCCCATTT 3120
3121 TCTAGGCATTGTGAATAGGTAGGTAGCTAGTCACACTTTTCAGACCAATTCAAACCTGTCT 3180
3181 ATGCACAAAATTCCCGTGGGCCTAGATGGAGATAATTTTTTTTCTTCTCAGCTTTATGA 3240
3241 AGAGAAGGGAAACTGTCTAGGATTCAGCTGAACCACCAGGAACCTGGCAACATCACGATT 3300
3301 TAAGCTAAGGTTGGGAGGCTAACGAGTCTACCTCCCTCTTTGTAAATCAAAGAATTGTTT 3360
3361 AAAATGGGATTGTCAATCCTTTAAATAAAGATGAACTTGGTTTCAAGCCAAATGTGAATT 3420
3421 TATTTGGGTTGGTAGCAGAGCAGCAGCACCTTCAAATTCCTCAGCCAAAGCAGATGTTTTT 3480
3481 GCCCTTTCTGCTTCACTGCATGGATACAGTTGGTAAATGTAATAATATGGCAGAATTTT 3540
3541 ATAGGAAACTTCCTAGGGAGGTAAATTATGGGAAGATTAAGAAAGGTACAAATTGCTGAG 3600
3601 GAGAAGCAGGAAACCTGTTTCCTTAGTGGCTTTTATCCCCTCGGCATGCGATGGGGCTGA 3660
3661 TGTTTCTATAATTGCCTCAGACTTTCACATTTACTAGTAGGGCTGAGAGAGGCTTTAGTG 3720
3721 AGGAAAGAATATTCAGAATAAAACGGTTGAGAAAGCTGAGAAGACCATTGAGTTTTGATC 3780
3781 AGTTGTGAATAGAGTGCAAAGCCATGGCCAAGCTGTTTTTGGAAACGCTGGCCGGCGTGT 3840
3841 CTTCAGTGGA AAAAGCAAATCAAATGGAGCGAGAGCAAAGGGGCGTCTCAGTCCTCAA 3900
3901 CCTACAATCACTGTATGGAATCGGTCCTGGCAGCTGAACATAGGAGGTCACTGGAACAAG 3960
3961 TGATAGTGCAGATTGGCTTTCAAACATCCTCCTGGCTTGAGTTTTATCAGCTACAATGTG 4020

Figure 5E

4021 GGTCTCTTTTGAAGCCTTAATTCACAACAGCAGCTTTTGGGGGTGGGGCTGGGCGGGT 4080
4081 GTTGTCAATTGTTCTTTCCCTTCCTGTAAGTGTGCTAGTTGCTGCCTCGTATCTCAGGTT 4140
4141 TTTCTCTGTTTTTGAGAAATGGACAGTTTTTTGACCAGGATGTGACTTCATGTTTCCTAT 4200
4201 GGTGACTTCTAAAACCAGCACAGAATGATATGACTCAACACAGACCGACTTGGTTATGGG 4260
4261 GATGATGAGCCGCACAGACCTCACTAGTTGTGCACAAATAATGTGCTATGATGGGGTGTA 4320
4321 AAGTGAAGGCAGAAGAGGGTCAGCCGCATTGTTATGATACTGGGAAAGTGCCGGTCAACG 4380
4381 ATTTGAGTTAGTTTTTAGATATACATTGAAATCTTTAATCAGACATTCTCAAGTTTCACA 4440
4441 CAGTAGTTTTTGATGTTATGTACACACACACCAAATGTGTAACAGTTCACCACTTCCAGA 4500
4501 GTGTGGTCATGCCCAAACATGTTTAAGAAAGGAAAGCAGTAGCTCCTTGCTAACGATGT 4560
4561 TTCAGGAGGTTTGGGGCACTTGGTTTTAATGAGCTTCTGTCAATTTAGGGCTTCTCTTGGC 4620
4621 CATGGTCCCCTTCCTTCTGGAAGTGTGATGTAGTCACATCCTACAGCCTTTAGTGCTGGT 4680
4681 TCACTAGTGTGAGATAATCAGTTCTTGGAAATCGAGACTGCCGTGGCGAAGGGGTGGCCTC 4740
4741 GGAGGCAGGCTCTGGAGCTGCTTGGATGTCTTTAGGTGGGGTGGTGGCTGGCTCTCTTCA 4800
4801 GCATGTAATTGGGGAAACCCTCGCGTCTACTAGGGGTGATACAGATGGTGATTTTAAAGA 4860
4861 GCAAACTAGACTTCTATGTGAGAAGTGCTGGAAAATGATTTAGGACGTGTAAAGTTAGA 4920
4921 TGGAAAGACTGTAAATGTTTAATATGAATATAGTGTTCTTTTGAAGTAAGGCCAGCTGTT 4980
4981 GAACGGTTAAACTGTGCATTTCTCATTTTGATGTGTCATGTATGTTAATGTATGAAATGA 5040
5041 TTAAATAAAATCAAACTGGTACCTGTTTATCCATAAAAAAAAAAAAAAAAAAAAAA 5100
5101 AAAAAAAAAAAG 5111

Figure 6A

	1	50
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(1)	MGHLPTGIHGARRLLPLLWLFVLFKNATAFHVTVQDDNNIVVSLEASDVI
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	51	100
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(51)	SPASVYVVKITGESKNYFFEFEEFNSTLPPPVIFKASYHGLYYIITLVVV
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	101	150
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(101)	NGNVVTKPSRSITVLTKPLPVTSVSIYDYKPSPETGVLFEIHYPEKYNVF
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	151	200
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(151)	TRVNISYWEKDFRTMLYKDFFKGKTVFNHWLPGMCYSNITFQLVSEATF
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	201	250
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(201)	NKSTLVEYSGVSHEPKQHRTAPYPPQNISVRIVNLKNNWEEQSGNFPEE
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	251	300
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(251)	SFMRSQDTIGKEKLFHFTEETPEIPSGNISSGWPDFNSSDYETTSQPYWW
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	301	350
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(301)	DSASAPESEDEFVSVLPEYENNSTLSETEKSTSGSFSFFPVQMILTWL
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	351	400
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(351)	PPKPPTAFDGFHIIHIEREENFTEYLMVDEEAHEFVAELKEPGKYKLSVTT
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----

12/155

FIGURE 6B

	401	450
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(401)	FSSSGSCETRKSQSAKSLSFYISPSGEWIEELTEKPOHVSVHVLSSTTAL
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	451	500
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(451)	MSWTSSQENYNSTIVSVSLTCQKQKESORLEKQYCTQVNSSKPIIENLV
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	501	550
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(501)	PGAQYQVVIYLRKGPLIGPPSDPVTFAIVPTGIKDLMLYPLGPTAVVLSW
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	551	600
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(551)	TRPYLGVFRKYVVMFYFNPATMTSEWTTYEIAATVSLTASVRIANLLP
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	601	650
BMV_HPP1_FL	(1)	-----
BMV_HPP1_A	(1)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(601)	AWYYNFRVTMVTWGDPELSCCDSSTISFITAPVAPEITSVEYFNLSLLYIS
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	651	700
BMV_HPP1_FL	(1)	-----MEAGINFNFGWKDYGVASLTIDMVKVMTFALQEG-K
BMV_HPP1_A	(1)	-----LVYINFNFGWKDYGVASLTILD MD VKVMTFALQEGKV
BMV_HPP1_B	(1)	-----
HS_RPTPO	(651)	WTYGD DT TDL SH SRML HW MVVAEGKKKIKKSV TR NVMTAILSLPPGDIYN
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	701	750
BMV_HPP1_FL	(37)	VIHCHAGLGRTGVLIAYLVFATRMTADQAIIVRAKRPNSIQTRGQLCVRE
BMV_HPP1_A	(37)	AIHCHAGLGRTG-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(701)	LSVTACTERG S NTSMLRLVKLEPAPPKSLFAVNKTQTSVTL L WVEEGVAD
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----
	751	800
BMV_HPP1_FL	(87)	FTQFLTPLRNISCCDPKAHAVTLPQYIRQRHLLHGYEARLLHVPKIIHLV
BMV_HPP1_A	(49)	-----
BMV_HPP1_B	(1)	-----
HS_RPTPO	(751)	FFEVFCCQVGS S OKTKLQEPVAVSSHVV T ISSLLPATAYNC S VTFSHDS
MM_RPTPO	(1)	-----
PYP3_SP	(1)	-----

FIGURE 6C

		801	850
BMV_HPP1_FL	(137)	CKLLLD AENRPVMMKDVSEGPLS A E I E K T M S E M V T M I D K E I L R H D S D V S N	
BMV_HPP1_A	(49)	-----	
BMV_HPP1_B	(1)	-----	
HS_RPTPO	(801)	PSVPTFIAVSTMVTEMNPNVVVISVLA ILS TLLIGL L LVT I I L R K K H L Q	
MM_RPTPO	(1)	-----M V T E V N P N V V I S V L A I L S T L L I G L L L V T I V I L R K K H L Q	
PYP3_SP	(1)	-----	
		851	900
BMV_HPP1_FL	(187)	PNPTAV A A D E D N R G M I S N E Q Q F D P L K K R N ----V C L Q P L T H L K R R L S Y S	
BMV_HPP1_A	(49)	-----	
BMV_HPP1_B	(1)	-----	
HS_RPTPO	(851)	MARECG A G T E V N F A S L E R D G K L P Y N M S ----	
MM_RPTPO	(40)	MARECG A G T E V N F A S L E R E G K L P Y S W R R S V F A L L T L L P S C L W T D Y L L A F Y	
PYP3_SP	(1)	-----	
		901	950
BMV_HPP1_FL	(233)	SDLKRAEN I L E Q G E I Q T V P A Q I L V C H K P R O K L I S H C Y I P Q S F E P D H K E A L	
BMV_HPP1_A	(49)	-----	
BMV_HPP1_B	(1)	-----	
HS_RPTPO	(878)	-----K N G I K K R K L I N F V O L D D F D A Y I K D M A K D S D Y K F S L Q F E E L K I I G L	
MM_RPTPO	(90)	I N P W S K N G I K K R K L I N F V O L D D F D S Y I K D M A K D S D Y K F S L Q F E E L K I I G L	
PYP3_SP	(1)	-----M S F K E V S T E N G V L T P L I T I K E K A Y M I E G L N E E E I E L	
		951	1000
BMV_HPP1_FL	(283)	VRSTLS F W S O K F G G L E G L K D N G S P I H G R T I P K E A Q O S G A F A D V S G S H S E G	
BMV_HPP1_A	(49)	-----	
BMV_HPP1_B	(1)	-----	
HS_RPTPO	(923)	D I P H F A A D L P L N R C K N R Y T N I L P Y D F S R V R L V S M N E E E G A D Y I N A N Y I P G	
MM_RPTPO	(140)	D I P H F A A D L P L N R C K N R Y T N I L P Y D F S R V R L V S M N E E E G A D Y I N A N Y I P G	
PYP3_SP	(38)	L N T R L K L S K K A L A R N R Y S N I V P Y E N T R V R L D P M W K - E A C D Y I N A S I W K I	
		1001	1050
BMV_HPP1_FL	(333)	EPVSPFANVHKD P N A H Q O V H C O C K T H G V G S P G S V O N S R T P R S P L D C G S S	
BMV_HPP1_A	(49)	-----	
BMV_HPP1_B	(1)	-----D V F W A L L W N T V -----	
HS_RPTPO	(973)	Y N S P O E Y I A T O G P L P E T R N D F W K M V L O O K -- S O L I V M L T Q C N E K R R V K C D	
MM_RPTPO	(190)	Y N S P O E Y I A T O G P L P E T R N D F W K M V L O O K -- S H I I V M L T Q C N E K R R V K C D	
PYP3_SP	(87)	P - S G K T E I A T O G P T S N S I D V F W K M V Q S V P K S G I I V M L T K L R E R H R L K C D	
		1051	1100
BMV_HPP1_FL	(383)	KAQFLV E H E T Q D S K D S E A A S H S A L Q S E L S A A R R I L A A K A L A N L N E V E K E E	
BMV_HPP1_A	(49)	-----	
BMV_HPP1_B	(12)	-----	
HS_RPTPO	(1021)	H Y W P F T E P I A Y G D I T V E M I S E E -----E Q D - D W A C R H E R	
MM_RPTPO	(238)	H Y W P F T E P I A Y G D I T V E M V S E E -----E E E - D W A S R H E R	
PYP3_SP	(136)	I Y W P V E L F E T L N I G D L S V I L V K V Y T -----L T S L N E V Q V R E E E	
		1101	1150
BMV_HPP1_FL	(433)	L K R K V E M W Q K L N S R D G A M E R I C G E R P F I L C S L M W S W V E X L E P V I T K E I V D	
BMV_HPP1_A	(49)	-----	
BMV_HPP1_B	(12)	-----	
HS_RPTPO	(1055)	I N Y A D E M O D V M H E N Y T A W P D H G V E T A N A A E S I L Q F V H M V R Q O A T K S K G E M	
MM_RPTPO	(272)	I N Y A D E A Q D V M H E N Y T G W P D H G V E P A N A A E S I L Q F V F T V R Q O A A K S K G E M	
PYP3_SP	(174)	I N K D G V K K K I L H E Y N G W P D F C A E H T F S L L S L T R Y I K S L S Y S P D F E T A E I	
		1151	1200
BMV_HPP1_FL	(483)	M L V D R A D A A E A L F L L E K G O H T I L C V L E C I V N I Q T I V D V E E A F L A H A T R A F	
BMV_HPP1_A	(49)	-----	
BMV_HPP1_B	(12)	-----	
HS_RPTPO	(1105)	I I H C S A G V G R T G T F I A L D R L L Q H I R D H E F V D I L G L V S E M R S Y R M S M V O T E	
MM_RPTPO	(322)	I I H C S A G V G R T G T F I A L D R L L Q H I R D H E F V D I L G L V S E M R S Y R M S M V O T E	
PYP3_SP	(224)	I V H C S A G C G R T G T F E A L F E I L S Q T D D S T S T S K F E V D N I A N I V S S L R S O R M	

FIGURE 6D

		1201	1237
BMV_HPP1_FL	(533)	KVNFDSENGPTVYNTRKIFKHTLEBKRKMTDGPKEGL	
BMV_HPP1_A	(49)	-----	
BMV_HPP1_B	(12)	-----	
HS_RPTPO	(1155)	EQYIFIHOCVQIMWMRKQOFCISDVIYENVSKS---	
MM_RPTPO	(372)	EQYIFIHOCVQIMWLRKQOFCISDVIYENVSKS---	
PYP3_SP	(274)	QSVQSDOLVFITYTVSQELLOGKEFLLPQL-----	

Figure 7A

		1	50
BMV_HPP2_FL	(1)	-----	-----
BMV_HPP2.partial	(1)	-----	-----
HS_CDC14A	(1)	-----	-----
HS_CDC14B	(1)	MKRKSERSSSWAAAPCSRCSSTSPGVKKIRSSSTQDPRRRDPODDVYL	
SC_CDC14	(1)	-----MRRSVYLDNTIE	
		51	100
BMV_HPP2_FL	(1)	-----	-----
BMV_HPP2.partial	(1)	-----	-----
HS_CDC14A	(1)	-MKDRLYFATLRNRPKSTVNTHYFSIDEELVYENFYADFGPLNLAMVYRY	
HS_CDC14B	(51)	DLTDRLCFALLYSRPKSASNVHYFSIDNELEYENFYADFGPLNLAMVYRY	
SC_CDC14	(13)	FLRGVYVLGAYDYTFEDTDELVEFFVEDALFYNSFHLDFGPMNIGHLYRF	
		101	150
BMV_HPP2_FL	(1)	-----	-----
BMV_HPP2.partial	(1)	-----	-----
HS_CDC14A	(50)	CCKLNKKLKSYSLSRKKTVHYTCFDOQRANAAFLIGAYAVIYKKTPEE	
HS_CDC14B	(101)	CCKINKKLKSITMLRKKTVHYTGSDQKQANAAFLVGCYMVYILGRTPPEE	
SC_CDC14	(63)	AVIFHEILNDPENANKAVVEYSSASTQRANAA CMLCCYMLVQAWTPHQ	
		151	200
BMV_HPP2_FL	(1)	-----	-----
BMV_HPP2.partial	(1)	-----	-----
HS_CDC14A	(100)	AYRALLSGSNPYYLFFRDASFGNCTYNLTILDCLQIRKGLQCFDFDFT	
HS_CDC14B	(151)	AYRIIFG-ETSYLFFRDAAYGSCNFYITLLDCFHAVKKAMQYGLNFNS	
SC_CDC14	(113)	VLQPLAQV-DPPFMPFRDAGYSNADFETITQDVVYGVWRRAKEKGLIDLHS	
		201	250
BMV_HPP2_FL	(1)	-----MGVOPPNFSVLPGRLAGIALPR-----	
BMV_HPP2.partial	(3)	GRRRGQVGAMGVOPPNFSVLPGRLAGIALPR-----	
HS_CDC14A	(150)	IDVDEYEHYERVENCDNCTVPGKFLAESGPHPKSKI-----ENGYPLHA	
HS_CDC14B	(200)	FNLDEYEHYKAEAGDNLNLIIDRFIAECGPHSRARL-----ESGYHQHS	
SC_CDC14	(162)	FNLESYKYEHEVEFGDFNVLTPE-DEIAFASPOEDHPKGYLATKSSHLNQP	
		251	300
BMV_HPP2_FL	(24)	LPAPHYQFLLDLGVRLVSLTERG-PPHSDSCPGLTLRLRLIPDFOPAPD	
BMV_HPP2.partial	(35)	LPAPHYQFLLDLGVRLVSLTERG-PPHSDSCPGLTLRLRLIPDFOPAPD	
HS_CDC14A	(195)	PEAYFPYFKKHVNTAVVRLNKKIYEAKRETDAQFEBHYDLFFIDGSTPSDN	
HS_CDC14B	(245)	PETIYIQYFKNHVTTIIRLNKRMVDAKRETDAQFDHDLFFADGSTPTDA	
SC_CDC14	(211)	FKSVLNFANNNVQLVRLNSRLYNKKHEEDIGIQHLDLIFEDGTCFPLS	
		301	350
BMV_HPP2_FL	(73)	QIDREVOIVDEANARGEAVGVHCALCEGRTGTMLACYLVKERGLAAGDAI	
BMV_HPP2.partial	(84)	QIDREVOIVDEANARGEAVGVHCALCEGRTGTMLACYLVKERGLAAGDAI	
HS_CDC14A	(245)	IVRRELNICENTEG---ATAVHCKAGLGRTGTLLIACYVMKHRYETHAEII	
HS_CDC14B	(295)	IVKEBELDICENAE---ATAVHCKAGLGRTGTLLIACYIMKHRYMTAAETH	
SC_CDC14	(261)	IVKNEVGAETIIRGGKLAHVHCKAGLGRTGCLIGAHLLIYTCETANECH	
		351	400
BMV_HPP2_FL	(123)	AEIRRLRPGSIETYEQEKAVEQFYORK-----	
BMV_HPP2.partial	(134)	AEIRRLRPGPIETYEQEKAVEQFYORKKXGALVPFYQALTPLPHVVDGAR	
HS_CDC14A	(292)	AWIRICRPGSIIGPQQH---FLEEKQASLWVGDIERSKLNRPSS---	
HS_CDC14B	(342)	AWVIRICRPGSVIGPQQ---FLVMKQTNLWLEGDYEROKLKGQENGQ---	
SC_CDC14	(311)	GFLREIRPGMVVGPOQH---WLYLHONDFREWKYTTRISLRKPSEAIG---	
		401	450
BMV_HPP2_FL	(151)	-----	-----
BMV_HPP2.partial	(184)	DEGKWTQVNLNPIAPIGXRXSSPPLQAGPDXRGGLYCFVEXMFTNQGKK	
HS_CDC14A	(335)	-EGSINKILSGIDDMSTGGNLSKTQNMERFGEDNLEDDDVEMKNGITQGD	
HS_CDC14B	(386)	HRAAFSKILSGVDDISINGVENQDQ-----QEPEPYSDDEIN-GVTQGD	
SC_CDC14	(355)	-----GLYPLISFEYRLQKKKLKDDKRVAQNNIEGELRDLTTPPSNGHG	

FIGURE 7B

		451		500
BMV_HPP2_FL	(151)	-----		-----
BMV_HPP2.partial	(234)	KKKKRKKKKKKKKR		-----
HS_CDC14A	(384)	KLRALKSQRQPRTPSPCAFRSDDTKGHPRAVSQPFRLSSSLQGS		SAVTLKT
HS_CDC14B	(430)	KLRALKSRRO	SK	TNAIPLTLISIRIKTVLR
SC_CDC14	(401)	ATSRNSSQP		STANNGSNSFKSSAVPQTS
		501		550
BMV_HPP2_FL	(151)	-----		-----
BMV_HPP2.partial	(249)	-----		-----
HS_CDC14A	(434)	SKMALSPSATAKRINRTSLSSGATVRSFSINSRLASSLGNLNAATDDPEN		
HS_CDC14B	(460)	-----		-----
SC_CDC14	(430)	-----	PGQPRKGQNGSNTIEDINNNRNPTSHANR	
		551		600
BMV_HPP2_FL	(151)	-----		-----
BMV_HPP2.partial	(249)	-----		-----
HS_CDC14A	(484)	KKTSSSSKAGFTASPFTNLLNGSSQPTTRNYPELNNNQYNRSSNSNGGNL		
HS_CDC14B	(460)	-----		-----
SC_CDC14	(459)	KVVIENNSDDDESMQDTNGTSNHYPKVSRRKNDISSASSSRMEDNEPSAT		
		601		647
BMV_HPP2_FL	(151)	-----		-----
BMV_HPP2.partial	(249)	-----		-----
HS_CDC14A	(534)	NSPPGPHSAKTEEHTTILRPSYTLGLSSSSARFLSRISPSLQSEYVHY		
HS_CDC14B	(460)	-----		-----
SC_CDC14	(509)	NINNAADDTILRQLLPKNRRVTSGRRTTSAAGGIRKISGSIKK		----

Figure 8

		1		50
BMV_HPP3	(1)	-----MARMNL	PASVDIAYKNVREFLITHNPTNTYFNRFLOELKQDGVTTIL	
DM_PRL1	(1)	MSITMRQDLRPAEALIEYKGMKFLITDRPSDITINHYTMELKKNNVNTV		
HS_PTPCAAX1	(1)	-----MARMNR	PAPVEVTYKNMREFLITHNPTNATLNKFIEELKKYGVTTI	
HS_PTPCAAX2	(1)	-----MNR	PAPVEISYENMREFLITHNPTNATLNKFIEELKKYGVTTI	
MM_PTPCAAX	(1)	-----MNR	PAPVEISYENMREFLITHNPTNATLNKFIEELKKYGVTTI	
CONSENSUS	(1)		RMNRPAPEISYKNMREFLITHNPTNATLNKFIEELKKYGVTTI	
		51		100
BMV_HPP3	(46)	VRVXKATYNIALLEKGSIQVPDWFEDDGTAPSSQIIDNWLLKLMKNKFED		
DM_PRL1	(51)	VRVCEPSYNTDELETQGITVKDLAFEDGTFFPQQVVDWFEFFVVLRYQ		
HS_PTPCAAX1	(46)	VRVCEATYDTTLVEKEGIHVLDWPFDDGAPPNQIVDDWLSLVKIKFREE		
HS_PTPCAAX2	(43)	VRVCDATYDKAPVEKEGIHVLDWPFDDGAPPNQIVDDWLNLLKTFREE		
MM_PTPCAAX	(43)	VRVCDATYDKAPVEKEGIHVLDWPFDDGAPPNQIVDDWLNLLKTFREE		
CONSENSUS	(51)	VRVCDATYD A VEKEGIHVLDWPFDDGAPPNQIVDDWL LLK KFREE		
		101		150
BMV_HPP3	(96)	--PGCCIAIHCVVGEGXLOLLVALALIEGGMKYENVVQFIRXKXHGTFNS		
DM_PRL1	(101)	QNPEACVAVHCVAGLGRAPVLVALALIELGLKYEAAVEMIRDKRRGATNA		
HS_PTPCAAX1	(96)	--PGCCIAVHCVAGLGRAPVLVALALIEGGMKYEDAVQFIROKRRGAFNS		
HS_PTPCAAX2	(93)	--PGCCVAVHCVAGLGRAPVLVALALIECGMKYEDAVQFIROKRRGAFNS		
MM_PTPCAAX	(93)	--PGCCVAVHCVAGLGRAPVLVALALIECGMKYEDAVQFIROKRRGAFNS		
CONSENSUS	(101)	PGCCVAVHCVAGLGRAPVLVALALIE GMKYEDAVQFIROKRRGAFNS		
		151		180
BMV_HPP3	(144)	KOLLYLEKYCLKICHLRNPRNN--CFLO		
DM_PRL1	(151)	KOLSELEKYKPNARLKHKNHKN--SCSVQ		
HS_PTPCAAX1	(144)	KOLLYLEKYRPKMRLRFKDSNGHRNCCIQ		
HS_PTPCAAX2	(141)	KOLLYLEKYRPKMRLRFRTDNGH--CCVQ		
MM_PTPCAAX	(141)	KOLLYLEKYRPKMRLRFRTDNGH--CCVQ		
CONSENSUS	(151)	KOLLYLEKYRPKMRLRFRTDNGH	CCVQ	

Figure 9A

BMV_HPP4	(1)	1101	1150
MM_OST-PTP	(1101)	RRRLKGRSEKNGFSQELMPYNLWRTHRPIPSHSF	LRQNYEAKSAHAHQAF
RN_PTP-OST	(1101)	WRCLKGRSEKDGFSKELMPYNLWRTHRPIPIHSF	RQSYEAKSAHAHQAF
CONSENSUS	(1101)	R LKGRSEK GFS ELMPYNLWRTHRPIP HSF	RQSYEAKSAHAHQAF
BMV_HPP4	(17)	1151	1200
MM_OST-PTP	(1151)	FLKFE-LKEVSKQOPRLEAEHPANTTKNCXPHVLPYDHSRVRLTQL	GEF
RN_PTP-OST	(1151)	FOEFELKEVGKDQPRLEAEHPANITKNRYPHVLPYDHSRVRLTQL	SGEF
CONSENSUS	(1151)	FOEFELKEVGKDQPRLEAEHPANITKNRYPHVLPYDHSRVRLTQL	GEF
BMV_HPP4	(66)	1201	1250
MM_OST-PTP	(1201)	HSDYINANLVP-YTRPQEFIASOGPLKKTLENFWRLVREQQVRI	IIMPTI
RN_PTP-OST	(1201)	HSDYINANFIPGYSHPQEFIIATOGPLKKTLEDFWRLVREQQVHVI	IIMLTIV
CONSENSUS	(1201)	HSDYINANFIPGYSHPQEFIIATOGPLKKTLEDFWRLVREQQVHVI	IIMLTIV
BMV_HPP4	(115)	1251	1300
MM_OST-PTP	(1251)	SMENGR-LCEHYWLTDPSTPDTHGHITILLAAEP	EDEWTKREFOLQHV-Q
RN_PTP-OST	(1251)	GMENGRVLCHEYWPNSTPVTTHGHITILLAAES	EDEWTRREFOLQHGA
CONSENSUS	(1251)	GMENGRVLCHEYWP NSTPVTTHGHITILLAAEP	EDEWTRREFOLQHG E
BMV_HPP4	(163)	1301	1350
MM_OST-PTP	(1301)	QKQRRVKQLQFTTWDHSEVPEAPSSLLAFVELVQEVKATQKG	PILVHC
RN_PTP-OST	(1301)	QKQRRVKQLQFTTWDHSEVPEAPSSLLAFVELVQEQVATQKG	PILVHC
CONSENSUS	(1301)	QKQRRVKQLQFTTWDHSEVPEAPSSLLAFVELVQEQVATQKG	PILVHC
BMV_HPP4	(213)	1351	1400
MM_OST-PTP	(1351)	RGCPCGVCMGRTGTFFVALSRLLQLEEEQMVDFVHAYVALRMH	QPLMIQT
RN_PTP-OST	(1351)	S-----AGVGRGTGTFFVALSPAVRQLEEEQVVDVENTVYILRL	HRPLMIQT
CONSENSUS	(1351)	S-----AGVGRGTGTFFVALRLRLQLEEEQVVDVENTVYILRL	HRPLMIQT
BMV_HPP4	(263)	1401	1450
MM_OST-PTP	(1396)	L-QYVFLHSCLLNKILEGPFNISESWPISVTLPOACAKRAAS	ANAGFLK
RN_PTP-OST	(1396)	LSQYIFLHSCLLNKILEGPDSDSGPISVMDFAQACAKRAAN	ANAGFLK
CONSENSUS	(1401)	LSQYIFLHSCLLNKILEGPDSDSGPISVMDFAQACAKRAAN	ANAGFLK
BMV_HPP4	(312)	1451	1500
MM_OST-PTP	(1446)	EY-----ETKDEAGFSAPFGYEODSPVSYDRSQGFSPVEES	SPDDMPL
RN_PTP-OST	(1446)	EYRLKQAIKDETCGLLEPPDYNNNSIASCHSQEQALALVEES	SPADNMLA
CONSENSUS	(1451)	EYKLLKQAIKDETCGLLEPPDYNNNSIVSRHSQEQFALVEES	CPEDSMLE
BMV_HPP4	(357)	1501	1550
MM_OST-PTP	(1496)	WKPMICALOGGPGSRDHTVLTGPAAGPKELWELVWQHRAHVLVSL	CPENVM
RN_PTP-OST	(1496)	ASLFP-----GGPSGRDHVLTGSAGPKELWEMVWEHGAHVLVSL	GLPDTK
CONSENSUS	(1501)	ASLFP-----GGPSGRDHVLTGSAGPKELWEMVWEHGAHVLVSL	GLPDTK
BMV_HPP4	(407)	1551	1600
MM_OST-PTP	(1542)	EK---EWPIEMQPVVTDVMTVHVVAES-STAGWFCITLLRVTHESR	KERE
RN_PTP-OST	(1542)	EKEPDIWPMEMQPIVTDVMTVHVVAESN-TAGWPSTLIRVIHGD	SGTERQ
CONSENSUS	(1551)	EKPPDIWPMEMQPIVTDVMTVHVVAESNTTGWFPSTLIRVIHGD	SGKERO
BMV_HPP4	(452)	1601	1650
MM_OST-PTP	(1591)	VQRLQFFYLEPGHELPAITLLPFLAAGVQCCSRGNNKKPCTLLSHS	NNKA
RN_PTP-OST	(1592)	VQCLOFFHCETGSELPAITLLPFLDAVGQCCSRGNSKKPCTLLSHS	SKVT
CONSENSUS	(1601)	VQCLOFFHCESGCELPAITLLPFLDAVGQCCSRGNSKKPCTLLSHS	SKNT

Figure 9B

		1651		1700
BMV_HPP4	(502)	TQLCTFLAMEQLLQQAGSECTVDIENVALQCSQACGLMTPTLQYVYLYN		
MM_OST-PTP	(1641)	NQLSTFLAMEQLLQQAGTERTVDVESVALKQTQACGLKPTTLEQYIYLYN		
RN_PTP-OST	(1642)	NQLSTFLAMEQLLQQAGTERTVDVENVALKQSQACGLMTPTLEQYIYLYN		
CONSENSUS	(1651)	NQLGTFLAMEQLLQQAGTERTVDVFENVALKQSQACGLMTPTLEQYIYLYN		

		1701		1720
BMV_HPP4	(551)	CLNSALADGLP-----		
MM_OST-PTP	(1691)	CLNSALRNRLPRARK-----		
RN_PTP-OST	(1692)	CLNSALLNGLPRACKWPAPC		
CONSENSUS	(1701)	CLNSAL NGLPRA K		

Figure 10A

	1		50
BMV_HPP5	(1)	-MAHEMIGTQIVTERIVALLSSTEKVLIDSRPFVEYNTSHILEAININ	
HS_DSPP8	(1)	MAGDRLPRKVMDAKKLASLLRGCGGGPLVIDSRSFVEYNSWHVLSVNIC	
MM_NPP1	(1)	MAGDRLPRKVMDAKKLASLLRGCGGGPLVIDSRSFVEYNSCHVLSVNIC	
CONSENSUS	(1)	MAGDRLPRKVMDAKKLASLLRGCGGGPLVIDSRSFVEYNS HVLSSVNIC	
	51		100
BMV_HPP5	(50)	CSKLMKRRLOODKVLITELIQHSAKHKVIDDCSOKVVVYDQSSODVASLS	
HS_DSPP8	(51)	CSKLVKRRLOOGKVTIAELIQPAARSOVEATEPQDVVVYDQSTRDASVLA	
MM_NPP1	(51)	CSKLVKRRLOOGKVTIAELIQPATRSQVDATEPQDVVVYDQSTRDASVLA	
CONSENSUS	(51)	CSKLVKRRLOOGKVTIAELIQPAARSOVDATEPQDVVVYDQSTRDASVLA	
	101		150
BMV_HPP5	(100)	SDCFLTVLLGKLEKSENSVHLIAGGFATFSRCFPGLCEGK-STLVETCTIS	
HS_DSPP8	(101)	ADSFLSILLSKLDGCFDSVAITLGGFATFSSCFPGLCEGKPAALPMSLS	
MM_NPP1	(101)	ADSFLSILLSKLDGCFDSVAITLGGFATFSSCFPGLCEGKPATLPMSLS	
CONSENSUS	(101)	ADSFLSILLSKLDGCFDSVAITLGGFATFSSCFPGLCEGKPATL PMSLS	
	151		200
BMV_HPP5	(149)	QPCLPVANIGPTRILENLYLGCORVDVLNKELMQONGIYVLNASNTPCKP	
HS_DSPP8	(151)	QPCLPVPSVGLTRILEHLYLGSQKDVLNKDLMTQNGISYVLNASNSCPKP	
MM_NPP1	(151)	QPCLPVPSVGLTRILEHLYLGSQKDVLNKDLMTQNGISYVLNASNSCPKP	
CONSENSUS	(151)	QPCLPVPSVGLTRILEHLYLGSQKDVLNKDLMTQNGISYVLNASNSCPKP	
	201		250
BMV_HPP5	(199)	DFIPESHFLRPVNDSTCEKILPWLDKSVDIEKAKASNGCVLVHCLAGI	
HS_DSPP8	(201)	DFICESRFRMPINDNYCEKILPWLDKSIEFIDKAKLSSCOVIVHCLAGI	
MM_NPP1	(201)	DFICESRFRMPINDNYCEKILPWLDKSIEFIDKAKLSSCOVIVHCLAGI	
CONSENSUS	(201)	DFICESRFRMPINDNYCEKILPWLDKSIEFIDKAKLSSCOVIVHCLAGI	
	251		300
BMV_HPP5	(249)	SRSATIAIAYIMKRMDSLDAYRFVKEKRPITSPNFNFLGQLLAYEKKI	
HS_DSPP8	(251)	SRSATIAIAYIMKTMGMSSDDAYRFVKDRRPSISPNFNFLGQLLEYERTL	
MM_NPP1	(251)	SRSATIAIAYIMKTMGMSSDDAYRFVKDRRPSISPNFNFLGQLLEYERST	
CONSENSUS	(251)	SRSATIAIAYIMKTMGMSSDDAYRFVKDRRPSISPNFNFLGQLLEYER L	
	301		350
BMV_HPP5	(299)	KNOTGASGPKSKLKLPLEKPEPVPAVSEGGQKSETPISEPCCADSATSE	
HS_DSPP8	(301)	KLLAALQGDGP---TPSGTP---EPPPSPAAGAPLE---RLPPPTSESAATG	
MM_NPP1	(301)	KLLAALQTDGP---HTGTP---EPLMGPAACIPLP---RLPPSTSESAATG	
CONSENSUS	(301)	KLLAALQGD L EP P PAAG PLP RLPPPTSESAATG	
	351		400
BMV_HPP5	(349)	AAGQRP---VHPASVPSVPSVQPSLLEDSPVVOALSGLHLSADRIEDSNKL	
HS_DSPP8	(344)	NAAAR---EGGLSAGGEPPAPPTPATSAALQGLRGLHLSSDRIQDTNRL	
MM_NPP1	(343)	SEAATAAREGSPSAGGDAPLPSTAPATSAALQGLRGLHLSSDRIQDTNRL	
CONSENSUS	(351)	AAAR EG SAGG PP PPT PATSALQOGLRGLHLSSDRIQDTNRL	
	401		450
BMV_HPP5	(397)	KRSFSLDIKSVSYASMAASLHGFSSSEDALEYKYSTTLDGTNKLQFS	
HS_DSPP8	(391)	KRSFSLDIKSAYAPSRRPDGGPP-----DPGEAPKLCKLD	
MM_NPP1	(393)	KRSFSLDIKSAYAPSRRPDGGPP-----DPGEAPKLCKLD	
CONSENSUS	(401)	KRSFSLDIKSAYAPSRRPD GGPP DPGEAPKLCKLD	
	451		500
BMV_HPP5	(447)	PVQELSEQTEETSPDKKEASIPKKLQTAEPSPDSQSKRLHSVRTSSSGTQ	
HS_DSPP8	(427)	SPSGAALGLSSSPDSPDAPEARPRRRRPP-----P-----AG	
MM_NPP1	(429)	SPSGGTLGLPSPDSPDSVFECPRRRRRPP-----P-----AS	
CONSENSUS	(451)	SPSG LGLPSPDSPDA PE RPRRRR P A	
	501		550
BMV_HPP5	(497)	RSLLSPLRSQS-VEDNYHTSFLFGLSTSQHLLTKSAGLGLKGWHSIDILA	
HS_DSPP8	(463)	SPARSPAHSLGLNFGDAAROTPRHGLSALSAPGLPGPGQAPAGGAWAPPL	
MM_NPP1	(464)	SPARSPAHGLGLNFGDAROTPRHGLSALSAPGLPGPGQAPAGGQWVPL	
CONSENSUS	(501)	SPARSPAH LGLNFGD AROTPRHGLSALSAPGLPGPGQAPAGG W PPL	

[illegible]

Figure 11




Figure 12.

BMV HPP5

<u>Protein</u>	<u>Genbank ID</u>	<u>Identities</u>	<u>Similarities</u>
human dual specificity phosphatase 8	gi NP_004411	46%	58%
mouse neuronal tyrosine/threonine phosphatase 1	gi NP_032774	43%	56%

RET31

<u>Protein</u>	<u>Genbank ID</u>	<u>Identities</u>	<u>Similarities</u>
human protein-tyrosine phosphatase DUS8 protein	gi U27193	50.3%	56.8%
the human dual specificity MAP kinase DUSP6 protein	gi AB013382	36.5%	48.3%
human map kinase phosphatase MKP-5 protein	gi AB026436	34.3%	47.2%
mouse RET31 protein	N/A	90%	92%

mRET31

<u>Protein</u>	<u>Genbank ID</u>	<u>Identities</u>	<u>Similarities</u>
human protein-tyrosine phosphatase DUS8 protein	gi U27193	48.5%	55.7%
the human dual specificity MAP kinase DUSP6 protein	gi AB013382	37.4%	49.7%
human map kinase phosphatase MKP-5 protein	gi AB026436	35.2%	46.9%
human RET31 protein	N/A	90%	92%

Figure 13A

1 GAAAAGAAGACGAGGAGGAGAGCGACGGGACGGGACGCGAGCGGGAGCGCAGCCGCCCTC 60

61 TCGGCTCCGCGGCGGCCTCGCAAGTCCGGGAGGCGAGGGGGCCCGAGGGGAGACGCC 120

121 GTGACAACTTTCGTTTCCCTCTGAGGGAATTGGGAGGTCGGCGGCCCCAAAAGCTTTCAG 180

181 TCCAGTGTAAGCTGTTGGAGCGCGGGAGCAAAGGTAAAGAATGATGTAATGCGCTGGCT 240

241 GCTCCAAAGCATCTTTTGTGTGGAATGGTTATTCCAGTCATCTCTTTATGAATCAAATG 300

301 TGAGGGGCTGCTTTGTGGACGGAGTCCTTTGCAAGAGCACATCAACGGGAAAGAGAAAGA 360

361 GACATTCACTTGGAGGGCTCTTGCTGAAAATGGGTTTAACTCTCCTTTTGCCAGTCACCA 420

421 CCAGCCTGACCTCATACTTTTAGTACAATGGAGTGGCTGAGCCTTTGAGCACACCACC 480

481 ATTACATCATCGTGGCAAATTAAAGAAGGAGGTGGGAAAAGAGGACTTATTGTTGTCAIG 540
1 M 1

541 GCCCATGAGATGATTGGAAC TCAAATTGTTACTGAGAGGTGGTGGCTCTGCTGGAAAGT 600
2 A H E M I G T Q I V T E R L V A L L E S 21

601 GGAACGGAAAAAGTGCTGCTAATTGATAGCCGGCCATTGTGGAATACAATACATCCAC 660
22 G T E K V L L I D S R P F V E Y N T S H 41

661 ATTTTGAAGCCATTAATATCAACTGCTCCAAGCTTATGAAGCGAAGGTTGCAACAGGAC 720
42 I L E A I N I N C S K L M K R R L Q Q D 61

721 AAAGTGTTAATTACAGAGCTCATCCAGCATTGAGCGAAACATAAGGTTGACATTGATTGC 780
62 K V L I T E L I Q H S A K H K V D I D C 81

781 AGTCAGAAGGTTGTAGTTTACGATCAAAGCTCCCAAGATGTTGCCTCTCTCTCTTCAGAC 840
82 S Q K V V V Y D Q S S Q D V A S L S S D 101

841 TGTTTTCTCACTGTACTTCTGGGTAAACTGGAGAAGAGCTTCAACTCTGTTACCTGCTT 900
102 C F L T V L L G K L E K S F N S V H L L 121

901 GCAGGTGGGTTTGCTGAGTTCTCTCGTTGTTTCCCTGGCCTCTGTGAAGGAAAATCCACT 960
122 A G G F A E F S R C F P G L C E G K S T 141

Figure 13B

961	CTAGTCCCTACCTGCATTCTCAGCCTTGCTTACCTGTTGCCAACATTGGGCCAACCCGA	1020
142	L V P T C I S Q P C L P V A N I <u>G P T R</u>	161
1021	ATTCTTCCCAATCTTTATCTTGGCTGCCAGCGAGATGTCCTCAACAAGGAGCTGATACAG	1080
162	<u>I L P N L Y L G C O R D V L N K E L I Q</u>	181
1081	CAGAATGGGATTGGTTATGTGTTAAATGCCAGCTATACCTGTCCAAAGCCTGACTTTATC	1140
182	<u>Q N G I G Y V L N A S Y T C P K P D F I</u>	201
1141	CCCAGTCTCATTTCCTGCGTGTGCCTGTGAATGACAGCTTTTGTGAGAAAATTTGCCG	1200
202	<u>P E S H F L R V P V N D S F C E K I L P</u>	221
1201	TGGTTGGACAAATCAGTAGATTTTCATTGAGAAAGCAAAGCCTCCAATGGATGTGTTCTA	1260
222	<u>W L D K S V D F I E K A K A S N G C V L</u>	241
1261	GTGCACTGTTTAGCTGGGATCTCCCGCTCCGCCACCATCGCTATCGCCTACATCATGAAG	1320
242	<u>V H L A G I S R S A T I A I A Y I M K</u>	261
1321	AGGATGGACATGTCTTTAGATGAAGCTTACAGATTTGTGAAAGAAAAAGACCTACTATA	1380
262	<u>R M D M S L D E A Y R F V K E K R P T I</u>	281
1381	TCTCCAAACTTCAATTTTCTGGGCCAACTCCTGGACTATGAGAAGAAGATTAAGAACCAG	1440
282	<u>S P N F N F L G Q L L D Y E K K I K N Q</u>	301
1441	ACTGGAGCATCAGGGCCAAAGAGCAAACCTCAAGCTGCTGCACCTGGAGAAGCCAAATGAA	1500
302	T G A S G P K S K L K L L H L E K P N E	321
1501	CCTGTCCCTGCTGTCTCAGAGGGTGGACAGAAAAGCGAGACGCCCCTCAGTCCACCCTGT	1560
322	P V P A V S E G G Q K S E T P L S P P C	341
1561	GCCGACTCTGTACCTCAGAGGCAGCAGGACAAAGGCCCGTGCATCCCGCCAGCGTGCCC	1620
342	A D S A T S E A A G Q R P V H P A S V P	361
1621	AGCGTGCCCAGCGTGCAGCCGTCGCTGTTAGAGGACAGCCCGCTGGTACAGGCGCTCAGT	1680
362	S V P S V Q P S L L E D S P L V Q A L S	381
1681	GGGCTGCACCTGTCCGCAGACAGGCTGGAAGACAGCAATAAGCTCAAGCGTTCCTTCTCT	1740
382	G L H L S A D R L E D S N K L K R S F S	401
1741	CTGGATATCAAATCAGTTTCATATTCAGCCAGCATGGCAGCATCCTTACATGGCTTCTCC	1800
402	L D I K S V S Y S A S M A A S L H G F S	421
1801	TCATCAGAAGATGCTTTGGAATACTACAAACCTTCCACTACTCTGGATGGGACCAACAAG	1860
422	S S E D A L E Y Y K P S T T L D G T N K	441

Figure 13C

1861 CTATGCCAGTTCTCCCCTGTTTCAGGAACATATCGGAGCAGACTCCCGAAACCAGTCCTGAT 1920
442 L C Q F S P V Q E L S E Q T P E T S P D 461

1921 AAGGAGGAAGCCAGCATCCCCAAGAAGCTGCAGACCGCCAGGCCTTCAGACAGCCAGAGC 1980
462 K E E A S I P K K L Q T A R P S D S Q S 481

1981 AAGCGATTGCATTTCGGTCAGAACCAGCAGCAGTGGCACC GCCCAGAGGTCCCTTTTATCT 2040
482 K R L H S V R T S S S G T A Q R S L L S 501

2041 CCACTGCATCGAAGTGGGAGCGTGGAGGACAATTACCACACCAGCTTCCTTTTCGGCCTT 2100
502 P L H R S G S V E D N Y H T S F L F G L 521

2101 TCCACCAGCCAGCAGCACCTCACGAAGTCTGCTGGCCTGGGCCTTAAGGGCTGGCACTCG 2160
522 S T S Q Q H L T K S A G L G L K G W H S 541

2161 GATATCTTGGCCCCCAGACCTCTACCCCTTCCCTGACCAGCAGCTGGTATTTTGCCACA 2220
542 D I L A P Q T S T P S L T S S W Y F A T 561

2221 GAGTCCTCACACTTCTACTCTGCCTCAGCCATCTACGGAGGCAGTGCCAGTTACTCTGCC 2280
562 E S S H F Y S A S A I Y G G S A S Y S A 581

2281 TACAGCTGCAGCCAGCTGCCCACTTGCGGAGACCAAGTCTATTCTGTGCGCAGGCGGCAG 2340
582 Y S C S Q L P T C G D Q V Y S V R R R Q 601

2341 AAGCCAAGTGACAGAGCTGACTCGCGGCGGAGCTGGCATGAAGAGAGCCCTTTGAAAAG 2400
602 K P S D R A D S R R S W H E E S P F E K 621

2401 CAGTTTAAACGCAGAAGCTGCCAAATGGAATTTGGAGAGAGCATCATGTCAGAGAACAGG 2460
622 Q F K R R S C Q M E F G E S I M S E N R 641

2461 TCACGGGAAGAGCTGGGGAAAGTGGGCAGTCAGTCTAGCTTTTCGGGCAGCATGGAAATC 2520
642 S R E E L G K V G S Q S S F S G S M E I 661

2521 ATTGAGGTCTCCTGAGAAGAAAGACACTTGTGACTTCTATAGACAATTTTTTTTTTCTTG 2580
662 I E V S 665

2581 TTCACAAAAAATTCCTGTAAATCTGAAATATATATATGTACATACATATATATTTTTG 2640

2641 GAAATGGAGCTATGGTGTAAGCAACAGGTGGATCAACCCAGTTGTTACTCTCTTAAC 2700

2701 ATCTGCATTTGAGAGATCAGCTAATACTTCTCTCAACAAAAATGGAAGGGCAGATGCTAG 2760

2761 AATCCCCCTAGACGGAGGAAAACCATTTTATTTCAGTGAATTACACATCCTCTTGTCTT 2820

Figure 13D

2821 AAAAAAGCAAGTGTCTTTGGTGTGGAGGACAAAATCCCCTACCATTTTCACGTTGTGCT 2880
2881 ACTAAGAGATCTCAAATATTAGTCTTTGTCCGGACCCTTCCATAGTACACCTTAGCGCTG 2940
2941 AGACTGAGCCAGCTTGGGGGTCAGGTAGGTAGACCCTGTTAGGGACAGAGCCTAGTGGTA 3000
3001 AATCCAAGAGAAATGATCCTATCCAAAGCTGATTCACAAACCCACGCTCACCTGACAGCC 3060
3061 GAGGGACACGAGCATCACTCTGCTGGACGGACCATTAGGGGCCTTGCCAAGGTCTACCTT 3120
3121 AGAGCAAACCCAGTACCTCAGACAGGAAAGTCGGGGCTTTGACCACTACCATATCTGGTA 3180
3181 GCCCATTTTCTAGGCATTGTGAATAGGTAGGTAGCTAGTCACACTTTTCAGACCAATTCA 3240
3241 AACTGTCTATGCACAAAATCCCGTGGGCCTAGATGGAGATAATTTTTTTTCTTCTCAG 3300
3301 CTTTATGAAGAGAAGGGAAACTGTCTAGGATTCAGCTGAACCACCAGGAACCTGGCAACA 3360
3361 TCACGATTTAAGCTAAGGTTGGGAGGCTAACGAGTCTACCTCCCTCTTGTAATCAAAG 3420
3421 AATTGTTTAAATGGGATTGTCAATCCTTTAAATAAAGATGAACTTGGTTTCAAGCCAAA 3480
3481 TGTGAATTTATTTGGGTTGGTAGCAGAGCAGCAGCACCTTCAAATTCTCAGCCAAAGCAG 3540
3541 ATGTTTTTGGCCCTTCTGCTTCACTGCATGGATACAGTTGGTAAAATGTAATAATATGGC 3600
3601 AGAATTTTATAGGAAACTTCCTAGGGAGGTAAATTATGGGAAGATTAAGAAAGGTACAAA 3660
3661 TTGCTGAGGAGAAGCAGGAAACCTGTTTCCTTAGTGGCTTTTATCCCCTCGGCATGCGAT 3720
3721 GGGGCTGATGTTTCTATGATTGCCTCAGACTTTCACATTTACTAGTAGGGCTGAGAGAGG 3780
3781 CTTTAGTGAGGAAGGAATATTGAGAATAAAACGGTTGAGAAAGCTGAGAAGACCATTGAG 3840
3841 TTTTGATCAGTTGTGAATAGAGTGCAAAGCCATGGCCAAGCTGTTTTTGGAAACGCTGGC 3900
3901 CGGCGTGTCTTCAGTGGAAAAAGCAAATCAAATGGAGCGAGAGCAAAGGGGCGTCTCA 3960

Figure 13E

3961 GTCCTCAACCTACAATCACTGTATGGAATCGGTCCTGGCAGCTGAACATAGGAGGTCACT 4020
4021 GGAACAAGTGATAGTGCAGATTGGCTTTCAAACATCCTCCTGGCTTGAGTTTATCAGCT 4080
4081 ACAATGTGGGTCCTCTTTTGAAGCCTTAATTCACAACAGCAGCTTTTGGGGGTGGGGCT 4140
4141 GGGCGGGTGTTGTCATTGTTCTTTCCCTTCCTGTAAGTGTGCTAGTTGCTGCCTCGTAT 4200
4201 CTCAGGTTTTTCTCTGTTTTTGAGAAATGGACAGTTTTTGGACCAGGATGTGACTTCATG 4260
4261 TTTCTATGGTGACTTCTAAAACCAGCACAGAATGATATGACTCAACACAGACCGACTTG 4320
4321 GTTATGGGGATGATGAGCCGCACAGACCTCACTAGTTGTGCACAAATAATGTGCTATGAT 4380
4381 GGGGTGTAAAGTGAAGGCAGAAGAGGGTCAGCCGCATTGTTATGATACTGGGAAAGTGCT 4440
4441 GGTCAACGATTTGAGTTAGTTTTTAGATATACATTGAAATCTTTAATCAGACATTCTCAA 4500
4501 GTTTCACACAGTAGTTTTTGATGTTATGTACACACACACCAAATGTGTAACAGTTCACCA 4560
4561 CTTCCAGAGTGTGGTCATGCCCAAAACATGTTTAAGAAAGGAAAGCAGTAGCTCCTTGCT 4620
4621 AACGATGTTTCAGGAGGTTTGGGGCACTTGGTTTTAATGAGCTTCTGTCATTTAGGGCTT 4680
4681 CTCTTGGCCATGGTCCCCTTCCTTCTGGAAGTGTGATGTAGTCACATCCTACAGCCTTTA 4740
4741 GTGCTGGTTCAGTAGTGTGAGATAATCAGTTCTTGAATCGAGACTGCCGTGGCGAAGGG 4800
4801 GTGGCCTCGGAGGCAGGCTCTGGAGCTGCTTGGATGTCTTTAGGTGGGGTGGTGGCTGGC 4860
4861 TCTCTTCAGCATGTAATTGGGGAAACCCCTCGCGTCTACTAGGGGTGATACAGATGGTGAT 4920
4921 TTAAAGAGCAAACTAGACTTCTATGTGAGAAGTGCTGGAAAATGATTTAGGACATGTG 4980
4981 TAAAGTTAGATGGAAAGACTGTAAATGTTTAATATGAATATAGTGTTCTTTGAAGTAAG 5040
5041 GCCAGCTGTTGAACGGTTAAACTGTGCATTTCTCATTTTGATGTGTCATGTATGTTAATG 5100
5101 TATGAAATGATTAAATAAAATCAAAACTGGTACCTGTTTATACATAAAATACGAGAAAAGA 5160

Figure 13F

5161 CCTATCTTTGCAGCCATAAACTCGGTGGGAACACCACCACTCAAGTTGCCAAAGGAGGCA 5220
5221 GTGGTGAAACCTGTCCTGTTCTCACTTAAATGAGGATTTAGCTCAAAATAAAGTGGTGGT 5280
5281 GTCATCAGGTTTATTCCGTGTTCTGTCATTACATGGAACACCGGATGATTAGCTAACAG 5340
5341 TTTAGTGCCAGCCTTCATTCTTTACTGTGTACGTTAAATGCACACTACAGTGAAAAAGCC 5400
5401 TAAGACACTTGGTAAATATTTTCTAGCTGACTGATTCCAGAACACACAAG 5450

Figure 14A

		1	50
RET31	(1)	-----	-----
mRET31	(1)	-----	-----
DUS6	(1)	-----	-----
DUS8	(1)	-----	-----
MKP-5	(1)	MPPSPLDDR VVVALSRPVRPQDLNLC LDSSYLGSANPGSNSHPPVIATTV	
		51	100
RET31	(1)	-----	-----
mRET31	(1)	-----	-----
DUS6	(1)	-----	-----
DUS8	(1)	-----	-----
MKP-5	(51)	VSLKAANLTYMPSSSGSARS LNCGCSSASCCTVATYDKDNQAQTQAI AAG	
		101	150
RET31	(1)	-----MAHEMIGTQIVTERIVAILLESCT-----	
mRET31	(1)	-----MAHEMIGTQIVTESIVAILLESCT-----	
DUS6	(1)	-----MIDTLRPVPFASEMAISKTVAWINEOLELGN-----	
DUS8	(1)	-----MAGDRLPRKVM DAKKIASILRGCP-----	
MKP-5	(101)	TTTTAIGTSTTCPANQMVNNNENIGSLSSSSGVGSPVSGTPKQLASIKII	
		151	200
RET31	(24)	-----EKVLLIDSRPFVEYNTSHILEAININCSKLM-----	
mRET31	(24)	-----EKVLLIDSRPFVEYNTSHILEAININCSKLM-----	
DUS6	(32)	-----ERLLMDCRPQELYESSHIESAINVAIPGIM-----	
DUS8	(25)	-----GGPLVIDSRPFVEYNSWHVLSNVNICCSKLV-----	
MKP-5	(151)	YPNDLAKKMTKCSKSHLPSQGPVITDCRPFMEYNKSHIQGAVHINCADKI	
		201	250
RET31	(55)	KRRLOQD--KVLITELIQHSAKHKVDIDCSQKVVVYDOSS--QDVASLSSD	
mRET31	(55)	KRRLOQD--KVLITELIQHSTKHKVDIDCNQRVVVYDHS--QDVGSLSSD	
DUS6	(63)	LRRLQKGNLPVRALFTRGEDRDRFTRRCGTDTIVVLYDESSSDWNENTGGE	
DUS8	(56)	KRRLOQG--KVTIAELIQPAARSQVEATEPQDVVVYDOST--RDASVLAD	
MKP-5	(201)	SRRRLQOGKITVLDLITSCREGKDSFKRIFSKELIVYDENTNEPSRVMP SQ	
		251	300
RET31	(102)	CFLTVLLGKLEKSFNSVHLLAGGFAEFSSRCFPGLCEGK--STLVPTCTISQP	
mRET31	(102)	CFLTVLLGKLEKSFNSVHLLAGGFAEFSSRCFPGLCEGK--STLVPTCTISQP	
DUS6	(113)	SLIGLEIKKIKDEGCRAFYLEGGSKEQAEFSLHCETN--LDGSCSSSP	
DUS8	(103)	SELSILLSKLDGCFDSVAITTEGFATFSSCFPGLCEGKPAALLPMSLSQP	
MKP-5	(251)	-PLHIVLES LKREGKEPLV LKGLSSEKONHENLCDNSLQLOQECREVGGG	
		301	350
RET31	(151)	CLPVANIG-----PTRI	
mRET31	(151)	CLPVANIG-----PTRI	
DUS6	(161)	PLPVLGLCGGLRISSDSSSDIESDLDRDPNSATDS DGSPLSNSQPSFVEI	
DUS8	(153)	CLPVESVG-----LTRI	
MKP-5	(300)	ASAASSLLPQPIPTTPDIEN-----AELTPI	
		351	400
RET31	(163)	LPNLYLGCQORDVLNKELIQONGIGYVLNASYTCP--KPDFIPESHFLRVPV	
mRET31	(163)	LPNLYLGCQORDVLNKDLMOONGIGYVLNASNTCP--KPDFIPESHFLRVPV	
DUS6	(211)	LPFLYLGC AKDSTNLDVLEEFGIKYILNVTPLNPLNFENAGEFKYKQIPT	
DUS8	(165)	LPHLYLGSQKDV LNKDLMTONGISYVLNASNSCP--KPDFICESREMRVET	
MKP-5	(326)	LPFLFLGNEQDAQDLDTMORLNI GYVINVTTHLPLYHYEKGFLNFKRLPA	

Figure 14B

		401		450
RET31	(212)	NDSFCEKILPWLDKSVDFIEKAKASNGCVLVHCLAGISRSATIAIAYIMK		
mRET31	(212)	NDSFCEKILPWLDKSVDFIEKAKASNGCVLIHCLAGISRSATIAIAYIMK		
DUS6	(261)	SDHWSONLSQFFPEAISFTDEARGKNCGVIVHCLAGISRSVTVTVAIYIMQ		
DUS8	(214)	NDNYCEKLLPWLDKSIETIDKAKLSSCOVIVHCLAGISRSATIAIAYIMK		
MKP-5	(376)	TDSNKQNLROYFEEAFETIEEAHQCGKGLLIHCQAGVRSATTIVIAIYIMK		
		451		500
RET31	(262)	RMDMSLDEAYRFVKEKRETIISPNNFNLGQLLDYEKKIKNOTGASCPKSKL		
mRET31	(262)	RMDMSLDEAYRFVKEKRETIISPNNFMGQIMDYKTIINNOTGMSCPKSKL		
DUS6	(311)	KLNLISMNDAYDIVKMKSNISPNNFMGQLLDFFERTILGLSSPCDNRVPAQ		
DUS8	(264)	TMGMSSDDAYRFVKDRRESISPNNFNLGQLLEYERTIKLLAALQCDPG--		
MKP-5	(426)	HTRMTMTDAYKFKVCKRETIISPNNFMGQLLEFEEDLNNGVTPIRLTPKL		
		501		550
RET31	(312)	KILHLEKPNEPVPVAVSEGGOKSETPLSPPCADSATSEAAGORP--VHPAS		
mRET31	(312)	KILLHLDKPSEPVPVAASEGGWKSALSLSPPCAN-STSEASGQRL--VHPAS		
DUS6	(361)	QLYFTTPSNQNVYQVDSLQST-----		
DUS8	(312)	-TPSG----TPEPPSPAPAGAPLPRLPPEPTSESAATGNAAAREGGLSAGG		
MKP-5	(476)	MGVETVV-----		
		551		600
RET31	(360)	VPSVPSVQPSLLEDSPFVQALSGLHLSADRLEDSENKLRFSFSLDIKSVSY		
mRET31	(359)	VP---RLOPSLLEDSPFVQALSGLQLSSEKLEDSTKLRFSFSLDIKSVSY		
DUS6	(382)	-----		
DUS8	(357)	EP---PAPPTPPATSAALQGLRGLHLSSDRLODTNRLKRSFSLDIKSA-V		
MKP-5	(483)	-----		
		601		650
RET31	(410)	SASMAASLHCFSSSEDALEYKPSSTLDGTNKLCOFSPVQELSEOTPESTS		
mRET31	(406)	SASMAASLHCFSS-EBALDYCKPSATLDGTNKLCOFSPVQEVSEQSPETS		
DUS6	(382)	-----		
DUS8	(403)	APSRRPDGPSPDPGEAPKLCGLDSPSG-----AALGLSSPSP-DS		
MKP-5	(483)	-----		
		651		700
RET31	(460)	PDKEEASIPKKLQTAEPDSQSKRLHSVRTSSSGTAQRSLLSPLHRSQS-		
mRET31	(455)	PDKEEAHIPKQPQPPRPSESQVTRLHSVRTGSSGSTQRPFFSPLHRSQS-		
DUS6	(382)	-----		
DUS8	(443)	PDAAPEARPRPRRRPREP-----AGSPARSPAFSLCLN		
MKP-5	(483)	-----		
		701		750
RET31	(509)	VEDNYHTSFLEGLSTSQQHLTKSAG--LGLKGWHSDDLAPOTSTPSLTSS		
mRET31	(504)	VEDNYHTNLFLEGLSTSQQHLTKSAG--LGLKGWHSDDLAPQSSAPSLTSS		
DUS6	(382)	-----		
DUS8	(476)	FGDAARQTPRHGLSALSAPGLPGPGQAPAGPGAWAPPLDSP--GTSPDPGP		
MKP-5	(483)	-----		
		751		800
RET31	(557)	WYFATESSHFYASAIYGCASYSAYSCSOLPTCGDQVYSVRRRQKPSDR		
mRET31	(552)	WYFATEPSHLYSASAIYGCNSSYSAYSCGQLPTCSDQIYSVRRRQKPTDR		
DUS6	(382)	-----		
DUS8	(524)	WCFSPPE-----GAQAGGVLFAPFGRAGAPGPGGSDLRREARAAP		
MKP-5	(483)	-----		

Figure 14C

		801	850
RET31	(607)	ADSRRSWHEESPFKQFKRRSCOMEFGESIMSENRSREELGKVGSSSSFS	
mRET31	(602)	ADSRRSWHEESPFKQFKRRSCOMEFGESIMSENRSREELGKVGSSSSFS	
DUS6	(382)	-----	
DUS8	(567)	RDARTGWPEEPAPETQFKRRSCOMEFEFGMVEGRARGEELAAICKQASFS	
MKP-5	(483)	-----	
		851	
RET31	(657)	GSMETIEVS	
mRET31	(652)	GSMETIEVS	
DUS6	(382)	-----	
DUS8	(617)	GSVEVIEVS	
MKP-5	(483)	-----	

Figure 15




Figure 16A

1 GACTGAGGTTGTCAGCCAGTGTAAGCTGTTGGAGTGAGGGCAGAAAGGTAAAGGATGA 60
61 TGTAATGCCTGGCTGCCCTAGAGCATCTTTGTTGTGGGATGGGTATTCCTCATCTCT 120
121 ATGAATCTAGTGTGAGGGGCTGCTTTGTGGAAGGAATCCTTTGCAAGAGCATATCAACAG 180
181 GAAAGAGAAAGAGACATTTCAGTTGGAGGGCTCTTGCTGAAATGGATTAACTCTCCTCTT 240
241 GCCAGTCACCACTAGCCTGACCTCATACATTTTTAGTACAATGGAGTGGCTGAGCCTTTG 300
301 AGCACAGCACCATTACATCATCGTGGCAAATTAAGAACGAGGTGGGGAAAGAGGACTTA 360
361 TTGTTGTCATGGCCCATGAGATGATTGGAACCTCAAATTGTTACTGAGAGCTTGGTGGCTC 420
1 M A H E M I G T Q I V T E S L V A L 18
421 TGCTGGAAAGTGGAAACGGAAAAAGTGTCTAATTGATAGCCGACCATTGTGGAATACA 480
19 L E S G T E K V L L I D S R P F V E Y N 38
481 ATACGTCTCACATTTTGGAAAGCCATTAATATCAACTGCTCCAACTGATGAAGCGAAGGT 540
39 T S H I L E A I N I N C S K L M K R R L 58
541 TGCAACAGGACAAAGTATTAATTACAGAACTAATCCACCAATCTACAAAGCATAAGGTTG 600
59 Q Q D K V L I T E L I H Q S T K H K V D 78
601 ACATTGACTGCAATCAAAGAGTGGTAGTTTATGATCACAGTTCACAAGATGTTGGTTCTC 660
79 I D C N Q R V V V Y D H S S Q D V G S L 98
661 TGTCGTCAGACTGCTTTCTCACTGTACTTCTGGGTAAGCTGGAGAGAAGCTTCAACTCTG 720
99 S S D C F L T V L L G K L E R S F N S V 118
721 TCCACCTGCTTGCAGGTGGCTTTGCTGAGTTCTCTCGTTGTTTCCCTGGCCTCTGTGAAG 780
119 H L L A G G F A E F S R C F P G L C E G 138
781 GAAAGTCCACTCTAGTCCCTACCTGCATATCTCAGCCTTGCTTACCTGTTGCGAACATTG 840
139 K S T L V P T C I S Q P C L P V A N I G 158
841 GGCCAACTCGAATTCTTCCCAATCTCTATCTTGGCTGCCAGCGAGATGTCCTCAACAAGG 900
159 P T R I L P N L Y L G C O R D V L N K D 178
901 ACCTGATGCAACAGAATGGGATTGGCTATGTGTTAAATGCCAGCAATACCTGTCCAAAGC 960
179 L M O O N G I G Y V L N A S N T C P K P 198

Figure 16B

961	CTGACTTCATACCTGAATCTCACTTCCTGCGAGTGCCTGTGAATGACAGCTTTTGTGAGA	1020
199	<u>D F I P E S H F L R V P V N D S F C E K</u>	218
1021	AAATCCTACCATGGTTGGACAAGTCTGTGGATTTTCATTGAGAAAGCAAAGCCTCCAATG	1080
219	<u>I L P W L D K S V D F I E K A K A S N G</u>	238
1081	GCTGTGTGCTTATCCACTGCTTAGCTGGGATCTCTCGCTCCGCCACTATTGCTATTGCCT	1140
239	<u>C V L I H C L A G I S R S A T I A I A Y</u>	258
1141	ACATCATGAAGAGGATGGACATGTCTCTAGATGAGGCTTACAGATTTGTGAAAGAAAAA	1200
259	<u>I M K R M D M S L D E A Y R F V K E K R</u>	278
1201	GACCTACTATATCTCCGAATTTTAATTTTATGGGCCAACTCATGGACTATGAGAAGACGA	1260
279	<u>P T I S P N F N F M G Q L M D Y E K T I</u>	298
1261	TTAATAACCAGACTGGAATGTCAGGGCCAAAGAGCAAACCTGAAGCTGCTGCACCTAGACA	1320
299	N N Q T G M S G P K S K L K L L H L D K	318
1321	AACCCAGTGAGCCCGTGCCTGCAGCCTCAGAGGGCGGATGGAAGAGTGCACCTGTCTCTCA	1380
319	P S E P V P A A S E G G W K S A L S L S	338
1381	GTCCACCCGTGCCAACTCGACCTCGGAGGCATCAGGGCAAAGGCTTGTGCATCCTGCAA	1440
339	P P C A N S T S E A S G Q R L V H P A S	358
1441	GTGTGCCCCGCTTACAGCCGTCACCTCTTAGAGGACAGTCCGCTGGTACAGGCGCTCAGTG	1500
359	V P R L Q P S L L E D S P L V Q A L S G	378
1501	GGCTCCAGCTGTCTCAGAGAAGCTGGAAGACAGCACTAAGCTCAAGCGTTCCTTCTCTC	1560
379	L Q L S S E K L E D S T K L K R S F S L	398
1561	TCGATATCAAATCTGTTTCATATTCAGCCAGTATGGCCGCTCCCTACACGGCTTCTCGT	1620
399	D I K S V S Y S A S M A A S L H G F S S	418
1621	CAGAGGAGGCTTTAGACTACTGCAAACCTTCTGCCACACTGGATGGGACCAACAAGCTCT	1680
419	E E A L D Y C K P S A T L D G T N K L C	438
1681	GCCAGTTCTCCCCCGTTCAGGAGGTATCAGAACAGAGTCCAGAGACCAGCCCGGATAAGG	1740
439	Q F S P V Q E V S E Q S P E T S P D K E	458
1741	AGGAGGCCCCACATCCCCAAGCAGCCCCAACCTCCCAGGCCTTCTGAGAGCCAGGTCACAC	1800
459	E A H I P K Q P Q P P R P S E S Q V T R	478
1801	GCTTGCACTCAGTGAGAACCGGCAGTAGTGGGTCCACCCAGAGGCCCTTCTTCTCGCCAC	1860
479	L H S V R T G S S G S T Q R P F F S P L	498

Figure .16C

1861 TGCATCGGAGCGGGAGTGTAGAGGACAATTACCATAACCAACTTCCTTTTTGGCCTTTCCA 1920
499 H R S G S V E D N Y H T N F L F G L S T 518

1921 CCAGCCAGCAACACCTCACCAAGTCTGCAGGGCTTGGCCTCAAGGGCTGGCACTCAGATA 1980
519 S Q Q H L T K S A G L G L K G W H S D I 538

1981 TTCTGGCTCCCCAGTCTCTGCCCCCTCCCTGACCAGCAGTTGGTATTTTGTACGGAGC 2040
539 L A P Q S S A P S L T S S W Y F A T E P 558

2041 CTTCACTTGTACTCTGCTTCAGCCATCTATGGAGGCAACAGCAGTTACTCTGCCTACA 2100
559 S H L Y S A S A I Y G G N S S Y S A Y S 578

2101 GCTGTGGCCAGCTGCCCCTTGCAGTGACCAAATCTATTCTGTTTCGTAGGCGGCAGAAGC 2160
579 C G Q L P T C S D Q I Y S V R R R Q K P 598

2161 CTACTGACAGAGCTGACTCGAGGCGGAGCTGGCATGAAGAGAGCCCCTTTGAAAAGCAGT 2220
599 T D R A D S R R S W H E E S P F E K Q F 618

2221 TTAAACGCAGAAGCTGCCAAATGGAATTTGGAGAGAGCATTATGTCGGAGAACAGGTCCA 2280
619 K R R S C Q M E F G E S I M S E N R S R 638

2281 GGGAGGAGCTGGGCAAGGTGGGCAGCCAGTCCAGCTTCTCCGGCAGCATGGAGATCATCG 2340
639 E E L G K V G S Q S S F S G S M E I I E 658

2341 AGGTCTCTTGAGAAGACCTCGTCGCTTCTGTTGACAGTTTTGTTTCCTGTTACAAAAA 2400
659 V S 660

2401 TAGTCCCTGTAAATCTGAAATATGTATATGTACATACATATATATTTTTGGAATATAGAG 2460

2461 CTACGGTATAAAAGCAACAGATGGATCAACACAGTTGTTCTCTCAGCACCTGCACTGAGA 2520

2521 ATAGCTAACTCTCAGAAAAGATTGGAAGGGTAGATGTTAGAATTCTCCCAGCCAGGAGAA 2580

2581 GAGATTTGGTTCAGTGAATTGCACATCTTCTTGTTCCTACAAAAGCAAGGGTTTTGTTTG 2640

2641 TTTGTATGTTGTTTGTGTTTTAATGTTAGAGGGCAAAATCCCTCCCATTTTACGTGCAAC 2700

2701 AGAGGTCTCAGAACTCATCTCTGTCCAGGCCCTTCCCTAGTGACCTTAGCGCTAA 2756

Figure 17.

Ret31_DSPc G P R N C Q R V L K E L Q Q N G A S Y T C K P D F I P S H F
DUS8_DSPc G L R H Y S Q K V L K L T Q N G S A S N S C K P D F I C S R F
MKP5_DSPc E L P F F N E Q A Q D L T Q R L N G V I V T T H L L Y H Y E K G L F N Y
DUS6_DSPc F P V E F F C A K S T L D V L E E F G K T L V T P N L N L F E N A G F K Y

Ret31_DSPc L V V N S F C E K I L P W L D K S V D E K K A S N G C I V I A A A
DUS8_DSPc M V I N N Y C E K L P W L D K S I E D K K L S S C Q I V I A A A
DUS6_DSPc K Q I I S H W S Q N S Q F F P E A I S D E R G K N C G I V I A A A
MKP5_DSPc K L A T S N K Q N R Q Y F E E A F E E E H Q C G K G L I V I A A A

Ret31_DSPc I R M D L D E R E T L D Y K K
DUS8_DSPc I T M G S D R S L I E Y R T
MKP5_DSPc L H T R M T M D K G K F I L M L I E F E D
DUS6_DSPc L Q K L N L M N D T M K K S N L M D F R T

Figure 18




Figure 19A

1 GAAAAGAAGACGAGGAGGAGAGCGACGGGACGGGACGCGAGCGGGAGCGCAGCCGCCCTC 60

61 TCGGCTCCGCGGGCGGCCTCGCAAGTCCGGGAGGCGAGGGGGCCCGAGGGGAGACGCC 120

121 GTGACAACTTTTCGTTTCCCTCTGAGGGAATTGGGAGGTGCGCGCCCCAAAAGCTTTCAG 180

181 TCCAGTGTAAGCTGTTGGAGCGCGGGAGCAAAGGTAAAGAATGATGTAATGCGCTGGCT 240

241 GCTCCAAAGCATCTTTTGTGTGGAATGGTTATTCCAGTCATCTCTTTATGAATCAAATG 300

301 TGAGGGGCTGCTTTGTGGACGGAGTCCTTTGCAAGAGCACATCAACGGGAAAGAGAAAGA 360

361 GACATTCACCTGGAGGGCTCTTGCTGAAAATGGGTTTAACTCTCCTTTTGCCAGTCACCA 420

421 CCAGCCTGACCTCATACACTTTTAGTACAATGGAGTGGCTGAGCCTTTGAGCACACCACC 480

481 ATTACATCATCGTGCCAAATTAAAGAAGGAGGTGGGAAAAGAGGACTTATTGTTGTCATG 540
1 M 1

541 GCCCATGAGATGATTGGAAC TCAAATTGTTACTGAGAGGTTGGTGGCTCTGCTGGAAAGT 600
2 A H E M I G T Q I V T E R L V A L L E S 21

601 GGAACGGAAAAAGTGCTGCTAATTGATAGCCGGCCATTGTGGAATACAATACATCCAC 660
22 G T E K V L L I D S R P F V E Y N T S H 41

661 ATTTTGAAGCCATTAATATCAACTGCTCCAAGCTTATGAAGCGAAGGTTGCAACAGGAC 720
42 I L E A I N I N C S K L M K R R L Q Q D 61

721 AAAGTGTTAATTACAGAGCTCATCCAGCATTGAGCGAAACATAAGGTTGACATTGATTGC 780
62 K V L I T E L I Q H S A K H K V D I D C 81

781 AGTCAGAAGGTTGTAGTTTACGATCAAAGCTCCCAAGATGTTGCCTCTCTCTCTTCAGAC 840
82 S Q K V V V Y D Q S S Q D V A S L S S D 101

841 TGTTTTCTCACTGTACTTCTGGGTAAACTGGAGAAGAGCTTCAACTCTGTTACCTGCTT 900
102 C F L T V L L G K L E K S F N S V H L L 121

901 GCAGGTGGGTTTGTGCTGAGTTCTCTCGTTGTTTCCCTGGCCTCTGTGAAGGAAAATCCACT 960
122 A G G F A E F S R C F P G L C E G K S T 141

Figure 19B

961	CTAGTCCCTACCTGCATTTCTCAGCCTTGCTTACCTGTTGCCAACATTGGGCCAACCCGA	1020
142	L V P T C I S Q P C L P V A N I G P T R	161
1021	ATTCTTCCCAATCTTTATCTTGGCTGCCAGCGAGATGTCTCAACAAGGAGCTGATACAG	1080
162	I L P N L Y L G C Q R D V L N K E L I Q	181
1081	CAGAATGGGATTGGTTATGTGTTAAATGCCAGCTATACCTGTCCAAGCCTGACTTTATC	1140
182	Q N G I G Y V L N A S Y T C P K P D F I	201
1141	CCCGAGTCTCATTTCTGCGTGTGCCTGTGAATGACAGCTTTTGTGAGAAAATTTTGCCG	1200
202	P E S H F L R V P V N D S F C E K I L P	221
1201	TGGTTGGACAAATCAGTAGATTTTCATTGAGAAAGCAAAGCCTCCAATGGATGTGTTCTA	1260
222	W L D K S V D F I E K A K A S N G C V L	241
1261	GTGCACTGTTTAGCTGGGATCTCCCGCTCCGCCACCATCGCTATCGCCTACATCATGAAG	1320
242	V H C L A G I S R S A T I A I A Y I M K	261
1321	AGGATGGACATGTCTTTAGATGAAGCTTACAGATTTGTGAAAGAAAAAGACCTACTATA	1380
262	R M D M S L D E A Y R F V K E K R P T I	281
1381	TCTCCAACTTCAATTTTCTGGGCCAACTCCTGGACTATGAGAAGAAGATTAAGAACCAG	1440
282	S P N F N F L G Q L L D Y E K K I K N Q	301
1441	ACTGGAGCATCAGGGCCAAAGAGCAAACCTCAAGCTGCTGCACCTGGAGAAGCCAAATGAA	1500
302	T G A S G P K S K L K L L H L E K P N E	321
1501	CCTGTCCCTGCTGTCTCAGAGGGTGGACAGAAAAGCGAGACGCCCCCTCAGTCCACCCTGT	1560
322	P V P A V S E G G Q K S E T P L S P P C	341
1561	GCCGACTCTGCTACCTCAGAGGCAGCAGGACAAAGGCCCGTGCATCCCGCCAGCGTGCCC	1620
342	A D S A T S E A A G Q R P V H P A S V P	361
1621	AGCGTGCCCGAGCGTGCAGCCGTCGCTGTTAGAGGACAGCCCGCTGGTACAGGCGCTCAGT	1680
362	S V P S V Q P S L L E D S P L V Q A L S	381
1681	GGGCTGCACCTGTCCGCAGACAGGCTGGAAGACAGCAATAAGCTCAAGCGTTTCCTTCTCT	1740
382	G L H L S A D R L E D S N K L K R S F S	401
1741	CTGGATATCAAATCAGTTTCATATTCAGCCAGCATGGCAGCATCCTTACATGGCTTCTCC	1800
402	L D I K S V S Y S A S M A A S L H G F S	421
1801	TCATCAGAAGATGCTTTGGAATACTACAAACCTTCCACTACTCTGGATGGGACCAACAAG	1860
422	S S E D A L E Y Y K P S T T L D G T N K	441

Figure 19C

1861 CTATGCCAGTTCTCCCCTGTTTCAGGAACATATCGGAGCAGACTCCCGAAACCAGTCCTGAT 1920
442 L C Q F S P V Q E L S E Q T P E T S P D 461

1921 AAGGAGGAAGCCAGCATCCCCAAGAAGCTGCAGACCGCCAGGCCTTCAGACAGCCAGAGC 1980
462 K E E A S I P K K L Q T A R P S D S Q S 481

1981 AAGCGATTGCATTTCGGTCAGAACCAGCAGCAGTGGCACC GCCCAGAGGTCCCTTTTATCT 2040
482 K R L H S V R T S S S G T A Q R S L L S 501

2041 CCACTGCATCGAAGTGGGAGCGTGGAGGACAATTACCACACCAGCTTCCTTTTCGGCCTT 2100
502 P L H R S G S V E D N Y H T S F L F G L 521

2101 TCCACCAGCCAGCAGCACCTCACGAAGTCTGCTGGCCTGGGCCTTAAGGGCTGGCACTCG 2160
522 S T S Q Q H L T K S A G L G L K G W H S 541

2161 GATATCTTGGCCCCCAGACCTCTACCCCTTCCCTGACCAGCAGCTGGTATTTTGCCACA 2220
542 D I L A P Q T S T P S L T S S W Y F A T 561

2221 GAGTCCTCACACTTCTACTCTGCCTCAGCCATCTACGGAGGCAGTGCCAGTTACTCTGCC 2280
562 E S S H F Y S A S A I Y G G S A S Y S A 581

2281 TACAGCTGCAGCCAGCTGCCCCACTTGC GGAGACCAAGTCTATTCTGTGCGCAGGCGGCAG 2340
582 Y S C S Q L P T C G D Q V Y S V R R R Q 601

2341 AAGCCAAGTGACAGAGCTGACTCGCGGCGGAGCTGGCATGAAGAGAGCCCCCTTTGAAAAG 2400
602 K P S D R A D S R R S W H E E S P F E K 621

2401 CAGTTTAAACGCAGAAGCTGCCAAATGGAATTTGGAGAGAGCATCATGTCAGAGAACAGG 2460
622 Q F K R R S C Q M E F G E S I M S E N R 641

2461 TCACGGGAAGAGCTGGGGAAAGTGGGCAGTCAGTCTAGCTTTTCGGGCAGCATGGAATC 2520
642 S R E E L G K V G S Q S S F S G S M E I 661

2521 ATTGAGGTCTCCTGAGAAGAAAGACACTTGTGACTTCTATAGACAATTTTTTTTTTCTTG 2580
662 I E V S 665

2581 TTCACAAAAAATTCCCTGTAAATCTGAAATATATATATGTACATACATATATATTTTG 2640

2641 GAAAATGGAGCTATGGTGTAAGCAACAGGTGGATCAACCCAGTTGTTACTCTCTTAAC 2700

2701 ATCTGCATTTGAGAGATCAGCTAATACTTCTCTCAACAAAAATGGAAGGGCAGATGCTAG 2760

2761 AATCCCCCTAGACGGAGGAAAACCATTTTATTCAGTGAATTACACATCCTCTTGTCTT 2820

Figure 19D

2821 AAAAAAGCAAGTGTCTTTGGTGTGGAGGACAAAATCCCCTACCATTTTCACGTTGTGCT 2880
2881 ACTAAGAGATCTCAAATATTAGTCTTTGTCCGGACCCTTCCATAGTACACCTTAGCGCTG 2940
2941 AGACTGAGCCAGCTTGGGGTCAGGTAGGTAGACCCTGTTAGGGACAGAGCCTAGTGGA 3000
3001 AATCCAAGAGAAATGATCCTATCCAAAGCTGATTCACAAACCCACGCTCACCTGACAGCC 3060
3061 GAGGGACACGAGCATCACTCTGCTGGACGGACCATTAGGGGCCTTGCCAAGGTCTACCTT 3120
3121 AGAGCAAACCCAGTACCTCAGACAGGAAAGTCGGGGCTTTGACCACTACCATATCTGGA 3180
3181 GCCCATTTTCTAGGCATTGTGAATAGGTAGGTAGCTAGTCACACTTTTCAGACCAATTCA 3240
3241 AACTGTCTATGCACAAAATTCCCGTGGGCCTAGATGGAGATAATTTTTTTTCTTCTCAG 3300
3301 CTTTATGAAGAGAAGGGAAACTGTCTAGGATTCAGCTGAACCACCAGGAACCTGGCAACA 3360
3361 TCACGATTTAAGCTAAGGTTGGGAGGCTAACGAGTCTACCTCCCTCTTTGTAAATCAAAG 3420
3421 AATTGTTTAAATGGGATTGTCAATCCTTTAAATAAAGATGAACTTGGTTTCAAGCCAAA 3480
3481 TGTGAATTTATTTGGGTTGGTAGCAGAGCAGCAGCACCTTCAAATTCTCAGCCAAAGCAG 3540
3541 ATGTTTTTGGCCTTCTGCTTCACTGCATGGATACAGTTGGTAAAATGTAATAATATGGC 3600
3601 AGAATTTTATAGGAACTTCCTAGGGAGGTAAATTATGGGAAGATTAAGAAAGGTACAAA 3660
3661 TTGCTGAGGAGAAGCAGGAAACCTGTTTCCTTAGTGGCTTTTATCCCCTCGGCATGCGAT 3720
3721 GGGGCTGATGTTTCTATGATTGCCTCAGACTTTCACATTTACTAGTAGGGCTGAGAGAGG 3780
3781 CTTTAGTGAGGAAGGAATATTAGAATAAAACGGTTGAGAAAGCTGAGAAGACCATTGAG 3840
3841 TTTTGATCAGTTGTGAATAGAGTGCAAAGCCATGGCCAAGCTGTTTTTGGAAACGCTGGC 3900
3901 CGGCGTGTCTTCAGTGGA AAAAGCAAATCAAATGGAGCGAGAGCAAAGGGCGTCCTCA 3960
3961 GTCCTCAACCTACAATCACTGTATGGAATCGGTCTGGCAGCTGAACATAGGAGGTCACT 4020

Figure 19E

4021 GGAACAAGTGATAGTGCAGATTGGCTTTCAAACATCCTCCTGGCTTGAGTTTATCAGCT 4080
4081 ACAATGTGGGTCCTCTTTTGAAGCCTTAATTCACAACAGCAGCTTTTGGGGGTGGGGCT 4140
4141 GGGCGGGTGTGTGTCATTGTTCTTTCCCTTCCTGTAAGTGTGCTAGTTGCTGCCTCGTAT 4200
4201 CTCAGGTTTTTCTCTGTTTTTGAGAAATGGACAGTTTTTTGACCAGGATGTGACTTCATG 4260
4261 TTCCTATGGTGA CTTCTAAAACCAGCACAGAATGATATGACTCAACACAGACCGACTTG 4320
4321 GTTATGGGGATGATGAGCCGCACAGACCTCACTAGTTGTGCACAAATAATGTGCTATGAT 4380
4381 GGGGTGTAAAGTGAAGGCAGAAGAGGGTCAGCCGCATTGTTATGATACTGGGAAAGTGCT 4440
4441 GGTCAACGATTTGAGTTAGTTTTTAGATATACATTGAAATCTTTAATCAGACATTCTCAA 4500
4501 GTTTCACACAGTAGTTTTTGATGTTATGTACACACACACCAAATGTGTAACAGTTCACCA 4560
4561 CTTCCAGAGTGTGGTCATGCCCAAACATGTTTAAGAAAGGAAAGCAGTAGCTCCTTGCT 4620
4621 AACGATGTTTCAGGAGGTTTGGGGCACTTGTTTTTAATGAGCTTCTGTCATTTAGGGCTT 4680
4681 CTCTTGGCCATGGTCCCCTTCCTTCTGGAACGTGATGTAGTCACATCCTACAGCCTTTA 4740
4741 GTGCTGGTTCACTAGTGTGAGATAATCAGTTCTTGGAATCGAGACTGCCGTGGCGAAGGG 4800
4801 GTGGCCTCGGAGGCAGGCTCTGGAGCTGCTTGATGTCTTTAGGTGGGGTGGTGGCTGGC 4860
4861 TCTCTTCAGCATGTAATTGGGGAAACCCTCGCGTCTACTAGGGGTGATACAGATGGTGAT 4920
4921 TTAAAGAGCAAACTAGACTTCTATGTGAGAAGTGCTGGAAAATGATTTAGGACATGTG 4980
4981 TAAAGTTAGATGGAAAGACTGTAAATGTTAATATGAATATAGTGTTCTTTTGAAGTAAG 5040
5041 GCCAGCTGTTGAACGGTTAACTGTGCATTTCTCATTTTGATGTGTCATGTATGTTAATG 5100
5101 TATGAAATGATTAAATAAAATCAAACTGGTACCTGTTTATACATAAATACGAGAAAAGA 5160

Figure 19F

5161 CCTATCTTTGCAGCCATAAACTCGGTGGGAACACCACCACTCAAGTTGCCAAAGGAGGCA 5220
5221 GTGGTGAAACCTGTCCTGTTCTCACTTAAATGAGGATTTAGCTCAAAATAAAGTGGTGGT 5280
5281 GTCATCAGGTTTATTCCGTGTTCTGTCATTCACATGGAACACCGGATGATTAGCTAACAG 5340
5341 TTTAGTGCCAGCCTTCATTCTTTACTGTGTACGTTAAATGCACACTACAGTGAAAAAGCC 5400
5401 TAAGACACTTGGTAAATATTTCTAGCTGACTGATTCCAGAACACACAAG 5450

Figures 20A

1 CCACGCGTCCGGCTCTTGCCCTCCAGTGCCATGCAGGTGCAGGATGCAACCAGGCGGGCC 60
61 TCAGCCGTGCGCTTCTCAGCTCCTTTCTCAGGGCCGCCGGCACTCCACCTCAGACCCA 120
121 GTACTGCGGCTGCAGCAGGCCCCGGCGGGGCTCTGGCTTGGGCTCCGGCTCTGCCACGAAG 180
181 CTGCTGTCTCGTCCTCTCTCCAGGTGATGGTGGCTGTTTCTCAGTCAGCCATGCAGAG 240
241 GGAAACCCAACCTTTCCCCGAAAGAAAAAGAAATTTAGAACGTCCAACACCAAAGTACACA 300
301 AAAGTAGGGGAGCGTTTACGGCATGTCATTCTGGACACATGGCATGTTCCATGGCGTGT 360
361 GGCGGTAGAGCTTGCAAGTATGAGAACCCAGCCCGCTGGAGTGAGCAGGAGCAAGCCATT 420
421 AAGGGGGTTTACTCATCTGGGTCACTGATAATATACTGGCCATGGCCCCGCCATCCTCT 480
481 GAGCTCCTGGAGAAGTACCACATCATTGATCAGTTCCTCAGCCATGGCATAAAAAACAATA 540
541 ATCAACCTCCAGCGCCCTGGTGAGCATGCTAGCTGTGGGAACCTCTGGAACAAGAAAGT 600
601 GGCTTCACATACCTTCTGAGGCTTTTCATGGAGGCTGGCATTACTTCTACAATTTGGA 660
1 M E A G I Y F Y N F G 11
661 TGAAGGATTATGGTGTAGCGTCTCTTACTACTATCCTAGATATGGTGAAGGTGATGACA 720
12 W K D Y G V A S L T T I L D M V K V M T 31
721 TTTGCCTTACAGGAAGGAAAAGTAGCTATCCATTGTCATGCAGGGCTTGGTCTGAACAGGT 780
32 F A L Q E G K V A I H C H A G L G R T G 51
781 GTTTTAATAGCCTGTTACTTAGTTTTTGCAACGAGAATGACTGCTGACCAAGCAATTATA 840
52 V L I A C Y L V F A T R M T A D Q A I I 71
841 TTTGTGCGGGCAAAGCGACCCAATTCCATACAAACCAGAGGACAGCTCCTCTGTGTAAGG 900
72 F V R A K R P N S I Q T R G Q L L C V R 91
901 GAATTTACTCAGTTTCTAACTCCTCTCCGCAATATATTCTCTGCTGTGATCCCAAAGCA 960
92 E F T Q F L T P L R N I F S C C D P K A 111
961 CATGCTGTACCTTACCTCAATATCTAATTCGCCAGCGTCATCTGCTTCATGGTTATGAG 1020
112 H A V T L P Q Y L I R Q R H L L H G Y E 131
1021 GCACGACTTCTGAAACACGTGCCAAAAATTATCCACCTAGTTTGCAAATTGCTGCTGGAC 1080
132 A R L L K H V P K I I H L V C K L L L D 151
1081 TTAGCGGAGAACAGGCCAGTGATGATGAAGGATGTGTCCGAAGGACCTGGTCTCTCTGCT 1140
152 L A E N R P V M M K D V S E G P G L S A 171

Figures 20B

1141 GAAATAGAAAAGACAATGTCTGAGATGGTCACCATGCAGCTGGATAAAGAGTTACTGAGG 1200
172 E I E K T M S E M V T M Q L D K E L L R 191

1201 CATGACAGTGATGTGTCCAACCCGCTAACCCCACTGCAGTGGCAGCAGATTTTGACAAT 1260
192 H D S D V S N P P N P T A V A A D F D N 211

1261 CGAGGCATGATTTTCTCCAATGAGCAACAGTTTGACCCTCTTTGGAAAAGCGGAATGTT 1320
212 R G M I F S N E Q Q F D P L W K R R N V 231

1321 GAGTGCCTTCAACCCCTGACTCATCTGAAAAGGCGGCTCAGCTACAGTGACTCAGATTTA 1380
232 E C L Q P L T H L K R R L S Y S D S D L 251

1381 AAGAGGGCCGAGAACCTCCTGGAGCAAGGGGAGACTCCACAGACAGTGCCTGCCAGATC 1440
252 K R A E N L L E Q G E T P Q T V P A Q I 271

1441 TTGGTTGGCCACAAGCCAGGCAGCAGAAGCTCATAAGCCATTGTTACATCCACAGTCT 1500
272 L V G H K P R Q Q K L I S H C Y I P Q S 291

1501 CCAGAACCAGACTTACACAAGGAAGCCTTGGTTTCGAGCACACTTTCTTTCTGGAGTCAG 1560
292 P E P D L H K E A L V R S T L S F W S Q 311

1561 TCAAAGTTTGGAGGCCTGGAAGGACTCAAAGATAATGGGTCACCAATTTTCCATGGAAGG 1620
312 S K F G G L E G L K D N G S P I F H G R 331

1621 ATCATTCCAAAGGAAGCACAGCAGAGTGGAGCTTTCTCTGCAGATGTTTCAGGCTCACAC 1680
332 I I P K E A Q Q S G A F S A D V S G S H 351

1681 AGCCCTGGGGAGCCAGTTTCACCCAGCTTTGCAAATGTCCATAAGGATCCAAACCCTGCT 1740
352 S P G E P V S P S F A N Y H K D P N P A 371

1741 CACCAGCAAGTGTCTCACTGTCAAGTGTAAAACATCATGGTGTGGGAGCCCTGGCTCTGTC 1800
372 H Q Q V S H C Q C K T H G V G S P G S V 391

1801 AGGCAGAACAGCAGGACACCCGAAGCCCTCTGGACTGTGGCTCCAGTCCCAAAGCACAG 1860
392 R Q N S R T P R S P L D C G S S P K A Q 411

1861 TTCTTGGTTGAACATGAAACCCAGGACAGTAAAGATCTGTCTGAAGCAGCTTCACACTCT 1920
412 F L V E H E T Q D S K D L S E A A S H S 431

1921 GCATTACAGTCTGAATTGAGTGTCTGAGGCAAGAAGAATACTGGCGGCCAAAGCCCTAGCA 1980
432 A L Q S E L S A E A R R I L A A K A L A 451

1981 AATTTAAATGAATCTGTAGAAAAGGAGGAAGTAAAAGGAAGGTAGAAATGTGGCAGAAA 2040
452 N L N E S V E K E E L K R K V E M W Q K 471

2041 GAGCTTAATTTCCGAGATGGAGCTTGGGAAAGAATATGTGGCGAGAGGGACCCTTTTCATC 2100
472 E L N S R D G A W E R I C G E R D P F I 491

Figures 20C

2101 CTATGCAGCTTGATGTGGTCTTGGGTGGAGCAACTGAAGGAGCCTGTAATCACCAAAGAG 2160
492 L C S L M W S W V E Q L K E P V I T K E 511

2161 GATGTGGACATGTTGGTTGACAGGCGAGCAGATGCCGAGAGCACTTTTTTTATTAGAG 2220
512 D V D M L V D R R A D A A E A L F L L E 531

2221 AAGGGACAGCACCAGACTATTCTCTGCGTGTTCGACTGCATAGTGAACCTGCAGACAATT 2280
532 K G Q H Q T I L C V L H C I V N L Q T I 551

2281 CCCGTGGATGTGGAGGAAGCTTTCCTTGCCCATGCCATTAAAGGCATTCACTAAGGTTAAT 2340
552 P V D V E E A F L A H A I K A F T K V N 571

2341 TTTGATTCTGAAAATGGACCAACAGTTTACAACACCCTGAAGAAAATATTTAAGCACACG 2400
572 F D S E N G P T V Y N T L K K I F K H T 591

2401 CTGGAAGAAAAAAGAAAAATGACAAAAGATGGCCCTAAGCCTGGCCTCTAGCTTTCACCTC 2460
592 L E E K R K M T K D G P K P G L * 607

2461 ATGGTGAATATTTTCAGACCTAAAGATCCAGATAGTATCTCTGTTCATATGTGAATAAGTT 2520

2521 GAAGATTGTGGGGCTACTTTTTCTCATAGCACTTTATTTTGAATGTTGTTAGTTTGTGCT 2580

2581 GAGAATGGTCGTCGGTATTGAACCAATTATTTATTTTAAAATATATTTAAGCTACATT 2640

2641 TTGTTTTGAAAAATGCCATAAATTTGGTGCCACTTCTTTTATTTATTTGACTGAGTTA 2700

2701 ATATTATTGTATTAACATTTTAAGTATATGGTGTTCATTCTTATTTCTTTTGACATT 2760

2761 TGGAAATAATCATAACTTGCTTTCCAAAATAACCATTTCTTGATGGAACCTTCCTAG 2820

2821 AGTTTTTACCAAATAGCTAACTTTAGTAGTAAAACCTCATTGTGTATCCATTCCCCACA 2880

2881 GATGAACTAAGAAAGTCACCAAGTGTCTTAAGCTGTTTTATATTGTTACGAAGAAGGCT 2940

2941 ATTGCTACAATATTTTTAAAGGTTTCTTTTAACTTTGAAATTTTTGTTTTTCCTTT 3000

3001 CTTTTTATAAATGTAAAGAGGGTTTCAAAGCATATTATTTTTCAGAGAGATTAGTTTT 3060

3061 ACTTTAATGGAGTGAAGTGTGAAGTGGTGGGATTTTTGCTGTAGAAAGTAGACTTGCT 3120

3121 CTTTGTCTAGATTTCCAAACACCTTGCCAGCCTTGGCTGTCAAAGGAGGCAGGAGCAGT 3180

3181 TCTCAACACACCAAGCCTTATTTCCCACTCCCTTGGGTTGCTGCTGAGCCAAATAGCATCT 3240

3241 TTACAGAGGAAGTGGGATCAGAGGCAGGAAGTGTGGAAGTTGCTAAGAAGCAGGGCTTG 3300

Figures 20D

3301 CCTCTGTCTCTCCCGGGGACTCCACAGGGATATTCGTGCAGGGCAGGGGCTCTGTGCCAGC 3360
3361 CCTGCTCTCTCAGATGCCACAGCCACTCTGCAGAGGTGACTCTTGGAGCTGGAGGAAGTC 3420
3421 AAAACTGGGCCACTGTTTGTACTGATGGTGTATTAGCATGAGCAGCGTGGCCCTGGCCCC 3480
3481 ACACTCCCAAATCTGCCACTCCATAGACCCACTTGCCTCAAGGCTTTATATTTGGCTGCT 3540
3541 TTCTTACAATGAGAATTAAGATTTTAAACTGAAGTTGACCATACAGGTTGCATTAGCCC 3600
3601 TAACTGGCTTCATGTAAGAAGGGTGACTGCCTAAACTAGTTCCTTGTAAAGCTGAACCATC 3660
3661 AATTATCAGTTGAAGCCATACTTTTATTTAAATTAATATACGTAGATACCAGAGGCCAAG 3720
3721 CCACAGAGAGGATAATAGTTCTTCCCAATAAAGGTGATATTAATCAGACTAATTCGAAC 3780
3781 TAAAGAAGTTACTGCTTAAAGACGGAATTTAGGGGAAGCAAGACTCATTTAGAACAAAT 3840
3841 GAAATTTCTCCAGTCTACATTTCTGAATTGACTTCTAGCACATCAAAAATATTTAGTC 3900
3901 ATTATCAGTCTCATTAAGTAAATGCCAAATGCTAAATGCAGTGTCTTTTCACTGTTT 3960
3961 TAATTTTCTTGGGAAATTGAGTCCAGTGGATGTTAATGGAGTGGGTGCCCCATCCCTGAA 4020
4021 ATGTCTTATTTTCAAGTGCCTGGCCTGGGAAAGAAGGGGAAGAAACAATTGCATTATATC 4080
4081 CAAAGATACACTATAAAAATAGAGTTTTTACCAAAAAAAGATGTTTGTCTCATCTCAGT 4140
4141 AGGCCTCATTTGGGCAAGTGACCCACAGGTCTTTTGGCGAGTTTGCTATTTGCCTGTTGA 4200
4201 AATACTTGTTTCACTTAGAGAACAGTTATGATGTGACCATAGCATGGCACAACTAAAAA 4260
4261 TCTAAGCCTGAAACCTGAAAAAGAGATATGACAAGGGAAATTAATCAGGCTATACATAA 4320
4321 GTATTGTATTTATTTGAATAAAAAATAAAAGAGCAACCCATAAAAAAAAAAAAAAAAAAA 4380
4381 AAAAAAAAAAAAAAG 4393

Figures 21

1 CCACGCGTCCGGCGAGGGGACGCGTGGGCGGAGCGGGGCTGGCCAGCCTCGGCCCCCATG 60

61 ACCCGCTGTCTGTGCCCTTTCCAGCGATGGGCGTGCAGCCCCCAACTTCTCTGGGT 120
1 M G V Q P P N F S W V 11

121 GCTTCCGGGCGGCTGGCGGACTGGCGCTGCCGCGGCTCCCCGCCACTACCAGTTCCT 180
11 L P G R L A G L A L P R L P A H Y Q F L 31

181 GTTGGACCTGGGCGTGGCGCACCTGGTGTCCCTGACGGAGCGCGGGCCCCCTCACAGCGA 240
31 L D L G V R H L V S L T E R G P P H S D 51

241 CAGCTGCCCCGGCCTCACCTGCACCGCTGCGCATCCCCGACTTCTGCCCCGCGGCCCC 300
51 S C P G L T L H R L R I P D F C P P A P 71

301 CGACCAGATCGACCGCTTCGTGCAGATCGTGGACGAGGCCAACGCACGGGGAGAGGCTGT 360
71 D Q I D R F V Q I V D E A N A R G E A V 91

361 GGGAGTGCACCTGTGCTCTGGGCTTTGGCCGCACTGGCACCATGCTGGCCTGTTACCTGGT 420
91 G V H C A L G F G R T G T M L A C Y L V 111

421 GAAGGAGCGGGGCTTGGCTGCAGGAGATGCCATTGCTGAAATCCGACGACTACGACCCGG 480
111 K E R G L A A G D A I A E I R R L R P G 131

481 CTCCATCGAGACCTATGAGCAGGAGAAAGCAGTCTTCCAGTTCTACCAGCGAACGAAATA 540
131 S I E T Y E Q E K A V F Q F Y Q R T K * 150

541 AGGGGCCTTAGTACCCTTCTACCAGGCCTCACTCCCCTTCCCCATGTTGTCGATGGGGC 600

601 CAGAGATGAAGGAAGTGGACTAAAGTATTAAACCCTCTAGCTCCCATTGGGTGAAGACA 660

661 CTGAAGTAGCCACCCCTGCAGGCAGGTCTGATTGAAGGGGAGGCTTGTA CTGCTTTGT 720

721 TGAATAAATGAGTTTTACGAACCAGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 780

781 AA 840

841 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGC 878

Figure 22




Figure 23




Figure 24.

BMY_HPP1

<u>Protein</u>	<u>Genbank ID</u>	<u>Identities</u>	<u>Similarities</u>
human protein tyrosine phosphatase	gi P32587	27%	39.6%
mouse protein tyrosine phosphatase	gi NP_035346	27.9%	40.5%
Schizosacchomyces Pombe protein tyrosine phosphatase PYP3 protein	gi NP_002839	27.5%	36.7%

BMY_HPP2

<u>Protein</u>	<u>Genbank ID</u>	<u>Identities</u>	<u>Similarities</u>
human S. cerevisiae CDC14 homolog A	gi NP_003663	33.1%	44.1%
human S. cerevisiae CDC14 homolog B	gi NP_003662	33.1%	45.8%
yeast soluble tyrosine-specific protein phosphatase Cdc14p protein	gi NP_002839	33.1%	45.8%


Figure 25.

RET31			
<u>Protein</u>	<u>Genbank ID</u>	<u>Identities</u>	<u>Similarities</u>
human protein-tyrosine phosphatase DUS8 protein	gi U27193	50.3%	56.8%
the human dual specificity MAP kinase DUSP6 protein	gi AB013382	36.5%	48.3%
human map kinase phosphatase MKP-5 protein	gi AB026436	34.3%	47.2%
mouse RET31 protein	N/A	90%	92%

Figure 27

HPPI	MAAGVLPQNE	QPYSTLVNNS	EC.VANMKGN	LERPTPKYTK	39
pdblaax	MEMEKEFEQI	DKSGSWAAIY	QDIRHEASDF	PCRVAKLPKN	KNRNRIRDVS	50
HPPI	VGERLRHVIP	GHMACSMACG	GRACKYENPA	RWSEQEQAIK	GVYSSWVTDN	89
pdblaax	PFDH..SRIK	LHQEDNDYIN	ASLIKME...EAQRS	YILTQGPLPN	90
HPPI	ILAMARPSSE	LLEKYHIIDQ	FLSHGIKTII	NLQRPGE..H	ASCGNPLEQE	137
pdblaaxTCGHEWEM	VWEQKSRGVV	MLNRVMEKGS	LKCAQYWPQK	128
HPPI	S.....GFTYL	PEAFMEAG..IYFYNFG	158
pdblaax	EEKEMIFEDT	NLKLTLISED	IKSYYTVRQL	ELENLTTQET	REILHFHYTT	178
	**			** * *		
HPPI	WKDYGVA.SI	TTILDMVKVMTFALQE	GKVAIHCHAG	LGRTGVLIAC	203
pdblaax	WPDFGVPESP	ASFLNFLFKV	RESGSLSPFH	GPVVVHSSAG	IGRSGTFCLA	228
HPPI	YLVFATR...MTADQ	AIIFVRAKRP	NSI....QTR	GQLLCVREFT	241
pdblaax	DTCLLLMDKR	KDPSSVDIKK	VLEMRKFRM	GLIQTADQLR	FSYLAVIEGA	278
HPPI	QFLTPLRNIF	SCCDPKAHAV	TLPQYLIRQR	HLLHGYEARL	LKHVPKIIHL	291
pdblaax	KFIM.....	GDSSVQDQWK	ELSHEDLEPP	PGHIPPPPRP	312
HPPI	VCKLLLDLAE	NRPVMMKDVS	EGPGLSAEIE	KTMSEMVTMQ	LDKELLRHDS	301
pdblaax	PKRILEPHN.	321

Figure 28



HPP1 Homology Model

Figure 29




Figure 30

Relative Abundance of BMV_HPP2 in Normal Tissues





Figure 31

```
      20      30      40      50      60      70
pdblvrA GCYSLPSQPCNEVTPRIYVGNASVAQDIPKLQKLGITHVLNAAEGRSFMHVNTNANFYKD
      :  ::  ....  :  !.  :  ..
BMY_HPP2 MGVPQPNFVSWVLPGRLAGLALPRLPAHYQFLLDLGVRLVSLTE-RGPPHSDSCP-----
      10      20      30      40      50

      80      90      100      110      120      130
pdblvrA SGITYLGIKANDTQEFNLSA--YFERAADFIDQALAQKNGRVLVHCREGYRSPTLVIAIY
      ::  ..  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
BMY_HPP2 -GLTLHRLRIPD---FCPPAPDQIDRFVQIVDEANARGEA-VGVHICALGFGRGTGMLACY
      .  60      70      80      90      100

      140      150      160      170      180
pdblvrA LMMRQKMDVKSALSIVRQNRIGPNDGFLAQLCQLNDRLAKEGKLP
      :  .  .  .  .  .  .  :  :
BMY_HPP2 LVKERGLAAGDAIAEIRRLRPGSIETYEQEKAVFQFYQRTK
      110      120      130      140      150
```

Figure 32.



HPP2 Homology Model


Figure 33

Figure 34




Figure 35

Relative Abundance of BMY_HPP5 in Normal Tissues




Figure 36




Figure 37

```


                                10      20      30
pdblmpk      ASFPVEILPFPLYLGCAKDNLDVLEEFGIKYI
              :..... :. : ..... :. :
BMY_HPP5     SRCFPGLCEGKSTLVPTCISQPCLPVANIGPTRILPNLYLGCQRDVLNKELMQQNGIGYV
              130      140      150      160      170      180

              40      50      60      70      80      90
pdblmpk      LNVTFPNLPNLFENAGEFKYKQIPISDHWSQNLSQFFPEAISFIDEARGKNCGVLVHSLAG
              :... :. : : ..... :. : ..... :. : ..... :. : ..... :. :
BMY_HPP5     LNASNTCPKP-DFIPESHFLRVPVNSFCEKILPWLDKSVDFIEKAKASNGCVLVHCLAG
              190      200      210      220      230      240

              100      110      120      130      140
pdblmpk      ISRSVTVTVAYLMQKLNLSMNDAYDIVKMKKSNISPNFNFMGQLLDFERTL
              :..... :. : ..... :. : ..... :. : ..... :. : ..... :. :
BMY_HPP5     ISRSATIAIAYIMKRMDMSLDEAYRFVKEKRPTISPNFNFGLGQLLAYEKKIKNQTGASGP
              250      260      270      280      290      300

BMY_HPP5     KSKLKLPLEKPNEPVPVAVSEGGQKSETPLSPPCADSATSEAAGQRPVHPASVPSVPSVQ
              310      320      330      340      350      360
```

Figure 38.



HPP5 Homology Model


Figure 39

TABLE III

GENBANK ACCESSION NO:Q9ZSE4 SERINE/THREONINE PROTEIN PHOSPHATASE TYPE 2A.
GENBANK ACCESSION NO:Q16341 PROTEIN-TYROSINE PHOSPHATASE.
GENBANK ACCESSION NO:P2C2_CAEEL PROBABLE PROTEIN PHOSPHATASE 2C T23F11.1 (EC 3.1.3.16) (PP2C).
GENBANK ACCESSION NO:Q92140 PROTEIN PHOSPHATASE 2A, CATALYTIC SUBUNIT, BETA ISOFORM.
GENBANK ACCESSION NO:Q28006 BA14 TYROSINE PHOSPHATASE (EC 3.1.3.48).
GENBANK ACCESSION NO:O14428 SERINE/THREONINE PROTEIN PHOSPHATASE PPT1.
GENBANK ACCESSION NO:P2CG_MOUSE PROTEIN PHOSPHATASE 2C GAMMA ISOFORM (EC 3.1.3.16) (PP2C-GAMMA) (PROTEIN PHOSPHATASE 1C) (FIBROBLAST GROWTH FACTOR INDUCIBLE PROTEIN 13) (FIN13).
GENBANK ACCESSION NO:Q64604 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F POLYPEPTIDE PRECURSOR (EC 3.1.3.48) (LAR PROTEIN) (LEUKOCYTE ANTIGEN RELATED) (LEUKOCYTE COMMON ANTIGEN-RELATED PHOSPHATASE) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:O43655 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, R (EC 3.1.3.48) (RECEPTOR PROTEIN TYROSINE PHOSPHATASE) (FRAGMENT).
GENBANK ACCESSION NO:O75551 PROTEIN PHOSPHATASE 2C ALPHA 2.
GENBANK ACCESSION NO:Q64605 LEUKOCYTE COMMON ANTIGEN-RELATED PHOSPHATASE PTP2 PRECURSOR (EC 3.1.3.48) (PROTEIN-TYROSINE PHOSPHATASE LAR-PTP2) (PHOSPHOTYROSINE PHOSPHATASE LAR-PTP2) (PTPASE LAR-PTP2) (PTP NE-3) (PTP-P1) (CPTP1) (PTP-SIGMA).
GENBANK ACCESSION NO:PTPK_HUMAN PROTEIN-TYROSINE PHOSPHATASE KAPPA PRECURSOR (EC 3.1.3.48) (R-PTP- KAPPA).
GENBANK ACCESSION NO:PP11_DROME SERINE/THREONINE PROTEIN PHOSPHATASE ALPHA-1 ISOFORM (EC 3.1.3.16).
GENBANK ACCESSION NO:Q42981 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:O88740 PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:O81955 PP1A PROTEIN.
GENBANK ACCESSION NO:PTNB_MOUSE PROTEIN-TYROSINE PHOSPHATASE SYP (EC 3.1.3.48).
GENBANK ACCESSION NO:O81956 PP2A1 PROTEIN.
GENBANK ACCESSION NO:P2BA_HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT, ALPHA ISOFORM (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT, ALPHA ISOFORM) (CAM-PRP CATALYTIC SUBUNIT).
GENBANK ACCESSION NO:P2BA_BOVIN SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT, ALPHA ISOFORM (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT, ALPHA ISOFORM) (CAM-PRP CATALYTIC SUBUNIT).
GENBANK ACCESSION NO:PT12_STYPL PROTEIN-TYROSINE PHOSPHATASE 12 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:P2A4_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-4 CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:PTPM_MOUSE PROTEIN-TYROSINE PHOSPHATASE MU PRECURSOR (EC 3.1.3.48) (R-PTP-MU).
GENBANK ACCESSION NO:PCP2_HUMAN PROTEIN-TYROSINE PHOSPHATASE PCP-2 PRECURSOR (EC 3.1.3.48).
GENBANK ACCESSION NO:P2BC_MOUSE SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT, GAMMA ISOFORM (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT, GAMMA ISOFORM) (CALCINEURIN, TESTIS-SPECIFIC CATALYTIC SUBUNIT) (CAM-PRP CATALYTIC SUBUNIT).
GENBANK ACCESSION NO:O00197 RECEPTOR PROTEIN TYROSINE PHOSPHATASE HPTP-J PRECURSOR (EC 3.1.3.48).
GENBANK ACCESSION NO:O61722 PUTATIVE PRENYLATED PROTEIN TYROSINE PHOSPHATASE. PRL-1.
GENBANK ACCESSION NO:PPE1_SCHPO SERINE/THREONINE PROTEIN PHOSPHATASE PPE1 (EC 3.1.3.16) (PHOSPHATASE ESP1).
GENBANK ACCESSION NO:Q9XGT7 SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-3 CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:PP14_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP1 ISOZYME 4 (EC 3.1.3.16).
GENBANK ACCESSION NO:O76451 SERINE/THREONINE PROTEIN PHOSPHATASE I (FRAGMENT).
GENBANK ACCESSION NO:O35564 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, L (EC 3.1.3.48) (FTP-1).
GENBANK ACCESSION NO:PPX1_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP-X ISOZYME 1 (EC 3.1.3.16).

GENBANK ACCESSION NO:O65844 PROTEIN PHOSPHATASE 1, CATALYTIC BETA SUBUNIT.
GENBANK ACCESSION NO:Q62917 LAR RECEPTOR-LINKED TYROSINE PHOSPHATASE (EC 3.1.3.48).
GENBANK ACCESSION NO:O65845 PROTEIN PHOSPHATASE 1, CATALYTIC GSMMS SUBUNIT.
GENBANK ACCESSION NO:Q64538 PHOSPHOPROTEIN PHOSPHATASE (FRAGMENT).
GENBANK ACCESSION NO:O65846 PROTEIN PHOSPHATASE 1 CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:PTN3_HUMAN PROTEIN-TYROSINE PHOSPHATASE H1 (EC 3.1.3.48) (PTP-H1).
GENBANK ACCESSION NO:P2C3_YEAST PROTEIN PHOSPHATASE 2C HOMOLOG 3 (EC 3.1.3.16) (PP2C-3).
GENBANK ACCESSION NO:O65847 PROTEIN PHOSPHATASE 1, CATALYTIC EPSILON SUBUNIT.
GENBANK ACCESSION NO:PPP6_HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE 6 (EC 3.1.3.16) (PP6).
GENBANK ACCESSION NO:O88591 PROTEIN PHOSPHATASE TYPE 2A CATALYTIC SUBUNIT ALPHA ISOFORM.
GENBANK ACCESSION NO:P2AB_PIG SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-BETA, CATALYTIC SUBUNIT (EC 3.1.3.16) (FRAGMENT).
GENBANK ACCESSION NO:PT06_STYPL PROTEIN-TYROSINE PHOSPHATASE 6 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:P2A_BRANA SERINE/THREONINE PROTEIN PHOSPHATASE PP2A CATALYTIC SUBUNIT (EC 3.1.3.16) (FRAGMENT).
GENBANK ACCESSION NO:P2A_MEDSA SERINE/THREONINE PROTEIN PHOSPHATASE PP2A CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:PTNC_HUMAN PROTEIN-TYROSINE PHOSPHATASE G1 (EC 3.1.3.48) (PTPG1).
GENBANK ACCESSION NO:O15253 SERINE /THREONINE PROTEIN PHOSPHATASE.
GENBANK ACCESSION NO:P2CB_MOUSE PROTEIN PHOSPHATASE 2C BETA ISOFORM (EC 3.1.3.16) (PP2C-BETA) (IA) (PROTEIN PHOSPHATASE 1B).
GENBANK ACCESSION NO:Q61152 PROTEIN-TYROSINE PHOSPHATASE 18 (EC 3.1.3.48) (PTP-K1) (FETAL LIVER PHOSPHATASE 1) (FLP1) (PTP 49) (PTP HSCF).
GENBANK ACCESSION NO:O22626 PROTEIN PHOSPHATASE X ISOFORM 2.
GENBANK ACCESSION NO:Q9XGU3 PHOSPHATASE PP1.
GENBANK ACCESSION NO:PTPF_HUMAN LAR PROTEIN PRECURSOR (LEUKOCYTE ANTIGEN RELATED) (EC 3.1.3.48).
GENBANK ACCESSION NO:Q64621 RECEPTOR-LINKED PROTEIN TYROSINE PHOSPHATASE (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:YME1_CAEEL PUTATIVE SERINE/THREONINE PROTEIN PHOSPHATASE F56C9.1 IN CHROMOSOME III (EC 3.1.3.16).
GENBANK ACCESSION NO:Q64622 PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (FRAGMENT).
GENBANK ACCESSION NO:Q24708 PROTEIN-TYROSINE PHOSPHATASE CORKSCREW (EC 3.1.3.48) (CSW) (FRAGMENT).
GENBANK ACCESSION NO:Q15718 PTPSIGMA PRECURSOR (EC 3.1.3.48).
GENBANK ACCESSION NO:PTFA_RAT PROTEIN-TYROSINE PHOSPHATASE ALPHA PRECURSOR (EC 3.1.3.48) (R-PTP- ALPHA).
GENBANK ACCESSION NO:Q63739 TYROSINE PHOSPHATASE.
GENBANK ACCESSION NO:P91569 PROBABLE SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:WZB_ECOLI PROBABLE LOW MOLECULAR WEIGHT PROTEIN-TYROSINE-PHOSPHATASE WZB (EC 3.1.3.48).
GENBANK ACCESSION NO:PP1G_MOUSE SERINE/THREONINE PROTEIN PHOSPHATASE PP1-GAMMA CATALYTIC SUBUNIT (EC 3.1.3.16) (PP-1G).
GENBANK ACCESSION NO:O88765 PROTEIN TYROSINE PHOSPHATASE.
GENBANK ACCESSION NO:Q98945 PROTEIN TYROSINE PHOSPHATASE CRYP-2 PRECURSOR (EC 3.1.3.48).
GENBANK ACCESSION NO:YOR5_KLEPN PUTATIVE LOW MOLECULAR WEIGHT PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (ORF5).
GENBANK ACCESSION NO:P2BB_RAT SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT, BETA ISOFORM (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT, BETA ISOFORM) (CAM-PRP CATALYTIC SUBUNIT).
GENBANK ACCESSION NO:Q9Y0B7 PROTEIN PHOSPHATASE 4 CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:Q04071 PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT C (EC 3.1.3.16) (PP-2BC) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT) (FRAGMENT).
GENBANK ACCESSION NO:YWLE_BACSU PUTATIVE LOW MOLECULAR WEIGHT PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48).
GENBANK ACCESSION NO:Q9ZTF1 PUTATIVE TRANSCRIPTION FACTOR (FRAGMENT).

GENBANK ACCESSION NO:Q62132 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, Q PRECURSOR (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE SL) (PHOSPHOTYROSINE PHOSPHATASE).
GENBANK ACCESSION NO:P70602 PROTEIN TYROSINE PHOSPHATASE 20 (EC 3.1.3.48).
GENBANK ACCESSION NO:P2A1_NEUCR SERINE/THREONINE PROTEIN PHOSPHATASE PP2A CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:Q62135 PROTEIN-TYROSINE PHOSPHATASE 13 (EC 3.1.3.48) (RIP).
GENBANK ACCESSION NO:O17047 PROTEIN PHOSPHATASE WITH EF-HANDS.
GENBANK ACCESSION NO:O43049 SERINE/THREONINE PROTEIN PHOSPHATASE.
GENBANK ACCESSION NO:Q9XF94 SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-2 CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:PPP4_RABIT SERINE/THREONINE PROTEIN PHOSPHATASE 4 (EC 3.1.3.16) (PP4) (PROTEIN PHOSPHATASE X) (PP-X).
GENBANK ACCESSION NO:PPZ_SCHPO SERINE/THREONINE PROTEIN PHOSPHATASE PP-Z (EC 3.1.3.16).
GENBANK ACCESSION NO:Q12974 PROTEIN-TYROSINE PHOSPHATASE.
GENBANK ACCESSION NO:Q63745 PROTEIN TYROSINE PHOSPHATASE (EC 3.1.3.48).
GENBANK ACCESSION NO:P2A3_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE PPH3 (EC 3.1.3.16).
GENBANK ACCESSION NO:P97470 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16) (FRAGMENT).
GENBANK ACCESSION NO:O75664 DJ707K17.1 (RECEPTOR PROTEIN TYROSINE PHOSPHATASE (RPTP-RHO, EC 3.1.3.48)) (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q62937 PP-1M (FRAGMENT).
GENBANK ACCESSION NO:Q27786 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:Q27787 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:PTN6 HUMAN PROTEIN-TYROSINE PHOSPHATASE 1C (EC 3.1.3.48) (PTP-1C) (HEMATOPOIETIC CELL PROTEIN-TYROSINE PHOSPHATASE) (SH-PTP1).
GENBANK ACCESSION NO:Q60998 PROTEIN-TYROSINE PHOSPHATE PHI (EC 3.1.3.48) (PTP PHI).
GENBANK ACCESSION NO:PTPA_MYCTU PROBABLE LOW MOLECULAR WEIGHT PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (PTPASE).
GENBANK ACCESSION NO:PT09_STYPL PROTEIN-TYROSINE PHOSPHATASE 9 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q99849 PROTEIN TYROSINE PHOSPHATASE HOMOLOG HPRL-R (FRAGMENT).
GENBANK ACCESSION NO:P2C_LEICH PROTEIN PHOSPHATASE 2C (EC 3.1.3.16) (PP2C).
GENBANK ACCESSION NO:P2CA_RAT PROTEIN PHOSPHATASE 2C ALPHA ISOFORM (EC 3.1.3.16) (PP2C-ALPHA) (1A) (PROTEIN PHOSPHATASE 1A).
GENBANK ACCESSION NO:PTPA_HUMAN PROTEIN-TYROSINE PHOSPHATASE ALPHA PRECURSOR (EC 3.1.3.48) (R-PTP-ALPHA).
GENBANK ACCESSION NO:P2A1_SCHPO MINOR SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-1 CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:PTN8_MOUSE HEMATOPOIETIC CELL PROTEIN-TYROSINE PHOSPHATASE 70Z-PEP (EC 3.1.3.48).
GENBANK ACCESSION NO:Q10728 SERINE/THREONINE PROTEIN PHOSPHATASE PP1 SMOOTH MUSCLE REGULATORY M110 SUBUNIT (110 KDA SUBUNIT).
GENBANK ACCESSION NO:Q9YDZ2 266AA LONG HYPOTHETICAL SERINE/THREONINE PROTEIN PHOSPHATASE PP2A CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:Q10729 SERINE/THREONINE PROTEIN PHOSPHATASE PP1 SMOOTH MUSCLE REGULATORY M21 SUBUNIT (21 KDA SUBUNIT).
GENBANK ACCESSION NO:PP1_BRANA SERINE/THREONINE PROTEIN PHOSPHATASE PP1 (EC 3.1.3.16) (FRAGMENT).
GENBANK ACCESSION NO:Q64641 BRAIN-ENRICHED MEMBRANE-ASSOCIATED PROTEIN TYROSINE PHOSPHATASE (BEM)-1 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q64642 BRAIN-ENRICHED MEMBRANE-ASSOCIATED PROTEIN TYROSINE PHOSPHATASE 2 (EC 3.1.3.48) (BEM-2) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (FRAGMENT).
GENBANK ACCESSION NO:P2B2_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT A2 (EC 3.1.3.16) (CALCINEURIN A2) (CALMODULIN-BINDING PROTEIN 2).
GENBANK ACCESSION NO:O77294 SERINE-THREONINE PROTEIN PHOSPHATASE.
GENBANK ACCESSION NO:Q64486 MPTPDELTA (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (FRAGMENT).
GENBANK ACCESSION NO:PP11_SCHPO SERINE/THREONINE PROTEIN PHOSPHATASE PP1-1 (EC 3.1.3.16).

GENBANK ACCESSION NO:Q64487 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, D PRECURSOR (EC 3.1.3.48) (PROTEIN-TYROSINE PHOSPHATASE DELTA) (R-PTP-DELTA).
GENBANK ACCESSION NO:PT10_STYPL PROTEIN-TYROSINE PHOSPHATASE 10 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:EPSP_BURSO PROBABLE LOW MOLECULAR WEIGHT PROTEIN-TYROSINE-PHOSPHATASE EPSP (EC 3.1.3.48).
GENBANK ACCESSION NO:P2A2_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-2 CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:PTPK_MOUSE PROTEIN-TYROSINE PHOSPHATASE KAPPA PRECURSOR (EC 3.1.3.48) (R-PTP- KAPPA).
GENBANK ACCESSION NO:Q9XGH7 PROTEIN PHOSPHATASE 2A CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:Q00219 SERINE/THREONINE PROTEIN PHOSPHATASE PP1(5.9) (EC 3.1.3.16).
GENBANK ACCESSION NO:P2BA_MOUSE SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT, ALPHA ISOFORM (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT, ALPHA ISOFORM) (CAM-PRP CATALYTIC SUBUNIT).
GENBANK ACCESSION NO:PP12_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP1 ISOZYME 2 (EC 3.1.3.16).
GENBANK ACCESSION NO:O43941 PROTEIN PHOSPHATASE-2C.
GENBANK ACCESSION NO:LAR_DROME PROTEIN-TYROSINE PHOSPHATASE DLAR PRECURSOR (EC 3.1.3.48) (PROTEIN- TYROSINE-PHOSPHATE PHOSPHOHYDROLASE).
GENBANK ACCESSION NO:P2CA_RABIT PROTEIN PHOSPHATASE 2C ALPHA ISOFORM (EC 3.1.3.16) (PP2C-ALPHA) (PROTEIN PHOSPHATASE 1A) (1A).
GENBANK ACCESSION NO:Q07808 PROTEIN-TYROSINE PHOSPHATASE 1 (EC 3.1.3.48) (PTPASE 1) (PTP-P1).
GENBANK ACCESSION NO:Q90815 PROTEIN-TYROSINE PHOSPHATASE (EC 3.1.3.48).
GENBANK ACCESSION NO:P2A_DROME SERINE/THREONINE PROTEIN PHOSPHATASE PP2A (EC 3.1.3.16) (MICROTUBULE STAR PROTEIN).
GENBANK ACCESSION NO:Q24495 RECEPTOR PROTEIN-TYROSINE PHOSPHATASE PRECURSOR (EC 3.1.3.48).
GENBANK ACCESSION NO:Q90816 PROTEIN-TYROSINE PHOSPHATASE (FRAGMENT).
GENBANK ACCESSION NO:Q64653 PROTEIN TYROSINE PHOSPHATASE (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (FRAGMENT).
GENBANK ACCESSION NO:Q63682 PROTEIN PHOSPHATASE-1A (FRAGMENT).
GENBANK ACCESSION NO:Y328_SYNY3 PUTATIVE LOW MOLECULAR WEIGHT PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48).
GENBANK ACCESSION NO:PPP4_HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE 4 (EC 3.1.3.16) (PP4) (PROTEIN PHOSPHATASE X) (PP-X).
GENBANK ACCESSION NO:YQF3_CAEEL PUTATIVE SERINE/THREONINE PROTEIN PHOSPHATASE C34C12.3 IN CHROMOSOME III (EC 3.1.3.16).
GENBANK ACCESSION NO:Q64494 PROTEIN-TYROSINE PHOSPHATASE S (EC 3.1.3.48) (R-PTP-S) (FRAGMENT).
GENBANK ACCESSION NO:Q64495 PROTEIN-TYROSINE PHOSPHATASE DELTA (EC 3.1.3.48) (R-PTP-DELTA) (FRAGMENT).
GENBANK ACCESSION NO:Q29585 PHOSPHOPROTEIN PHOSPHATASE (EC 3.1.3.16) (SERINE/THREONINE SPECIFIC PROTEIN PHOSPHATASE) (PROTEIN PHOSPHATASE-1) (PROTEIN PHOSPHATASE-2A) (PROTEIN PHOSPHATASE-2B) (PROTEIN PHOSPHATASE-2C) (FRAGMENT).
GENBANK ACCESSION NO:Q64497 PROTEIN-TYROSINE PHOSPHATASE BETA (EC 3.1.3.48) (R-PTP- BETA) (FRAGMENT).
GENBANK ACCESSION NO:PP1_BRAOL SERINE/THREONINE PROTEIN PHOSPHATASE PP1 (EC 3.1.3.16).
GENBANK ACCESSION NO:Q62797 PROTEIN TYROSINE PHOSPHATASE BK PRECURSOR (EC 3.1.3.48) (PTP-BK) (PROTEIN TYROSINE PHOSPHATASE D30).
GENBANK ACCESSION NO:O75688 PP2C PROTEIN.
GENBANK ACCESSION NO:PT04_STYPL PROTEIN-TYROSINE PHOSPHATASE 4 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q13332 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, S PRECURSOR (EC 3.1.3.48) (PROTEIN-TYROSINE PHOSPHATASE SIGMA) (R-PTP-SIGMA) (PTPRS).
GENBANK ACCESSION NO:YT91_CAEEL PUTATIVE SERINE/THREONINE PROTEIN PHOSPHATASE C06A1.3 IN CHROMOSOME II (EC 3.1.3.16).
GENBANK ACCESSION NO:PTPD_HUMAN PROTEIN-TYROSINE PHOSPHATASE DELTA PRECURSOR (EC 3.1.3.48) (R-PTP- DELTA).
GENBANK ACCESSION NO:O22662 PROTEIN PHOSPHATASE U (FRAGMENT).
GENBANK ACCESSION NO:O15297 WIP1.

GENBANK ACCESSION NO:PP12_DROME SERINE/THREONINE PROTEIN PHOSPHATASE ALPHA-2 ISOFORM (EC 3.1.3.16).
GENBANK ACCESSION NO:O62829 PROTEIN PHOSPHATASE 2C ALPHA (EC 3.1.3.16).
GENBANK ACCESSION NO:Q93095 PROTEIN TYROSINE PHOSPHATASE PEP (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (FRAGMENT).
GENBANK ACCESSION NO:Q91556 PROTEIN TYROSINE PHOSPHATASE ALPHA PRECURSOR (EC 3.1.3.48).
GENBANK ACCESSION NO:O52787 PTP PROTEIN.
GENBANK ACCESSION NO:Q93096 PROTEIN TYROSINE PHOSPHATASE HPRL-1N (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (FRAGMENT).
GENBANK ACCESSION NO:PTNC_MOUSE PROTEIN-TYROSINE PHOSPHATASE P19 (EC 3.1.3.48) (P19-PTP) (MPTP-PEST).
GENBANK ACCESSION NO:Q62884 DENSITY-ENHANCED PHOSPHATASE-1 PRECURSOR (EC 3.1.3.48) (DEP-1) (VASCULAR PROTEIN TYROSINE PHOSPHATASE 1).
GENBANK ACCESSION NO:P2BB HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT, BETA ISOFORM (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT, BETA ISOFORM) (CAM-PRP CATALYTIC SUBUNIT).
GENBANK ACCESSION NO:PPAC_BOVIN LOW MOLECULAR WEIGHT PHOSPHOTYROSINE PROTEIN PHOSPHATASE (EC 3.1.3.48) (LOW MOLECULAR WEIGHT CYTOSOLIC ACID PHOSPHATASE) (EC 3.1.3.2) (PTPASE).
GENBANK ACCESSION NO:Q99952 PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:Q9YHE4 PROTEIN TYROSINE PHOSPHATASE MEG1 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q9YHE5 PROTEIN TYROSINE PHOSPHATASE MEG1 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q9YHE6 PROTEIN TYROSINE PHOSPHATASE SH-PTP2 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q9YHE7 PROTEIN TYROSINE PHOSPHATASE H1 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:O00810 PROTEIN TYROSINE PHOSPHATASE.
GENBANK ACCESSION NO:PP1B_DROME SERINE/THREONINE PROTEIN PHOSPHATASE BETA ISOFORM (EC 3.1.3.16).
GENBANK ACCESSION NO:PPAC_RAT LOW MOLECULAR WEIGHT PHOSPHOTYROSINE PROTEIN PHOSPHATASE ACP1/ACP2 (EC 3.1.3.48) (LOW MOLECULAR WEIGHT CYTOSOLIC ACID PHOSPHATASE) (EC 3.1.3.2) (PTPASE).
GENBANK ACCESSION NO:P2B1_DROME SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT 1 (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A1 SUBUNIT).
GENBANK ACCESSION NO:PPV_DROME SERINE/THREONINE PROTEIN PHOSPHATASE PP-V (EC 3.1.3.16).
GENBANK ACCESSION NO:Q24032 CORKSCREW PROTEIN Y1229 (EC 3.1.3.48).
GENBANK ACCESSION NO:Q24033 PROTEIN-TYROSINE PHOSPHATASE CORKSCREW, ISOFORM 4A (EC 3.1.3.48) (CSW).
GENBANK ACCESSION NO:Q42812 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:O62830 PROTEIN PHOSPHATASE 2C BETA (EC 3.1.3.16).
GENBANK ACCESSION NO:Q95040 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:PP1_PHAVU SERINE/THREONINE PROTEIN PHOSPHATASE PP1 (EC 3.1.3.16).
GENBANK ACCESSION NO:P70643 RECEPTOR TYPE PROTEIN TYROSINE PHOSPHATASE PSI (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:PP15_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP1 ISOZYME 5 (EC 3.1.3.16).
GENBANK ACCESSION NO:P70644 RECEPTOR TYPE PROTEIN TYROSINE PHOSPHATASE MY (FRAGMENT).
GENBANK ACCESSION NO:O18931 PROTEIN PHOSPHATASE TYPE 1 BETA CATALYTIC SUBUNIT (FRAGMENT).
GENBANK ACCESSION NO:O04856 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:O18932 PROTEIN PHOSPHATASE 2A-ALPHA CATALYTIC SUBUNIT (FRAGMENT).
GENBANK ACCESSION NO:O04857 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:O04858 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:PPX2_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP-X ISOZYME 2 (EC 3.1.3.16).
GENBANK ACCESSION NO:P2A1 YEAST SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-1

CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:O04859 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:Q9Y2R2 PROTEIN TYROSINE PHOSPHATASE HOMOLOG (EC 3.1.3.48).
GENBANK ACCESSION NO:Q9WU22 PROTEIN TYROSINE PHOSPHATASE MEG-01 (EC 3.1.3.48).
GENBANK ACCESSION NO:O43966 PROTEIN PHOSPHATASE 2C.
GENBANK ACCESSION NO:PP1_MEDVA SERINE/THREONINE PROTEIN PHOSPHATASE PP1 (EC 3.1.3.16).
GENBANK ACCESSION NO:Q64675 LEUKOCYTE COMMON ANTIGEN-RELATED PHOSPHATASE PRECURSOR (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:PTN4_HUMAN PROTEIN-TYROSINE PHOSPHATASE MEG1 (EC 3.1.3.48) (PTPASE-MEG1) (MEG).
GENBANK ACCESSION NO:P2CA HUMAN PROTEIN PHOSPHATASE 2C ALPHA ISOFORM (EC 3.1.3.16) (PP2C-ALPHA) (IA) (PROTEIN PHOSPHATASE 1A).
GENBANK ACCESSION NO:P2AA_CHICK SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-ALPHA, CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:PT07_STYPL PROTEIN-TYROSINE PHOSPHATASE 7 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:PP11_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE PP1-1 (EC 3.1.3.16).
GENBANK ACCESSION NO:PPAL_SCHPO LOW MOLECULAR WEIGHT PHOSPHOTYROSINE PROTEIN PHOSPHATASE (EC 3.1.3.48) (LOW MOLECULAR WEIGHT CYTOSOLIC ACID PHOSPHATASE) (EC 3.1.3.2) (PTPASE) (SMALL TYROSINE PHOSPHATASE).
GENBANK ACCESSION NO:Q9Y879 CALCINEURIN A CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:P2CB_RAT PROTEIN PHOSPHATASE 2C BETA ISOFORM (EC 3.1.3.16) (PP2C-BETA) (IA) (PROTEIN PHOSPHATASE 1B).
GENBANK ACCESSION NO:O15712 PROTEIN PHOSPHATASE 2B.
GENBANK ACCESSION NO:PPZ1_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE PP-Z1 (EC 3.1.3.16).
GENBANK ACCESSION NO:Q9X4B8 PUTATIVE ACID PHOSPHATASE WZB.
GENBANK ACCESSION NO:PTN6_MOUSE PROTEIN-TYROSINE PHOSPHATASE 1C (EC 3.1.3.48) (PTP-1C) (HEMATOPOIETIC CELL PROTEIN-TYROSINE PHOSPHATASE) (70Z-SHP) (SH-PTP1).
GENBANK ACCESSION NO:O04860 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:P2C2_SCHPO PROTEIN PHOSPHATASE 2C HOMOLOG 2 (EC 3.1.3.16) (PP2C-2).
GENBANK ACCESSION NO:P2B1_CRYNE SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT A1 (EC 3.1.3.16) (CALCINEURIN A1).
GENBANK ACCESSION NO:Q64046 MG2+ DEPENDENT PROTEIN PHOSPHATASE BETA ISOFORM.
GENBANK ACCESSION NO:Q61373 PROTEIN TYROSINE PHOSPHATASE (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q9XZE5 PROTEIN PHOSPHATASE 2A CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:O81716 PROTEIN PHOSPHATASE 2C - LIKE PROTEIN.
GENBANK ACCESSION NO:O14829 PROTEIN PHOSPHATASE WITH EF-HANDS-1.
GENBANK ACCESSION NO:Q16826 PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:PP11_ACECL SERINE/THREONINE PROTEIN PHOSPHATASE PP1 ISOZYME 1 (EC 3.1.3.16).
GENBANK ACCESSION NO:Q16827 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, O PRECURSOR (EC 3.1.3.48) (PROTEIN TYROSINE PHOSPHATASE U2) (GLOMERULAR EPITHELIAL PROTEIN 1) (GLEPP1) (PHOSPHOTYROSINE PHOSPHATASE U2) (PTPASE U2) (PTP-U2).
GENBANK ACCESSION NO:O75870 PTPSIGMA (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:PTPA_MOUSE PROTEIN-TYROSINE PHOSPHATASE ALPHA PRECURSOR (EC 3.1.3.48) (R-PTP- ALPHA) (LCA-RELATED PHOSPHATASE).
GENBANK ACCESSION NO:O43979 SERINE-THREONINE PHOSPHOPROTEIN PHOSPHATASE.
GENBANK ACCESSION NO:O94748 PROTEIN PHOSPHATASE-Z-LIKE SERINE/THREONINE PROTEIN PHOSPHATASE.
GENBANK ACCESSION NO:Q90687 PROTEIN-TYROSINE PHOSPHATASE N11 (EC 3.1.3.48) (PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11).
GENBANK ACCESSION NO:PTP6_DROME PROTEIN-TYROSINE PHOSPHATASE DPTP PRECURSOR (EC 3.1.3.48) (PROTEIN- TYROSINE-PHOSPHATE PHOSPHOHYDROLASE).
GENBANK ACCESSION NO:Q62987 PROTEIN TYROSINE PHOSPHATASE SH-PTP2 (FRAGMENT).
GENBANK ACCESSION NO:Q62988 PROTEIN TYROSINE PHOSPHATASE ALPHA (FRAGMENT).
GENBANK ACCESSION NO:Q62989 PROTEIN TYROSINE PHOSPHATASE GAMMA (FRAGMENT).
GENBANK ACCESSION NO:AMSI_ERWAM PROBABLE LOW MOLECULAR WEIGHT PROTEIN-TYROSINE-PHOSPHATASE AMSI (EC 3.1.3.48).
GENBANK ACCESSION NO:PT16_STYPL PROTEIN-TYROSINE PHOSPHATASE 16 (EC 3.1.3.48)

(FRAGMENT).
GENBANK ACCESSION NO:PPQ1_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE PPQ (EC 3.1.3.16).
GENBANK ACCESSION NO:PPY_DROME SERINE/THREONINE PROTEIN PHOSPHATASE PP-Y (EC 3.1.3.16).
GENBANK ACCESSION NO:O14830 PROTEIN PHOSPHATASE WITH EF-HANDS-2 LONG FORM.
GENBANK ACCESSION NO:O14831 PROTEIN PHOSPHATASE WITH EF-HANDS-2 SHORT FORM.
GENBANK ACCESSION NO:O04951 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:O77023 DPP2C1.
GENBANK ACCESSION NO:Q42912 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:RDGC DROME SERINE/THREONINE PROTEIN PHOSPHATASE RDGC (EC 3.1.3.16) (RETINAL DEGENERATION C PROTEIN).
GENBANK ACCESSION NO:O76932 SERINE /THREONINE SPECIFIC PROTEIN PHOSPHATASE 4 (EC 3.1.3.16).
GENBANK ACCESSION NO:P2AA_HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-ALPHA, CATALYTIC SUBUNIT (EC 3.1.3.16) (REPLICATION PROTEIN C) (RP-C).
GENBANK ACCESSION NO:P2A4_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-LIKE PPG1 (EC 3.1.3.16).
GENBANK ACCESSION NO:Q9W6R4 PROTEIN PHOSPHATASE 1.
GENBANK ACCESSION NO:PP1_EMENI SERINE/THREONINE PROTEIN PHOSPHATASE PP1 (EC 3.1.3.16).
GENBANK ACCESSION NO:O59927 SERINE/THREONINE PROTEIN PHOSPHATASE TYPE 1.
GENBANK ACCESSION NO:PTPA_STRCO LOW MOLECULAR WEIGHT PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (PTPASE) (SMALL, ACIDIC PHOSPHOTYROSINE PROTEIN PHOSPHATASE) (PY PROTEIN PHOSPHATASE).
GENBANK ACCESSION NO:Q64696 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F POLYPEPTIDE (EC 3.1.3.48) (LAR PROTEIN) (LEUKOCYTE ANTIGEN RELATED) (FRAGMENT).
GENBANK ACCESSION NO:PTN7_HUMAN PROTEIN-TYROSINE PHOSPHATASE LC-PTP (EC 3.1.3.48) (HEMATOPOIETIC PROTEIN-TYROSINE PHOSPHATASE) (HEPTP).
GENBANK ACCESSION NO:CSW_DROME PROTEIN-TYROSINE PHOSPHATASE CORKSCREW (EC 3.1.3.48).
GENBANK ACCESSION NO:Q64699 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, S PRECURSOR (EC 3.1.3.48) (PROTEIN-TYROSINE PHOSPHATASE SIGMA) (RPTP-SIGMA) (PROTEIN TYROSINE PHOSPHATASE PTPT9) (PTPASE NU-3).
GENBANK ACCESSION NO:PP11_TRYBB SERINE/THREONINE PROTEIN PHOSPHATASE PP1(4.8) (EC 3.1.3.16).
GENBANK ACCESSION NO:PP1_MAIZE SERINE/THREONINE PROTEIN PHOSPHATASE PP1 (EC 3.1.3.16).
GENBANK ACCESSION NO:PT25_STYPL PROTEIN-TYROSINE PHOSPHATASE 25 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:PP1A_HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE PP1-ALPHA 1 CATALYTIC SUBUNIT (EC 3.1.3.16) (PP-1A).
GENBANK ACCESSION NO:PPP5_RAT SERINE/THREONINE PROTEIN PHOSPHATASE 5 (EC 3.1.3.16) (PP5) (PROTEIN PHOSPHATASE T) (PPT).
GENBANK ACCESSION NO:PTPB_HUMAN PROTEIN-TYROSINE PHOSPHATASE BETA PRECURSOR (EC 3.1.3.48) (R-PTP- BETA).
GENBANK ACCESSION NO:P2C1_CAEL PROBABLE PROTEIN PHOSPHATASE 2C F42G9.1 (EC 3.1.3.16) (PP2C).
GENBANK ACCESSION NO:P2A2_SCHPO MAJOR SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-2 CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:O44328 RECEPTOR TYROSINE PHOSPHATASE (EC 3.1.3.48).
GENBANK ACCESSION NO:O94044 PHOSPHOTYROSINE PROTEIN PHOSPHATASE.
GENBANK ACCESSION NO:O44329 RECEPTOR TYROSINE PHOSPHATASE (EC 3.1.3.48).
GENBANK ACCESSION NO:PTPJ_HUMAN PROTEIN-TYROSINE PHOSPHATASE ETA PRECURSOR (EC 3.1.3.48) (R-PTP-ETA) (DENSITY ENHANCED PHOSPHATASE-1) (DEP-1) (CD148 ANTIGEN).
GENBANK ACCESSION NO:Q9YI74 SERINE/THREONINE PHOSPHATASE.
GENBANK ACCESSION NO:O08367 SERINE /THREONINE SPECIFIC PROTEIN PHOSPHATASE (EC 3.1.3.16) (SERINE/THREONINE SPECIFIC PROTEIN PHOSPHATASE) (PHOSPHOPROTEIN PHOSPHATASE) (PROTEIN PHOSPHATASE-1) (PROTEIN PHOSPHATASE-2A) (PROTEIN PHOSPHATASE-2B) (PROTEIN PHOSPHATASE-2C).
GENBANK ACCESSION NO:Q9YI75 SERINE/THREONINE PHOSPHATASE.
GENBANK ACCESSION NO:Q9YI76 SERINE/THREONINE PHOSPHATASE.
GENBANK ACCESSION NO:O57438 CALCINEURIN A.
GENBANK ACCESSION NO:PTP1_DROME PROTEIN-TYROSINE PHOSPHATASE 10D PRECURSOR (EC 3.1.3.48) (RECEPTOR- LINKED PROTEIN-TYROSINE PHOSPHATASE 10D).
GENBANK ACCESSION NO:O82469 PROTEIN PHOSPHATASE-2C.

GENBANK ACCESSION NO:PP12_SCHPO SERINE/THREONINE PROTEIN PHOSPHATASE PP1-2 (EC 3.1.3.16) (SUPPRESSOR PROTEIN SDS21).
GENBANK ACCESSION NO:PT11_STYPL PROTEIN-TYROSINE PHOSPHATASE 11 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:PTP9_DROME PROTEIN-TYROSINE PHOSPHATASE 99A PRECURSOR (EC 3.1.3.48) (RECEPTOR- LINKED PROTEIN-TYROSINE PHOSPHATASE 99A).
GENBANK ACCESSION NO:Q9Y1W9 SPTPN6 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:P2A3_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-3 CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:PTPO_RAT OSTEOTESTICULAR PROTEIN TYROSINE PHOSPHATASE PRECURSOR (EC 3.1.3.48) (OST-PTP).
GENBANK ACCESSION NO:P2BB_MOUSE SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT, BETA ISOFORM (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT, BETA ISOFORM) (CAM-PRP CATALYTIC SUBUNIT) (FRAGMENT).
GENBANK ACCESSION NO:Q14513 TYROSINE PHOSPHATASE PRECURSOR (EC 3.1.3.48).
GENBANK ACCESSION NO:PP1G_XENLA SERINE/THREONINE PROTEIN PHOSPHATASE PP1-GAMMA CATALYTIC SUBUNIT (EC 3.1.3.16) (PP-1G).
GENBANK ACCESSION NO:P70125 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, L (EC 3.1.3.48) (RECEPTOR PROTEIN TYROSINE PHOSPHATASE-LAMDA).
GENBANK ACCESSION NO:P2B1_SCHPO SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:Q23345 SIMILAR TO OTHER PROTEIN PHOSPHATASES 1.
GENBANK ACCESSION NO:PPAL_YEAST LOW MOLECULAR WEIGHT PHOSPHOTYROSINE PROTEIN PHOSPHATASE (EC 3.1.3.48) (LOW MOLECULAR WEIGHT CYTOSOLIC ACID PHOSPHATASE) (EC 3.1.3.2) (PTPASE).
GENBANK ACCESSION NO:PP13_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP1 ISOZYME 3 (EC 3.1.3.16).
GENBANK ACCESSION NO:O82470 PROTEIN PHOSPHATASE-2C.
GENBANK ACCESSION NO:O82471 PROTEIN PHOSPHATASE-2C.
GENBANK ACCESSION NO:O49346 A SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16) (SERINE/THREONINE SPECIFIC PROTEIN PHOSPHATASE) (PHOSPHOPROTEIN PHOSPHATASE) (PROTEIN PHOSPHATASE-1) (PROTEIN PHOSPHATASE-2A) (PROTEIN PHOSPHATASE-2B) (PROTEIN PHOSPHATASE-2C).
GENBANK ACCESSION NO:YSD1_CAEEL PUTATIVE SERINE/THREONINE PROTEIN PHOSPHATASE C23G10.1 IN CHROMOSOME II (EC 3.1.3.16).
GENBANK ACCESSION NO:PTN2_HUMAN T-CELL PROTEIN-TYROSINE PHOSPHATASE (EC 3.1.3.48) (TCPTP).
GENBANK ACCESSION NO:P2C2_YEAST PROTEIN PHOSPHATASE 2C HOMOLOG 2 (EC 3.1.3.16) (PP2C-2).
GENBANK ACCESSION NO:PPP5_HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE 5 (EC 3.1.3.16) (PP5) (PROTEIN PHOSPHATASE T) (PP-T) (PPT).
GENBANK ACCESSION NO:O82479 PROTEIN PHOSPHATASE-2C (FRAGMENT).
GENBANK ACCESSION NO:P2C PARTE PROTEIN PHOSPHATASE 2C (EC 3.1.3.16) (PP2C).
GENBANK ACCESSION NO:Q9Y1X5 SPTPR2B (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q9Y1X6 SPTPR4 (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:P2CG_HUMAN PROTEIN PHOSPHATASE 2C GAMMA ISOFORM (EC 3.1.3.16) (PP2C-GAMMA) (PROTEIN PHOSPHATASE 1C).
GENBANK ACCESSION NO:P2CG_BOVIN PROTEIN PHOSPHATASE 2C GAMMA ISOFORM (EC 3.1.3.16) (PP2C-GAMMA) (PROTEIN PHOSPHATASE 1B) (MAGNESIUM-DEPENDENT CALCIUM INHIBITABLE PHOSPHATASE) (MCPP).
GENBANK ACCESSION NO:P2A_HELAN SERINE/THREONINE PROTEIN PHOSPHATASE PP2A CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:PTNB_HUMAN PROTEIN-TYROSINE PHOSPHATASE 2C (EC 3.1.3.48) (PTP-2C) (PTP-1D) (SH-PTP3) (SH-PTP2) (SHP-2).
GENBANK ACCESSION NO:P2CA_MOUSE PROTEIN PHOSPHATASE 2C ALPHA ISOFORM (EC 3.1.3.16) (PP2C-ALPHA) (IA) (PROTEIN PHOSPHATASE 1A).
GENBANK ACCESSION NO:P91420 PROBABLE SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:PTPE_HUMAN PROTEIN-TYROSINE PHOSPHATASE EPSILON PRECURSOR (EC 3.1.3.48) (R-PTP- EPSILON).
GENBANK ACCESSION NO:Q15255 PROTEIN-TYROSINE PHOSPHATASE ETA PRECURSOR (EC 3.1.3.48) (R-PTP-ETA).
GENBANK ACCESSION NO:Q91054 CD45 HOMOLOG (EC 3.1.3.48).
GENBANK ACCESSION NO:Q15256 PROTEIN-TYROSINE PHOSPHATASE PCPTP1 PRECURSOR (EC 3.1.3.48) (PROTEIN- TYROSINE-PHOSPHATASE PCPTP1) (NC-PTPCOM1).
GENBANK ACCESSION NO:SD22 SCHPO PROTEIN PHOSPHATASES PP1 REGULATORY SUBUNIT

SDS22.
GENBANK ACCESSION NO:O15757 PROTEIN PHOSPHATASE TYPE 1-LIKE CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:PTPM_HUMAN PROTEIN-TYROSINE PHOSPHATASE MU PRECURSOR (EC 3.1.3.48) (R-PTP-MU).
GENBANK ACCESSION NO:PP13_DROME SERINE/THREONINE PROTEIN PHOSPHATASE ALPHA-3 ISOFORM (EC 3.1.3.16).
GENBANK ACCESSION NO:Q27475 PROBABLE SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:PTNB RAT PROTEIN-TYROSINE PHOSPHATASE SYP (EC 3.1.3.48).
GENBANK ACCESSION NO:P2BC HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT, GAMMA ISOFORM (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT, GAMMA ISOFORM) (CALCINEURIN, TESTIS-SPECIFIC CATALYTIC SUBUNIT) (CAM-PRP CATALYTIC SUBUNIT).
GENBANK ACCESSION NO:Q95097 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:Q9ZSQ7 PROTEIN PHOSPHATASE 2C HOMOLOG.
GENBANK ACCESSION NO:YD44_SCHPO PUTATIVE SERINE/THREONINE PROTEIN PHOSPHATASE C22H10.04 (EC 3.1.3.16).
GENBANK ACCESSION NO:Q9WUV7 SERINE/THREONINE SPECIFIC PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:PPX1_PARTE SERINE/THREONINE PROTEIN PHOSPHATASE PP-X HOMOLOG (EC 3.1.3.16).
GENBANK ACCESSION NO:PTPO MOUSE EMBRYONIC STEM CELL PROTEIN TYROSINE PHOSPHATASE PRECURSOR (EC 3.1.3.48) (ES CELL PHOSPHATASE).
GENBANK ACCESSION NO:P2B2_DROME SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT 2, (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A2 SUBUNIT).
GENBANK ACCESSION NO:Q9Z1G2 SERINE/THREONINE PROTEIN PHOSPHATASE TYPE 1 ALPHA.
GENBANK ACCESSION NO:Q07161 PROTEIN PHOSPHATASE PP1-ALPHA 2, CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:O15920 PROTEIN PHOSPHATASE-BETA.
GENBANK ACCESSION NO:P2B_EMENI SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT).
GENBANK ACCESSION NO:YY06_CAEEL PUTATIVE SERINE/THREONINE PROTEIN PHOSPHATASE C27B7.6 IN CHROMOSOME IV (EC 3.1.3.16).
GENBANK ACCESSION NO:Q29500 PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:Q15263 PROTEIN TYROSINE PHOSPHATASE (PTP-BAS, TYPE 1).
GENBANK ACCESSION NO:Q15264 PROTEIN TYROSINE PHOSPHATASE (PTP-BAS, TYPE 2).
GENBANK ACCESSION NO:Q15426 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, H PRECURSOR (EC 3.1.3.48) (PROTEIN TYROSINE PHOSPHATASE SAP-1) (STOMACH CANCER-ASSOCIATED PTP).
GENBANK ACCESSION NO:PP12_RABIT SERINE/THREONINE PROTEIN PHOSPHATASE PP1-ALPHA 2 CATALYTIC SUBUNIT (EC 3.1.3.16) (PP-1A).
GENBANK ACCESSION NO:O02658 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:Q15265 PROTEIN TYROSINE PHOSPHATASE (PTP-BAS, TYPE 3).
GENBANK ACCESSION NO:O70275 PROTEIN TYROSINE PHOSPHATASE 4A3 (MPRL-3).
GENBANK ACCESSION NO:Q27560 SERINE/THREONINE PROTEIN PHOSPHATASE CALCINEURIN A (EC 3.1.3.16).
GENBANK ACCESSION NO:O82733 SERINE/THREONINE PROTEIN PHOSPHATASE TYPE ONE.
GENBANK ACCESSION NO:P2AB_RABIT SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-BETA, CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:PP16_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP1 ISOZYME 6 (EC 3.1.3.16).
GENBANK ACCESSION NO:P91273 PROBABLE SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:O82734 SERINE/THREONINE PROTEIN PHOSPHATASE TYPE ONE.
GENBANK ACCESSION NO:O75365 HPRL-3.
GENBANK ACCESSION NO:P81718 PROTEIN-TYROSINE PHOSPHATASE N6 (EC 3.1.3.48).
GENBANK ACCESSION NO:P2A_ACECL SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-1 CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:P2A2_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-2 CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:Q9W6V5 SUPPORTING-CELL ANTIGEN PRECURSOR (EC 3.1.3.48).
GENBANK ACCESSION NO:Q04101 PROTEIN PHOSPHATASE PP1-BETA CATALYTIC SUBUNIT (EC 3.1.3.16) (FRAGMENT).
GENBANK ACCESSION NO:PP12_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE PP1-2 (EC

3.1.3.16).
GENBANK ACCESSION NO:Q04102 PROTEIN PHOSPHATASE PP1-C CATALYTIC SUBUNIT (EC 3.1.3.16) (FRAGMENT).
GENBANK ACCESSION NO:Q04103 PROTEIN PHOSPHATASE PP1-D CATALYTIC SUBUNIT (EC 3.1.3.16) (FRAGMENT).
GENBANK ACCESSION NO:PPT1_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE T (EC 3.1.3.16) (PPT).
GENBANK ACCESSION NO:Q04104 PROTEIN PHOSPHATASE PP-X CATALYTIC SUBUNIT (EC 3.1.3.16) (FRAGMENT).
GENBANK ACCESSION NO:P2AA_MOUSE SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-ALPHA, CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:PPP6_RAT SERINE/THREONINE PROTEIN PHOSPHATASE 6 (EC 3.1.3.16) (PP6) (PROTEIN PHOSPHATASE V) (PP-V).
GENBANK ACCESSION NO:PP1G_HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE PP1-GAMMA CATALYTIC SUBUNIT (EC 3.1.3.16) (PP-1G).
GENBANK ACCESSION NO:PPZ2_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE PP-22 (EC 3.1.3.16).
GENBANK ACCESSION NO:Q64501 PROTEIN TYROSINE PHOSPHATASE D28 (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (FRAGMENT).
GENBANK ACCESSION NO:Q64502 PROTEIN TYROSINE PHOSPHATASE (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (FRAGMENT).
GENBANK ACCESSION NO:Q12923 PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 13 (EC 3.1.3.48) (PROTEIN-TYROSINE PHOSPHATASE 1E) (PTP-BAS, TYPE 1) (PROTEIN-TYROSINE PHOSPHATASE PTPL1) (PROTEIN-TYROSINE PHOSPHATASE 1, FAS-ASSOCIATED) (FAP-1).
GENBANK ACCESSION NO:Q92124 PHOSPHOTYRUSYL-PROTEIN PHOSPHATASE (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:Q64503 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, S PRECURSOR (EC 3.1.3.48) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:Q64504 PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (FRAGMENT).
GENBANK ACCESSION NO:P2C3_SCHPO PROTEIN PHOSPHATASE 2C HOMOLOG 3 (EC 3.1.3.16) (PP2C-3).
GENBANK ACCESSION NO:O48641 PROTEIN PHOSPHATASE 1 CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:Q15197 PROTEIN TYROSINE PHOSPHATASE (FRAGMENT).
GENBANK ACCESSION NO:Q27573 SERINE/THREONINE PROTEIN PHOSPHATASE (EC 3.1.3.16).
GENBANK ACCESSION NO:Q63294 LEUKOCYTE COMMON ANTIGEN RELATED PROTEIN (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q64509 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11 (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).
GENBANK ACCESSION NO:PP12_ACECL SERINE/THREONINE PROTEIN PHOSPHATASE PP1 ISOZYME 2 (EC 3.1.3.16).
GENBANK ACCESSION NO:P2B1_YEAST SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT A1 (EC 3.1.3.16) (CALCINEURIN A1) (CALMODULIN-BINDING PROTEIN 1).
GENBANK ACCESSION NO:Q63295 LEUCOCYTE COMMON ANTIGEN-RELATED PROTEIN (EC 3.1.3.48) (LAR) (FRAGMENT).
GENBANK ACCESSION NO:Q35299 PROTEIN PHOSPHATASE 5.
GENBANK ACCESSION NO:Q63296 LEUCOCYTE COMMON ANTIGEN-RELATED PROTEIN (EC 3.1.3.48) (FRAGMENT).
GENBANK ACCESSION NO:Q92682 PROTEIN-TYROSINE PHOSPHATASE NC-PTPCOM1 (EC 3.1.3.48) (PROTEIN-TYROSINE-PHOSPHATASE).
GENBANK ACCESSION NO:Q9ZSS3 PROTEIN PHOSPHATASE 2A CATALYTIC SUBUNIT.
GENBANK ACCESSION NO:PP1_ORYSA SERINE/THREONINE PROTEIN PHOSPHATASE PP1 (EC 3.1.3.16).
GENBANK ACCESSION NO:P2B_NEUCR SERINE/THREONINE PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT (EC 3.1.3.16) (CALMODULIN-DEPENDENT CALCINEURIN A SUBUNIT).
GENBANK ACCESSION NO:P2A1_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-1 CATALYTIC SUBUNIT (EC 3.1.3.16).
GENBANK ACCESSION NO:YCCY_ECOLI PROBABLE LOW MOLECULAR WEIGHT PROTEIN-TYROSINE-PHOSPHATASE YCCY (EC 3.1.3.48).
GENBANK ACCESSION NO:P78399 PROTEIN TYROSINE PHOSPHATASE RECEPTOR OMICRON (EC 3.1.3.48).
GENBANK ACCESSION NO:PTPJ_MOUSE PROTEIN-TYROSINE PHOSPHATASE ETA PRECURSOR (EC

3.1.3.48) (R-PTP-ETA) (HPTP BETA-LIKE TYROSINE PHOSPHATASE).				
GENBANK ACCESSION NO:PT17_STYPL PROTEIN-TYROSINE PHOSPHATASE 17 (EC 3.1.3.48) (FRAGMENT).				
GENBANK ACCESSION NO:PP11_ARATH SERINE/THREONINE PROTEIN PHOSPHATASE PP1 ISOZYME 1 (EC 3.1.3.16).				
GENBANK ACCESSION NO:Q9ZRF6 SERINE/THREONINE PROTEIN PHOSPHATASE 2A-3 CATALYTIC SUBUNIT.				
GENBANK ACCESSION NO:Q64512 PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 13 (EC 3.1.3.48) (PROTEIN-TYROSINE PHOSPHATASE RIP) (PHOSPHOPROTEIN PHOSPHATASE) (PROTEIN-TYROSINE-PHOSPHATASE) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE) (PTP36).				
GENBANK ACCESSION NO:O75702 PROTEIN-TYROSINE-PHOSPHATASE, ISOFORM 3 (EC 3.1.3.48) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).				
GENBANK ACCESSION NO:O95063 LYMPHOID PHOSPHATASE LYP1 (EC 3.1.3.48).				
GENBANK ACCESSION NO:O95064 LYMPHOID PHOSPHATASE LYP2 (EC 3.1.3.48).				
GENBANK ACCESSION NO:O35385 PROTEIN PHOSPHATASE WITH EF-HANDS-2.				
GENBANK ACCESSION NO:Q92850 RECEPTOR PROTEIN TYROSINE PHOSPHATASE PSI (EC 3.1.3.48).				
GENBANK ACCESSION NO:O96914 PROTEIN SERINE/THREONINE PHOSPHATASE ALPHA.				
GENBANK ACCESSION NO:P2AB_HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE PP2A-BETA, CATALYTIC SUBUNIT (EC 3.1.3.16).				
GENBANK ACCESSION NO:P2A PARTE SERINE/THREONINE PROTEIN PHOSPHATASE PP2A CATALYTIC SUBUNIT (EC 3.1.3.16) (PPN).				
GENBANK ACCESSION NO:O88739 PROTEIN-TYROSINE-PHOSPHATASE (EC 3.1.3.48) (PHOSPHOTYROSINE PHOSPHATASE) (PTPASE).				
GENBANK ACCESSION NO:Q91969 PROTEIN TYROSINE PHOSPHATASE PRECURSOR (EC 3.1.3.48).				
GENBANK ACCESSION NO:PP12_TRYBB SERINE/THREONINE PROTEIN PHOSPHATASE PP1(5.9) (EC 3.1.3.16).				
GENBANK ACCESSION NO:PP1B_HUMAN SERINE/THREONINE PROTEIN PHOSPHATASE PP1-BETA CATALYTIC SUBUNIT (EC 3.1.3.16) (PP-1B).				
GENBANK ACCESSION NO:O42205 PROTEIN PHOSPHATASE 5 (FRAGMENT).				
GENBANK ACCESSION NO:PPP5_MOUSE SERINE/THREONINE PROTEIN PHOSPHATASE 5 (EC 3.1.3.16) (PP5) (PROTEIN PHOSPHATASE T) (PPT) (FRAGMENT).				
GENBANK ACCESSION NO:PTN7_RAT PROTEIN-TYROSINE PHOSPHATASE LC-PTP (EC 3.1.3.48) (HEMATOPOIETIC PROTEIN-TYROSINE PHOSPHATASE) (HEPTP).				
VH01	VACCC	VH01	VACCC	STANDARD; PRT; 171 AA.
YOPH YERPS YOPH YERPS				
PTN1	ID	PTN1	HUMAN	STANDARD; PRT; 435 AA.
CDC25 GI 266561 SP P30307 MPI3 HUMAN M-PHASE INDUCER PHOSPHATASE 3 (DUAL SPECIFICITY PHOSPHATASE CDC25C)				
CDC14 YEAST GI 6321141 REF NP_011219.1 SOLUBLE TYROSINE-SPECIFIC PROTEIN PHOSPHATASE; CDC14P [SACCHAROMYCES CEREVISIAE]				
CDC14B_HUMAN GI 4502699 REF NP_003662.1 S. CEREVISIAE CDC14 HOMOLOG, GENE B [HOMO SAPIENS]				
CDC14A_HUMAN GI 4502697 REF NP_003663.1 S. CEREVISIAE CDC14 HOMOLOG, GENE A [HOMO SAPIENS]				

Table V.

Predicted exons of BMY_HPP4

Exon	Start	End	Sequence
1	71352	71414	CTCAGGCAGAACTATGAGGCCAAGAGTGCTCATGCGCACCAGGCTTTCTTTTGAATTCGAG (SEQ ID NO:11)
2	71577	71667	GAGCTGAAGGAGGTGAGCAAGGAGCAGCCCAGACTGGAGGCTGAGTACCCTGCCAACA CCACCAAGAACTGTTAACCACATGTGCTACCCT (SEQ ID NO:12)
3	71776	71852	ATGACCACTCCAGGGTCAGGCTGACCCAGCTGGAGGGAGAGCCTCATTCTGACTACAT CAATGCCAACTTGGTCCCA (SEQ ID NO:13)
4	72885	73019	GGCTACACCCGCCACAGGAGTTTATTGCCTCTCAGGGGCCCTCTCAAGAAAACACTGG AGAAGTTCTGGCGGCTGGTGCGGGAGCAGCAGGTCCGCATCATCATATGCCGACCAT CAGCATGGAGAACGGGAGG (SEQ ID NO:14)
5	73700	73822	GTGCTGTGTGAGCATTACTGGCTGACCGACTCTACCCGGACACCCATGGTCACATCA CCATCCACCTCCTAGCTGAGGAGCCTGAGGATGAGTGGACCAAGCGGGAATTCAGCT GCAGCAC (SEQ ID NO:15)
6	74418	74578	GTTGTCCAGCAACATCAACGGAGGGTGGAGCAACTGCAGTTCACCACCTGATCCGACC ACAGCATCCTTGAGGCTCCAGCTCCCTGCTCGCCTTTATGGAGCTGGTACAGTAGCA GGCAAGGGCCACCCAGGGCGTGGGACCCATCCTGGTGCACTGCAG (SEQ ID NO:16)
7	74700	74850	GGGCTGTCCCTGCGGTGTGGGCATGGGCCGGACAGGCACCTTCGTGGCCCTGTGAGG CTGCTGCAGCAGCTGGAGGAGGAGCAGATGGTAGACGTGTTCCATGCTGTGTATGCAC TCCGATGCACAGCCCCCTCATGATCCAGACCCTG (SEQ ID NO:17)
8	75210	75277	AGCCAGTACGTCTTCTGCACAGCTGCCTACTGAACAAGATTCTGGAAGGACCCTTCA ACATCTCTGA (SEQ ID NO:18)
9	75407	75494	GTCTTGGCCCATCTCTGTGACGGACCTCCCGCAGGCGTGTGCCAAGAGGGCAGCCAGT GCCAATGCTGGCTTCTTGAAGGAGTACGAG (SEQ ID NO:19)
10	75613	75679	GCCATCAAGGACGAGGCTGGCTTTTCCGCACCCCCGCTGGCTATGAGCAGGACAGCC CCGTCTCCT (SEQ ID NO:20)
11	75769	75826	ATGACCGTTCTCAGGGGCAGTTTCTCCGCTGGAGGAGAGCCCCCTGACGACATGCC (SEQ ID NO:21)
12	75960	76119	TCTCTGGAAGCCAATGATCTGTGCTCTGCAGGGTGGGCCCTCTGGCCGTGATCATACG GTGCTGACTGGCCCCGAGGGCCAAAGGAGCTCTGGGAGCTGGTGTGGCAGCACAGGG CTCATGTGCTTGTCTCTTTGCCCACCAATGTCATGGAGAAG (SEQ ID NO:22)
13	76266	76376	GAATTCTGGCCAACGGAGATGCAGCCCCTAGTCACAGACATGGTGACGGTGCACTGGG TGGCTGAGAGCAGCAGCAGGCTGGTTCTGTACCCTCCTCAGGGTCACACAT (SEQ ID NO:23)
14	76481	76644	GGGAGAGCAGGAAGGAAAGGAGGTGCAGAGACTGCAATTTCCATACCTGGAGCCTG GGCATGAGCTGCCCGCCACCCTGCTGCCCTTCTGGCTGTGTGGGCCAGTGCTG CTCTCGGGGCAACAACAAGAGCCGGGCACACTGCTCAGCCACTCCAA (SEQ ID NO:24)
15	76992	77127	CAAGGGTGCAACCCAGCTGGGCACCTTCCTGGCCATGGAGCAGCTGCTGCAGCAGGCA GGGTCTGAGTGACCGTGGATATCTTTAACGTGGCCCTGCAGCAGTCTCAGGCCTGTG GCCTTATGACCCCAACACTG (SEQ ID NO:25)
16	77369	77425	AAGCAGTATGTCTACCTCTACAACCTGTCTGAACAGCGCGCTGGCAGACGGGCTGCCC (SEQ ID NO:26)

Table VI

Gene	Left Cloning Primer	Right Cloning Primer	Internal RevComp Cloning Primer	Internal Cloning Primer	EP Sense Primer	EP Anti-Sense Primer
BMV_HPP1	CGGATGGAAGGATTATGGT (SEQ ID NO:43)	CTGTGACCAAGCC CTG (SEQ ID NO:44)	TGACAAATGGATAGTACTTTCTTCT GTAAAGCAAAATGTCATCACCTTCACCAT ATCTAGGATAGTAGTAAGAGAGCC (SEQ ID NO:45)	N/A	TACAATTTGGGATGGAA GGATTAT (SEQ ID NO:154)	GCATGACAAATGGATAGCTA CTTT (SEQ ID NO:155)
"	TTCGGATGGAAGGATTATGG (SEQ ID NO:46)	CTGTGACCAAGCC CTG (SEQ ID NO:47)	TGACAAATGGATAGTACTTTCTTCT GTAAAGCAAAATGTCATCACCTTCACCAT ATCTAGGATAGTAGTAAGAGAGCC (SEQ ID NO:48)	N/A	N/A	N/A
BMV_HPP2	CCAACTTCTCTGGGTGCT (SEQ ID NO:49)	CTCCGTGAGGACAC CAG (SEQ ID NO:50)	GTGCGGCACGCCCGAGGTCCAAAGGAA CTGTAGTGTGGCGGGAGCCGCGGAG CGCCAGTCCCGCCGAGCGCGCCGGA (SEQ ID NO:51)	N/A	GAGAAAGCAGTCTTCCAGT TCTAC (SEQ ID NO:156)	ATGGAGCTAGAGGTTTAAT ACT (SEQ ID NO:157)
"	CAACTTCTCTGGGTGCTTTC (SEQ ID NO:52)	CAGCTGTGCTGTGA GGG (SEQ ID NO:53)	CTCCGTGAGGACACCAAGGTGCGGAC GCCAGGTCCAAACAGGAAGTGTGTG GGCGGGAGCGCGCGGCGGAGTCC (SEQ ID NO:54)	N/A	N/A	N/A
BMV_HPP3	CTCCCTGCTCTGTGGACAT (SEQ ID NO:55)	AACCTGGATGCTTCC CTTCT (SEQ ID NO:56)	AAAAGAGCAATGTGTAAAGTGTCTTTC ATACTCTTACTATGTGTGAACCTCCATC CTGCTTAAAGTTCCTGTAAAGAACTCT (SEQ ID NO:57)	N/A	N/A	N/A
"	TGCTTCTGTGGACATGTGAT (SEQ ID NO:58)	AACCTGGATGCTTCC CTTCT (SEQ ID NO:59)	AAAAGAGCAATGTGTAAAGTGTCTTTC ATACTCTTACTATGTGTGAACCTCCATC CTGCTTAAAGTTCCTGTAAAGAACTCT (SEQ ID NO:60)	N/A	N/A	N/A
BMV_HPP4	GGCAGAACTATGAGGCCAA G (SEQ ID NO:61)	GACCTGGAGTGGTC ATAGG (SEQ ID NO:62)	GCTCATGCGCACAGGCTTCTTTTGA AATTCGAGGAGCTGAAGAGGAGTGAGCA AGGAGCAGCCAGACTGGAGGCTGA (SEQ ID NO:63)	N/A	N/A	N/A
"	GCACAGGCTTCTTTTGA (SEQ ID NO:64)	GACCTGGAGTGGTC ATAGG (SEQ ID NO:65)	TCCAGGAGCTGAAGGAGGTGAGCAAGG AGCAGCCAGACTGGAGGCTGAGTACC CTGCCAACACCCACCAAGAACTGTAA (SEQ ID NO:66)	N/A	N/A	N/A
"	AGGCAGAACTATGAGGCCA A (SEQ ID NO:71)	GACCTGGAGTGGTC ATAGG (SEQ ID NO:72)	TCAGCCTCCAGTCTGGGCTGCTCTTGC TCACCTCTCAGCTCCGAAATTTCAA AAAGAAAGCCTGTGGTGGCATGAGC (SEQ ID NO:74)	GCTCATGCGCACAGG CTTCTTTTGAATTC GAGGAGCTGAAGGAG GTGAGCAAGGAGCAGC CCAGACTGGAGGCTGA (SEQ ID NO:73)	N/A	N/A
BMV_HPP5	GGCCAAAGAGCAAACTCAA G (SEQ ID NO:69)	GCATAGCTTGTGGT CCCAT (SEQ ID NO:70)	N/A	N/A	ATGGGACCAACAAGCTA TGC (SEQ ID NO:67)	TTATCAGGACTGGTTTCGG G (SEQ ID NO:68)

Table VIII

Atom No	Atom name	Residue	Residue No	X coord	Y coord	Z coord
1	N	MET	1	69.582	18.182	8.672
2	CA	MET	1	69.395	19.541	8.131
3	C	MET	1	70.570	19.947	7.256
4	O	MET	1	70.396	20.201	6.059
5	CB	MET	1	69.269	20.550	9.267
6	CG	MET	1	68.073	20.254	10.160
7	SD	MET	1	67.870	21.392	11.549
8	CE	MET	1	67.694	22.936	10.625
9	N	ALA	2	71.766	19.777	7.798
10	CA	ALA	2	72.997	20.244	7.135
11	C	ALA	2	73.470	19.379	5.963
12	O	ALA	2	74.399	19.766	5.248
13	CB	ALA	2	74.103	20.321	8.182
14	N	ALA	3	72.827	18.242	5.755
15	CA	ALA	3	73.118	17.415	4.583
16	C	ALA	3	72.087	17.628	3.469
17	O	ALA	3	72.257	17.097	2.366
18	CB	ALA	3	73.129	15.952	5.009
19	N	GLY	4	71.058	18.418	3.754
20	CA	GLY	4	69.967	18.671	2.798
21	C	GLY	4	69.309	17.377	2.327
22	O	GLY	4	69.228	17.114	1.124
23	N	VAL	5	68.792	16.606	3.271
24	CA	VAL	5	68.290	15.269	2.935
25	C	VAL	5	67.085	14.887	3.803
26	O	VAL	5	66.835	13.713	4.111
27	CB	VAL	5	69.467	14.309	3.108
28	CG1	VAL	5	69.856	14.148	4.572
29	CG2	VAL	5	69.222	12.952	2.454
30	N	LEU	6	66.245	15.878	4.045
31	CA	LEU	6	65.060	15.698	4.912
32	C	LEU	6	64.105	14.540	4.542
33	O	LEU	6	63.856	13.736	5.454
34	CB	LEU	6	64.282	17.010	5.011
35	CG	LEU	6	64.512	17.720	6.344
36	CD1	LEU	6	64.147	16.806	7.510
37	CD2	LEU	6	65.943	18.232	6.500
38	N	PRO	7	63.677	14.339	3.292
39	CA	PRO	7	62.757	13.220	3.028
40	C	PRO	7	63.352	11.816	3.190
41	O	PRO	7	62.579	10.904	3.506
42	CB	PRO	7	62.275	13.409	1.625
43	CG	PRO	7	63.027	14.558	0.983
44	CD	PRO	7	63.918	15.128	2.068
45	N	GLN	8	64.670	11.673	3.259
46	CA	GLN	8	65.250	10.338	3.447
47	C	GLN	8	65.289	9.903	4.908
48	O	GLN	8	65.636	8.751	5.182
49	CB	GLN	8	66.654	10.268	2.873
50	CG	GLN	8	66.628	10.270	1.352
51	CD	GLN	8	68.031	9.988	0.833
52	OE1	GLN	8	68.459	10.546	-0.184
53	NE2	GLN	8	68.740	9.136	1.554
54	N	ASN	9	64.901	10.785	5.815
55	CA	ASN	9	64.698	10.384	7.205
56	C	ASN	9	63.244	9.968	7.410
57	O	ASN	9	62.944	9.083	8.221
58	CB	ASN	9	64.990	11.583	8.104
59	CG	ASN	9	66.375	12.157	7.822
60	OD1	ASN	9	67.397	11.480	7.985
61	ND2	ASN	9	66.392	13.417	7.424

62	N	GLU	10	62.390	10.452	6.522
63	CA	GLU	10	60.956	10.177	6.614
64	C	GLU	10	60.605	8.894	5.876
65	O	GLU	10	59.725	8.146	6.320
66	CB	GLU	10	60.222	11.364	6.002
67	CG	GLU	10	60.573	12.649	6.745
68	CD	GLU	10	60.015	13.867	6.017
69	OE1	GLU	10	60.266	13.966	4.824
70	OE2	GLU	10	59.569	14.781	6.701
71	N	GLN	11	61.423	8.553	4.896
72	CA	GLN	11	61.272	7.276	4.185
73	C	GLN	11	61.393	6.035	5.090
74	O	GLN	11	60.421	5.272	5.090
75	CB	GLN	11	62.255	7.214	3.018
76	CG	GLN	11	61.929	8.252	1.948
77	CD	GLN	11	60.572	7.967	1.301
78	OE1	GLN	11	60.424	7.000	0.547
79	NE2	GLN	11	59.615	8.842	1.563
80	N	PRO	12	62.416	5.858	5.928
81	CA	PRO	12	62.396	4.703	6.838
82	C	PRO	12	61.285	4.734	7.899
83	O	PRO	12	60.776	3.655	8.219
84	CB	PRO	12	63.740	4.679	7.498
85	CG	PRO	12	64.528	5.909	7.086
86	CD	PRO	12	63.643	6.651	6.104
87	N	TYR	13	60.721	5.892	8.217
88	CA	TYR	13	59.612	5.912	9.181
89	C	TYR	13	58.322	5.470	8.496
90	O	TYR	13	57.589	4.648	9.058
91	CB	TYR	13	59.435	7.317	9.750
92	CG	TYR	13	60.630	7.853	10.531
93	CD1	TYR	13	60.876	9.220	10.549
94	CD2	TYR	13	61.455	6.986	11.238
95	CE1	TYR	13	61.970	9.718	11.243
96	CE2	TYR	13	62.551	7.482	11.931
97	CZ	TYR	13	62.810	8.846	11.923
98	OH	TYR	13	63.964	9.325	12.505
99	N	SER	14	58.271	5.707	7.194
100	CA	SER	14	57.170	5.235	6.347
101	C	SER	14	57.337	3.768	5.941
102	O	SER	14	56.452	3.205	5.291
103	CB	SER	14	57.142	6.091	5.085
104	OG	SER	14	57.018	7.452	5.473
105	N	THR	15	58.452	3.163	6.315
106	CA	THR	15	58.670	1.739	6.078
107	C	THR	15	58.496	0.951	7.378
108	O	THR	15	58.252	-0.261	7.356
109	CB	THR	15	60.094	1.583	5.555
110	OG1	THR	15	60.252	2.470	4.457
111	CG2	THR	15	60.388	0.165	5.079
112	N	LEU	16	58.570	1.658	8.496
113	CA	LEU	16	58.401	1.037	9.818
114	C	LEU	16	56.980	1.194	10.354
115	O	LEU	16	56.624	0.571	11.363
116	CB	LEU	16	59.374	1.694	10.792
117	CG	LEU	16	60.826	1.428	10.409
118	CD1	LEU	16	61.781	2.252	11.266
119	CD2	LEU	16	61.158	-0.058	10.496
120	N	VAL	17	56.197	2.008	9.664
121	CA	VAL	17	54.788	2.266	9.995
122	C	VAL	17	53.993	0.972	10.214
123	O	VAL	17	54.216	-0.044	9.539
124	CB	VAL	17	54.229	3.071	8.820
125	CG1	VAL	17	54.351	2.306	7.509
126	CG2	VAL	17	52.795	3.523	9.037

127	N	ASN	18	53.139	0.982	11.226
128	CA	ASN	18	52.379	-0.223	11.563
129	C	ASN	18	51.049	-0.245	10.820
130	O	ASN	18	50.052	0.386	11.194
131	CB	ASN	18	52.174	-0.298	13.069
132	CG	ASN	18	53.534	-0.362	13.762
133	OD1	ASN	18	53.935	0.571	14.468
134	ND2	ASN	18	54.237	-1.459	13.540
135	N	ASN	19	51.075	-1.017	9.750
136	CA	ASN	19	49.936	-1.159	8.843
137	C	ASN	19	48.936	-2.200	9.350
138	O	ASN	19	49.078	-3.402	9.100
139	CB	ASN	19	50.500	-1.593	7.491
140	CG	ASN	19	51.685	-0.700	7.116
141	OD1	ASN	19	51.561	0.529	7.063
142	ND2	ASN	19	52.818	-1.333	6.852
143	N	SER	20	47.949	-1.721	10.088
144	CA	SER	20	46.889	-2.590	10.618
145	C	SER	20	45.830	-2.891	9.562
146	O	SER	20	45.525	-2.040	8.721
147	CB	SER	20	46.232	-1.875	11.801
148	OG	SER	20	45.102	-2.630	12.237
149	N	GLU	21	45.339	-4.120	9.571
150	CA	GLU	21	44.151	-4.470	8.780
151	C	GLU	21	42.990	-3.623	9.296
152	O	GLU	21	42.894	-3.409	10.508
153	CB	GLU	21	43.865	-5.955	8.991
154	CG	GLU	21	42.687	-6.464	8.166
155	CD	GLU	21	42.494	-7.954	8.426
156	OE1	GLU	21	43.469	-8.582	8.815
157	OE2	GLU	21	41.380	-8.429	8.263
158	N	CYS	22	42.217	-3.047	8.392
159	CA	CYS	22	41.161	-2.120	8.792
160	C	CYS	22	39.765	-2.693	8.569
161	O	CYS	22	39.563	-3.630	7.786
162	CB	CYS	22	41.360	-0.857	7.974
163	SG	CYS	22	43.044	-0.206	8.046
164	N	VAL	23	38.801	-2.093	9.248
165	CA	VAL	23	37.410	-2.559	9.153
166	C	VAL	23	36.644	-1.812	8.059
167	O	VAL	23	35.572	-2.256	7.621
168	CB	VAL	23	36.740	-2.372	10.516
169	CG1	VAL	23	36.590	-0.899	10.877
170	CG2	VAL	23	35.391	-3.076	10.594
171	N	ALA	24	37.294	-0.816	7.480
172	CA	ALA	24	36.669	0.010	6.445
173	C	ALA	24	36.847	-0.557	5.038
174	O	ALA	24	36.343	0.014	4.069
175	CB	ALA	24	37.252	1.412	6.533
176	N	ASN	25	37.456	-1.729	4.950
177	CA	ASN	25	37.721	-2.366	3.660
178	C	ASN	25	36.534	-3.178	3.137
179	O	ASN	25	36.524	-3.565	1.963
180	CB	ASN	25	38.930	-3.280	3.838
181	CG	ASN	25	40.179	-2.458	4.151
182	OD1	ASN	25	40.470	-2.127	5.308
183	ND2	ASN	25	40.901	-2.124	3.099
184	N	MET	26	35.538	-3.416	3.977
185	CA	MET	26	34.328	-4.102	3.504
186	C	MET	26	33.381	-3.091	2.866
187	O	MET	26	33.376	-1.924	3.270
188	CB	MET	26	33.654	-4.832	4.661
189	CG	MET	26	33.177	-3.886	5.754
190	SD	MET	26	32.426	-4.700	7.181
191	CE	MET	26	33.870	-5.620	7.759

192	N	LYS	27	32.484	-3.577	2.021
193	CA	LYS	27	31.626	-2.711	1.187
194	C	LYS	27	30.792	-1.697	1.974
195	O	LYS	27	30.871	-0.498	1.677
196	CB	LYS	27	30.697	-3.613	0.383
197	CG	LYS	27	29.798	-2.809	-0.555
198	CD	LYS	27	28.844	-3.672	-1.388
199	CE	LYS	27	29.482	-4.306	-2.629
200	NZ	LYS	27	30.336	-5.470	-2.332
201	N	GLY	28	30.225	-2.129	3.092
202	CA	GLY	28	29.458	-1.231	3.969
203	C	GLY	28	30.290	-0.040	4.450
204	O	GLY	28	29.996	1.104	4.083
205	N	ASN	29	31.466	-0.337	4.977
206	CA	ASN	29	32.335	0.704	5.533
207	C	ASN	29	33.239	1.388	4.500
208	O	ASN	29	33.918	2.358	4.860
209	CB	ASN	29	33.195	0.102	6.632
210	CG	ASN	29	32.343	-0.411	7.789
211	OD1	ASN	29	31.243	0.082	8.065
212	ND2	ASN	29	32.880	-1.409	8.463
213	N	LEU	30	33.112	1.040	3.226
214	CA	LEU	30	33.875	1.715	2.163
215	C	LEU	30	33.311	3.095	1.834
216	O	LEU	30	34.001	3.921	1.228
217	CB	LEU	30	33.839	0.868	0.893
218	CG	LEU	30	34.861	-0.261	0.909
219	CD1	LEU	30	34.663	-1.187	-0.285
220	CD2	LEU	30	36.278	0.297	0.916
221	N	GLU	31	32.115	3.379	2.326
222	CA	GLU	31	31.537	4.722	2.198
223	C	GLU	31	31.873	5.616	3.401
224	O	GLU	31	31.357	6.738	3.502
225	CB	GLU	31	30.029	4.560	2.047
226	CG	GLU	31	29.433	3.878	3.269
227	CD	GLU	31	28.144	3.156	2.901
228	OE1	GLU	31	28.003	2.802	1.740
229	OE2	GLU	31	27.327	2.949	3.791
230	N	ARG	32	32.699	5.117	4.310
231	CA	ARG	32	33.060	5.883	5.506
232	C	ARG	32	34.325	6.737	5.316
233	O	ARG	32	34.177	7.964	5.387
234	CB	ARG	32	33.155	4.948	6.710
235	CG	ARG	32	31.839	4.213	6.909
236	CD	ARG	32	31.781	3.498	8.249
237	NE	ARG	32	30.378	3.247	8.608
238	CZ	ARG	32	29.731	3.986	9.510
239	NH1	ARG	32	30.398	4.885	10.237
240	NH2	ARG	32	28.440	3.757	9.756
241	N	PRO	33	35.516	6.182	5.096
242	CA	PRO	33	36.646	7.045	4.744
243	C	PRO	33	36.534	7.511	3.299
244	O	PRO	33	36.825	6.765	2.356
245	CB	PRO	33	37.868	6.204	4.929
246	CG	PRO	33	37.438	4.755	5.064
247	CD	PRO	33	35.920	4.768	5.055
248	N	THR	34	36.102	8.749	3.141
249	CA	THR	34	35.990	9.338	1.799
250	C	THR	34	37.323	9.447	1.024
251	O	THR	34	37.283	9.160	-0.179
252	CB	THR	34	35.246	10.673	1.873
253	OG1	THR	34	35.822	11.478	2.892
254	CG2	THR	34	33.783	10.455	2.243
255	N	PRO	35	38.464	9.823	1.599
256	CA	PRO	35	39.706	9.336	0.998

257	C	PRO	35	39.844	7.831	1.226
258	O	PRO	35	40.187	7.406	2.336
259	CB	PRO	35	40.802	10.087	1.689
260	CG	PRO	35	40.226	10.777	2.914
261	CD	PRO	35	38.737	10.475	2.893
262	N	LYS	36	39.863	7.088	0.128
263	CA	LYS	36	39.914	5.614	0.169
264	C	LYS	36	41.286	5.061	0.579
265	O	LYS	36	41.397	3.917	1.032
266	CB	LYS	36	39.577	5.120	-1.237
267	CG	LYS	36	39.491	3.599	-1.326
268	CD	LYS	36	39.361	3.134	-2.772
269	CE	LYS	36	38.129	3.728	-3.447
270	NZ	LYS	36	38.033	3.283	-4.847
271	N	TYR	37	42.295	5.915	0.564
272	CA	TYR	37	43.631	5.512	1.004
273	C	TYR	37	43.846	5.752	2.502
274	O	TYR	37	44.880	5.347	3.045
275	CB	TYR	37	44.681	6.269	0.185
276	CG	TYR	37	44.657	7.798	0.284
277	CD1	TYR	37	45.380	8.439	1.284
278	CD2	TYR	37	43.942	8.550	-0.642
279	CE1	TYR	37	45.363	9.824	1.378
280	CE2	TYR	37	43.923	9.935	-0.550
281	CZ	TYR	37	44.630	10.568	0.464
282	OH	TYR	37	44.587	11.941	0.577
283	N	THR	38	42.871	6.340	3.176
284	CA	THR	38	43.050	6.648	4.596
285	C	THR	38	42.213	5.707	5.456
286	O	THR	38	41.131	6.059	5.941
287	CB	THR	38	42.641	8.094	4.837
288	OG1	THR	38	43.174	8.881	3.782
289	CG2	THR	38	43.202	8.609	6.156
290	N	LYS	39	42.750	4.519	5.663
291	CA	LYS	39	42.036	3.494	6.428
292	C	LYS	39	42.502	3.416	7.886
293	O	LYS	39	43.693	3.264	8.184
294	CB	LYS	39	42.239	2.161	5.716
295	CG	LYS	39	41.590	2.151	4.335
296	CD	LYS	39	40.076	2.292	4.440
297	CE	LYS	39	39.405	2.337	3.072
298	NZ	LYS	39	39.662	1.106	2.313
299	N	VAL	40	41.531	3.529	8.777
300	CA	VAL	40	41.769	3.425	10.225
301	C	VAL	40	41.831	1.958	10.671
302	O	VAL	40	40.993	1.144	10.260
303	CB	VAL	40	40.638	4.187	10.919
304	CG1	VAL	40	39.268	3.784	10.385
305	CG2	VAL	40	40.691	4.087	12.438
306	N	GLY	41	42.816	1.646	11.505
307	CA	GLY	41	43.080	0.269	11.961
308	C	GLY	41	41.885	-0.455	12.586
309	O	GLY	41	40.856	0.143	12.912
310	N	GLU	42	42.086	-1.735	12.843
311	CA	GLU	42	40.995	-2.603	13.318
312	C	GLU	42	40.700	-2.470	14.817
313	O	GLU	42	39.903	-1.616	15.224
314	CB	GLU	42	41.372	-4.056	13.016
315	CG	GLU	42	40.208	-5.037	13.176
316	CD	GLU	42	39.111	-4.717	12.172
317	OE1	GLU	42	39.427	-4.667	10.996
318	OE2	GLU	42	38.001	-4.442	12.611
319	N	ARG	43	41.515	-3.159	15.603
320	CA	ARG	43	41.196	-3.553	16.987
321	C	ARG	43	41.019	-2.475	18.056

322	O	ARG	43	40.698	-1.315	17.771
323	CB	ARG	43	42.252	-4.560	17.413
324	CG	ARG	43	42.024	-5.844	16.627
325	CD	ARG	43	43.145	-6.861	16.793
326	NE	ARG	43	42.810	-8.099	16.069
327	CZ	ARG	43	43.092	-8.326	14.782
328	NH1	ARG	43	42.660	-9.446	14.197
329	NH2	ARG	43	43.743	-7.410	14.061
330	N	LEU	44	41.420	-2.857	19.260
331	CA	LEU	44	40.940	-2.274	20.535
332	C	LEU	44	41.307	-0.825	20.889
333	O	LEU	44	40.872	-0.346	21.941
334	CB	LEU	44	41.471	-3.171	21.649
335	CG	LEU	44	40.988	-4.610	21.499
336	CD1	LEU	44	41.711	-5.534	22.473
337	CD2	LEU	44	39.476	-4.712	21.677
338	N	ARG	45	42.074	-0.139	20.064
339	CA	ARG	45	42.359	1.270	20.330
340	C	ARG	45	42.277	2.045	19.017
341	O	ARG	45	42.438	3.271	18.953
342	CB	ARG	45	43.741	1.367	20.972
343	CG	ARG	45	44.040	2.774	21.469
344	CD	ARG	45	45.316	2.817	22.295
345	NE	ARG	45	45.143	2.075	23.552
346	CZ	ARG	45	46.140	1.431	24.157
347	NH1	ARG	45	47.350	1.403	23.596
348	NH2	ARG	45	45.919	0.787	25.305
349	N	HIS	46	41.904	1.325	17.978
350	CA	HIS	46	41.969	1.898	16.641
351	C	HIS	46	40.653	2.581	16.302
352	O	HIS	46	40.472	3.723	16.742
353	CB	HIS	46	42.340	0.803	15.655
354	CG	HIS	46	43.700	0.165	15.909
355	ND1	HIS	46	44.770	0.745	16.483
356	CD2	HIS	46	44.075	-1.114	15.581
357	CE1	HIS	46	45.787	-0.136	16.538
358	NE2	HIS	46	45.357	-1.287	15.976
359	N	VAL	47	39.754	1.908	15.599
360	CA	VAL	47	38.471	2.532	15.221
361	C	VAL	47	37.658	2.971	16.434
362	O	VAL	47	37.399	2.178	17.348
363	CB	VAL	47	37.650	1.541	14.392
364	CG1	VAL	47	36.163	1.879	14.354
365	CG2	VAL	47	38.190	1.434	12.977
366	N	ILE	48	37.362	4.260	16.470
367	CA	ILE	48	36.458	4.827	17.472
368	C	ILE	48	35.032	4.352	17.216
369	O	ILE	48	34.421	4.650	16.181
370	CB	ILE	48	36.563	6.348	17.385
371	CG1	ILE	48	37.887	6.817	17.971
372	CG2	ILE	48	35.404	7.035	18.090
373	CD1	ILE	48	37.969	6.480	19.456
374	N	PRO	49	34.540	3.554	18.149
375	CA	PRO	49	33.270	2.865	17.959
376	C	PRO	49	32.085	3.791	18.185
377	O	PRO	49	32.083	4.621	19.102
378	CB	PRO	49	33.270	1.770	18.979
379	CG	PRO	49	34.423	1.991	19.946
380	CD	PRO	49	35.204	3.174	19.399
381	N	GLY	50	31.104	3.670	17.312
382	CA	GLY	50	29.816	4.304	17.576
383	C	GLY	50	29.050	3.408	18.537
384	O	GLY	50	29.066	2.179	18.400
385	N	HIS	51	28.351	4.019	19.478
386	CA	HIS	51	27.698	3.254	20.556

387	C	HIS	51	26.280	2.772	20.229
388	O	HIS	51	25.346	3.003	21.005
389	CB	HIS	51	27.673	4.099	21.828
390	CG	HIS	51	28.989	4.180	22.588
391	ND1	HIS	51	29.133	4.531	23.880
392	CD2	HIS	51	30.253	3.914	22.109
393	CE1	HIS	51	30.439	4.492	24.214
394	NE2	HIS	51	31.130	4.112	23.117
395	N	MET	52	26.136	2.082	19.109
396	CA	MET	52	24.848	1.485	18.743
397	C	MET	52	25.075	0.169	18.005
398	O	MET	52	25.986	0.049	17.177
399	CB	MET	52	24.018	2.457	17.907
400	CG	MET	52	24.634	2.773	16.550
401	SD	MET	52	23.695	3.953	15.554
402	CE	MET	52	22.077	3.150	15.606
403	N	ALA	53	24.147	-0.754	18.204
404	CA	ALA	53	24.284	-2.128	17.691
405	C	ALA	53	23.978	-2.325	16.202
406	O	ALA	53	24.059	-3.457	15.713
407	CB	ALA	53	23.376	-3.036	18.512
408	N	CYS	54	23.645	-1.260	15.491
409	CA	CYS	54	23.405	-1.382	14.053
410	C	CYS	54	24.734	-1.431	13.308
411	O	CYS	54	25.184	-2.517	12.923
412	CB	CYS	54	22.566	-0.201	13.582
413	SG	CYS	54	20.908	-0.110	14.297
414	N	SER	55	25.369	-0.277	13.169
415	CA	SER	55	26.666	-0.190	12.481
416	C	SER	55	27.231	1.228	12.501
417	O	SER	55	26.638	2.156	11.940
418	CB	SER	55	26.511	-0.655	11.034
419	OG	SER	55	25.477	0.106	10.424
420	N	MET	56	28.353	1.384	13.187
421	CA	MET	56	29.096	2.656	13.196
422	C	MET	56	30.600	2.436	13.331
423	O	MET	56	31.173	2.695	14.400
424	CB	MET	56	28.646	3.551	14.348
425	CG	MET	56	27.381	4.345	14.049
426	SD	MET	56	26.900	5.538	15.320
427	CE	MET	56	28.370	6.588	15.307
428	N	ALA	57	31.242	2.052	12.240
429	CA	ALA	57	32.706	1.893	12.247
430	C	ALA	57	33.392	3.145	11.700
431	O	ALA	57	33.988	3.123	10.616
432	CB	ALA	57	33.076	0.686	11.397
433	N	CYS	58	33.390	4.185	12.518
434	CA	CYS	58	33.824	5.524	12.102
435	C	CYS	58	35.305	5.618	11.734
436	O	CYS	58	36.155	4.864	12.227
437	CB	CYS	58	33.512	6.469	13.251
438	SG	CYS	58	31.786	6.444	13.783
439	N	GLY	59	35.596	6.575	10.865
440	CA	GLY	59	36.968	6.800	10.382
441	C	GLY	59	37.774	7.717	11.303
442	O	GLY	59	38.007	8.895	10.997
443	N	GLY	60	38.232	7.142	12.401
444	CA	GLY	60	39.017	7.884	13.390
445	C	GLY	60	39.619	6.940	14.424
446	O	GLY	60	38.932	6.039	14.914
447	N	ARG	61	40.895	7.121	14.717
448	CA	ARG	61	41.560	6.257	15.705
449	C	ARG	61	41.929	6.985	16.991
450	O	ARG	61	42.244	8.181	16.984
451	CB	ARG	61	42.771	5.545	15.095

452	CG	ARG	61	43.632	6.425	14.197
453	CD	ARG	61	44.466	7.462	14.939
454	NE	ARG	61	45.563	6.879	15.722
455	CZ	ARG	61	46.833	7.006	15.334
456	NH1	ARG	61	47.823	6.728	16.183
457	NH2	ARG	61	47.107	7.616	14.183
458	N	ALA	62	41.903	6.251	18.089
459	CA	ALA	62	42.264	6.837	19.383
460	C	ALA	62	43.750	6.672	19.674
461	O	ALA	62	44.193	5.620	20.148
462	CB	ALA	62	41.458	6.156	20.482
463	N	CYS	63	44.500	7.745	19.497
464	CA	CYS	63	45.938	7.694	19.774
465	C	CYS	63	46.234	7.938	21.252
466	O	CYS	63	46.357	9.083	21.706
467	CB	CYS	63	46.645	8.743	18.931
468	SG	CYS	63	48.445	8.739	19.045
469	N	LYS	64	46.226	6.848	22.001
470	CA	LYS	64	46.613	6.860	23.412
471	C	LYS	64	48.054	6.384	23.552
472	O	LYS	64	48.406	5.291	23.091
473	CB	LYS	64	45.675	5.924	24.169
474	CG	LYS	64	46.126	5.674	25.604
475	CD	LYS	64	45.182	4.716	26.320
476	CE	LYS	64	45.706	4.351	27.703
477	NZ	LYS	64	47.001	3.660	27.607
478	N	TYR	65	48.885	7.218	24.151
479	CA	TYR	65	50.292	6.848	24.356
480	C	TYR	65	50.417	5.930	25.573
481	O	TYR	65	50.529	6.362	26.725
482	CB	TYR	65	51.115	8.124	24.463
483	CG	TYR	65	51.006	8.959	23.186
484	CD1	TYR	65	50.248	10.122	23.169
485	CD2	TYR	65	51.651	8.538	22.030
486	CE1	TYR	65	50.138	10.869	22.004
487	CE2	TYR	65	51.545	9.283	20.862
488	CZ	TYR	65	50.789	10.448	20.853
489	OH	TYR	65	50.703	11.202	19.702
490	N	GLU	66	50.503	4.650	25.250
491	CA	GLU	66	50.281	3.565	26.211
492	C	GLU	66	51.266	3.423	27.361
493	O	GLU	66	52.477	3.638	27.234
494	CB	GLU	66	50.240	2.244	25.435
495	CG	GLU	66	51.547	1.850	24.735
496	CD	GLU	66	52.510	1.069	25.640
497	OE1	GLU	66	52.038	0.495	26.612
498	OE2	GLU	66	53.675	0.978	25.281
499	N	ASN	67	50.676	3.106	28.499
500	CA	ASN	67	51.379	2.400	29.576
501	C	ASN	67	50.476	1.416	30.372
502	O	ASN	67	50.631	1.373	31.597
503	CB	ASN	67	51.998	3.439	30.515
504	CG	ASN	67	50.965	4.467	30.982
505	OD1	ASN	67	49.852	4.121	31.398
506	ND2	ASN	67	51.342	5.730	30.899
507	N	PRO	68	49.614	0.599	29.756
508	CA	PRO	68	48.551	-0.034	30.556
509	C	PRO	68	48.957	-1.352	31.228
510	O	PRO	68	48.432	-1.685	32.297
511	CB	PRO	68	47.449	-0.296	29.577
512	CG	PRO	68	48.006	-0.199	28.167
513	CD	PRO	68	49.432	0.295	28.323
514	N	ALA	69	49.875	-2.081	30.617
515	CA	ALA	69	50.325	-3.359	31.167
516	C	ALA	69	51.279	-3.132	32.327

517	O	ALA	69	51.904	-2.070	32.438
518	CB	ALA	69	51.024	-4.157	30.072
519	N	ARG	70	51.339	-4.116	33.206
520	CA	ARG	70	52.260	-4.056	34.338
521	C	ARG	70	53.692	-3.993	33.818
522	O	ARG	70	54.103	-4.803	32.978
523	CB	ARG	70	52.044	-5.292	35.204
524	CG	ARG	70	52.811	-5.206	36.519
525	CD	ARG	70	52.437	-6.363	37.438
526	NE	ARG	70	50.978	-6.406	37.637
527	CZ	ARG	70	50.356	-5.922	38.715
528	NH1	ARG	70	51.061	-5.383	39.713
529	NH2	ARG	70	49.026	-5.996	38.804
530	N	TRP	71	54.353	-2.913	34.207
531	CA	TRP	71	55.728	-2.595	33.803
532	C	TRP	71	55.796	-2.191	32.323
533	O	TRP	71	56.612	-2.714	31.553
534	CB	TRP	71	56.646	-3.779	34.113
535	CG	TRP	71	58.131	-3.471	34.056
536	CD1	TRP	71	58.826	-2.625	34.894
537	CD2	TRP	71	59.090	-3.999	33.115
538	NE1	TRP	71	60.126	-2.615	34.511
539	CE2	TRP	71	60.328	-3.422	33.451
540	CE3	TRP	71	58.998	-4.885	32.055
541	CZ2	TRP	71	61.460	-3.735	32.710
542	CZ3	TRP	71	60.132	-5.193	31.316
543	CH2	TRP	71	61.358	-4.623	31.643
544	N	SER	72	54.883	-1.327	31.909
545	CA	SER	72	55.032	-0.686	30.599
546	C	SER	72	55.985	0.489	30.750
547	O	SER	72	55.906	1.236	31.731
548	CB	SER	72	53.687	-0.207	30.082
549	OG	SER	72	52.882	-1.347	29.831
550	N	GLU	73	56.853	0.672	29.773
551	CA	GLU	73	57.920	1.661	29.944
552	C	GLU	73	57.522	3.093	29.602
553	O	GLU	73	57.643	3.941	30.493
554	CB	GLU	73	59.110	1.268	29.076
555	CG	GLU	73	60.262	2.254	29.257
556	CD	GLU	73	61.423	1.890	28.339
557	OE1	GLU	73	62.144	0.964	28.684
558	OE2	GLU	73	61.479	2.443	27.251
559	N	GLN	74	56.848	3.279	28.472
560	CA	GLN	74	56.699	4.592	27.792
561	C	GLN	74	56.706	5.853	28.655
562	O	GLN	74	57.733	6.205	29.246
563	CB	GLN	74	55.438	4.607	26.937
564	CG	GLN	74	55.538	3.644	25.759
565	CD	GLN	74	56.829	3.885	24.980
566	OE1	GLN	74	57.730	3.040	25.007
567	NE2	GLN	74	56.924	5.037	24.336
568	N	GLU	75	55.709	6.690	28.427
569	CA	GLU	75	55.673	7.990	29.110
570	C	GLU	75	54.257	8.379	29.514
571	O	GLU	75	53.510	7.587	30.102
572	CB	GLU	75	56.253	9.101	28.225
573	CG	GLU	75	57.772	9.052	28.023
574	CD	GLU	75	58.150	8.215	26.800
575	OE1	GLU	75	57.252	7.925	26.017
576	OE2	GLU	75	59.327	7.934	26.630
577	N	GLN	76	53.950	9.642	29.269
578	CA	GLN	76	52.644	10.211	29.608
579	C	GLN	76	51.567	9.679	28.670
580	O	GLN	76	51.692	9.778	27.444
581	CB	GLN	76	52.706	11.737	29.491

582	CG	GLN	76	53.713	12.381	30.447
583	CD	GLN	76	55.051	12.678	29.763
584	OE1	GLN	76	55.341	12.161	28.674
585	NE2	GLN	76	55.886	13.421	30.467
586	N	ALA	77	50.454	9.272	29.259
587	CA	ALA	77	49.352	8.659	28.498
588	C	ALA	77	48.325	9.656	27.966
589	O	ALA	77	47.129	9.543	28.258
590	CB	ALA	77	48.647	7.641	29.385
591	N	ILE	78	48.783	10.610	27.174
592	CA	ILE	78	47.863	11.583	26.584
593	C	ILE	78	47.159	10.969	25.373
594	O	ILE	78	47.630	9.975	24.802
595	CB	ILE	78	48.617	12.867	26.257
596	CG1	ILE	78	49.834	12.617	25.382
597	CG2	ILE	78	49.034	13.570	27.545
598	CD1	ILE	78	50.571	13.918	25.084
599	N	LYS	79	45.944	11.438	25.134
600	CA	LYS	79	45.081	10.825	24.115
601	C	LYS	79	44.481	11.830	23.126
602	O	LYS	79	43.805	12.794	23.512
603	CB	LYS	79	43.937	10.128	24.838
604	CG	LYS	79	44.406	9.091	25.850
605	CD	LYS	79	43.212	8.464	26.555
606	CE	LYS	79	42.351	9.537	27.213
607	NZ	LYS	79	41.150	8.950	27.826
608	N	GLY	80	44.633	11.515	21.851
609	CA	GLY	80	44.036	12.335	20.784
610	C	GLY	80	43.501	11.483	19.632
611	O	GLY	80	44.212	10.640	19.078
612	N	VAL	81	42.248	11.699	19.275
613	CA	VAL	81	41.645	10.946	18.169
614	C	VAL	81	41.923	11.618	16.828
615	O	VAL	81	41.529	12.766	16.605
616	CB	VAL	81	40.139	10.838	18.392
617	CG1	VAL	81	39.428	10.202	17.201
618	CG2	VAL	81	39.835	10.047	19.656
619	N	TYR	82	42.616	10.905	15.955
620	CA	TYR	82	42.869	11.403	14.593
621	C	TYR	82	41.642	11.074	13.759
622	O	TYR	82	41.294	9.897	13.614
623	CB	TYR	82	44.077	10.717	13.952
624	CG	TYR	82	45.487	10.949	14.516
625	CD1	TYR	82	45.732	11.013	15.882
626	CD2	TYR	82	46.546	11.062	13.624
627	CE1	TYR	82	47.020	11.204	16.355
628	CE2	TYR	82	47.837	11.255	14.094
629	CZ	TYR	82	48.070	11.324	15.461
630	OH	TYR	82	49.348	11.512	15.934
631	N	SER	83	40.980	12.095	13.251
632	CA	SER	83	39.709	11.877	12.560
633	C	SER	83	39.681	12.397	11.126
634	O	SER	83	40.202	13.473	10.793
635	CB	SER	83	38.626	12.573	13.362
636	OG	SER	83	38.754	12.154	14.715
637	N	SER	84	38.979	11.633	10.307
638	CA	SER	84	38.657	12.044	8.941
639	C	SER	84	37.614	13.156	8.975
640	O	SER	84	37.138	13.562	10.045
641	CB	SER	84	38.116	10.851	8.165
642	OG	SER	84	39.118	9.845	8.164
643	N	TRP	85	37.338	13.718	7.815
644	CA	TRP	85	36.427	14.855	7.758
645	C	TRP	85	34.976	14.424	7.836
646	O	TRP	85	34.582	13.351	7.365

647	CB	TRP	85	36.711	15.752	6.550
648	CG	TRP	85	36.868	15.131	5.172
649	CD1	TRP	85	37.923	14.370	4.729
650	CD2	TRP	85	35.964	15.264	4.047
651	NE1	TRP	85	37.710	14.038	3.432
652	CE2	TRP	85	36.556	14.558	2.987
653	CE3	TRP	85	34.763	15.926	3.868
654	CZ2	TRP	85	35.916	14.509	1.754
655	CZ3	TRP	85	34.132	15.877	2.628
656	CH2	TRP	85	34.706	15.169	1.578
657	N	VAL	86	34.220	15.241	8.548
658	CA	VAL	86	32.795	15.003	8.784
659	C	VAL	86	31.962	15.331	7.540
660	O	VAL	86	31.477	16.446	7.312
661	CB	VAL	86	32.410	15.833	10.005
662	CG1	VAL	86	32.857	17.276	9.871
663	CG2	VAL	86	30.934	15.752	10.347
664	N	THR	87	31.913	14.332	6.679
665	CA	THR	87	31.179	14.425	5.422
666	C	THR	87	29.687	14.290	5.708
667	O	THR	87	29.264	13.423	6.478
668	CB	THR	87	31.674	13.310	4.495
669	OG1	THR	87	33.097	13.322	4.485
670	CG2	THR	87	31.195	13.474	3.056
671	N	ASP	88	28.901	15.089	5.003
672	CA	ASP	88	27.435	15.148	5.153
673	C	ASP	88	26.700	13.962	4.503
674	O	ASP	88	25.473	13.854	4.604
675	CB	ASP	88	27.005	16.467	4.503
676	CG	ASP	88	25.501	16.716	4.588
677	OD1	ASP	88	24.837	16.511	3.580
678	OD2	ASP	88	25.065	17.212	5.614
679	N	ASN	89	27.451	13.050	3.908
680	CA	ASN	89	26.886	11.881	3.225
681	C	ASN	89	26.010	11.001	4.126
682	O	ASN	89	26.427	10.514	5.179
683	CB	ASN	89	28.025	11.060	2.598
684	CG	ASN	89	29.028	10.431	3.582
685	OD1	ASN	89	29.207	10.861	4.730
686	ND2	ASN	89	29.677	9.388	3.093
687	N	ILE	90	24.732	10.991	3.785
688	CA	ILE	90	23.753	10.066	4.369
689	C	ILE	90	23.098	9.270	3.239
690	O	ILE	90	22.384	8.280	3.459
691	CB	ILE	90	22.734	10.894	5.156
692	CG1	ILE	90	21.559	10.056	5.653
693	CG2	ILE	90	22.253	12.084	4.333
694	CD1	ILE	90	20.503	10.892	6.367
695	N	LEU	91	23.611	9.539	2.050
696	CA	LEU	91	23.026	9.037	0.801
697	C	LEU	91	23.152	7.529	0.577
698	O	LEU	91	22.277	6.964	-0.087
699	CB	LEU	91	23.751	9.752	-0.331
700	CG	LEU	91	23.219	9.334	-1.695
701	CD1	LEU	91	21.758	9.741	-1.853
702	CD2	LEU	91	24.069	9.925	-2.811
703	N	ALA	92	24.013	6.855	1.320
704	CA	ALA	92	24.203	5.419	1.115
705	C	ALA	92	23.143	4.573	1.822
706	O	ALA	92	23.045	3.369	1.563
707	CB	ALA	92	25.588	5.058	1.618
708	N	MET	93	22.324	5.212	2.643
709	CA	MET	93	21.169	4.543	3.241
710	C	MET	93	19.932	4.726	2.359
711	O	MET	93	18.919	4.037	2.525

712	CB	MET	93	20.936	5.176	4.605
713	CG	MET	93	19.904	4.421	5.430
714	SD	MET	93	19.548	5.143	7.045
715	CE	MET	93	19.043	6.790	6.496
716	N	ALA	94	20.034	5.635	1.403
717	CA	ALA	94	18.959	5.817	0.426
718	C	ALA	94	19.291	4.973	-0.795
719	O	ALA	94	18.406	4.452	-1.485
720	CB	ALA	94	18.884	7.287	0.035
721	N	ARG	95	20.584	4.847	-1.037
722	CA	ARG	95	21.078	3.858	-1.985
723	C	ARG	95	20.910	2.497	-1.330
724	O	ARG	95	21.093	2.377	-0.115
725	CB	ARG	95	22.534	4.160	-2.316
726	CG	ARG	95	22.641	5.568	-2.884
727	CD	ARG	95	23.788	5.689	-3.879
728	NE	ARG	95	23.556	4.782	-5.017
729	CZ	ARG	95	22.886	5.121	-6.122
730	NH1	ARG	95	22.469	6.378	-6.300
731	NH2	ARG	95	22.697	4.217	-7.086
732	N	PRO	96	20.634	1.485	-2.135
733	CA	PRO	96	19.763	0.377	-1.695
734	C	PRO	96	20.355	-0.654	-0.724
735	O	PRO	96	19.710	-1.685	-0.514
736	CB	PRO	96	19.348	-0.321	-2.954
737	CG	PRO	96	20.006	0.337	-4.153
738	CD	PRO	96	20.759	1.531	-3.598
739	N	SER	97	21.524	-0.428	-0.146
740	CA	SER	97	22.109	-1.500	0.656
741	C	SER	97	23.013	-1.054	1.802
742	O	SER	97	23.704	-1.922	2.351
743	CB	SER	97	22.930	-2.386	-0.268
744	OG	SER	97	24.007	-1.596	-0.754
745	N	SER	98	23.082	0.223	2.146
746	CA	SER	98	24.019	0.556	3.226
747	C	SER	98	23.609	1.676	4.187
748	O	SER	98	22.446	1.818	4.582
749	CB	SER	98	25.400	0.793	2.622
750	OG	SER	98	25.275	1.682	1.527
751	N	GLU	99	24.631	2.341	4.700
752	CA	GLU	99	24.506	3.173	5.903
753	C	GLU	99	24.464	4.683	5.668
754	O	GLU	99	24.930	5.222	4.655
755	CB	GLU	99	25.728	2.848	6.757
756	CG	GLU	99	25.804	1.351	7.039
757	CD	GLU	99	27.232	0.924	7.370
758	OE1	GLU	99	27.830	0.307	6.500
759	OE2	GLU	99	27.578	0.974	8.541
760	N	LEU	100	23.825	5.346	6.616
761	CA	LEU	100	23.952	6.802	6.752
762	C	LEU	100	25.328	7.047	7.355
763	O	LEU	100	25.861	6.148	8.016
764	CB	LEU	100	22.856	7.388	7.649
765	CG	LEU	100	23.035	7.149	9.152
766	CD1	LEU	100	22.368	8.257	9.958
767	CD2	LEU	100	22.547	5.778	9.621
768	N	LEU	101	25.945	8.179	7.071
769	CA	LEU	101	27.336	8.312	7.496
770	C	LEU	101	27.658	9.477	8.434
771	O	LEU	101	26.914	9.821	9.364
772	CB	LEU	101	28.233	8.340	6.267
773	CG	LEU	101	29.157	7.127	6.178
774	CD1	LEU	101	30.092	7.081	7.376
775	CD2	LEU	101	28.386	5.820	6.051
776	N	GLU	102	28.772	10.116	8.124

777	CA	GLU	102	29.608	10.691	9.182
778	C	GLU	102	29.334	12.107	9.659
779	O	GLU	102	29.966	12.491	10.651
780	CB	GLU	102	31.077	10.507	8.808
781	CG	GLU	102	31.374	10.810	7.345
782	CD	GLU	102	32.824	10.443	7.033
783	OE1	GLU	102	33.377	9.651	7.786
784	OE2	GLU	102	33.352	10.968	6.062
785	N	LYS	103	28.309	12.788	9.177
786	CA	LYS	103	28.083	14.123	9.735
787	C	LYS	103	27.446	14.019	11.115
788	O	LYS	103	27.920	14.654	12.064
789	CB	LYS	103	27.207	14.984	8.839
790	CG	LYS	103	27.417	16.443	9.233
791	CD	LYS	103	26.409	17.389	8.599
792	CE	LYS	103	25.011	17.138	9.149
793	NZ	LYS	103	24.057	18.130	8.630
794	N	TYR	104	26.600	13.016	11.278
795	CA	TYR	104	25.983	12.783	12.581
796	C	TYR	104	26.847	11.854	13.428
797	O	TYR	104	26.937	12.032	14.651
798	CB	TYR	104	24.619	12.148	12.340
799	CG	TYR	104	23.863	11.778	13.610
800	CD1	TYR	104	23.700	12.715	14.624
801	CD2	TYR	104	23.323	10.505	13.743
802	CE1	TYR	104	23.019	12.370	15.783
803	CE2	TYR	104	22.642	10.158	14.902
804	CZ	TYR	104	22.499	11.090	15.922
805	OH	TYR	104	21.954	10.703	17.125
806	N	HIS	105	27.701	11.097	12.760
807	CA	HIS	105	28.493	10.095	13.471
808	C	HIS	105	29.681	10.699	14.206
809	O	HIS	105	29.883	10.316	15.364
810	CB	HIS	105	28.944	9.013	12.498
811	CG	HIS	105	27.816	8.119	12.014
812	ND1	HIS	105	27.909	7.152	11.083
813	CD2	HIS	105	26.512	8.119	12.455
814	CE1	HIS	105	26.704	6.573	10.918
815	NE2	HIS	105	25.839	7.171	11.766
816	N	ILE	106	30.159	11.847	13.745
817	CA	ILE	106	31.229	12.545	14.472
818	C	ILE	106	30.692	13.214	15.741
819	O	ILE	106	31.338	13.133	16.796
820	CB	ILE	106	31.845	13.588	13.542
821	CG1	ILE	106	32.562	12.932	12.366
822	CG2	ILE	106	32.812	14.492	14.298
823	CD1	ILE	106	33.820	12.190	12.803
824	N	ILE	107	29.409	13.544	15.720
825	CA	ILE	107	28.757	14.124	16.896
826	C	ILE	107	28.391	13.035	17.903
827	O	ILE	107	28.568	13.223	19.115
828	CB	ILE	107	27.496	14.835	16.422
829	CG1	ILE	107	27.836	15.847	15.334
830	CG2	ILE	107	26.792	15.522	17.587
831	CD1	ILE	107	26.584	16.538	14.806
832	N	ASP	108	28.180	11.833	17.390
833	CA	ASP	108	27.923	10.676	18.249
834	C	ASP	108	29.208	10.193	18.914
835	O	ASP	108	29.172	9.807	20.087
836	CB	ASP	108	27.365	9.538	17.402
837	CG	ASP	108	26.050	9.928	16.738
838	OD1	ASP	108	25.815	9.451	15.634
839	OD2	ASP	108	25.258	10.599	17.385
840	N	GLN	109	30.342	10.437	18.277
841	CA	GLN	109	31.632	10.092	18.881

842	C	GLN	109	31.991	11.082	19.984
843	O	GLN	109	32.399	10.653	21.075
844	CB	GLN	109	32.690	10.135	17.788
845	CG	GLN	109	32.379	9.125	16.692
846	CD	GLN	109	33.233	9.416	15.463
847	OE1	GLN	109	32.718	9.563	14.346
848	NE2	GLN	109	34.531	9.522	15.686
849	N	PHE	110	31.571	12.327	19.803
850	CA	PHE	110	31.764	13.353	20.834
851	C	PHE	110	31.020	12.981	22.104
852	O	PHE	110	31.659	12.752	23.142
853	CB	PHE	110	31.206	14.694	20.367
854	CG	PHE	110	31.950	15.394	19.238
855	CD1	PHE	110	31.252	16.247	18.393
856	CD2	PHE	110	33.314	15.208	19.065
857	CE1	PHE	110	31.914	16.901	17.366
858	CE2	PHE	110	33.979	15.862	18.037
859	CZ	PHE	110	33.277	16.708	17.188
860	N	LEU	111	29.754	12.635	21.938
861	CA	LEU	111	28.891	12.344	23.087
862	C	LEU	111	29.102	10.953	23.688
863	O	LEU	111	28.781	10.751	24.864
864	CB	LEU	111	27.447	12.460	22.614
865	CG	LEU	111	27.138	13.856	22.083
866	CD1	LEU	111	25.781	13.888	21.388
867	CD2	LEU	111	27.209	14.902	23.191
868	N	SER	112	29.753	10.062	22.961
869	CA	SER	112	29.974	8.709	23.478
870	C	SER	112	31.297	8.564	24.222
871	O	SER	112	31.474	7.595	24.970
872	CB	SER	112	29.958	7.730	22.309
873	OG	SER	112	31.072	8.006	21.468
874	N	HIS	113	32.216	9.496	24.029
875	CA	HIS	113	33.502	9.387	24.724
876	C	HIS	113	33.821	10.601	25.588
877	O	HIS	113	34.852	10.624	26.274
878	CB	HIS	113	34.588	9.175	23.680
879	CG	HIS	113	34.422	7.875	22.918
880	ND1	HIS	113	34.259	6.654	23.459
881	CD2	HIS	113	34.398	7.718	21.554
882	CE1	HIS	113	34.146	5.742	22.472
883	NE2	HIS	113	34.227	6.401	21.296
884	N	GLY	114	32.968	11.609	25.517
885	CA	GLY	114	33.180	12.836	26.288
886	C	GLY	114	34.321	13.619	25.659
887	O	GLY	114	35.222	14.105	26.355
888	N	ILE	115	34.289	13.676	24.339
889	CA	ILE	115	35.368	14.280	23.557
890	C	ILE	115	35.398	15.792	23.743
891	O	ILE	115	34.365	16.465	23.626
892	CB	ILE	115	35.115	13.933	22.092
893	CG1	ILE	115	35.139	12.423	21.876
894	CG2	ILE	115	36.122	14.601	21.164
895	CD1	ILE	115	36.538	11.849	22.044
896	N	LYS	116	36.582	16.316	24.018
897	CA	LYS	116	36.753	17.768	24.159
898	C	LYS	116	36.915	18.452	22.807
899	O	LYS	116	38.014	18.875	22.439
900	CB	LYS	116	37.950	18.072	25.052
901	CG	LYS	116	37.528	18.042	26.515
902	CD	LYS	116	36.401	19.047	26.742
903	CE	LYS	116	35.954	19.087	28.197
904	NZ	LYS	116	34.842	20.032	28.385
905	N	THR	117	35.771	18.654	22.162
906	CA	THR	117	35.621	19.299	20.844

907	C	THR	117	36.648	18.926	19.776
908	O	THR	117	37.519	18.053	19.938
909	CB	THR	117	35.541	20.816	21.002
910	OG1	THR	117	36.584	21.254	21.862
911	CG2	THR	117	34.221	21.237	21.635
912	N	ILE	118	36.417	19.519	18.621
913	CA	ILE	118	37.154	19.154	17.415
914	C	ILE	118	38.293	20.137	17.125
915	O	ILE	118	38.134	21.365	17.127
916	CB	ILE	118	36.111	19.041	16.300
917	CG1	ILE	118	36.394	17.862	15.387
918	CG2	ILE	118	35.967	20.316	15.472
919	CD1	ILE	118	35.199	17.607	14.475
920	N	ILE	119	39.479	19.570	17.023
921	CA	ILE	119	40.674	20.350	16.721
922	C	ILE	119	40.793	20.532	15.219
923	O	ILE	119	40.752	19.571	14.442
924	CB	ILE	119	41.914	19.650	17.272
925	CG1	ILE	119	41.943	19.687	18.787
926	CG2	ILE	119	43.203	20.255	16.732
927	CD1	ILE	119	43.309	19.252	19.300
928	N	ASN	120	40.887	21.793	14.849
929	CA	ASN	120	41.073	22.224	13.474
930	C	ASN	120	42.289	21.600	12.809
931	O	ASN	120	43.225	21.128	13.468
932	CB	ASN	120	41.324	23.726	13.520
933	CG	ASN	120	42.587	24.064	14.330
934	OD1	ASN	120	43.722	23.857	13.883
935	ND2	ASN	120	42.373	24.726	15.450
936	N	LEU	121	42.237	21.568	11.492
937	CA	LEU	121	43.450	21.309	10.725
938	C	LEU	121	43.658	22.383	9.669
939	O	LEU	121	44.718	23.017	9.638
940	CB	LEU	121	43.401	19.937	10.078
941	CG	LEU	121	43.758	18.834	11.061
942	CD1	LEU	121	43.749	17.491	10.352
943	CD2	LEU	121	45.124	19.094	11.686
944	N	GLN	122	42.658	22.588	8.826
945	CA	GLN	122	42.776	23.597	7.762
946	C	GLN	122	41.405	24.198	7.420
947	O	GLN	122	40.431	23.956	8.148
948	CB	GLN	122	43.472	22.918	6.571
949	CG	GLN	122	42.637	22.364	5.408
950	CD	GLN	122	41.586	21.316	5.773
951	OE1	GLN	122	40.551	21.635	6.372
952	NE2	GLN	122	41.814	20.107	5.301
953	N	ARG	123	41.383	25.111	6.459
954	CA	ARG	123	40.112	25.569	5.888
955	C	ARG	123	39.445	24.433	5.122
956	O	ARG	123	40.049	23.849	4.213
957	CB	ARG	123	40.393	26.662	4.872
958	CG	ARG	123	41.253	27.780	5.428
959	CD	ARG	123	41.601	28.783	4.336
960	NE	ARG	123	42.307	28.108	3.234
961	CZ	ARG	123	41.813	28.011	1.997
962	NH1	ARG	123	40.617	28.532	1.710
963	NH2	ARG	123	42.510	27.382	1.049
964	N	PRO	124	38.145	24.301	5.323
965	CA	PRO	124	37.364	23.270	4.624
966	C	PRO	124	37.193	23.506	3.115
967	O	PRO	124	37.145	22.529	2.352
968	CB	PRO	124	36.025	23.312	5.298
969	CG	PRO	124	35.971	24.462	6.290
970	CD	PRO	124	37.338	25.117	6.238
971	N	GLY	125	37.365	24.749	2.681

972	CA	GLY	125	37.105	25.138	1.286
973	C	GLY	125	38.355	25.187	0.405
974	O	GLY	125	38.711	26.232	-0.149
975	N	GLU	126	38.986	24.037	0.269
976	CA	GLU	126	40.101	23.843	-0.667
977	C	GLU	126	39.916	22.450	-1.249
978	O	GLU	126	40.518	21.484	-0.769
979	CB	GLU	126	41.447	23.985	0.044
980	CG	GLU	126	41.418	23.386	1.443
981	CD	GLU	126	42.827	23.187	1.989
982	OE1	GLU	126	43.143	22.054	2.330
983	OE2	GLU	126	43.529	24.172	2.170
984	N	HIS	127	39.086	22.388	-2.284
985	CA	HIS	127	38.432	21.139	-2.715
986	C	HIS	127	37.507	20.715	-1.578
987	O	HIS	127	37.160	21.537	-0.720
988	CB	HIS	127	39.428	20.020	-3.031
989	CG	HIS	127	40.524	20.386	-4.013
990	ND1	HIS	127	40.380	20.673	-5.321
991	CD2	HIS	127	41.867	20.482	-3.730
992	CE1	HIS	127	41.588	20.951	-5.853
993	NE2	HIS	127	42.507	20.833	-4.867
994	N	ALA	128	37.057	19.473	-1.596
995	CA	ALA	128	36.279	18.949	-0.457
996	C	ALA	128	37.239	18.486	0.640
997	O	ALA	128	37.448	17.284	0.848
998	CB	ALA	128	35.421	17.786	-0.938
999	N	SER	129	37.783	19.449	1.364
1000	CA	SER	129	38.948	19.170	2.196
1001	C	SER	129	38.606	18.981	3.665
1002	O	SER	129	39.463	18.541	4.443
1003	CB	SER	129	39.899	20.341	2.036
1004	OG	SER	129	41.207	19.906	2.364
1005	N	CYS	130	37.383	19.319	4.035
1006	CA	CYS	130	36.922	19.121	5.411
1007	C	CYS	130	35.443	19.471	5.489
1008	O	CYS	130	35.022	20.499	4.954
1009	CB	CYS	130	37.717	20.028	6.350
1010	SG	CYS	130	37.778	19.479	8.067
1011	N	GLY	131	34.661	18.613	6.116
1012	CA	GLY	131	33.228	18.891	6.272
1013	C	GLY	131	32.962	19.833	7.445
1014	O	GLY	131	33.828	20.030	8.306
1015	N	ASN	132	31.771	20.409	7.462
1016	CA	ASN	132	31.397	21.326	8.548
1017	C	ASN	132	30.022	21.008	9.141
1018	O	ASN	132	28.984	21.206	8.499
1019	CB	ASN	132	31.402	22.761	8.028
1020	CG	ASN	132	30.993	23.686	9.170
1021	OD1	ASN	132	31.421	23.490	10.313
1022	ND2	ASN	132	30.109	24.621	8.876
1023	N	PRO	133	30.034	20.467	10.351
1024	CA	PRO	133	28.805	20.288	11.135
1025	C	PRO	133	28.365	21.525	11.944
1026	O	PRO	133	27.252	21.530	12.484
1027	CB	PRO	133	29.169	19.190	12.086
1028	CG	PRO	133	30.689	19.125	12.189
1029	CD	PRO	133	31.220	20.045	11.100
1030	N	LEU	134	29.197	22.552	12.020
1031	CA	LEU	134	28.928	23.682	12.914
1032	C	LEU	134	28.041	24.744	12.279
1033	O	LEU	134	28.259	25.185	11.141
1034	CB	LEU	134	30.260	24.310	13.315
1035	CG	LEU	134	31.145	23.316	14.065
1036	CD1	LEU	134	32.514	23.914	14.370

1037	CD2	LEU	134	30.473	22.846	15.350
1038	N	GLU	135	27.052	25.166	13.048
1039	CA	GLU	135	26.172	26.258	12.626
1040	C	GLU	135	26.925	27.581	12.758
1041	O	GLU	135	27.237	28.036	13.864
1042	CB	GLU	135	24.932	26.225	13.514
1043	CG	GLU	135	23.821	27.140	13.016
1044	CD	GLU	135	22.549	26.877	13.820
1045	OE1	GLU	135	22.673	26.118	14.775
1046	OE2	GLU	135	21.489	27.082	13.244
1047	N	GLN	136	27.229	28.168	11.611
1048	CA	GLN	136	28.077	29.366	11.560
1049	C	GLN	136	27.301	30.640	11.864
1050	O	GLN	136	27.862	31.618	12.369
1051	CB	GLN	136	28.643	29.459	10.150
1052	CG	GLN	136	29.423	28.203	9.787
1053	CD	GLN	136	29.725	28.195	8.293
1054	OE1	GLN	136	29.167	27.387	7.541
1055	NE2	GLN	136	30.573	29.120	7.877
1056	N	GLU	137	26.014	30.614	11.574
1057	CA	GLU	137	25.150	31.722	11.974
1058	C	GLU	137	24.177	31.221	13.030
1059	O	GLU	137	23.581	30.149	12.864
1060	CB	GLU	137	24.418	32.291	10.762
1061	CG	GLU	137	23.632	31.233	10.000
1062	CD	GLU	137	22.867	31.887	8.855
1063	OE1	GLU	137	22.781	31.265	7.805
1064	OE2	GLU	137	22.472	33.032	9.020
1065	N	SER	138	24.060	31.986	14.104
1066	CA	SER	138	23.226	31.604	15.250
1067	C	SER	138	23.669	30.259	15.822
1068	O	SER	138	23.109	29.207	15.490
1069	CB	SER	138	21.759	31.541	14.830
1070	OG	SER	138	21.003	31.101	15.948
1071	N	GLY	139	24.724	30.304	16.614
1072	CA	GLY	139	25.233	29.096	17.258
1073	C	GLY	139	25.932	29.478	18.553
1074	O	GLY	139	25.311	30.001	19.485
1075	N	PHE	140	27.227	29.235	18.587
1076	CA	PHE	140	28.023	29.597	19.759
1077	C	PHE	140	28.840	30.846	19.478
1078	O	PHE	140	28.592	31.552	18.495
1079	CB	PHE	140	28.918	28.428	20.147
1080	CG	PHE	140	28.135	27.244	20.707
1081	CD1	PHE	140	27.682	27.283	22.019
1082	CD2	PHE	140	27.860	26.139	19.910
1083	CE1	PHE	140	26.966	26.212	22.539
1084	CE2	PHE	140	27.144	25.069	20.430
1085	CZ	PHE	140	26.699	25.104	21.745
1086	N	THR	141	29.746	31.146	20.391
1087	CA	THR	141	30.615	32.321	20.264
1088	C	THR	141	31.653	32.097	19.162
1089	O	THR	141	31.853	30.956	18.731
1090	CB	THR	141	31.286	32.549	21.615
1091	OG1	THR	141	31.941	33.806	21.601
1092	CG2	THR	141	32.300	31.460	21.949
1093	N	TYR	142	32.113	33.186	18.565
1094	CA	TYR	142	33.120	33.121	17.492
1095	C	TYR	142	34.209	34.181	17.682
1096	O	TYR	142	33.982	35.362	17.393
1097	CB	TYR	142	32.444	33.394	16.145
1098	CG	TYR	142	31.164	32.611	15.854
1099	CD1	TYR	142	29.955	33.292	15.775
1100	CD2	TYR	142	31.204	31.238	15.644
1101	CE1	TYR	142	28.781	32.597	15.517

1102	CE2	TYR	142	30.029	30.541	15.388
1103	CZ	TYR	142	28.821	31.223	15.331
1104	OH	TYR	142	27.647	30.531	15.136
1105	N	LEU	143	35.382	33.759	18.123
1106	CA	LEU	143	36.538	34.667	18.266
1107	C	LEU	143	37.080	35.096	16.903
1108	O	LEU	143	37.544	34.255	16.125
1109	CB	LEU	143	37.626	33.929	19.044
1110	CG	LEU	143	38.909	34.741	19.216
1111	CD1	LEU	143	38.692	35.937	20.135
1112	CD2	LEU	143	40.028	33.864	19.764
1113	N	PRO	144	37.040	36.395	16.638
1114	CA	PRO	144	37.290	36.941	15.294
1115	C	PRO	144	38.764	37.165	14.918
1116	O	PRO	144	39.135	38.289	14.563
1117	CB	PRO	144	36.570	38.254	15.289
1118	CG	PRO	144	36.205	38.629	16.718
1119	CD	PRO	144	36.580	37.430	17.569
1120	N	GLU	145	39.605	36.149	15.032
1121	CA	GLU	145	40.963	36.277	14.489
1122	C	GLU	145	40.975	35.718	13.074
1123	O	GLU	145	40.394	34.654	12.829
1124	CB	GLU	145	41.981	35.541	15.345
1125	CG	GLU	145	42.179	36.208	16.698
1126	CD	GLU	145	43.285	35.485	17.462
1127	OE1	GLU	145	44.016	34.732	16.832
1128	OE2	GLU	145	43.291	35.596	18.681
1129	N	ALA	146	41.745	36.358	12.205
1130	CA	ALA	146	41.772	36.020	10.769
1131	C	ALA	146	41.935	34.533	10.483
1132	O	ALA	146	40.993	33.877	10.028
1133	CB	ALA	146	42.932	36.756	10.123
1134	N	PHE	147	43.069	33.979	10.873
1135	CA	PHE	147	43.301	32.550	10.640
1136	C	PHE	147	42.961	31.685	11.856
1137	O	PHE	147	43.265	30.485	11.846
1138	CB	PHE	147	44.743	32.302	10.203
1139	CG	PHE	147	45.104	32.760	8.783
1140	CD1	PHE	147	44.119	33.164	7.890
1141	CD2	PHE	147	46.434	32.753	8.382
1142	CE1	PHE	147	44.463	33.575	6.609
1143	CE2	PHE	147	46.780	33.163	7.101
1144	CZ	PHE	147	45.795	33.577	6.215
1145	N	MET	148	42.316	32.267	12.857
1146	CA	MET	148	42.010	31.551	14.106
1147	C	MET	148	40.652	31.969	14.670
1148	O	MET	148	40.578	32.723	15.652
1149	CB	MET	148	43.081	31.840	15.157
1150	CG	MET	148	44.417	31.178	14.841
1151	SD	MET	148	45.728	31.446	16.054
1152	CE	MET	148	47.004	30.406	15.307
1153	N	GLU	149	39.594	31.418	14.102
1154	CA	GLU	149	38.246	31.738	14.593
1155	C	GLU	149	37.769	30.699	15.601
1156	O	GLU	149	37.243	29.646	15.223
1157	CB	GLU	149	37.257	31.790	13.435
1158	CG	GLU	149	35.869	32.194	13.924
1159	CD	GLU	149	34.845	32.048	12.803
1160	OE1	GLU	149	33.686	31.814	13.118
1161	OE2	GLU	149	35.250	32.129	11.652
1162	N	ALA	150	37.921	31.009	16.875
1163	CA	ALA	150	37.520	30.058	17.921
1164	C	ALA	150	36.026	30.099	18.231
1165	O	ALA	150	35.539	31.038	18.872
1166	CB	ALA	150	38.307	30.354	19.192

1167	N	GLY	151	35.325	29.061	17.810
1168	CA	GLY	151	33.903	28.917	18.129
1169	C	GLY	151	33.774	28.180	19.456
1170	O	GLY	151	34.010	28.752	20.529
1171	N	ILE	152	33.405	26.911	19.373
1172	CA	ILE	152	33.506	26.032	20.544
1173	C	ILE	152	34.898	25.412	20.573
1174	O	ILE	152	35.379	24.937	21.608
1175	CB	ILE	152	32.429	24.951	20.513
1176	CG1	ILE	152	32.175	24.424	19.105
1177	CG2	ILE	152	31.146	25.457	21.154
1178	CD1	ILE	152	31.091	23.354	19.103
1179	N	TYR	153	35.500	25.380	19.396
1180	CA	TYR	153	36.934	25.163	19.253
1181	C	TYR	153	37.399	25.983	18.059
1182	O	TYR	153	36.591	26.481	17.266
1183	CB	TYR	153	37.281	23.689	19.105
1184	CG	TYR	153	38.254	23.211	20.184
1185	CD1	TYR	153	38.314	23.882	21.401
1186	CD2	TYR	153	39.080	22.118	19.957
1187	CE1	TYR	153	39.184	23.452	22.393
1188	CE2	TYR	153	39.952	21.687	20.948
1189	CZ	TYR	153	40.001	22.353	22.164
1190	OH	TYR	153	40.847	21.907	23.155
1191	N	PHE	154	38.697	26.194	18.010
1192	CA	PHE	154	39.306	27.134	17.065
1193	C	PHE	154	39.332	26.579	15.648
1194	O	PHE	154	39.605	25.390	15.453
1195	CB	PHE	154	40.737	27.401	17.532
1196	CG	PHE	154	41.024	26.975	18.976
1197	CD1	PHE	154	40.623	27.774	20.041
1198	CD2	PHE	154	41.705	25.787	19.219
1199	CE1	PHE	154	40.861	27.363	21.345
1200	CE2	PHE	154	41.946	25.379	20.523
1201	CZ	PHE	154	41.517	26.163	21.585
1202	N	TYR	155	38.948	27.412	14.696
1203	CA	TYR	155	39.098	27.093	13.273
1204	C	TYR	155	40.399	27.642	12.704
1205	O	TYR	155	40.728	28.823	12.878
1206	CB	TYR	155	37.925	27.670	12.498
1207	CG	TYR	155	36.878	26.626	12.143
1208	CD1	TYR	155	35.532	26.965	12.087
1209	CD2	TYR	155	37.283	25.325	11.871
1210	CE1	TYR	155	34.589	26.000	11.757
1211	CE2	TYR	155	36.343	24.360	11.541
1212	CZ	TYR	155	34.998	24.701	11.485
1213	OH	TYR	155	34.069	23.738	11.166
1214	N	ASN	156	41.072	26.784	11.958
1215	CA	ASN	156	42.381	27.092	11.379
1216	C	ASN	156	42.226	27.502	9.928
1217	O	ASN	156	41.957	26.676	9.053
1218	CB	ASN	156	43.217	25.821	11.428
1219	CG	ASN	156	44.698	26.066	11.163
1220	OD1	ASN	156	45.090	26.814	10.255
1221	ND2	ASN	156	45.506	25.410	11.975
1222	N	PHE	157	42.505	28.760	9.663
1223	CA	PHE	157	42.413	29.259	8.294
1224	C	PHE	157	43.786	29.501	7.672
1225	O	PHE	157	43.881	30.120	6.605
1226	CB	PHE	157	41.580	30.534	8.279
1227	CG	PHE	157	40.146	30.340	8.764
1228	CD1	PHE	157	39.321	29.410	8.144
1229	CD2	PHE	157	39.666	31.095	9.825
1230	CE1	PHE	157	38.016	29.235	8.586
1231	CE2	PHE	157	38.361	30.922	10.265

1232	CZ	PHE	157	37.536	29.992	9.646
1233	N	GLY	158	44.832	28.999	8.307
1234	CA	GLY	158	46.189	29.294	7.843
1235	C	GLY	158	46.902	28.091	7.240
1236	O	GLY	158	47.685	28.239	6.293
1237	N	TRP	159	46.672	26.924	7.814
1238	CA	TRP	159	47.369	25.725	7.348
1239	C	TRP	159	46.776	25.224	6.033
1240	O	TRP	159	45.568	24.991	5.916
1241	CB	TRP	159	47.249	24.653	8.424
1242	CG	TRP	159	48.486	23.794	8.580
1243	CD1	TRP	159	49.470	23.579	7.641
1244	CD2	TRP	159	48.873	23.051	9.756
1245	NE1	TRP	159	50.408	22.760	8.179
1246	CE2	TRP	159	50.094	22.428	9.445
1247	CE3	TRP	159	48.300	22.881	11.006
1248	CZ2	TRP	159	50.731	21.642	10.396
1249	CZ3	TRP	159	48.942	22.092	11.952
1250	CH2	TRP	159	50.152	21.475	11.649
1251	N	LYS	160	47.624	25.195	5.021
1252	CA	LYS	160	47.244	24.638	3.723
1253	C	LYS	160	47.419	23.122	3.765
1254	O	LYS	160	48.291	22.620	4.488
1255	CB	LYS	160	48.167	25.248	2.669
1256	CG	LYS	160	47.720	24.950	1.238
1257	CD	LYS	160	48.755	25.330	0.179
1258	CE	LYS	160	49.780	24.225	-0.106
1259	NZ	LYS	160	50.743	24.013	0.988
1260	N	ASP	161	46.556	22.404	3.060
1261	CA	ASP	161	46.691	20.945	2.953
1262	C	ASP	161	48.086	20.566	2.463
1263	O	ASP	161	48.620	21.144	1.507
1264	CB	ASP	161	45.627	20.370	2.014
1265	CG	ASP	161	45.747	20.900	0.582
1266	OD1	ASP	161	45.211	21.967	0.311
1267	OD2	ASP	161	46.358	20.212	-0.223
1268	N	TYR	162	48.697	19.685	3.240
1269	CA	TYR	162	50.052	19.168	3.003
1270	C	TYR	162	51.103	20.280	2.954
1271	O	TYR	162	51.941	20.310	2.046
1272	CB	TYR	162	50.059	18.374	1.697
1273	CG	TYR	162	49.043	17.233	1.651
1274	CD1	TYR	162	49.079	16.226	2.609
1275	CD2	TYR	162	48.082	17.204	0.647
1276	CE1	TYR	162	48.150	15.194	2.566
1277	CE2	TYR	162	47.153	16.172	0.603
1278	CZ	TYR	162	47.190	15.170	1.564
1279	OH	TYR	162	46.267	14.147	1.522
1280	N	GLY	163	51.052	21.184	3.919
1281	CA	GLY	163	52.056	22.251	3.988
1282	C	GLY	163	52.548	22.471	5.412
1283	O	GLY	163	52.355	21.627	6.297
1284	N	VAL	164	53.243	23.577	5.615
1285	CA	VAL	164	53.727	23.930	6.957
1286	C	VAL	164	53.446	25.394	7.294
1287	O	VAL	164	53.652	26.294	6.472
1288	CB	VAL	164	55.226	23.647	7.064
1289	CG1	VAL	164	55.522	22.159	7.235
1290	CG2	VAL	164	56.004	24.230	5.888
1291	N	ALA	165	52.895	25.602	8.477
1292	CA	ALA	165	52.682	26.960	8.987
1293	C	ALA	165	53.917	27.413	9.763
1294	O	ALA	165	54.829	26.612	10.000
1295	CB	ALA	165	51.446	26.974	9.880
1296	N	SER	166	53.981	28.696	10.081

1297	CA	SER	166	55.134	29.222	10.827
1298	C	SER	166	55.206	28.591	12.210
1299	O	SER	166	54.179	28.208	12.787
1300	CB	SER	166	55.016	30.733	11.008
1301	OG	SER	166	54.381	30.978	12.260
1302	N	LEU	167	56.401	28.624	12.777
1303	CA	LEU	167	56.646	28.091	14.124
1304	C	LEU	167	55.706	28.734	15.133
1305	O	LEU	167	54.831	28.050	15.675
1306	CB	LEU	167	58.081	28.394	14.575
1307	CG	LEU	167	59.173	27.486	14.000
1308	CD1	LEU	167	59.566	27.847	12.568
1309	CD2	LEU	167	60.417	27.574	14.877
1310	N	THR	168	55.665	30.056	15.110
1311	CA	THR	168	54.860	30.796	16.086
1312	C	THR	168	53.347	30.667	15.887
1313	O	THR	168	52.653	30.557	16.905
1314	CB	THR	168	55.270	32.261	16.033
1315	OG1	THR	168	54.985	32.775	14.736
1316	CG2	THR	168	56.764	32.402	16.293
1317	N	THR	169	52.866	30.447	14.668
1318	CA	THR	169	51.425	30.226	14.487
1319	C	THR	169	50.988	28.809	14.853
1320	O	THR	169	49.834	28.611	15.248
1321	CB	THR	169	51.041	30.496	13.036
1322	OG1	THR	169	51.736	29.580	12.202
1323	CG2	THR	169	51.404	31.909	12.603
1324	N	ILE	170	51.907	27.860	14.871
1325	CA	ILE	170	51.524	26.527	15.321
1326	C	ILE	170	51.658	26.442	16.834
1327	O	ILE	170	50.764	25.907	17.503
1328	CB	ILE	170	52.425	25.484	14.670
1329	CG1	ILE	170	52.401	25.606	13.152
1330	CG2	ILE	170	51.985	24.083	15.080
1331	CD1	ILE	170	53.336	24.592	12.503
1332	N	LEU	171	52.593	27.206	17.374
1333	CA	LEU	171	52.840	27.147	18.816
1334	C	LEU	171	51.840	27.976	19.612
1335	O	LEU	171	51.397	27.517	20.672
1336	CB	LEU	171	54.261	27.611	19.105
1337	CG	LEU	171	55.280	26.719	18.403
1338	CD1	LEU	171	56.698	27.206	18.659
1339	CD2	LEU	171	55.126	25.258	18.811
1340	N	ASP	172	51.303	29.033	19.023
1341	CA	ASP	172	50.250	29.760	19.736
1342	C	ASP	172	48.896	29.081	19.525
1343	O	ASP	172	48.082	29.077	20.455
1344	CB	ASP	172	50.214	31.248	19.350
1345	CG	ASP	172	49.557	31.556	18.001
1346	OD1	ASP	172	49.834	30.852	17.044
1347	OD2	ASP	172	48.884	32.576	17.929
1348	N	MET	173	48.792	28.266	18.484
1349	CA	MET	173	47.564	27.508	18.254
1350	C	MET	173	47.456	26.354	19.245
1351	O	MET	173	46.462	26.274	19.980
1352	CB	MET	173	47.595	26.952	16.833
1353	CG	MET	173	46.286	26.292	16.397
1354	SD	MET	173	44.923	27.378	15.898
1355	CE	MET	173	44.327	27.971	17.498
1356	N	VAL	174	48.568	25.667	19.470
1357	CA	VAL	174	48.554	24.541	20.410
1358	C	VAL	174	48.621	24.973	21.875
1359	O	VAL	174	48.155	24.217	22.733
1360	CB	VAL	174	49.698	23.575	20.103
1361	CG1	VAL	174	49.528	22.933	18.735

1362	CG2	VAL	174	51.070	24.225	20.219
1363	N	LYS	175	48.941	26.231	22.137
1364	CA	LYS	175	48.966	26.709	23.520
1365	C	LYS	175	47.573	27.157	23.972
1366	O	LYS	175	47.325	27.310	25.173
1367	CB	LYS	175	49.966	27.858	23.613
1368	CG	LYS	175	50.843	27.759	24.861
1369	CD	LYS	175	50.068	28.004	26.150
1370	CE	LYS	175	50.857	27.559	27.372
1371	NZ	LYS	175	51.160	26.121	27.291
1372	N	VAL	176	46.641	27.274	23.040
1373	CA	VAL	176	45.268	27.575	23.441
1374	C	VAL	176	44.443	26.286	23.556
1375	O	VAL	176	43.335	26.301	24.110
1376	CB	VAL	176	44.659	28.544	22.428
1377	CG1	VAL	176	43.342	29.119	22.938
1378	CG2	VAL	176	45.615	29.697	22.155
1379	N	MET	177	45.023	25.166	23.148
1380	CA	MET	177	44.303	23.887	23.195
1381	C	MET	177	44.238	23.299	24.602
1382	O	MET	177	45.236	22.830	25.161
1383	CB	MET	177	44.991	22.893	22.268
1384	CG	MET	177	44.920	23.350	20.817
1385	SD	MET	177	45.681	22.240	19.613
1386	CE	MET	177	45.300	23.164	18.107
1387	N	THR	178	43.034	23.311	25.148
1388	CA	THR	178	42.785	22.687	26.449
1389	C	THR	178	42.695	21.175	26.275
1390	O	THR	178	41.769	20.664	25.637
1391	CB	THR	178	41.473	23.232	27.004
1392	OG1	THR	178	41.603	24.643	27.118
1393	CG2	THR	178	41.161	22.671	28.388
1394	N	PHE	179	43.670	20.476	26.832
1395	CA	PHE	179	43.723	19.020	26.675
1396	C	PHE	179	42.899	18.305	27.744
1397	O	PHE	179	42.239	17.305	27.441
1398	CB	PHE	179	45.182	18.599	26.783
1399	CG	PHE	179	45.605	17.563	25.750
1400	CD1	PHE	179	45.058	17.599	24.474
1401	CD2	PHE	179	46.546	16.595	26.074
1402	CE1	PHE	179	45.446	16.663	23.524
1403	CE2	PHE	179	46.933	15.660	25.124
1404	CZ	PHE	179	46.384	15.693	23.849
1405	N	ALA	180	42.832	18.924	28.917
1406	CA	ALA	180	42.058	18.435	30.076
1407	C	ALA	180	42.026	16.914	30.225
1408	O	ALA	180	41.072	16.267	29.774
1409	CB	ALA	180	40.634	18.967	29.962
1410	N	LEU	181	42.892	16.407	31.091
1411	CA	LEU	181	43.068	14.951	31.266
1412	C	LEU	181	42.018	14.314	32.199
1413	O	LEU	181	42.150	13.159	32.618
1414	CB	LEU	181	44.482	14.717	31.797
1415	CG	LEU	181	44.962	13.284	31.576
1416	CD1	LEU	181	44.904	12.909	30.099
1417	CD2	LEU	181	46.370	13.084	32.128
1418	N	GLN	182	41.006	15.088	32.558
1419	CA	GLN	182	39.898	14.583	33.363
1420	C	GLN	182	38.719	14.224	32.460
1421	O	GLN	182	37.697	13.711	32.931
1422	CB	GLN	182	39.495	15.690	34.327
1423	CG	GLN	182	40.682	16.109	35.188
1424	CD	GLN	182	40.349	17.383	35.956
1425	OE1	GLN	182	39.583	18.225	35.476
1426	NE2	GLN	182	40.996	17.549	37.096

1427	N	GLU	183	38.840	14.551	31.183
1428	CA	GLU	183	37.771	14.260	30.223
1429	C	GLU	183	38.265	13.284	29.161
1430	O	GLU	183	39.333	12.679	29.312
1431	CB	GLU	183	37.271	15.551	29.572
1432	CG	GLU	183	36.287	16.343	30.444
1433	CD	GLU	183	36.963	17.180	31.533
1434	OE1	GLU	183	36.262	17.593	32.444
1435	OE2	GLU	183	38.143	17.472	31.381
1436	N	GLY	184	37.472	13.111	28.118
1437	CA	GLY	184	37.827	12.176	27.051
1438	C	GLY	184	38.821	12.792	26.077
1439	O	GLY	184	39.341	13.897	26.285
1440	N	LYS	185	39.074	12.052	25.013
1441	CA	LYS	185	40.052	12.451	23.992
1442	C	LYS	185	39.645	13.740	23.291
1443	O	LYS	185	38.475	14.140	23.312
1444	CB	LYS	185	40.179	11.368	22.916
1445	CG	LYS	185	40.876	10.079	23.355
1446	CD	LYS	185	39.952	9.039	23.985
1447	CE	LYS	185	38.873	8.586	23.011
1448	NZ	LYS	185	38.014	7.560	23.620
1449	N	VAL	186	40.632	14.439	22.766
1450	CA	VAL	186	40.337	15.581	21.896
1451	C	VAL	186	40.268	15.048	20.459
1452	O	VAL	186	40.880	14.009	20.180
1453	CB	VAL	186	41.444	16.611	22.095
1454	CG1	VAL	186	42.714	16.224	21.343
1455	CG2	VAL	186	40.986	18.009	21.701
1456	N	ALA	187	39.449	15.633	19.599
1457	CA	ALA	187	39.310	15.068	18.244
1458	C	ALA	187	39.915	15.942	17.149
1459	O	ALA	187	39.243	16.836	16.633
1460	CB	ALA	187	37.830	14.857	17.952
1461	N	ILE	188	41.104	15.583	16.700
1462	CA	ILE	188	41.822	16.361	15.679
1463	C	ILE	188	41.389	15.903	14.292
1464	O	ILE	188	41.661	14.757	13.916
1465	CB	ILE	188	43.303	16.068	15.867
1466	CG1	ILE	188	43.645	16.132	17.346
1467	CG2	ILE	188	44.165	17.048	15.077
1468	CD1	ILE	188	45.105	15.801	17.583
1469	N	HIS	189	40.809	16.793	13.511
1470	CA	HIS	189	40.123	16.322	12.310
1471	C	HIS	189	40.218	17.235	11.076
1472	O	HIS	189	40.412	18.452	11.201
1473	CB	HIS	189	38.666	16.150	12.734
1474	CG	HIS	189	37.645	16.907	11.916
1475	ND1	HIS	189	36.854	16.388	10.962
1476	CD2	HIS	189	37.343	18.245	12.007
1477	CE1	HIS	189	36.081	17.366	10.449
1478	NE2	HIS	189	36.380	18.512	11.098
1479	N	CYS	190	40.267	16.579	9.918
1480	CA	CYS	190	39.981	17.179	8.591
1481	C	CYS	190	40.238	16.212	7.439
1482	O	CYS	190	39.808	15.059	7.500
1483	CB	CYS	190	40.651	18.521	8.306
1484	SG	CYS	190	39.629	19.964	8.719
1485	N	HIS	191	41.024	16.646	6.462
1486	CA	HIS	191	41.066	16.005	5.128
1487	C	HIS	191	41.406	14.514	5.072
1488	O	HIS	191	40.917	13.830	4.165
1489	CB	HIS	191	42.094	16.759	4.301
1490	CG	HIS	191	41.915	16.692	2.796
1491	ND1	HIS	191	40.837	16.247	2.123

1492	CD2	HIS	191	42.834	17.096	1.856
1493	CE1	HIS	191	41.058	16.361	0.796
1494	NE2	HIS	191	42.293	16.888	0.633
1495	N	ALA	192	42.169	14.000	6.020
1496	CA	ALA	192	42.425	12.564	6.015
1497	C	ALA	192	42.543	11.995	7.425
1498	O	ALA	192	41.792	11.092	7.814
1499	CB	ALA	192	43.710	12.303	5.240
1500	N	GLY	193	43.521	12.502	8.155
1501	CA	GLY	193	43.855	11.952	9.468
1502	C	GLY	193	45.374	11.866	9.584
1503	O	GLY	193	45.935	11.748	10.677
1504	N	LEU	194	46.025	11.919	8.436
1505	CA	LEU	194	47.486	11.976	8.389
1506	C	LEU	194	47.978	13.408	8.189
1507	O	LEU	194	47.199	14.364	8.323
1508	CB	LEU	194	47.962	11.051	7.272
1509	CG	LEU	194	47.154	11.149	5.974
1510	CD1	LEU	194	47.563	12.342	5.111
1511	CD2	LEU	194	47.327	9.872	5.163
1512	N	GLY	195	49.288	13.538	8.046
1513	CA	GLY	195	49.927	14.801	7.650
1514	C	GLY	195	49.977	15.824	8.774
1515	O	GLY	195	50.637	15.643	9.806
1516	N	ARG	196	49.081	16.787	8.646
1517	CA	ARG	196	48.978	17.886	9.603
1518	C	ARG	196	48.322	17.443	10.904
1519	O	ARG	196	48.654	18.000	11.955
1520	CB	ARG	196	48.128	18.967	8.956
1521	CG	ARG	196	48.810	19.526	7.717
1522	CD	ARG	196	47.793	20.137	6.766
1523	NE	ARG	196	46.986	19.058	6.181
1524	CZ	ARG	196	45.667	18.928	6.324
1525	NH1	ARG	196	44.983	19.818	7.043
1526	NH2	ARG	196	45.036	17.897	5.764
1527	N	THR	197	47.639	16.307	10.874
1528	CA	THR	197	47.051	15.770	12.106
1529	C	THR	197	48.178	15.219	12.966
1530	O	THR	197	48.372	15.661	14.108
1531	CB	THR	197	46.113	14.611	11.787
1532	OG1	THR	197	45.332	14.898	10.637
1533	CG2	THR	197	45.181	14.306	12.952
1534	N	GLY	198	49.064	14.504	12.286
1535	CA	GLY	198	50.254	13.915	12.899
1536	C	GLY	198	51.148	14.995	13.489
1537	O	GLY	198	51.301	15.042	14.716
1538	N	VAL	199	51.495	15.978	12.671
1539	CA	VAL	199	52.389	17.064	13.107
1540	C	VAL	199	51.831	17.887	14.267
1541	O	VAL	199	52.541	18.074	15.263
1542	CB	VAL	199	52.607	18.018	11.935
1543	CG1	VAL	199	53.525	19.175	12.315
1544	CG2	VAL	199	53.162	17.298	10.718
1545	N	LEU	200	50.535	18.156	14.250
1546	CA	LEU	200	49.937	19.032	15.260
1547	C	LEU	200	49.958	18.397	16.646
1548	O	LEU	200	50.546	18.976	17.572
1549	CB	LEU	200	48.501	19.308	14.833
1550	CG	LEU	200	47.866	20.429	15.646
1551	CD1	LEU	200	48.671	21.714	15.513
1552	CD2	LEU	200	46.431	20.658	15.191
1553	N	ILE	201	49.574	17.133	16.725
1554	CA	ILE	201	49.565	16.485	18.038
1555	C	ILE	201	50.939	15.940	18.416
1556	O	ILE	201	51.251	15.910	19.609

1557	CB	ILE	201	48.522	15.371	18.065
1558	CG1	ILE	201	48.510	14.636	19.395
1559	CG2	ILE	201	48.747	14.392	16.921
1560	CD1	ILE	201	47.526	13.469	19.398
1561	N	ALA	200	51.836	15.794	17.458
1562	CA	ALA	200	53.167	15.313	17.798
1563	C	ALA	200	54.113	16.437	18.228
1564	O	ALA	200	55.036	16.173	19.012
1565	CB	ALA	200	53.716	14.528	16.615
1566	N	CYS	203	53.768	17.681	17.924
1567	CA	CYS	203	54.506	18.803	18.522
1568	C	CYS	203	54.186	18.848	20.008
1569	O	CYS	203	55.092	18.732	20.846
1570	CB	CYS	203	54.044	20.150	17.965
1571	SG	CYS	203	54.255	20.541	16.215
1572	N	TYR	204	52.901	18.691	20.289
1573	CA	TYR	204	52.381	18.790	21.653
1574	C	TYR	204	52.749	17.561	22.485
1575	O	TYR	204	53.101	17.701	23.662
1576	CB	TYR	204	50.864	18.893	21.507
1577	CG	TYR	204	50.116	19.555	22.660
1578	CD1	TYR	204	50.148	20.938	22.789
1579	CD2	TYR	204	49.398	18.789	23.569
1580	CE1	TYR	204	49.449	21.556	23.815
1581	CE2	TYR	204	48.698	19.407	24.596
1582	CZ	TYR	204	48.717	20.790	24.711
1583	OH	TYR	204	47.900	21.415	25.632
1584	N	LEU	205	52.906	16.431	21.818
1585	CA	LEU	205	53.356	15.200	22.469
1586	C	LEU	205	54.809	15.287	22.905
1587	O	LEU	205	55.090	15.078	24.090
1588	CB	LEU	205	53.221	14.057	21.469
1589	CG	LEU	205	53.947	12.800	21.938
1590	CD1	LEU	205	53.322	12.211	23.199
1591	CD2	LEU	205	53.993	11.765	20.824
1592	N	VAL	206	55.672	15.817	22.055
1593	CA	VAL	206	57.088	15.847	22.410
1594	C	VAL	206	57.393	16.985	23.378
1595	O	VAL	206	58.169	16.766	24.318
1596	CB	VAL	206	57.900	15.968	21.131
1597	CG1	VAL	206	59.388	16.041	21.436
1598	CG2	VAL	206	57.610	14.782	20.220
1599	N	PHE	207	56.547	18.003	23.359
1600	CA	PHE	207	56.645	19.108	24.318
1601	C	PHE	207	56.094	18.744	25.700
1602	O	PHE	207	56.551	19.302	26.705
1603	CB	PHE	207	55.851	20.278	23.739
1604	CG	PHE	207	55.550	21.412	24.716
1605	CD1	PHE	207	54.280	21.522	25.271
1606	CD2	PHE	207	56.532	22.338	25.041
1607	CE1	PHE	207	53.997	22.549	26.162
1608	CE2	PHE	207	56.247	23.366	25.930
1609	CZ	PHE	207	54.981	23.470	26.492
1610	N	ALA	208	55.203	17.768	25.765
1611	CA	ALA	208	54.683	17.326	27.059
1612	C	ALA	208	55.512	16.177	27.620
1613	O	ALA	208	55.587	15.994	28.842
1614	CB	ALA	208	53.240	16.870	26.879
1615	N	THR	209	56.200	15.477	26.734
1616	CA	THR	209	57.076	14.388	27.154
1617	C	THR	209	58.424	14.948	27.589
1618	O	THR	209	58.584	15.171	28.799
1619	CB	THR	209	57.205	13.376	26.017
1620	OG1	THR	209	55.894	12.910	25.726
1621	CG2	THR	209	58.034	12.158	26.414

1622	N	ARG	210	59.269	15.261	26.607
1623	CA	ARG	210	60.654	15.787	26.732
1624	C	ARG	210	61.591	15.051	25.762
1625	O	ARG	210	62.702	15.514	25.476
1626	CB	ARG	210	61.214	15.596	28.142
1627	CG	ARG	210	62.513	16.344	28.397
1628	CD	ARG	210	63.009	16.054	29.806
1629	NE	ARG	210	63.160	14.602	29.997
1630	CZ	ARG	210	64.308	14.029	30.363
1631	NH1	ARG	210	64.399	12.699	30.423
1632	NH2	ARG	210	65.386	14.783	30.593
1633	N	MET	211	61.107	13.959	25.191
1634	CA	MET	211	62.011	13.028	24.496
1635	C	MET	211	61.987	13.101	22.970
1636	O	MET	211	61.642	14.125	22.372
1637	CB	MET	211	61.716	11.610	24.965
1638	CG	MET	211	62.045	11.464	26.447
1639	SD	MET	211	61.917	9.793	27.118
1640	CE	MET	211	63.095	8.963	26.025
1641	N	THR	212	62.472	12.025	22.370
1642	CA	THR	212	62.704	11.973	20.917
1643	C	THR	212	61.428	11.990	20.078
1644	O	THR	212	60.654	11.022	20.036
1645	CB	THR	212	63.516	10.724	20.582
1646	OG1	THR	212	62.793	9.578	21.008
1647	CG2	THR	212	64.862	10.723	21.296
1648	N	ALA	213	61.417	12.955	19.174
1649	CA	ALA	213	60.283	13.143	18.268
1650	C	ALA	213	60.223	12.096	17.160
1651	O	ALA	213	59.122	11.690	16.784
1652	CB	ALA	213	60.405	14.527	17.641
1653	N	ASP	214	61.346	11.453	16.882
1654	CA	ASP	214	61.392	10.442	15.820
1655	C	ASP	214	60.791	9.111	16.267
1656	O	ASP	214	60.036	8.495	15.505
1657	CB	ASP	214	62.851	10.221	15.434
1658	CG	ASP	214	63.484	11.524	14.953
1659	OD1	ASP	214	64.100	12.192	15.774
1660	OD2	ASP	214	63.304	11.851	13.789
1661	N	GLN	215	60.890	8.823	17.556
1662	CA	GLN	215	60.332	7.569	18.062
1663	C	GLN	215	58.864	7.766	18.406
1664	O	GLN	215	58.042	6.877	18.144
1665	CB	GLN	215	61.126	7.135	19.285
1666	CG	GLN	215	62.579	6.874	18.905
1667	CD	GLN	215	63.393	6.499	20.138
1668	OE1	GLN	215	62.988	6.770	21.273
1669	NE2	GLN	215	64.561	5.930	19.896
1670	N	ALA	216	58.519	9.022	18.639
1671	CA	ALA	216	57.124	9.399	18.840
1672	C	ALA	216	56.364	9.429	17.515
1673	O	ALA	216	55.193	9.035	17.482
1674	CB	ALA	216	57.103	10.783	19.475
1675	N	ILE	217	57.084	9.610	16.419
1676	CA	ILE	217	56.467	9.571	15.091
1677	C	ILE	217	56.199	8.148	14.627
1678	O	ILE	217	55.099	7.882	14.127
1679	CB	ILE	217	57.383	10.289	14.106
1680	CG1	ILE	217	57.254	11.793	14.297
1681	CG2	ILE	217	57.084	9.895	12.666
1682	CD1	ILE	217	55.788	12.204	14.249
1683	N	ILE	218	57.014	7.210	15.082
1684	CA	ILE	218	56.752	5.808	14.753
1685	C	ILE	218	55.648	5.250	15.648
1686	O	ILE	218	54.806	4.482	15.170

1687	CB	ILE	218	58.040	5.015	14.932
1688	CG1	ILE	218	59.150	5.614	14.077
1689	CG2	ILE	218	57.828	3.550	14.565
1690	CD1	ILE	218	60.463	4.863	14.268
1691	N	PHE	219	55.467	5.878	16.799
1692	CA	PHE	219	54.383	5.500	17.707
1693	C	PHE	219	53.045	6.102	17.253
1694	O	PHE	219	51.998	5.458	17.396
1695	CB	PHE	219	54.774	6.017	19.086
1696	CG	PHE	219	54.100	5.316	20.258
1697	CD1	PHE	219	53.657	4.006	20.127
1698	CD2	PHE	219	53.951	5.983	21.466
1699	CE1	PHE	219	53.051	3.369	21.201
1700	CE2	PHE	219	53.345	5.346	22.540
1701	CZ	PHE	219	52.894	4.040	22.406
1702	N	VAL	220	53.122	7.177	16.482
1703	CA	VAL	220	51.942	7.783	15.849
1704	C	VAL	220	51.517	7.005	14.602
1705	O	VAL	220	50.322	6.913	14.291
1706	CB	VAL	220	52.323	9.217	15.479
1707	CG1	VAL	220	51.462	9.805	14.369
1708	CG2	VAL	220	52.339	10.123	16.705
1709	N	ARG	221	52.459	6.272	14.037
1710	CA	ARG	221	52.173	5.371	12.922
1711	C	ARG	221	51.741	3.979	13.380
1712	O	ARG	221	51.435	3.133	12.530
1713	CB	ARG	221	53.448	5.218	12.110
1714	CG	ARG	221	53.920	6.543	11.536
1715	CD	ARG	221	55.208	6.352	10.748
1716	NE	ARG	221	55.636	7.604	10.111
1717	CZ	ARG	221	55.365	7.904	8.839
1718	NH1	ARG	221	54.633	7.069	8.098
1719	NH2	ARG	221	55.808	9.047	8.315
1720	N	ALA	222	51.664	3.754	14.683
1721	CA	ALA	222	51.379	2.412	15.198
1722	C	ALA	222	49.900	2.040	15.278
1723	O	ALA	222	49.584	0.854	15.429
1724	CB	ALA	222	52.005	2.283	16.582
1725	N	LYS	223	49.004	3.005	15.150
1726	CA	LYS	223	47.575	2.667	15.191
1727	C	LYS	223	46.885	2.938	13.857
1728	O	LYS	223	45.687	2.667	13.693
1729	CB	LYS	223	46.900	3.472	16.291
1730	CG	LYS	223	47.630	3.317	17.618
1731	CD	LYS	223	46.938	4.095	18.726
1732	CE	LYS	223	47.809	4.139	19.974
1733	NZ	LYS	223	49.073	4.837	19.697
1734	N	ARG	224	47.666	3.431	12.912
1735	CA	ARG	224	47.147	3.846	11.607
1736	C	ARG	224	48.321	4.292	10.752
1737	O	ARG	224	49.103	5.146	11.190
1738	CB	ARG	224	46.204	5.033	11.801
1739	CG	ARG	224	45.387	5.352	10.551
1740	CD	ARG	224	44.553	6.612	10.753
1741	NE	ARG	224	43.516	6.749	9.718
1742	CZ	ARG	224	42.332	7.317	9.960
1743	NH1	ARG	224	42.083	7.852	11.157
1744	NH2	ARG	224	41.408	7.379	9.001
1745	N	PRO	225	48.481	3.675	9.594
1746	CA	PRO	225	49.468	4.142	8.619
1747	C	PRO	225	49.187	5.576	8.169
1748	O	PRO	225	48.168	5.854	7.529
1749	CB	PRO	225	49.373	3.178	7.476
1750	CG	PRO	225	48.264	2.175	7.752
1751	CD	PRO	225	47.681	2.550	9.103

1752	N	ASN	226	50.051	6.484	8.590
1753	CA	ASN	226	49.907	7.893	8.213
1754	C	ASN	226	51.166	8.475	7.572
1755	O	ASN	226	51.836	7.819	6.767
1756	CB	ASN	226	49.475	8.710	9.432
1757	CG	ASN	226	50.246	8.368	10.705
1758	OD1	ASN	226	51.482	8.407	10.751
1759	ND2	ASN	226	49.477	8.208	11.763
1760	N	SER	227	51.397	9.745	7.864
1761	CA	SER	227	52.518	10.508	7.301
1762	C	SER	227	52.726	11.761	8.141
1763	O	SER	227	51.771	12.228	8.774
1764	CB	SER	227	52.179	10.912	5.871
1765	OG	SER	227	51.010	11.718	5.921
1766	N	ILE	228	53.915	12.338	8.076
1767	CA	ILE	228	54.200	13.523	8.888
1768	C	ILE	228	55.332	14.377	8.291
1769	O	ILE	228	56.360	13.864	7.824
1770	CB	ILE	228	54.507	13.008	10.301
1771	CG1	ILE	228	54.609	14.098	11.363
1772	CG2	ILE	228	55.779	12.168	10.300
1773	CD1	ILE	228	56.030	14.622	11.522
1774	N	GLN	229	55.062	15.672	8.204
1775	CA	GLN	229	56.072	16.676	7.810
1776	C	GLN	229	57.048	16.881	8.970
1777	O	GLN	229	56.891	17.816	9.770
1778	CB	GLN	229	55.411	18.023	7.490
1779	CG	GLN	229	54.343	17.983	6.390
1780	CD	GLN	229	52.947	17.774	6.981
1781	OE1	GLN	229	52.486	16.635	7.123
1782	NE2	GLN	229	52.279	18.870	7.287
1783	N	THR	230	58.161	16.171	8.910
1784	CA	THR	230	59.014	16.015	10.092
1785	C	THR	230	59.873	17.229	10.407
1786	O	THR	230	59.963	17.584	11.587
1787	CB	THR	230	59.896	14.792	9.874
1788	OG1	THR	230	59.044	13.696	9.563
1789	CG2	THR	230	60.705	14.438	11.119
1790	N	ARG	231	60.223	18.023	9.408
1791	CA	ARG	231	61.030	19.217	9.700
1792	C	ARG	231	60.161	20.356	10.238
1793	O	ARG	231	60.612	21.111	11.111
1794	CB	ARG	231	61.757	19.675	8.444
1795	CG	ARG	231	62.753	20.779	8.786
1796	CD	ARG	231	63.495	21.289	7.557
1797	NE	ARG	231	64.480	22.312	7.943
1798	CZ	ARG	231	64.289	23.622	7.765
1799	NH1	ARG	231	63.177	24.062	7.171
1800	NH2	ARG	231	65.223	24.491	8.157
1801	N	GLY	232	58.870	20.269	9.954
1802	CA	GLY	232	57.906	21.230	10.483
1803	C	GLY	232	57.764	20.996	11.979
1804	O	GLY	232	58.006	21.913	12.774
1805	N	GLN	233	57.638	19.730	12.346
1806	CA	GLN	233	57.517	19.368	13.759
1807	C	GLN	233	58.840	19.487	14.525
1808	O	GLN	233	58.814	19.807	15.720
1809	CB	GLN	233	57.028	17.933	13.848
1810	CG	GLN	233	56.808	17.533	15.300
1811	CD	GLN	233	56.588	16.036	15.379
1812	OE1	GLN	233	55.971	15.445	14.486
1813	NE2	GLN	233	57.073	15.444	16.456
1814	N	LEU	234	59.965	19.441	13.831
1815	CA	LEU	234	61.251	19.663	14.498
1816	C	LEU	234	61.388	21.116	14.934

1817	O	LEU	234	61.561	21.367	16.133
1818	CB	LEU	234	62.386	19.307	13.549
1819	CG	LEU	234	62.499	17.804	13.337
1820	CD1	LEU	234	63.564	17.482	12.295
1821	CD2	LEU	234	62.791	17.087	14.651
1822	N	LEU	235	61.009	22.030	14.055
1823	CA	LEU	235	61.052	23.462	14.382
1824	C	LEU	235	59.991	23.830	15.420
1825	O	LEU	235	60.292	24.524	16.403
1826	CB	LEU	235	60.771	24.230	13.096
1827	CG	LEU	235	61.899	24.100	12.080
1828	CD1	LEU	235	61.433	24.513	10.689
1829	CD2	LEU	235	63.115	24.912	12.510
1830	N	CYS	236	58.863	23.145	15.321
1831	CA	CYS	236	57.731	23.292	16.241
1832	C	CYS	236	58.148	22.984	17.676
1833	O	CYS	236	58.174	23.884	18.528
1834	CB	CYS	236	56.717	22.245	15.784
1835	SG	CYS	236	54.977	22.428	16.227
1836	N	VAL	237	58.724	21.807	17.856
1837	CA	VAL	237	59.107	21.361	19.193
1838	C	VAL	237	60.335	22.087	19.730
1839	O	VAL	237	60.288	22.536	20.881
1840	CB	VAL	237	59.393	19.866	19.138
1841	CG1	VAL	237	59.988	19.373	20.451
1842	CG2	VAL	237	58.137	19.078	18.788
1843	N	ARG	238	61.260	22.468	18.863
1844	CA	ARG	238	62.478	23.114	19.358
1845	C	ARG	238	62.259	24.558	19.797
1846	O	ARG	238	62.926	24.995	20.743
1847	CB	ARG	238	63.563	23.055	18.291
1848	CG	ARG	238	64.036	21.621	18.081
1849	CD	ARG	238	65.218	21.556	17.123
1850	NE	ARG	238	64.868	22.091	15.798
1851	CZ	ARG	238	65.183	21.462	14.665
1852	NH1	ARG	238	64.849	21.996	13.489
1853	NH2	ARG	238	65.833	20.297	14.707
1854	N	GLU	239	61.224	25.211	19.294
1855	CA	GLU	239	60.937	26.558	19.784
1856	C	GLU	239	59.984	26.516	20.979
1857	O	GLU	239	60.149	27.300	21.923
1858	CB	GLU	239	60.317	27.376	18.658
1859	CG	GLU	239	60.272	28.867	18.988
1860	CD	GLU	239	61.632	29.523	18.734
1861	OE1	GLU	239	62.520	28.794	18.306
1862	OE2	GLU	239	61.628	30.739	18.600
1863	N	PHE	240	59.178	25.470	21.061
1864	CA	PHE	240	58.205	25.384	22.155
1865	C	PHE	240	58.848	24.846	23.432
1866	O	PHE	240	58.475	25.258	24.537
1867	CB	PHE	240	57.067	24.474	21.715
1868	CG	PHE	240	55.720	24.821	22.340
1869	CD1	PHE	240	55.523	26.072	22.912
1870	CD2	PHE	240	54.683	23.898	22.316
1871	CE1	PHE	240	54.294	26.393	23.474
1872	CE2	PHE	240	53.455	24.219	22.878
1873	CZ	PHE	240	53.261	25.466	23.459
1874	N	THR	241	59.968	24.162	23.268
1875	CA	THR	241	60.747	23.709	24.427
1876	C	THR	241	61.567	24.827	25.066
1877	O	THR	241	61.885	24.710	26.253
1878	CB	THR	241	61.685	22.575	24.028
1879	OG1	THR	241	62.454	22.992	22.905
1880	CG2	THR	241	60.919	21.311	23.655
1881	N	GLN	242	61.686	25.969	24.406

1882	CA	GLN	242	62.369	27.114	25.016
1883	C	GLN	242	61.419	27.821	25.981
1884	O	GLN	242	61.806	28.164	27.108
1885	CB	GLN	242	62.748	28.062	23.892
1886	CG	GLN	242	63.592	27.365	22.837
1887	CD	GLN	242	63.619	28.214	21.573
1888	OE1	GLN	242	62.789	29.116	21.400
1889	NE2	GLN	242	64.482	27.833	20.649
1890	N	PHE	243	60.141	27.719	25.648
1891	CA	PHE	243	59.070	28.208	26.515
1892	C	PHE	243	58.905	27.312	27.737
1893	O	PHE	243	58.722	27.804	28.858
1894	CB	PHE	243	57.781	28.203	25.694
1895	CG	PHE	243	56.495	28.262	26.512
1896	CD1	PHE	243	55.812	27.090	26.815
1897	CD2	PHE	243	55.996	29.482	26.939
1898	CE1	PHE	243	54.649	27.137	27.570
1899	CE2	PHE	243	54.830	29.530	27.692
1900	CZ	PHE	243	54.160	28.358	28.013
1901	N	LEU	244	59.192	26.035	27.547
1902	CA	LEU	244	59.078	25.073	28.637
1903	C	LEU	244	60.281	25.136	29.575
1904	O	LEU	244	60.124	24.955	30.788
1905	CB	LEU	244	59.005	23.685	28.010
1906	CG	LEU	244	58.760	22.589	29.040
1907	CD1	LEU	244	57.442	22.817	29.773
1908	CD2	LEU	244	58.772	21.215	28.380
1909	N	THR	245	61.445	25.483	29.052
1910	CA	THR	245	62.631	25.506	29.913
1911	C	THR	245	63.461	26.790	29.845
1912	O	THR	245	64.191	27.044	28.880
1913	CB	THR	245	63.536	24.318	29.576
1914	OG1	THR	245	63.864	24.360	28.194
1915	CG2	THR	245	62.876	22.973	29.859
1916	N	PRO	246	63.363	27.578	30.903
1917	CA	PRO	246	62.130	27.756	31.682
1918	C	PRO	246	61.264	28.938	31.202
1919	O	PRO	246	60.512	29.493	32.015
1920	CB	PRO	246	62.677	28.110	33.029
1921	CG	PRO	246	64.034	28.776	32.803
1922	CD	PRO	246	64.353	28.571	31.325
1923	N	LEU	247	61.440	29.408	29.975
1924	CA	LEU	247	60.953	30.753	29.656
1925	C	LEU	247	59.526	30.783	29.120
1926	O	LEU	247	59.300	30.898	27.907
1927	CB	LEU	247	61.916	31.394	28.667
1928	CG	LEU	247	61.737	32.908	28.636
1929	CD1	LEU	247	61.841	33.491	30.040
1930	CD2	LEU	247	62.756	33.559	27.710
1931	N	ARG	248	58.631	31.077	30.051
1932	CA	ARG	248	57.195	31.190	29.765
1933	C	ARG	248	56.831	32.488	29.030
1934	O	ARG	248	55.842	32.521	28.282
1935	CB	ARG	248	56.460	31.117	31.100
1936	CG	ARG	248	54.948	31.075	30.919
1937	CD	ARG	248	54.231	30.896	32.252
1938	NE	ARG	248	52.782	30.741	32.046
1939	CZ	ARG	248	52.157	29.563	32.113
1940	NH1	ARG	248	52.846	28.454	32.392
1941	NH2	ARG	248	50.839	29.494	31.909
1942	N	ASN	249	57.792	33.399	28.964
1943	CA	ASN	249	57.619	34.659	28.233
1944	C	ASN	249	57.754	34.469	26.719
1945	O	ASN	249	57.318	35.338	25.955
1946	CB	ASN	249	58.682	35.655	28.690

1947	CG	ASN	249	58.612	35.938	30.192
1948	OD1	ASN	249	57.616	35.656	30.868
1949	ND2	ASN	249	59.692	36.509	30.697
1950	N	ILE	250	58.147	33.279	26.287
1951	CA	ILE	250	58.235	33.000	24.855
1952	C	ILE	250	56.867	32.748	24.218
1953	O	ILE	250	56.710	33.081	23.039
1954	CB	ILE	250	59.194	31.832	24.650
1955	CG1	ILE	250	60.592	32.291	25.035
1956	CG2	ILE	250	59.185	31.311	23.217
1957	CD1	ILE	250	61.640	31.230	24.746
1958	N	PHE	251	55.832	32.538	25.020
1959	CA	PHE	251	54.483	32.489	24.441
1960	C	PHE	251	53.999	33.904	24.120
1961	O	PHE	251	53.466	34.132	23.027
1962	CB	PHE	251	53.523	31.842	25.429
1963	CG	PHE	251	52.080	31.775	24.937
1964	CD1	PHE	251	51.804	31.378	23.634
1965	CD2	PHE	251	51.042	32.107	25.796
1966	CE1	PHE	251	50.489	31.326	23.189
1967	CE2	PHE	251	49.727	32.053	25.351
1968	CZ	PHE	251	49.451	31.665	24.047
1969	N	SER	252	54.530	34.859	24.867
1970	CA	SER	252	54.213	36.271	24.657
1971	C	SER	252	55.084	36.888	23.563
1972	O	SER	252	54.852	38.034	23.168
1973	CB	SER	252	54.441	37.012	25.967
1974	OG	SER	252	53.641	36.382	26.959
1975	N	CYS	253	56.055	36.133	23.071
1976	CA	CYS	253	56.824	36.548	21.899
1977	C	CYS	253	56.288	35.853	20.649
1978	O	CYS	253	56.185	36.474	19.580
1979	CB	CYS	253	58.284	36.169	22.119
1980	SG	CYS	253	59.406	36.564	20.759
1981	N	CYS	254	55.744	34.662	20.843
1982	CA	CYS	254	55.149	33.912	19.732
1983	C	CYS	254	53.789	34.471	19.348
1984	O	CYS	254	53.473	34.505	18.157
1985	CB	CYS	254	54.992	32.445	20.119
1986	SG	CYS	254	56.525	31.502	20.282
1987	N	ASP	255	53.104	35.098	20.288
1988	CA	ASP	255	51.852	35.799	19.963
1989	C	ASP	255	52.055	36.943	18.944
1990	O	ASP	255	51.515	36.807	17.836
1991	CB	ASP	255	51.181	36.283	21.250
1992	CG	ASP	255	50.782	35.099	22.129
1993	OD1	ASP	255	50.766	35.269	23.342
1994	OD2	ASP	255	50.430	34.070	21.569
1995	N	PRO	256	52.873	37.966	19.197
1996	CA	PRO	256	53.062	38.993	18.167
1997	C	PRO	256	53.848	38.544	16.929
1998	O	PRO	256	53.637	39.152	15.877
1999	CB	PRO	256	53.771	40.125	18.844
2000	CG	PRO	256	54.195	39.688	20.231
2001	CD	PRO	256	53.635	38.290	20.410
2002	N	LYS	257	54.577	37.436	16.983
2003	CA	LYS	257	55.275	36.925	15.791
2004	C	LYS	257	54.396	35.967	14.970
2005	O	LYS	257	54.698	35.662	13.810
2006	CB	LYS	257	56.554	36.234	16.264
2007	CG	LYS	257	57.405	35.682	15.122
2008	CD	LYS	257	57.794	36.754	14.112
2009	CE	LYS	257	58.627	36.170	12.978
2010	NZ	LYS	257	59.863	35.563	13.498
2011	N	ALA	258	53.275	35.561	15.543

2012	CA	ALA	258	52.279	34.787	14.802
2013	C	ALA	258	51.330	35.735	14.091
2014	O	ALA	258	50.635	35.345	13.143
2015	CB	ALA	258	51.490	33.927	15.782
2016	N	HIS	259	51.351	36.979	14.546
2017	CA	HIS	259	50.622	38.067	13.896
2018	C	HIS	259	49.127	37.750	13.860
2019	O	HIS	259	48.573	37.492	12.783
2020	CB	HIS	259	51.163	38.213	12.478
2021	CG	HIS	259	52.589	38.699	12.265
2022	ND1	HIS	259	53.367	39.406	13.109
2023	CD2	HIS	259	53.330	38.485	11.128
2024	CE1	HIS	259	54.557	39.642	12.519
2025	NE2	HIS	259	54.534	39.070	11.297
2026	N	ALA	260	48.498	37.865	15.022
2027	CA	ALA	260	47.150	37.325	15.256
2028	C	ALA	260	46.071	38.294	15.757
2029	O	ALA	260	45.088	37.825	16.350
2030	CB	ALA	260	47.297	36.212	16.289
2031	N	VAL	261	46.218	39.591	15.536
2032	CA	VAL	261	45.226	40.568	16.034
2033	C	VAL	261	43.856	40.327	15.381
2034	O	VAL	261	43.785	39.611	14.374
2035	CB	VAL	261	45.810	41.973	15.807
2036	CG1	VAL	261	44.925	42.963	15.060
2037	CG2	VAL	261	46.330	42.585	17.101
2038	N	THR	262	42.783	40.756	16.037
2039	CA	THR	262	41.399	40.544	15.539
2040	C	THR	262	41.018	41.377	14.300
2041	O	THR	262	40.131	42.238	14.338
2042	CB	THR	262	40.421	40.849	16.671
2043	OG1	THR	262	40.629	42.189	17.106
2044	CG2	THR	262	40.643	39.920	17.860
2045	N	LEU	263	41.686	41.070	13.201
2046	CA	LEU	263	41.479	41.693	11.893
2047	C	LEU	263	41.537	40.590	10.837
2048	O	LEU	263	41.860	39.450	11.181
2049	CB	LEU	263	42.596	42.716	11.660
2050	CG	LEU	263	42.390	44.000	12.459
2051	CD1	LEU	263	43.542	44.971	12.228
2052	CD2	LEU	263	41.061	44.659	12.100
2053	N	PRO	264	41.177	40.885	9.593
2054	CA	PRO	264	41.320	39.894	8.510
2055	C	PRO	264	42.766	39.614	8.063
2056	O	PRO	264	42.989	38.701	7.260
2057	CB	PRO	264	40.538	40.462	7.367
2058	CG	PRO	264	40.144	41.894	7.686
2059	CD	PRO	264	40.603	42.149	9.111
2060	N	GLN	265	43.730	40.369	8.565
2061	CA	GLN	265	45.139	40.102	8.263
2062	C	GLN	265	45.712	39.077	9.235
2063	O	GLN	265	45.468	39.166	10.443
2064	CB	GLN	265	45.912	41.390	8.482
2065	CG	GLN	265	45.307	42.576	7.752
2066	CD	GLN	265	45.867	43.836	8.395
2067	OE1	GLN	265	45.727	44.023	9.611
2068	NE2	GLN	265	46.496	44.670	7.587
2069	N	TYR	266	46.477	38.133	8.718
2070	CA	TYR	266	47.222	37.226	9.599
2071	C	TYR	266	48.533	36.814	8.941
2072	O	TYR	266	48.561	36.531	7.737
2073	CB	TYR	266	46.375	35.993	9.892
2074	CG	TYR	266	46.846	35.156	11.082
2075	CD1	TYR	266	47.914	34.282	10.957
2076	CD2	TYR	266	46.168	35.250	12.293

2077	CE1	TYR	266	48.339	33.541	12.052
2078	CE2	TYR	266	46.590	34.511	13.386
2079	CZ	TYR	266	47.687	33.669	13.268
2080	OH	TYR	266	48.270	33.153	14.406
2081	N	LEU	267	49.608	36.969	9.700
2082	CA	LEU	267	50.990	36.553	9.351
2083	C	LEU	267	51.687	37.319	8.204
2084	O	LEU	267	52.908	37.200	8.056
2085	CB	LEU	267	50.964	35.051	9.053
2086	CG	LEU	267	52.348	34.405	9.071
2087	CD1	LEU	267	53.051	34.636	10.406
2088	CD2	LEU	267	52.258	32.913	8.766
2089	N	ILE	268	50.980	38.145	7.452
2090	CA	ILE	268	51.649	38.899	6.387
2091	C	ILE	268	52.075	40.255	6.934
2092	O	ILE	268	53.250	40.481	7.243
2093	CB	ILE	268	50.691	39.048	5.206
2094	CG1	ILE	268	50.062	37.704	4.861
2095	CG2	ILE	268	51.408	39.578	3.968
2096	CD1	ILE	268	49.201	37.824	3.609
2097	N	ARG	269	51.102	41.140	7.063
2098	CA	ARG	269	51.312	42.431	7.731
2099	C	ARG	269	50.438	42.463	8.973
2100	O	ARG	269	49.210	42.553	8.849
2101	CB	ARG	269	50.903	43.596	6.825
2102	CG	ARG	269	51.977	44.083	5.846
2103	CD	ARG	269	52.201	43.159	4.652
2104	NE	ARG	269	53.060	43.788	3.638
2105	CZ	ARG	269	53.875	43.097	2.838
2106	NH1	ARG	269	54.042	41.787	3.030
2107	NH2	ARG	269	54.593	43.730	1.908
2108	N	GLN	270	51.044	42.321	10.140
2109	CA	GLN	270	50.231	42.266	11.360
2110	C	GLN	270	50.936	42.706	12.647
2111	O	GLN	270	51.571	43.768	12.687
2112	CB	GLN	270	49.675	40.859	11.489
2113	CG	GLN	270	48.166	40.801	11.297
2114	CD	GLN	270	47.509	41.516	12.461
2115	OE1	GLN	270	47.850	41.228	13.619
2116	NE2	GLN	270	46.723	42.532	12.148
2117	N	ARG	271	50.917	41.825	13.640
2118	CA	ARG	271	51.167	42.164	15.059
2119	C	ARG	271	52.516	42.735	15.486
2120	O	ARG	271	52.563	43.318	16.574
2121	CB	ARG	271	50.955	40.928	15.915
2122	CG	ARG	271	49.598	40.918	16.595
2123	CD	ARG	271	49.564	39.849	17.678
2124	NE	ARG	271	48.287	39.873	18.398
2125	CZ	ARG	271	48.175	39.580	19.693
2126	NH1	ARG	271	49.260	39.246	20.394
2127	NH2	ARG	271	46.982	39.635	20.288
2128	N	HIS	272	53.533	42.761	14.646
2129	CA	HIS	272	54.746	43.465	15.066
2130	C	HIS	272	54.623	44.982	14.917
2131	O	HIS	272	55.416	45.721	15.510
2132	CB	HIS	272	55.959	42.920	14.330
2133	CG	HIS	272	56.550	41.738	15.067
2134	ND1	HIS	272	56.411	41.487	16.382
2135	CD2	HIS	272	57.324	40.730	14.546
2136	CE1	HIS	272	57.072	40.357	16.696
2137	NE2	HIS	272	57.637	39.890	15.560
2138	N	LEU	273	53.587	45.441	14.231
2139	CA	LEU	273	53.265	46.868	14.245
2140	C	LEU	273	51.779	47.090	14.549
2141	O	LEU	273	51.421	48.002	15.308

2142	CB	LEU	273	53.683	47.545	12.929
2143	CG	LEU	273	53.058	46.979	11.648
2144	CD1	LEU	273	52.735	48.096	10.663
2145	CD2	LEU	273	53.917	45.906	10.976
2146	N	LEU	274	50.958	46.128	14.161
2147	CA	LEU	274	49.504	46.278	14.283
2148	C	LEU	274	48.935	45.785	15.611
2149	O	LEU	274	47.770	46.074	15.906
2150	CB	LEU	274	48.821	45.575	13.117
2151	CG	LEU	274	49.232	46.196	11.783
2152	CD1	LEU	274	48.627	45.438	10.611
2153	CD2	LEU	274	48.849	47.669	11.706
2154	N	HIS	275	49.765	45.207	16.465
2155	CA	HIS	275	49.303	44.912	17.822
2156	C	HIS	275	49.352	46.205	18.621
2157	O	HIS	275	48.359	46.573	19.263
2158	CB	HIS	275	50.224	43.879	18.454
2159	CG	HIS	275	49.801	43.393	19.823
2160	ND1	HIS	275	48.552	43.380	20.328
2161	CD2	HIS	275	50.630	42.878	20.790
2162	CE1	HIS	275	48.583	42.871	21.576
2163	NE2	HIS	275	49.868	42.560	21.861
2164	N	GLY	276	50.365	47.002	18.312
2165	CA	GLY	276	50.497	48.347	18.873
2166	C	GLY	276	49.388	49.236	18.328
2167	O	GLY	276	48.648	49.843	19.109
2168	N	TYR	277	49.162	49.149	17.027
2169	CA	TYR	277	48.084	49.907	16.380
2170	C	TYR	277	46.689	49.582	16.920
2171	O	TYR	277	45.977	50.518	17.301
2172	CB	TYR	277	48.142	49.604	14.889
2173	CG	TYR	277	46.984	50.167	14.072
2174	CD1	TYR	277	46.087	49.298	13.462
2175	CD2	TYR	277	46.831	51.540	13.928
2176	CE1	TYR	277	45.029	49.801	12.718
2177	CE2	TYR	277	45.773	52.045	13.185
2178	CZ	TYR	277	44.874	51.174	12.584
2179	OH	TYR	277	43.804	51.675	11.875
2180	N	GLU	278	46.390	48.317	17.176
2181	CA	GLU	278	45.062	47.975	17.700
2182	C	GLU	278	44.933	48.316	19.184
2183	O	GLU	278	43.861	48.770	19.609
2184	CB	GLU	278	44.793	46.490	17.475
2185	CG	GLU	278	43.383	46.111	17.924
2186	CD	GLU	278	43.087	44.647	17.608
2187	OE1	GLU	278	43.545	43.794	18.358
2188	OE2	GLU	278	42.500	44.392	16.568
2189	N	ALA	279	46.056	48.371	19.882
2190	CA	ALA	279	46.037	48.798	21.278
2191	C	ALA	279	45.847	50.308	21.379
2192	O	ALA	279	45.014	50.743	22.179
2193	CB	ALA	279	47.351	48.398	21.939
2194	N	ARG	280	46.353	51.048	20.403
2195	CA	ARG	280	46.166	52.503	20.384
2196	C	ARG	280	44.787	52.895	19.860
2197	O	ARG	280	44.251	53.932	20.276
2198	CB	ARG	280	47.246	53.137	19.517
2199	CG	ARG	280	48.632	52.850	20.080
2200	CD	ARG	280	49.720	53.554	19.278
2201	NE	ARG	280	49.675	53.180	17.854
2202	CZ	ARG	280	50.687	52.578	17.225
2203	NH1	ARG	280	50.643	52.407	15.902
2204	NH2	ARG	280	51.790	52.248	17.901
2205	N	LEU	281	44.144	51.986	19.142
2206	CA	LEU	281	42.743	52.185	18.772

2207	C	LEU	281	41.882	52.076	20.018
2208	O	LEU	281	41.204	53.048	20.377
2209	CB	LEU	281	42.304	51.115	17.778
2210	CG	LEU	281	43.038	51.213	16.447
2211	CD1	LEU	281	42.662	50.045	15.543
2212	CD2	LEU	281	42.758	52.542	15.753
2213	N	LEU	282	42.214	51.094	20.840
2214	CA	LEU	282	41.483	50.872	22.092
2215	C	LEU	282	41.787	51.938	23.146
2216	O	LEU	282	40.890	52.265	23.927
2217	CB	LEU	282	41.852	49.501	22.662
2218	CG	LEU	282	40.897	48.370	22.263
2219	CD1	LEU	282	40.911	48.056	20.768
2220	CD2	LEU	282	41.220	47.105	23.049
2221	N	LYS	283	42.911	52.629	23.012
2222	CA	LYS	283	43.269	53.704	23.946
2223	C	LYS	283	42.569	55.030	23.661
2224	O	LYS	283	42.520	55.878	24.558
2225	CB	LYS	283	44.771	53.941	23.872
2226	CG	LYS	283	45.564	52.746	24.386
2227	CD	LYS	283	47.047	52.907	24.074
2228	CE	LYS	283	47.829	51.648	24.428
2229	NZ	LYS	283	49.233	51.770	24.004
2230	N	HIS	284	42.012	55.217	22.474
2231	CA	HIS	284	41.229	56.438	22.258
2232	C	HIS	284	39.739	56.119	22.218
2233	O	HIS	284	38.894	57.020	22.284
2234	CB	HIS	284	41.686	57.187	21.006
2235	CG	HIS	284	41.436	56.528	19.665
2236	ND1	HIS	284	42.300	55.763	18.972
2237	CD2	HIS	284	40.290	56.618	18.910
2238	CE1	HIS	284	41.725	55.372	17.820
2239	NE2	HIS	284	40.480	55.897	17.783
2240	N	VAL	285	39.429	54.835	22.162
2241	CA	VAL	285	38.036	54.374	22.231
2242	C	VAL	285	37.418	53.980	23.610
2243	O	VAL	285	36.182	54.045	23.637
2244	CB	VAL	285	37.992	53.180	21.268
2245	CG1	VAL	285	36.726	52.339	21.341
2246	CG2	VAL	285	38.228	53.643	19.835
2247	N	PRO	286	38.098	53.921	24.763
2248	CA	PRO	286	37.892	52.728	25.613
2249	C	PRO	286	36.593	52.685	26.424
2250	O	PRO	286	36.247	51.622	26.949
2251	CB	PRO	286	39.046	52.699	26.566
2252	CG	PRO	286	39.856	53.967	26.421
2253	CD	PRO	286	39.264	54.692	25.236
2254	N	LYS	287	35.870	53.789	26.517
2255	CA	LYS	287	34.638	53.804	27.311
2256	C	LYS	287	33.451	54.400	26.558
2257	O	LYS	287	32.380	54.572	27.153
2258	CB	LYS	287	34.877	54.600	28.592
2259	CG	LYS	287	35.950	53.958	29.470
2260	CD	LYS	287	36.161	54.682	30.801
2261	CE	LYS	287	35.295	54.139	31.941
2262	NZ	LYS	287	33.860	54.429	31.781
2263	N	ILE	288	33.621	54.727	25.288
2264	CA	ILE	288	32.524	55.399	24.587
2265	C	ILE	288	31.492	54.407	24.035
2266	O	ILE	288	31.795	53.520	23.226
2267	CB	ILE	288	33.098	56.320	23.503
2268	CG1	ILE	288	32.021	57.241	22.938
2269	CG2	ILE	288	33.775	55.554	22.373
2270	CD1	ILE	288	31.480	58.179	24.012
2271	N	ILE	289	30.256	54.614	24.464

2272	CA	ILE	289	29.096	53.831	24.008
2273	C	ILE	289	29.032	53.791	22.474
2274	O	ILE	289	29.660	54.619	21.800
2275	CB	ILE	289	27.852	54.489	24.622
2276	CG1	ILE	289	26.565	53.695	24.399
2277	CG2	ILE	289	27.691	55.918	24.114
2278	CD1	ILE	289	25.353	54.411	24.985
2279	N	HIS	290	28.505	52.681	21.969
2280	CA	HIS	290	28.391	52.354	20.529
2281	C	HIS	290	29.670	51.717	19.987
2282	O	HIS	290	29.666	50.518	19.683
2283	CB	HIS	290	28.015	53.567	19.675
2284	CG	HIS	290	26.680	54.193	20.023
2285	ND1	HIS	290	25.463	53.686	19.753
2286	CD2	HIS	290	26.481	55.391	20.668
2287	CE1	HIS	290	24.517	54.525	20.221
2288	NE2	HIS	290	25.148	55.579	20.787
2289	N	LEU	291	30.789	52.412	20.100
2290	CA	LEU	291	32.033	51.859	19.564
2291	C	LEU	291	32.629	50.847	20.540
2292	O	LEU	291	32.973	49.733	20.124
2293	CB	LEU	291	33.004	52.998	19.285
2294	CG	LEU	291	34.173	52.519	18.433
2295	CD1	LEU	291	33.679	51.767	17.201
2296	CD2	LEU	291	35.061	53.689	18.029
2297	N	VAL	292	32.408	51.086	21.822
2298	CA	VAL	292	32.774	50.101	22.846
2299	C	VAL	292	31.684	49.050	23.046
2300	O	VAL	292	31.981	47.952	23.527
2301	CB	VAL	292	33.104	50.844	24.135
2302	CG1	VAL	292	33.169	49.957	25.371
2303	CG2	VAL	292	34.420	51.570	23.949
2304	N	CYS	293	30.541	49.248	22.411
2305	CA	CYS	293	29.507	48.217	22.453
2306	C	CYS	293	29.878	47.126	21.455
2307	O	CYS	293	29.913	45.945	21.823
2308	CB	CYS	293	28.164	48.833	22.084
2309	SG	CYS	293	26.763	47.692	22.050
2310	N	LYS	294	30.471	47.555	20.351
2311	CA	LYS	294	30.979	46.614	19.352
2312	C	LYS	294	32.304	46.015	19.810
2313	O	LYS	294	32.482	44.793	19.728
2314	CB	LYS	294	31.204	47.384	18.059
2315	CG	LYS	294	29.934	48.104	17.628
2316	CD	LYS	294	30.194	49.019	16.440
2317	CE	LYS	294	28.946	49.812	16.072
2318	NZ	LYS	294	29.217	50.721	14.947
2319	N	LEU	295	33.079	46.808	20.531
2320	CA	LEU	295	34.361	46.341	21.066
2321	C	LEU	295	34.179	45.257	22.127
2322	O	LEU	295	34.752	44.171	21.973
2323	CB	LEU	295	35.077	47.537	21.681
2324	CG	LEU	295	36.442	47.161	22.244
2325	CD1	LEU	295	37.346	46.611	21.146
2326	CD2	LEU	295	37.089	48.363	22.923
2327	N	LEU	296	33.212	45.429	23.014
2328	CA	LEU	296	32.970	44.417	24.046
2329	C	LEU	296	32.164	43.239	23.519
2330	O	LEU	296	32.369	42.116	23.992
2331	CB	LEU	296	32.243	45.050	25.223
2332	CG	LEU	296	33.133	46.049	25.951
2333	CD1	LEU	296	32.373	46.714	27.092
2334	CD2	LEU	296	34.400	45.377	26.471
2335	N	LEU	297	31.474	43.427	22.406
2336	CA	LEU	297	30.824	42.294	21.751

2337	C	LEU	297	31.868	41.426	21.055
2338	O	LEU	297	31.866	40.206	21.252
2339	CB	LEU	297	29.826	42.822	20.728
2340	CG	LEU	297	29.079	41.686	20.039
2341	CD1	LEU	297	28.331	40.828	21.055
2342	CD2	LEU	297	28.121	42.228	18.986
2343	N	ASP	298	32.913	42.063	20.547
2344	CA	ASP	298	34.019	41.333	19.921
2345	C	ASP	298	34.895	40.655	20.971
2346	O	ASP	298	35.296	39.505	20.767
2347	CB	ASP	298	34.881	42.314	19.129
2348	CG	ASP	298	34.088	42.994	18.016
2349	OD1	ASP	298	33.227	42.337	17.444
2350	OD2	ASP	298	34.453	44.109	17.664
2351	N	LEU	299	34.934	41.230	22.164
2352	CA	LEU	299	35.699	40.648	23.277
2353	C	LEU	299	34.935	39.529	23.991
2354	O	LEU	299	35.540	38.725	24.710
2355	CB	LEU	299	36.024	41.752	24.284
2356	CG	LEU	299	37.442	42.316	24.157
2357	CD1	LEU	299	37.735	42.931	22.791
2358	CD2	LEU	299	37.703	43.343	25.252
2359	N	ALA	300	33.634	39.452	23.757
2360	CA	ALA	300	32.828	38.332	24.252
2361	C	ALA	300	32.707	37.241	23.190
2362	O	ALA	300	32.213	36.139	23.458
2363	CB	ALA	300	31.442	38.849	24.619
2364	N	GLU	301	33.155	37.558	21.989
2365	CA	GLU	301	33.195	36.566	20.927
2366	C	GLU	301	34.561	35.897	20.900
2367	O	GLU	301	34.582	34.684	21.068
2368	CB	GLU	301	32.883	37.222	19.587
2369	CG	GLU	301	31.460	37.771	19.529
2370	CD	GLU	301	30.432	36.681	19.818
2371	OE1	GLU	301	29.425	37.000	20.433
2372	OE2	GLU	301	30.688	35.542	19.449
2373	OXT	GLU	301	35.530	36.567	20.587

Table IX

Atom No	Atom name	Residue	Residue No	x coord	y coord	z coord
1	N	MET	1	1.491	5.335	9.487
5	CA	MET	1	2.465	4.265	9.217
6	CB	MET	1	2.302	3.734	7.795
7	CG	MET	1	0.916	3.146	7.555
8	SD	MET	1	0.637	2.487	5.894
9	CE	MET	1	-1.071	1.927	6.088
10	C	MET	1	3.899	4.759	9.385
11	O	MET	1	4.181	5.962	9.368
12	N	GLY	2	4.795	3.807	9.565
14	CA	GLY	2	6.223	4.121	9.650
15	C	GLY	2	6.848	3.946	8.275
16	O	GLY	2	7.036	2.817	7.808
17	N	VAL	3	7.195	5.058	7.649
19	CA	VAL	3	7.712	4.996	6.279
20	CB	VAL	3	7.307	6.264	5.538
21	CG1	VAL	3	5.795	6.314	5.406
22	CG2	VAL	3	7.819	7.525	6.223
23	C	VAL	3	9.223	4.793	6.234
24	O	VAL	3	9.760	4.480	5.165
25	N	GLN	4	9.859	5.000	7.381
27	CA	GLN	4	11.277	4.693	7.677
28	CB	GLN	4	12.266	5.066	6.568
29	CG	GLN	4	12.590	3.899	5.628
30	CD	GLN	4	13.264	2.728	6.347
31	OE1	GLN	4	12.720	2.136	7.287
32	NE2	GLN	4	14.429	2.364	5.841
35	C	GLN	4	11.684	5.427	8.942
36	O	GLN	4	12.123	6.584	8.860
37	N	PRO	5	11.671	4.714	10.060
38	CA	PRO	5	11.800	5.329	11.392
39	CB	PRO	5	11.830	4.177	12.351
40	CG	PRO	5	11.564	2.883	11.597
41	CD	PRO	5	11.397	3.276	10.139
42	C	PRO	5	13.051	6.203	11.511
43	O	PRO	5	14.083	5.883	10.911
44	N	PRO	6	12.944	7.340	12.189
45	CA	PRO	6	11.729	7.784	12.906
46	CB	PRO	6	12.248	8.754	13.921
47	CG	PRO	6	13.660	9.172	13.541
48	CD	PRO	6	14.056	8.277	12.379
49	C	PRO	6	10.660	8.489	12.051
50	O	PRO	6	9.716	9.063	12.611
51	N	ASN	7	10.857	8.539	10.745
53	CA	ASN	7	9.926	9.200	9.833
54	CB	ASN	7	10.606	9.316	8.470
55	CG	ASN	7	11.924	10.089	8.588
56	OD1	ASN	7	11.916	11.300	8.837
57	ND2	ASN	7	13.033	9.386	8.417
60	C	ASN	7	8.597	8.456	9.689
61	O	ASN	7	8.533	7.261	9.358
62	N	PHE	8	7.553	9.199	10.020
64	CA	PHE	8	6.150	8.809	9.821
65	CB	PHE	8	5.392	8.898	11.140
66	CG	PHE	8	5.888	7.982	12.252
67	CD1	PHE	8	5.687	6.612	12.162

68	CE1	PHE	8	6.130	5.775	13.177
69	CZ	PHE	8	6.771	6.309	14.287
70	CE2	PHE	8	6.966	7.681	14.379
71	CD2	PHE	8	6.524	8.518	13.364
72	C	PHE	8	5.507	9.783	8.837
73	O	PHE	8	4.278	9.890	8.725
74	N	SER	9	6.363	10.593	8.240
76	CA	SER	9	5.939	11.629	7.296
77	CB	SER	9	7.187	12.341	6.785
78	OG	SER	9	7.860	12.896	7.909
79	C	SER	9	5.149	11.062	6.120
80	O	SER	9	5.273	9.875	5.797
81	N	TRP	10	4.124	11.825	5.769
83	CA	TRP	10	3.278	11.625	4.582
84	CB	TRP	10	4.120	11.113	3.417
85	CG	TRP	10	3.363	10.272	2.411
86	CD1	TRP	10	2.272	10.620	1.641
87	NE1	TRP	10	1.907	9.534	0.913
89	CE2	TRP	10	2.716	8.486	1.157
90	CZ2	TRP	10	2.726	7.175	0.704
91	CH2	TRP	10	3.703	6.302	1.162
92	CZ3	TRP	10	4.671	6.721	2.063
93	CE3	TRP	10	4.662	8.032	2.533
94	CD2	TRP	10	3.682	8.905	2.087
95	C	TRP	10	2.055	10.739	4.804
96	O	TRP	10	0.959	11.140	4.401
97	N	VAL	11	2.199	9.670	5.571
99	CA	VAL	11	1.107	8.704	5.726
100	CB	VAL	11	1.720	7.350	6.036
101	CG1	VAL	11	2.189	6.629	4.780
102	CG2	VAL	11	2.857	7.524	7.030
103	C	VAL	11	0.112	9.064	6.822
104	O	VAL	11	-0.896	8.367	6.979
105	N	LEU	12	0.369	10.124	7.569
107	CA	LEU	12	-0.601	10.515	8.591
108	CB	LEU	12	0.091	11.328	9.674
109	CG	LEU	12	1.079	10.478	10.462
110	CD1	LEU	12	1.786	11.316	11.520
111	CD2	LEU	12	0.378	9.287	11.108
112	C	LEU	12	-1.777	11.285	7.989
113	O	LEU	12	-1.621	12.283	7.269
114	N	PRO	13	-2.957	10.743	8.241
115	CA	PRO	13	-4.199	11.444	7.950
116	CB	PRO	13	-5.273	10.409	8.098
117	CG	PRO	13	-4.680	9.188	8.784
118	CD	PRO	13	-3.195	9.477	8.939
119	C	PRO	13	-4.408	12.575	8.944
120	O	PRO	13	-3.895	12.543	10.069
121	N	GLY	14	-5.316	13.464	8.588
123	CA	GLY	14	-5.657	14.607	9.443
124	C	GLY	14	-6.418	14.212	10.707
125	O	GLY	14	-6.397	14.939	11.706
126	N	ARG	15	-7.001	13.023	10.689
128	CA	ARG	15	-7.730	12.499	11.846
129	CB	ARG	15	-8.661	11.403	11.348
130	CG	ARG	15	-9.606	11.903	10.265
131	CD	ARG	15	-10.433	10.749	9.714
132	NE	ARG	15	-9.549	9.689	9.203
133	CZ	ARG	15	-9.713	8.395	9.487
134	NH1	ARG	15	-8.852	7.493	9.009

135	NH2	ARG	15	-10.724	8.004	10.266
136	C	ARG	15	-6.826	11.893	12.923
137	O	ARG	15	-7.320	11.614	14.022
138	N	LEU	16	-5.536	11.752	12.655
140	CA	LEU	16	-4.617	11.203	13.658
141	CB	LEU	16	-4.132	9.836	13.175
142	CG	LEU	16	-3.840	8.860	14.315
143	CD1	LEU	16	-2.597	9.224	15.121
144	CD2	LEU	16	-5.051	8.686	15.225
145	C	LEU	16	-3.444	12.172	13.827
146	O	LEU	16	-2.326	11.909	13.361
147	N	ALA	17	-3.711	13.270	14.517
149	CA	ALA	17	-2.708	14.334	14.650
150	CB	ALA	17	-2.682	15.115	13.345
151	C	ALA	17	-2.995	15.299	15.798
152	O	ALA	17	-4.154	15.507	16.176
153	N	GLY	18	-1.933	15.892	16.324
155	CA	GLY	18	-2.057	16.952	17.334
156	C	GLY	18	-1.412	16.613	18.680
157	O	GLY	18	-1.545	17.402	19.618
158	N	LEU	19	-0.564	15.591	18.666
160	CA	LEU	19	0.035	14.921	19.847
161	CB	LEU	19	1.544	14.920	19.643
162	CG	LEU	19	2.278	13.938	20.552
163	CD1	LEU	19	3.524	13.459	19.855
164	CD2	LEU	19	2.635	14.450	21.947
165	C	LEU	19	-0.256	15.506	21.230
166	O	LEU	19	0.213	16.608	21.556
167	N	ALA	20	-0.944	14.702	22.032
169	CA	ALA	20	-1.162	14.939	23.474
170	CB	ALA	20	-1.564	16.392	23.784
171	C	ALA	20	-2.231	14.008	24.032
172	O	ALA	20	-2.310	12.826	23.693
173	N	LEU	21	-3.100	14.615	24.826
175	CA	LEU	21	-4.236	13.948	25.491
176	CB	LEU	21	-4.835	14.975	26.447
177	CG	LEU	21	-3.851	15.345	27.552
178	CD1	LEU	21	-4.420	16.451	28.432
179	CD2	LEU	21	-3.485	14.119	28.391
180	C	LEU	21	-5.294	13.449	24.494
181	O	LEU	21	-5.094	13.581	23.281
182	N	PRO	22	-6.300	12.717	24.959
183	CA	PRO	22	-7.377	12.247	24.063
184	CB	PRO	22	-7.896	11.023	24.748
185	CG	PRO	22	-7.465	11.055	26.210
186	CD	PRO	22	-6.505	12.227	26.331
187	C	PRO	22	-8.553	13.223	23.820
188	O	PRO	22	-9.529	12.809	23.185
189	N	ARG	23	-8.486	14.464	24.285
191	CA	ARG	23	-9.667	15.352	24.237
192	CB	ARG	23	-10.046	15.734	25.662
193	CG	ARG	23	-10.456	14.530	26.501
194	CD	ARG	23	-10.859	14.964	27.907
195	NE	ARG	23	-11.985	15.913	27.853
196	CZ	ARG	23	-12.838	16.111	28.862
197	NH1	ARG	23	-12.714	15.413	29.993
198	NH2	ARG	23	-13.836	16.986	28.726
199	C	ARG	23	-9.450	16.656	23.456
200	O	ARG	23	-9.149	17.686	24.069
201	N	LEU	24	-9.665	16.608	22.147

203	CA	LEU	24	-9.565	17.774	21.233
204	CB	LEU	24	-8.127	18.307	21.278
205	CG	LEU	24	-8.022	19.818	21.495
206	CD1	LEU	24	-9.006	20.340	22.532
207	CD2	LEU	24	-6.596	20.227	21.837
208	C	LEU	24	-10.003	17.234	19.852
209	O	LEU	24	-10.485	16.097	19.870
210	N	PRO	25	-9.995	17.987	18.748
211	CA	PRO	25	-10.621	17.497	17.498
212	CB	PRO	25	-10.371	18.560	16.469
213	CG	PRO	25	-9.727	19.760	17.133
214	CD	PRO	25	-9.583	19.392	18.599
215	C	PRO	25	-10.094	16.145	17.008
216	O	PRO	25	-10.704	15.105	17.284
217	N	ALA	26	-8.992	16.170	16.273
219	CA	ALA	26	-8.388	14.935	15.754
220	CB	ALA	26	-7.240	15.296	14.821
221	C	ALA	26	-7.869	14.076	16.898
222	O	ALA	26	-7.708	14.561	18.027
223	N	HIS	27	-7.646	12.801	16.628
225	CA	HIS	27	-7.168	11.940	17.701
226	CB	HIS	27	-7.678	10.528	17.541
227	CG	HIS	27	-7.659	9.815	18.875
228	ND1	HIS	27	-7.725	8.493	19.089
230	CE1	HIS	27	-7.678	8.251	20.413
231	NE2	HIS	27	-7.587	9.443	21.046
232	CD2	HIS	27	-7.580	10.418	20.109
233	C	HIS	27	-5.650	11.995	17.761
234	O	HIS	27	-4.904	11.498	16.911
235	N	TYR	28	-5.217	12.620	18.834
237	CA	TYR	28	-3.826	12.997	19.016
238	CB	TYR	28	-3.804	14.505	19.215
239	CG	TYR	28	-4.532	15.170	20.393
240	CD1	TYR	28	-3.833	16.119	21.131
241	CE1	TYR	28	-4.425	16.747	22.214
242	CZ	TYR	28	-5.740	16.451	22.543
243	OH	TYR	28	-6.264	16.927	23.728
244	CE2	TYR	28	-6.466	15.559	21.768
245	CD2	TYR	28	-5.868	14.931	20.690
246	C	TYR	28	-3.110	12.230	20.131
247	O	TYR	28	-1.874	12.301	20.225
248	N	GLN	29	-3.839	11.342	20.788
250	CA	GLN	29	-3.247	10.517	21.843
251	CB	GLN	29	-4.385	9.917	22.672
252	CG	GLN	29	-3.869	9.030	23.803
253	CD	GLN	29	-3.143	9.854	24.860
254	OE1	GLN	29	-3.757	10.673	25.555
255	NE2	GLN	29	-1.871	9.544	25.050
258	C	GLN	29	-2.375	9.394	21.285
259	O	GLN	29	-1.329	9.088	21.874
260	N	PHE	30	-2.619	9.006	20.041
262	CA	PHE	30	-1.791	7.952	19.436
263	CB	PHE	30	-2.497	7.342	18.237
264	CG	PHE	30	-3.503	6.261	18.605
265	CD1	PHE	30	-3.079	5.135	19.297
266	CE1	PHE	30	-3.990	4.144	19.638
267	CZ	PHE	30	-5.326	4.279	19.282
268	CE2	PHE	30	-5.749	5.403	18.584
269	CD2	PHE	30	-4.837	6.395	18.244
270	C	PHE	30	-0.414	8.447	19.020

271	O	PHE	30	0.547	7.686	19.186
272	N	LEU	31	-0.264	9.749	18.837
274	CA	LEU	31	1.061	10.274	18.516
275	CB	LEU	31	0.934	11.609	17.795
276	CG	LEU	31	0.348	11.458	16.398
277	CD1	LEU	31	0.303	12.815	15.710
278	CD2	LEU	31	1.167	10.478	15.563
279	C	LEU	31	1.892	10.448	19.782
280	O	LEU	31	3.110	10.218	19.744
281	N	LEU	32	1.213	10.543	20.917
283	CA	LEU	32	1.912	10.610	22.202
284	CB	LEU	32	0.954	11.175	23.258
285	CG	LEU	32	1.612	11.511	24.603
286	CD1	LEU	32	0.816	12.572	25.350
287	CD2	LEU	32	1.833	10.299	25.506
288	C	LEU	32	2.376	9.206	22.566
289	O	LEU	32	3.512	9.037	23.018
290	N	ASP	33	1.651	8.222	22.058
292	CA	ASP	33	2.010	6.818	22.275
293	CB	ASP	33	0.774	5.950	22.040
294	CG	ASP	33	-0.431	6.392	22.875
295	OD1	ASP	33	-0.238	6.939	23.956
296	OD2	ASP	33	-1.543	6.171	22.412
297	C	ASP	33	3.118	6.362	21.315
298	O	ASP	33	3.711	5.298	21.525
299	N	LEU	34	3.419	7.166	20.305
301	CA	LEU	34	4.511	6.851	19.378
302	CB	LEU	34	4.052	7.158	17.956
303	CG	LEU	34	2.922	6.235	17.514
304	CD1	LEU	34	2.354	6.672	16.169
305	CD2	LEU	34	3.385	4.782	17.460
306	C	LEU	34	5.785	7.647	19.675
307	O	LEU	34	6.847	7.328	19.125
308	N	GLY	35	5.682	8.668	20.512
310	CA	GLY	35	6.859	9.465	20.889
311	C	GLY	35	7.265	10.450	19.793
312	O	GLY	35	8.458	10.628	19.505
313	N	VAL	36	6.268	11.034	19.151
315	CA	VAL	36	6.521	12.009	18.082
316	CB	VAL	36	5.254	12.078	17.224
317	CG1	VAL	36	5.331	13.109	16.106
318	CG2	VAL	36	4.917	10.708	16.646
319	C	VAL	36	6.891	13.362	18.699
320	O	VAL	36	6.422	13.691	19.792
321	N	ARG	37	7.864	14.042	18.120
323	CA	ARG	37	8.238	15.361	18.639
324	CB	ARG	37	9.693	15.329	19.087
325	CG	ARG	37	9.893	14.311	20.204
326	CD	ARG	37	9.104	14.678	21.455
327	NE	ARG	37	9.179	13.596	22.448
328	CZ	ARG	37	8.463	13.591	23.575
329	NH1	ARG	37	7.657	14.618	23.857
330	NH2	ARG	37	8.571	12.571	24.429
331	C	ARG	37	8.034	16.436	17.584
332	O	ARG	37	7.786	17.608	17.905
333	N	HIS	38	8.139	16.027	16.332
335	CA	HIS	38	7.888	16.951	15.219
336	CB	HIS	38	9.023	16.869	14.206
337	CG	HIS	38	10.205	17.779	14.482
338	ND1	HIS	38	10.966	17.831	15.593

340	CE1	HIS	38	11.916	18.774	15.440
341	NE2	HIS	38	11.751	19.325	14.216
342	CD2	HIS	38	10.702	18.721	13.615
343	C	HIS	38	6.569	16.626	14.536
344	O	HIS	38	6.286	15.454	14.257
345	N	LEU	39	5.793	17.660	14.264
347	CA	LEU	39	4.482	17.485	13.632
348	CB	LEU	39	3.408	17.536	14.710
349	CG	LEU	39	2.030	17.272	14.114
350	CD1	LEU	39	1.905	15.823	13.654
351	CD2	LEU	39	0.936	17.606	15.114
352	C	LEU	39	4.203	18.580	12.602
353	O	LEU	39	3.881	19.719	12.956
354	N	VAL	40	4.302	18.235	11.332
356	CA	VAL	40	4.016	19.234	10.292
357	CB	VAL	40	5.123	19.172	9.240
358	CG1	VAL	40	4.983	20.265	8.183
359	CG2	VAL	40	6.492	19.273	9.902
360	C	VAL	40	2.627	19.002	9.684
361	O	VAL	40	2.229	17.856	9.445
362	N	SER	41	1.867	20.078	9.562
364	CA	SER	41	0.526	20.034	8.961
365	CB	SER	41	-0.424	20.839	9.847
366	OG	SER	41	-1.720	20.853	9.249
367	C	SER	41	0.551	20.681	7.584
368	O	SER	41	0.581	21.912	7.507
369	N	LEU	42	0.423	19.890	6.530
371	CA	LEU	42	0.473	20.457	5.169
372	CB	LEU	42	1.040	19.439	4.187
373	CG	LEU	42	2.561	19.439	4.205
374	CD1	LEU	42	3.098	18.599	3.056
375	CD2	LEU	42	3.089	20.859	4.070
376	C	LEU	42	-0.865	20.942	4.621
377	O	LEU	42	-0.890	21.612	3.582
378	N	THR	43	-1.949	20.668	5.323
380	CA	THR	43	-3.266	21.116	4.856
381	CB	THR	43	-4.205	19.919	4.924
382	OG1	THR	43	-3.537	18.825	4.317
383	CG2	THR	43	-5.511	20.151	4.171
384	C	THR	43	-3.789	22.276	5.708
385	O	THR	43	-4.857	22.835	5.428
386	N	GLU	44	-2.938	22.735	6.612
388	CA	GLU	44	-3.326	23.674	7.668
389	CB	GLU	44	-3.472	25.086	7.107
390	CG	GLU	44	-3.808	26.101	8.198
391	CD	GLU	44	-2.818	25.947	9.340
392	OE1	GLU	44	-1.659	26.254	9.101
393	OE2	GLU	44	-3.167	25.267	10.304
394	C	GLU	44	-4.610	23.234	8.359
395	O	GLU	44	-5.693	23.788	8.142
396	N	ARG	45	-4.467	22.225	9.195
398	CA	ARG	45	-5.610	21.795	10.000
399	CB	ARG	45	-6.112	20.443	9.512
400	CG	ARG	45	-4.998	19.413	9.440
401	CD	ARG	45	-5.533	18.082	8.933
402	NE	ARG	45	-6.158	18.243	7.613
403	CZ	ARG	45	-7.360	17.748	7.307
404	NH1	ARG	45	-7.936	18.074	6.149
405	NH2	ARG	45	-8.042	17.044	8.214
406	C	ARG	45	-5.271	21.765	11.484

407	O	ARG	45	-5.920	21.050	12.257
408	N	GLY	46	-4.287	22.556	11.883
410	CA	GLY	46	-3.879	22.543	13.291
411	C	GLY	46	-2.936	23.682	13.673
412	O	GLY	46	-1.737	23.644	13.379
413	N	PRO	47	-3.489	24.660	14.373
414	CA	PRO	47	-2.680	25.637	15.110
415	CB	PRO	47	-3.673	26.591	15.703
416	CG	PRO	47	-5.080	26.075	15.456
417	CD	PRO	47	-4.919	24.787	14.669
418	C	PRO	47	-1.843	24.947	16.187
419	O	PRO	47	-2.299	23.969	16.796
420	N	PRO	48	-0.721	25.557	16.550
421	CA	PRO	48	0.272	24.897	17.414
422	CB	PRO	48	1.522	25.708	17.256
423	CG	PRO	48	1.197	26.987	16.502
424	CD	PRO	48	-0.262	26.872	16.096
425	C	PRO	48	-0.127	24.827	18.891
426	O	PRO	48	0.454	24.032	19.638
427	N	HIS	49	-1.260	25.425	19.224
429	CA	HIS	49	-1.739	25.515	20.602
430	CB	HIS	49	-2.794	26.615	20.655
431	CG	HIS	49	-2.372	27.894	19.956
432	ND1	HIS	49	-1.423	28.759	20.362
434	CE1	HIS	49	-1.329	29.769	19.473
435	NE2	HIS	49	-2.234	29.539	18.494
436	CD2	HIS	49	-2.886	28.389	18.780
437	C	HIS	49	-2.352	24.199	21.072
438	O	HIS	49	-2.217	23.859	22.254
439	N	SER	50	-2.702	23.347	20.119
441	CA	SER	50	-3.216	22.015	20.457
442	CB	SER	50	-3.907	21.431	19.225
443	OG	SER	50	-2.950	21.313	18.179
444	C	SER	50	-2.084	21.083	20.903
445	O	SER	50	-2.283	20.257	21.799
446	N	ASP	51	-0.872	21.410	20.479
448	CA	ASP	51	0.321	20.654	20.852
449	CB	ASP	51	1.157	20.376	19.601
450	CG	ASP	51	0.496	19.364	18.665
451	OD1	ASP	51	-0.494	19.737	18.049
452	OD2	ASP	51	1.186	18.410	18.320
453	C	ASP	51	1.168	21.440	21.843
454	O	ASP	51	2.274	21.009	22.193
455	N	SER	52	0.634	22.550	22.336
457	CA	SER	52	1.413	23.466	23.179
458	CB	SER	52	0.802	24.858	23.083
459	OG	SER	52	1.568	25.732	23.898
460	C	SER	52	1.470	23.023	24.641
461	O	SER	52	2.359	23.465	25.382
462	N	CYS	53	0.635	22.067	25.019
464	CA	CYS	53	0.740	21.518	26.376
465	CB	CYS	53	-0.570	20.835	26.765
466	SG	CYS	53	-2.008	21.929	26.788
467	C	CYS	53	1.979	20.611	26.536
468	O	CYS	53	2.767	20.904	27.440
469	N	PRO	54	2.189	19.558	25.743
470	CA	PRO	54	3.504	18.890	25.774
471	CB	PRO	54	3.262	17.546	25.163
472	CG	PRO	54	1.899	17.549	24.486
473	CD	PRO	54	1.299	18.920	24.756

474	C	PRO	54	4.637	19.621	25.023
475	O	PRO	54	5.793	19.194	25.124
476	N	GLY	55	4.325	20.660	24.261
478	CA	GLY	55	5.357	21.460	23.588
479	C	GLY	55	5.925	20.770	22.348
480	O	GLY	55	7.122	20.465	22.285
481	N	LEU	56	5.065	20.510	21.379
483	CA	LEU	56	5.513	19.864	20.131
484	CB	LEU	56	4.428	19.013	19.467
485	CG	LEU	56	4.179	17.665	20.127
486	CD1	LEU	56	5.480	16.994	20.538
487	CD2	LEU	56	3.241	17.785	21.326
488	C	LEU	56	5.967	20.884	19.104
489	O	LEU	56	5.544	22.047	19.114
490	N	THR	57	6.706	20.384	18.131
492	CA	THR	57	7.177	21.224	17.028
493	CB	THR	57	8.523	20.687	16.562
494	OG1	THR	57	9.308	20.384	17.709
495	CG2	THR	57	9.268	21.705	15.708
496	C	THR	57	6.183	21.179	15.871
497	O	THR	57	6.384	20.437	14.901
498	N	LEU	58	5.091	21.913	16.020
500	CA	LEU	58	4.046	21.941	14.992
501	CB	LEU	58	2.690	22.178	15.663
502	CG	LEU	58	1.500	21.585	14.893
503	CD1	LEU	58	0.230	21.637	15.731
504	CD2	LEU	58	1.235	22.237	13.539
505	C	LEU	58	4.343	23.041	13.977
506	O	LEU	58	4.370	24.233	14.307
507	N	HIS	59	4.574	22.631	12.743
509	CA	HIS	59	4.785	23.612	11.675
510	CB	HIS	59	6.137	23.380	11.021
511	CG	HIS	59	7.277	23.803	11.928
512	ND1	HIS	59	7.252	24.797	12.839
514	CE1	HIS	59	8.452	24.877	13.445
515	NE2	HIS	59	9.242	23.914	12.919
516	CD2	HIS	59	8.529	23.240	11.990
517	C	HIS	59	3.630	23.602	10.680
518	O	HIS	59	3.236	22.562	10.138
519	N	ARG	60	3.090	24.790	10.472
521	CA	ARG	60	1.839	24.962	9.727
522	CB	ARG	60	1.040	26.008	10.485
523	CG	ARG	60	0.871	25.621	11.944
524	CD	ARG	60	0.279	26.776	12.733
525	NE	ARG	60	-1.075	27.109	12.272
526	CZ	ARG	60	-1.714	28.225	12.627
527	NH1	ARG	60	-1.103	29.125	13.399
528	NH2	ARG	60	-2.954	28.452	12.192
529	C	ARG	60	2.037	25.465	8.301
530	O	ARG	60	2.521	26.582	8.083
531	N	LEU	61	1.661	24.633	7.346
533	CA	LEU	61	1.677	25.024	5.929
534	CB	LEU	61	2.781	24.264	5.195
535	CG	LEU	61	4.172	24.567	5.751
536	CD1	LEU	61	5.239	23.709	5.080
537	CD2	LEU	61	4.515	26.046	5.613
538	C	LEU	61	0.320	24.711	5.300
539	O	LEU	61	-0.362	23.771	5.721
540	N	ARG	62	-0.099	25.514	4.340
542	CA	ARG	62	-1.389	25.242	3.696

543	CB	ARG	62	-2.382	26.360	3.979
544	CG	ARG	62	-3.774	25.940	3.515
545	CD	ARG	62	-4.804	27.039	3.737
546	NE	ARG	62	-4.488	28.219	2.920
547	CZ	ARG	62	-5.233	28.603	1.881
548	NH1	ARG	62	-4.894	29.690	1.184
549	NH2	ARG	62	-6.320	27.905	1.543
550	C	ARG	62	-1.234	25.083	2.193
551	O	ARG	62	-1.238	26.060	1.435
552	N	ILE	63	-1.078	23.840	1.781
554	CA	ILE	63	-0.983	23.526	0.360
555	CB	ILE	63	0.271	22.682	0.139
556	CG2	ILE	63	0.477	22.375	-1.341
557	CG1	ILE	63	1.497	23.395	0.698
558	CD1	ILE	63	2.764	22.580	0.472
559	C	ILE	63	-2.228	22.761	-0.077
560	O	ILE	63	-2.542	21.699	0.468
561	N	PRO	64	-2.985	23.354	-0.984
562	CA	PRO	64	-4.024	22.601	-1.685
563	CB	PRO	64	-4.708	23.605	-2.561
564	CG	PRO	64	-3.951	24.926	-2.494
565	CD	PRO	64	-2.806	24.706	-1.518
566	C	PRO	64	-3.379	21.493	-2.507
567	O	PRO	64	-2.364	21.730	-3.168
568	N	ASP	65	-3.939	20.296	-2.440
570	CA	ASP	65	-3.409	19.158	-3.207
571	CB	ASP	65	-3.961	17.880	-2.587
572	CG	ASP	65	-3.129	16.657	-2.960
573	OD1	ASP	65	-1.912	16.755	-2.874
574	OD2	ASP	65	-3.722	15.600	-3.116
575	C	ASP	65	-3.880	19.277	-4.653
576	O	ASP	65	-4.968	18.808	-5.005
577	N	PHE	66	-3.050	19.893	-5.477
579	CA	PHE	66	-3.494	20.269	-6.821
580	CB	PHE	66	-4.181	21.629	-6.695
581	CG	PHE	66	-5.613	21.721	-7.222
582	CD1	PHE	66	-6.416	20.590	-7.277
583	CE1	PHE	66	-7.717	20.683	-7.752
584	CZ	PHE	66	-8.217	21.909	-8.172
585	CE2	PHE	66	-7.415	23.041	-8.118
586	CD2	PHE	66	-6.113	22.947	-7.643
587	C	PHE	66	-2.337	20.377	-7.812
588	O	PHE	66	-1.347	19.640	-7.747
589	N	CYS	67	-2.561	21.237	-8.791
591	CA	CYS	67	-1.571	21.560	-9.826
592	CB	CYS	67	-2.312	21.774	-11.140
593	SG	CYS	67	-3.226	20.341	-11.759
594	C	CYS	67	-0.645	22.773	-9.551
595	O	CYS	67	0.514	22.664	-9.967
596	N	PRO	68	-1.078	23.906	-8.989
597	CA	PRO	68	-0.109	24.980	-8.721
598	CB	PRO	68	-0.885	26.113	-8.125
599	CG	PRO	68	-2.351	25.727	-8.029
600	CD	PRO	68	-2.447	24.330	-8.616
601	C	PRO	68	1.012	24.535	-7.778
602	O	PRO	68	0.771	23.980	-6.702
603	N	PRO	69	2.231	24.787	-8.225
604	CA	PRO	69	3.439	24.392	-7.504
605	CB	PRO	69	4.555	24.571	-8.489
606	CG	PRO	69	4.025	25.281	-9.725

607	CD	PRO	69	2.533	25.445	-9.503
608	C	PRO	69	3.706	25.261	-6.280
609	O	PRO	69	3.349	26.443	-6.249
610	N	ALA	70	4.354	24.672	-5.290
612	CA	ALA	70	4.856	25.466	-4.159
613	CB	ALA	70	3.961	25.221	-2.950
614	C	ALA	70	6.309	25.120	-3.811
615	O	ALA	70	6.576	24.693	-2.679
616	N	PRO	71	7.255	25.506	-4.662
617	CA	PRO	71	8.610	24.941	-4.572
618	CB	PRO	71	9.249	25.253	-5.890
619	CG	PRO	71	8.358	26.208	-6.666
620	CD	PRO	71	7.097	26.373	-5.838
621	C	PRO	71	9.457	25.507	-3.429
622	O	PRO	71	10.352	24.812	-2.935
623	N	ASP	72	9.002	26.597	-2.831
625	CA	ASP	72	9.733	27.239	-1.734
626	CB	ASP	72	9.277	28.691	-1.633
627	CG	ASP	72	9.459	29.396	-2.975
628	OD1	ASP	72	10.596	29.691	-3.310
629	OD2	ASP	72	8.482	29.469	-3.709
630	C	ASP	72	9.479	26.539	-0.399
631	O	ASP	72	10.266	26.686	0.545
632	N	GLN	73	8.515	25.630	-0.392
634	CA	GLN	73	8.223	24.863	0.814
635	CB	GLN	73	6.791	24.343	0.714
636	CG	GLN	73	5.768	25.470	0.539
637	CD	GLN	73	5.306	26.071	1.870
638	OE1	GLN	73	4.161	25.855	2.285
639	NE2	GLN	73	6.160	26.870	2.487
642	C	GLN	73	9.197	23.698	0.972
643	O	GLN	73	9.472	23.314	2.114
644	N	ILE	74	9.939	23.397	-0.087
646	CA	ILE	74	10.915	22.303	-0.062
647	CB	ILE	74	11.453	22.127	-1.479
648	CG2	ILE	74	12.705	21.258	-1.491
649	CG1	ILE	74	10.383	21.558	-2.402
650	CD1	ILE	74	9.911	20.188	-1.931
651	C	ILE	74	12.084	22.586	0.874
652	O	ILE	74	12.374	21.751	1.739
653	N	ASP	75	12.518	23.837	0.916
655	CA	ASP	75	13.676	24.194	1.739
656	CB	ASP	75	14.085	25.627	1.420
657	CG	ASP	75	14.508	25.755	-0.040
658	OD1	ASP	75	15.667	25.482	-0.319
659	OD2	ASP	75	13.662	26.090	-0.859
660	C	ASP	75	13.331	24.091	3.216
661	O	ASP	75	13.863	23.201	3.895
662	N	ARG	76	12.180	24.659	3.538
664	CA	ARG	76	11.717	24.740	4.920
665	CB	ARG	76	10.475	25.618	4.901
666	CG	ARG	76	9.935	25.918	6.291
667	CD	ARG	76	8.634	26.701	6.173
668	NE	ARG	76	8.807	27.821	5.234
669	CZ	ARG	76	7.935	28.822	5.103
670	NH1	ARG	76	6.846	28.865	5.873
671	NH2	ARG	76	8.161	29.790	4.212
672	C	ARG	76	11.348	23.368	5.467
673	O	ARG	76	11.873	22.972	6.514
674	N	PHE	77	10.748	22.554	4.614

676	CA	PHE	77	10.268	21.240	5.032
677	CB	PHE	77	9.382	20.707	3.914
678	CG	PHE	77	8.430	19.598	4.334
679	CD1	PHE	77	8.884	18.293	4.474
680	CE1	PHE	77	8.006	17.290	4.860
681	CZ	PHE	77	6.673	17.595	5.102
682	CE2	PHE	77	6.219	18.900	4.964
683	CD2	PHE	77	7.098	19.902	4.581
684	C	PHE	77	11.424	20.274	5.267
685	O	PHE	77	11.458	19.614	6.316
686	N	VAL	78	12.473	20.408	4.473
688	CA	VAL	78	13.632	19.536	4.635
689	CB	VAL	78	14.473	19.615	3.367
690	CG1	VAL	78	15.853	19.014	3.576
691	CG2	VAL	78	13.757	18.939	2.202
692	C	VAL	78	14.455	19.929	5.856
693	O	VAL	78	14.808	19.037	6.638
694	N	GLN	79	14.423	21.203	6.209
696	CA	GLN	79	15.146	21.665	7.396
697	CB	GLN	79	15.285	23.178	7.277
698	CG	GLN	79	16.061	23.517	6.009
699	CD	GLN	79	16.031	25.015	5.719
700	OE1	GLN	79	14.984	25.590	5.394
701	NE2	GLN	79	17.208	25.613	5.755
704	C	GLN	79	14.416	21.280	8.686
705	O	GLN	79	15.067	20.794	9.622
706	N	ILE	80	13.097	21.183	8.602
708	CA	ILE	80	12.284	20.753	9.747
709	CB	ILE	80	10.817	20.972	9.397
710	CG2	ILE	80	9.919	20.421	10.499
711	CG1	ILE	80	10.516	22.443	9.152
712	CD1	ILE	80	9.114	22.627	8.579
713	C	ILE	80	12.488	19.270	10.043
714	O	ILE	80	12.862	18.908	11.167
715	N	VAL	81	12.518	18.467	8.992
717	CA	VAL	81	12.670	17.025	9.186
718	CB	VAL	81	12.057	16.315	7.982
719	CG1	VAL	81	11.958	14.814	8.221
720	CG2	VAL	81	10.663	16.866	7.705
721	C	VAL	81	14.139	16.643	9.406
722	O	VAL	81	14.412	15.635	10.075
723	N	ASP	82	15.048	17.551	9.078
725	CA	ASP	82	16.461	17.376	9.429
726	CB	ASP	82	17.326	18.363	8.648
727	CG	ASP	82	17.488	17.928	7.199
728	OD1	ASP	82	17.504	16.727	6.966
729	OD2	ASP	82	17.708	18.792	6.360
730	C	ASP	82	16.697	17.631	10.910
731	O	ASP	82	17.466	16.889	11.527
732	N	GLU	83	15.870	18.464	11.518
734	CA	GLU	83	16.013	18.745	12.946
735	CB	GLU	83	15.269	20.046	13.228
736	CG	GLU	83	15.349	20.464	14.690
737	CD	GLU	83	14.559	21.754	14.880
738	OE1	GLU	83	14.901	22.511	15.777
739	OE2	GLU	83	13.646	21.976	14.098
740	C	GLU	83	15.438	17.602	13.783
741	O	GLU	83	16.046	17.209	14.788
742	N	ALA	84	14.451	16.916	13.228
744	CA	ALA	84	13.871	15.755	13.911

745	CB	ALA	84	12.575	15.391	13.206
746	C	ALA	84	14.806	14.550	13.871
747	O	ALA	84	15.153	14.012	14.931
748	N	ASN	85	15.411	14.347	12.707
750	CA	ASN	85	16.353	13.237	12.467
751	CB	ASN	85	16.372	12.885	10.974
752	CG	ASN	85	15.164	12.053	10.524
753	OD1	ASN	85	15.204	10.815	10.530
754	ND2	ASN	85	14.154	12.735	10.018
757	C	ASN	85	17.791	13.547	12.906
758	O	ASN	85	18.686	12.721	12.693
759	N	ALA	86	18.024	14.735	13.447
761	CA	ALA	86	19.339	15.068	14.003
762	CB	ALA	86	19.559	16.574	13.918
763	C	ALA	86	19.378	14.625	15.458
764	O	ALA	86	20.445	14.404	16.043
765	N	ARG	87	18.191	14.498	16.024
767	CA	ARG	87	18.029	13.842	17.315
768	CB	ARG	87	17.136	14.699	18.198
769	CG	ARG	87	17.711	16.094	18.400
770	CD	ARG	87	16.802	16.924	19.298
771	NE	ARG	87	16.593	16.243	20.586
772	CZ	ARG	87	17.076	16.694	21.746
773	NH1	ARG	87	16.871	15.999	22.867
774	NH2	ARG	87	17.786	17.824	21.781
775	C	ARG	87	17.377	12.491	17.060
776	O	ARG	87	17.181	12.099	15.905
777	N	GLY	88	17.010	11.796	18.120
779	CA	GLY	88	16.302	10.521	17.947
780	C	GLY	88	14.805	10.710	18.177
781	O	GLY	88	14.192	10.003	18.983
782	N	GLU	89	14.226	11.672	17.477
784	CA	GLU	89	12.828	12.027	17.743
785	CB	GLU	89	12.716	13.531	17.973
786	CG	GLU	89	13.759	14.080	18.946
787	CD	GLU	89	13.797	13.327	20.275
788	OE1	GLU	89	14.897	12.949	20.657
789	OE2	GLU	89	12.739	13.072	20.833
790	C	GLU	89	11.940	11.641	16.570
791	O	GLU	89	12.284	11.894	15.410
792	N	ALA	90	10.773	11.102	16.880
794	CA	ALA	90	9.845	10.719	15.815
795	CB	ALA	90	8.736	9.857	16.394
796	C	ALA	90	9.269	11.946	15.115
797	O	ALA	90	8.989	12.982	15.737
798	N	VAL	91	9.166	11.840	13.804
800	CA	VAL	91	8.658	12.956	13.004
801	CB	VAL	91	9.792	13.517	12.152
802	CG1	VAL	91	10.618	12.419	11.497
803	CG2	VAL	91	9.305	14.542	11.133
804	C	VAL	91	7.457	12.546	12.158
805	O	VAL	91	7.563	11.827	11.152
806	N	GLY	92	6.315	13.060	12.572
808	CA	GLY	92	5.055	12.760	11.904
809	C	GLY	92	4.560	13.976	11.135
810	O	GLY	92	4.434	15.084	11.668
811	N	VAL	93	4.406	13.790	9.841
813	CA	VAL	93	3.872	14.873	9.021
814	CB	VAL	93	4.878	15.275	7.954
815	CG1	VAL	93	4.323	16.435	7.141

816	CG2	VAL	93	6.217	15.661	8.574
817	C	VAL	93	2.570	14.426	8.381
818	O	VAL	93	2.539	13.434	7.641
819	N	HIS	94	1.511	15.143	8.703
821	CA	HIS	94	0.194	14.792	8.202
822	CB	HIS	94	-0.779	14.660	9.372
823	CG	HIS	94	-1.184	15.959	10.035
824	ND1	HIS	94	-2.316	16.649	9.800
826	CE1	HIS	94	-2.336	17.748	10.579
827	NE2	HIS	94	-1.205	17.747	11.320
828	CD2	HIS	94	-0.487	16.649	10.998
829	C	HIS	94	-0.338	15.827	7.226
830	O	HIS	94	0.070	16.997	7.170
831	N	CYS	95	-1.251	15.341	6.417
833	CA	CYS	95	-2.046	16.220	5.574
834	CB	CYS	95	-1.582	16.100	4.130
835	SG	CYS	95	-1.201	14.431	3.563
836	C	CYS	95	-3.508	15.855	5.781
837	O	CYS	95	-3.951	15.736	6.927
838	N	ALA	96	-4.250	15.709	4.701
840	CA	ALA	96	-5.637	15.267	4.821
841	CB	ALA	96	-6.441	15.866	3.673
842	C	ALA	96	-5.736	13.746	4.769
843	O	ALA	96	-6.041	13.096	5.777
844	N	LEU	97	-5.350	13.195	3.629
846	CA	LEU	97	-5.541	11.761	3.364
847	CB	LEU	97	-6.061	11.618	1.938
848	CG	LEU	97	-7.424	12.274	1.757
849	CD1	LEU	97	-7.826	12.289	0.287
850	CD2	LEU	97	-8.485	11.578	2.603
851	C	LEU	97	-4.289	10.893	3.491
852	O	LEU	97	-4.369	9.692	3.221
853	N	GLY	98	-3.160	11.471	3.863
855	CA	GLY	98	-1.905	10.712	3.845
856	C	GLY	98	-1.423	10.513	2.406
857	O	GLY	98	-0.999	9.419	2.015
858	N	PHE	99	-1.469	11.594	1.641
860	CA	PHE	99	-1.251	11.547	0.182
861	CB	PHE	99	-2.616	11.474	-0.511
862	CG	PHE	99	-3.192	10.104	-0.885
863	CD1	PHE	99	-3.878	9.981	-2.086
864	CE1	PHE	99	-4.417	8.757	-2.460
865	CZ	PHE	99	-4.273	7.652	-1.632
866	CE2	PHE	99	-3.591	7.773	-0.428
867	CD2	PHE	99	-3.052	8.998	-0.056
868	C	PHE	99	-0.557	12.796	-0.380
869	O	PHE	99	-0.048	13.664	0.348
870	N	GLY	100	-0.417	12.749	-1.698
872	CA	GLY	100	-0.103	13.897	-2.577
873	C	GLY	100	1.075	14.775	-2.168
874	O	GLY	100	2.244	14.396	-2.322
875	N	ARG	101	0.729	15.928	-1.614
877	CA	ARG	101	1.686	16.936	-1.135
878	CB	ARG	101	0.927	17.888	-0.223
879	CG	ARG	101	-0.201	18.623	-0.920
880	CD	ARG	101	-1.283	18.948	0.098
881	NE	ARG	101	-1.896	17.700	0.576
882	CZ	ARG	101	-3.186	17.589	0.898
883	NH1	ARG	101	-3.956	18.677	0.959
884	NH2	ARG	101	-3.684	16.400	1.241

885	C	ARG	101	2.789	16.356	-0.269
886	O	ARG	101	3.971	16.474	-0.612
887	N	THR	102	2.407	15.540	0.697
889	CA	THR	102	3.390	15.105	1.682
890	CB	THR	102	2.679	14.825	2.994
891	OG1	THR	102	1.644	15.784	3.158
892	CG2	THR	102	3.654	14.984	4.147
893	C	THR	102	4.169	13.881	1.208
894	O	THR	102	5.317	13.690	1.626
895	N	GLY	103	3.672	13.246	0.157
897	CA	GLY	103	4.393	12.138	-0.478
898	C	GLY	103	5.542	12.723	-1.279
899	O	GLY	103	6.702	12.320	-1.116
900	N	THR	104	5.230	13.846	-1.901
902	CA	THR	104	6.198	14.624	-2.667
903	CB	THR	104	5.406	15.745	-3.332
904	OG1	THR	104	4.456	15.144	-4.200
905	CG2	THR	104	6.276	16.698	-4.141
906	C	THR	104	7.271	15.227	-1.762
907	O	THR	104	8.468	15.074	-2.041
908	N	MET	105	6.860	15.660	-0.581
910	CA	MET	105	7.804	16.223	0.387
911	CB	MET	105	7.004	16.865	1.511
912	CG	MET	105	6.267	18.112	1.045
913	SD	MET	105	7.320	19.480	0.521
914	CE	MET	105	6.036	20.703	0.184
915	C	MET	105	8.737	15.175	0.990
916	O	MET	105	9.949	15.417	1.065
917	N	LEU	106	8.240	13.964	1.181
919	CA	LEU	106	9.076	12.898	1.738
920	CB	LEU	106	8.159	11.785	2.234
921	CG	LEU	106	8.949	10.640	2.858
922	CD1	LEU	106	9.734	11.113	4.078
923	CD2	LEU	106	8.017	9.497	3.231
924	C	LEU	106	10.039	12.341	0.691
925	O	LEU	106	11.224	12.154	1.000
926	N	ALA	107	9.622	12.368	-0.565
928	CA	ALA	107	10.491	11.911	-1.651
929	CB	ALA	107	9.668	11.787	-2.928
930	C	ALA	107	11.629	12.893	-1.882
931	O	ALA	107	12.796	12.478	-1.891
932	N	CYS	108	11.323	14.173	-1.741
934	CA	CYS	108	12.341	15.206	-1.914
935	CB	CYS	108	11.642	16.542	-2.105
936	SG	CYS	108	12.748	17.934	-2.406
937	C	CYS	108	13.277	15.298	-0.712
938	O	CYS	108	14.475	15.541	-0.900
939	N	TYR	109	12.809	14.873	0.451
941	CA	TYR	109	13.672	14.839	1.633
942	CB	TYR	109	12.798	14.666	2.871
943	CG	TYR	109	13.600	14.590	4.165
944	CD1	TYR	109	14.169	15.746	4.682
945	CE1	TYR	109	14.911	15.689	5.851
946	CZ	TYR	109	15.085	14.477	6.503
947	OH	TYR	109	15.816	14.431	7.670
948	CE2	TYR	109	14.515	13.318	5.992
949	CD2	TYR	109	13.772	13.376	4.821
950	C	TYR	109	14.667	13.685	1.554
951	O	TYR	109	15.853	13.881	1.855
952	N	LEU	110	14.252	12.592	0.935

954	CA	LEU	110	15.150	11.449	0.760
955	CB	LEU	110	14.325	10.233	0.355
956	CG	LEU	110	13.330	9.830	1.438
957	CD1	LEU	110	12.394	8.732	0.941
958	CD2	LEU	110	14.044	9.397	2.714
959	C	LEU	110	16.191	11.738	-0.315
960	O	LEU	110	17.384	11.472	-0.104
961	N	VAL	111	15.799	12.500	-1.320
963	CA	VAL	111	16.768	12.884	-2.343
964	CB	VAL	111	16.050	13.510	-3.534
965	CG1	VAL	111	17.044	13.820	-4.649
966	CG2	VAL	111	14.951	12.599	-4.065
967	C	VAL	111	17.788	13.872	-1.788
968	O	VAL	111	18.968	13.511	-1.681
969	N	LYS	112	17.289	14.906	-1.131
971	CA	LYS	112	18.133	16.028	-0.706
972	CB	LYS	112	17.180	17.183	-0.414
973	CG	LYS	112	17.884	18.500	-0.111
974	CD	LYS	112	16.855	19.613	0.058
975	CE	LYS	112	17.500	20.951	0.399
976	NZ	LYS	112	16.473	21.985	0.600
977	C	LYS	112	18.991	15.749	0.529
978	O	LYS	112	20.076	16.325	0.655
979	N	GLU	113	18.579	14.836	1.393
981	CA	GLU	113	19.397	14.591	2.583
982	CB	GLU	113	18.529	14.748	3.822
983	CG	GLU	113	17.987	16.166	3.915
984	CD	GLU	113	19.126	17.184	3.998
985	OE1	GLU	113	20.005	16.998	4.829
986	OE2	GLU	113	19.035	18.179	3.292
987	C	GLU	113	20.068	13.226	2.605
988	O	GLU	113	21.094	13.067	3.275
989	N	ARG	114	19.526	12.261	1.882
991	CA	ARG	114	20.133	10.929	1.913
992	CB	ARG	114	19.027	9.877	1.987
993	CG	ARG	114	18.007	10.100	3.109
994	CD	ARG	114	18.468	9.660	4.504
995	NE	ARG	114	19.401	10.604	5.145
996	CZ	ARG	114	19.035	11.496	6.069
997	NH1	ARG	114	19.929	12.362	6.549
998	NH2	ARG	114	17.764	11.557	6.473
999	C	ARG	114	20.981	10.678	0.673
1000	O	ARG	114	21.785	9.739	0.645
1001	N	GLY	115	20.796	11.510	-0.341
1003	CA	GLY	115	21.510	11.329	-1.609
1004	C	GLY	115	20.837	10.222	-2.414
1005	O	GLY	115	21.470	9.522	-3.214
1006	N	LEU	116	19.546	10.079	-2.178
1008	CA	LEU	116	18.772	8.997	-2.773
1009	CB	LEU	116	17.727	8.589	-1.744
1010	CG	LEU	116	16.894	7.413	-2.217
1011	CD1	LEU	116	17.791	6.206	-2.449
1012	CD2	LEU	116	15.804	7.092	-1.207
1013	C	LEU	116	18.073	9.479	-4.032
1014	O	LEU	116	17.284	10.424	-3.967
1015	N	ALA	117	18.279	8.782	-5.138
1017	CA	ALA	117	17.611	9.152	-6.394
1018	CB	ALA	117	17.987	8.151	-7.478
1019	C	ALA	117	16.095	9.176	-6.220
1020	O	ALA	117	15.533	8.384	-5.450

1021	N	ALA	118	15.436	9.995	-7.025
1023	CA	ALA	118	13.988	10.211	-6.878
1024	CB	ALA	118	13.582	11.375	-7.772
1025	C	ALA	118	13.158	8.978	-7.230
1026	O	ALA	118	12.188	8.680	-6.523
1027	N	GLY	119	13.708	8.131	-8.087
1029	CA	GLY	119	13.088	6.840	-8.399
1030	C	GLY	119	13.061	5.926	-7.175
1031	O	GLY	119	11.993	5.425	-6.807
1032	N	ASP	120	14.148	5.926	-6.418
1034	CA	ASP	120	14.251	5.042	-5.254
1035	CB	ASP	120	15.707	4.948	-4.815
1036	CG	ASP	120	16.663	4.621	-5.955
1037	OD1	ASP	120	17.707	5.261	-6.008
1038	OD2	ASP	120	16.324	3.788	-6.785
1039	C	ASP	120	13.448	5.601	-4.081
1040	O	ASP	120	12.790	4.829	-3.370
1041	N	ALA	121	13.314	6.918	-4.028
1043	CA	ALA	121	12.517	7.550	-2.975
1044	CB	ALA	121	12.743	9.056	-3.034
1045	C	ALA	121	11.037	7.244	-3.166
1046	O	ALA	121	10.409	6.689	-2.253
1047	N	ILE	122	10.594	7.289	-4.413
1049	CA	ILE	122	9.197	6.973	-4.717
1050	CB	ILE	122	8.869	7.495	-6.109
1051	CG2	ILE	122	7.440	7.144	-6.508
1052	CG1	ILE	122	9.065	8.999	-6.192
1053	CD1	ILE	122	8.752	9.479	-7.602
1054	C	ILE	122	8.919	5.472	-4.668
1055	O	ILE	122	7.833	5.088	-4.224
1056	N	ALA	123	9.935	4.647	-4.860
1058	CA	ALA	123	9.738	3.198	-4.754
1059	CB	ALA	123	10.936	2.490	-5.375
1060	C	ALA	123	9.582	2.754	-3.303
1061	O	ALA	123	8.662	1.985	-3.000
1062	N	GLU	124	10.257	3.447	-2.402
1064	CA	GLU	124	10.142	3.136	-0.975
1065	CB	GLU	124	11.335	3.773	-0.276
1066	CG	GLU	124	12.629	3.171	-0.810
1067	CD	GLU	124	13.834	3.993	-0.375
1068	OE1	GLU	124	13.702	4.737	0.586
1069	OE2	GLU	124	14.844	3.928	-1.066
1070	C	GLU	124	8.834	3.682	-0.410
1071	O	GLU	124	8.128	2.970	0.317
1072	N	ILE	125	8.393	4.785	-0.991
1074	CA	ILE	125	7.097	5.367	-0.647
1075	CB	ILE	125	7.051	6.755	-1.282
1076	CG2	ILE	125	5.634	7.296	-1.424
1077	CG1	ILE	125	7.924	7.721	-0.492
1078	CD1	ILE	125	7.832	9.129	-1.062
1079	C	ILE	125	5.942	4.500	-1.142
1080	O	ILE	125	5.103	4.112	-0.321
1081	N	ARG	126	6.119	3.899	-2.307
1083	CA	ARG	126	5.076	3.066	-2.908
1084	CB	ARG	126	5.407	2.931	-4.391
1085	CG	ARG	126	4.329	2.180	-5.161
1086	CD	ARG	126	2.960	2.828	-4.972
1087	NE	ARG	126	1.928	2.146	-5.771
1088	CZ	ARG	126	1.204	1.105	-5.349
1089	NH1	ARG	126	1.392	0.602	-4.126

1090	NH2	ARG	126	0.283	0.568	-6.151
1091	C	ARG	126	4.976	1.688	-2.251
1092	O	ARG	126	3.871	1.139	-2.172
1093	N	ARG	127	6.031	1.259	-1.574
1095	CA	ARG	127	5.951	0.002	-0.827
1096	CB	ARG	127	7.340	-0.599	-0.665
1097	CG	ARG	127	7.992	-0.873	-2.013
1098	CD	ARG	127	9.253	-1.709	-1.840
1099	NE	ARG	127	10.083	-1.187	-0.744
1100	CZ	ARG	127	11.278	-0.622	-0.922
1101	NH1	ARG	127	11.739	-0.405	-2.156
1102	NH2	ARG	127	11.981	-0.212	0.135
1103	C	ARG	127	5.323	0.199	0.551
1104	O	ARG	127	4.970	-0.785	1.212
1105	N	LEU	128	5.150	1.443	0.966
1107	CA	LEU	128	4.425	1.710	2.207
1108	CB	LEU	128	5.111	2.827	2.998
1109	CG	LEU	128	6.092	2.324	4.058
1110	CD1	LEU	128	5.422	1.304	4.972
1111	CD2	LEU	128	7.379	1.752	3.473
1112	C	LEU	128	2.978	2.110	1.920
1113	O	LEU	128	2.077	1.727	2.679
1114	N	ARG	129	2.761	2.777	0.793
1116	CA	ARG	129	1.427	3.293	0.438
1117	CB	ARG	129	1.031	4.282	1.537
1118	CG	ARG	129	-0.411	4.773	1.494
1119	CD	ARG	129	-0.591	5.850	2.558
1120	NE	ARG	129	-1.998	6.222	2.754
1121	CZ	ARG	129	-2.534	6.300	3.974
1122	NH1	ARG	129	-1.803	5.970	5.040
1123	NH2	ARG	129	-3.810	6.660	4.124
1124	C	ARG	129	1.450	4.008	-0.923
1125	O	ARG	129	2.368	4.778	-1.228
1126	N	PRO	130	0.469	3.706	-1.756
1127	CA	PRO	130	0.213	4.511	-2.959
1128	CB	PRO	130	-0.828	3.738	-3.711
1129	CG	PRO	130	-1.370	2.628	-2.821
1130	CD	PRO	130	-0.549	2.674	-1.544
1131	C	PRO	130	-0.326	5.908	-2.632
1132	O	PRO	130	-0.940	6.120	-1.580
1133	N	GLY	131	-0.088	6.856	-3.526
1135	CA	GLY	131	-0.756	8.161	-3.404
1136	C	GLY	131	0.130	9.399	-3.532
1137	O	GLY	131	0.387	10.084	-2.535
1138	N	SER	132	0.443	9.765	-4.765
1140	CA	SER	132	1.174	11.013	-5.045
1141	CB	SER	132	2.674	10.743	-5.102
1142	OG	SER	132	3.106	10.386	-3.795
1143	C	SER	132	0.702	11.627	-6.364
1144	O	SER	132	0.463	10.910	-7.342
1145	N	ILE	133	0.544	12.940	-6.372
1147	CA	ILE	133	0.050	13.633	-7.571
1148	CB	ILE	133	-0.575	14.966	-7.146
1149	CG2	ILE	133	-0.945	15.872	-8.318
1150	CG1	ILE	133	-1.815	14.721	-6.301
1151	CD1	ILE	133	-2.665	15.984	-6.247
1152	C	ILE	133	1.173	13.830	-8.589
1153	O	ILE	133	2.241	14.357	-8.258
1154	N	GLU	134	0.858	13.565	-9.851
1156	CA	GLU	134	1.848	13.637	-10.935

1157	CB	GLU	134	1.226	13.055	-12.197
1158	CG	GLU	134	0.892	11.578	-12.033
1159	CD	GLU	134	0.188	11.072	-13.288
1160	OE1	GLU	134	0.284	11.753	-14.299
1161	OE2	GLU	134	-0.574	10.124	-13.159
1162	C	GLU	134	2.338	15.052	-11.246
1163	O	GLU	134	3.504	15.195	-11.627
1164	N	THR	135	1.612	16.071	-10.814
1166	CA	THR	135	2.082	17.439	-11.029
1167	CB	THR	135	0.925	18.406	-10.834
1168	OG1	THR	135	-0.146	18.009	-11.678
1169	CG2	THR	135	1.340	19.819	-11.219
1170	C	THR	135	3.200	17.777	-10.045
1171	O	THR	135	4.247	18.269	-10.482
1172	N	TYR	136	3.145	17.168	-8.871
1174	CA	TYR	136	4.200	17.364	-7.872
1175	CB	TYR	136	3.647	17.007	-6.503
1176	CG	TYR	136	2.593	17.957	-5.958
1177	CD1	TYR	136	2.754	19.331	-6.085
1178	CE1	TYR	136	1.784	20.192	-5.589
1179	CZ	TYR	136	0.662	19.673	-4.956
1180	OH	TYR	136	-0.365	20.508	-4.586
1181	CE2	TYR	136	0.514	18.302	-4.802
1182	CD2	TYR	136	1.484	17.443	-5.299
1183	C	TYR	136	5.406	16.470	-8.149
1184	O	TYR	136	6.541	16.839	-7.813
1185	N	GLU	137	5.180	15.442	-8.952
1187	CA	GLU	137	6.265	14.549	-9.349
1188	CB	GLU	137	5.719	13.155	-9.656
1189	CG	GLU	137	4.785	12.608	-8.578
1190	CD	GLU	137	5.422	12.575	-7.186
1191	OE1	GLU	137	6.135	11.623	-6.914
1192	OE2	GLU	137	4.977	13.366	-6.368
1193	C	GLU	137	6.973	15.096	-10.588
1194	O	GLU	137	8.138	14.762	-10.831
1195	N	GLN	138	6.334	16.009	-11.297
1197	CA	GLN	138	7.038	16.697	-12.375
1198	CB	GLN	138	6.020	17.242	-13.378
1199	CG	GLN	138	6.593	17.418	-14.789
1200	CD	GLN	138	7.711	18.459	-14.852
1201	OE1	GLN	138	7.527	19.615	-14.453
1202	NE2	GLN	138	8.856	18.036	-15.359
1205	C	GLN	138	7.830	17.832	-11.744
1206	O	GLN	138	9.028	17.975	-12.020
1207	N	GLU	139	7.235	18.401	-10.710
1209	CA	GLU	139	7.822	19.523	-9.979
1210	CB	GLU	139	6.784	20.076	-9.008
1211	CG	GLU	139	5.631	20.789	-9.694
1212	CD	GLU	139	4.577	21.116	-8.643
1213	OE1	GLU	139	3.406	20.882	-8.904
1214	OE2	GLU	139	4.978	21.486	-7.547
1215	C	GLU	139	9.066	19.204	-9.155
1216	O	GLU	139	9.860	18.291	-9.445
1217	N	LYS	140	9.013	19.819	-7.986
1219	CA	LYS	140	10.132	20.030	-7.062
1220	CB	LYS	140	9.556	21.013	-6.045
1221	CG	LYS	140	8.214	20.466	-5.559
1222	CD	LYS	140	7.437	21.413	-4.657
1223	CE	LYS	140	6.136	20.760	-4.204
1224	NZ	LYS	140	5.352	21.653	-3.340

1225	C	LYS	140	10.659	18.811	-6.308
1226	O	LYS	140	11.628	18.950	-5.556
1227	N	ALA	141	10.067	17.644	-6.490
1229	CA	ALA	141	10.575	16.481	-5.770
1230	CB	ALA	141	9.434	15.828	-5.018
1231	C	ALA	141	11.189	15.445	-6.686
1232	O	ALA	141	12.180	14.800	-6.321
1233	N	VAL	142	10.646	15.313	-7.882
1235	CA	VAL	142	11.112	14.219	-8.731
1236	CB	VAL	142	9.960	13.276	-9.049
1237	CG1	VAL	142	10.451	12.006	-9.744
1238	CG2	VAL	142	9.205	12.915	-7.777
1239	C	VAL	142	11.793	14.739	-9.985
1240	O	VAL	142	13.010	14.930	-9.941
1241	N	PHE	143	11.039	15.138	-10.999
1243	CA	PHE	143	11.676	15.455	-12.282
1244	CB	PHE	143	10.634	15.597	-13.382
1245	CG	PHE	143	9.954	14.292	-13.786
1246	CD1	PHE	143	8.636	14.302	-14.227
1247	CE1	PHE	143	8.014	13.113	-14.588
1248	CZ	PHE	143	8.712	11.913	-14.515
1249	CE2	PHE	143	10.034	11.906	-14.087
1250	CD2	PHE	143	10.656	13.095	-13.727
1251	C	PHE	143	12.546	16.705	-12.210
1252	O	PHE	143	13.767	16.565	-12.358
1253	N	GLN	144	12.013	17.787	-11.663
1255	CA	GLN	144	12.795	19.027	-11.582
1256	CB	GLN	144	11.858	20.182	-11.266
1257	CG	GLN	144	10.866	20.430	-12.392
1258	CD	GLN	144	9.865	21.499	-11.970
1259	OE1	GLN	144	9.977	22.066	-10.877
1260	NE2	GLN	144	8.789	21.612	-12.730
1263	C	GLN	144	13.899	18.976	-10.530
1264	O	GLN	144	14.992	19.499	-10.780
1265	N	PHE	145	13.747	18.123	-9.530
1267	CA	PHE	145	14.789	18.046	-8.507
1268	CB	PHE	145	14.174	17.614	-7.185
1269	CG	PHE	145	15.117	17.799	-6.002
1270	CD1	PHE	145	16.060	18.817	-6.028
1271	CE1	PHE	145	16.928	18.993	-4.959
1272	CZ	PHE	145	16.852	18.147	-3.862
1273	CE2	PHE	145	15.912	17.125	-3.839
1274	CD2	PHE	145	15.046	16.948	-4.910
1275	C	PHE	145	15.896	17.074	-8.921
1276	O	PHE	145	17.066	17.324	-8.618
1277	N	TYR	146	15.575	16.155	-9.813
1279	CA	TYR	146	16.572	15.226	-10.339
1280	CB	TYR	146	15.851	13.970	-10.831
1281	CG	TYR	146	16.737	12.742	-10.981
1282	CD1	TYR	146	17.740	12.497	-10.051
1283	CE1	TYR	146	18.546	11.372	-10.179
1284	CZ	TYR	146	18.343	10.493	-11.234
1285	OH	TYR	146	19.139	9.376	-11.360
1286	CE2	TYR	146	17.339	10.735	-12.163
1287	CD2	TYR	146	16.533	11.860	-12.034
1288	C	TYR	146	17.338	15.873	-11.489
1289	O	TYR	146	18.529	15.599	-11.669
1290	N	GLN	147	16.746	16.906	-12.070
1292	CA	GLN	147	17.453	17.732	-13.054
1293	CB	GLN	147	16.406	18.449	-13.901

1294	CG	GLN	147	15.549	17.427	-14.643
1295	CD	GLN	147	14.345	18.080	-15.314
1296	OE1	GLN	147	13.487	18.690	-14.663
1297	NE2	GLN	147	14.234	17.837	-16.608
1300	C	GLN	147	18.362	18.738	-12.344
1301	O	GLN	147	19.451	19.052	-12.841
1302	N	ARG	148	18.048	18.993	-11.083
1304	CA	ARG	148	18.876	19.832	-10.213
1305	CB	ARG	148	17.949	20.396	-9.142
1306	CG	ARG	148	18.542	21.580	-8.392
1307	CD	ARG	148	17.557	22.055	-7.335
1308	NE	ARG	148	16.198	22.087	-7.900
1309	CZ	ARG	148	15.087	22.121	-7.160
1310	NH1	ARG	148	15.170	22.258	-5.835
1311	NH2	ARG	148	13.890	22.094	-7.754
1312	C	ARG	148	19.999	19.011	-9.562
1313	O	ARG	148	21.002	19.576	-9.109
1314	N	THR	149	19.942	17.699	-9.743
1316	CA	THR	149	20.972	16.781	-9.236
1317	CB	THR	149	20.338	15.401	-9.049
1318	OG1	THR	149	19.179	15.553	-8.246
1319	CG2	THR	149	21.258	14.404	-8.349
1320	C	THR	149	22.159	16.691	-10.204
1321	O	THR	149	23.207	16.135	-9.856
1322	N	LYS	150	22.064	17.412	-11.313
1324	CA	LYS	150	23.145	17.484	-12.303
1325	CB	LYS	150	22.552	18.209	-13.509
1326	CG	LYS	150	23.565	18.460	-14.618
1327	CD	LYS	150	23.042	19.495	-15.608
1328	CE	LYS	150	22.778	20.830	-14.914
1329	NZ	LYS	150	24.010	21.383	-14.325
1330	C	LYS	150	24.372	18.264	-11.805
1331	O	LYS	150	25.484	18.044	-12.301
1332	N	GLU	151	24.202	19.068	-10.767
1334	CA	GLU	151	25.341	19.791	-10.190
1335	CB	GLU	151	24.824	21.021	-9.441
1336	CG	GLU	151	23.695	20.691	-8.469
1337	CD	GLU	151	23.111	21.967	-7.872
1338	OE1	GLU	151	23.517	22.322	-6.775
1339	OE2	GLU	151	22.311	22.593	-8.553
1340	C	GLU	151	26.191	18.878	-9.295
1341	O	GLU	151	26.041	18.951	-8.083
1342	OXT	GLU	151	27.093	18.256	-9.838

Table X

Atom No	Atom name	Residue	Residue No	x coord	y coord	z coord
1271	N	PRO	159	7.810	59.922	28.682
1272	CA	PRO	159	7.834	60.673	27.424
1273	CB	PRO	159	6.519	61.385	27.362
1274	CG	PRO	159	5.766	61.156	28.664
1275	CD	PRO	159	6.652	60.259	29.513
1276	C	PRO	159	9.003	61.649	27.419
1277	O	PRO	159	9.148	62.480	28.324
1278	N	THR	160	9.817	61.560	26.386
1280	CA	THR	160	11.063	62.328	26.377
1281	CB	THR	160	12.168	61.440	25.831
1282	OG1	THR	160	12.161	60.233	26.582
1283	CG2	THR	160	13.525	62.113	25.990
1284	C	THR	160	10.970	63.589	25.534
1285	O	THR	160	10.738	63.526	24.323
1286	N	ARG	161	11.150	64.726	26.181
1288	CA	ARG	161	11.183	66.001	25.462
1289	CB	ARG	161	11.339	67.120	26.484
1290	CG	ARG	161	11.208	68.500	25.851
1291	CD	ARG	161	11.629	69.598	26.819
1292	NE	ARG	161	13.058	69.463	27.148
1293	CZ	ARG	161	13.521	69.226	28.379
1294	NH1	ARG	161	12.672	69.116	29.403
1295	NH2	ARG	161	14.834	69.100	28.583
1296	C	ARG	161	12.376	66.009	24.511
1297	O	ARG	161	13.487	65.624	24.893
1298	N	ILE	162	12.111	66.309	23.252
1300	CA	ILE	162	13.177	66.368	22.253
1301	CB	ILE	162	12.753	65.567	21.024
1302	CG2	ILE	162	13.842	65.603	19.958
1303	CG1	ILE	162	12.418	64.122	21.382
1304	CD1	ILE	162	13.635	63.356	21.892
1305	C	ILE	162	13.402	67.823	21.869
1306	O	ILE	162	14.536	68.281	21.682
1307	N	LEU	163	12.300	68.549	21.819
1309	CA	LEU	163	12.333	69.988	21.536
1310	CB	LEU	163	11.808	70.243	20.122
1311	CG	LEU	163	12.835	69.894	19.050
1312	CD1	LEU	163	12.244	70.054	17.656
1313	CD2	LEU	163	14.079	70.762	19.197
1314	C	LEU	163	11.466	70.721	22.550
1315	O	LEU	163	10.632	70.092	23.213
1316	N	PRO	164	11.703	72.012	22.725
1317	CA	PRO	164	10.737	72.843	23.446
1318	CB	PRO	164	11.263	74.242	23.358
1319	CG	PRO	164	12.565	74.238	22.571
1320	CD	PRO	164	12.804	72.796	22.156
1321	C	PRO	164	9.354	72.708	22.817
1322	O	PRO	164	9.170	72.931	21.615
1323	N	ASN	165	8.421	72.281	23.654
1325	CA	ASN	165	7.035	71.973	23.265
1326	CB	ASN	165	6.370	73.188	22.628
1327	CG	ASN	165	6.228	74.328	23.628
1328	OD1	ASN	165	5.554	74.179	24.654
1329	ND2	ASN	165	6.774	75.473	23.259
1332	C	ASN	165	6.920	70.781	22.313
1333	O	ASN	165	6.005	70.751	21.479
1334	N	LEU	166	7.743	69.766	22.528
1336	CA	LEU	166	7.694	68.542	21.715
1337	CB	LEU	166	8.507	68.743	20.438
1338	CG	LEU	166	8.613	67.459	19.613

1339	CD1	LEU	166	7.243	66.934	19.198
1340	CD2	LEU	166	9.495	67.656	18.386
1341	C	LEU	166	8.242	67.343	22.489
1342	O	LEU	166	9.458	67.203	22.685
1343	N	TYR	167	7.326	66.479	22.889
1345	CA	TYR	167	7.661	65.244	23.606
1346	CB	TYR	167	6.751	65.099	24.825
1347	CG	TYR	167	7.047	66.005	26.019
1348	CD1	TYR	167	6.568	67.309	26.051
1349	CE1	TYR	167	6.835	68.120	27.149
1350	CZ	TYR	167	7.573	67.620	28.213
1351	OH	TYR	167	7.776	68.406	29.326
1352	CE2	TYR	167	8.046	66.316	28.186
1353	CD2	TYR	167	7.779	65.508	27.090
1354	C	TYR	167	7.477	64.016	22.714
1355	O	TYR	167	6.441	63.841	22.060
1356	N	LEU	168	8.487	63.166	22.723
1358	CA	LEU	168	8.456	61.889	22.009
1359	CB	LEU	168	9.904	61.458	21.802
1360	CG	LEU	168	10.031	60.174	20.994
1361	CD1	LEU	168	9.446	60.354	19.600
1362	CD2	LEU	168	11.490	59.745	20.909
1363	C	LEU	168	7.727	60.843	22.848
1364	O	LEU	168	8.101	60.587	24.002
1365	N	GLY	169	6.710	60.237	22.261
1367	CA	GLY	169	5.895	59.257	22.975
1368	C	GLY	169	5.992	57.843	22.405
1369	O	GLY	169	5.272	57.451	21.476
1370	N	CYS	170	6.877	57.075	23.011
1372	CA	CYS	170	6.962	55.637	22.743
1373	CB	CYS	170	8.266	55.120	23.348
1374	SG	CYS	170	8.700	53.387	23.049
1375	C	CYS	170	5.772	54.968	23.422
1376	O	CYS	170	5.354	55.430	24.490
1377	N	GLN	171	5.388	53.797	22.933
1379	CA	GLN	171	4.230	53.025	23.430
1380	CB	GLN	171	4.108	51.825	22.499
1381	CG	GLN	171	5.387	50.998	22.578
1382	CD	GLN	171	5.407	49.864	21.564
1383	OE1	GLN	171	6.432	49.650	20.907
1384	NE2	GLN	171	4.271	49.211	21.394
1387	C	GLN	171	4.332	52.480	24.867
1388	O	GLN	171	3.398	51.816	25.329
1389	N	ARG	172	5.436	52.731	25.555
1391	CA	ARG	172	5.604	52.289	26.939
1392	CB	ARG	172	7.038	51.800	27.117
1393	CG	ARG	172	7.400	50.730	26.092
1394	CD	ARG	172	6.526	49.488	26.229
1395	NE	ARG	172	6.825	48.529	25.157
1396	CZ	ARG	172	6.807	47.207	25.336
1397	NH1	ARG	172	6.506	46.701	26.535
1398	NH2	ARG	172	7.090	46.392	24.318
1399	C	ARG	172	5.342	53.446	27.903
1400	O	ARG	172	5.244	53.239	29.119
1401	N	ASP	173	5.183	54.637	27.348
1403	CA	ASP	173	4.962	55.838	28.160
1404	CB	ASP	173	5.188	57.086	27.313
1405	CG	ASP	173	6.621	57.152	26.808
1406	OD1	ASP	173	7.488	56.556	27.438
1407	OD2	ASP	173	6.857	57.886	25.856
1408	C	ASP	173	3.558	55.868	28.742
1409	O	ASP	173	2.586	55.445	28.105
1410	N	VAL	174	3.467	56.365	29.962
1412	CA	VAL	174	2.163	56.446	30.630
1413	CB	VAL	174	2.373	56.566	32.139

1414	CG1	VAL	174	1.055	56.735	32.891
1415	CG2	VAL	174	3.125	55.356	32.675
1416	C	VAL	174	1.364	57.639	30.113
1417	O	VAL	174	1.762	58.797	30.283
1418	N	LEU	175	0.206	57.346	29.543
1420	CA	LEU	175	-0.702	58.394	29.049
1421	CB	LEU	175	-1.527	57.836	27.897
1422	CG	LEU	175	-0.675	57.638	26.651
1423	CD1	LEU	175	-1.479	56.974	25.540
1424	CD2	LEU	175	-0.108	58.972	26.178
1425	C	LEU	175	-1.645	58.911	30.134
1426	O	LEU	175	-2.867	58.748	30.049
1427	N	ASN	176	-1.067	59.505	31.162
1429	CA	ASN	176	-1.863	60.067	32.249
1430	CB	ASN	176	-1.081	59.893	33.548
1431	CG	ASN	176	-1.887	60.398	34.738
1432	OD1	ASN	176	-1.914	61.603	35.013
1433	ND2	ASN	176	-2.584	59.485	35.390
1436	C	ASN	176	-2.126	61.537	31.950
1437	O	ASN	176	-1.178	62.322	31.834
1438	N	LYS	177	-3.386	61.939	31.994
1440	CA	LYS	177	-3.742	63.305	31.584
1441	CB	LYS	177	-5.253	63.389	31.401
1442	CG	LYS	177	-5.678	64.803	31.020
1443	CD	LYS	177	-7.140	64.870	30.596
1444	CE	LYS	177	-7.372	64.142	29.277
1445	NZ	LYS	177	-8.756	64.328	28.811
1446	C	LYS	177	-3.261	64.383	32.556
1447	O	LYS	177	-2.667	65.360	32.080
1448	N	GLU	178	-3.132	64.034	33.827
1450	CA	GLU	178	-2.633	64.996	34.812
1451	CB	GLU	178	-2.907	64.469	36.214
1452	CG	GLU	178	-2.362	65.422	37.273
1453	CD	GLU	178	-2.326	64.727	38.627
1454	OE1	GLU	178	-2.944	63.675	38.737
1455	OE2	GLU	178	-1.735	65.281	39.546
1456	C	GLU	178	-1.130	65.173	34.651
1457	O	GLU	178	-0.668	66.316	34.563
1458	N	LEU	179	-0.466	64.094	34.269
1460	CA	LEU	179	0.980	64.110	34.041
1461	CB	LEU	179	1.442	62.650	34.005
1462	CG	LEU	179	2.927	62.451	33.702
1463	CD1	LEU	179	3.498	61.304	34.528
1464	CD2	LEU	179	3.183	62.216	32.213
1465	C	LEU	179	1.329	64.845	32.748
1466	O	LEU	179	2.333	65.571	32.712
1467	N	MET	180	0.413	64.856	31.796
1469	CA	MET	180	0.649	65.614	30.571
1470	CB	MET	180	-0.261	65.095	29.465
1471	CG	MET	180	0.038	63.631	29.162
1472	SD	MET	180	-0.821	62.933	27.733
1473	CE	MET	180	-2.525	63.329	28.179
1474	C	MET	180	0.410	67.099	30.810
1475	O	MET	180	1.274	67.904	30.439
1476	N	GLN	181	-0.508	67.410	31.710
1478	CA	GLN	181	-0.753	68.808	32.077
1479	CB	GLN	181	-2.083	68.880	32.818
1480	CG	GLN	181	-3.225	68.380	31.940
1481	CD	GLN	181	-4.522	68.322	32.740
1482	OE1	GLN	181	-4.974	67.247	33.159
1483	NE2	GLN	181	-5.108	69.488	32.939
1486	C	GLN	181	0.362	69.363	32.966
1487	O	GLN	181	0.765	70.515	32.774
1488	N	GLN	182	1.029	68.482	33.697
1490	CA	GLN	182	2.188	68.872	34.513

1491	CB	GLN	182	2.373	67.811	35.590
1492	CG	GLN	182	1.165	67.769	36.517
1493	CD	GLN	182	1.232	66.556	37.438
1494	OE1	GLN	182	0.810	65.449	37.075
1495	NE2	GLN	182	1.696	66.796	38.650
1498	C	GLN	182	3.479	68.994	33.700
1499	O	GLN	182	4.458	69.573	34.183
1500	N	ASN	183	3.465	68.490	32.477
1502	CA	ASN	183	4.597	68.659	31.560
1503	CB	ASN	183	4.841	67.355	30.804
1504	CG	ASN	183	5.774	66.424	31.582
1505	OD1	ASN	183	6.998	66.487	31.420
1506	ND2	ASN	183	5.195	65.551	32.387
1509	C	ASN	183	4.345	69.797	30.571
1510	O	ASN	183	5.234	70.153	29.787
1511	N	GLY	184	3.136	70.340	30.600
1513	CA	GLY	184	2.778	71.482	29.753
1514	C	GLY	184	2.211	71.046	28.406
1515	O	GLY	184	2.220	71.826	27.445
1516	N	ILE	185	1.753	69.807	28.340
1518	CA	ILE	185	1.241	69.238	27.090
1519	CB	ILE	185	1.373	67.717	27.164
1520	CG2	ILE	185	0.772	67.030	25.942
1521	CG1	ILE	185	2.837	67.322	27.322
1522	CD1	ILE	185	3.009	65.809	27.389
1523	C	ILE	185	-0.206	69.655	26.863
1524	O	ILE	185	-1.093	69.385	27.685
1525	N	GLY	186	-0.429	70.291	25.727
1527	CA	GLY	186	-1.752	70.800	25.376
1528	C	GLY	186	-2.207	70.187	24.062
1529	O	GLY	186	-3.407	70.157	23.753
1530	N	TYR	187	-1.239	69.767	23.267
1532	CA	TYR	187	-1.544	69.081	22.011
1533	CB	TYR	187	-0.900	69.854	20.863
1534	CG	TYR	187	-1.538	71.217	20.579
1535	CD1	TYR	187	-1.014	72.377	21.140
1536	CE1	TYR	187	-1.600	73.607	20.873
1537	CZ	TYR	187	-2.710	73.675	20.042
1538	OH	TYR	187	-3.299	74.893	19.786
1539	CE2	TYR	187	-3.233	72.522	19.476
1540	CD2	TYR	187	-2.645	71.294	19.745
1541	C	TYR	187	-1.053	67.634	22.050
1542	O	TYR	187	0.029	67.340	22.571
1543	N	VAL	188	-1.887	66.726	21.576
1545	CA	VAL	188	-1.518	65.303	21.553
1546	CB	VAL	188	-2.387	64.524	22.540
1547	CG1	VAL	188	-2.002	63.048	22.553
1548	CG2	VAL	188	-2.292	65.097	23.950
1549	C	VAL	188	-1.680	64.717	20.151
1550	O	VAL	188	-2.798	64.541	19.650
1551	N	LEU	189	-0.558	64.351	19.563
1553	CA	LEU	189	-0.536	63.798	18.210
1554	CB	LEU	189	0.669	64.417	17.504
1555	CG	LEU	189	0.605	64.373	15.979
1556	CD1	LEU	189	1.550	65.408	15.384
1557	CD2	LEU	189	0.899	62.991	15.407
1558	C	LEU	189	-0.410	62.278	18.301
1559	O	LEU	189	0.602	61.751	18.775
1560	N	ASN	190	-1.431	61.581	17.841
1562	CA	ASN	190	-1.420	60.121	17.902
1563	CB	ASN	190	-2.760	59.630	18.441
1564	CG	ASN	190	-2.789	58.109	18.367
1565	OD1	ASN	190	-3.450	57.533	17.495
1566	ND2	ASN	190	-1.926	57.480	19.143
1569	C	ASN	190	-1.139	59.514	16.529

1570	O	ASN	190	-1.955	59.608	15.606
1571	N	ALA	191	-0.025	58.806	16.447
1573	CA	ALA	191	0.407	58.172	15.194
1574	CB	ALA	191	1.908	58.389	15.046
1575	C	ALA	191	0.112	56.670	15.130
1576	O	ALA	191	0.899	55.919	14.542
1577	N	SER	192	-0.958	56.224	15.766
1579	CA	SER	192	-1.206	54.782	15.854
1580	CB	SER	192	-1.912	54.479	17.170
1581	OG	SER	192	-1.059	54.926	18.225
1582	C	SER	192	-1.992	54.260	14.649
1583	O	SER	192	-2.502	55.028	13.822
1584	N	ASN	193	-1.985	52.944	14.516
1586	CA	ASN	193	-2.607	52.290	13.363
1587	CB	ASN	193	-2.303	50.793	13.362
1588	CG	ASN	193	-2.461	50.148	14.738
1589	OD1	ASN	193	-3.403	50.423	15.490
1590	ND2	ASN	193	-1.525	49.268	15.045
1593	C	ASN	193	-4.102	52.546	13.265
1594	O	ASN	193	-4.865	52.431	14.231
1595	N	THR	194	-4.471	52.920	12.050
1597	CA	THR	194	-5.833	53.284	11.624
1598	CB	THR	194	-6.594	52.008	11.267
1599	OG1	THR	194	-6.679	51.178	12.419
1600	CG2	THR	194	-5.879	51.224	10.172
1601	C	THR	194	-6.628	54.102	12.643
1602	O	THR	194	-7.778	53.767	12.949
1603	N	CYS	195	-6.038	55.184	13.127
1605	CA	CYS	195	-6.763	56.090	14.023
1606	CB	CYS	195	-5.924	56.299	15.279
1607	SG	CYS	195	-5.598	54.819	16.262
1608	C	CYS	195	-6.992	57.434	13.342
1609	O	CYS	195	-6.096	58.279	13.351
1610	N	PRO	196	-8.127	57.602	12.686
1611	CA	PRO	196	-8.392	58.842	11.953
1612	CB	PRO	196	-9.475	58.481	10.984
1613	CG	PRO	196	-10.070	57.140	11.389
1614	CD	PRO	196	-9.222	56.638	12.548
1615	C	PRO	196	-8.853	59.980	12.862
1616	O	PRO	196	-9.020	59.801	14.074
1617	N	LYS	197	-8.872	61.162	12.264
1619	CA	LYS	197	-9.517	62.397	12.769
1620	CB	LYS	197	-11.033	62.207	12.961
1621	CG	LYS	197	-11.443	61.549	14.278
1622	CD	LYS	197	-12.955	61.388	14.391
1623	CE	LYS	197	-13.667	62.736	14.402
1624	NZ	LYS	197	-15.125	62.567	14.529
1625	C	LYS	197	-8.890	63.026	14.018
1626	O	LYS	197	-8.593	62.383	15.033
1627	N	PRO	198	-8.633	64.316	13.884
1628	CA	PRO	198	-8.458	65.184	15.049
1629	CB	PRO	198	-8.097	66.522	14.486
1630	CG	PRO	198	-8.299	66.495	12.979
1631	CD	PRO	198	-8.726	65.078	12.637
1632	C	PRO	198	-9.747	65.276	15.861
1633	O	PRO	198	-10.852	65.161	15.319
1634	N	ASP	199	-9.590	65.480	17.156
1636	CA	ASP	199	-10.746	65.583	18.054
1637	CB	ASP	199	-11.299	64.182	18.311
1638	CG	ASP	199	-12.690	64.271	18.937
1639	OD1	ASP	199	-13.012	63.414	19.745
1640	OD2	ASP	199	-13.391	65.220	18.610
1641	C	ASP	199	-10.340	66.243	19.372
1642	O	ASP	199	-9.345	65.861	19.998

1643	N	PHE	200	-11.089	67.256	19.774
1645	CA	PHE	200	-10.774	67.952	21.027
1646	CB	PHE	200	-11.397	69.344	20.991
1647	CG	PHE	200	-11.066	70.229	22.194
1648	CD1	PHE	200	-12.007	71.133	22.672
1649	CE1	PHE	200	-11.703	71.942	23.759
1650	CZ	PHE	200	-10.460	71.848	24.370
1651	CE2	PHE	200	-9.521	70.942	23.896
1652	CD2	PHE	200	-9.825	70.134	22.809
1653	C	PHE	200	-11.306	67.178	22.231
1654	O	PHE	200	-12.516	67.115	22.468
1655	N	ILE	201	-10.386	66.576	22.964
1657	CA	ILE	201	-10.736	65.876	24.200
1658	CB	ILE	201	-10.063	64.506	24.191
1659	CG2	ILE	201	-10.399	63.709	25.447
1660	CG1	ILE	201	-10.483	63.723	22.950
1661	CD1	ILE	201	-9.845	62.339	22.914
1662	C	ILE	201	-10.246	66.740	25.359
1663	O	ILE	201	-9.065	66.659	25.705
1664	N	PRO	202	-11.199	67.254	26.123
1665	CA	PRO	202	-11.264	68.709	26.425
1666	CB	PRO	202	-12.547	68.886	27.179
1667	CG	PRO	202	-13.369	67.615	27.069
1668	CD	PRO	202	-12.547	66.681	26.203
1669	C	PRO	202	-10.116	69.368	27.205
1670	O	PRO	202	-10.119	70.594	27.344
1671	N	GLU	203	-9.144	68.616	27.689
1673	CA	GLU	203	-7.980	69.248	28.305
1674	CB	GLU	203	-7.541	68.427	29.510
1675	CG	GLU	203	-8.638	68.361	30.568
1676	CD	GLU	203	-8.914	69.745	31.154
1677	OE1	GLU	203	-7.992	70.309	31.728
1678	OE2	GLU	203	-10.080	70.111	31.188
1679	C	GLU	203	-6.840	69.357	27.292
1680	O	GLU	203	-5.879	70.098	27.524
1681	N	SER	204	-6.958	68.635	26.186
1683	CA	SER	204	-5.957	68.708	25.112
1684	CB	SER	204	-4.875	67.658	25.356
1685	OG	SER	204	-4.087	68.080	26.463
1686	C	SER	204	-6.560	68.499	23.722
1687	O	SER	204	-7.566	67.800	23.537
1688	N	HIS	205	-5.935	69.132	22.745
1690	CA	HIS	205	-6.337	68.947	21.346
1691	CB	HIS	205	-5.946	70.170	20.526
1692	CG	HIS	205	-6.757	71.416	20.809
1693	ND1	HIS	205	-7.917	71.758	20.219
1695	CE1	HIS	205	-8.346	72.932	20.723
1696	NE2	HIS	205	-7.441	73.337	21.642
1697	CD2	HIS	205	-6.454	72.414	21.706
1698	C	HIS	205	-5.649	67.724	20.760
1699	O	HIS	205	-4.417	67.681	20.650
1700	N	PHE	206	-6.445	66.735	20.398
1702	CA	PHE	206	-5.893	65.503	19.830
1703	CB	PHE	206	-6.668	64.291	20.349
1704	CG	PHE	206	-6.362	63.842	21.780
1705	CD1	PHE	206	-5.799	62.589	21.988
1706	CE1	PHE	206	-5.520	62.156	23.278
1707	CZ	PHE	206	-5.809	62.973	24.364
1708	CE2	PHE	206	-6.379	64.222	24.159
1709	CD2	PHE	206	-6.659	64.653	22.869
1710	C	PHE	206	-5.931	65.515	18.306
1711	O	PHE	206	-6.837	66.076	17.678
1712	N	LEU	207	-4.886	64.954	17.730
1714	CA	LEU	207	-4.811	64.736	16.283
1715	CB	LEU	207	-3.694	65.595	15.695

1716	CG	LEU	207	-3.473	65.318	14.206
1717	CD1	LEU	207	-4.703	65.670	13.380
1718	CD2	LEU	207	-2.256	66.066	13.678
1719	C	LEU	207	-4.496	63.274	16.009
1720	O	LEU	207	-3.339	62.857	16.142
1721	N	ARG	208	-5.513	62.488	15.709
1723	CA	ARG	208	-5.245	61.105	15.342
1724	CB	ARG	208	-6.391	60.218	15.792
1725	CG	ARG	208	-6.334	59.973	17.292
1726	CD	ARG	208	-7.433	59.012	17.719
1727	NE	ARG	208	-7.094	58.362	18.993
1728	CZ	ARG	208	-7.477	57.116	19.280
1729	NH1	ARG	208	-7.020	56.515	20.381
1730	NH2	ARG	208	-8.225	56.435	18.408
1731	C	ARG	208	-4.979	60.985	13.847
1732	O	ARG	208	-5.726	61.482	12.991
1733	N	VAL	209	-3.809	60.437	13.581
1735	CA	VAL	209	-3.318	60.229	12.222
1736	CB	VAL	209	-1.807	60.448	12.257
1737	CG1	VAL	209	-1.179	60.279	10.881
1738	CG2	VAL	209	-1.470	61.820	12.826
1739	C	VAL	209	-3.628	58.806	11.779
1740	O	VAL	209	-3.208	57.841	12.430
1741	N	PRO	210	-4.391	58.682	10.704
1742	CA	PRO	210	-4.766	57.368	10.164
1743	CB	PRO	210	-5.846	57.657	9.167
1744	CG	PRO	210	-5.951	59.161	8.962
1745	CD	PRO	210	-4.969	59.788	9.937
1746	C	PRO	210	-3.598	56.647	9.489
1747	O	PRO	210	-3.458	56.678	8.259
1748	N	VAL	211	-2.783	55.981	10.289
1750	CA	VAL	211	-1.663	55.217	9.746
1751	CB	VAL	211	-0.511	55.251	10.742
1752	CG1	VAL	211	0.701	54.528	10.172
1753	CG2	VAL	211	-0.144	56.683	11.108
1754	C	VAL	211	-2.077	53.773	9.505
1755	O	VAL	211	-2.116	52.964	10.437
1756	N	ASN	212	-2.475	53.477	8.281
1758	CA	ASN	212	-2.814	52.095	7.945
1759	CB	ASN	212	-3.391	52.062	6.531
1760	CG	ASN	212	-3.885	50.667	6.165
1761	OD1	ASN	212	-3.091	49.803	5.778
1762	ND2	ASN	212	-5.169	50.438	6.371
1765	C	ASN	212	-1.548	51.245	8.086
1766	O	ASN	212	-0.436	51.712	7.825
1767	N	ASP	213	-1.721	50.020	8.552
1769	CA	ASP	213	-0.585	49.153	8.890
1770	CB	ASP	213	-1.025	48.214	10.012
1771	CG	ASP	213	-2.251	47.397	9.602
1772	OD1	ASP	213	-3.355	47.845	9.884
1773	OD2	ASP	213	-2.058	46.299	9.099
1774	C	ASP	213	-0.023	48.339	7.717
1775	O	ASP	213	0.936	47.584	7.915
1776	N	SER	214	-0.602	48.459	6.532
1778	CA	SER	214	-0.058	47.751	5.366
1779	CB	SER	214	-1.032	47.848	4.198
1780	OG	SER	214	-1.051	49.200	3.758
1781	C	SER	214	1.271	48.364	4.947
1782	O	SER	214	1.475	49.577	5.070
1783	N	PHE	215	2.070	47.566	4.259
1785	CA	PHE	215	3.412	47.996	3.831
1786	CB	PHE	215	4.265	46.755	3.594
1787	CG	PHE	215	4.533	45.953	4.865
1788	CD1	PHE	215	5.122	46.572	5.961
1789	CE1	PHE	215	5.363	45.848	7.121

1790	CZ	PHE	215	5.017	44.505	7.186
1791	CE2	PHE	215	4.432	43.885	6.089
1792	CD2	PHE	215	4.190	44.609	4.928
1793	C	PHE	215	3.432	48.889	2.583
1794	O	PHE	215	4.509	49.209	2.072
1795	N	CYS	216	2.264	49.299	2.113
1797	CA	CYS	216	2.173	50.207	0.970
1798	CB	CYS	216	1.009	49.750	0.098
1799	SG	CYS	216	1.098	48.041	-0.484
1800	C	CYS	216	1.939	51.654	1.414
1801	O	CYS	216	1.796	52.544	0.568
1802	N	GLU	217	1.881	51.886	2.717
1804	CA	GLU	217	1.550	53.228	3.222
1805	CB	GLU	217	1.106	53.114	4.672
1806	CG	GLU	217	-0.102	52.197	4.791
1807	CD	GLU	217	-1.242	52.682	3.905
1808	OE1	GLU	217	-1.800	53.726	4.218
1809	OE2	GLU	217	-1.568	51.975	2.962
1810	C	GLU	217	2.691	54.239	3.122
1811	O	GLU	217	3.853	53.964	3.449
1812	N	LYS	218	2.313	55.425	2.680
1814	CA	LYS	218	3.241	56.553	2.604
1815	CB	LYS	218	3.047	57.226	1.251
1816	CG	LYS	218	4.097	58.293	0.979
1817	CD	LYS	218	3.893	58.903	-0.401
1818	CE	LYS	218	4.921	59.989	-0.685
1819	NZ	LYS	218	4.708	60.575	-2.016
1820	C	LYS	218	2.951	57.524	3.747
1821	O	LYS	218	1.867	58.112	3.832
1822	N	ILE	219	3.941	57.698	4.604
1824	CA	ILE	219	3.795	58.509	5.814
1825	CB	ILE	219	4.689	57.887	6.889
1826	CG2	ILE	219	4.646	58.672	8.196
1827	CG1	ILE	219	4.278	56.442	7.150
1828	CD1	ILE	219	2.874	56.363	7.741
1829	C	ILE	219	4.179	59.962	5.549
1830	O	ILE	219	3.709	60.860	6.256
1831	N	LEU	220	4.807	60.203	4.411
1833	CA	LEU	220	5.187	61.570	4.006
1834	CB	LEU	220	5.902	61.485	2.664
1835	CG	LEU	220	7.197	60.693	2.812
1836	CD1	LEU	220	7.880	60.476	1.469
1837	CD2	LEU	220	8.152	61.375	3.786
1838	C	LEU	220	4.054	62.627	3.972
1839	O	LEU	220	4.258	63.658	4.625
1840	N	PRO	221	2.870	62.399	3.400
1841	CA	PRO	221	1.821	63.428	3.514
1842	CB	PRO	221	0.704	62.962	2.631
1843	CG	PRO	221	1.033	61.587	2.075
1844	CD	PRO	221	2.409	61.245	2.614
1845	C	PRO	221	1.313	63.659	4.948
1846	O	PRO	221	1.090	64.820	5.327
1847	N	TRP	222	1.408	62.644	5.796
1849	CA	TRP	222	1.005	62.794	7.195
1850	CB	TRP	222	0.689	61.429	7.794
1851	CG	TRP	222	-0.579	60.738	7.326
1852	CD1	TRP	222	-0.798	59.377	7.365
1853	NE1	TRP	222	-2.052	59.126	6.897
1855	CE2	TRP	222	-2.671	60.262	6.545
1856	CZ2	TRP	222	-3.934	60.525	6.025
1857	CH2	TRP	222	-4.315	61.827	5.753
1858	CZ3	TRP	222	-3.442	62.886	5.998
1859	CE3	TRP	222	-2.173	62.631	6.516
1860	CD2	TRP	222	-1.789	61.334	6.785
1861	C	TRP	222	2.102	63.453	8.022

1862	O	TRP	222	1.792	64.136	9.003
1863	N	LEU	223	3.320	63.447	7.503
1865	CA	LEU	223	4.414	64.182	8.136
1866	CB	LEU	223	5.751	63.687	7.598
1867	CG	LEU	223	6.030	62.250	8.017
1868	CD1	LEU	223	7.328	61.744	7.398
1869	CD2	LEU	223	6.080	62.130	9.534
1870	C	LEU	223	4.287	65.670	7.857
1871	O	LEU	223	4.537	66.471	8.762
1872	N	ASP	224	3.635	66.014	6.760
1874	CA	ASP	224	3.373	67.424	6.462
1875	CB	ASP	224	2.833	67.532	5.039
1876	CG	ASP	224	3.803	66.906	4.037
1877	OD1	ASP	224	4.995	67.150	4.166
1878	OD2	ASP	224	3.324	66.265	3.110
1879	C	ASP	224	2.341	67.975	7.445
1880	O	ASP	224	2.650	68.910	8.200
1881	N	LYS	225	1.297	67.188	7.662
1883	CA	LYS	225	0.232	67.576	8.595
1884	CB	LYS	225	-0.901	66.566	8.460
1885	CG	LYS	225	-2.020	66.846	9.457
1886	CD	LYS	225	-3.065	65.735	9.450
1887	CE	LYS	225	-2.455	64.393	9.841
1888	NZ	LYS	225	-3.481	63.338	9.885
1889	C	LYS	225	0.711	67.574	10.045
1890	O	LYS	225	0.487	68.556	10.768
1891	N	SER	226	1.576	66.630	10.373
1893	CA	SER	226	2.082	66.521	11.739
1894	CB	SER	226	2.653	65.123	11.947
1895	OG	SER	226	3.777	64.952	11.096
1896	C	SER	226	3.139	67.575	12.064
1897	O	SER	226	3.093	68.111	13.175
1898	N	VAL	227	3.843	68.085	11.064
1900	CA	VAL	227	4.790	69.176	11.312
1901	CB	VAL	227	5.781	69.264	10.156
1902	CG1	VAL	227	6.560	70.574	10.189
1903	CG2	VAL	227	6.732	68.074	10.160
1904	C	VAL	227	4.050	70.497	11.469
1905	O	VAL	227	4.399	71.285	12.357
1906	N	ASP	228	2.872	70.574	10.870
1908	CA	ASP	228	2.023	71.750	11.050
1909	CB	ASP	228	0.871	71.685	10.049
1910	CG	ASP	228	1.379	71.634	8.610
1911	OD1	ASP	228	0.674	71.059	7.788
1912	OD2	ASP	228	2.371	72.293	8.328
1913	C	ASP	228	1.451	71.778	12.466
1914	O	ASP	228	1.635	72.777	13.174
1915	N	PHE	229	1.066	70.611	12.959
1917	CA	PHE	229	0.464	70.509	14.295
1918	CB	PHE	229	-0.196	69.139	14.388
1919	CG	PHE	229	-1.042	68.891	15.635
1920	CD1	PHE	229	-2.321	69.426	15.714
1921	CE1	PHE	229	-3.105	69.190	16.836
1922	CZ	PHE	229	-2.610	68.419	17.879
1923	CE2	PHE	229	-1.331	67.886	17.802
1924	CD2	PHE	229	-0.546	68.122	16.680
1925	C	PHE	229	1.497	70.672	15.411
1926	O	PHE	229	1.258	71.433	16.360
1927	N	ILE	230	2.706	70.191	15.170
1929	CA	ILE	230	3.773	70.331	16.162
1930	CB	ILE	230	4.883	69.334	15.845
1931	CG2	ILE	230	6.064	69.525	16.786
1932	CG1	ILE	230	4.393	67.897	15.934
1933	CD1	ILE	230	5.503	66.930	15.540
1934	C	ILE	230	4.354	71.741	16.165

1935	O	ILE	230	4.669	72.265	17.240
1936	N	GLU	231	4.253	72.435	15.045
1938	CA	GLU	231	4.761	73.803	14.992
1939	CB	GLU	231	5.053	74.155	13.540
1940	CG	GLU	231	5.797	75.477	13.419
1941	CD	GLU	231	6.190	75.694	11.963
1942	OE1	GLU	231	7.262	75.238	11.590
1943	OE2	GLU	231	5.381	76.247	11.231
1944	C	GLU	231	3.760	74.781	15.593
1945	O	GLU	231	4.174	75.746	16.248
1946	N	LYS	232	2.492	74.403	15.605
1948	CA	LYS	232	1.496	75.223	16.293
1949	CB	LYS	232	0.103	74.842	15.807
1950	CG	LYS	232	-0.073	75.177	14.330
1951	CD	LYS	232	-1.464	74.794	13.839
1952	CE	LYS	232	-1.738	73.313	14.067
1953	NZ	LYS	232	-3.065	72.927	13.561
1954	C	LYS	232	1.594	75.037	17.802
1955	O	LYS	232	1.614	76.039	18.526
1956	N	ALA	233	1.968	73.842	18.232
1958	CA	ALA	233	2.162	73.599	19.666
1959	CB	ALA	233	2.174	72.096	19.894
1960	C	ALA	233	3.471	74.183	20.189
1961	O	ALA	233	3.523	74.671	21.328
1962	N	LYS	234	4.449	74.311	19.308
1964	CA	LYS	234	5.730	74.895	19.695
1965	CB	LYS	234	6.798	74.373	18.739
1966	CG	LYS	234	8.196	74.824	19.143
1967	CD	LYS	234	9.262	74.205	18.247
1968	CE	LYS	234	10.664	74.616	18.684
1969	NZ	LYS	234	11.685	74.023	17.805
1970	C	LYS	234	5.698	76.421	19.680
1971	O	LYS	234	6.348	77.047	20.526
1972	N	ALA	235	4.821	76.998	18.875
1974	CA	ALA	235	4.715	78.460	18.830
1975	CB	ALA	235	4.370	78.881	17.406
1976	C	ALA	235	3.665	79.004	19.794
1977	O	ALA	235	3.742	80.169	20.204
1978	N	SER	236	2.745	78.152	20.212
1980	CA	SER	236	1.736	78.568	21.189
1981	CB	SER	236	0.418	77.878	20.862
1982	OG	SER	236	0.053	78.240	19.537
1983	C	SER	236	2.143	78.213	22.613
1984	O	SER	236	1.558	78.748	23.563
1985	N	ASN	237	3.216	77.445	22.738
1987	CA	ASN	237	3.701	76.962	24.037
1988	CB	ASN	237	4.146	78.125	24.922
1989	CG	ASN	237	5.345	78.825	24.288
1990	OD1	ASN	237	6.427	78.236	24.164
1991	ND2	ASN	237	5.136	80.064	23.878
1994	C	ASN	237	2.629	76.119	24.710
1995	O	ASN	237	1.961	76.542	25.662
1996	N	GLY	238	2.451	74.938	24.145
1998	CA	GLY	238	1.461	73.974	24.628
1999	C	GLY	238	1.837	72.589	24.119
2000	O	GLY	238	0.995	71.895	23.529
2001	N	CYS	239	2.982	72.139	24.612
2003	CA	CYS	239	3.725	70.941	24.168
2004	CB	CYS	239	4.387	70.323	25.393
2005	SG	CYS	239	5.410	71.424	26.398
2006	C	CYS	239	2.907	69.848	23.494
2007	O	CYS	239	1.839	69.447	23.977
2008	N	VAL	240	3.415	69.384	22.368
2010	CA	VAL	240	2.763	68.277	21.673

2011	CB	VAL	240	2.771	68.557	20.173
2012	CG1	VAL	240	4.169	68.889	19.679
2013	CG2	VAL	240	2.162	67.419	19.362
2014	C	VAL	240	3.443	66.949	21.995
2015	O	VAL	240	4.670	66.816	21.910
2016	N	LEU	241	2.652	66.024	22.507
2018	CA	LEU	241	3.128	64.656	22.723
2019	CB	LEU	241	2.402	64.062	23.927
2020	CG	LEU	241	2.804	62.611	24.186
2021	CD1	LEU	241	4.297	62.483	24.460
2022	CD2	LEU	241	2.008	62.020	25.342
2023	C	LEU	241	2.830	63.820	21.484
2024	O	LEU	241	1.660	63.604	21.150
2025	N	VAL	242	3.871	63.411	20.782
2027	CA	VAL	242	3.692	62.559	19.601
2028	CB	VAL	242	4.743	62.918	18.560
2029	CG1	VAL	242	4.575	62.071	17.303
2030	CG2	VAL	242	4.664	64.399	18.214
2031	C	VAL	242	3.825	61.097	20.009
2032	O	VAL	242	4.932	60.549	20.059
2033	N	HIS	243	2.688	60.475	20.264
2035	CA	HIS	243	2.668	59.131	20.844
2036	CB	HIS	243	1.799	59.180	22.099
2037	CG	HIS	243	1.992	58.018	23.055
2038	ND1	HIS	243	1.427	56.797	22.981
2040	CE1	HIS	243	1.853	56.044	24.014
2041	NE2	HIS	243	2.686	56.804	24.757
2042	CD2	HIS	243	2.782	58.023	24.180
2043	C	HIS	243	2.125	58.080	19.878
2044	O	HIS	243	1.027	58.217	19.313
2045	N	CYS	244	2.876	57.004	19.731
2047	CA	CYS	244	2.405	55.873	18.927
2048	CB	CYS	244	3.325	55.672	17.734
2049	SG	CYS	244	2.828	54.350	16.608
2050	C	CYS	244	2.344	54.595	19.769
2051	O	CYS	244	3.374	54.023	20.133
2052	N	LEU	245	1.138	54.053	19.864
2054	CA	LEU	245	0.892	52.873	20.711
2055	CB	LEU	245	-0.610	52.805	20.966
2056	CG	LEU	245	-1.097	53.960	21.831
2057	CD1	LEU	245	-2.605	54.149	21.705
2058	CD2	LEU	245	-0.690	53.751	23.285
2059	C	LEU	245	1.322	51.573	20.043
2060	O	LEU	245	1.554	50.565	20.724
2061	N	ALA	246	1.562	51.635	18.742
2063	CA	ALA	246	1.991	50.460	17.991
2064	CB	ALA	246	1.425	50.559	16.582
2065	C	ALA	246	3.511	50.340	17.913
2066	O	ALA	246	4.021	49.300	17.484
2067	N	GLY	247	4.218	51.351	18.387
2069	CA	GLY	247	5.676	51.309	18.318
2070	C	GLY	247	6.289	52.696	18.244
2071	O	GLY	247	5.753	53.597	17.584
2072	N	ILE	248	7.541	52.754	18.667
2074	CA	ILE	248	8.309	54.008	18.678
2075	CB	ILE	248	9.544	53.780	19.556
2076	CG2	ILE	248	10.278	52.506	19.154
2077	CG1	ILE	248	10.506	54.965	19.565
2078	CD1	ILE	248	9.877	56.213	20.175
2079	C	ILE	248	8.726	54.464	17.273
2080	O	ILE	248	8.894	55.670	17.066
2081	N	SER	249	8.548	53.599	16.286
2083	CA	SER	249	8.948	53.904	14.914
2084	CB	SER	249	8.702	52.668	14.063

2085	OG	SER	249	9.535	51.626	14.547
2086	C	SER	249	8.172	55.074	14.323
2087	O	SER	249	8.802	56.077	13.979
2088	N	ARG	250	6.862	55.093	14.508
2090	CA	ARG	250	6.064	56.145	13.870
2091	CB	ARG	250	4.629	55.657	13.752
2092	CG	ARG	250	4.576	54.344	12.985
2093	CD	ARG	250	3.153	53.813	12.894
2094	NE	ARG	250	3.111	52.544	12.152
2095	CZ	ARG	250	2.123	51.662	12.300
2096	NH1	ARG	250	1.149	51.902	13.177
2097	NH2	ARG	250	2.119	50.533	11.588
2098	C	ARG	250	6.103	57.457	14.646
2099	O	ARG	250	6.185	58.525	14.025
2100	N	SER	251	6.352	57.371	15.943
2102	CA	SER	251	6.427	58.595	16.746
2103	CB	SER	251	6.123	58.278	18.210
2104	OG	SER	251	7.062	57.334	18.708
2105	C	SER	251	7.800	59.249	16.599
2106	O	SER	251	7.883	60.478	16.465
2107	N	ALA	252	8.798	58.429	16.309
2109	CA	ALA	252	10.142	58.935	16.056
2110	CB	ALA	252	11.137	57.805	16.273
2111	C	ALA	252	10.268	59.440	14.629
2112	O	ALA	252	10.911	60.471	14.414
2113	N	THR	253	9.453	58.905	13.736
2115	CA	THR	253	9.440	59.380	12.352
2116	CB	THR	253	8.625	58.406	11.508
2117	OG1	THR	253	9.334	57.178	11.471
2118	CG2	THR	253	8.463	58.891	10.072
2119	C	THR	253	8.825	60.768	12.261
2120	O	THR	253	9.421	61.652	11.633
2121	N	ILE	254	7.834	61.030	13.097
2123	CA	ILE	254	7.224	62.358	13.106
2124	CB	ILE	254	5.853	62.247	13.757
2125	CG2	ILE	254	5.221	63.621	13.928
2126	CG1	ILE	254	4.952	61.341	12.926
2127	CD1	ILE	254	3.547	61.268	13.504
2128	C	ILE	254	8.083	63.382	13.844
2129	O	ILE	254	8.256	64.497	13.334
2130	N	ALA	255	8.826	62.936	14.845
2132	CA	ALA	255	9.707	63.860	15.567
2133	CB	ALA	255	10.123	63.216	16.884
2134	C	ALA	255	10.947	64.212	14.747
2135	O	ALA	255	11.255	65.401	14.590
2136	N	ILE	256	11.461	63.238	14.014
2138	CA	ILE	256	12.631	63.468	13.167
2139	CB	ILE	256	13.209	62.118	12.759
2140	CG2	ILE	256	14.277	62.283	11.689
2141	CG1	ILE	256	13.786	61.378	13.958
2142	CD1	ILE	256	14.249	59.983	13.557
2143	C	ILE	256	12.267	64.267	11.923
2144	O	ILE	256	12.977	65.232	11.616
2145	N	ALA	257	11.057	64.080	11.417
2147	CA	ALA	257	10.613	64.850	10.253
2148	CB	ALA	257	9.383	64.182	9.656
2149	C	ALA	257	10.271	66.287	10.625
2150	O	ALA	257	10.563	67.203	9.842
2151	N	TYR	258	9.902	66.504	11.877
2153	CA	TYR	258	9.688	67.871	12.334
2154	CB	TYR	258	8.931	67.890	13.654
2155	CG	TYR	258	8.683	69.315	14.140
2156	CD1	TYR	258	7.806	70.130	13.437

2157	CE1	TYR	258	7.576	71.432	13.860
2158	CZ	TYR	258	8.229	71.917	14.984
2159	OH	TYR	258	7.935	73.179	15.447
2160	CE2	TYR	258	9.120	71.111	15.680
2161	CD2	TYR	258	9.351	69.809	15.254
2162	C	TYR	258	11.014	68.590	12.517
2163	O	TYR	258	11.150	69.697	11.992
2164	N	ILE	259	12.039	67.889	12.974
2166	CA	ILE	259	13.350	68.527	13.150
2167	CB	ILE	259	14.226	67.598	13.982
2168	CG2	ILE	259	15.612	68.193	14.181
2169	CG1	ILE	259	13.593	67.313	15.337
2170	CD1	ILE	259	14.455	66.354	16.149
2171	C	ILE	259	14.024	68.802	11.804
2172	O	ILE	259	14.536	69.912	11.586
2173	N	MET	260	13.763	67.933	10.841
2175	CA	MET	260	14.296	68.114	9.490
2176	CB	MET	260	14.010	66.853	8.683
2177	CG	MET	260	14.786	65.655	9.213
2178	SD	MET	260	14.376	64.077	8.439
2179	CE	MET	260	14.817	64.490	6.740
2180	C	MET	260	13.669	69.305	8.776
2181	O	MET	260	14.412	70.145	8.258
2182	N	LYS	261	12.377	69.514	8.963
2184	CA	LYS	261	11.704	70.625	8.281
2185	CB	LYS	261	10.258	70.188	8.068
2186	CG	LYS	261	9.447	71.160	7.220
2187	CD	LYS	261	8.056	70.592	6.960
2188	CE	LYS	261	7.168	71.552	6.179
2189	NZ	LYS	261	5.823	70.979	5.996
2190	C	LYS	261	11.759	71.942	9.068
2191	O	LYS	261	11.736	73.020	8.463
2192	N	ARG	262	12.016	71.854	10.362
2194	CA	ARG	262	12.046	73.043	11.222
2195	CB	ARG	262	11.654	72.575	12.623
2196	CG	ARG	262	11.618	73.676	13.676
2197	CD	ARG	262	10.536	74.711	13.393
2198	NE	ARG	262	10.381	75.612	14.546
2199	CZ	ARG	262	10.979	76.801	14.652
2200	NH1	ARG	262	11.729	77.267	13.651
2201	NH2	ARG	262	10.793	77.542	15.747
2202	C	ARG	262	13.424	73.698	11.278
2203	O	ARG	262	13.521	74.929	11.349
2204	N	MET	263	14.473	72.899	11.192
2206	CA	MET	263	15.819	73.469	11.292
2207	CB	MET	263	16.469	72.887	12.542
2208	CG	MET	263	17.636	73.737	13.033
2209	SD	MET	263	17.219	75.450	13.433
2210	CE	MET	263	15.941	75.154	14.678
2211	C	MET	263	16.657	73.189	10.043
2212	O	MET	263	17.829	73.583	9.971
2213	N	ASP	264	16.027	72.567	9.057
2215	CA	ASP	264	16.683	72.159	7.803
2216	CB	ASP	264	17.184	73.378	7.033
2217	CG	ASP	264	17.608	72.969	5.626
2218	OD1	ASP	264	16.730	72.867	4.781
2219	OD2	ASP	264	18.798	72.781	5.413
2220	C	ASP	264	17.817	71.187	8.110
2221	O	ASP	264	19.007	71.511	8.005
2222	N	MET	265	17.422	70.008	8.554
2224	CA	MET	265	18.393	68.987	8.964
2225	CB	MET	265	18.257	68.747	10.465
2226	CG	MET	265	18.659	69.991	11.252
2227	SD	MET	265	18.493	69.900	13.049
2228	CE	MET	265	19.643	68.553	13.395

2229	C	MET	265	18.210	67.675	8.211
2230	O	MET	265	17.121	67.342	7.729
2231	N	SER	266	19.305	66.946	8.097
2233	CA	SER	266	19.275	65.618	7.480
2234	CB	SER	266	20.700	65.160	7.195
2235	OG	SER	266	21.287	64.788	8.437
2236	C	SER	266	18.652	64.614	8.435
2237	O	SER	266	18.636	64.840	9.652
2238	N	LEU	267	18.352	63.437	7.910
2240	CA	LEU	267	17.824	62.339	8.726
2241	CB	LEU	267	17.490	61.188	7.778
2242	CG	LEU	267	17.124	59.902	8.513
2243	CD1	LEU	267	15.935	60.100	9.443
2244	CD2	LEU	267	16.846	58.772	7.531
2245	C	LEU	267	18.847	61.879	9.763
2246	O	LEU	267	18.504	61.759	10.946
2247	N	ASP	268	20.114	61.926	9.382
2249	CA	ASP	268	21.202	61.569	10.295
2250	CB	ASP	268	22.526	61.630	9.537
2251	CG	ASP	268	22.457	60.802	8.256
2252	OD1	ASP	268	22.183	61.394	7.220
2253	OD2	ASP	268	22.622	59.595	8.342
2254	C	ASP	268	21.267	62.538	11.466
2255	O	ASP	268	21.062	62.115	12.612
2256	N	GLU	269	21.285	63.832	11.175
2258	CA	GLU	269	21.395	64.837	12.234
2259	CB	GLU	269	21.624	66.181	11.560
2260	CG	GLU	269	22.967	66.232	10.846
2261	CD	GLU	269	22.978	67.413	9.887
2262	OE1	GLU	269	24.047	67.959	9.656
2263	OE2	GLU	269	21.942	67.619	9.266
2264	C	GLU	269	20.146	64.939	13.109
2265	O	GLU	269	20.283	65.064	14.331
2266	N	ALA	270	18.980	64.678	12.544
2268	CA	ALA	270	17.754	64.770	13.334
2269	CB	ALA	270	16.575	64.932	12.387
2270	C	ALA	270	17.557	63.548	14.223
2271	O	ALA	270	17.222	63.718	15.402
2272	N	TYR	271	18.038	62.395	13.783
2274	CA	TYR	271	17.934	61.198	14.621
2275	CB	TYR	271	18.044	59.951	13.750
2276	CG	TYR	271	17.886	58.641	14.520
2277	CD1	TYR	271	16.999	58.562	15.588
2278	CE1	TYR	271	16.866	57.376	16.297
2279	CZ	TYR	271	17.615	56.266	15.930
2280	OH	TYR	271	17.553	55.121	16.695
2281	CE2	TYR	271	18.486	56.333	14.851
2282	CD2	TYR	271	18.619	57.522	14.143
2283	C	TYR	271	19.026	61.187	15.688
2284	O	TYR	271	18.753	60.800	16.832
2285	N	ARG	272	20.141	61.840	15.408
2287	CA	ARG	272	21.185	61.963	16.426
2288	CB	ARG	272	22.523	62.222	15.748
2289	CG	ARG	272	22.978	60.971	15.006
2290	CD	ARG	272	24.355	61.137	14.378
2291	NE	ARG	272	24.332	62.082	13.251
2292	CZ	ARG	272	25.283	62.995	13.050
2293	NH1	ARG	272	26.251	63.159	13.954
2294	NH2	ARG	272	25.226	63.792	11.982
2295	C	ARG	272	20.870	63.054	17.446
2296	O	ARG	272	21.251	62.913	18.614
2297	N	PHE	273	19.981	63.968	17.093
2299	CA	PHE	273	19.504	64.947	18.068
2300	CB	PHE	273	18.958	66.157	17.319

2301	CG	PHE	273	18.551	67.310	18.228
2302	CD1	PHE	273	19.525	68.151	18.749
2303	CE1	PHE	273	19.163	69.201	19.583
2304	CZ	PHE	273	17.826	69.409	19.896
2305	CE2	PHE	273	16.852	68.568	19.375
2306	CD2	PHE	273	17.214	67.519	18.541
2307	C	PHE	273	18.411	64.333	18.942
2308	O	PHE	273	18.388	64.572	20.158
2309	N	VAL	274	17.705	63.357	18.394
2311	CA	VAL	274	16.709	62.636	19.187
2312	CB	VAL	274	15.757	61.882	18.267
2313	CG1	VAL	274	14.789	61.044	19.085
2314	CG2	VAL	274	14.982	62.838	17.371
2315	C	VAL	274	17.376	61.662	20.155
2316	O	VAL	274	17.024	61.682	21.340
2317	N	LYS	275	18.504	61.086	19.759
2319	CA	LYS	275	19.266	60.236	20.687
2320	CB	LYS	275	20.178	59.287	19.921
2321	CG	LYS	275	19.391	58.332	19.034
2322	CD	LYS	275	20.254	57.154	18.596
2323	CE	LYS	275	21.503	57.599	17.842
2324	NZ	LYS	275	21.154	58.252	16.572
2325	C	LYS	275	20.114	61.051	21.663
2326	O	LYS	275	20.486	60.545	22.727
2327	N	GLU	276	20.246	62.339	21.394
2329	CA	GLU	276	20.914	63.252	22.320
2330	CB	GLU	276	21.337	64.477	21.515
2331	CG	GLU	276	22.061	65.526	22.348
2332	CD	GLU	276	22.358	66.739	21.474
2333	OE1	GLU	276	23.388	66.726	20.813
2334	OE2	GLU	276	21.508	67.616	21.410
2335	C	GLU	276	19.971	63.665	23.452
2336	O	GLU	276	20.433	64.057	24.530
2337	N	LYS	277	18.673	63.516	23.237
2339	CA	LYS	277	17.717	63.755	24.320
2340	CB	LYS	277	16.526	64.542	23.781
2341	CG	LYS	277	16.945	65.900	23.219
2342	CD	LYS	277	17.605	66.783	24.277
2343	CE	LYS	277	16.634	67.198	25.380
2344	NZ	LYS	277	15.588	68.093	24.861
2345	C	LYS	277	17.254	62.431	24.929
2346	O	LYS	277	16.857	62.382	26.099
2347	N	ARG	278	17.358	61.365	24.151
2349	CA	ARG	278	17.092	60.016	24.661
2350	CB	ARG	278	15.598	59.737	24.629
2351	CG	ARG	278	15.286	58.490	25.446
2352	CD	ARG	278	15.671	58.702	26.905
2353	NE	ARG	278	15.521	57.462	27.679
2354	CZ	ARG	278	14.551	57.261	28.575
2355	NH1	ARG	278	13.636	58.207	28.797
2356	NH2	ARG	278	14.497	56.109	29.247
2357	C	ARG	278	17.788	58.953	23.817
2358	O	ARG	278	17.253	58.513	22.791
2359	N	PRO	279	18.865	58.407	24.357
2360	CA	PRO	279	19.695	57.439	23.624
2361	CB	PRO	279	20.985	57.409	24.383
2362	CG	PRO	279	20.810	58.144	25.704
2363	CD	PRO	279	19.413	58.737	25.675
2364	C	PRO	279	19.119	56.017	23.523
2365	O	PRO	279	19.740	55.157	22.892
2366	N	THR	280	17.952	55.772	24.103
2368	CA	THR	280	17.367	54.423	24.084
2369	CB	THR	280	16.712	54.130	25.429
2370	OG1	THR	280	15.545	54.930	25.544
2371	CG2	THR	280	17.641	54.431	26.600

2372	C	THR	280	16.317	54.248	22.985
2373	O	THR	280	15.642	53.212	22.948
2374	N	ILE	281	16.116	55.264	22.160
2376	CA	ILE	281	15.115	55.153	21.093
2377	CB	ILE	281	14.813	56.551	20.551
2378	CG2	ILE	281	16.083	57.286	20.142
2379	CG1	ILE	281	13.837	56.482	19.386
2380	CD1	ILE	281	13.684	57.828	18.700
2381	C	ILE	281	15.584	54.230	19.963
2382	O	ILE	281	16.686	54.379	19.424
2383	N	SER	282	14.748	53.255	19.639
2385	CA	SER	282	15.037	52.375	18.497
2386	CB	SER	282	15.537	51.035	19.031
2387	OG	SER	282	14.601	50.550	19.986
2388	C	SER	282	13.826	52.177	17.575
2389	O\	SER	282	13.052	51.226	17.737
2390	N	PRO	283	13.662	53.083	16.622
2391	CA	PRO	283	12.697	52.888	15.538
2392	CB	PRO	283	12.593	54.226	14.873
2393	CG	PRO	283	13.738	55.102	15.354
2394	CD	PRO	283	14.466	54.288	16.410
2395	C	PRO	283	13.187	51.838	14.543
2396	O	PRO	283	14.376	51.503	14.508
2397	N	ASN	284	12.251	51.247	13.821
2399	CA	ASN	284	12.632	50.318	12.752
2400	CB	ASN	284	11.479	49.389	12.358
2401	CG	ASN	284	10.260	50.105	11.771
2402	OD1	ASN	284	10.370	51.002	10.925
2403	ND2	ASN	284	9.097	49.598	12.139
2406	C	ASN	284	13.162	51.088	11.546
2407	O	ASN	284	12.869	52.277	11.360
2408	N	PHE	285	13.795	50.352	10.650
2410	CA	PHE	285	14.449	50.943	9.478
2411	CB	PHE	285	15.557	49.993	9.015
2412	CG	PHE	285	15.106	48.601	8.557
2413	CD1	PHE	285	14.778	48.385	7.223
2414	CE1	PHE	285	14.370	47.127	6.801
2415	CZ	PHE	285	14.299	46.079	7.709
2416	CE2	PHE	285	14.642	46.288	9.039
2417	CD2	PHE	285	15.051	47.546	9.461
2418	C	PHE	285	13.501	51.228	8.310
2419	O	PHE	285	13.902	51.921	7.365
2420	N	ASN	286	12.221	50.940	8.483
2422	CA	ASN	286	11.293	50.967	7.349
2423	CB	ASN	286	10.018	50.217	7.729
2424	CG	ASN	286	10.255	48.757	8.132
2425	OD1	ASN	286	11.362	48.209	8.051
2426	ND2	ASN	286	9.172	48.131	8.558
2429	C	ASN	286	10.913	52.399	7.003
2430	O	ASN	286	10.858	52.770	5.822
2431	N	PHE	287	10.922	53.243	8.020
2433	CA	PHE	287	10.572	54.648	7.825
2434	CB	PHE	287	9.917	55.164	9.096
2435	CG	PHE	287	8.607	54.455	9.423
2436	CD1	PHE	287	7.497	54.649	8.611
2437	CE1	PHE	287	6.305	53.997	8.897
2438	CZ	PHE	287	6.223	53.152	9.996
2439	CE2	PHE	287	7.331	52.962	10.810
2440	CD2	PHE	287	8.523	53.614	10.524
2441	C	PHE	287	11.771	55.518	7.457
2442	O	PHE	287	11.567	56.621	6.935
2443	N	LEU	288	12.963	54.939	7.450
2445	CA	LEU	288	14.158	55.729	7.142
2446	CB	LEU	288	15.388	54.990	7.657
2447	CG	LEU	288	15.341	54.812	9.171

2448	CD1	LEU	288	16.527	53.988	9.658
2449	CD2	LEU	288	15.301	56.158	9.888
2450	C	LEU	288	14.283	55.970	5.640
2451	O	LEU	288	14.716	57.055	5.235
2452	N	GLY	289	13.636	55.116	4.862
2454	CA	GLY	289	13.570	55.303	3.409
2455	C	GLY	289	12.730	56.528	3.051
2456	O	GLY	289	13.199	57.412	2.320
2457	N	GLN	290	11.610	56.689	3.742
2459	CA	GLN	290	10.724	57.815	3.450
2460	CB	GLN	290	9.321	57.510	3.969
2461	CG	GLN	290	8.737	56.292	3.258
2462	CD	GLN	290	7.268	56.087	3.625
2463	OE1	GLN	290	6.621	56.979	4.188
2464	NE2	GLN	290	6.741	54.941	3.226
2467	C	GLN	290	11.251	59.111	4.059
2468	O	GLN	290	11.137	60.156	3.410
2469	N	LEU	291	12.083	59.002	5.082
2471	CA	LEU	291	12.705	60.197	5.659
2472	CB	LEU	291	13.154	59.874	7.076
2473	CG	LEU	291	11.952	59.682	7.995
2474	CD1	LEU	291	12.369	59.130	9.352
2475	CD2	LEU	291	11.174	60.984	8.153
2476	C	LEU	291	13.883	60.693	4.819
2477	O	LEU	291	14.070	61.911	4.708
2478	N	LEU	292	14.461	59.810	4.019
2480	CA	LEU	292	15.504	60.226	3.077
2481	CB	LEU	292	16.303	59.003	2.647
2482	CG	LEU	292	17.192	58.497	3.774
2483	CD1	LEU	292	17.823	57.157	3.415
2484	CD2	LEU	292	18.263	59.527	4.125
2485	C	LEU	292	14.901	60.893	1.846
2486	O	LEU	292	15.444	61.896	1.366
2487	N	ALA	293	13.677	60.511	1.516
2489	CA	ALA	293	12.967	61.156	0.406
2490	CB	ALA	293	11.885	60.209	-0.097
2491	C	ALA	293	12.333	62.474	0.849
2492	O	ALA	293	12.334	63.450	0.088
2493	N	TYR	294	12.072	62.569	2.144
2495	CA	TYR	294	11.563	63.800	2.760
2496	CB	TYR	294	11.081	63.422	4.159
2497	CG	TYR	294	10.455	64.529	5.006
2498	CD1	TYR	294	11.237	65.246	5.903
2499	CE1	TYR	294	10.662	66.235	6.689
2500	CZ	TYR	294	9.304	66.499	6.583
2501	OH	TYR	294	8.709	67.371	7.468
2502	CE2	TYR	294	8.519	65.788	5.685
2503	CD2	TYR	294	9.097	64.800	4.897
2504	C	TYR	294	12.664	64.851	2.866
2505	O	TYR	294	12.406	66.038	2.635
2506	N	GLU	295	13.900	64.378	2.912
2508	CA	GLU	295	15.067	65.260	2.961
2509	CB	GLU	295	16.239	64.422	3.468
2510	CG	GLU	295	17.511	65.241	3.650
2511	CD	GLU	295	18.641	64.341	4.132
2512	OE1	GLU	295	18.369	63.478	4.959
2513	OE2	GLU	295	19.781	64.615	3.783
2514	C	GLU	295	15.419	65.847	1.591
2515	O	GLU	295	16.150	66.843	1.517
2516	N	LYS	296	14.816	65.332	0.532
2518	CA	LYS	296	15.134	65.839	-0.801
2519	CB	LYS	296	15.062	64.667	-1.774
2520	CG	LYS	296	15.672	65.011	-3.128
2521	CD	LYS	296	15.732	63.787	-4.036

2522	CE	LYS	296	16.437	64.105	-5.350
2523	NZ	LYS	296	16.548	62.904	-6.193
2524	C	LYS	296	14.188	66.967	-1.226
2525	O	LYS	296	14.530	67.756	-2.117
2526	N	LYS	297	13.087	67.141	-0.512
2528	CA	LYS	297	12.156	68.219	-0.869
2529	CB	LYS	297	10.726	67.688	-0.879
2530	CG	LYS	297	9.742	68.783	-1.284
2531	CD	LYS	297	10.067	69.352	-2.661
2532	CE	LYS	297	9.246	70.605	-2.941
2533	NZ	LYS	297	9.576	71.679	-1.989
2534	C	LYS	297	12.277	69.410	0.082
2535	O	LYS	297	11.553	69.526	1.078
2536	N	ILE	298	13.195	70.299	-0.254
2538	CA	ILE	298	13.370	71.527	0.525
2539	CB	ILE	298	14.864	71.718	0.786
2540	CG2	ILE	298	15.137	72.947	1.649
2541	CG1	ILE	298	15.440	70.479	1.463
2542	CD1	ILE	298	16.919	70.658	1.788
2543	C	ILE	298	12.767	72.723	-0.217
2544	O	ILE	298	12.943	72.876	-1.432
2545	N	LYS	299	11.991	73.501	0.521
2547	CA	LYS	299	11.353	74.724	0.012
2548	CB	LYS	299	10.719	75.409	1.225
2549	CG	LYS	299	10.135	76.796	0.945
2550	CD	LYS	299	8.667	76.777	0.516
2551	CE	LYS	299	8.426	76.135	-0.845
2552	NZ	LYS	299	6.997	76.161	-1.188
2553	C	LYS	299	12.334	75.698	-0.646
2554	O	LYS	299	13.275	76.187	-0.010

SEQUENCE LISTING

<110> Bristol-Myers Squibb Company

<120> POLYNUCLEOTIDES ENCODING NOVEL HUMAN PHOSPHATASES

<130> D0072.PCT

<150> US 60/256,868

<151> 2000-12-20

<150> US 60/280,186

<151> 2001-03-30

<150> US 60/287,735

<151> 2001-05-01

<150> US 60/295,848

<151> 2001-06-05

<150> US 60/300,465

<151> 2001-06-25

<160> 208

<170> PatentIn version 3.0

<210> 1

<211> 144

<212> DNA

<213> HOMO SAPIENS

<400> 1

ctagtttact tctacaattt cggatggaag gattatgggtg tagcgtctct tactactatc 60

ctagatatgg tgaaggatgat gacatttgcc ttacaggaag gaaaagtagc tatccattgt 120

catgcagggc ttggtcgaac aggt 144

<210> 2

<211> 48

<212> PRT

<213> HOMO SAPIENS

<400> 2

Leu Val Tyr Phe Tyr Asn Phe Gly Trp Lys Asp Tyr Gly Val Ala Ser
1 5 10 15

Leu Thr Thr Ile Leu Asp Met Val Lys Val Met Thr Phe Ala Leu Gln
20 25 30

Glu Gly Lys Val Ala Ile His Cys His Ala Gly Leu Gly Arg Thr Gly
35 40 45

<210> 3

<211> 33

<212> DNA

<213> HOMO SAPIENS

<400> 3
gatgtcttct gggccctcct gtggaacaca gtt

33

<210> 4
<211> 11
<212> PRT
<213> HOMO SAPIENS

<400> 4

Asp Val Phe Trp Ala Leu Leu Trp Asn Thr Val
1 5 10

<210> 5
<211> 746
<212> DNA
<213> HOMO SAPIENS

<400> 5
gtggcccggg aggcgccgag gccaggtagg tgcgatgggc gtgcagcccc ccaacttctc 60
ctgggtgctt ccggggccggc tggcgggaact ggcgctgccc cggtcctccc cccactacca 120
gttcctgttg gacctgggag tgcggcacct ggtgtccctg acggagcgcg gggccctca 180
cagcgacagc tgccccggcc tcacctgca ccgcctgcgc atccccgact tctgccccgc 240
ggcccccgac cagatcgacc gttcgtgca gatcgtggac gaggccaacg cacggggaga 300
ggctgtggga gtgcaactgtg ctctgggctt tggccgcact ggcaccatgc tggcctgtta 360
cctggtgaag gagcggggct tggctgcagg agatgccatt gctgaaatcc gacgactacg 420
accgggcccc atcgagacct atgagcagga gaaagcagtc ttccagttct accagcgaac 480
gaaataaggg gccttagtac ctttctacca ggccctcact ccccttcccc atgttgtcga 540
tggggccaga gatgaaggga agtggactaa agtattaaac cctctagctc ccattggctg 600
aagacactga agtagccac ccctgcaggc aggtcctgat tgaaggggag gcttgtactg 660
ctttgttgaa taaatgagtt ttacgaacca gggaaaaaaaa aaaaaaaaaa aaagaaaaaa 720
aaaaaaaaaa aaaaaaaaaa aaagaa 746

<210> 6
<211> 248
<212> PRT
<213> HOMO SAPIENS

<220>
<221> VARIANT
<222> (160)..(160)
<223> wherein 'Xaa' is any amino acid.

<220>
<221> VARIANT
<222> (200)..(200)

<223> wherein 'Xaa' is any amino acid.

<220>

<221> VARIANT

<222> (202)..(202)

<223> wherein 'Xaa' is any amino acid.

<220>

<221> VARIANT

<222> (214)..(214)

<223> wherein 'Xaa' is any amino acid.

<220>

<221> VARIANT

<222> (223)..(223)

<223> wherein 'Xaa' is any amino acid.

<400> 6

Trp	Pro	Gly	Arg	Arg	Arg	Gly	Gln	Val	Gly	Ala	Met	Gly	Val	Gln	Pro	1	5	10	15
Pro	Asn	Phe	Ser	Trp	Val	Leu	Pro	Gly	Arg	Leu	Ala	Gly	Leu	Ala	Leu	20	25	30	
Pro	Arg	Leu	Pro	Ala	His	Tyr	Gln	Phe	Leu	Leu	Asp	Leu	Gly	Val	Arg	35	40	45	
His	Leu	Val	Ser	Leu	Thr	Glu	Arg	Gly	Pro	Pro	His	Ser	Asp	Ser	Cys	50	55	60	
Pro	Gly	Leu	Thr	Leu	His	Arg	Leu	Arg	Ile	Pro	Asp	Phe	Cys	Pro	Pro	65	70	75	80
Ala	Pro	Asp	Gln	Ile	Asp	Arg	Phe	Val	Gln	Ile	Val	Asp	Glu	Ala	Asn	85	90	95	
Ala	Arg	Gly	Glu	Ala	Val	Gly	Val	His	Cys	Ala	Leu	Gly	Phe	Gly	Arg	100	105	110	
Thr	Gly	Thr	Met	Leu	Ala	Cys	Tyr	Leu	Val	Lys	Glu	Arg	Gly	Leu	Ala	115	120	125	
Ala	Gly	Asp	Ala	Ile	Ala	Glu	Ile	Arg	Arg	Leu	Arg	Pro	Gly	Pro	Ile	130	135	140	
Glu	Thr	Tyr	Glu	Gln	Glu	Lys	Ala	Val	Phe	Gln	Phe	Tyr	Gln	Arg	Thr	145	150	155	160
Lys	Xaa	Gly	Ala	Leu	Val	Pro	Phe	Tyr	Gln	Ala	Leu	Thr	Pro	Leu	Pro	165	170	175	
His	Val	Val	Asp	Gly	Ala	Arg	Asp	Glu	Gly	Lys	Trp	Thr	Lys	Val	Leu	180	185	190	
Asn	Pro	Leu	Ala	Pro	Ile	Gly	Xaa	Arg	His	Xaa	Ser	Ser	Pro	Pro	Leu	195	200	205	

Gln Ala Gly Pro Asp Xaa Arg Gly Gly Leu Tyr Cys Phe Val Glu Xaa
 210 215 220

Met Ser Phe Thr Asn Gln Gly Lys Lys Lys Lys Lys Lys Arg Lys Lys
 225 230 235 240

Lys Lys Lys Lys Lys Lys Lys Arg
 245

<210> 7
 <211> 511
 <212> DNA
 <213> HOMO SAPIENS

<400> 7
 atggcctagaa tgaacctccc tgcttctgtg gacattgcat acaaaaatgt gagatttctt 60
 attacacaca acccaaccaa tacctacttt aatagattct tacaggaact taagcaggat 120
 ggagttacca ccatagtaag agtatgaaaa gcaacttaca acattgctct tttagagaag 180
 ggaagcatcc aggttcogga ctggcctttt gatgatggta cagcaccatc cagccagata 240
 attgataact ggttaaaact tatgaaaaat aaatttcatg aagatcctgg ttgttgtatt 300
 gcaattcact gtgtttagg ttttgggtga gctccagttg ctagttgccc tagctttaat 360
 tgaagggtgga atgaaatatg aaaatgtagt acagttcatc agataaaagt gacatggaac 420
 ttttaacagc aaacaacttt tgtatttga gaaatattgt cttaaaatat gcttgcacct 480
 cagaaatccc agaaataact gtttccttca g 511

<210> 8
 <211> 170
 <212> PRT
 <213> HOMO SAPIENS

<220>
 <221> Variant
 <222> (49)..(49)
 <223> wherein 'Xaa' is any amino acid.

<220>
 <221> Variant
 <222> (110)..(110)
 <223> wherein 'Xaa' is any amino acid.

<220>
 <221> Variant
 <222> (121)..(121)
 <223> wherein 'Xaa' is any amino acid.

<220>
 <221> Variant
 <222> (127)..(127)

<223> wherein 'Xaa' is any amino acid.

<220>

<221> Variant

<222> (154)..(154)

<223> wherein 'Xaa' is any amino acid.

<400> 8

Met	Ala	Arg	Met	Asn	Leu	Pro	Ala	Ser	Val	Asp	Ile	Ala	Tyr	Lys	Asn	
1				5					10					15		
Val	Arg	Phe	Leu	Ile	Thr	His	Asn	Pro	Thr	Asn	Thr	Tyr	Phe	Asn	Arg	
			20					25					30			
Phe	Leu	Gln	Glu	Leu	Lys	Gln	Asp	Gly	Val	Thr	Thr	Ile	Val	Arg	Val	
		35					40					45				
Xaa	Lys	Ala	Thr	Tyr	Asn	Ile	Ala	Leu	Leu	Glu	Lys	Gly	Ser	Ile	Gln	
	50					55					60					
Val	Pro	Asp	Trp	Pro	Phe	Asp	Asp	Gly	Thr	Ala	Pro	Ser	Ser	Gln	Ile	
65					70					75					80	
Ile	Asp	Asn	Trp	Leu	Lys	Leu	Met	Lys	Asn	Lys	Phe	His	Glu	Asp	Pro	
				85					90					95		
Gly	Cys	Cys	Ile	Ala	Ile	His	Cys	Val	Val	Gly	Phe	Gly	Xaa	Ala	Pro	
			100					105					110			
Val	Ala	Ser	Cys	Pro	Ser	Phe	Asn	Xaa	Arg	Trp	Asn	Glu	Ile	Xaa	Lys	
		115					120					125				
Cys	Ser	Thr	Val	His	Gln	Ile	Lys	Val	Thr	Trp	Asn	Phe	Xaa	Gln	Gln	
		130				135					140					
Thr	Thr	Phe	Val	Phe	Gly	Glu	Ile	Leu	Ser	Xaa	Asn	Met	Leu	Ala	Pro	
145					150					155				160		
Gln	Lys	Ser	Gln	Lys	Xaa	Leu	Phe	Pro	Ser							
				165					170							

<210> 9

<211> 1710

<212> DNA

<213> HOMO SAPIENS

<400> 9

ctcaggcaga actatgaggc caagagtgtc catgcgcacc aggcctttctt tttgaaattc	60
gaggagctga aggagggtgag caaggagcag cccagactgg aggcctgagta ccctgccaac	120
accaccaaga actgttaacc acatgtgcta ccctatgacc actccagggt caggctgacc	180
cagctggagg gagagcctca ttctgactac atcaatgcc aacttggtccc aggctacacc	240
cgccacaggg agttcattgc ctctcagggg cctctcaaga aaacactgga gaacttctgg	300
cggctggtgc gggagcagca ggtccgcac atcatcatgc cgaccatcag catggagaac	360


```

gggaggggtgc tgtgtgagca ttactggctg accgactcta ccccgacac ccatgggtcac      420
atcacpatcc acctcctagc tgaggagcct gaggatgagt ggaccaagcg ggaattccag      480
ctgcagcacg ttgtccagca acatcaacgg aggggtggagc aactgcagtt caccacctga      540
tccgaccaca gcatccttga ggctcccagc tccctgctcg cctttatgga gctggtacag      600
tagcaggcaa ggccaccca gggcgtggga cccatcctgg tgcaactgag gggctgtccc      660
tgcggtgtgg gcatgggccc gacaggcacc ttcgtggccc tgcgaggct gctgcagcag      720
ctggaggagg agcagatggg agacgtgttc catgctgtgt atgcactccg gatgcaccag      780
cccctcatga tccagaccct gagccagtac gtcttcctgc acagctgcct actgaacaag      840
attctggaag gacccttcaa catctctgag tcttggcca tctctgtgac ggacctcccg      900
caggcgtgtg ccaagagggc agccagtgcc aatgctggct tcttgaagga gtacgaggcc      960
atcaaggacg aggctggctt ttccgcaccc ccgcctggct atgagcagga cagccccgtc     1020
tcctatgacc gttctcaggg gcagttttct ccggtggagg agagcccccc tgacgacatg     1080
cctctctgga agccaatgat ctgtgctctg cagggtgggc cctctggccg tgatcatacg     1140
gtgctgactg gccccgcagg gccaaaggag ctctgggagc tgggtgtggca gcacagggt     1200
catgtgcttg tctctctttg cccacccaat gtcattggaga aggaattctg gccaacggag     1260
atgcagcccg tagtcacaga catggtgacg gtgcactggg tggctgagag cagcacagca     1320
ggctggttct gtaccctcct cagggtcaca catggggaga gcaggaagga aaggagggtg     1380
cagagactgc aatttcata cctggagcct gggcatgagc tgcccgccac caccctgctg     1440
cccttcctgg ctgctgtggg ccagtgtgc tctcggggca acaacaagaa gccgggcaca     1500
ctgctcagcc actccaacaa gggtgcaacc cagctgggca ccttcctggc catggagcag     1560
ctgctgcagc aggcagggtc tgagtgcacc gtggatatct ttaacgtggc cctgcagcag     1620
tctcaggcct gtggccttat gacccaaca ctgaagcagt atgtctacct ctacaactgt     1680
ctgaacagcg cgctggcaga cgggctgccc                                     1710

```

```

<210> 10
<211> 570
<212> PRT
<213> HOMO SAPIENS

```

```

<220>
<221> Variant
<222> (46)..(46)
<223> wherein 'Xaa' is any amino acid.

```

```

<220>
<221> Variant

```

<222> (180)..(180)

<223> wherein 'Xaa' is any amino acid.

<220>

<221> Variant

<222> (201)..(201)

<223> wherein 'Xaa' is any amino acid.

<400> .10

Leu Arg Gln Asn Tyr Glu Ala Lys Ser Ala His Ala His Gln Ala Phe
 1 5 10 15

Phe Leu Lys Phe Glu Glu Leu Lys Glu Val Ser Lys Glu Gln Pro Arg
 20 25 30

Leu Glu Ala Glu Tyr Pro Ala Asn Thr Thr Lys Asn Cys Xaa Pro His
 35 40 45

Val Leu Pro Tyr Asp His Ser Arg Val Arg Leu Thr Gln Leu Glu Gly
 50 55 60

Glu Pro His Ser Asp Tyr Ile Asn Ala Asn Leu Val Pro Gly Tyr Thr
 65 70 75 80

Arg Pro Gln Glu Phe Ile Ala Ser Gln Gly Pro Leu Lys Lys Thr Leu
 85 90 95

Glu Asn Phe Trp Arg Leu Val Arg Glu Gln Gln Val Arg Ile Ile Ile
 100 105 110

Met Pro Thr Ile Ser Met Glu Asn Gly Arg Val Leu Cys Glu His Tyr
 115 120 125

Trp Leu Thr Asp Ser Thr Pro Asp Thr His Gly His Ile Thr Ile His
 130 135 140

Leu Leu Ala Glu Glu Pro Glu Asp Glu Trp Thr Lys Arg Glu Phe Gln
 145 150 155 160

Leu Gln His Val Val Gln Gln His Gln Arg Arg Val Glu Gln Leu Gln
 165 170 175

Phe Thr Thr Xaa Ser Asp His Ser Ile Leu Glu Ala Pro Ser Ser Leu
 180 185 190

Leu Ala Phe Met Glu Leu Val Gln Xaa Gln Ala Arg Ala Thr Gln Gly
 195 200 205

Val Gly Pro Ile Leu Val His Cys Arg Gly Cys Pro Cys Gly Val Gly
 210 215 220

Met Gly Arg Thr Gly Thr Phe Val Ala Leu Ser Arg Leu Leu Gln Gln
 225 230 235 240

Leu Glu Glu Glu Gln Met Val Asp Val Phe His Ala Val Tyr Ala Leu
 245 250 255

Arg Met His Gln Pro Leu Met Ile Gln Thr Leu Ser Gln Tyr Val Phe

260					265					270					
Leu	His	Ser	Cys	Leu	Leu	Asn	Lys	Ile	Leu	Glu	Gly	Pro	Phe	Asn	Ile
	275						280					285			
Ser	Glu	Ser	Trp	Pro	Ile	Ser	Val	Thr	Asp	Leu	Pro	Gln	Ala	Cys	Ala
	290					295					300				
Lys	Arg	Ala	Ala	Ser	Ala	Asn	Ala	Gly	Phe	Leu	Lys	Glu	Tyr	Glu	Ala
305					310					315					320
Ile	Lys	Asp	Glu	Ala	Gly	Phe	Ser	Ala	Pro	Pro	Pro	Gly	Tyr	Glu	Gln
				325					330					335	
Asp	Ser	Pro	Val	Ser	Tyr	Asp	Arg	Ser	Gln	Gly	Gln	Phe	Ser	Pro	Val
			340					345					350		
Glu	Glu	Ser	Pro	Pro	Asp	Asp	Met	Pro	Leu	Trp	Lys	Pro	Met	Ile	Cys
		355					360					365			
Ala	Leu	Gln	Gly	Gly	Pro	Ser	Gly	Arg	Asp	His	Thr	Val	Leu	Thr	Gly
	370					375					380				
Pro	Ala	Gly	Pro	Lys	Glu	Leu	Trp	Glu	Leu	Val	Trp	Gln	His	Arg	Ala
385					390					395					400
His	Val	Leu	Val	Ser	Leu	Cys	Pro	Pro	Asn	Val	Met	Glu	Lys	Glu	Phe
				405					410					415	
Trp	Pro	Thr	Glu	Met	Gln	Pro	Val	Val	Thr	Asp	Met	Val	Thr	Val	His
			420					425					430		
Trp	Val	Ala	Glu	Ser	Ser	Thr	Ala	Gly	Trp	Phe	Cys	Thr	Leu	Leu	Arg
		435					440					445			
Val	Thr	His	Gly	Glu	Ser	Arg	Lys	Glu	Arg	Glu	Val	Gln	Arg	Leu	Gln
		450				455					460				
Phe	Pro	Tyr	Leu	Glu	Pro	Gly	His	Glu	Leu	Pro	Ala	Thr	Thr	Leu	Leu
465					470					475					480
Pro	Phe	Leu	Ala	Ala	Val	Gly	Gln	Cys	Cys	Ser	Arg	Gly	Asn	Asn	Lys
				485					490					495	
Lys	Pro	Gly	Thr	Leu	Leu	Ser	His	Ser	Asn	Lys	Gly	Ala	Thr	Gln	Leu
			500					505					510		
Gly	Thr	Phe	Leu	Ala	Met	Glu	Gln	Leu	Leu	Gln	Gln	Ala	Gly	Ser	Glu
		515					520					525			
Cys	Thr	Val	Asp	Ile	Phe	Asn	Val	Ala	Leu	Gln	Gln	Ser	Gln	Ala	Cys
		530				535					540				
Gly	Leu	Met	Thr	Pro	Thr	Leu	Lys	Gln	Tyr	Val	Tyr	Leu	Tyr	Asn	Cys
545					550					555					560
Leu	Asn	Ser	Ala	Leu	Ala	Asp	Gly	Leu	Pro						
				565					570						

<210> 11

<211> 63

<212> DNA
 <213> HOMO SAPIENS

<400> 11
 ctcaggcaga actatgaggc caagagtgct catgcgccacc aggctttctt ttgaaattc 60
 gag 63

<210> 12
 <211> 91
 <212> DNA
 <213> HOMO SAPIENS

<400> 12
 gagctgaagg aggtgagcaa ggagcagccc agactggagg ctgagtaccc tgccaacacc 60
 accaagaact gttaaccaca tgtgctaccc t 91

<210> 13
 <211> 77
 <212> DNA
 <213> HOMO SAPIENS

<400> 13
 atgaccactc cagggtcagg ctgaccagc tggagggaga gcctcattct gactacatca 60
 atgccaaactt ggtccca 77

<210> 14
 <211> 135
 <212> DNA
 <213> HOMO SAPIENS

<400> 14
 ggctacaccc gccacagga gttcattgcc tctcaggggc ctctcaagaa aacactggag 60
 aacttctggc ggctgggtgcg ggagcagcag gtcgcgcatca tcatcatgcc gaccatcagc 120
 atggagaacg ggagg 135

<210> 15
 <211> 123
 <212> DNA
 <213> HOMO SAPIENS

<400> 15
 gtgctgtgtg agcattactg gctgaccgac tctaccccg gacacccatgg tcacatcacc 60
 atccacctcc tagctgagga gcctgaggat gagtggacca agcgggaatt ccagctgcag 120
 cac 123

<210> 16
 <211> 161
 <212> DNA
 <213> HOMO SAPIENS

<400> 16
 gttgtccagc aacatcaacg gaggggtggag caactgcagt tcaccacctg atccgaccac 60
 agcatccttg aggctcccag ctccctgctc gcctttatgg agctggtaca gtagcaggca 120
 agggccaccc agggcgtggg acccatcctg gtgcactgca g 161

<210> 17
 <211> 151
 <212> DNA
 <213> HOMO SAPIENS

<400> 17
 gggctgtccc tgcggtgtgg gcatgggccc gacaggcacc ttcgtggccc tgtcgaggct 60
 gctgcagcag ctggaggagg agcagatggt agacgtgttc catgctgtgt atgcactccg 120
 gatgcaccag cccctcatga tccagaccct g 151

<210> 18
 <211> 68
 <212> DNA
 <213> HOMO SAPIENS

<400> 18
 agccagtacg tcttcctgca cagctgccta ctgaacaaga ttctggaagg acccttcaac 60
 atctctga 68

<210> 19
 <211> 88
 <212> DNA
 <213> HOMO SAPIENS

<400> 19
 gtcttgcccc atctctgtga cggacctccc gcaggcgtgt gccaagaggg cagccagtgc 60
 caatgctggc ttcttgaagg agtacgag 88

<210> 20
 <211> 67
 <212> DNA
 <213> HOMO SAPIENS

<400> 20
 gccatcaagg acgaggctgg cttttccgca cccccgctg gctatgagca ggacagcccc 60
 gtctcct 67

<210> 21
 <211> 58
 <212> DNA
 <213> HOMO SAPIENS

<400> 21

atgaccgttc tcaggggcag ttttctccgg tggaggagag ccccoctgac gacatgcc 58

<210> 22
 <211> 160
 <212> DNA
 <213> HOMO SAPIENS

<400> 22
 tctctggaag ccaatgatct gtgctctgca ggggtggccc tctggccgtg atcatacggg 60
 gctgactggc cccgcagggc caaaggagct ctgggagctg gtgtggcagc acagggctca 120
 tgtgcttgtc tctctttgcc cacccaatgt catggagaag 160

<210> 23
 <211> 111
 <212> DNA
 <213> HOMO SAPIENS

<400> 23
 gaattctggc caacggagat gcagcccgta gtcacagaca tggtgacggg gcaactgggtg 60
 gctgagagca gcacagcagg ctggttctgt accctcctca gggtcacaca t 111

<210> 24
 <211> 164
 <212> DNA
 <213> HOMO SAPIENS

<400> 24
 ggggagagca ggaaggaaag ggaggtgcag agactgcaat ttccatacct ggagcctggg 60
 catgagctgc ccgccaccac cctgctgccc ttcttggtg ctgtgggcca gtgctgctct 120
 cggggcaaca acaagaagcc gggcacactg ctcagccact ccaa 164

<210> 25
 <211> 136
 <212> DNA
 <213> HOMO SAPIENS

<400> 25
 caaggggtgca acccagctgg gcaccttcct ggccatggag cagctgctgc agcaggcagg 60
 gtctgagtgc accgtggata tctttaacgt ggccctgcag cagtctcagg cctgtggcct 120
 tatgacccca aactg 136

<210> 26
 <211> 57
 <212> DNA
 <213> HOMO SAPIENS

<400> 26
 aagcagtatg tctaccteta caactgtctg aacagcgcgc tggcagacgg gctgccc 57

<210> 27
 <211> 1188
 <212> PRT
 <213> HOMO SAPIENS

<400> 27

```

Met Gly His Leu Pro Thr Gly Ile His Gly Ala Arg Arg Leu Leu Pro
1          5          10          15

Leu Leu Trp Leu Phe Val Leu Phe Lys Asn Ala Thr Ala Phe His Val
20          25          30

Thr Val Gln Asp Asp Asn Asn Ile Val Val Ser Leu Glu Ala Ser Asp
35          40          45

Val Ile Ser Pro Ala Ser Val Tyr Val Val Lys Ile Thr Gly Glu Ser
50          55          60

Lys Asn Tyr Phe Phe Glu Phe Glu Glu Phe Asn Ser Thr Leu Pro Pro
65          70          75          80

Pro Val Ile Phe Lys Ala Ser Tyr His Gly Leu Tyr Tyr Ile Ile Thr
85          90          95

Leu Val Val Val Asn Gly Asn Val Val Thr Lys Pro Ser Arg Ser Ile
100         105         110

Thr Val Leu Thr Lys Pro Leu Pro Val Thr Ser Val Ser Ile Tyr Asp
115         120         125

Tyr Lys Pro Ser Pro Glu Thr Gly Val Leu Phe Glu Ile His Tyr Pro
130         135         140

Glu Lys Tyr Asn Val Phe Thr Arg Val Asn Ile Ser Tyr Trp Glu Gly
145         150         155         160

Lys Asp Phe Arg Thr Met Leu Tyr Lys Asp Phe Phe Lys Gly Lys Thr
165         170         175

Val Phe Asn His Trp Leu Pro Gly Met Cys Tyr Ser Asn Ile Thr Phe
180         185         190

Gln Leu Val Ser Glu Ala Thr Phe Asn Lys Ser Thr Leu Val Glu Tyr
195         200         205

Ser Gly Val Ser His Glu Pro Lys Gln His Arg Thr Ala Pro Tyr Pro
210         215         220

Pro Gln Asn Ile Ser Val Arg Ile Val Asn Leu Asn Lys Asn Asn Trp
225         230         235         240

Glu Glu Gln Ser Gly Asn Phe Pro Glu Glu Ser Phe Met Arg Ser Gln
245         250         255

Asp Thr Ile Gly Lys Glu Lys Leu Phe His Phe Thr Glu Glu Thr Pro
260         265         270

Glu Ile Pro Ser Gly Asn Ile Ser Ser Gly Trp Pro Asp Phe Asn Ser
275         280         285

```

Ser Asp Tyr Glu Thr Thr Ser Gln Pro Tyr Trp Trp Asp Ser Ala Ser
 290 295 300
 Ala Ala Pro Glu Ser Glu Asp Glu Phe Val Ser Val Leu Pro Met Glu
 305 310 315 320
 Tyr Glu Asn Asn Ser Thr Leu Ser Glu Thr Glu Lys Ser Thr Ser Gly
 325 330 335
 Ser Phe Ser Phe Phe Pro Val Gln Met Ile Leu Thr Trp Leu Pro Pro
 340 345 350
 Lys Pro Pro Thr Ala Phe Asp Gly Phe His Ile His Ile Glu Arg Glu
 355 360 365
 Glu Asn Phe Thr Glu Tyr Leu Met Val Asp Glu Glu Ala His Glu Phe
 370 375 380
 Val Ala Glu Leu Lys Glu Pro Gly Lys Tyr Lys Leu Ser Val Thr Thr
 385 390 395 400
 Phe Ser Ser Ser Gly Ser Cys Glu Thr Arg Lys Ser Gln Ser Ala Lys
 405 410 415
 Ser Leu Ser Phe Tyr Ile Ser Pro Ser Gly Glu Trp Ile Glu Glu Leu
 420 425 430
 Thr Glu Lys Pro Gln His Val Ser Val His Val Leu Ser Ser Thr Thr
 435 440 445
 Ala Leu Met Ser Trp Thr Ser Ser Gln Glu Asn Tyr Asn Ser Thr Ile
 450 455 460
 Val Ser Val Val Ser Leu Thr Cys Gln Lys Gln Lys Glu Ser Gln Arg
 465 470 475 480
 Leu Glu Lys Gln Tyr Cys Thr Gln Val Asn Ser Ser Lys Pro Ile Ile
 485 490 495
 Glu Asn Leu Val Pro Gly Ala Gln Tyr Gln Val Val Ile Tyr Leu Arg
 500 505 510
 Lys Gly Pro Leu Ile Gly Pro Pro Ser Asp Pro Val Thr Phe Ala Ile
 515 520 525
 Val Pro Thr Gly Ile Lys Asp Leu Met Leu Tyr Pro Leu Gly Pro Thr
 530 535 540
 Ala Val Val Leu Ser Trp Thr Arg Pro Tyr Leu Gly Val Phe Arg Lys
 545 550 555 560
 Tyr Val Val Glu Met Phe Tyr Phe Asn Pro Ala Thr Met Thr Ser Glu
 565 570 575
 Trp Thr Thr Tyr Tyr Glu Ile Ala Ala Thr Val Ser Leu Thr Ala Ser
 580 585 590
 Val Arg Ile Ala Asn Leu Leu Pro Ala Trp Tyr Tyr Asn Phe Arg Val
 595 600 605

Thr	Met	Val	Thr	Trp	Gly	Asp	Pro	Glu	Leu	Ser	Cys	Cys	Asp	Ser	Ser	610	615	620	
Thr	Ile	Ser	Phe	Ile	Thr	Ala	Pro	Val	Ala	Pro	Glu	Ile	Thr	Ser	Val	625	630	635	640
Glu	Tyr	Phe	Asn	Ser	Leu	Leu	Tyr	Ile	Ser	Trp	Thr	Tyr	Gly	Asp	Asp	645	650	655	
Thr	Thr	Asp	Leu	Ser	His	Ser	Arg	Met	Leu	His	Trp	Met	Val	Val	Ala	660	665	670	
Glu	Gly	Lys	Lys	Lys	Ile	Lys	Lys	Ser	Val	Thr	Arg	Asn	Val	Met	Thr	675	680	685	
Ala	Ile	Leu	Ser	Leu	Pro	Pro	Gly	Asp	Ile	Tyr	Asn	Leu	Ser	Val	Thr	690	695	700	
Ala	Cys	Thr	Glu	Arg	Gly	Ser	Asn	Thr	Ser	Met	Leu	Arg	Leu	Val	Lys	705	710	715	720
Leu	Glu	Pro	Ala	Pro	Pro	Lys	Ser	Leu	Phe	Ala	Val	Asn	Lys	Thr	Gln	725	730	735	
Thr	Ser	Val	Thr	Leu	Leu	Trp	Val	Glu	Glu	Gly	Val	Ala	Asp	Phe	Phe	740	745	750	
Glu	Val	Phe	Cys	Gln	Gln	Val	Gly	Ser	Ser	Gln	Lys	Thr	Lys	Leu	Gln	755	760	765	
Glu	Pro	Val	Ala	Val	Ser	Ser	His	Val	Val	Thr	Ile	Ser	Ser	Leu	Leu	770	775	780	
Pro	Ala	Thr	Ala	Tyr	Asn	Cys	Ser	Val	Thr	Ser	Phe	Ser	His	Asp	Ser	785	790	795	800
Pro	Ser	Val	Pro	Thr	Phe	Ile	Ala	Val	Ser	Thr	Met	Val	Thr	Glu	Met	805	810	815	
Asn	Pro	Asn	Val	Val	Val	Ile	Ser	Val	Leu	Ala	Ile	Leu	Ser	Thr	Leu	820	825	830	
Leu	Ile	Gly	Leu	Leu	Leu	Val	Thr	Leu	Ile	Ile	Leu	Arg	Lys	Lys	His	835	840	845	
Leu	Gln	Met	Ala	Arg	Glu	Cys	Gly	Ala	Gly	Thr	Phe	Val	Asn	Phe	Ala	850	855	860	
Ser	Leu	Glu	Arg	Asp	Gly	Lys	Leu	Pro	Tyr	Asn	Trp	Ser	Lys	Asn	Gly	865	870	875	880
Leu	Lys	Lys	Arg	Lys	Leu	Thr	Asn	Pro	Val	Gln	Leu	Asp	Asp	Phe	Asp	885	890	895	
Ala	Tyr	Ile	Lys	Asp	Met	Ala	Lys	Asp	Ser	Asp	Tyr	Lys	Phe	Ser	Leu	900	905	910	
Gln	Phe	Glu	Glu	Leu	Lys	Leu	Ile	Gly	Leu	Asp	Ile	Pro	His	Phe	Ala	915	920	925	
Ala	Asp	Leu	Pro	Leu	Asn	Arg	Cys	Lys	Asn	Arg	Tyr	Thr	Asn	Ile	Leu				

930 935 940
 Pro Tyr Asp Phe Ser Arg Val Arg Leu Val Ser Met Asn Glu Glu Glu
 945 950 955 960
 Gly Ala Asp Tyr Ile Asn Ala Asn Tyr Ile Pro Gly Tyr Asn Ser Pro
 965 970 975
 Gln Glu Tyr Ile Ala Thr Gln Gly Pro Leu Pro Glu Thr Arg Asn Asp
 980 985 990
 Phe Trp Lys Met Val Leu Gln Gln Lys Ser Gln Ile Ile Val Met Leu
 995 1000 1005
 Thr Gln Cys Asn Glu Lys Arg Arg Val Lys Cys Asp His Tyr Trp
 1010 1015 1020
 Pro Phe Thr Glu Glu Pro Ile Ala Tyr Gly Asp Ile Thr Val Glu
 1025 1030 1035
 Met Ile Ser Glu Glu Glu Gln Asp Asp Trp Ala Cys Arg His Phe
 1040 1045 1050
 Arg Ile Asn Tyr Ala Asp Glu Met Gln Asp Val Met His Phe Asn
 1055 1060 1065
 Tyr Thr Ala Trp Pro Asp His Gly Val Pro Thr Ala Asn Ala Ala
 1070 1075 1080
 Glu Ser Ile Leu Gln Phe Val His Met Val Arg Gln Gln Ala Thr
 1085 1090 1095
 Lys Ser Lys Gly Pro Met Ile Ile His Cys Ser Ala Gly Val Gly
 1100 1105 1110
 Arg Thr Gly Thr Phe Ile Ala Leu Asp Arg Leu Leu Gln His Ile
 1115 1120 1125
 Arg Asp His Glu Phe Val Asp Ile Leu Gly Leu Val Ser Glu Met
 1130 1135 1140
 Arg Ser Tyr Arg Met Ser Met Val Gln Thr Glu Glu Gln Tyr Ile
 1145 1150 1155
 Phe Ile His Gln Cys Val Gln Leu Met Trp Met Lys Lys Lys Gln
 1160 1165 1170
 Gln Phe Cys Ile Ser Asp Val Ile Tyr Glu Asn Val Ser Lys Ser
 1175 1180 1185

<210> 28
 <211> 405
 <212> PRT
 <213> Mus musculus

<400> 28

Met Val Thr Glu Val Asn Pro Asn Val Val Val Ile Ser Val Leu Ala
 1 5 10 15

Ile Leu Ser Thr Leu Leu Ile Gly Leu Leu Leu Val Thr Leu Val Ile

20					25					30					
Leu	Arg	Lys	Lys	His	Leu	Gln	Met	Ala	Arg	Glu	Cys	Gly	Ala	Gly	Thr
		35					40					45			
Phe	Val	Asn	Phe	Ala	Ser	Leu	Glu	Arg	Glu	Gly	Lys	Leu	Pro	Tyr	Ser
	50					55					60				
Trp	Arg	Arg	Ser	Val	Phe	Ala	Leu	Leu	Thr	Leu	Leu	Pro	Ser	Cys	Leu
65						70					75				80
Trp	Thr	Asp	Tyr	Leu	Leu	Ala	Phe	Tyr	Ile	Asn	Pro	Trp	Ser	Lys	Asn
				85					90					95	
Gly	Leu	Lys	Lys	Arg	Lys	Leu	Thr	Asn	Pro	Val	Gln	Leu	Asp	Asp	Phe
			100					105					110		
Asp	Ser	Tyr	Ile	Lys	Asp	Met	Ala	Lys	Asp	Ser	Asp	Tyr	Lys	Phe	Ser
		115					120					125			
Leu	Gln	Phe	Glu	Glu	Leu	Lys	Leu	Ile	Gly	Leu	Asp	Ile	Pro	His	Phe
	130					135					140				
Ala	Ala	Asp	Leu	Pro	Leu	Asn	Arg	Cys	Lys	Asn	Arg	Tyr	Thr	Asn	Ile
145						150					155				160
Leu	Pro	Tyr	Asp	Phe	Ser	Arg	Val	Arg	Leu	Val	Ser	Met	Asn	Glu	Glu
				165					170					175	
Glu	Gly	Ala	Asp	Tyr	Ile	Asn	Ala	Asn	Tyr	Ile	Pro	Gly	Tyr	Asn	Ser
			180					185					190		
Pro	Gln	Glu	Tyr	Ile	Ala	Thr	Gln	Gly	Pro	Leu	Pro	Glu	Thr	Arg	Asn
		195					200					205			
Asp	Phe	Trp	Lys	Met	Val	Leu	Gln	Gln	Lys	Ser	His	Ile	Ile	Val	Met
	210					215					220				
Leu	Thr	Gln	Cys	Asn	Glu	Lys	Arg	Arg	Val	Lys	Cys	Asp	His	Tyr	Trp
225						230					235				240
Pro	Phe	Thr	Glu	Glu	Pro	Ile	Ala	Tyr	Gly	Asp	Ile	Thr	Val	Glu	Met
				245					250					255	
Val	Ser	Glu	Glu	Glu	Glu	Glu	Asp	Trp	Ala	Ser	Arg	His	Phe	Arg	Ile
			260					265					270		
Asn	Tyr	Ala	Asp	Glu	Ala	Gln	Asp	Val	Met	His	Phe	Asn	Tyr	Thr	Gly
		275					280					285			
Trp	Pro	Asp	His	Gly	Val	Pro	Pro	Ala	Asn	Ala	Ala	Glu	Ser	Ile	Leu
						295					300				
Gln	Phe	Val	Phe	Thr	Val	Arg	Gln	Gln	Ala	Ala	Lys	Ser	Lys	Gly	Pro
305						310					315				320
Met	Ile	Ile	His	Cys	Ser	Ala	Gly	Val	Gly	Arg	Thr	Gly	Thr	Phe	Ile
				325					330					335	
Ala	Leu	Asp	Arg	Leu	Leu	Gln	His	Ile	Arg	Asp	His	Glu	Phe	Val	Asp
				340				345					350		

Ile Leu Gly Leu Val Ser Glu Met Arg Ser Tyr Arg Met Ser Met Val
 355 360 365

Gln Thr Glu Glu Gln Tyr Ile Phe Ile His Gln Cys Val Gln Leu Met
 370 375 380

Trp Leu Arg Lys Lys Gln Gln Phe Cys Ile Ser Asp Val Ile Tyr Glu
 385 390 395 400

Asn Val Ser Lys Ser
 405

<210> 29

<211> 303

<212> PRT

<213> Schizosaccharomyces pombe

<400> 29

Met Ser Phe Lys Glu Val Ser Thr Glu Asn Gly Val Leu Thr Pro Leu
 1 5 10 15

Ile Thr Ile Lys Glu Lys Ala Tyr Met Ile Ile Glu Gly Leu Asn Glu
 20 25 30

Glu Glu Ile Glu Leu Leu Asn Thr Arg Leu Pro Lys Leu Ser Lys Lys
 35 40 45

Ala Leu Ala Arg Asn Arg Tyr Ser Asn Ile Val Pro Tyr Glu Asn Thr
 50 55 60

Arg Val Arg Leu Asp Pro Met Trp Lys Glu Ala Cys Asp Tyr Ile Asn
 65 70 75 80

Ala Ser Ile Val Lys Ile Pro Ser Gly Lys Thr Phe Ile Ala Thr Gln
 85 90 95

Gly Pro Thr Ser Asn Ser Ile Asp Val Phe Trp Lys Met Val Trp Gln
 100 105 110

Ser Val Pro Lys Ser Gly Ile Ile Val Met Leu Thr Lys Leu Arg Glu
 115 120 125

Arg His Arg Leu Lys Cys Asp Ile Tyr Trp Pro Val Glu Leu Phe Glu
 130 135 140

Thr Leu Asn Ile Gly Asp Leu Ser Val Ile Leu Val Lys Val Tyr Thr
 145 150 155 160

Leu Thr Ser Leu Asn Glu Val Gln Val Arg Glu Phe Glu Leu Asn Lys
 165 170 175

Asp Gly Val Lys Lys Lys Ile Leu His Phe Tyr Tyr Asn Gly Trp Pro
 180 185 190

Asp Phe Gly Ala Pro His Thr Phe Ser Leu Leu Ser Leu Thr Arg Tyr
 195 200 205

Ile Lys Ser Leu Ser Tyr Ser Pro Asp Phe Glu Thr Ala Pro Ile Ile
 210 215 220

Val His Cys Ser Ala Gly Cys Gly Arg Thr Gly Thr Phe Met Ala Leu
225 230 235 240

Phe Glu Ile Leu Ser Gln Thr Asp Asp Ser Thr Ser Thr Ser Lys Phe
245 250 255

Glu Val Asp Asn Ile Ala Asn Ile Val Ser Ser Leu Arg Ser Gln Arg
260 265 270

Met Gln Ser Val Gln Ser Val Asp Gln Leu Val Phe Leu Tyr Thr Val
275 280 285

Ser Gln Glu Leu Leu Gln Gly Lys Glu Phe Leu Leu Pro Gln Leu
290 295 300

<210> 30

<211> 580

<212> PRT

<213> homo sapiens

<400> 30

Met Lys Asp Arg Leu Tyr Phe Ala Thr Leu Arg Asn Arg Pro Lys Ser
1 5 10 15

Thr Val Asn Thr His Tyr Phe Ser Ile Asp Glu Glu Leu Val Tyr Glu
20 25 30

Asn Phe Tyr Ala Asp Phe Gly Pro Leu Asn Leu Ala Met Val Tyr Arg
35 40 45

Tyr Cys Cys Lys Leu Asn Lys Lys Leu Lys Ser Tyr Ser Leu Ser Arg
50 55 60

Lys Lys Ile Val His Tyr Thr Cys Phe Asp Gln Arg Lys Arg Ala Asn
65 70 75 80

Ala Ala Phe Leu Ile Gly Ala Tyr Ala Val Ile Tyr Leu Lys Lys Thr
85 90 95

Pro Glu Glu Ala Tyr Arg Ala Leu Leu Ser Gly Ser Asn Pro Pro Tyr
100 105 110

Leu Pro Phe Arg Asp Ala Ser Phe Gly Asn Cys Thr Tyr Asn Leu Thr
115 120 125

Ile Leu Asp Cys Leu Gln Gly Ile Arg Lys Gly Leu Gln His Gly Phe
130 135 140

Phe Asp Phe Glu Thr Ile Asp Val Asp Glu Tyr Glu His Tyr Glu Arg
145 150 155 160

Val Glu Asn Gly Asp Phe Asn Cys Ile Val Pro Gly Lys Phe Leu Ala
165 170 175

Phe Ser Gly Pro His Pro Lys Ser Lys Ile Glu Asn Gly Tyr Pro Leu
180 185 190

His Ala Pro Glu Ala Tyr Phe Pro Tyr Phe Lys Lys His Asn Val Thr
195 200 205

Ala Val Val Arg Leu Asn Lys Lys Ile Tyr Glu Ala Lys Arg Phe Thr	210	215	220
Asp Ala Gly Phe Glu His Tyr Asp Leu Phe Phe Ile Asp Gly Ser Thr	225	230	235 240
Pro Ser Asp Asn Ile Val Arg Arg Phe Leu Asn Ile Cys Glu Asn Thr	245	250	255
Glu Gly Ala Ile Ala Val His Cys Lys Ala Gly Leu Gly Arg Thr Gly	260	265	270
Thr Leu Ile Ala Cys Tyr Val Met Lys His Tyr Arg Phe Thr His Ala	275	280	285
Glu Ile Ile Ala Trp Ile Arg Ile Cys Arg Pro Gly Ser Ile Ile Gly	290	295	300
Pro Gln Gln His Phe Leu Glu Glu Lys Gln Ala Ser Leu Trp Val Gln	305	310	315 320
Gly Asp Ile Phe Arg Ser Lys Leu Lys Asn Arg Pro Ser Ser Glu Gly	325	330	335
Ser Ile Asn Lys Ile Leu Ser Gly Leu Asp Asp Met Ser Ile Gly Gly	340	345	350
Asn Leu Ser Lys Thr Gln Asn Met Glu Arg Phe Gly Glu Asp Asn Leu	355	360	365
Glu Asp Asp Asp Val Glu Met Lys Asn Gly Ile Thr Gln Gly Asp Lys	370	375	380
Leu Arg Ala Leu Lys Ser Gln Arg Gln Pro Arg Thr Ser Pro Ser Cys	385	390	395 400
Ala Phe Arg Ser Asp Asp Thr Lys Gly His Pro Arg Ala Val Ser Gln	405	410	415
Pro Phe Arg Leu Ser Ser Ser Leu Gln Gly Ser Ala Val Thr Leu Lys	420	425	430
Thr Ser Lys Met Ala Leu Ser Pro Ser Ala Thr Ala Lys Arg Ile Asn	435	440	445
Arg Thr Ser Leu Ser Ser Gly Ala Thr Val Arg Ser Phe Ser Ile Asn	450	455	460
Ser Arg Leu Ala Ser Ser Leu Gly Asn Leu Asn Ala Ala Thr Asp Asp	465	470	475 480
Pro Glu Asn Lys Lys Thr Ser Ser Ser Ser Lys Ala Gly Phe Thr Ala	485	490	495
Ser Pro Phe Thr Asn Leu Leu Asn Gly Ser Ser Gln Pro Thr Thr Arg	500	505	510
Asn Tyr Pro Glu Leu Asn Asn Asn Gln Tyr Asn Arg Ser Ser Asn Ser	515	520	525

Asn Gly Gly Asn Leu Asn Ser Pro Pro Gly Pro His Ser Ala Lys Thr
 530 535 540

Glu Glu His Thr Thr Ile Leu Arg Pro Ser Tyr Thr Gly Leu Ser Ser
 545 550 555 560

Ser Ser Ala Arg Phe Leu Ser Arg Ser Ile Pro Ser Leu Gln Ser Glu
 565 570 575

Tyr Val His Tyr
 580

<210> 31

<211> 459

<212> PRT

<213> homo sapiens

<400> 31

Met Lys Arg Lys Ser Glu Arg Arg Ser Ser Trp Ala Ala Ala Pro Pro
 1 5 10 15

Cys Ser Arg Arg Cys Ser Ser Thr Ser Pro Gly Val Lys Lys Ile Arg
 20 25 30

Ser Ser Thr Gln Gln Asp Pro Arg Arg Asp Pro Gln Asp Asp Val
 35 40 45

Tyr Leu Asp Ile Thr Asp Arg Leu Cys Phe Ala Ile Leu Tyr Ser Arg
 50 55 60

Pro Lys Ser Ala Ser Asn Val His Tyr Phe Ser Ile Asp Asn Glu Leu
 65 70 75 80

Glu Tyr Glu Asn Phe Tyr Ala Asp Phe Gly Pro Leu Asn Leu Ala Met
 85 90 95

Val Tyr Arg Tyr Cys Cys Lys Ile Asn Lys Lys Leu Lys Ser Ile Thr
 100 105 110

Met Leu Arg Lys Lys Ile Val His Phe Thr Gly Ser Asp Gln Arg Lys
 115 120 125

Gln Ala Asn Ala Ala Phe Leu Val Gly Cys Tyr Met Val Ile Tyr Leu
 130 135 140

Gly Arg Thr Pro Glu Glu Ala Tyr Arg Ile Leu Ile Phe Gly Glu Thr
 145 150 155 160

Ser Tyr Ile Pro Phe Arg Asp Ala Ala Tyr Gly Ser Cys Asn Phe Tyr
 165 170 175

Ile Thr Leu Leu Asp Cys Phe His Ala Val Lys Lys Ala Met Gln Tyr
 180 185 190

Gly Phe Leu Asn Phe Asn Ser Phe Asn Leu Asp Glu Tyr Glu His Tyr
 195 200 205

Glu Lys Ala Glu Asn Gly Asp Leu Asn Trp Ile Ile Pro Asp Arg Phe
 210 215 220

Ile Ala Phe Cys Gly Pro His Ser Arg Ala Arg Leu Glu Ser Gly Tyr
 225 230 235 240
 His Gln His Ser Pro Glu Thr Tyr Ile Gln Tyr Phe Lys Asn His Asn
 245 250 255
 Val Thr Thr Ile Ile Arg Leu Asn Lys Arg Met Tyr Asp Ala Lys Arg
 260 265 270
 Phe Thr Asp Ala Gly Phe Asp His His Asp Leu Phe Phe Ala Asp Gly
 275 280 285
 Ser Thr Pro Thr Asp Ala Ile Val Lys Glu Phe Leu Asp Ile Cys Glu
 290 295 300
 Asn Ala Glu Gly Ala Ile Ala Val His Cys Lys Ala Gly Leu Gly Arg
 305 310 315 320
 Thr Gly Thr Leu Ile Ala Cys Tyr Ile Met Lys His Tyr Arg Met Thr
 325 330 335
 Ala Ala Glu Thr Ile Ala Trp Val Arg Ile Cys Arg Pro Gly Ser Val
 340 345 350
 Ile Gly Pro Gln Gln Gln Phe Leu Val Met Lys Gln Thr Asn Leu Trp
 355 360 365
 Leu Glu Gly Asp Tyr Phe Arg Gln Lys Leu Lys Gly Gln Glu Asn Gly
 370 375 380
 Gln His Arg Ala Ala Phe Ser Lys Leu Leu Ser Gly Val Asp Asp Ile
 385 390 395 400
 Ser Ile Asn Gly Val Glu Asn Gln Asp Gln Gln Glu Pro Glu Pro Tyr
 405 410 415
 Ser Asp Asp Asp Glu Ile Asn Gly Val Thr Gln Gly Asp Arg Leu Arg
 420 425 430
 Ala Leu Lys Ser Arg Arg Gln Ser Lys Thr Asn Ala Ile Pro Leu Thr
 435 440 445
 Leu Ser Ile Ser Arg Thr Lys Thr Val Leu Arg
 450 455

<210> 32
 <211> 551
 <212> PRT
 <213> Saccharomyces cerevisiae

<400> 32

Met Arg Arg Ser Val Tyr Leu Asp Asn Thr Ile Glu Phe Leu Arg Gly
 1 5 10 15
 Arg Val Tyr Leu Gly Ala Tyr Asp Tyr Thr Pro Glu Asp Thr Asp Glu
 20 25 30
 Leu Val Phe Phe Thr Val Glu Asp Ala Ile Phe Tyr Asn Ser Phe His
 35 40 45

Leu Asp Phe Gly Pro Met Asn Ile Gly His Leu Tyr Arg Phe Ala Val
 50 55 60
 Ile Phe His Glu Ile Leu Asn Asp Pro Glu Asn Ala Asn Lys Ala Val
 65 70 75 80
 Val Phe Tyr Ser Ser Ala Ser Thr Arg Gln Arg Ala Asn Ala Ala Cys
 85 90 95
 Met Leu Cys Cys Tyr Met Ile Leu Val Gln Ala Trp Thr Pro His Gln
 100 105 110
 Val Leu Gln Pro Leu Ala Gln Val Asp Pro Pro Phe Met Pro Phe Arg
 115 120 125
 Asp Ala Gly Tyr Ser Asn Ala Asp Phe Glu Ile Thr Ile Gln Asp Val
 130 135 140
 Val Tyr Gly Val Trp Arg Ala Lys Glu Lys Gly Leu Ile Asp Leu His
 145 150 155 160
 Ser Phe Asn Leu Glu Ser Tyr Glu Lys Tyr Glu His Val Glu Phe Gly
 165 170 175
 Asp Phe Asn Val Leu Thr Pro Asp Phe Ile Ala Phe Ala Ser Pro Gln
 180 185 190
 Glu Asp His Pro Lys Gly Tyr Leu Ala Thr Lys Ser Ser His Leu Asn
 195 200 205
 Gln Pro Phe Lys Ser Val Leu Asn Phe Phe Ala Asn Asn Asn Val Gln
 210 215 220
 Leu Val Val Arg Leu Asn Ser His Leu Tyr Asn Lys Lys His Phe Glu
 225 230 235 240
 Asp Ile Gly Ile Gln His Leu Asp Leu Ile Phe Glu Asp Gly Thr Cys
 245 250 255
 Pro Asp Leu Ser Ile Val Lys Asn Phe Val Gly Ala Ala Glu Thr Ile
 260 265 270
 Ile Lys Arg Gly Gly Lys Ile Ala Val His Cys Lys Ala Gly Leu Gly
 275 280 285
 Arg Thr Gly Cys Leu Ile Gly Ala His Leu Ile Tyr Thr Tyr Gly Phe
 290 295 300
 Thr Ala Asn Glu Cys Ile Gly Phe Leu Arg Phe Ile Arg Pro Gly Met
 305 310 315 320
 Val Val Gly Pro Gln Gln His Trp Leu Tyr Leu His Gln Asn Asp Phe
 325 330 335
 Arg Glu Trp Lys Tyr Thr Thr Arg Ile Ser Leu Lys Pro Ser Glu Ala
 340 345 350
 Ile Gly Gly Leu Tyr Pro Leu Ile Ser Leu Glu Glu Tyr Arg Leu Gln
 355 360 365
 Lys Lys Lys Leu Lys Asp Asp Lys Arg Val Ala Gln Asn Asn Ile Glu

370 375 380
 Gly Glu Leu Arg Asp Leu Thr Met Thr Pro Pro Ser Asn Gly His Gly
 385 390 395 400
 Ala Leu Ser Ala Arg Asn Ser Ser Gln Pro Ser Thr Ala Asn Asn Gly
 405 410 415
 Ser Asn Ser Phe Lys Ser Ser Ala Val Pro Gln Thr Ser Pro Gly Gln
 420 425 430
 Pro Arg Lys Gly Gln Asn Gly Ser Asn Thr Ile Glu Asp Ile Asn Asn
 435 440 445
 Asn Arg Asn Pro Thr Ser His Ala Asn Arg Lys Val Val Ile Glu Ser
 450 455 460
 Asn Asn Ser Asp Asp Glu Ser Met Gln Asp Thr Asn Gly Thr Ser Asn
 465 470 475 480
 His Tyr Pro Lys Val Ser Arg Lys Lys Asn Asp Ile Ser Ser Ala Ser
 485 490 495
 Ser Ser Arg Met Glu Asp Asn Glu Pro Ser Ala Thr Asn Ile Asn Asn
 500 505 510
 Ala Ala Asp Asp Thr Ile Leu Arg Gln Leu Leu Pro Lys Asn Arg Arg
 515 520 525
 Val Thr Ser Gly Arg Arg Thr Thr Ser Ala Ala Gly Gly Ile Arg Lys
 530 535 540
 Ile Ser Gly Ser Ile Lys Lys
 545 550

<210> 33
 <211> 173
 <212> PRT
 <213> homo sapiens

<400> 33

Met Ala Arg Met Asn Arg Pro Ala Pro Val Glu Val Thr Tyr Lys Asn
 1 5 10 15
 Met Arg Phe Leu Ile Thr His Asn Pro Thr Asn Ala Thr Leu Asn Lys
 20 25 30
 Phe Ile Glu Glu Leu Lys Lys Tyr Gly Val Thr Thr Ile Val Arg Val
 35 40 45
 Cys Glu Ala Thr Tyr Asp Thr Thr Leu Val Glu Lys Glu Gly Ile His
 50 55 60
 Val Leu Asp Trp Pro Phe Asp Asp Gly Ala Pro Pro Ser Asn Gln Ile
 65 70 75 80
 Val Asp Asp Trp Leu Ser Leu Val Lys Ile Lys Phe Arg Glu Glu Pro
 85 90 95
 Gly Cys Cys Ile Ala Val His Cys Val Ala Gly Leu Gly Arg Ala Pro

100 105 110
 Val Leu Val Ala Leu Ala Leu Ile Glu Gly Gly Met Lys Tyr Glu Asp
 115 120 125
 Ala Val Gln Phe Ile Arg Gln Lys Arg Arg Gly Ala Phe Asn Ser Lys
 130 135 140
 Gln Leu Leu Tyr Leu Glu Lys Tyr Arg Pro Lys Met Arg Leu Arg Phe
 145 150 155 160
 Lys Asp Ser Asn Gly His Arg Asn Asn Cys Cys Ile Gln
 165 170

<210> 34
 <211> 167
 <212> PRT
 <213> homo sapiens

<400> 34

Met Asn Arg Pro Ala Pro Val Glu Ile Ser Tyr Glu Asn Met Arg Phe
 1 5 10 15
 Leu Ile Thr His Asn Pro Thr Asn Ala Thr Leu Asn Lys Phe Thr Glu
 20 25 30
 Glu Leu Lys Lys Tyr Gly Val Thr Thr Leu Val Arg Val Cys Asp Ala
 35 40 45
 Thr Tyr Asp Lys Ala Pro Val Glu Lys Glu Gly Ile His Val Leu Asp
 50 55 60
 Trp Pro Phe Asp Asp Gly Ala Pro Pro Pro Asn Gln Ile Val Asp Asp
 65 70 75 80
 Trp Leu Asn Leu Leu Lys Thr Lys Phe Arg Glu Glu Pro Gly Cys Cys
 85 90 95
 Val Ala Val His Cys Val Ala Gly Leu Gly Arg Ala Pro Val Leu Val
 100 105 110
 Ala Leu Ala Leu Ile Glu Cys Gly Met Lys Tyr Glu Asp Ala Val Gln
 115 120 125
 Phe Ile Arg Gln Lys Arg Arg Gly Ala Phe Asn Ser Lys Gln Leu Leu
 130 135 140
 Tyr Leu Glu Lys Tyr Arg Pro Lys Met Arg Leu Arg Phe Arg Asp Thr
 145 150 155 160
 Asn Gly His Cys Cys Val Gln
 165

<210> 35
 <211> 167
 <212> PRT
 <213> Mus musculus

<400> 35

Met Asn Arg Pro Ala Pro Val Glu Ile Ser Tyr Glu Asn Met Arg Phe
 1 5 10 15
 Leu Ile Thr His Asn Pro Thr Asn Ala Thr Leu Asn Lys Phe Thr Glu
 20 25 30
 Glu Leu Lys Lys Tyr Gly Val Thr Thr Leu Val Arg Val Cys Asp Ala
 35 40 45
 Thr Tyr Asp Lys Ala Pro Val Glu Lys Glu Gly Ile His Val Leu Asp
 50 55 60
 Trp Pro Phe Asp Asp Gly Ala Pro Pro Pro Asn Gln Ile Val Asp Asp
 65 70 75 80
 Trp Leu Asn Leu Leu Lys Thr Leu Phe Arg Glu Glu Pro Gly Cys Cys
 85 90 95
 Val Ala Val His Cys Val Ala Gly Ile Gly Arg Ala Pro Val Leu Val
 100 105 110
 Ala Leu Ala Leu Ile Glu Cys Gly Met Lys Tyr Glu Asp Ala Val Gln
 115 120 125
 Phe Ile Arg Gln Lys Arg Arg Gly Ala Phe Asn Ser Lys Gln Leu Leu
 130 135 140
 Tyr Leu Glu Lys Tyr Arg Pro Lys Met Arg Leu Arg Phe Arg Asp Thr
 145 150 155 160
 Asn Gly His Cys Cys Val Gln
 165

<210> 36
 <211> 178
 <212> PRT
 <213> Drosophila melanogaster

<400> 36

Met Ser Ile Thr Met Arg Gln Lys Asp Leu Arg Pro Ala Pro Ala Leu
 1 5 10 15
 Ile Glu Tyr Lys Gly Met Lys Phe Leu Ile Thr Asp Arg Pro Ser Asp
 20 25 30
 Ile Thr Ile Asn His Tyr Ile Met Glu Leu Lys Lys Asn Asn Val Asn
 35 40 45
 Thr Val Val Arg Val Cys Glu Pro Ser Tyr Asn Thr Asp Glu Leu Glu
 50 55 60
 Thr Gln Gly Ile Thr Val Lys Asp Leu Ala Phe Glu Asp Gly Thr Phe
 65 70 75 80
 Pro Pro Gln Gln Val Val Asp Glu Trp Phe Glu Phe Phe Val Val Leu
 85 90 95
 Tyr Arg Tyr Gln Gln Asn Pro Glu Ala Cys Val Ala Val His Cys Val
 100 105 110

Ala Gly Leu Gly Arg Ala Pro Val Leu Val Ala Leu Ala Leu Ile Glu
 115 120 125

Leu Gly Leu Lys Tyr Glu Ala Ala Val Glu Met Ile Arg Asp Lys Arg
 130 135 140

Arg Gly Ala Ile Asn Ala Lys Gln Leu Ser Phe Leu Glu Lys Tyr Lys
 145 150 155 160

Pro Lys Ala Arg Leu Lys His Lys Asn Gly His Lys Asn Ser Cys Ser
 165 170 175

Val Gln

<210> 37
 <211> 1705
 <212> PRT
 <213> Mus musculus

<400> 37

Met Arg Pro Leu Ile Leu Leu Ala Ala Leu Leu Trp Leu Gln Asp Ser
 1 5 10 15

Leu Ala Gln Glu Asp Val Cys Ser Ser Leu Asp Gly Ser Pro Asp Arg
 20 25 30

Gln Gly Gly Gly Pro Pro Leu Ser Val Asn Val Ser Ser Arg Gly Lys
 35 40 45

Pro Thr Ser Leu Phe Leu Ser Trp Val Ala Ala Glu Pro Gly Gly Phe
 50 55 60

Asp Tyr Ala Leu Cys Leu Arg Ala Met Asn Leu Ser Gly Phe Pro Glu
 65 70 75 80

Gly Gln Gln Leu Gln Ala His Thr Asn Glu Ser Ser Phe Glu Phe His
 85 90 95

Gly Leu Val Pro Gly Ser Arg Tyr Gln Leu Glu Leu Thr Val Leu Arg
 100 105 110

Pro Cys Trp Gln Asn Val Thr Ile Thr Leu Thr Ala Arg Thr Ala Pro
 115 120 125

Thr Val Val Arg Gly Leu Gln Leu His Ser Thr Gly Ser Pro Ala Ser
 130 135 140

Leu Glu Ala Ser Trp Ser Asp Ala Ser Gly Asp Gln Asp Ser Tyr Gln
 145 150 155 160

Leu Leu Leu Tyr His Pro Glu Ser His Thr Leu Ala Cys Asn Val Ser
 165 170 175

Val Ser Pro Asp Thr Leu Ser Tyr Asn Phe Gly Asp Leu Leu Pro Gly
 180 185 190

Ser Gln Tyr Val Leu Glu Val Ile Thr Trp Ala Gly Ser Leu His Ala
 195 200 205

Lys Thr Ser Ile Leu Gln Trp Thr Glu Pro Val Pro Pro Asp His Leu
 210 215 220
 Thr Leu Arg Ala Leu Gly Thr Ser Ser Leu Gln Ala Phe Trp Asn Ser
 225 230 235 240
 Ser Glu Gly Ala Thr Trp Phe His Leu Ile Leu Thr Asp Leu Leu Glu
 245 250 255
 Gly Thr Asn Leu Thr Lys Val Val Arg Gln Gly Ile Ser Thr His Thr
 260 265 270
 Phe Leu Arg Leu Ser Pro Gly Thr Pro Tyr Gln Leu Lys Ile Cys Ala
 275 280 285
 Ala Ala Gly Pro His Gln Ile Trp Gly Pro Asn Ala Thr Glu Trp Thr
 290 295 300
 Tyr Pro Ser Tyr Pro Ser Asp Leu Val Leu Thr Pro Leu Trp Asn Glu
 305 310 315 320
 Leu Trp Ala Ser Trp Lys Ala Gly Gln Gly Ala Arg Asp Gly Tyr Val
 325 330 335
 Leu Lys Leu Ser Gly Pro Val Glu Asn Thr Thr Thr Leu Gly Pro Glu
 340 345 350
 Glu Cys Asn Ala Val Phe Pro Gly Pro Leu Pro Pro Gly His Tyr Thr
 355 360 365
 Leu Gly Leu Arg Val Leu Ala Gly Pro Tyr Asp Ala Trp Val Glu Gly
 370 375 380
 Ser Ile Trp Leu Ala Glu Ser Ala Ala Arg Pro Met Glu Val Pro Gly
 385 390 395 400
 Ala Arg Leu Trp Leu Glu Gly Leu Glu Ala Thr Lys Gln Pro Gly Arg
 405 410 415
 Arg Ala Leu Leu Tyr Ser Val Asp Ala Pro Gly Leu Leu Gly Asn Ile
 420 425 430
 Ser Val Ser Ser Gly Ala Thr His Val Thr Phe Cys Gly Leu Val Pro
 435 440 445
 Gly Ala His Tyr Arg Val Asp Ile Ala Ser Ser Met Gly Asp Ile Thr
 450 455 460
 Gln Ser Leu Thr Gly Tyr Thr Ser Pro Leu Pro Pro Gln Ser Leu Glu
 465 470 475 480
 Ile Ile Ser Arg Asn Ser Pro Ser Asp Leu Thr Ile Gly Trp Ala Pro
 485 490 495
 Ala Pro Gly Gln Met Glu Gly Tyr Lys Val Thr Trp His Gln Asp Gly
 500 505 510
 Ser Gln Arg Ser Pro Gly Asp Leu Val Asp Leu Gly Pro Asp Ile Ser
 515 520 525
 Ser Leu Thr Leu Lys Ser Leu Val Pro Gly Ser Cys Tyr Thr Val Ser

530					535					540					
Ala	Trp	Ala	Trp	Ser	Gly	Asn	Leu	Ser	Ser	Asp	Ser	Gln	Lys	Ile	His
545					550					555					560
Ser	Cys	Thr	Arg	Pro	Ala	Pro	Pro	Thr	Asn	Leu	Ser	Leu	Gly	Phe	Ala
				565					570					575	
His	Gln	Pro	Ala	Thr	Leu	Arg	Ala	Ser	Trp	Cys	His	Pro	Pro	Gly	Gly
			580					585					590		
Arg	Asp	Ala	Phe	Gln	Leu	Arg	Leu	Tyr	Arg	Leu	Arg	Pro	Leu	Thr	Leu
		595					600					605			
Glu	Ser	Glu	Lys	Ile	Leu	Ser	Gln	Glu	Ala	Gln	Asn	Phe	Ser	Trp	Ala
	610					615					620				
Gln	Leu	Pro	Ala	Gly	Tyr	Glu	Phe	Gln	Val	Gln	Leu	Ser	Thr	Leu	Trp
	625					630					635				640
Gly	Ser	Glu	Glu	Ser	Gly	Ser	Ala	Asn	Thr	Thr	Gly	Trp	Thr	Pro	Pro
				645					650					655	
Ser	Ala	Pro	Thr	Leu	Val	Asn	Val	Thr	Ser	Glu	Ala	Pro	Thr	Gln	Leu
			660					665						670	
His	Val	Ser	Trp	Val	His	Ala	Ala	Gly	Asp	Arg	Ser	Ser	Tyr	Gln	Val
		675					680					685			
Thr	Leu	Tyr	Gln	Glu	Ser	Thr	Arg	Thr	Ala	Thr	Ser	Ile	Val	Gly	Pro
	690					695						700			
Lys	Ala	Asp	Ser	Thr	Ser	Phe	Trp	Gly	Leu	Thr	Pro	Gly	Thr	Lys	Tyr
	705					710					715				720
Lys	Val	Glu	Ala	Ile	Ser	Trp	Ala	Gly	Pro	Leu	Tyr	Thr	Ala	Ala	Ala
				725					730					735	
Asn	Val	Ser	Ala	Trp	Thr	Tyr	Pro	Leu	Thr	Pro	Asn	Glu	Leu	Leu	Ala
			740					745					750		
Ser	Met	Gln	Ala	Gly	Ser	Ala	Val	Val	Asn	Leu	Ala	Trp	Pro	Ser	Gly
		755					760					765			
Pro	Leu	Gly	Gln	Gly	Thr	Cys	His	Ala	Gln	Leu	Ser	Asp	Ala	Gly	His
	770					775					780				
Leu	Ser	Trp	Glu	Gln	Pro	Leu	Ser	Leu	Gly	Gln	Asp	Leu	Leu	Met	Leu
	785					790					795				800
Arg	Asn	Leu	Ile	Pro	Gly	His	Thr	Val	Ser	Leu	Ser	Val	Lys	Cys	Arg
				805					810					815	
Ala	Gly	Pro	Leu	Gln	Ala	Ser	Thr	His	Pro	Leu	Val	Leu	Ser	Val	Glu
			820					825					830		
Pro	Gly	Pro	Val	Glu	Asp	Val	Phe	Cys	Gln	Pro	Glu	Ala	Thr	Tyr	Leu
		835					840					845			
Ser	Leu	Asn	Trp	Thr	Met	Pro	Thr	Gly	Asp	Val	Ala	Val	Cys	Leu	Val
	850					855					860				

Glu Val Glu Gln Leu Val Pro Gly Gly Ser Ala His Phe Val Phe Gln
 865 870 875 880
 Val Asn Thr Ser Glu Asp Ala Leu Leu Leu Pro Asn Leu Thr Pro Thr
 885 890 895
 Thr Ser Tyr Arg Leu Ser Leu Thr Val Leu Gly Gly Asn Arg Gln Trp
 900 905 910
 Ser Arg Ala Val Thr Leu Val Cys Thr Thr Ser Ala Glu Val Trp His
 915 920 925
 Pro Pro Glu Leu Ala Glu Ala Pro Gln Val Glu Leu Gly Thr Gly Met
 930 935 940
 Gly Val Thr Val Thr Arg Gly Met Phe Gly Lys Asp Asp Gly Gln Ile
 945 950 955 960
 Gln Trp Tyr Gly Ile Ile Ala Thr Ile Asn Met Thr Leu Ala Gln Pro
 965 970 975
 Ser Gln Glu Ala Ile Asn His Thr Trp Tyr Asp His Tyr Tyr Arg Gly
 980 985 990
 His Asp Ser Tyr Leu Ala Leu Leu Phe Pro Asn Pro Phe Tyr Pro Glu
 995 1000 1005
 Pro Trp Ala Val Pro Arg Ser Trp Thr Val Pro Val Gly Thr Glu
 1010 1015 1020
 Asp Cys Asp Asn Thr Gln Glu Ile Cys Asn Gly His Leu Lys Pro
 1025 1030 1035
 Gly Phe Gln Tyr Arg Phe Ser Ile Ala Ala Phe Ser Arg Leu Ser
 1040 1045 1050
 Ser Pro Glu Thr Ile Leu Ala Phe Ser Ala Phe Ser Glu Pro Gln
 1055 1060 1065
 Ala Ser Ile Ser Leu Val Ala Met Pro Leu Thr Val Met Met Gly
 1070 1075 1080
 Thr Val Val Gly Cys Ile Ile Ile Val Cys Ala Val Leu Cys Leu
 1085 1090 1095
 Leu Cys Arg Arg Arg Leu Lys Gly Pro Arg Ser Glu Lys Asn Gly
 1100 1105 1110
 Phe Ser Gln Glu Leu Met Pro Tyr Asn Leu Trp Arg Thr His Arg
 1115 1120 1125
 Pro Ile Pro Ser His Ser Phe Arg Gln Ser Tyr Glu Ala Lys Ser
 1130 1135 1140
 Ala Arg Ala His Gln Ala Phe Phe Gln Glu Phe Glu Glu Leu Lys
 1145 1150 1155
 Glu Val Gly Lys Asp Gln Pro Arg Leu Glu Ala Glu His Pro Ala
 1160 1165 1170

30

[illegible]

```
<210> 38
<211> 1711
<212> PRT
<213> Rattus norvegicus
```

<400> 38

Met Arg Pro Leu Ile Leu Leu Ala Ala Leu Leu Trp Leu Gln Gly Phe
1 5 10 15

Leu Ala Glu Asp Asp Ala Cys Ser Ser Leu Gly Gly Ser Pro Asp Arg
20 25 30

Gln Gly Gly Gly Pro Leu Leu Ser Val Asn Val Ser Ser His Gly Lys

35					40					45					
Ser	Thr	Ser	Leu	Phe	Leu	Ser	Trp	Val	Ala	Ala	Glu	Leu	Gly	Gly	Phe
50						55					60				
Asp	Tyr	Ala	Leu	Ser	Leu	Arg	Ser	Val	Asp	Ser	Ser	Gly	Ser	Pro	Glu
65					70					75					80
Gly	Gln	Gln	Leu	Gln	Ala	His	Thr	Asn	Glu	Ser	Gly	Phe	Glu	Phe	His
				85					90					95	
Gly	Leu	Val	Pro	Gly	Ser	Arg	Tyr	Gln	Leu	Lys	Leu	Thr	Val	Leu	Arg
			100					105					110		
Pro	Cys	Trp	Gln	Asn	Val	Thr	Ile	Thr	Leu	Thr	Ala	Arg	Thr	Ala	Pro
			115				120					125			
Thr	Val	Val	Arg	Gly	Leu	Gln	Leu	His	Ser	Ala	Gly	Ser	Pro	Ala	Arg
	130					135					140				
Leu	Glu	Ala	Ser	Trp	Ser	Asp	Ala	Pro	Gly	Asp	Gln	Asp	Ser	Tyr	Gln
145					150					155					160
Leu	Leu	Leu	Tyr	His	Leu	Glu	Ser	Gln	Thr	Leu	Ala	Cys	Asn	Val	Ser
				165					170					175	
Val	Ser	Pro	Asp	Thr	Leu	Ser	Tyr	Ser	Phe	Gly	Asp	Leu	Leu	Pro	Gly
			180					185					190		
Thr	Gln	Tyr	Val	Leu	Glu	Val	Ile	Thr	Trp	Ala	Gly	Ser	Leu	His	Ala
			195				200					205			
Lys	Thr	Ser	Ile	Leu	Gln	Trp	Thr	Glu	Pro	Val	Pro	Pro	Asp	His	Leu
	210					215					220				
Ala	Leu	Arg	Ala	Leu	Gly	Thr	Ser	Ser	Leu	Gln	Ala	Phe	Trp	Asn	Ser
225					230					235					240
Ser	Glu	Gly	Ala	Thr	Ser	Phe	His	Leu	Met	Leu	Thr	Asp	Leu	Leu	Gly
				245					250					255	
Gly	Thr	Asn	Thr	Thr	Ala	Val	Ile	Arg	Gln	Gly	Val	Ser	Thr	His	Thr
			260					265					270		
Phe	Leu	His	Leu	Ser	Pro	Gly	Thr	Pro	His	Glu	Leu	Lys	Ile	Cys	Ala
			275				280					285			
Ser	Ala	Gly	Pro	His	Gln	Ile	Trp	Gly	Pro	Ser	Ala	Thr	Glu	Trp	Thr
			290			295					300				
Tyr	Pro	Ser	Tyr	Pro	Ser	Asp	Leu	Val	Leu	Thr	Pro	Leu	Arg	Asn	Glu
305					310					315					320
Leu	Trp	Ala	Ser	Trp	Lys	Ala	Gly	Leu	Gly	Ala	Arg	Asp	Gly	Tyr	Val
				325					330					335	
Leu	Lys	Leu	Ser	Gly	Pro	Met	Glu	Ser	Thr	Ser	Thr	Leu	Gly	Pro	Glu
			340					345					350		
Glu	Cys	Asn	Ala	Val	Phe	Pro	Gly	Pro	Leu	Pro	Pro	Gly	His	Tyr	Thr
			355				360					365			

Leu Gln Leu Lys Val Leu Ala Gly Pro Tyr Asp Ala Trp Val Glu Gly
 370 375 380
 Ser Thr Trp Leu Ala Glu Ser Ala Ala Leu Pro Arg Glu Val Pro Gly
 385 390 395 400
 Ala Arg Leu Trp Leu Asp Gly Leu Glu Ala Ser Lys Gln Pro Gly Arg
 405 410 415
 Arg Ala Leu Leu Tyr Ser Asp Asp Ala Pro Gly Ser Leu Gly Asn Ile
 420 425 430
 Ser Val Pro Ser Gly Ala Thr His Val Ile Phe Cys Gly Leu Val Pro
 435 440 445
 Gly Ala His Tyr Arg Val Asp Ile Ala Ser Ser Thr Gly Asp Ile Ser
 450 455 460
 Gln Ser Ile Ser Gly Tyr Thr Ser Pro Leu Pro Pro Gln Ser Leu Glu
 465 470 475 480
 Val Ile Ser Arg Ser Ser Pro Ser Asp Leu Thr Ile Ala Trp Gly Pro
 485 490 495
 Ala Pro Gly Gln Leu Glu Gly Tyr Lys Val Thr Trp His Gln Asp Gly
 500 505 510
 Ser Gln Arg Ser Pro Gly Asp Leu Val Asp Leu Gly Pro Asp Thr Leu
 515 520 525
 Ser Leu Thr Leu Lys Ser Leu Val Pro Gly Ser Ser Tyr Thr Val Ser
 530 535 540
 Ala Trp Ala Trp Ala Gly Asn Leu Gly Ser Asp Ser Gln Lys Ile His
 545 550 555 560
 Ser Cys Thr Arg Pro Ala Pro Pro Thr Asn Leu Ser Leu Gly Phe Ala
 565 570 575
 His Gln Pro Ala Ala Leu Lys Ala Ser Trp Tyr His Pro Pro Gly Gly
 580 585 590
 Arg Asp Ala Phe His Leu Arg Leu Tyr Arg Leu Arg Pro Leu Thr Leu
 595 600 605
 Glu Ser Glu Lys Val Leu Pro Arg Glu Ala Gln Asn Phe Ser Trp Ala
 610 615 620
 Gln Leu Thr Ala Gly Cys Glu Phe Gln Val Gln Leu Ser Thr Leu Trp
 625 630 635 640
 Gly Ser Glu Arg Ser Ser Ser Ala Asn Ala Thr Gly Trp Thr Pro Pro
 645 650 655
 Ser Ala Pro Thr Leu Val Asn Val Thr Ser Asp Ala Pro Thr Gln Leu
 660 665 670
 Gln Val Ser Trp Ala His Val Pro Gly Gly Arg Ser Arg Tyr Gln Val
 675 680 685

Thr Leu Tyr Gln Glu Ser Thr Arg Thr Ala Thr Ser Ile Met Gly Pro
 690 695 700
 Lys Glu Asp Gly Thr Ser Phe Leu Gly Leu Thr Pro Gly Thr Lys Tyr
 705 710 715 720
 Lys Val Glu Val Ile Ser Trp Ala Gly Pro Leu Tyr Thr Ala Ala Ala
 725 730 735
 Asn Val Ser Ala Trp Thr Tyr Pro Leu Ile Pro Asn Glu Leu Leu Val
 740 745 750
 Ser Met Gln Ala Gly Ser Ala Val Val Asn Leu Ala Trp Pro Ser Gly
 755 760 765
 Pro Leu Gly Gln Gly Ala Cys His Ala Gln Leu Ser Asp Ala Gly His
 770 775 780
 Leu Ser Trp Glu Gln Pro Leu Lys Leu Gly Gln Glu Leu Phe Met Leu
 785 790 795 800
 Arg Asp Leu Thr Pro Gly His Thr Ile Ser Met Ser Val Arg Cys Arg
 805 810 815
 Ala Gly Pro Leu Gln Ala Ser Thr His Leu Val Val Leu Ser Val Glu
 820 825 830
 Pro Gly Pro Val Glu Asp Val Leu Cys His Pro Glu Ala Thr Tyr Leu
 835 840 845
 Ala Leu Asn Trp Thr Met Pro Ala Gly Asp Val Asp Val Cys Leu Val
 850 855 860
 Val Val Glu Arg Leu Val Pro Gly Gly Gly Thr His Phe Val Phe Gln
 865 870 875 880
 Val Asn Thr Ser Gly Asp Ala Leu Leu Leu Pro Asn Leu Met Pro Thr
 885 890 895
 Thr Ser Tyr Arg Leu Ser Leu Thr Val Leu Gly Arg Asn Ser Arg Trp
 900 905 910
 Ser Arg Ala Val Ser Leu Val Cys Ser Thr Ser Ala Glu Ala Trp His
 915 920 925
 Pro Pro Glu Leu Ala Glu Pro Pro Gln Val Glu Leu Gly Thr Gly Met
 930 935 940
 Gly Val Thr Val Met Arg Gly Met Phe Gly Lys Asp Asp Gly Gln Ile
 945 950 955 960
 Gln Trp Tyr Gly Ile Ile Ala Thr Ile Asn Met Thr Leu Ala Gln Pro
 965 970 975
 Ser Arg Glu Ala Ile Asn Tyr Thr Trp Tyr Asp His Tyr Tyr Arg Gly
 980 985 990
 Cys Glu Ser Phe Leu Ala Leu Leu Phe Pro Asn Pro Phe Tyr Pro Glu
 995 1000 1005
 Pro Trp Ala Gly Pro Arg Ser Trp Thr Val Pro Val Gly Thr Glu

1010	1015	1020
Asp Cys Asp Asn Thr Gln Glu 1025	Ile Cys Asn Gly Arg 1030	Leu Lys Ser 1035
Gly Phe Gln Tyr Arg Phe Ser 1040	Val Val Ala Phe Ser 1045	Arg Leu Asn 1050
Thr Pro Glu Thr Ile Leu Ala 1055	Phe Ser Ala Phe Ser 1060	Glu Pro Arg 1065
Ala Ser Ile Ser Leu Ala Ile 1070	Ile Pro Leu Thr Val 1075	Met Leu Gly 1080
Ala Val Val Gly Ser Ile Val 1085	Ile Val Cys Ala Val 1090	Leu Cys Leu 1095
Leu Arg Trp Arg Cys Leu Lys 1100	Gly Pro Arg Ser Glu 1105	Lys Asp Gly 1110
Phe Ser Lys Glu Leu Met Pro 1115	Tyr Asn Leu Trp Arg 1120	Thr His Arg 1125
Pro Ile Pro Ile His Ser Phe 1130	Arg Gln Ser Tyr Glu 1135	Ala Lys Ser 1140
Ala His Ala His Gln Thr Phe 1145	Phe Gln Glu Phe Glu 1150	Glu Leu Lys 1155
Glu Val Gly Lys Asp Gln Pro 1160	Arg Leu Glu Ala Glu 1165	His Pro Asp 1170
Asn Ile Ile Lys Asn Arg Tyr 1175	Pro His Val Leu Pro 1180	Tyr Asp His 1185
Ser Arg Val Arg Leu Thr Gln 1190	Leu Pro Gly Glu Pro 1195	His Ser Asp 1200
Tyr Ile Asn Ala Asn Phe Ile 1205	Pro Gly Tyr Ser His 1210	Thr Gln Glu 1215
Ile Ile Ala Thr Gln Gly Pro 1220	Leu Lys Lys Thr Leu 1225	Glu Asp Phe 1230
Trp Arg Leu Val Trp Glu Gln 1235	Gln Val His Val Ile 1240	Ile Met Leu 1245
Thr Val Gly Met Glu Asn Gly 1250	Arg Val Leu Cys Glu 1255	His Tyr Trp 1260
Pro Ala Asn Ser Thr Pro Val 1265	Thr His Gly His Ile 1270	Thr Ile His 1275
Leu Leu Ala Glu Glu Pro Glu 1280	Asp Glu Trp Thr Arg 1285	Arg Glu Phe 1290
Gln Leu Gln His Gly Thr Glu 1295	Gln Lys Gln Arg Arg 1300	Val Lys Gln 1305
Leu Gln Phe Thr Thr Trp Pro 1310	Asp His Ser Val Pro 1315	Glu Ala Pro 1320

Ser	Ser	Leu	Leu	Ala	Phe	Val	Glu	Leu	Val	Gln	Glu	Gln	Val	Gln
1325						1330					1335			
Ala	Thr	Gln	Gly	Lys	Gly	Pro	Ile	Leu	Val	His	Cys	Ser	Ala	Gly
1340						1345					1350			
Val	Gly	Arg	Thr	Gly	Thr	Phe	Val	Ala	Leu	Leu	Arg	Leu	Leu	Arg
1355						1360					1365			
Gln	Leu	Glu	Glu	Glu	Lys	Val	Ala	Asp	Val	Phe	Asn	Thr	Val	Tyr
1370						1375					1380			
Ile	Leu	Arg	Leu	His	Arg	Pro	Leu	Met	Ile	Gln	Thr	Leu	Ser	Gln
1385						1390					1395			
Tyr	Ile	Phe	Leu	His	Ser	Cys	Leu	Leu	Asn	Lys	Ile	Leu	Glu	Gly
1400						1405					1410			
Pro	Pro	Asp	Ser	Ser	Asp	Ser	Gly	Pro	Ile	Ser	Val	Met	Asp	Phe
1415						1420					1425			
Ala	Gln	Ala	Cys	Ala	Lys	Arg	Ala	Ala	Asn	Ala	Asn	Ala	Gly	Phe
1430						1435					1440			
Leu	Lys	Glu	Tyr	Lys	Leu	Leu	Lys	Gln	Ala	Ile	Lys	Asp	Gly	Thr
1445						1450					1455			
Gly	Ser	Leu	Leu	Pro	Pro	Pro	Asp	Tyr	Asn	Gln	Asn	Ser	Ile	Val
1460						1465					1470			
Ser	Arg	Arg	His	Ser	Gln	Glu	Gln	Phe	Ala	Leu	Val	Glu	Glu	Cys
1475						1480					1485			
Pro	Glu	Asp	Ser	Met	Leu	Glu	Ala	Ser	Leu	Phe	Pro	Gly	Gly	Pro
1490						1495					1500			
Ser	Gly	Cys	Asp	His	Val	Val	Leu	Thr	Gly	Ser	Ala	Gly	Pro	Lys
1505						1510					1515			
Glu	Leu	Trp	Glu	Met	Val	Trp	Glu	His	Asp	Ala	His	Val	Leu	Val
1520						1525					1530			
Ser	Leu	Gly	Leu	Pro	Asp	Thr	Lys	Glu	Lys	Pro	Pro	Asp	Ile	Trp
1535						1540					1545			
Pro	Val	Glu	Met	Gln	Pro	Ile	Val	Thr	Asp	Met	Val	Thr	Val	His
1550						1555					1560			
Arg	Val	Ser	Glu	Ser	Asn	Thr	Thr	Thr	Gly	Trp	Pro	Ser	Thr	Leu
1565						1570					1575			
Phe	Arg	Val	Ile	His	Gly	Glu	Ser	Gly	Lys	Glu	Arg	Gln	Val	Gln
1580						1585					1590			
Cys	Leu	Gln	Phe	Pro	Cys	Ser	Glu	Ser	Gly	Cys	Glu	Leu	Pro	Ala
1595						1600					1605			
Asn	Thr	Leu	Leu	Thr	Phe	Leu	Asp	Ala	Val	Gly	Gln	Cys	Cys	Phe
1610						1615					1620			

Arg Gly Lys Ser Lys Lys Pro Gly Thr Leu Leu Ser His Ser Ser
 1625 1630 1635

Lys Asn Thr Asn Gln Leu Gly Thr Phe Leu Ala Met Glu Gln Leu
 1640 1645 1650

Leu Gln Gln Ala Gly Thr Glu Arg Thr Val Asp Val Phe Asn Val
 1655 1660 1665

Ala Leu Lys Gln Ser Gln Ala Cys Gly Leu Met Thr Pro Thr Leu
 1670 1675 1680

Glu Gln Tyr Ile Tyr Leu Tyr Asn Cys Leu Asn Ser Ala Leu Leu
 1685 1690 1695

Asn Gly Leu Pro Arg Ala Gly Lys Trp Pro Ala Pro Cys
 1700 1705 1710

<210> 39

<211> 625

<212> PRT

<213> HOMO SAPIENS

<400> 39

Met Ala Gly Asp Arg Leu Pro Arg Lys Val Met Asp Ala Lys Lys Leu
 1 5 10 15

Ala Ser Leu Leu Arg Gly Gly Pro Gly Gly Pro Leu Val Ile Asp Ser
 20 25 30

Arg Ser Phe Val Glu Tyr Asn Ser Trp His Val Leu Ser Ser Val Asn
 35 40 45

Ile Cys Cys Ser Lys Leu Val Lys Arg Arg Leu Gln Gln Gly Lys Val
 50 55 60

Thr Ile Ala Glu Leu Ile Gln Pro Ala Ala Arg Ser Gln Val Glu Ala
 65 70 75 80

Thr Glu Pro Gln Asp Val Val Val Tyr Asp Gln Ser Thr Arg Asp Ala
 85 90 95

Ser Val Leu Ala Ala Asp Ser Phe Leu Ser Ile Leu Leu Ser Lys Leu
 100 105 110

Asp Gly Cys Phe Asp Ser Val Ala Ile Leu Thr Gly Gly Phe Ala Thr
 115 120 125

Phe Ser Ser Cys Phe Pro Gly Leu Cys Glu Gly Lys Pro Ala Ala Leu
 130 135 140

Leu Pro Met Ser Leu Ser Gln Pro Cys Leu Pro Val Pro Ser Val Gly
 145 150 155 160

Leu Thr Arg Ile Leu Pro His Leu Tyr Leu Gly Ser Gln Lys Asp Val
 165 170 175

Leu Asn Lys Asp Leu Met Thr Gln Asn Gly Ile Ser Tyr Val Leu Asn
 180 185 190

Ala	Ser	Asn	Ser	Cys	Pro	Lys	Pro	Asp	Phe	Ile	Cys	Glu	Ser	Arg	Phe	
		195					200					205				
Met	Arg	Val	Pro	Ile	Asn	Asp	Asn	Tyr	Cys	Glu	Lys	Leu	Leu	Pro	Trp	
	210					215					220					
Leu	Asp	Lys	Ser	Ile	Glu	Phe	Ile	Asp	Lys	Ala	Lys	Leu	Ser	Ser	Cys	
225					230					235					240	
Gln	Val	Ile	Val	His	Cys	Leu	Ala	Gly	Ile	Ser	Arg	Ser	Ala	Thr	Ile	
				245					250					255		
Ala	Ile	Ala	Tyr	Ile	Met	Lys	Thr	Met	Gly	Met	Ser	Ser	Asp	Asp	Ala	
			260					265					270			
Tyr	Arg	Phe	Val	Lys	Asp	Arg	Arg	Pro	Ser	Ile	Ser	Pro	Asn	Phe	Asn	
	275						280					285				
Phe	Leu	Gly	Gln	Leu	Leu	Glu	Tyr	Glu	Arg	Thr	Leu	Lys	Leu	Leu	Ala	
	290					295					300					
Ala	Leu	Gln	Gly	Asp	Pro	Gly	Thr	Pro	Ser	Gly	Thr	Pro	Glu	Pro	Pro	
305					310					315					320	
Pro	Ser	Pro	Ala	Ala	Gly	Ala	Pro	Leu	Pro	Arg	Leu	Pro	Pro	Pro	Thr	
				325					330					335		
Ser	Glu	Ser	Ala	Ala	Thr	Gly	Asn	Ala	Ala	Ala	Arg	Glu	Gly	Gly	Leu	
			340					345					350			
Ser	Ala	Gly	Gly	Glu	Pro	Pro	Ala	Pro	Pro	Thr	Pro	Pro	Ala	Thr	Ser	
	355						360					365				
Ala	Leu	Gln	Gln	Gly	Leu	Arg	Gly	Leu	His	Leu	Ser	Ser	Asp	Arg	Leu	
	370					375					380					
Gln	Asp	Thr	Asn	Arg	Leu	Lys	Arg	Ser	Phe	Ser	Leu	Asp	Ile	Lys	Ser	
385					390					395					400	
Ala	Tyr	Ala	Pro	Ser	Arg	Arg	Pro	Asp	Gly	Pro	Gly	Pro	Pro	Asp	Pro	
				405					410					415		
Gly	Glu	Ala	Pro	Lys	Leu	Cys	Lys	Leu	Asp	Ser	Pro	Ser	Gly	Ala	Ala	
			420					425					430			
Leu	Gly	Leu	Ser	Ser	Pro	Ser	Pro	Asp	Ser	Pro	Asp	Ala	Ala	Pro	Glu	
	435						440					445				
Ala	Arg	Pro	Arg	Pro	Arg	Arg	Arg	Pro	Arg	Pro	Pro	Ala	Gly	Ser	Pro	
	450					455					460					
Ala	Arg	Ser	Pro	Ala	His	Ser	Leu	Gly	Leu	Asn	Phe	Gly	Asp	Ala	Ala	
465					470					475					480	
Arg	Gln	Thr	Pro	Arg	His	Gly	Leu	Ser	Ala	Leu	Ser	Ala	Pro	Gly	Leu	
				485					490					495		
Pro	Gly	Pro	Gly	Gln	Pro	Ala	Gly	Pro	Gly	Ala	Trp	Ala	Pro	Pro	Leu	
			500					505					510			
Asp	Ser	Pro	Gly	Thr	Pro	Ser	Pro	Asp	Gly	Pro	Trp	Cys	Phe	Ser	Pro	

515 520 525
 Glu Gly Ala Gln Gly Ala Gly Gly Val Leu Phe Ala Pro Phe Gly Arg
 530 535 540
 Ala Gly Ala Pro Gly Pro Gly Gly Gly Ser Asp Leu Arg Arg Arg Glu
 545 550 555 560
 Ala Ala Arg Ala Glu Pro Arg Asp Ala Arg Thr Gly Trp Pro Glu Glu
 565 570 575
 Pro Ala Pro Glu Thr Gln Phe Lys Arg Arg Ser Cys Gln Met Glu Phe
 580 585 590
 Glu Glu Gly Met Val Glu Gly Arg Ala Arg Gly Glu Glu Leu Ala Ala
 595 600 605
 Leu Gly Lys Gln Ala Ser Phe Ser Gly Ser Val Glu Val Ile Glu Val
 610 615 620
 Ser
 625
 <210> 40
 <211> 663
 <212> PRT
 <213> Mus musculus
 <400> 40
 Met Ala Gly Asp Arg Leu Pro Arg Lys Val Met Asp Ala Lys Lys Leu
 1 5 10 15
 Ala Ser Leu Leu Arg Gly Gly Pro Gly Gly Pro Leu Val Ile Asp Ser
 20 25 30
 Arg Ser Phe Val Glu Tyr Asn Ser Cys His Val Leu Ser Ser Val Asn
 35 40 45
 Ile Cys Cys Ser Lys Leu Val Lys Arg Arg Leu Gln Gln Gly Lys Val
 50 55 60
 Thr Ile Ala Glu Leu Ile Gln Pro Ala Thr Arg Ser Gln Val Asp Ala
 65 70 75 80
 Thr Glu Pro Gln Asp Val Val Val Tyr Asp Gln Ser Thr Arg Asp Ala
 85 90 95
 Ser Val Leu Ala Ala Asp Ser Phe Leu Ser Ile Leu Leu Ser Lys Leu
 100 105 110
 Asp Gly Cys Phe Asp Ser Val Ala Ile Leu Thr Gly Gly Phe Ala Thr
 115 120 125
 Phe Ser Ser Cys Phe Pro Gly Leu Cys Glu Gly Lys Pro Ala Thr Leu
 130 135 140
 Pro Ser Met Ser Leu Ser Gln Pro Cys Leu Pro Val Pro Ser Val Gly
 145 150 155 160
 Leu Thr Arg Ile Leu Pro His Leu Tyr Leu Gly Ser Gln Lys Asp Val

165					170					175								
Leu	Asn	Lys	Asp	180	Leu	Met	Thr	Gln	185	Asn	Gly	Ile	Ser	190	Tyr	Val	Leu	Asn
Ala	Ser	Asn	Ser	195	Cys	Pro	Lys	Pro	200	Asp	Phe	Ile	Cys	205	Glu	Ser	Arg	Phe
Met	Arg	Ile	Pro	210	Ile	Asn	Asp	Asn	215	Tyr	Cys	Glu	Lys	220	Leu	Leu	Pro	Trp
Leu	Asp	Lys	Ser	225	Ile	Glu	Phe	Ile	230	Asp	Lys	Ala	Lys	235	Leu	Ser	Ser	Cys
Gln	Val	Ile	Val	245	His	Cys	Leu	Ala	250	Gly	Ile	Ser	Arg	255	Ser	Ala	Thr	Ile
Ala	Ile	Ala	Tyr	260	Ile	Met	Lys	Thr	265	Met	Gly	Met	Ser	270	Ser	Asp	Asp	Ala
Tyr	Arg	Phe	Val	275	Lys	Asp	Arg	Arg	280	Pro	Ser	Ile	Ser	285	Pro	Asn	Phe	Asn
Phe	Leu	Gly	Gln	290	Leu	Leu	Glu	Tyr	295	Glu	Arg	Ser	Leu	300	Lys	Leu	Leu	Ala
Ala	Leu	Gln	Thr	305	Asp	Gly	Pro	His	310	Leu	Gly	Thr	Pro	315	Glu	Pro	Leu	Met
Gly	Pro	Ala	Ala	325	Gly	Ile	Pro	Leu	330	Arg	Leu	Pro	Pro	335	Ser	Thr	Ser	
Glu	Ser	Ala	Ala	340	Thr	Gly	Ser	Glu	345	Ala	Ala	Thr	Ala	350	Arg	Glu	Gly	
Ser	Pro	Ser	Ala	355	Gly	Gly	Asp	Ala	360	Pro	Ile	Pro	Ser	365	Thr	Ala	Pro	Ala
Thr	Ser	Ala	Leu	370	Gln	Gln	Gly	Leu	375	Arg	Gly	Leu	His	380	Leu	Ser	Ser	Asp
Arg	Leu	Gln	Asp	385	Thr	Asn	Arg	Leu	390	Lys	Arg	Ser	Phe	395	Ser	Leu	Asp	Ile
Lys	Ser	Ala	Tyr	405	Ala	Pro	Ser	Arg	410	Arg	Pro	Asp	Phe	415	Pro	Gly	Pro	Pro
Asp	Pro	Gly	Glu	420	Ala	Pro	Lys	Leu	425	Cys	Lys	Leu	Asp	430	Ser	Pro	Ser	Gly
Gly	Thr	Leu	Gly	435	Leu	Pro	Ser	Pro	440	Ser	Pro	Asp	Ser	445	Pro	Asp	Ser	Val
Pro	Glu	Cys	Arg	450	Pro	Arg	Pro	Arg	455	Arg	Arg	Arg	Pro	460	Pro	Pro	Ala	Ser
Pro	Ala	Arg	Ser	465	Pro	Ala	His	Gly	470	Leu	Gly	Leu	Asn	475	Phe	Gly	Asp	Thr
Ala	Arg	Gln	Thr	485	Pro	Arg	His	Gly	490	Leu	Ser	Ala	Leu	495	Ser	Ala	Pro	Gly

Leu Pro Gly Pro Gly Gln Pro Ala Gly Pro Gly Gly Trp Val Pro Pro
 500 505 510
 Leu Asp Ser Pro Gly Thr Pro Ser Pro Asp Gly Pro Trp Cys Phe Ser
 515 520 525
 Pro Glu Gly Ala Gln Gly Pro Gly Ala Val Phe Ser Ala Phe Gly Arg
 530 535 540
 Val Ser Ala Gly Ala Pro Gly Pro Gly Asn Ser Ser Ser Ser Gly Gly
 545 550 555 560
 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
 565 570 575
 Ser Ser Ser Ser Asn Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser
 580 585 590
 Ser Ser Ser Ser Ser Ser Ser Ser Asp Leu Arg Arg Arg Asp Val Arg
 595 600 605
 Thr Gly Trp Pro Glu Glu Pro Ala Ala Asp Ala Gln Phe Lys Arg Arg
 610 615 620
 Ser Cys Gln Met Glu Phe Glu Glu Gly Met Val Glu Gly Arg Ala Arg
 625 630 635 640
 Gly Glu Glu Leu Ala Ala Leu Gly Lys Gln Thr Ser Phe Ser Gly Ser
 645 650 655
 Val Glu Val Ile Glu Val Ser
 660

<210> 41
 <211> 5111
 <212> DNA
 <213> HOMO SAPIENS

<400> 41
 atgttcattt taaaaaactt caggatgggc acaaacacac agaagtggga aatgaataaa 60
 agagtattga taaatttttg aaaattgttg aagctgagta atgggctttc agtccagtgt 120
 aaagctgttg gagcgcgga gcaaaggtaa agaattgatgt aatgcgctgg ctgctccaaa 180
 gcatcttttg ttgtggaatg gttattccag tcatctcttt atgaatcaaa tgtgaggggc 240
 tgctttgttg acggagtcct ttgcaagagc acatcaacgg gaaagagaaa gagacattca 300
 cttggagggc tcttgtctgaa aatgggttta actctccttt tgccagtcac caccagcctg 360
 acctcataca ctttttagtac aatggagtgg ctgagccttt gagcacacca ccattacatc 420
 atcgtggcaa attaaagaag gaggtgggaa aagaggactt attgttgtca tggcccatga 480
 gatgattgga actcaaattg ttactgagag gttggtggct ctgctggaaa gtggaacgga 540
 aaaagtgtg ctaattgata gccggccatt tgtggaatac aatacatccc acattttgga 600
 agccattaat atcaactgct ccaagcttat gaagcgaagg ttgcaacagg acaaagtgtt 660

aattacagag ctcatccagc attcagcgaa acataagggtt gacattgatt gcagtcagaa	720
ggttgtagtt tacgatcaaa gctcccaaga tgttgccctct ctctcttcag actgttttct	780
cactgtactt ctgggtaaac tggagaagag cttcaactct gttcacctgc ttgcagggtgg	840
gtttgctgag ttctctcggt gtttccttgg cctctgtgaa ggaaaatcca ctctagtccc	900
tacctgcatt tctcagcctt gcttacctgt tgccaacatt gggccaaccc gaattcttcc	960
caatctttat cttggctgcc agcgagatgt cctcaacaag gagctgatgc agcagaatgg	1020
gattggttat gtgttaaatg ccagcaatac ctgtccaaag cctgacttta tccccgagtc	1080
tcatttcctg cgtgtgcctg tgaatgacag cttttgtgag aaaattttgc cgtgggttga	1140
caaatcagta gatttcattg agaaagcaaa agcctccaat ggatgtgttc tagtgactg	1200
tttagctggg atctcccgct ccgccaccat cgctatcgcc tacatcatga agaggatgga	1260
catgtcttta gatgaagctt acagatttgt gaaagaaaaa agacctacta tatctccaaa	1320
cttcaatttt ctgggccaac tcttggccta tgagaagaag attaagaacc agactggagc	1380
atcagggcca aagagcaaac tcaagctgct gccctggag aagccaaatg aacctgtccc	1440
tgctgtctca gagggtggac agaaaagcga gacgcccctc agtccaccct gtgccgactc	1500
tgctacctca gaggcagcag gacaaaggcc cgtgcatccc gccagcgtgc ccagcgtgcc	1560
cagcgtgcag ccgtcgtgt tagaggacag ccgctggta caggcgtca gtgggctgca	1620
cctgtccgca gacaggctgg aagacagcaa taagctcaag cgttccttct ctctggatat	1680
caaatcagtt tcatattcag ccagcatggc agcatcctta catggcttct cctcatcaga	1740
agatgctttg gaatactaca aaccttcac tactctggat gggaccaaca agctatgcca	1800
gttctcccct gttcaggaac tatcgagca gactcccgaa accagtcctg ataaggagga	1860
agccagcatc cccaagaagc tgcagaccgc caggccttca gacagccaga gcaagcgatt	1920
gcattcggtc agaaccagca gcagtggcac cgcccagagg tcccttttat ctccactgca	1980
tcgaagtggg agcgtggagg acaattacca caccagcttc cttttcggcc tttccaccag	2040
ccagcagcac ctacgaagt ctgctggcct gggccttaag ggotggcact cggatatctt	2100
ggccccccag acctctaccc cttccctgac cagcagctgg tattttgcca cagagtcctc	2160
acatttctac tctgcctcag ccatctacgg aggcagtgcc agttactctg cctacagctg	2220
cagccagctg cccacttgcg gagaccaagt ctattctgtg cgcaggcggc agaagccaag	2280
tgacagagct gactcgcggc ggagctggca tgaagagagc ccctttgaaa agcagtttaa	2340
acgcagaagc tgccaaatgg aatttgaga gagcatcatg tcagagaaca ggtcacggga	2400
agagctgggg aaagtgggca gtcagtctag cttttcgggc agcatggaaa tcattgaggt	2460

ctcctgagaa gaaagacact tgtgacttct atagacaatt tttttttctt gttcacaanaa	2520
aaattccctg ggaatctgaa atatgtatgt gggcatacat atatatTTTT ggaaaatgga	2580
gctatgggtgt aaaagcaaca ggtggatcaa cccagttgtt actctcttaa catctgcatt	2640
tcagagatca gctaatactt gctctcaaca aaaatggaag ggcagatgct agaatcccc	2700
ctagacggag gaaaaccatt ttattcagt g aattacacat cctcttggtt ttaaaaaagc	2760
aagtgtcttt ggtgttgag gacaaaatcc cctaccattt tcacgttggt ctactaagag	2820
atctcaaata ttagtctttg tccggaccct tccatagtag accttagcgc tgagactgag	2880
ccagcttggg ggtcaggtag gtagaccctg ttagggacag agcctagtgg taaatccaag	2940
agaaatgatc ctatccaaag ctgattcaca aaccacgct cacctgacag ccgagggaca	3000
cgagcatcac tctgctggac ggaccattag gggccttgcc aaggtctacc ttagagcaaa	3060
cccagtagct cagacaggaa agtcggggct ttgaccacta ccatatctgg tagccattt	3120
tctaggcatt gtgaataggt aggtagctag tcacactttt cagaccaatt caaactgtct	3180
atgcacaaaa ttcccgtggg cctagatgga gataattttt ttttcttctc agctttatga	3240
agagaaggga aactgtctag gattcagctg aaccaccagg aacctggcaa catcacgatt	3300
taagctaagg ttgggaggct aacgagtcta cctccctctt tgtaaataca agaattgttt	3360
aaaatgggat tgtoaactct ttaaataaag atgaacttgg tttcaagcca aatgtgaatt	3420
tatttgggtt ggtagcagag cagcagcacc ttcaaatctt cagccaaaagc agatgttttt	3480
gccctttctg cttcactgca tggatacagt tggtaaaatg taataatatg gcagaatttt	3540
ataggaaact tcctagggag gtaaattatg ggaagattaa gaaaggtaca aattgctgag	3600
gagaagcagg aaacctgttt ccttagtggc ttttatcccc tcggcatgag atggggctga	3660
tgtttctata attgcctcag actttcacat ttactagtag ggctgagaga ggcttttagt	3720
aggaaagaat attcagaata aaacggttga gaaagctgag aagaccattg agttttgatc	3780
agttgtgaat agagtcaaa gccatggcca agctgttttt ggaaacgctg gccggcgtgt	3840
cttcagtgga aaaagcaaat caaatggag cgagagcaaa ggggcgtcct cagtccctca	3900
cctacaatca ctgtatggaa tcggctctgg cagctgaaca taggaggtca ctggaacaag	3960
tgatagtga gattggcttt caaacatcct cctggcttga gttttatcag ctacaatgtg	4020
ggctctcttt tgaagcctta attcacaaca gcagcttttt ggggggtggg ctgggcgggt	4080
gttgtcattg ttctttccct tcctgtaagt gtcgctagtt gctgcctcgt atctcaggtt	4140
tttctctgtt ttgagaaat ggacagtttt ttgaccagga tgtgacttca tgtttcctat	4200
ggtgacttct aaaaccagca cagaatgata tgactcaaca cagaccgact tggttatggg	4260
gatgatgagc cgcacagacc tcactagttg tgcacaaata atgtgctatg atgggggtga	4320

```

aagtgaaggc agaagagggc cagccgcatt gttatgatac tgggaaagtg ccggtcaacg 4380
atttgagtta gtttttagat atacattgaa atctttaatc agacattctc aagtttcaca 4440
cagtagtttt tgatgttatg tacacacaca ccaaagtgtg aacagttcac cacttccaga 4500
gtgtgggtcat gcccacaaaca tgtttaagaa aggaaagcag tagctccttg ctaacgatgt 4560
ttcaggaggt ttggggcact tggttttaat gagcttctgt catttagggc ttctcttggc 4620
catgggtccc ttcttcttgg aactgtgatg tagtcacatc ctacagcctt tagtgctggg 4680
tcactagtgt cagataatca gttcttggaa tcgagactgc cgtggcgaag ggggtggcctc 4740
ggaggcaggc tctggagctg cttggatgtc tttaggtggg gtgggtggctg gctctcttca 4800
gcatgtaatt ggggaaaccc tcgcgtctac taggggtgat acagatgggtg attttaaaga 4860
gcaaaactag acttctatgt gagaagtgtt ggaaaatgat ttaggacgtg taaagttaga 4920
tggaagact gtaaagtgtt aatatgaata tagtgttctt ttgaagtaag gccagctgtt 4980
gaacgggttaa actgtgcatt tctcattttg atgtgtcatg tatgttaatg tatgaaatga 5040
ttaaataaaa tcaaaactgg tacctgttta tccataaaaa aaaaaaaaaa aaaaaaaaaa 5100
aaaaaaaaa g 5111

```

```

<210> 42
<211> 665
<212> PRT
<213> HOMO SAPIENS

```

```

<400> 42

```

```

Met Ala His Glu Met Ile Gly Thr Gln Ile Val Thr Glu Arg Leu Val
1           5           10           15
Ala Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp Ser Arg
20          25          30
Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile Asn Ile
35          40          45
Asn Cys Ser Lys Leu Met Lys Arg Arg Leu Gln Gln Asp Lys Val Leu
50          55          60
Ile Thr Glu Leu Ile Gln His Ser Ala Lys His Lys Val Asp Ile Asp
65          70          75          80
Cys Ser Gln Lys Val Val Val Tyr Asp Gln Ser Ser Gln Asp Val Ala
85          90          95
Ser Leu Ser Ser Asp Cys Phe Leu Thr Val Leu Leu Gly Lys Leu Glu
100         105         110
Lys Ser Phe Asn Ser Val His Leu Leu Ala Gly Gly Phe Ala Glu Phe
115         120         125

```

Ser Arg Cys Phe Pro Gly Leu Cys Glu Gly Lys Ser Thr Leu Val Pro
 130 135 140
 Thr Cys Ile Ser Gln Pro Cys Leu Pro Val Ala Asn Ile Gly Pro Thr
 145 150 155 160
 Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp Val Leu Asn
 165 170 175
 Lys Glu Leu Met Gln Gln Asn Gly Ile Gly Tyr Val Leu Asn Ala Ser
 180 185 190
 Asn Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His Phe Leu Arg
 195 200 205
 Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro Trp Leu Asp
 210 215 220
 Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn Gly Cys Val
 225 230 235 240
 Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile Ala Ile
 245 250 255
 Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu Ala Tyr Arg
 260 265 270
 Phe Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Asn Phe Asn Phe Leu
 275 280 285
 Gly Gln Leu Leu Ala Tyr Glu Lys Lys Ile Lys Asn Gln Thr Gly Ala
 290 295 300
 Ser Gly Pro Lys Ser Lys Leu Lys Leu Leu Pro Leu Glu Lys Pro Asn
 305 310 315 320
 Glu Pro Val Pro Ala Val Ser Glu Gly Gly Gln Lys Ser Glu Thr Pro
 325 330 335
 Leu Ser Pro Pro Cys Ala Asp Ser Ala Thr Ser Glu Ala Ala Gly Gln
 340 345 350
 Arg Pro Val His Pro Ala Ser Val Pro Ser Val Pro Ser Val Gln Pro
 355 360 365
 Ser Leu Leu Glu Asp Ser Pro Leu Val Gln Ala Leu Ser Gly Leu His
 370 375 380
 Leu Ser Ala Asp Arg Leu Glu Asp Ser Asn Lys Leu Lys Arg Ser Phe
 385 390 395 400
 Ser Leu Asp Ile Lys Ser Val Ser Tyr Ser Ala Ser Met Ala Ala Ser
 405 410 415
 Leu His Gly Phe Ser Ser Ser Glu Asp Ala Leu Glu Tyr Tyr Lys Pro
 420 425 430
 Ser Thr Thr Leu Asp Gly Thr Asn Lys Leu Cys Gln Phe Ser Pro Val
 435 440 445
 Gln Glu Leu Ser Glu Gln Thr Pro Glu Thr Ser Pro Asp Lys Glu Glu

450	455	460
Ala Ser Ile Pro Lys Lys Leu Gln Thr Ala Arg Pro Ser Asp Ser Gln 465	470	475 480
Ser Lys Arg Leu His Ser Val Arg Thr Ser Ser Ser Gly Thr Ala Gln 485	490	495
Arg Ser Leu Leu Ser Pro Leu His Arg Ser Gly Ser Val Glu Asp Asn 500	505	510
Tyr His Thr Ser Phe Leu Phe Gly Leu Ser Thr Ser Gln Gln His Leu 515	520	525
Thr Lys Ser Ala Gly Leu Gly Leu Lys Gly Trp His Ser Asp Ile Leu 530	535	540
Ala Pro Gln Thr Ser Thr Pro Ser Leu Thr Ser Ser Trp Tyr Phe Ala 545	550	555 560
Thr Glu Ser Ser His Phe Tyr Ser Ala Ser Ala Ile Tyr Gly Gly Ser 565	570	575
Ala Ser Tyr Ser Ala Tyr Ser Cys Ser Gln Leu Pro Thr Cys Gly Asp 580	585	590
Gln Val Tyr Ser Val Arg Arg Arg Gln Lys Pro Ser Asp Arg Ala Asp 595	600	605
Ser Arg Arg Ser Trp His Glu Glu Ser Pro Phe Glu Lys Gln Phe Lys 610	615	620
Arg Arg Ser Cys Gln Met Glu Phe Gly Glu Ser Ile Met Ser Glu Asn 625	630	635 640
Arg Ser Arg Glu Glu Leu Gly Lys Val Gly Ser Gln Ser Ser Phe Ser 645	650	655
Gly Ser Met Glu Ile Ile Glu Val Ser 660	665	

<210> 43
 <211> 20
 <212> DNA
 <213> HOMO SAPIENS

<400> 43
 cggatggaag gattatggtg

20

<210> 44
 <211> 18
 <212> DNA
 <213> HOMO SAPIENS

<400> 44
 ctgttcgacc aagccctg

18

<210> 45
 <211> 80

<212> DNA
<213> HOMO SAPIENS

<400> 45
tgacaatgga tagctacttt tccttcctgt aaggcaaagtc tcatcacctt caccatatct 60
aggatagtag taagagacgc 80

<210> 46
<211> 20
<212> DNA
<213> HOMO SAPIENS

<400> 46
ttcggatgga aggattatgg 20

<210> 47
<211> 18
<212> DNA
<213> HOMO SAPIENS

<400> 47
ctgttcgacc aagccctg 18

<210> 48
<211> 80
<212> DNA
<213> HOMO SAPIENS

<400> 48
tgacaatgga tagctacttt tccttcctgt aaggcaaagtc tcatcacctt caccatatct 60
aggatagtag taagagacgc 80

<210> 49
<211> 19
<212> DNA
<213> HOMO SAPIENS

<400> 49
ccaacttctc ctgggtgct 19

<210> 50
<211> 18
<212> DNA
<213> HOMO SAPIENS

<400> 50
ctccgtcagg gacaccag 18

<210> 51
<211> 79
<212> DNA
<213> HOMO SAPIENS

<400> 51
 gtgccgcacg cccaggtcca acaggaactg gtagtgggcg gggagccgcg gcagcgccag 60
 tcccgcagc cggcccga 79

<210> 52
 <211> 20
 <212> DNA
 <213> HOMO SAPIENS

<400> 52
 caacttctcc tgggtgcttc 20

<210> 53
 <211> 18
 <212> DNA
 <213> HOMO SAPIENS

<400> 53
 cagctgtcgc tgtgaggg 18

<210> 54
 <211> 80
 <212> DNA
 <213> HOMO SAPIENS

<400> 54
 ctccgtcagg gacaccaggt gccgcacgcc caggtccaac aggaactggt agtgggcggg 60
 gagccgcggc agcgccagtc 80

<210> 55
 <211> 20
 <212> DNA
 <213> HOMO SAPIENS

<400> 55
 ctccctgctt ctgtggacat 20

<210> 56
 <211> 20
 <212> DNA
 <213> HOMO SAPIENS

<400> 56
 aacctggatg cttcccttct 20

<210> 57
 <211> 80
 <212> DNA
 <213> HOMO SAPIENS

<400> 57
 aaaagagcaa tggtgtaagt tgcttttcat actcttacta tggtggtaac tccatcctgc 60

ttaagttcct gtaagaatct

80

<210> 58

<211> 20

<212> DNA

<213> HOMO SAPIENS

<400> 58

tgcttctgtg gacattgcat

20

<210> 59

<211> 20

<212> DNA

<213> HOMO SAPIENS

<400> 59

aacctggatg cttcccttct

20

<210> 60

<211> 80

<212> DNA

<213> HOMO SAPIENS

<400> 60

aaaagagcaa tgttgtaagt tgcttttcat actcttacta tggtggtaac tccatcctgc

60

ttaagttcct gtaagaatct

80

<210> 61

<211> 20

<212> DNA

<213> HOMO SAPIENS

<400> 61

ggcagaacta tgaggccaag

20

<210> 62

<211> 20

<212> DNA

<213> HOMO SAPIENS

<400> 62

gaccctggag tggatcatagg

20

<210> 63

<211> 80

<212> DNA

<213> HOMO SAPIENS

<400> 63

gctcatgcgc accaggcttt ctttttgaaa ttcgaggagc tgaaggaggt gagcaaggag

60

cagcccagac tggaggetga

80

<210> 64
<211> 20
<212> DNA
<213> HOMO SAPIENS

<400> 64
gcaccaggct ttctttttga 20

<210> 65
<211> 20
<212> DNA
<213> HOMO SAPIENS

<400> 65
gaccctggag tggatcatagg 20

<210> 66
<211> 80
<212> DNA
<213> HOMO SAPIENS

<400> 66
tcgaggagct gaaggaggat agcaaggagc agcccagact ggaggctgag taccctgcca 60
acaccaccaa gaactgttaa 80

<210> 67
<211> 20
<212> DNA
<213> HOMO SAPIENS

<400> 67
atgggaccaa caagctatgc 20

<210> 68
<211> 20
<212> DNA
<213> HOMO SAPIENS

<400> 68
ttatcaggac tggtttcggg 20

<210> 69
<211> 20
<212> DNA
<213> HOMO SAPIENS

<400> 69
ggccaaagag caaactcaag 20

<210> 70
<211> 20
<212> DNA
<213> HOMO SAPIENS

<400> 70
gcatagcttg ttggtcccat

20

<210> 71
<211> 20
<212> DNA
<213> HOMO SAPIENS

<400> 71
aggcagaact atgaggccaa

20

<210> 72
<211> 20
<212> DNA
<213> HOMO SAPIENS

<400> 72
gaccctggag tggcatagg

20

<210> 73
<211> 80
<212> DNA
<213> HOMO SAPIENS

<400> 73
gctcatgctc accaggcttt ctttttgaaa ttcgaggagc tgaaggaggt gagcaaggag

60

cagcccagac tggaggctga

80

<210> 74
<211> 80
<212> DNA
<213> HOMO SAPIENS

<400> 74
tcagcctcca gtctgggctg ctcttgctc acctccttca gtcctcga tttcaaaaag

60

aaagcctggt gcgcatgagc

80

<210> 75
<211> 8
<212> PRT
<213> bacteriophage T7

<400> 75

Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

<210> 76
<211> 733
<212> DNA
<213> homo sapiens

<400> 76
gggatccgga gcccaaattct tctgacaaaa ctacacatg cccaccgtgc ccagcacctg

60

```

aattcgaggg tgcaccgtca gtcttctct tcccccaaa acccaaggac accctcatga 120
tctcccgga tcttgaggtc acatgogtgg tgggtggacgt aagccacgaa gaccctgagg 180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300
ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg 360
agaaaacat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420
catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctgggc aaaggcttct 480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagAAC aactacaaga 540
ccatgcctcc cgtgctggac tccgacggct ccttcttct ctacagcaag ctcaccgtgg 600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggtcttgc 660
acaaccacta cagcgagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720
gactctagag gat 733

```

```

<210> 77
<211> 7
<212> PRT
<213> HOMO SAPIENS

```

```
<400> 77
```

```

Asp Tyr Ile Asn Ala Ser Asn
1           5

```

```

<210> 78
<211> 6
<212> PRT
<213> HOMO SAPIENS

```

```

<220>
<221> VARIANT
<222> (2)..(2)
<223> wherein 'Xaa' is any amino acid.

```

```

<220>
<221> VARIANT
<222> (3)..(3)
<223> wherein 'Xaa' is any amino acid.

```

```
<400> 78
```

```

Cys Xaa Xaa Tyr Trp Pro
1           5

```

```

<210> 79
<211> 9
<212> PRT

```

<213> HOMO SAPIENS

<220>

<221> Variant

<222> (5)..(5)

<223> wherein 'Xaa' is any amino acid.

<220>

<221> Variant

<222> (6)..(6)

<223> wherein 'Xaa' is any amino acid.

<220>

<221> Variant

<222> (7)..(7)

<223> wherein 'Xaa' is any amino acid.

<220>

<221> Variant

<222> (8)..(8)

<223> wherein 'Xaa' is any amino acid.

<400> 79

Ile Val Val Met Xaa Xaa Xaa Xaa Glu
1 5

<210> 80

<211> 8

<212> PRT

<213> HOMO SAPIENS

<400> 80

Asp Asn Tyr Ile Asn Ala Ser Asn
1 5

<210> 81

<211> 6

<212> PRT

<213> HOMO SAPIENS

<220>

<221> Variant

<222> (2)..(2)

<223> wherein 'Xaa' is any amino acid.

<220>

<221> Variant

<222> (3)..(3)

<223> wherein 'Xaa' is any amino acid.

<400> 81

Cys Xaa Xaa Tyr Trp Pro

1

5

<210> 82
 <211> 9
 <212> PRT
 <213> HOMO SAPIENS

<220>
 <221> Variant
 <222> (5)..(5)
 <223> wherein 'Xaa' is any amino acid.

<220>
 <221> Variant
 <222> (6)..(6)
 <223> wherein 'Xaa' is any amino acid.

<220>
 <221> Variant
 <222> (7)..(7)
 <223> wherein 'Xaa' is any amino acid.

<220>
 <221> Variant
 <222> (8)..(8)
 <223> wherein 'Xaa' is any amino acid.

<400> 82

Ile Val Val Met Xaa Xaa Xaa Xaa Glu
 1 5

<210> 83
 <211> 511
 <212> DNA
 <213> homo sapiens

<400> 83
 atggctagaa tgaacctccc tgcttctgtg gacattgcat acaaaaatgt gagatttctt 60
 attacacaca acccaacca tacctacttt aatagattct tacaggaact taagcaggat 120
 ggagttacca ccatagtaag agtatgaaaa gcaacttaca acattgctct tttagagaag 180
 ggaagcatcc aggttccgga ctggcctttt gatgatggta cagcaccatc cagccagata 240
 attgataact ggttaaaact tatgaaaaat aaatttcattg aagatcctgg ttgttgattt 300
 gcaattcact gtgttgtagg ttttgggtga gctccagttg ctagttgccc tagctttaat 360
 tgaaggtgga atgaaatatg aaaatgtagt acagttcatc agataaaaagt gacatggaac 420
 ttttaacagc aaacaacttt tgtatttgga gaaatattgt cttaaaatat gcttgacact 480
 cagaaatccc agaaataact gtttccttca g 511

<210> 84
 <211> 167
 <212> PRT
 <213> homo sapiens

<400> 84

Met Ala Arg Met Asn Leu Pro Ala Ser Val Asp Ile Ala Tyr Lys Asn
 1 5 10 15
 Val Arg Phe Leu Ile Thr His Asn Pro Thr Asn Thr Tyr Phe Asn Arg
 20 25 30
 Phe Leu Gln Glu Leu Lys Gln Asp Gly Val Thr Thr Ile Val Arg Val
 35 40 45
 Lys Ala Thr Tyr Asn Ile Ala Leu Leu Glu Lys Gly Ser Ile Gln Val
 50 55 60
 Pro Asp Trp Pro Phe Asp Asp Gly Thr Ala Pro Ser Ser Gln Ile Ile
 65 70 75 80
 Asp Asn Trp Leu Lys Leu Met Lys Asn Lys Phe His Glu Asp Pro Gly
 85 90 95
 Cys Cys Ile Ala Ile His Cys Val Val Gly Phe Gly Glu Leu Gln Leu
 100 105 110
 Leu Val Ala Leu Ala Leu Ile Glu Gly Gly Met Lys Tyr Glu Asn Val
 115 120 125
 Val Gln Phe Ile Arg Lys His Gly Thr Phe Asn Ser Lys Gln Leu Leu
 130 135 140
 Tyr Leu Glu Lys Tyr Cys Leu Lys Ile Cys Leu His Leu Arg Asn Pro
 145 150 155 160
 Arg Asn Asn Cys Phe Leu Gln
 165

<210> 85
 <211> 14
 <212> PRT
 <213> homo sapiens

<400> 85

Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile
 1 5 10

<210> 86
 <211> 14
 <212> PRT
 <213> homo sapiens

<400> 86

Glu Ala Ile Asn Ile Asn Cys Ser Lys Leu Met Lys Arg Arg
 1 5 10

<210> 87

<211> 14
<212> PRT
<213> homo sapiens

<400> 87

Ile Gly Tyr Val Leu Asn Ala Ser Asn Thr Cys Pro Lys Pro
1 5 10

<210> 88
<211> 14
<212> PRT
<213> homo sapiens

<400> 88

Leu Arg Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu
1 5 10

<210> 89
<211> 14
<212> PRT
<213> homo sapiens

<400> 89

Glu Lys Lys Ile Lys Asn Gln Thr Gly Ala Ser Gly Pro Lys
1 5 10

<210> 90
<211> 14
<212> PRT
<213> homo sapiens

<400> 90

Ser Ile Met Ser Glu Asn Arg Ser Arg Glu Glu Leu Gly Lys
1 5 10

<210> 91
<211> 13
<212> PRT
<213> homo sapiens

<400> 91

Gly Thr Gln Ile Val Thr Glu Arg Leu Val Ala Leu Leu
1 5 10

<210> 92
<211> 13
<212> PRT
<213> homo sapiens

<400> 92

Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp
1 5 10

<210> 93
<211> 13

<212> PRT
<213> homo sapiens

<400> 93

Glu Leu Ile Gln His Ser Ala Lys His Lys Val Asp Ile
1 5 10

<210> 94
<211> 13
<212> PRT
<213> homo sapiens

<400> 94

Val Asp Ile Asp Cys Ser Gln Lys Val Val Val Tyr Asp
1 5 10

<210> 95
<211> 13
<212> PRT
<213> homo sapiens

<400> 95

Asp Arg Leu Glu Asp Ser Asn Lys Leu Lys Arg Ser Phe
1 5 10

<210> 96
<211> 13
<212> PRT
<213> homo sapiens

<400> 96

Thr Thr Leu Asp Gly Thr Asn Lys Leu Cys Gln Phe Ser
1 5 10

<210> 97
<211> 13
<212> PRT
<213> homo sapiens

<400> 97

Pro Lys Lys Leu Gln Thr Ala Arg Pro Ser Asp Ser Gln
1 5 10

<210> 98
<211> 13
<212> PRT
<213> homo sapiens

<400> 98

Pro Ser Asp Ser Gln Ser Lys Arg Leu His Ser Val Arg
1 5 10

<210> 99
<211> 13
<212> PRT

<213> homo sapiens

<400> 99

Ser Lys Arg Leu His Ser Val Arg Thr Ser Ser Ser Gly
1 5 10

<210> 100

<211> 13

<212> PRT

<213> homo sapiens

<400> 100

Gly Asp Gln Val Tyr Ser Val Arg Arg Arg Gln Lys Pro
1 5 10

<210> 101

<211> 13

<212> PRT

<213> homo sapiens

<400> 101

Arg Arg Gln Lys Pro Ser Asp Arg Ala Asp Ser Arg Arg
1 5 10

<210> 102

<211> 13

<212> PRT

<213> homo sapiens

<400> 102

Ser Asp Arg Ala Asp Ser Arg Arg Ser Trp His Glu Glu
1 5 10

<210> 103

<211> 23

<212> PRT

<213> homo sapiens

<400> 103

Asn Gly Cys Val Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala
1 5 10 15

Thr Ile Ala Ile Ala Tyr Ile
20

<210> 104

<211> 39

<212> DNA

<213> Homo sapiens

<400> 104

gcagcagcgg ccgcatcgcc tacatcatga agaggatgg

39

<210> 105

<211> 37

<212> DNA
 <213> Homo sapiens

 <400> 105
 gcagcagtcg acggagacct caatgatttc catgctg 37

 <210> 106
 <211> 39
 <212> DNA
 <213> Homo sapiens

 <400> 106
 gcagcagcgg ccgcatggcc catgagatga ttggaactc 39

 <210> 107
 <211> 37
 <212> DNA
 <213> Homo sapiens

 <400> 107
 gcagcagtcg acctgcacgc tgggcacgct gggcacg 37

 <210> 108
 <211> 5450
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> CDS
 <222> (538)..(2532)

 <400> 108
 gaaaagaaga cgaggaggag agcgacggga cgggacgcga gcgggagcgc agccgccectc 60
 tcggctccgc ggcgggcgct cgcaagtccg ggaggcgagg ggggcccgag gggagacgcc 120
 gtgacaactt tcgtttccct ctgagggaaat tgggaggtcg gcggccccaa aagctttcag 180
 tccagtgtaa agctgttgga gcgcgggagc aaaggtaaag aatgatgtaa tgcgctggct 240
 gctccaaagc atcttttgtt gtggaatggt tattccagtc atctctttat gaatcaaag 300
 tgaggggctg ctttgtggac ggagtccttt gcaagagcac atcaacggga aagagaaaga 360
 gacattcact tggagggctc ttgctgaaaa tgggtttaac tctccttttg ccagtcacca 420
 ccagcctgac ctcatacact tttagtacaa tggagtggct ggcctttga gcacaccacc 480
 attacatcat cgtggcaaat taaagaagga ggtgggaaaa gaggacttat tgttgtc 537
 atg gcc cat gag atg att gga act caa att gtt act gag agg ttg gtg 585
 Met Ala His Glu Met Ile Gly Thr Gln Ile Val Thr Glu Arg Leu Val
 1 5 10 15
 gct ctg ctg gaa agt gga acg gaa aaa gtg ctg cta att gat agc cgg 633
 Ala Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp Ser Arg
 20 25 30

cca ttt gtg gaa tac aat aca tcc cac att ttg gaa gcc att aat atc	681
Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile Asn Ile	
35 40 45	
aac tgc tcc aag ctt atg aag cga agg ttg caa cag gac aaa gtg tta	729
Asn Cys Ser Lys Leu Met Lys Arg Arg Leu Gln Gln Asp Lys Val Leu	
50 55 60	
att aca gag ctc atc cag cat tca gcg aaa cat aag gtt gac att gat	777
Ile Thr Glu Leu Ile Gln His Ser Ala Lys His Lys Val Asp Ile Asp	
65 70 75 80	
tgc agt cag aag gtt gta gtt tac gat caa agc tcc caa gat gtt gcc	825
Cys Ser Gln Lys Val Val Val Tyr Asp Gln Ser Ser Gln Asp Val Ala	
85 90 95	
tct ctc tct tca gac tgt ttt ctc act gta ctt ctg ggt aaa ctg gag	873
Ser Leu Ser Ser Asp Cys Phe Leu Thr Val Leu Leu Gly Lys Leu Glu	
100 105 110	
aag agc ttc aac tct gtt cac ctg ctt gca ggt ggg ttt gct gag ttc	921
Lys Ser Phe Asn Ser Val His Leu Leu Ala Gly Gly Phe Ala Glu Phe	
115 120 125	
tct cgt tgt ttc cct ggc ctc tgt gaa gga aaa tcc act cta gtc cct	969
Ser Arg Cys Phe Pro Gly Leu Cys Glu Gly Lys Ser Thr Leu Val Pro	
130 135 140	
acc tgc att tct cag cct tgc tta cct gtt gcc aac att ggg cca acc	1017
Thr Cys Ile Ser Gln Pro Cys Leu Pro Val Ala Asn Ile Gly Pro Thr	
145 150 155 160	
cga att ctt ccc aat ctt tat ctt ggc tgc cag cga gat gtc ctc aac	1065
Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp Val Leu Asn	
165 170 175	
aag gag ctg ata cag cag aat ggg att ggt tat gtg tta aat gcc agc	1113
Lys Glu Leu Ile Gln Gln Asn Gly Ile Gly Tyr Val Leu Asn Ala Ser	
180 185 190	
tat acc tgt cca aag cct gac ttt atc ccc gag tct cat ttc ctg cgt	1161
Tyr Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His Phe Leu Arg	
195 200 205	
gtg cct gtg aat gac agc ttt tgt gag aaa att ttg ccg tgg ttg gac	1209
Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro Trp Leu Asp	
210 215 220	
aaa tca gta gat ttc att gag aaa gca aaa gcc tcc aat gga tgt gtt	1257
Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn Gly Cys Val	
225 230 235 240	
cta gtg cac tgt tta gct ggg atc tcc cgc tcc gcc acc atc gct atc	1305
Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile Ala Ile	
245 250 255	
gcc tac atc atg aag agg atg gac atg tct tta gat gaa gct tac aga	1353
Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu Ala Tyr Arg	
260 265 270	
ttt gtg aaa gaa aaa aga cct act ata tct cca aac ttc aat ttt ctg	1401

Phe Val	Lys Glu	Lys Arg	Pro Thr	Ile Ser	Pro Asn	Phe Asn	Phe Leu	
275			280			285		
ggc caa	ctc ctg	gac tat	gag aag	aag att	aag aac	cag act	gga gca	1449
Gly Gln	Leu Leu	Asp Tyr	Glu Lys	Lys Ile	Lys Asn	Gln Thr	Gly Ala	
290			295		300			
tca ggg	cca aag	agc aaa	ctc aag	ctg ctg	cac ctg	gag aag	cca aat	1497
Ser Gly	Pro Lys	Ser Lys	Leu Lys	Leu Leu	His Leu	Glu Lys	Pro Asn	
305		310			315		320	
gaa cct	gtc cct	gct gtc	tca gag	ggt gga	cag aaa	agc gag	acg ccc	1545
Glu Pro	Val Pro	Ala Val	Ser Glu	Gly Gly	Gln Lys	Ser Glu	Thr Pro	
		325		330			335	
ctc agt	cca ccc	tgt gcc	gac tct	gct acc	tca gag	gca gca	gga caa	1593
Leu Ser	Pro Pro	Cys Ala	Asp Ser	Ala Thr	Ser Glu	Ala Ala	Gly Gln	
	340			345			350	
agg ccc	gtg cat	ccc gcc	agc gtg	ccc agc	gtg ccc	agc gtg	cag ccg	1641
Arg Pro	Val His	Pro Ala	Ser Val	Pro Ser	Val Pro	Ser Val	Gln Pro	
	355		360			365		
tcg ctg	tta gag	gac agc	ccg ctg	gta cag	gcg ctc	agt ggg	ctg cac	1689
Ser Leu	Leu Glu	Asp Ser	Pro Leu	Val Gln	Ala Leu	Ser Gly	Leu His	
370			375			380		
ctg tcc	gca gac	agg ctg	gaa gac	agc aat	aag ctc	aag cgt	tcc ttc	1737
Leu Ser	Ala Asp	Arg Leu	Glu Asp	Ser Asn	Lys Leu	Lys Arg	Ser Phe	
385		390			395		400	
tct ctg	gat atc	aaa tca	gtt tca	tat tca	gcc agc	atg gca	gca tcc	1785
Ser Leu	Asp Ile	Lys Ser	Val Ser	Tyr Ser	Ala Ser	Met Ala	Ala Ser	
	405			410			415	
tta cat	ggc ttc	tcc tca	tca gaa	gat gct	ttg gaa	tac tac	aaa cct	1833
Leu His	Gly Phe	Ser Ser	Ser Glu	Asp Ala	Leu Glu	Tyr Tyr	Lys Pro	
	420			425		430		
tcc act	act ctg	gat ggg	acc aac	aag cta	tgc cag	ttc tcc	cct gtt	1881
Ser Thr	Thr Leu	Asp Gly	Thr Asn	Lys Leu	Cys Gln	Phe Ser	Pro Val	
	435		440			445		
cag gaa	cta tcg	gag cag	act ccc	gaa acc	agt cct	gat aag	gag gaa	1929
Gln Glu	Leu Ser	Glu Gln	Thr Pro	Glu Thr	Ser Pro	Asp Lys	Glu Glu	
450		455			460			
gcc agc	atc ccc	aag aag	ctg cag	acc gcc	agg cct	tca gac	agc cag	1977
Ala Ser	Ile Pro	Lys Lys	Leu Gln	Thr Ala	Arg Pro	Ser Asp	Ser Gln	
465		470			475		480	
agc aag	cga ttg	cat tcg	gtc aga	acc agc	agc agt	ggc acc	gcc cag	2025
Ser Lys	Arg Leu	His Ser	Val Arg	Thr Ser	Ser Ser	Ser Gly	Thr Ala	
	485			490			495	
agg tcc	ctt tta	tct cca	ctg cat	cga agt	ggg agc	gtg gag	gac aat	2073
Arg Ser	Leu Leu	Ser Pro	Leu His	Arg Ser	Gly Ser	Val Glu	Asp Asn	
	500			505		510		
tac cac	acc agc	ttc ctt	ttc ggc	ctt tcc	acc agc	cag cag	cac ctc	2121
Tyr His	Thr Ser	Phe Leu	Phe Gly	Leu Ser	Thr Ser	Gln Gln	His Leu	

515	520	525	
acg aag tct gct ggc ctg ggc ctt aag ggc tgg cac tcg gat atc ttg Thr Lys Ser Ala Gly Leu Gly Leu Lys Gly Trp His Ser Asp Ile Leu 530 535 540			2169
gcc ccc cag acc tct acc cct tcc ctg acc agc agc tgg tat ttt gcc Ala Pro Gln Thr Ser Thr Pro Ser Leu Thr Ser Ser Trp Tyr Phe Ala 545 550 555 560			2217
aca gag tcc tca cac ttc tac tct gcc tca gcc atc tac gga ggc agt Thr Glu Ser Ser His Phe Tyr Ser Ala Ser Ala Ile Tyr Gly Gly Ser 565 570 575			2265
gcc agt tac tct gcc tac agc tgc agc cag ctg ccc act tgc gga gac Ala Ser Tyr Ser Ala Tyr Ser Cys Ser Gln Leu Pro Thr Cys Gly Asp 580 585 590			2313
caa gtc tat tct gtg cgc agg cgg cag aag cca agt gac aga gct gac Gln Val Tyr Ser Val Arg Arg Arg Gln Lys Pro Ser Asp Arg Ala Asp 595 600 605			2361
tcg cgg cgg agc tgg cat gaa gag agc ccc ttt gaa aag cag ttt aaa Ser Arg Arg Ser Trp His Glu Glu Ser Pro Phe Glu Lys Gln Phe Lys 610 615 620			2409
cgc aga agc tgc caa atg gaa ttt gga gag agc atc atg tca gag aac Arg Arg Ser Cys Gln Met Glu Phe Gly Glu Ser Ile Met Ser Glu Asn 625 630 635 640			2457
agg tca cgg gaa gag ctg ggg aaa gtg ggc agt cag tct agc ttt tcg Arg Ser Arg Glu Glu Leu Gly Lys Val Gly Ser Gln Ser Ser Phe Ser 645 650 655			2505
ggc agc atg gaa atc att gag gtc tcc tgagaagaaa gacacttggtg Gly Ser Met Glu Ile Ile Glu Val Ser 660 665			2552
acttctatag acaatttttt ttttcttggt cacaaaaaaa ttccctgtaa atctgaaata			2612
tatatatgta catacatata tatttttgga aaatggagct atgggtgtaaa agcaacaggt			2672
ggatcaaccc agttgttact ctcttaacat ctgcatttga gagatcagct aatacttctc			2732
tcaacaaaaa tggaagggca gatgctagaa tccccctag acggaggaaa accattttat			2792
tcagtgaatt acacatcctc ttgttcttaa aaaagcaagt gtctttggtg ttggaggaca			2852
aaatcoccta ccattttcac gttgtgctac taagagatct caaatattag tctttgtccg			2912
gacccttcca tagtacacct tagcgtgag actgagccag cttgggggtc aggtaggtag			2972
accctgttag ggacagagcc tagtggtaaa tccaagagaa atgacatctat ccaaagctga			3032
ttcacaacc cagctcacc tgacagccga gggacacgag catcactctg ctggacggac			3092
cattaggggc cttgccaagg tctaccttag agcaaacca gtacctcaga caggaaagtc			3152
ggggctttga ccactaccat atctggtagc ccattttcta ggcattgtga ataggtaggt			3212
agctagtcac acttttcaga ccaattcaaa ctgtctatgc aaaaaattcc cgtgggccta			3272

gatggagata atttttttttt cttctcagct ttatgaagag aagggaact gtctaggatt	3332
cagctgaacc accaggaacc tggcaacatc acgatttaag ctaagggttg gaggctaacg	3392
agtctacctc cctctttgta aatcaaagaa ttgtttaaaa tgggattgtc aatcctttaa	3452
ataaagatga acttggtttc aagccaaatg tgaatttatt tgggttggtg gcagagcagc	3512
agcaccttca aattctcagc caaagcagat gtttttgccc tttctgcttc actgcatgga	3572
tacagttggt aaaatgtaat aatatggcag aattttatag gaaacttcct agggaggtaa	3632
attatgggaa gattaagaaa ggtacaaatt gctgaggaga agcaggaaac ctgtttcctt	3692
agtggctttt atcccctcgg catgcgatgg ggctgatggt tctatgattg cctcagactt	3752
tcacatttac tagtagggct gagagaggct ttagtgagga aggaatattc agaataaaac	3812
ggttgagaaa gctgagaaga ccattgagtt ttgatcagtt gtgaatagag tgcaaagcca	3872
tggccaagct gtttttgga acgctggccg gcgtgtcttc agtggaaaaa gcaaatcaaa	3932
atggagcgag agcaaagggg cgtcctcagt cctcaacct caatcactgt atggaatcgg	3992
tcctggcagc tgaacatagg aggtcactgg aacaagtgat agtgcagatt ggctttcaaa	4052
catcctcctg gcttgagttt tatcagctac aatgtgggtc ctcttttgaa gccttaattc	4112
acaacagcag ctttttgggg gtggggctgg gcgggtgttg tcattgttct ttcccttcct	4172
gtaagtgtcg ctagttgctg cctcgtatct cagggttttc tctgttttg agaaatggac	4232
agttttttga ccaggatgtg acttcatggt tcctatggtg acttctaaaa ccagcacaga	4292
atgatatgac tcaacacaga ccgacttggg tatggggatg atgagccgca cagacctcac	4352
tagttgtgca caaataatgt gctatgatgg ggtgtaaagt gaaggcagaa gagggtcagc	4412
cgcattgtta tgatactggg aaagtgtggt tcaacgattt gaggtagttt ttagatatac	4472
attgaaatct ttaatcagac attctcaagt ttcacacagt agtttttgat gttatgtaca	4532
cacacaccaa atgtgtaaca gttcaccact tccagagtgt ggtcatgcc aaaacatggt	4592
taagaaagga aagcagtagc tccttgctaa cgatgtttca ggaggtttg ggcacttggg	4652
tttaatgagc ttctgtcatt tagggcttct cttggccatg gtcccttcc ttctggaact	4712
gtgatgtagt cacatcctac agcctttagt gctggttcac tagtgtcaga taatcagttc	4772
ttggaatcga gactgccgtg gcgaaggggt ggctcggag gcaggctctg gagctgcttg	4832
gatgtcttta ggtgggtggt tggctggctc tcttcagcat gtaattgggg aaaccctcgc	4892
gtctactagg ggtgatacag atggtgattt taaagagcaa aactagactt ctatgtgaga	4952
agtgtggaa aatgatttag gacatgtgta aagttagatg gaaagactgt aaatgtttaa	5012
tatgaatata gtgttctttt gaagtaaggc cagctgttga acggttaaac tgtgcatttc	5072

```

tcattttgat gtgtcatgta tgtaaagta tgaaatgatt aaataaaaatc aaaactggta 5132
cctgtttata cataaatagc agaaaagacc tatctttgca gccataaaact cggtgggaac 5192
accaccactc aagttgcaa aggaggcagt ggtgaaacct gtcctgttct cacttaaag 5252
aggatttagc tcaaaataaa gtggtggtgt catcagggtt attccgtgtt ctgtcattca 5312
catggaacac cggatgatta gctaacagtt tagtgccagc cttcattctt tactgtgtac 5372
gttaaagca cactacagtg aaaaagccta agacacttgg taaatatttt ctagctgact 5432
gattccagaa cacacaag 5450

```

```

<210> 109
<211> 665
<212> PRT
<213> Homo sapiens

```

```

<400> 109

```

```

Met Ala His Glu Met Ile Gly Thr Gln Ile Val Thr Glu Arg Leu Val
1           5           10           15

```

```

Ala Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp Ser Arg
20           25           30

```

```

Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile Asn Ile
35           40           45

```

```

Asn Cys Ser Lys Leu Met Lys Arg Arg Leu Gln Gln Asp Lys Val Leu
50           55           60

```

```

Ile Thr Glu Leu Ile Gln His Ser Ala Lys His Lys Val Asp Ile Asp
65           70           75           80

```

```

Cys Ser Gln Lys Val Val Val Tyr Asp Gln Ser Ser Gln Asp Val Ala
85           90           95

```

```

Ser Leu Ser Ser Asp Cys Phe Leu Thr Val Leu Leu Gly Lys Leu Glu
100          105          110

```

```

Lys Ser Phe Asn Ser Val His Leu Leu Ala Gly Gly Phe Ala Glu Phe
115          120          125

```

```

Ser Arg Cys Phe Pro Gly Leu Cys Glu Gly Lys Ser Thr Leu Val Pro
130          135          140

```

```

Thr Cys Ile Ser Gln Pro Cys Leu Pro Val Ala Asn Ile Gly Pro Thr
145          150          155          160

```

Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp Val Leu Asn
 165 170 175

Lys Glu Leu Ile Gln Gln Asn Gly Ile Gly Tyr Val Leu Asn Ala Ser
 180 185 190

Tyr Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His Phe Leu Arg
 195 200 205

Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro Trp Leu Asp
 210 215 220

Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn Gly Cys Val
 225 230 235 240

Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile Ala Ile
 245 250 255

Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu Ala Tyr Arg
 260 265 270

Phe Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Asn Phe Asn Phe Leu
 275 280 285

Gly Gln Leu Leu Asp Tyr Glu Lys Lys Ile Lys Asn Gln Thr Gly Ala
 290 295 300

Ser Gly Pro Lys Ser Lys Leu Lys Leu Leu His Leu Glu Lys Pro Asn
 305 310 315 320

Glu Pro Val Pro Ala Val Ser Glu Gly Gly Gln Lys Ser Glu Thr Pro
 325 330 335

Leu Ser Pro Pro Cys Ala Asp Ser Ala Thr Ser Glu Ala Ala Gly Gln
 340 345 350

Arg Pro Val His Pro Ala Ser Val Pro Ser Val Pro Ser Val Gln Pro
 355 360 365

Ser Leu Leu Glu Asp Ser Pro Leu Val Gln Ala Leu Ser Gly Leu His
 370 375 380

Leu Ser Ala Asp Arg Leu Glu Asp Ser Asn Lys Leu Lys Arg Ser Phe
 385 390 395 400

Ser Leu Asp Ile Lys Ser Val Ser Tyr Ser Ala Ser Met Ala Ala Ser
 405 410 415

Leu His Gly Phe Ser Ser Ser Glu Asp Ala Leu Glu Tyr Tyr Lys Pro
 420 425 430

Ser Thr Thr Leu Asp Gly Thr Asn Lys Leu Cys Gln Phe Ser Pro Val
 435 440 445

Gln Glu Leu Ser Glu Gln Thr Pro Glu Thr Ser Pro Asp Lys Glu Glu
 450 455 460

Ala Ser Ile Pro Lys Lys Leu Gln Thr Ala Arg Pro Ser Asp Ser Gln
 465 470 475 480

Ser Lys Arg Leu His Ser Val Arg Thr Ser Ser Ser Gly Thr Ala Gln
 485 490 495

Arg Ser Leu Leu Ser Pro Leu His Arg Ser Gly Ser Val Glu Asp Asn
 500 505 510

Tyr His Thr Ser Phe Leu Phe Gly Leu Ser Thr Ser Gln Gln His Leu
 515 520 525

Thr Lys Ser Ala Gly Leu Gly Leu Lys Gly Trp His Ser Asp Ile Leu
 530 535 540

Ala Pro Gln Thr Ser Thr Pro Ser Leu Thr Ser Ser Trp Tyr Phe Ala
 545 550 555 560

Thr Glu Ser Ser His Phe Tyr Ser Ala Ser Ala Ile Tyr Gly Gly Ser
 565 570 575

Ala Ser Tyr Ser Ala Tyr Ser Cys Ser Gln Leu Pro Thr Cys Gly Asp
 580 585 590

Gln Val Tyr Ser Val Arg Arg Arg Gln Lys Pro Ser Asp Arg Ala Asp
 595 600 605

Ser Arg Arg Ser Trp His Glu Glu Ser Pro Phe Glu Lys Gln Phe Lys
 610 615 620

Arg Arg Ser Cys Gln Met Glu Phe Gly Glu Ser Ile Met Ser Glu Asn
 625 630 635 640

Arg Ser Arg Glu Glu Leu Gly Lys Val Gly Ser Gln Ser Ser Phe Ser

645

650

655

Gly Ser Met Glu Ile Ile Glu Val Ser
 660 665

<210> 110
 <211> 625
 <212> PRT
 <213> Homo sapiens

<400> 110

Met Ala Gly Asp Arg Leu Pro Arg Lys Val Met Asp Ala Lys Lys Leu
 1 5 10 15
 Ala Ser Leu Leu Arg Gly Gly Pro Gly Gly Pro Leu Val Ile Asp Ser
 20 25 30
 Arg Ser Phe Val Glu Tyr Asn Ser Trp His Val Leu Ser Ser Val Asn
 35 40 45
 Ile Cys Cys Ser Lys Leu Val Lys Arg Arg Leu Gln Gln Gly Lys Val
 50 55 60
 Thr Ile Ala Glu Leu Ile Gln Pro Ala Ala Arg Ser Gln Val Glu Ala
 65 70 75 80
 Thr Glu Pro Gln Asp Val Val Val Tyr Asp Gln Ser Thr Arg Asp Ala
 85 90 95
 Ser Val Leu Ala Ala Asp Ser Phe Leu Ser Ile Leu Leu Ser Lys Leu
 100 105 110
 Asp Gly Cys Phe Asp Ser Val Ala Ile Leu Thr Gly Gly Phe Ala Thr
 115 120 125
 Phe Ser Ser Cys Phe Pro Gly Leu Cys Glu Gly Lys Pro Ala Ala Leu
 130 135 140
 Leu Pro Met Ser Leu Ser Gln Pro Cys Leu Pro Val Pro Ser Val Gly
 145 150 155 160
 Leu Thr Arg Ile Leu Pro His Leu Tyr Leu Gly Ser Gln Lys Asp Val
 165 170 175
 Leu Asn Lys Asp Leu Met Thr Gln Asn Gly Ile Ser Tyr Val Leu Asn
 180 185 190
 Ala Ser Asn Ser Cys Pro Lys Pro Asp Phe Ile Cys Glu Ser Arg Phe
 195 200 205
 Met Arg Val Pro Ile Asn Asp Asn Tyr Cys Glu Lys Leu Leu Pro Trp
 210 215 220
 Leu Asp Lys Ser Ile Glu Phe Ile Asp Lys Ala Lys Leu Ser Ser Cys
 225 230 235 240
 Gln Val Ile Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile
 245 250 255

Ala Ile Ala Tyr Ile Met Lys Thr Met Gly Met Ser Ser Asp Asp Ala
 260 265 270
 Tyr Arg Phe Val Lys Asp Arg Arg Pro Ser Ile Ser Pro Asn Phe Asn
 275 280 285
 Phe Leu Gly Gln Leu Leu Glu Tyr Glu Arg Thr Leu Lys Leu Leu Ala
 290 295 300
 Ala Leu Gln Gly Asp Pro Gly Thr Pro Ser Gly Thr Pro Glu Pro Pro
 305 310 315 320
 Pro Ser Pro Ala Ala Gly Ala Pro Leu Pro Arg Leu Pro Pro Pro Thr
 325 330 335
 Ser Glu Ser Ala Ala Thr Gly Asn Ala Ala Ala Arg Glu Gly Gly Leu
 340 345 350
 Ser Ala Gly Gly Glu Pro Pro Ala Pro Pro Thr Pro Pro Ala Thr Ser
 355 360 365
 Ala Leu Gln Gln Gly Leu Arg Gly Leu His Leu Ser Ser Asp Arg Leu
 370 375 380
 Gln Asp Thr Asn Arg Leu Lys Arg Ser Phe Ser Leu Asp Ile Lys Ser
 385 390 395 400
 Ala Tyr Ala Pro Ser Arg Arg Pro Asp Gly Pro Gly Pro Pro Asp Pro
 405 410 415
 Gly Glu Ala Pro Lys Leu Cys Lys Leu Asp Ser Pro Ser Gly Ala Ala
 420 425 430
 Leu Gly Leu Ser Ser Pro Ser Pro Asp Ser Pro Asp Ala Ala Pro Glu
 435 440 445
 Ala Arg Pro Arg Pro Arg Arg Arg Pro Arg Pro Pro Ala Gly Ser Pro
 450 455 460
 Ala Arg Ser Pro Ala His Ser Leu Gly Leu Asn Phe Gly Asp Ala Ala
 465 470 475 480
 Arg Gln Thr Pro Arg His Gly Leu Ser Ala Leu Ser Ala Pro Gly Leu
 485 490 495
 Pro Gly Pro Gly Gln Pro Ala Gly Pro Gly Ala Trp Ala Pro Pro Leu
 500 505 510
 Asp Ser Pro Gly Thr Pro Ser Pro Asp Gly Pro Trp Cys Phe Ser Pro
 515 520 525
 Glu Gly Ala Gln Gly Ala Gly Gly Val Leu Phe Ala Pro Phe Gly Arg
 530 535 540
 Ala Gly Ala Pro Gly Pro Gly Gly Gly Ser Asp Leu Arg Arg Arg Glu
 545 550 555 560
 Ala Ala Arg Ala Glu Pro Arg Asp Ala Arg Thr Gly Trp Pro Glu Glu
 565 570 575

Pro Ala Pro Glu Thr Gln Phe Lys Arg Arg Ser Cys Gln Met Glu Phe
 580 585 590

Glu Glu Gly Met Val Glu Gly Arg Ala Arg Gly Glu Glu Leu Ala Ala
 595 600 605

Leu Gly Lys Gln Ala Ser Phe Ser Gly Ser Val Glu Val Ile Glu Val
 610 615 620

Ser
 625

<210> 111

<211> 381

<212> PRT

<213> Homo sapiens

<400> 111

Met Ile Asp Thr Leu Arg Pro Val Pro Phe Ala Ser Glu Met Ala Ile
 1 5 10 15

Ser Lys Thr Val Ala Trp Leu Asn Glu Gln Leu Glu Leu Gly Asn Glu
 20 25 30

Arg Leu Leu Leu Met Asp Cys Arg Pro Gln Glu Leu Tyr Glu Ser Ser
 35 40 45

His Ile Glu Ser Ala Ile Asn Val Ala Ile Pro Gly Ile Met Leu Arg
 50 55 60

Arg Leu Gln Lys Gly Asn Leu Pro Val Arg Ala Leu Phe Thr Arg Gly
 65 70 75 80

Glu Asp Arg Asp Arg Phe Thr Arg Arg Cys Gly Thr Asp Thr Val Val
 85 90 95

Leu Tyr Asp Glu Ser Ser Ser Asp Trp Asn Glu Asn Thr Gly Gly Glu
 100 105 110

Ser Leu Leu Gly Leu Leu Leu Lys Lys Leu Lys Asp Glu Gly Cys Arg
 115 120 125

Ala Phe Tyr Leu Glu Gly Gly Phe Ser Lys Phe Gln Ala Glu Phe Ser
 130 135 140

Leu His Cys Glu Thr Asn Leu Asp Gly Ser Cys Ser Ser Ser Ser Pro
 145 150 155 160

Pro Leu Pro Val Leu Gly Leu Gly Gly Leu Arg Ile Ser Ser Asp Ser
 165 170 175

Ser Ser Asp Ile Glu Ser Asp Leu Asp Arg Asp Pro Asn Ser Ala Thr
 180 185 190

Asp Ser Asp Gly Ser Pro Leu Ser Asn Ser Gln Pro Ser Phe Pro Val
 195 200 205

Glu Ile Leu Pro Phe Leu Tyr Leu Gly Cys Ala Lys Asp Ser Thr Asn
 210 215 220

Leu Asp Val Leu Glu Glu Phe Gly Ile Lys Tyr Ile Leu Asn Val Thr
 225 230 235 240
 Pro Asn Leu Pro Asn Leu Phe Glu Asn Ala Gly Glu Phe Lys Tyr Lys
 245 250 255
 Gln Ile Pro Ile Ser Asp His Trp Ser Gln Asn Leu Ser Gln Phe Phe
 260 265 270
 Pro Glu Ala Ile Ser Phe Ile Asp Glu Ala Arg Gly Lys Asn Cys Gly
 275 280 285
 Val Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Val Thr Val Thr
 290 295 300
 Val Ala Tyr Leu Met Gln Lys Leu Asn Leu Ser Met Asn Asp Ala Tyr
 305 310 315 320
 Asp Ile Val Lys Met Lys Lys Ser Asn Ile Ser Pro Asn Phe Asn Phe
 325 330 335
 Met Gly Gln Leu Leu Asp Phe Glu Arg Thr Leu Gly Leu Ser Ser Pro
 340 345 350
 Cys Asp Asn Arg Val Pro Ala Gln Gln Leu Tyr Phe Thr Thr Pro Ser
 355 360 365
 Asn Gln Asn Val Tyr Gln Val Asp Ser Leu Gln Ser Thr
 370 375 380
 <210> 112
 <211> 482
 <212> PRT
 <213> Homo sapiens
 <400> 112
 Met Pro Pro Ser Pro Leu Asp Asp Arg Val Val Val Ala Leu Ser Arg
 1 5 10 15
 Pro Val Arg Pro Gln Asp Leu Asn Leu Cys Leu Asp Ser Ser Tyr Leu
 20 25 30
 Gly Ser Ala Asn Pro Gly Ser Asn Ser His Pro Pro Val Ile Ala Thr
 35 40 45
 Thr Val Val Ser Leu Lys Ala Ala Asn Leu Thr Tyr Met Pro Ser Ser
 50 55 60
 Ser Gly Ser Ala Arg Ser Leu Asn Cys Gly Cys Ser Ser Ala Ser Cys
 65 70 75 80
 Cys Thr Val Ala Thr Tyr Asp Lys Asp Asn Gln Ala Gln Thr Gln Ala
 85 90 95
 Ile Ala Ala Gly Thr Thr Thr Thr Ala Ile Gly Thr Ser Thr Thr Cys
 100 105 110
 Pro Ala Asn Gln Met Val Asn Asn Asn Glu Asn Thr Gly Ser Leu Ser
 115 120 125

Pro Ser Ser Gly Val Gly Ser Pro Val Ser Gly Thr Pro Lys Gln Leu
 130 135 140
 Ala Ser Ile Lys Ile Ile Tyr Pro Asn Asp Leu Ala Lys Lys Met Thr
 145 150 155 160
 Lys Cys Ser Lys Ser His Leu Pro Ser Gln Gly Pro Val Ile Ile Asp
 165 170 175
 Cys Arg Pro Phe Met Glu Tyr Asn Lys Ser His Ile Gln Gly Ala Val
 180 185 190
 His Ile Asn Cys Ala Asp Lys Ile Ser Arg Arg Arg Leu Gln Gln Gly
 195 200 205
 Lys Ile Thr Val Leu Asp Leu Ile Ser Cys Arg Glu Gly Lys Asp Ser
 210 215 220
 Phe Lys Arg Ile Phe Ser Lys Glu Ile Ile Val Tyr Asp Glu Asn Thr
 225 230 235 240
 Asn Glu Pro Ser Arg Val Met Pro Ser Gln Pro Leu His Ile Val Leu
 245 250 255
 Glu Ser Leu Lys Arg Glu Gly Lys Glu Pro Leu Val Leu Lys Gly Gly
 260 265 270
 Leu Ser Ser Phe Lys Gln Asn His Glu Asn Leu Cys Asp Asn Ser Leu
 275 280 285
 Gln Leu Gln Glu Cys Arg Glu Val Gly Gly Gly Ala Ser Ala Ala Ser
 290 295 300
 Ser Leu Leu Pro Gln Pro Ile Pro Thr Thr Pro Asp Ile Glu Asn Ala
 305 310 315 320
 Glu Leu Thr Pro Ile Leu Pro Phe Leu Phe Leu Gly Asn Glu Gln Asp
 325 330 335
 Ala Gln Asp Leu Asp Thr Met Gln Arg Leu Asn Ile Gly Tyr Val Ile
 340 345 350
 Asn Val Thr Thr His Leu Pro Leu Tyr His Tyr Glu Lys Gly Leu Phe
 355 360 365
 Asn Tyr Lys Arg Leu Pro Ala Thr Asp Ser Asn Lys Gln Asn Leu Arg
 370 375 380
 Gln Tyr Phe Glu Glu Ala Phe Glu Phe Ile Glu Glu Ala His Gln Cys
 385 390 395 400
 Gly Lys Gly Leu Leu Ile His Cys Gln Ala Gly Val Ser Arg Ser Ala
 405 410 415
 Thr Ile Val Ile Ala Tyr Leu Met Lys His Thr Arg Met Thr Met Thr
 420 425 430
 Asp Ala Tyr Lys Phe Val Lys Gly Lys Arg Pro Ile Ile Ser Pro Asn
 435 440 445
 Leu Asn Phe Met Gly Gln Leu Leu Glu Phe Glu Glu Asp Leu Asn Asn

450 455 460

Gly Val Thr Pro Arg Ile Leu Thr Pro Lys Leu Met Gly Val Glu Thr
 465 470 475 480

Val Val

<210> 113
 <211> 2756
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (369)..(2348)

<400> 113
 gactgagggt gtcagcccag tgtaaagctg ttggagtgag ggcagaaagg taaaggatga 60
 tgtaatgcct ggctgcccta gagcatcttt tggttgaggga tgggtattcc catcatctct 120
 atgaatctag tgtgaggggc tgctttgtgg aaggaatcct ttgcaagagc atatcaacag 180
 gaaagagaaa gagacattca gttggagggc tcttgctgaa atggatttaa ctctcctctt 240
 gccagtcacc actagcctga cctcatacat ttttagtaca atggagtggc tgagcctttg 300
 agcacagcac cattacatca tcgtggcaaa ttaaagaacg aggtggggaa agaggactta 360
 ttgttgtc atg gcc cat gag atg att gga act caa att gtt act gag agc 410
 Met Ala His Glu Met Ile Gly Thr Gln Ile Val Thr Glu Ser
 1 5 10

ttg gtg gct ctg ctg gaa agt gga acg gaa aaa gtg ctg cta att gat 458
 Leu Val Ala Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp
 15 20 25 30

agc cga cca ttt gtg gaa tac aat acg tct cac att ttg gaa gcc att 506
 Ser Arg Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile
 35 40 45

aat atc aac tgc tcc aaa ctg atg aag cga agg ttg caa cag gac aaa 554
 Asn Ile Asn Cys Ser Lys Leu Met Lys Arg Arg Leu Gln Gln Asp Lys
 50 55 60

gta tta att aca gaa cta atc cac caa tct aca aag cat aag gtt gac 602
 Val Leu Ile Thr Glu Leu Ile His Gln Ser Thr Lys His Lys Val Asp
 65 70 75

att gac tgc aat caa aga gtg gta gtt tat gat cac agt tca caa gat 650
 Ile Asp Cys Asn Gln Arg Val Val Val Tyr Asp His Ser Ser Gln Asp
 80 85 90

gtt ggt tct ctg tcg tca gac tgc ttt ctc act gta ctt ctg ggt aag 698
 Val Gly Ser Leu Ser Ser Asp Cys Phe Leu Thr Val Leu Leu Gly Lys
 95 100 105 110

ctg gag aga agc ttc aac tct gtc cac ctg ctt gca ggt ggc ttt gct 746
 Leu Glu Arg Ser Phe Asn Ser Val His Leu Leu Ala Gly Gly Phe Ala
 115 120 125

gag ttc tct cgt tgt ttc cct ggc ctc tgt gaa gga aag tcc act cta Glu Phe Ser Arg Cys Phe Pro Gly Leu Cys Glu Gly Lys Ser Thr Leu 130 135 140	794
gtc cct acc tgc ata tct cag cct tgc tta cct gtt gcg aac att ggg Val Pro Thr Cys Ile Ser Gln Pro Cys Leu Pro Val Ala Asn Ile Gly 145 150 155	842
cca act cga att ctt ccc aat ctc tat ctt ggc tgc cag cga gat gtc Pro Thr Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp Val 160 165 170	890
ctc aac aag gac ctg atg caa cag aat ggg att ggc tat gtg tta aat Leu Asn Lys Asp Leu Met Gln Gln Asn Gly Ile Gly Tyr Val Leu Asn 175 180 185 190	938
gcc agc aat acc tgt cca aag cct gac ttc ata cct gaa tct cac ttc Ala Ser Asn Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His Phe 195 200 205	986
ctg cga gtg cct gtg aat gac agc ttt tgt gag aaa atc cta cca tgg Leu Arg Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro Trp 210 215 220	1034
ttg gac aag tct gtg gat ttc att gag aaa gca aaa gcc tcc aat ggc Leu Asp Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn Gly 225 230 235	1082
tgt gtg ctt atc cac tgc tta gct ggg atc tct cgc tcc gcc act att Cys Val Leu Ile His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile 240 245 250	1130
gct att gcc tac atc atg aag agg atg gac atg tct cta gat gag gct Ala Ile Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu Ala 255 260 265 270	1178
tac aga ttt gtg aaa gaa aaa aga cct act ata tct ccg aat ttt aat Tyr Arg Phe Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Asn Phe Asn 275 280 285	1226
ttt atg ggc caa ctc atg gac tat gag aag acg att aat aac cag act Phe Met Gly Gln Leu Met Asp Tyr Glu Lys Thr Ile Asn Asn Gln Thr 290 295 300	1274
gga atg tca ggg cca aag agc aaa ctg aag ctg ctg cac cta gac aaa Gly Met Ser Gly Pro Lys Ser Lys Leu Lys Leu Leu His Leu Asp Lys 305 310 315	1322
ccc agt gag ccc gtg cct gca gcc tca gag ggc gga tgg aag agt gca Pro Ser Glu Pro Val Pro Ala Ala Ser Glu Gly Gly Trp Lys Ser Ala 320 325 330	1370
ctg tct ctc agt cca ccc tgt gcc aac tcg acc tcg gag gca tca ggg Leu Ser Leu Ser Pro Pro Cys Ala Asn Ser Thr Ser Glu Ala Ser Gly 335 340 345 350	1418
caa agg ctt gtg cat cct gca agt gtg ccc cgc tta cag ccg tca ctc Gln Arg Leu Val His Pro Ala Ser Val Pro Arg Leu Gln Pro Ser Leu 355 360 365	1466

tta gag gac agt ccg ctg gta cag gcg ctc agt ggg ctc cag ctg tcc	1514
Leu Glu Asp Ser Pro Leu Val Gln Ala Leu Ser Gly Leu Gln Leu Ser	
370 375 380	
tca gag aag ctg gaa gac agc act aag ctc aag cgt tcc ttc tct ctc	1562
Ser Glu Lys Leu Glu Asp Ser Thr Lys Leu Lys Arg Ser Phe Ser Leu	
385 390 395	
gat atc aaa tct gtt tca tat tca gcc agt atg gcc gcg tcc cta cac	1610
Asp Ile Lys Ser Val Ser Tyr Ser Ala Ser Met Ala Ala Ser Leu His	
400 405 410	
ggc ttc tcg tca gag gag gct tta gac tac tgc aaa cct tct gcc aca	1658
Gly Phe Ser Ser Glu Glu Ala Leu Asp Tyr Cys Lys Pro Ser Ala Thr	
415 420 425 430	
ctg gat ggg acc aac aag ctc tgc cag ttc tcc ccc gtt cag gag gta	1706
Leu Asp Gly Thr Asn Lys Leu Cys Gln Phe Ser Pro Val Gln Glu Val	
435 440 445	
tca gaa cag agt cca gag acc agc ccg gat aag gag gag gcc cac atc	1754
Ser Glu Gln Ser Pro Glu Thr Ser Pro Asp Lys Glu Glu Ala His Ile	
450 455 460	
ccc aag cag ccc caa cct ccc agg cct tct gag agc cag gtc aca cgc	1802
Pro Lys Gln Pro Gln Pro Pro Arg Pro Ser Glu Ser Gln Val Thr Arg	
465 470 475	
ttg cac tca gtg aga acc ggc agt agt ggg tcc acc cag agg ccc ttc	1850
Leu His Ser Val Arg Thr Gly Ser Ser Gly Ser Thr Gln Arg Pro Phe	
480 485 490	
ttc tcg cca ctg cat cgg agc ggg agt gta gag gac aat tac cat acc	1898
Phe Ser Pro Leu His Arg Ser Gly Ser Val Glu Asp Asn Tyr His Thr	
495 500 505 510	
aac ttc ctt ttt ggc ctt tcc acc agc cag caa cac ctc acc aag tct	1946
Asn Phe Leu Phe Gly Leu Ser Thr Ser Gln Gln His Leu Thr Lys Ser	
515 520 525	
gca ggg ctt ggc ctc aag ggc tgg cac tca gat att ctg gct ccc cag	1994
Ala Gly Leu Gly Leu Lys Gly Trp His Ser Asp Ile Leu Ala Pro Gln	
530 535 540	
tcc tct gcc ccc tcc ctg acc agc agt tgg tat ttt gct acg gag cct	2042
Ser Ser Ala Pro Ser Leu Thr Ser Ser Trp Tyr Phe Ala Thr Glu Pro	
545 550 555	
tca cac ttg tac tct gct tca gcc atc tat gga ggc aac agc agt tac	2090
Ser His Leu Tyr Ser Ala Ser Ala Ile Tyr Gly Gly Asn Ser Ser Tyr	
560 565 570	
tct gcc tac agc tgt ggc cag ctg ccc act tgc agt gac caa atc tat	2138
Ser Ala Tyr Ser Cys Gly Gln Leu Pro Thr Cys Ser Asp Gln Ile Tyr	
575 580 585 590	
tct gtt cgt agg cgg cag aag cct act gac aga gct gac tcg agg cgg	2186
Ser Val Arg Arg Arg Gln Lys Pro Thr Asp Arg Ala Asp Ser Arg Arg	
595 600 605	
agc tgg cat gaa gag agc ccc ttt gaa aag cag ttt aaa cgc aga agc	2234

Ser Trp His Glu Glu Ser Pro Phe Glu Lys Gln Phe Lys Arg Arg Ser
610 615 620

tgc caa atg gaa ttt gga gag agc att atg tcg gag aac agg tcc agg 2282
Cys Gln Met Glu Phe Gly Glu Ser Ile Met Ser Glu Asn Arg Ser Arg
625 630 635

gag gag ctg ggc aag gtg ggc agc cag tcc agc ttc tcc ggc agc atg 2330
Glu Glu Leu Gly Lys Val Gly Ser Gln Ser Ser Phe Ser Gly Ser Met
640 645 650

gag atc atc gag gtc tct tgagaagacc tcgtcgcttc tgttgacagt 2378
Glu Ile Ile Glu Val Ser
655 660

tttgtttcct gttcacaaaa aatagtccect gtaaactctga aatatgtata tgtacataca 2438

tatatatattt tggaatatag agctacggta taaaagcaac agatggatca acacagttgt 2498

tctctcagca cctgcactga gaatagctaa ctctcagaaa agattggaag ggtagatgtt 2558

agaattctcc cagccaggag aagagatttg gttcagtga ttgcacatct tcttgttcct 2618

acaaaagcaa gggttttgtt tgtttgtatg ttgtttgttt ttaatgttag agggcaaaat 2678

ccctcccatt ttcacgtgca acagaggtct cagaactcat ctctgtccag gcccttcct 2738

agtgcacctt agcgctaa 2756

<210> 114
<211> 660
<212> PRT
<213> Mus musculus

<400> 114

Met Ala His Glu Met Ile Gly Thr Gln Ile Val Thr Glu Ser Leu Val
1 5 10 15

Ala Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp Ser Arg
20 25 30

Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile Asn Ile
35 40 45

Asn Cys Ser Lys Leu Met Lys Arg Arg Leu Gln Gln Asp Lys Val Leu
50 55 60

Ile Thr Glu Leu Ile His Gln Ser Thr Lys His Lys Val Asp Ile Asp
65 70 75 80

Cys Asn Gln Arg Val Val Val Tyr Asp His Ser Ser Gln Asp Val Gly
85 90 95

Ser Leu Ser Ser Asp Cys Phe Leu Thr Val Leu Leu Gly Lys Leu Glu
 100 105 110

Arg Ser Phe Asn Ser Val His Leu Leu Ala Gly Gly Phe Ala Glu Phe
 115 120 125

Ser Arg Cys Phe Pro Gly Leu Cys Glu Gly Lys Ser Thr Leu Val Pro
 130 135 140

Thr Cys Ile Ser Gln Pro Cys Leu Pro Val Ala Asn Ile Gly Pro Thr
 145 150 155 160

Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp Val Leu Asn
 165 170 175

Lys Asp Leu Met Gln Gln Asn Gly Ile Gly Tyr Val Leu Asn Ala Ser
 180 185 190

Asn Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His Phe Leu Arg
 195 200 205

Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro Trp Leu Asp
 210 215 220

Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn Gly Cys Val
 225 230 235 240

Leu Ile His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile Ala Ile
 245 250 255

Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu Ala Tyr Arg
 260 265 270

Phe Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Asn Phe Asn Phe Met
 275 280 285

Gly Gln Leu Met Asp Tyr Glu Lys Thr Ile Asn Asn Gln Thr Gly Met
 290 295 300

Ser Gly Pro Lys Ser Lys Leu Lys Leu Leu His Leu Asp Lys Pro Ser
 305 310 315 320

Glu Pro Val Pro Ala Ala Ser Glu Gly Gly Trp Lys Ser Ala Leu Ser
 325 330 335

Leu Ser Pro Pro Cys Ala Asn Ser Thr Ser Glu Ala Ser Gly Gln Arg

340	345	350
Leu Val His Pro Ala Ser Val Pro Arg Leu Gln Pro Ser Leu Leu Glu 355 360 365		
Asp Ser Pro Leu Val Gln Ala Leu Ser Gly Leu Gln Leu Ser Ser Glu 370 375 380		
Lys Leu Glu Asp Ser Thr Lys Leu Lys Arg Ser Phe Ser Leu Asp Ile 385 390 395 400		
Lys Ser Val Ser Tyr Ser Ala Ser Met Ala Ala Ser Leu His Gly Phe 405 410 415		
Ser Ser Glu Glu Ala Leu Asp Tyr Cys Lys Pro Ser Ala Thr Leu Asp 420 425 430		
Gly Thr Asn Lys Leu Cys Gln Phe Ser Pro Val Gln Glu Val Ser Glu 435 440 445		
Gln Ser Pro Glu Thr Ser Pro Asp Lys Glu Glu Ala His Ile Pro Lys 450 455 460		
Gln Pro Gln Pro Pro Arg Pro Ser Glu Ser Gln Val Thr Arg Leu His 465 470 475 480		
Ser Val Arg Thr Gly Ser Ser Gly Ser Thr Gln Arg Pro Phe Phe Ser 485 490 495		
Pro Leu His Arg Ser Gly Ser Val Glu Asp Asn Tyr His Thr Asn Phe 500 505 510		
Leu Phe Gly Leu Ser Thr Ser Gln Gln His Leu Thr Lys Ser Ala Gly 515 520 525		
Leu Gly Leu Lys Gly Trp His Ser Asp Ile Leu Ala Pro Gln Ser Ser 530 535 540		
Ala Pro Ser Leu Thr Ser Ser Trp Tyr Phe Ala Thr Glu Pro Ser His 545 550 555 560		
Leu Tyr Ser Ala Ser Ala Ile Tyr Gly Gly Asn Ser Ser Tyr Ser Ala 565 570 575		
Tyr Ser Cys Gly Gln Leu Pro Thr Cys Ser Asp Gln Ile Tyr Ser Val 580 585 590		

Arg Arg Arg Gln Lys Pro Thr Asp Arg Ala Asp Ser Arg Arg Ser Trp
 595 600 605

His Glu Glu Ser Pro Phe Glu Lys Gln Phe Lys Arg Arg Ser Cys Gln
 610 615 620

Met Glu Phe Gly Glu Ser Ile Met Ser Glu Asn Arg Ser Arg Glu Glu
 625 630 635 640

Leu Gly Lys Val Gly Ser Gln Ser Ser Phe Ser Gly Ser Met Glu Ile
 645 650 655

Ile Glu Val Ser
 660

<210> 115
 <211> 408
 <212> DNA
 <213> Homo sapiens

<400> 115
 acaatggagt ggctgagcct ttgagcacac caccattaca tcatcgtggc aaattaaaga 60
 aggaggtggg aaaagaggac ttattgttgt catggcccat gagatgattg gaactcaaat 120
 tggtactgag aggttggtgg ctctgctgga aagtggaacg gaaaaagtgc tgctaattga 180
 tagccggcca tttgtggaat acaatacatc ccacattttg gaagccatta atatcaactg 240
 ctccaagctt atgaagcgaa ggttgcaaca ggacaaagtg ttaattacag agctcatcca 300
 gcattcagcg aacataaagg ttgacattga ttgcagtcag aaggttgtag tttacgatca 360
 aagctcccaa gatgttgccct ctctctcttc agactgtttt ctcaactgt 408

<210> 116
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 116

Gly Thr Gln Ile Val Thr Glu Arg Leu Val Ala Leu Leu
 1 5 10

<210> 117
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 117

Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp

1 5 10

<210> 118
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 118

Glu Leu Ile Gln His Ser Ala Lys His Lys Val Asp Ile
 1 5 10

<210> 119
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 119

Val Asp Ile Asp Cys Ser Gln Lys Val Val Val Tyr Asp
 1 5 10

<210> 120
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 120

Asp Arg Leu Glu Asp Ser Asn Lys Leu Lys Arg Ser Phe
 1 5 10

<210> 121
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 121

Thr Thr Leu Asp Gly Thr Asn Lys Leu Cys Gln Phe Ser
 1 5 10

<210> 122
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 122

Pro Lys Lys Leu Gln Thr Ala Arg Pro Ser Asp Ser Gln
 1 5 10

<210> 123
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 123

Pro Ser Asp Ser Gln Ser Lys Arg Leu His Ser Val Arg
 1 5 10

<210> 124
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 124

Ser Lys Arg Leu His Ser Val Arg Thr Ser Ser Ser Gly
 1 5 10

<210> 125
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 125

Gly Asp Gln Val Tyr Ser Val Arg Arg Arg Gln Lys Pro
 1 5 10

<210> 126
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 126

Arg Arg Gln Lys Pro Ser Asp Arg Ala Asp Ser Arg Arg
 1 5 10

<210> 127
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 127

Ser Asp Arg Ala Asp Ser Arg Arg Ser Trp His Glu Glu
 1 5 10

<210> 128
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 128

Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile
 1 5 10

<210> 129
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 129

Glu Ala Ile Asn Ile Asn Cys Ser Lys Leu Met Lys Arg Arg
 1 5 10

<210> 130
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 130

Ile Gly Tyr Val Leu Asn Ala Ser Tyr Thr Cys Pro Lys Pro
 1 5 10

<210> 131
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 131

Leu Arg Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu
 1 5 10

<210> 132
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 132

Glu Lys Lys Ile Lys Asn Gln Thr Gly Ala Ser Gly Pro Lys
 1 5 10

<210> 133
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 133

Ser Ile Met Ser Glu Asn Arg Ser Arg Glu Glu Leu Gly Lys
 1 5 10

<210> 134
 <211> 140
 <212> PRT
 <213> Homo sapiens

<400> 134

Gly Pro Thr Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp
 1 5 10 15

Val Leu Asn Lys Glu Leu Ile Gln Gln Asn Gly Ile Gly Tyr Val Leu
 20 25 30

Asn Ala Ser Tyr Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His
 35 40 45

Phe Leu Arg Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro
 50 55 60

Trp Leu Asp Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn
 65 70 75 80

Gly Cys Val Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr
85 90 95

Ile Ala Ile Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu
100 105 110

Ala Tyr Arg Phe Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Asn Phe
115 120 125

Asn Phe Leu Gly Gln Leu Leu Asp Tyr Glu Lys Lys
130 135 140

<210> 135

<211> 140

<212> PRT

<213> Mus musculus

<400> 135

Gly Pro Thr Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp
1 5 10 15

Val Leu Asn Lys Asp Leu Met Gln Gln Asn Gly Ile Gly Tyr Val Leu
20 25 30

Asn Ala Ser Asn Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His
35 40 45

Phe Leu Arg Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro
50 55 60

Trp Leu Asp Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn
65 70 75 80

Gly Cys Val Leu Ile His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr
85 90 95

Ile Ala Ile Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu
100 105 110

Ala Tyr Arg Phe Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Asn Phe
115 120 125

Asn Phe Met Gly Gln Leu Met Asp Tyr Glu Lys Thr
130 135 140

<210> 136

<211> 38

<212> DNA

<213> Homo sapiens

<400> 136

gcagcagcgg ccgcattggg ccaaccogaa ttcttccc

38

<210> 137

<211> 37

<212> DNA

<213> Homo sapiens

<400> 137
gcagcagtcg acggagacct caatgatttc catgctg 37

<210> 138
<211> 39
<212> DNA
<213> Homo sapiens

<400> 138
gcagcagcgg ccgcatggcc catgagatga ttggaactc 39

<210> 139
<211> 37
<212> DNA
<213> Homo sapiens

<400> 139
gcagcagtcg accttcttct catagtccag gagttgg 37

<210> 140
<211> 38
<212> DNA
<213> Homo sapiens

<400> 140
gcagcagcgg ccgcattggg ccaactcgaa ttcttccc 38

<210> 141
<211> 37
<212> DNA
<213> Homo sapiens

<400> 141
gcagcagtcg acagagacct cgatgatctc catgctg 37

<210> 142
<211> 39
<212> DNA
<213> Homo sapiens

<400> 142
gcagcagcgg ccgcatggcc catgagatga ttggaactc 39

<210> 143
<211> 37
<212> DNA
<213> Homo sapiens

<400> 143
gcagcagtcg accgtcttct catagtccat gagttgg 37

<210> 144
<211> 23
<212> PRT

<213> Homo sapiens

<400> 144

Asn Gly Cys Val Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala
 1 5 10 15

Thr Ile Ala Ile Ala Tyr Ile
 20

<210> 145

<211> 25

<212> DNA

<213> Homo sapiens

<400> 145

cacaccacca ttacatcatc gtggc 25

<210> 146

<211> 20

<212> DNA

<213> Homo sapiens

<400> 146

tgctgctctg ctaccaaccc 20

<210> 147

<211> 5450

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (538)..(2532)

<400> 147

gaaaagaaga cgaggaggag agcgacggga cgggacgcga gcgggagcgc agccgccctc 60

tgggctccgc ggcggcgcct cgcaagtccg ggaggcgagg ggggcccagag gggagacgcc 120

gtgacaactt tcgtttccct ctgagggaat tgggaggtcg gcggcccca aagctttcag 180

tccagtgtaa agctgttgga gcgcgggagc aaaggtaaag aatgatgtaa tgcgctggct 240

gtccaaagc atcttttgtt gtggaatggt tattccagtc atctctttat gaatcaaag 300

tgaggggctg ctttgtggac ggagtccttt gcaagagcac atcaacggga aagagaaaga 360

gacattcact tggagggctc ttgctgaaaa tgggtttaac tctccttttg ccagtcacca 420

ccagcctgac ctcatacact tttagtacaa tggagtggt gagcctttga gcacaccacc 480

attacatcat cgtggcaaat taaagaagga ggtgggaaaa gaggacttat tgttgtc 537

atg gcc cat gag atg att gga act caa att gtt act gag agg ttg gtg 585

Met Ala His Glu Met Ile Gly Thr Gln Ile Val Thr Glu Arg Leu Val
 1 5 10 15

gct ctg ctg gaa agt gga acg gaa aaa gtg ctg cta att gat agc cgg 633

Ala Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp Ser Arg	
20 25 30	
cca ttt gtg gaa tac aat aca tcc cac att ttg gaa gcc att aat atc	681
Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile Asn Ile	
35 40 45	
aac tgc tcc aag ctt atg aag cga agg ttg caa cag gac aaa gtg tta	729
Asn Cys Ser Lys Leu Met Lys Arg Arg Leu Gln Gln Asp Lys Val Leu	
50 55 60	
att aca gag ctc atc cag cat tca gcg aaa cat aag gtt gac att gat	777
Ile Thr Glu Leu Ile Gln His Ser Ala Lys His Lys Val Asp Ile Asp	
65 70 75 80	
tgc agt cag aag gtt gta gtt tac gat caa agc tcc caa gat gtt gcc	825
Cys Ser Gln Lys Val Val Val Tyr Asp Gln Ser Ser Gln Asp Val Ala	
85 90 95	
tct ctc tct tca gac tgt ttt ctc act gta ctt ctg ggt aaa ctg gag	873
Ser Leu Ser Ser Asp Cys Phe Leu Thr Val Leu Leu Gly Lys Leu Glu	
100 105 110	
aag agc ttc aac tct gtt cac ctg ctt gca ggt ggg ttt gct gag ttc	921
Lys Ser Phe Asn Ser Val His Leu Leu Ala Gly Gly Phe Ala Glu Phe	
115 120 125	
tct cgt tgt ttc cct ggc ctc tgt gaa gga aaa tcc act cta gtc cct	969
Ser Arg Cys Phe Pro Gly Leu Cys Glu Gly Lys Ser Thr Leu Val Pro	
130 135 140	
acc tgc att tct cag cct tgc tta cct gtt gcc aac att ggg cca acc	1017
Thr Cys Ile Ser Gln Pro Cys Leu Pro Val Ala Asn Ile Gly Pro Thr	
145 150 155 160	
cga att ctt ccc aat ctt tat ctt ggc tgc cag cga gat gtc ctc aac	1065
Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp Val Leu Asn	
165 170 175	
aag gag ctg ata cag cag aat ggg att ggt tat gtg tta aat gcc agc	1113
Lys Glu Leu Ile Gln Gln Asn Gly Ile Gly Tyr Val Leu Asn Ala Ser	
180 185 190	
tat acc tgt cca aag cct gac ttt atc ccc gag tct cat ttc ctg cgt	1161
Tyr Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His Phe Leu Arg	
195 200 205	
gtg cct gtg aat gac agc ttt tgt gag aaa att ttg ccg tgg ttg gac	1209
Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro Trp Leu Asp	
210 215 220	
aaa tca gta gat ttc att gag aaa gca aaa gcc tcc aat gga tgt gtt	1257
Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn Gly Cys Val	
225 230 235 240	
cta gtg cac tgt tta gct ggg atc tcc cgc tcc gcc acc atc gct atc	1305
Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile Ala Ile	
245 250 255	
gcc tac atc atg aag agg atg gac atg tct tta gat gaa gct tac aga	1353
Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu Ala Tyr Arg	

260	265	270	
ttt gtg aaa gaa aaa aga cct act ata tct cca aac ttc aat ttt ctg Phe Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Asn Phe Asn Phe Leu 275 280 285			1401
ggc caa ctc ctg gac tat gag aag aag att aag aac cag act gga gca Gly Gln Leu Leu Asp Tyr Glu Lys Lys Ile Lys Asn Gln Thr Gly Ala 290 295 300			1449
tca ggg cca aag agc aaa ctc aag ctg ctg cac ctg gag aag cca aat Ser Gly Pro Lys Ser Lys Leu Lys Leu Leu His Leu Glu Lys Pro Asn 305 310 315 320			1497
gaa cct gtc cct gct gtc tca gag ggt gga cag aaa agc gag acg ccc Glu Pro Val Pro Ala Val Ser Glu Gly Gly Gln Lys Ser Glu Thr Pro 325 330 335			1545
ctc agt cca ccc tgt gcc gac tct gct acc tca gag gca gca gga caa Leu Ser Pro Pro Cys Ala Asp Ser Ala Thr Ser Glu Ala Ala Gly Gln 340 345 350			1593
agg ccc gtg cat ccc gcc agc gtg ccc agc gtg ccc agc gtg cag ccg Arg Pro Val His Pro Ala Ser Val Pro Ser Val Pro Ser Val Gln Pro 355 360 365			1641
tcg ctg tta gag gac agc ccg ctg gta cag gcg ctc agt ggg ctg cac Ser Leu Leu Glu Asp Ser Pro Leu Val Gln Ala Leu Ser Gly Leu His 370 375 380			1689
ctg tcc gca gac agg ctg gaa gac agc aat aag ctc aag cgt tcc ttc Leu Ser Ala Asp Arg Leu Glu Asp Ser Asn Lys Leu Lys Arg Ser Phe 385 390 395 400			1737
tct ctg gat atc aaa tca gtt tca tat tca gcc agc atg gca gca tcc Ser Leu Asp Ile Lys Ser Val Ser Tyr Ser Ala Ser Met Ala Ala Ser 405 410 415			1785
tta cat ggc ttc tcc tca tca gaa gat gct ttg gaa tac tac aaa cct Leu His Gly Phe Ser Ser Ser Glu Asp Ala Leu Glu Tyr Tyr Lys Pro 420 425 430			1833
tcc act act ctg gat ggg acc aac aag cta tgc cag ttc tcc cct gtt Ser Thr Thr Leu Asp Gly Thr Asn Lys Leu Cys Gln Phe Ser Pro Val 435 440 445			1881
cag gaa cta tcg gag cag act ccc gaa acc agt cct gat aag gag gaa Gln Glu Leu Ser Glu Gln Thr Pro Glu Thr Ser Pro Asp Lys Glu Glu 450 455 460			1929
gcc agc atc ccc aag aag ctg cag acc gcc agg cct tca gac agc cag Ala Ser Ile Pro Lys Lys Leu Gln Thr Ala Arg Pro Ser Asp Ser Gln 465 470 475 480			1977
agc aag cga ttg cat tcg gtc aga acc agc agc agt ggc acc gcc cag Ser Lys Arg Leu His Ser Val Arg Thr Ser Ser Ser Gly Thr Ala Gln 485 490 495			2025
agg tcc ctt tta tct cca ctg cat cga agt ggg agc gtg gag gac aat Arg Ser Leu Leu Ser Pro Leu His Arg Ser Gly Ser Val Glu Asp Asn 500 505 510			2073

tac cac acc agc ttc ctt ttc ggc ctt tcc acc agc cag cag cac ctc Tyr His Thr Ser Phe Leu Phe Gly Leu Ser Thr Ser Gln Gln His Leu 515 520 525	2121
acg aag tct gct ggc ctg ggc ctt aag ggc tgg cac tcg gat atc ttg Thr Lys Ser Ala Gly Leu Gly Leu Lys Gly Trp His Ser Asp Ile Leu 530 535 540	2169
gcc ccc cag acc tct acc cct tcc ctg acc agc agc tgg tat ttt gcc Ala Pro Gln Thr Ser Thr Pro Ser Leu Thr Ser Ser Trp Tyr Phe Ala 545 550 555 560	2217
aca gag tcc tca cac ttc tac tct gcc tca gcc atc tac gga ggc agt Thr Glu Ser Ser His Phe Tyr Ser Ala Ser Ala Ile Tyr Gly Gly Ser 565 570 575	2265
gcc agt tac tct gcc tac agc tgc agc cag ctg ccc act tgc gga gac Ala Ser Tyr Ser Ala Tyr Ser Cys Ser Gln Leu Pro Thr Cys Gly Asp 580 585 590	2313
caa gtc tat tct gtg cgc agg cgg cag aag cca agt gac aga gct gac Gln Val Tyr Ser Val Arg Arg Arg Gln Lys Pro Ser Asp Arg Ala Asp 595 600 605	2361
tcg cgg cgg agc tgg cat gaa gag agc ccc ttt gaa aag cag ttt aaa Ser Arg Arg Ser Trp His Glu Glu Ser Pro Phe Glu Lys Gln Phe Lys 610 615 620	2409
cgc aga agc tgc caa atg gaa ttt gga gag agc atc atg tca gag aac Arg Arg Ser Cys Gln Met Glu Phe Gly Glu Ser Ile Met Ser Glu Asn 625 630 635 640	2457
agg tca cgg gaa gag ctg ggg aaa gtg ggc agt cag tct agc ttt tcg Arg Ser Arg Glu Glu Leu Gly Lys Val Gly Ser Gln Ser Ser Phe Ser 645 650 655	2505
ggc agc atg gaa atc att gag gtc tcc tgagaagaaa gacacttggtg Gly Ser Met Glu Ile Ile Glu Val Ser 660 665	2552
acttctatag acaatttttt ttttcttggt cacaataaaaa ttccctgtaa atctgaaata	2612
tatatatgta catacatata tattttttgga aaatggagct atggtgtaaa agcaacaggt	2672
ggatcaaccc agttgttact ctcttaacat ctgcatttga gagatcagct aatacttctc	2732
tcaacaaaaa tggaaggga gatgctagaa tccccctag acggaggaaa accattttat	2792
tcagtgaatt acacatcctc ttgttcttaa aaaagcaagt gtctttggtg ttggaggaca	2852
aaatccccta ccattttcac gttgtgctac taagagatct caaatattag tctttgtccg	2912
gacccttcca tagtacacct tagcgctgag actgagccag cttgggggtc aggtaggtag	2972
accctgttag ggacagagcc tagtggtaaa tccaagagaa atgatcctat ccaaagctga	3032
ttcacaacc cagctcacc tgacagccga gggacacgag catcactctg ctggacggac	3092
cattaggggc cttgccaagg tctaccttag agcaaacca gtacctcaga caggaaagtc	3152

ggggctttga ccactaccat atctggtagc ccattttcta ggcattgtga ataggtaggt	3212
agctagtcac acttttcaga ccaattcaaa ctgtctatgc acaaaattcc cgtgggccta	3272
gatggagata attttttttt cttctcagct ttatgaagag aagggaact gtctaggatt	3332
cagctgaacc accaggaacc tggcaacatc acgatttaag ctaaggttgg gaggctaacg	3392
agtctaccto cctctttgta aatcaaagaa ttgtttaaaa tgggattgtc aatcctttaa	3452
ataaagatga acttggtttc aagccaaatg tgaatttatt tgggttggtg gcagagcagc	3512
agcaccttca aattctcagc caaagcagat gtttttgccc tttctgcttc actgcatgga	3572
tacagttggt aaaatgtaat aatatggcag aattttatag gaaacttcct agggaggtaa	3632
attatgggaa gattaagaaa ggtacaaatt gctgaggaga agcaggaaac ctgtttcctt	3692
agtggctttt atcccctcg catgcgatgg ggctgatgtt tctatgattg cctcagactt	3752
tcacatttac tagtagggct gagagaggct ttagtgagga aggaatatc agaataaaac	3812
ggttgagaaa gctgagaaga ccattgagtt ttgatcagtt gtgaatagag tgcaaagcca	3872
tggccaagct gtttttgaa acgctggccg gcgtgtcttc agtggaaaaa gcaaatcaaa	3932
atggagcgag agcaaagggg cgtcctcagt cctcaaccta caatcactgt atggaatcgg	3992
tcctggcagc tgaacatagg aggtcactgg aacaagtgat agtgcagatt ggctttcaaa	4052
catcctctcg gcttgagttt tatcagctac aatgtgggtc ctcttttgaa gccttaattc	4112
acaacagcag ctttttgggg gtggggctgg ggggtgttg tcattgttct ttcccttctt	4172
gtaagtgtcg ctagttgctg cctcgatatc cagggttttc tctgttttg agaaatggac	4232
agttttttga ccaggatgtg acttcatgtt tcctatggtg acttctaaaa ccagcacaga	4292
atgatatgac tcaacacaga ccgacttggg tatggggatg atgagccgca cagacctcac	4352
tagttgtgca caaataatgt gctatgatgg ggtgtaaagt gaaggcagaa gagggtcagc	4412
cgcattgtta tgatactggg aaagtgctgg tcaacgattt gagttagttt ttagatatac	4472
attgaaatct ttaatcagac attctcaagt ttcacacagt agtttttgat gttatgtaca	4532
cacacaccaa atgtgtaaca gttcaccact tccagagtgt ggtcatgccc aaaacatgtt	4592
taagaaagga aagcagtagc tccttgctaa cgatgtttca ggaggtttg ggcaacttgg	4652
tttaatgagc ttctgtcatt tagggcttct cttggccatg gtcccccttc ttctggaact	4712
gtgatgtagt cacatcctac agccttttagt gctgggtcac tagtgtcaga taatcagttc	4772
ttggaatcga gactgccgtg gcgaaggggt ggcctcggag gcaggctctg gagctgcttg	4832
gatgtcttta ggtgggggtg tggtgggtc tcttcagcat gtaattgggg aaaccctcgc	4892
gtctactagg ggtgatacag atggtgattt taaagagcaa aactagactt ctatgtgaga	4952
agtgctggaa aatgatttag gacatgtgta aagttagatg gaaagactgt aatgtttaa	5012

tatgaatata gtgttctttt gaagtaaggc cagctgttga acggttaaac tgtgcatttc 5072
 tcattttgat gtgtcatgta tgtaaatgta tgaaatgatt aaataaaatc aaaactggta 5132
 cctgtttata cataaatacg agaaaagacc tatcttttga gccataaact cgggtgggaac 5192
 accaccactc aagttgccaa aggaggcagt ggtgaaacct gtcctgttct cacttaaattg 5252
 aggatttagc tcaaaataaa gtggtggtgt catcagggtt attccgtgtt ctgtcattca 5312
 catggaacac cggatgatta gctaacagtt tagtgccagc cttcattctt tactgtgtac 5372
 gttaaattga cactacagtg aaaaagccta agacacttgg taaatatttt ctagctgact 5432
 gattccagaa cacacaag 5450

<210> 148
 <211> 665
 <212> PRT
 <213> Homo sapiens

<400> 148

Met Ala His Glu Met Ile Gly Thr Gln Ile Val Thr Glu Arg Leu Val
 1 5 10 15

Ala Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp Ser Arg
 20 25 30

Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile Asn Ile
 35 40 45

Asn Cys Ser Lys Leu Met Lys Arg Arg Leu Gln Gln Asp Lys Val Leu
 50 55 60

Ile Thr Glu Leu Ile Gln His Ser Ala Lys His Lys Val Asp Ile Asp
 65 70 75 80

Cys Ser Gln Lys Val Val Val Tyr Asp Gln Ser Ser Gln Asp Val Ala
 85 90 95

Ser Leu Ser Ser Asp Cys Phe Leu Thr Val Leu Leu Gly Lys Leu Glu
 100 105 110

Lys Ser Phe Asn Ser Val His Leu Leu Ala Gly Gly Phe Ala Glu Phe
 115 120 125

Ser Arg Cys Phe Pro Gly Leu Cys Glu Gly Lys Ser Thr Leu Val Pro
 130 135 140

Thr Cys Ile Ser Gln Pro Cys Leu Pro Val Ala Asn Ile Gly Pro Thr
 145 150 155 160

Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp Val Leu Asn
 165 170 175

Lys Glu Leu Ile Gln Gln Asn Gly Ile Gly Tyr Val Leu Asn Ala Ser
 180 185 190

Tyr Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His Phe Leu Arg
 195 200 205

Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro Trp Leu Asp
 210 215 220

Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn Gly Cys Val
 225 230 235 240

Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile Ala Ile
 245 250 255

Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu Ala Tyr Arg
 260 265 270

Phe Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Asn Phe Asn Phe Leu
 275 280 285

Gly Gln Leu Leu Asp Tyr Glu Lys Lys Ile Lys Asn Gln Thr Gly Ala
 290 295 300

Ser Gly Pro Lys Ser Lys Leu Lys Leu Leu His Leu Glu Lys Pro Asn
 305 310 315 320

Glu Pro Val Pro Ala Val Ser Glu Gly Gly Gln Lys Ser Glu Thr Pro
 325 330 335

Leu Ser Pro Pro Cys Ala Asp Ser Ala Thr Ser Glu Ala Ala Gly Gln
 340 345 350

Arg Pro Val His Pro Ala Ser Val Pro Ser Val Pro Ser Val Gln Pro
 355 360 365

Ser Leu Leu Glu Asp Ser Pro Leu Val Gln Ala Leu Ser Gly Leu His
 370 375 380

Leu Ser Ala Asp Arg Leu Glu Asp Ser Asn Lys Leu Lys Arg Ser Phe

385 390 395 400
 Ser Leu Asp Ile Lys Ser Val Ser Tyr Ser Ala Ser Met Ala Ala Ser
 405 410 415
 Leu His Gly Phe Ser Ser Ser Glu Asp Ala Leu Glu Tyr Tyr Lys Pro
 420 425 430
 Ser Thr Thr Leu Asp Gly Thr Asn Lys Leu Cys Gln Phe Ser Pro Val
 435 440 445
 Gln Glu Leu Ser Glu Gln Thr Pro Glu Thr Ser Pro Asp Lys Glu Glu
 450 455 460
 Ala Ser Ile Pro Lys Lys Leu Gln Thr Ala Arg Pro Ser Asp Ser Gln
 465 470 475 480
 Ser Lys Arg Leu His Ser Val Arg Thr Ser Ser Ser Gly Thr Ala Gln
 485 490 495
 Arg Ser Leu Leu Ser Pro Leu His Arg Ser Gly Ser Val Glu Asp Asn
 500 505 510
 Tyr His Thr Ser Phe Leu Phe Gly Leu Ser Thr Ser Gln Gln His Leu
 515 520 525
 Thr Lys Ser Ala Gly Leu Gly Leu Lys Gly Trp His Ser Asp Ile Leu
 530 535 540
 Ala Pro Gln Thr Ser Thr Pro Ser Leu Thr Ser Ser Trp Tyr Phe Ala
 545 550 555 560
 Thr Glu Ser Ser His Phe Tyr Ser Ala Ser Ala Ile Tyr Gly Gly Ser
 565 570 575
 Ala Ser Tyr Ser Ala Tyr Ser Cys Ser Gln Leu Pro Thr Cys Gly Asp
 580 585 590
 Gln Val Tyr Ser Val Arg Arg Arg Gln Lys Pro Ser Asp Arg Ala Asp
 595 600 605
 Ser Arg Arg Ser Trp His Glu Glu Ser Pro Phe Glu Lys Gln Phe Lys
 610 615 620
 Arg Arg Ser Cys Gln Met Glu Phe Gly Glu Ser Ile Met Ser Glu Asn
 625 630 635 640

Arg Ser Arg Glu Glu Leu Gly Lys Val Gly Ser Gln Ser Ser Phe Ser
645 650 655

Gly Ser Met Glu Ile Ile Glu Val Ser
660 665

<210> 149
<211> 4393
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (628)..(2448)

<400> 149
ccacgcgtcc ggctcttgcc tcccagtgcc atgcaggtgc aggatgcaac caggcggccc 60
tcagccgtgc gcttcctcag ctccctttctc cagggccgcc ggcactccac ctccagaccca 120
gtactgcggc tgcagcaggc ccggcggggc tctggcttgg gctccggctc tgccacgaag 180
ctgctgtcct cgtcctctct ccaggtgatg gtggctgttt cctcagtcag ccatgcagag 240
ggaaacccaa ctttccccga aagaaaaaga aatttagaac gtccaacacc aaagtacaca 300
aaagtagggg agcgtttacg gcatgtcatt cctggacaca tggcatgttc catggcgtgt 360
ggcggtagag cttgcaagta tgagaaccca gccgcgtgga gtgagcagga gcaagccatt 420
aaggggggttt actcatcctg ggctactgat aatatactgg ccatggcccg cccatcctct 480
gagctcctgg agaagtacca catcattgat cagttcctca gccatggcat aaaaacaata 540
atcaacctcc agcgccttgg tgagcatgct agctgtggga accctctgga acaagaaagt 600
ggcttcacat accttcctga ggcttttc atg gag gct ggc att tac ttc tac aat 654
Met Glu Ala Gly Ile Tyr Phe Tyr Asn
1 5
ttc gga tgg aag gat tat ggt gta gcg tct ctt act act atc cta gat 702
Phe Gly Trp Lys Asp Tyr Gly Val Ala Ser Leu Thr Thr Ile Leu Asp
10 15 20 25
atg gtg aag gtg atg aca ttt gcc tta cag gaa gga aaa gta gct atc 750
Met Val Lys Val Met Thr Phe Ala Leu Gln Glu Gly Lys Val Ala Ile
30 35 40
cat tgt cat gca ggg ctt ggt cga aca ggt gtt tta ata gcc tgt tac 798
His Cys His Ala Gly Leu Gly Arg Thr Gly Val Leu Ile Ala Cys Tyr
45 50 55
tta gtt ttt gca acg aga atg act gct gac caa gca att ata ttt gtg 846
Leu Val Phe Ala Thr Arg Met Thr Ala Asp Gln Ala Ile Ile Phe Val
60 65 70
cgg gca aag cga ccc aat tcc ata caa acc aga gga cag ctc ctc tgt 894

Arg	Ala	Lys	Arg	Pro	Asn	Ser	Ile	Gln	Thr	Arg	Gly	Gln	Leu	Leu	Cys	
75						80					85					
gta	agg	gaa	ttt	act	cag	ttt	cta	act	cct	ctc	cgc	aat	ata	ttc	tct	942
Val	Arg	Glu	Phe	Thr	Gln	Phe	Leu	Thr	Pro	Leu	Arg	Asn	Ile	Phe	Ser	
90					95					100					105	
tgc	tgt	gat	ccc	aaa	gca	cat	gct	gtc	acc	tta	cct	caa	tat	cta	att	990
Cys	Cys	Asp	Pro		Lys	Ala	His	Ala	Val	Thr	Leu	Pro	Gln	Tyr	Leu	Ile
				110					115					120		
cgc	cag	cgt	cat	ctg	ctt	cat	ggt	tat	gag	gca	cga	ctt	ctg	aaa	cac	1038
Arg	Gln	Arg	His	Leu	Leu	His	Gly	Tyr	Glu	Ala	Arg	Leu	Leu	Lys	His	
			125					130					135			
gtg	cca	aaa	att	atc	cac	cta	gtt	tgc	aaa	ttg	ctg	ctg	gac	tta	gcg	1086
Val	Pro	Lys	Ile	Ile	His	Leu	Val	Cys	Lys	Leu	Leu	Leu	Asp	Leu	Ala	
	140						145					150				
gag	aac	agg	cca	gtg	atg	atg	aag	gat	gtg	tcc	gaa	gga	cct	ggt	ctc	1134
Glu	Asn	Arg	Pro	Val	Met	Met	Lys	Asp	Val	Ser	Glu	Gly	Pro	Gly	Leu	
	155					160					165					
tct	gct	gaa	ata	gaa	aag	aca	atg	tct	gag	atg	gtc	acc	atg	cag	ctg	1182
Ser	Ala	Glu	Ile	Glu	Lys	Thr	Met	Ser	Glu	Met	Val	Thr	Met	Gln	Leu	
170					175					180					185	
gat	aaa	gag	tta	ctg	agg	cat	gac	agt	gat	gtg	tcc	aac	ccg	cct	aac	1230
Asp	Lys	Glu	Leu	Leu	Arg	His	Asp	Ser	Asp	Val	Ser	Asn	Pro	Pro	Asn	
				190					195					200		
ccc	act	gca	gtg	gca	gca	gat	ttt	gac	aat	cga	ggc	atg	att	ttc	tcc	1278
Pro	Thr	Ala	Val	Ala	Ala	Asp	Phe	Asp	Asn	Arg	Gly	Met	Ile	Phe	Ser	
		205						210					215			
aat	gag	caa	cag	ttt	gac	cct	ctt	tgg	aaa	agg	cgg	aat	ggt	gag	tgc	1326
Asn	Glu	Gln	Gln	Phe	Asp	Pro	Leu	Trp	Lys	Arg	Arg	Asn	Val	Glu	Cys	
	220						225					230				
ctt	caa	ccc	ctg	act	cat	ctg	aaa	agg	cgg	ctc	agc	tac	agt	gac	tca	1374
Leu	Gln	Pro	Leu	Thr	His	Leu	Lys	Arg	Arg	Leu	Ser	Tyr	Ser	Asp	Ser	
	235					240					245					
gat	tta	aag	agg	gcc	gag	aac	ctc	ctg	gag	caa	ggg	gag	act	cca	cag	1422
Asp	Leu	Lys	Arg	Ala	Glu	Asn	Leu	Leu	Glu	Gln	Gly	Glu	Thr	Pro	Gln	
250					255					260					265	
aca	gtg	cct	gcc	cag	atc	ttg	gtt	ggc	cac	aag	ccc	agg	cag	cag	aag	1470
Thr	Val	Pro	Ala	Gln	Ile	Leu	Val	Gly	His	Lys	Pro	Arg	Gln	Gln	Lys	
				270					275					280		
ctc	ata	agc	cat	tgt	tac	atc	cca	cag	tct	cca	gaa	cca	gac	tta	cac	1518
Leu	Ile	Ser	His	Cys	Tyr	Ile	Pro	Gln	Ser	Pro	Glu	Pro	Asp	Leu	His	
			285					290					295			
aag	gaa	gcc	ttg	gtt	cgc	agc	aca	ctt	tct	ttc	tgg	agt	cag	tca	aag	1566
Lys	Glu	Ala	Leu	Val	Arg	Ser	Thr	Leu	Ser	Phe	Trp	Ser	Gln	Ser	Lys	
	300						305					310				
ttt	gga	ggc	ctg	gaa	gga	ctc	aaa	gat	aat	ggg	tca	cca	att	ttc	cat	1614
Phe	Gly	Gly	Leu	Glu	Gly	Leu	Lys	Asp	Asn	Gly	Ser	Pro	Ile	Phe	His	

315	320	325	
gga agg atc att cca aag gaa gca cag cag agt gga gct ttc tct gca Gly Arg Ile Ile Pro Lys Glu Ala Gln Gln Ser Gly Ala Phe Ser Ala 330 335 340 345			1662
gat gtt tca ggc tca cac agc cct ggg gag cca gtt tca ccc agc ttt Asp Val Ser Gly Ser His Ser Pro Gly Glu Pro Val Ser Pro Ser Phe 350 355 360			1710
gca aat gtc cat aag gat cca aac cct gct cac cag caa gtg tct cac Ala Asn Val His Lys Asp Pro Asn Pro Ala His Gln Gln Val Ser His 365 370 375			1758
tgt cag tgt aaa act cat ggt gtt ggg agc cct ggc tct gtc agg cag Cys Gln Cys Lys Thr His Gly Val Gly Ser Pro Gly Ser Val Arg Gln 380 385 390			1806
aac agc agg aca ccc cga agc cct ctg gac tgt ggc tcc agt ccc aaa Asn Ser Arg Thr Pro Arg Ser Pro Leu Asp Cys Gly Ser Ser Pro Lys 395 400 405			1854
gca cag ttc ttg gtt gaa cat gaa acc cag gac agt aaa gat ctg tct Ala Gln Phe Leu Val Glu His Glu Thr Gln Asp Ser Lys Asp Leu Ser 410 415 420 425			1902
gaa gca gct tca cac tct gca tta cag tct gaa ttg agt gct gag gca Glu Ala Ala Ser His Ser Ala Leu Gln Ser Glu Leu Ser Ala Glu Ala 430 435 440			1950
aga aga ata ctg gcg gcc aaa gcc cta gca aat tta aat gaa tct gta Arg Arg Ile Leu Ala Ala Lys Ala Leu Ala Asn Leu Asn Glu Ser Val 445 450 455			1998
gaa aag gag gaa cta aaa agg aag gta gaa atg tgg cag aaa gag ctt Glu Lys Glu Glu Leu Lys Arg Lys Val Glu Met Trp Gln Lys Glu Leu 460 465 470			2046
aat tcc cga gat gga gct tgg gaa aga ata tgt ggc gag agg gac cct Asn Ser Arg Asp Gly Ala Trp Glu Arg Ile Cys Gly Glu Arg Asp Pro 475 480 485			2094
ttc atc cta tgc agc ttg atg tgg tct tgg gtg gag caa ctg aag gag Phe Ile Leu Cys Ser Leu Met Trp Ser Trp Val Glu Gln Leu Lys Glu 490 495 500 505			2142
cct gta atc acc aaa gag gat gtg gac atg ttg gtt gac agg cga gca Pro Val Ile Thr Lys Glu Asp Val Asp Met Leu Val Asp Arg Arg Ala 510 515 520			2190
gat gcc gca gaa gca ctt ttt tta tta gag aag gga cag cac cag act Asp Ala Ala Glu Ala Leu Phe Leu Leu Glu Lys Gly Gln His Gln Thr 525 530 535			2238
att ctc tgc gtg ttg cac tgc ata gtg aac ctg cag aca att ccc gtg Ile Leu Cys Val Leu His Cys Ile Val Asn Leu Gln Thr Ile Pro Val 540 545 550			2286
gat gtg gag gaa gct ttc ctt gcc cat gcc att aag gca ttc act aag Asp Val Glu Glu Ala Phe Leu Ala His Ala Ile Lys Ala Phe Thr Lys 555 560 565			2334

gtt aat ttt gat tct gaa aat gga cca aca gtt tac aac acc ctg aag Val Asn Phe Asp Ser Glu Asn Gly Pro Thr Val Tyr Asn Thr Leu Lys 570 575 580 585	2382
aaa ata ttt aag cac acg ctg gaa gaa aaa aga aaa atg aca aaa gat Lys Ile Phe Lys His Thr Leu Glu Glu Lys Arg Lys Met Thr Lys Asp 590 595 600	2430
ggc cct aag cct ggc ctc tagctttcac tcatggtgaa tatttcagac Gly Pro Lys Pro Gly Leu 605	2478
ctaaagatcc agatagtatc tctgttcata tgtgaataag ttgaagattg tggggctact	2538
ttttctcata gcactttatt ttgaatgttg ttagtttgtg ctgagaatgg tcgtccgtat	2598
ttgaaccaat tatttattttt aaaatatatt taagctacat ttttgttttg aaaaattgcc	2658
ataaatttgg tgccactttc ttttatttat ttgactgagt taatattatt gtattaacat	2718
tttaagtata tgggtgtttac attcttattt cttttgacat tttggaaata atcataactt	2778
gtctttccaa aataaccatt ttcttgatgg aactcttcct agagttttta ccaaatagct	2838
aacttttagta gtaaaacctc attgtgtatc cattccccca cagatgaact aagaaagtca	2898
ccaagtgtct taagctgttt tatatttggt acgaagaagg ctattgctac aatattttta	2958
aaggtttctt ttttaacttt gaaatttttt gtttttcctt ttctttttat aaatgtaaca	3018
gagggtttca aagcatatta tttttcagag agatttagtt ttactttaat ggagtgactg	3078
tgaagtgggtt gggatttttt gcttgtagaa agtagacttg ctctttgtca gatttccaaa	3138
caaccttgcc agccttggct gtcaaaagga ggcaggagca gttctcaaca caccaagcct	3198
tattcccact cccttgggtt gctgctgagc caaatagcat ctttacagag gaagtgggat	3258
cagaggcagg aagtgtggaa agttgctaag aagcagggct tgctctgtc ctcccgggga	3318
ctccacaggg atattcgtgc agggcagggg ctctgtgcca gccctgctct ctccagatgcc	3378
acagccactc tgcagaggtg actcttggag ctggaggaag tcaaaactgg gccactgttt	3438
gtactgatgg tgtattagca tgagcagcgt ggccctggcc ccactccc aaatctgcca	3498
ctccatagac ccacttgcct caaggcttta tatttggtg ctttcttaca atgagaatta	3558
agatttttaa actgaagttg accatacagg ttgcattagc cctaactggc ttcattgaag	3618
aagggtgact gcctaaacta gttccttgta agctgaacca tcaattatca gttgaagcca	3678
tacttttatt taaattaata tacgtagata ccagaggcca agccacagag aggataatag	3738
ttcttcccaa taaagtgat attaatacaga ctaatttcga actaaagaag ttactgtta	3798
aagacggaat ttcaggggaa gcaagactca tttagaacaa atgaaatttc tccagtccta	3858
catttctgaa ttgacttcta gcacatcaaa aatatttcag tcattatcag tctcattaac	3918

tgaaatgcc aatgctaaat gcagtgttct ttcacactgt ttttaattttc ttgggaaatt 3978
 gagtccagt gatgttaatg gagggttg cccatccctg aaatgtctta ttttcaagt 4038
 cctggcctgg gaaagaagg gaagaaacaa ttgcattata tccaaagata cactataaaa 4098
 atagagtttt taccaaaaaa agatgtttgt tctcatctca gtaggcctca tttgggcaag 4158
 tgaccacag gtcttttggc gaggttgcta tttgcctgtt gaaatacttg tttcaactta 4218
 gagaacagtt atgatgtgac catagcatgg cacaactaaa aatctaagcc tgaaacctga 4278
 aaaaagagat atgacaagg aaattaatca ggctatacat aagtattgta tttatttgaa 4338
 taaaaataaa aagagcaacc cataaaaaaa aaaaaaaaaa aaaaaaaaaa aaaag 4393

<210> 150
 <211> 607
 <212> PRT
 <213> Homo sapiens

<400> 150

Met Glu Ala Gly Ile Tyr Phe Tyr Asn Phe Gly Trp Lys Asp Tyr Gly
 1 5 10 15

Val Ala Ser Leu Thr Thr Ile Leu Asp Met Val Lys Val Met Thr Phe
 20 25 30

Ala Leu Gln Glu Gly Lys Val Ala Ile His Cys His Ala Gly Leu Gly
 35 40 45

Arg Thr Gly Val Leu Ile Ala Cys Tyr Leu Val Phe Ala Thr Arg Met
 50 55 60

Thr Ala Asp Gln Ala Ile Ile Phe Val Arg Ala Lys Arg Pro Asn Ser
 65 70 75 80

Ile Gln Thr Arg Gly Gln Leu Leu Cys Val Arg Glu Phe Thr Gln Phe
 85 90 95

Leu Thr Pro Leu Arg Asn Ile Phe Ser Cys Cys Asp Pro Lys Ala His
 100 105 110

Ala Val Thr Leu Pro Gln Tyr Leu Ile Arg Gln Arg His Leu Leu His
 115 120 125

Gly Tyr Glu Ala Arg Leu Leu Lys His Val Pro Lys Ile Ile His Leu
 130 135 140

Val Cys Lys Leu Leu Leu Asp Leu Ala Glu Asn Arg Pro Val Met Met

145		150		155		160
Lys Asp Val Ser	Glu Gly Pro Gly Leu Ser Ala Glu Ile Glu Lys Thr					
	165		170			175
Met Ser Glu Met Val Thr Met Gln Leu Asp Lys Glu Leu Leu Arg His						
	180		185			190
Asp Ser Asp Val Ser Asn Pro Pro Asn Pro Thr Ala Val Ala Ala Asp						
	195		200			205
Phe Asp Asn Arg Gly Met Ile Phe Ser Asn Glu Gln Gln Phe Asp Pro						
	210		215			220
Leu Trp Lys Arg Arg Asn Val Glu Cys Leu Gln Pro Leu Thr His Leu						
	225		230			235
						240
Lys Arg Arg Leu Ser Tyr Ser Asp Ser Asp Leu Lys Arg Ala Glu Asn						
		245		250		255
Leu Leu Glu Gln Gly Glu Thr Pro Gln Thr Val Pro Ala Gln Ile Leu						
		260		265		270
Val Gly His Lys Pro Arg Gln Gln Lys Leu Ile Ser His Cys Tyr Ile						
		275		280		285
Pro Gln Ser Pro Glu Pro Asp Leu His Lys Glu Ala Leu Val Arg Ser						
		290		295		300
Thr Leu Ser Phe Trp Ser Gln Ser Lys Phe Gly Gly Leu Glu Gly Leu						
		305		310		315
						320
Lys Asp Asn Gly Ser Pro Ile Phe His Gly Arg Ile Ile Pro Lys Glu						
		325		330		335
Ala Gln Gln Ser Gly Ala Phe Ser Ala Asp Val Ser Gly Ser His Ser						
		340		345		350
Pro Gly Glu Pro Val Ser Pro Ser Phe Ala Asn Val His Lys Asp Pro						
		355		360		365
Asn Pro Ala His Gln Gln Val Ser His Cys Gln Cys Lys Thr His Gly						
		370		375		380
Val Gly Ser Pro Gly Ser Val Arg Gln Asn Ser Arg Thr Pro Arg Ser						
		385		390		395
						400

Pro Leu Asp Cys Gly Ser Ser Pro Lys Ala Gln Phe Leu Val Glu His
 405 410 415

Glu Thr Gln Asp Ser Lys Asp Leu Ser Glu Ala Ala Ser His Ser Ala
 420 425 430

Leu Gln Ser Glu Leu Ser Ala Glu Ala Arg Arg Ile Leu Ala Ala Lys
 435 440 445

Ala Leu Ala Asn Leu Asn Glu Ser Val Glu Lys Glu Glu Leu Lys Arg
 450 455 460

Lys Val Glu Met Trp Gln Lys Glu Leu Asn Ser Arg Asp Gly Ala Trp
 465 470 475 480

Glu Arg Ile Cys Gly Glu Arg Asp Pro Phe Ile Leu Cys Ser Leu Met
 485 490 495

Trp Ser Trp Val Glu Gln Leu Lys Glu Pro Val Ile Thr Lys Glu Asp
 500 505 510

Val Asp Met Leu Val Asp Arg Arg Ala Asp Ala Ala Glu Ala Leu Phe
 515 520 525

Leu Leu Glu Lys Gly Gln His Gln Thr Ile Leu Cys Val Leu His Cys
 530 535 540

Ile Val Asn Leu Gln Thr Ile Pro Val Asp Val Glu Glu Ala Phe Leu
 545 550 555 560

Ala His Ala Ile Lys Ala Phe Thr Lys Val Asn Phe Asp Ser Glu Asn
 565 570 575

Gly Pro Thr Val Tyr Asn Thr Leu Lys Lys Ile Phe Lys His Thr Leu
 580 585 590

Glu Glu Lys Arg Lys Met Thr Lys Asp Gly Pro Lys Pro Gly Leu
 595 600 605

<210> 151
 <211> 878
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS

<222> (89)..(538)

<400> 151

```

ccacgcgtcc ggcgagggga cgcgtgggcg gagcggggct ggccagcctc ggcccccatg      60
accgcgtgtc ctgtgccctt tcccagcg atg ggc gtg cag ccc ccc aac ttc      112
                               Met Gly Val Gln Pro Pro Asn Phe
                               1                               5

tcc tgg gtg ctt ccg ggc cgg ctg gcg gga ctg gcg ctg ccg cgg ctc      160
Ser Trp Val Leu Pro Gly Arg Leu Ala Gly Leu Ala Leu Pro Arg Leu
   10                               15                               20

ccc gcc cac tac cag ttc ctg ttg gac ctg ggc gtg cgg cac ctg gtg      208
Pro Ala His Tyr Gln Phe Leu Leu Asp Leu Gly Val Arg His Leu Val
   25                               30                               35                               40

tcc ctg acg gag cgc ggg ccc cct cac agc gac agc tgc ccc ggc ctc      256
Ser Leu Thr Glu Arg Gly Pro Pro His Ser Asp Ser Cys Pro Gly Leu
                               45                               50                               55

acc ctg cac cgc ctg cgc atc ccc gac ttc tgc ccg ccg gcc ccc gac      304
Thr Leu His Arg Leu Arg Ile Pro Asp Phe Cys Pro Pro Ala Pro Asp
                               60                               65                               70

cag atc gac cgc ttc gtg cag atc gtg gac gag gcc aac gca cgg gga      352
Gln Ile Asp Arg Phe Val Gln Ile Val Asp Glu Ala Asn Ala Arg Gly
   75                               80                               85

gag gct gtg gga gtg cac tgt gct ctg ggc ttt ggc cgc act ggc acc      400
Glu Ala Val Gly Val His Cys Ala Leu Gly Phe Gly Arg Thr Gly Thr
   90                               95                               100

atg ctg gcc tgt tac ctg gtg aag gag cgg ggc ttg gct gca gga gat      448
Met Leu Ala Cys Tyr Leu Val Lys Glu Arg Gly Leu Ala Ala Gly Asp
  105                               110                               115                               120

gcc att gct gaa atc cga cga cta cga ccc ggc tcc atc gag acc tat      496
Ala Ile Ala Glu Ile Arg Arg Leu Arg Pro Gly Ser Ile Glu Thr Tyr
                               125                               130                               135

gag cag gag aaa gca gtc ttc cag ttc tac cag cga acg aaa      538
Glu Gln Glu Lys Ala Val Phe Gln Phe Tyr Gln Arg Thr Lys
                               140                               145                               150

taaggggcct tagtaccctt ctaccaggcc ctcaactccc ttccccatgt tgtcgatggg      598
gccagagatg aagggaagtg gactaaagta ttaaaccctc tagctcccat tggctgaaga      658
cactgaagta gcccacccct gcaggcaggt cctgattgaa ggggaggcct gtactgcttt      718
gttgaataaaa tgagttttac gaaccaggaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      778
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      838
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaagggc      878

```

<210> 152

<211> 150

<212> PRT

<213> Homo sapiens

<400> 152

Met Gly Val Gln Pro Pro Asn Phe Ser Trp Val Leu Pro Gly Arg Leu
 1 5 10 15

Ala Gly Leu Ala Leu Pro Arg Leu Pro Ala His Tyr Gln Phe Leu Leu
 20 25 30

Asp Leu Gly Val Arg His Leu Val Ser Leu Thr Glu Arg Gly Pro Pro
 35 40 45

His Ser Asp Ser Cys Pro Gly Leu Thr Leu His Arg Leu Arg Ile Pro
 50 55 60

Asp Phe Cys Pro Pro Ala Pro Asp Gln Ile Asp Arg Phe Val Gln Ile
 65 70 75 80

Val Asp Glu Ala Asn Ala Arg Gly Glu Ala Val Gly Val His Cys Ala
 85 90 95

Leu Gly Phe Gly Arg Thr Gly Thr Met Leu Ala Cys Tyr Leu Val Lys
 100 105 110

Glu Arg Gly Leu Ala Ala Gly Asp Ala Ile Ala Glu Ile Arg Arg Leu
 115 120 125

Arg Pro Gly Ser Ile Glu Thr Tyr Glu Gln Glu Lys Ala Val Phe Gln
 130 135 140

Phe Tyr Gln Arg Thr Lys
 145 150

<210> 153

<211> 470

<212> PRT

<213> Homo sapiens

<400> 153

Met Glu Ala Gly Ile Tyr Phe Asn Phe Gly Trp Lys Asp Tyr Gly Val
 1 5 10 15

Ala Ser Leu Thr Thr Ile Asp Met Val Lys Val Met Thr Phe Ala Leu
 20 25 30

Gln Glu Gly Lys Val Ile His Cys His Ala Gly Leu Gly Arg Thr Gly
 35 40 45

Val Leu Ile Ala Tyr Leu Val Phe Ala Thr Arg Met Thr Ala Asp Gln

50	55	60
Ala Ile Ile Val Arg 65	Ala Lys Arg Pro Asn Ser 70	Ile Gln Thr Arg Gly 80
Gln Leu Cys Val Arg 85	Glu Phe Thr Gln Phe Leu Thr 90	Pro Leu Arg Asn 95
Ile Ser Cys Cys Asp 100	Pro Lys Ala His Ala Val Thr 105	Leu Pro Gln Tyr 110
Ile Arg Gln Arg His 115	Leu Leu His Gly Tyr Glu Ala Arg 120	Leu Leu His 125
Val Pro Lys Ile Ile His 130	Leu Val Cys Lys Leu Leu Leu Asp 135	Ala Glu 140
Asn Arg Pro Val Met 145	Met Lys Asp Val Ser Glu Gly 150	Pro Leu Ser Ala 155
Glu Ile Glu Lys Thr 165	Met Ser Glu Met Val Thr Met 170	Leu Asp Lys Glu 175
Leu Leu Arg His Asp 180	Ser Asp Val Ser Asn Pro Asn Pro 185	Thr Ala Val 190
Ala Ala Asp Phe Asp 195	Asn Arg Gly Met Ile Ser Asn 200	Glu Gln Gln Phe 205
Asp Pro Leu Trp Lys Arg 210	Arg Asn Val Cys Leu Gln Pro 215	Leu Thr His 220
Leu Lys Arg Arg Leu Ser 225	Tyr Ser Ser Asp Leu Lys Arg 230	Ala Glu Asn 235
Leu Leu Glu Gln Gly 245	Glu Thr Gln Thr Val Pro Ala 250	Gln Ile Leu Val 255
Gly His Lys Pro Arg 260	Gln Lys Leu Ile Ser His Cys Tyr 265	Ile Pro Gln 270
Ser Pro Glu Pro Asp 275	His Lys Glu Ala Leu Val Arg 280	Ser Thr Leu Ser 285
Phe Trp Ser Gln Lys 290	Phe Gly Gly Leu Glu Gly Leu Lys 295	Asp Asn Gly 300
Ser Pro Ile His Gly 305	Arg Ile Ile Pro Lys Glu Ala 310	Gln Gln Ser Gly 315
Ala Phe Ala Asp Val 325	Ser Gly Ser His Ser Pro Gly 330	Glu Pro Val Ser 335
Pro Phe Ala Asn Val 340	His Lys Asp Pro Asn Pro Ala 345	Gln Gln Val 350
His Cys Gln Cys Lys 355	Thr His Gly Val Gly Ser Pro 360	Gly Ser Val Gln 365
Asn Ser Arg Thr Pro 370	Arg Ser Pro Leu Asp Cys Gly 375	Ser Ser Lys Ala 380

Gln Phe Leu Val Glu His Glu Thr Gln Asp Ser Lys Asp Ser Glu Ala
385 390 395 400

Ala Ser His Ser Ala Leu Gln Ser Glu Leu Ser Ala Ala Arg Arg Ile
405 410 415

Leu Ala Ala Lys Ala Leu Ala Asn Leu Asn Glu Val Glu Lys Glu Glu
420 425 430

Leu Lys Arg Lys Val Glu Met Trp Gln Lys Leu Asn Ser Arg Asp Gly
435 440 445

Ala Trp Glu Arg Ile Cys Gly Glu Arg Pro Phe Ile Leu Cys Ser Leu
450 455 460

Met Trp Ser Trp Val Glu
465 470

<210> 154
<211> 24
<212> DNA
<213> Homo sapiens

<400> 154
tacaatttcg gatggaagga ttat 24

<210> 155
<211> 23
<212> DNA
<213> Homo sapiens

<400> 155
gcatgacaat ggatagctac ttt 23

<210> 156
<211> 24
<212> DNA
<213> Homo sapiens

<400> 156
gagaaagcag tcttccagtt ctac 24

<210> 157
<211> 24
<212> DNA
<213> Homo sapiens

<400> 157
atgggagcta gagggtttaa tact 24

<210> 158
<211> 14
<212> PRT
<213> Homo sapiens

<400> 158

Leu Thr Pro Leu Arg Asn Ile Ser Cys Cys Asp Pro Lys Ala
 1 5 10

<210> 159
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 159

Thr Leu Ser Phe Trp Ser Gln Lys Phe Gly Gly Leu Glu
 1 5 10

<210> 160
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 160

Val Gln Asn Ser Arg Thr Pro Arg Ser Pro Leu Asp Cys
 1 5 10

<210> 161
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 161

Pro Leu Asp Cys Gly Ser Ser Lys Ala Gln Phe Leu Val
 1 5 10

<210> 162
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 162

Pro Thr Val Tyr Asn Thr Lys Lys Ile Phe Lys His Thr
 1 5 10

<210> 163
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 163

Gln Glu Gly Lys Val Ile His Cys His Ala Gly Leu Gly Arg Thr Gly
 1 5 10 15

Val Leu Ile Ala Tyr Leu Val
 20

<210> 164
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 164

Gly Val Gln Pro Pro Asn Phe Ser Trp Val Leu Pro Gly Arg
 1 5 10

<210> 165

<211> 13

<212> PRT

<213> Homo sapiens

<400> 165

His Leu Val Ser Leu Thr Glu Arg Gly Pro Pro His Ser
 1 5 10

<210> 166

<211> 23

<212> PRT

<213> Homo sapiens

<400> 166

Gly Glu Ala Val Gly Val His Cys Ala Leu Gly Phe Gly Arg Thr Gly
 1 5 10 15

Thr Met Leu Ala Cys Tyr Leu
 20

<210> 167

<211> 39

<212> DNA

<213> Homo sapiens

<400> 167

gcagcagcgg ccgcaatttc ggatggaagg attatggtg 39

<210> 168

<211> 33

<212> DNA

<213> Homo sapiens

<400> 168

gcagcagtcg acgaggccag gcttagggcc atc 33

<210> 169

<211> 38

<212> DNA

<213> Homo sapiens

<400> 169

gcagcagcgg ccgcatggag gctggcattt acttctac 38

<210> 170

<211> 35

<212> DNA

<213> Homo sapiens

<400> 170
gcagcagtcg accacccaag accacatcaa gctgc 35

<210> 171
<211> 39
<212> DNA
<213> Homo sapiens

<400> 171
gcagcagcgg ccgcctgttg gacctgggcg tgcggcacc 39

<210> 172
<211> 37
<212> DNA
<213> Homo sapiens

<400> 172
gcagcagtcg actttcgttc gctggtagaa ctggaag 37

<210> 173
<211> 38
<212> DNA
<213> Homo sapiens

<400> 173
gcagcagcgg ccgcatgggc gtgcagcccc ccaacttc 38

<210> 174
<211> 37
<212> DNA
<213> Homo sapiens

<400> 174
gcagcagtcg accaccaggt aacaggccag catggtg 37

<210> 175
<211> 806
<212> PRT
<213> Homo sapiens

<400> 175

Met Gln Val Gln Asp Ala Thr Arg Arg Pro Ser Ala Val Arg Phe Leu
1 5 10 15

Ser Ser Phe Leu Gln Gly Arg Arg His Ser Thr Ser Asp Pro Val Leu
20 25 30

Arg Leu Gln Gln Ala Arg Arg Gly Ser Gly Leu Gly Ser Gly Ser Ala
35 40 45

Thr Lys Leu Leu Ser Ser Ser Ser Leu Gln Val Met Val Ala Val Ser
50 55 60

Ser Val Ser His Ala Glu Gly Asn Pro Thr Phe Pro Glu Arg Lys Arg
65 70 75 80

Asn Leu Glu Arg Pro Thr Pro Lys Tyr Thr Lys Val Gly Glu Arg Leu
 85 90 95
 Arg His Val Ile Pro Gly His Met Ala Cys Ser Met Ala Cys Gly Gly
 100 105 110
 Arg Ala Cys Lys Tyr Glu Asn Pro Ala Arg Trp Ser Glu Gln Glu Gln
 115 120 125
 Ala Ile Lys Gly Val Tyr Ser Ser Trp Val Thr Asp Asn Ile Leu Ala
 130 135 140
 Met Ala Arg Pro Ser Ser Glu Leu Leu Glu Lys Tyr His Ile Ile Asp
 145 150 155 160
 Gln Phe Leu Ser His Gly Ile Lys Thr Ile Ile Asn Leu Gln Arg Pro
 165 170 175
 Gly Glu His Ala Ser Cys Gly Asn Pro Leu Glu Gln Glu Ser Gly Phe
 180 185 190
 Thr Tyr Leu Pro Glu Ala Phe Met Glu Ala Gly Ile Tyr Phe Tyr Asn
 195 200 205
 Phe Gly Trp Lys Asp Tyr Gly Val Ala Ser Leu Thr Thr Ile Leu Asp
 210 215 220
 Met Val Lys Val Met Thr Phe Ala Leu Gln Glu Gly Lys Val Ala Ile
 225 230 235 240
 His Cys His Ala Gly Leu Gly Arg Thr Gly Val Leu Ile Ala Cys Tyr
 245 250 255
 Leu Val Phe Ala Thr Arg Met Thr Ala Asp Gln Ala Ile Ile Phe Val
 260 265 270
 Arg Ala Lys Arg Pro Asn Ser Ile Gln Thr Arg Gly Gln Leu Leu Cys
 275 280 285
 Val Arg Glu Phe Thr Gln Phe Leu Thr Pro Leu Arg Asn Ile Phe Ser
 290 295 300
 Cys Cys Asp Pro Lys Ala His Ala Val Thr Leu Pro Gln Tyr Leu Ile
 305 310 315 320
 Arg Gln Arg His Leu Leu His Gly Tyr Glu Ala Arg Leu Leu Lys His
 325 330 335
 Val Pro Lys Ile Ile His Leu Val Cys Lys Leu Leu Leu Asp Leu Ala
 340 345 350
 Glu Asn Arg Pro Val Met Met Lys Asp Val Ser Glu Gly Pro Gly Leu
 355 360 365
 Ser Ala Glu Ile Glu Lys Thr Met Ser Glu Met Val Thr Met Gln Leu
 370 375 380
 Asp Lys Glu Leu Leu Arg His Asp Ser Asp Val Ser Asn Pro Pro Asn
 385 390 395 400

107

725 730 735
 Ile Leu Cys Val Leu His Cys Ile Val Asn Leu Gln Thr Ile Pro Val
 740 745 750
 Asp Val Glu Glu Ala Phe Leu Ala His Ala Ile Lys Ala Phe Thr Lys
 755 760 765
 Val Asn Phe Asp Ser Glu Asn Gly Pro Thr Val Tyr Asn Thr Leu Lys
 770 775 780
 Lys Ile Phe Lys His Thr Leu Glu Glu Lys Arg Lys Met Thr Lys Asp
 785 790 795 800
 Gly Pro Lys Pro Gly Leu
 805

<210> 176

<211> 747

<212> PRT

<213> Homo sapiens

<400> 176

Met Val Ala Val Ser Ser Val Ser His Ala Glu Gly Asn Pro Thr Phe
 1 5 10 15
 Pro Glu Arg Lys Arg Asn Leu Glu Arg Pro Thr Pro Lys Tyr Thr Lys
 20 25 30
 Val Gly Glu Arg Leu Arg His Val Ile Pro Gly His Met Ala Cys Ser
 35 40 45
 Met Ala Cys Gly Gly Arg Ala Cys Lys Tyr Glu Asn Pro Ala Arg Trp
 50 55 60
 Ser Glu Gln Glu Gln Ala Ile Lys Gly Val Tyr Ser Ser Trp Val Thr
 65 70 75 80
 Asp Asn Ile Leu Ala Met Ala Arg Pro Ser Ser Glu Leu Leu Glu Lys
 85 90 95
 Tyr His Ile Ile Asp Gln Phe Leu Ser His Gly Ile Lys Thr Ile Ile
 100 105 110
 Asn Leu Gln Arg Pro Gly Glu His Ala Ser Cys Gly Asn Pro Leu Glu
 115 120 125
 Gln Glu Ser Gly Phe Thr Tyr Leu Pro Glu Ala Phe Met Glu Ala Gly
 130 135 140
 Ile Tyr Phe Tyr Asn Phe Gly Trp Lys Asp Tyr Gly Val Ala Ser Leu
 145 150 155 160
 Thr Thr Ile Leu Asp Met Val Lys Val Met Thr Phe Ala Leu Gln Glu
 165 170 175
 Gly Lys Val Ala Ile His Cys His Ala Gly Leu Gly Arg Thr Gly Val
 180 185 190
 Leu Ile Ala Cys Tyr Leu Val Phe Ala Thr Arg Met Thr Ala Asp Gln

195	200	205
Ala Ile Ile Phe Val Arg 210	Ala Lys Arg Pro Asn Ser 215	Ile Gln Thr Arg 220
Gly Gln Leu Leu Cys Val 225	Arg Glu Phe Thr Gln 230	Phe Leu Thr Pro Leu 235
Arg Asn Ile Phe Ser 245	Cys Cys Asp Pro Lys 250	Ala His Ala Val Thr Leu 255
Pro Gln Tyr Leu Ile Arg 260	Gln Arg His Leu Leu 265	His Gly Tyr Glu Ala 270
Arg Leu Leu Lys His Val 275	Pro Lys Ile Ile His 280	Leu Val Cys Lys Leu 285
Leu Leu Asp Leu Ala Glu 290	Asn Arg Pro Val Met 295	Met Lys Asp Val Ser 300
Glu Gly Pro Gly Leu Ser 305	Ala Glu Ile Glu Lys 310	Thr Met Ser Glu Met 315
Val Thr Met Gln Leu Asp 325	Lys Glu Leu Leu Arg 330	His Asp Ser Asp Val 335
Ser Asn Pro Pro Asn Pro 340	Thr Ala Val Ala Ala 345	Asp Phe Asp Asn Arg 350
Gly Met Ile Phe Ser Asn 355	Glu Gln Gln Phe Asp 360	Pro Leu Trp Lys Arg 365
Arg Asn Val Glu Cys Leu 370	Gln Pro Leu Thr His 375	Leu Lys Arg Arg Leu 380
Ser Tyr Ser Asp Ser Asp 385	Leu Lys Arg Ala Glu 390	Asn Leu Leu Glu Gln 395
Gly Glu Thr Pro Gln Thr 405	Val Pro Ala Gln Ile 410	Leu Val Gly His Lys 415
Pro Arg Gln Gln Lys Leu 420	Ile Ser His Cys Tyr 425	Ile Pro Gln Ser Pro 430
Glu Pro Asp Leu His Lys 435	Glu Ala Leu Val Arg 440	Ser Thr Leu Ser Phe 445
Trp Ser Gln Ser Lys Phe 450	Gly Gly Leu Glu Gly 455	Leu Lys Asp Asn Gly 460
Ser Pro Ile Phe His Gly 465	Arg Ile Ile Pro Lys 470	Glu Ala Gln Gln Ser 475
Gly Ala Phe Ser Ala Asp 485	Val Ser Gly Ser His 490	Ser Pro Gly Glu Pro 495
Val Ser Pro Ser Phe Ala 500	Asn Val His Lys Asp 505	Pro Asn Pro Ala His 510
Gln Gln Val Ser His Cys 515	Gln Cys Lys Thr His 520	Gly Val Gly Ser Pro 525

Gly Ser Val Arg Gln Asn Ser Arg Thr Pro Arg Ser Pro Leu Asp Cys
 530 535 540
 Gly Ser Ser Pro Lys Ala Gln Phe Leu Val Glu His Glu Thr Gln Asp
 545 550 555 560
 Ser Lys Asp Leu Ser Glu Ala Ala Ser His Ser Ala Leu Gln Ser Glu
 565 570 575
 Leu Ser Ala Glu Ala Arg Arg Ile Leu Ala Ala Lys Ala Leu Ala Asn
 580 585 590
 Leu Asn Glu Ser Val Glu Lys Glu Glu Leu Lys Arg Lys Val Glu Met
 595 600 605
 Trp Gln Lys Glu Leu Asn Ser Arg Asp Gly Ala Trp Glu Arg Ile Cys
 610 615 620
 Gly Glu Arg Asp Pro Phe Ile Leu Cys Ser Leu Met Trp Ser Trp Val
 625 630 635 640
 Glu Gln Leu Lys Glu Pro Val Ile Thr Lys Glu Asp Val Asp Met Leu
 645 650 655
 Val Asp Arg Arg Ala Asp Ala Ala Glu Ala Leu Phe Leu Leu Glu Lys
 660 665 670
 Gly Gln His Gln Thr Ile Leu Cys Val Leu His Cys Ile Val Asn Leu
 675 680 685
 Gln Thr Ile Pro Val Asp Val Glu Glu Ala Phe Leu Ala His Ala Ile
 690 695 700
 Lys Ala Phe Thr Lys Val Asn Phe Asp Ser Glu Asn Gly Pro Thr Val
 705 710 715 720
 Tyr Asn Thr Leu Lys Lys Ile Phe Lys His Thr Leu Glu Glu Lys Arg
 725 730 735
 Lys Met Thr Lys Asp Gly Pro Lys Pro Gly Leu
 740 745

<210> 177
 <211> 699
 <212> PRT
 <213> Homo sapiens

<400> 177

Met Ala Cys Gly Gly Arg Ala Cys Lys Tyr Glu Asn Pro Ala Arg Trp
 1 5 10 15
 Ser Glu Gln Glu Gln Ala Ile Lys Gly Val Tyr Ser Ser Trp Val Thr
 20 25 30
 Asp Asn Ile Leu Ala Met Ala Arg Pro Ser Ser Glu Leu Leu Glu Lys
 35 40 45
 Tyr His Ile Ile Asp Gln Phe Leu Ser His Gly Ile Lys Thr Ile Ile
 50 55 60

Asn Leu Gln Arg Pro Gly Glu His Ala Ser Cys Gly Asn Pro Leu Glu
 65 70 75 80
 Gln Glu Ser Gly Phe Thr Tyr Leu Pro Glu Ala Phe Met Glu Ala Gly
 85 90 95
 Ile Tyr Phe Tyr Asn Phe Gly Trp Lys Asp Tyr Gly Val Ala Ser Leu
 100 105 110
 Thr Thr Ile Leu Asp Met Val Lys Val Met Thr Phe Ala Leu Gln Glu
 115 120 125
 Gly Lys Val Ala Ile His Cys His Ala Gly Leu Gly Arg Thr Gly Val
 130 135 140
 Leu Ile Ala Cys Tyr Leu Val Phe Ala Thr Arg Met Thr Ala Asp Gln
 145 150 155 160
 Ala Ile Ile Phe Val Arg Ala Lys Arg Pro Asn Ser Ile Gln Thr Arg
 165 170 175
 Gly Gln Leu Leu Cys Val Arg Glu Phe Thr Gln Phe Leu Thr Pro Leu
 180 185 190
 Arg Asn Ile Phe Ser Cys Cys Asp Pro Lys Ala His Ala Val Thr Leu
 195 200 205
 Pro Gln Tyr Leu Ile Arg Gln Arg His Leu Leu His Gly Tyr Glu Ala
 210 215 220
 Arg Leu Leu Lys His Val Pro Lys Ile Ile His Leu Val Cys Lys Leu
 225 230 235 240
 Leu Leu Asp Leu Ala Glu Asn Arg Pro Val Met Met Lys Asp Val Ser
 245 250 255
 Glu Gly Pro Gly Leu Ser Ala Glu Ile Glu Lys Thr Met Ser Glu Met
 260 265 270
 Val Thr Met Gln Leu Asp Lys Glu Leu Leu Arg His Asp Ser Asp Val
 275 280 285
 Ser Asn Pro Pro Asn Pro Thr Ala Val Ala Ala Asp Phe Asp Asn Arg
 290 295 300
 Gly Met Ile Phe Ser Asn Glu Gln Gln Phe Asp Pro Leu Trp Lys Arg
 305 310 315 320
 Arg Asn Val Glu Cys Leu Gln Pro Leu Thr His Leu Lys Arg Arg Leu
 325 330 335
 Ser Tyr Ser Asp Ser Asp Leu Lys Arg Ala Glu Asn Leu Leu Glu Gln
 340 345 350
 Gly Glu Thr Pro Gln Thr Val Pro Ala Gln Ile Leu Val Gly His Lys
 355 360 365
 Pro Arg Gln Gln Lys Leu Ile Ser His Cys Tyr Ile Pro Gln Ser Pro
 370 375 380

Glu Pro Asp Leu His Lys Glu Ala Leu Val Arg Ser Thr Leu Ser Phe
 385 390 395 400
 Trp Ser Gln Ser Lys Phe Gly Gly Leu Glu Gly Leu Lys Asp Asn Gly
 405 410 415
 Ser Pro Ile Phe His Gly Arg Ile Ile Pro Lys Glu Ala Gln Gln Ser
 420 425 430
 Gly Ala Phe Ser Ala Asp Val Ser Gly Ser His Ser Pro Gly Glu Pro
 435 440 445
 Val Ser Pro Ser Phe Ala Asn Val His Lys Asp Pro Asn Pro Ala His
 450 455 460
 Gln Gln Val Ser His Cys Gln Cys Lys Thr His Gly Val Gly Ser Pro
 465 470 475 480
 Gly Ser Val Arg Gln Asn Ser Arg Thr Pro Arg Ser Pro Leu Asp Cys
 485 490 495
 Gly Ser Ser Pro Lys Ala Gln Phe Leu Val Glu His Glu Thr Gln Asp
 500 505 510
 Ser Lys Asp Leu Ser Glu Ala Ala Ser His Ser Ala Leu Gln Ser Glu
 515 520 525
 Leu Ser Ala Glu Ala Arg Arg Ile Leu Ala Ala Lys Ala Leu Ala Asn
 530 535 540
 Leu Asn Glu Ser Val Glu Lys Glu Glu Leu Lys Arg Lys Val Glu Met
 545 550 555 560
 Trp Gln Lys Glu Leu Asn Ser Arg Asp Gly Ala Trp Glu Arg Ile Cys
 565 570 575
 Gly Glu Arg Asp Pro Phe Ile Leu Cys Ser Leu Met Trp Ser Trp Val
 580 585 590
 Glu Gln Leu Lys Glu Pro Val Ile Thr Lys Glu Asp Val Asp Met Leu
 595 600 605
 Val Asp Arg Arg Ala Asp Ala Ala Glu Ala Leu Phe Leu Leu Glu Lys
 610 615 620
 Gly Gln His Gln Thr Ile Leu Cys Val Leu His Cys Ile Val Asn Leu
 625 630 635 640
 Gln Thr Ile Pro Val Asp Val Glu Glu Ala Phe Leu Ala His Ala Ile
 645 650 655
 Lys Ala Phe Thr Lys Val Asn Phe Asp Ser Glu Asn Gly Pro Thr Val
 660 665 670
 Tyr Asn Thr Leu Lys Lys Ile Phe Lys His Thr Leu Glu Glu Lys Arg
 675 680 685
 Lys Met Thr Lys Asp Gly Pro Lys Pro Gly Leu
 690 695

<210> 178

<211> 662
 <212> PRT
 <213> Homo sapiens

<400> 178

```

Met Ala Arg Pro Ser Ser Glu Leu Leu Glu Lys Tyr His Ile Ile Asp
1          5          10          15

Gln Phe Leu Ser His Gly Ile Lys Thr Ile Ile Asn Leu Gln Arg Pro
20          25          30

Gly Glu His Ala Ser Cys Gly Asn Pro Leu Glu Gln Glu Ser Gly Phe
35          40          45

Thr Tyr Leu Pro Glu Ala Phe Met Glu Ala Gly Ile Tyr Phe Tyr Asn
50          55          60

Phe Gly Trp Lys Asp Tyr Gly Val Ala Ser Leu Thr Thr Ile Leu Asp
65          70          75          80

Met Val Lys Val Met Thr Phe Ala Leu Gln Glu Gly Lys Val Ala Ile
85          90          95

His Cys His Ala Gly Leu Gly Arg Thr Gly Val Leu Ile Ala Cys Tyr
100         105         110

Leu Val Phe Ala Thr Arg Met Thr Ala Asp Gln Ala Ile Ile Phe Val
115         120         125

Arg Ala Lys Arg Pro Asn Ser Ile Gln Thr Arg Gly Gln Leu Leu Cys
130         135         140

Val Arg Glu Phe Thr Gln Phe Leu Thr Pro Leu Arg Asn Ile Phe Ser
145         150         155         160

Cys Cys Asp Pro Lys Ala His Ala Val Thr Leu Pro Gln Tyr Leu Ile
165         170         175

Arg Gln Arg His Leu Leu His Gly Tyr Glu Ala Arg Leu Leu Lys His
180         185         190

Val Pro Lys Ile Ile His Leu Val Cys Lys Leu Leu Leu Asp Leu Ala
195         200         205

Glu Asn Arg Pro Val Met Met Lys Asp Val Ser Glu Gly Pro Gly Leu
210         215         220

Ser Ala Glu Ile Glu Lys Thr Met Ser Glu Met Val Thr Met Gln Leu
225         230         235         240

Asp Lys Glu Leu Leu Arg His Asp Ser Asp Val Ser Asn Pro Pro Asn
245         250         255

Pro Thr Ala Val Ala Ala Asp Phe Asp Asn Arg Gly Met Ile Phe Ser
260         265         270

Asn Glu Gln Gln Phe Asp Pro Leu Trp Lys Arg Arg Asn Val Glu Cys
275         280         285

Leu Gln Pro Leu Thr His Leu Lys Arg Arg Leu Ser Tyr Ser Asp Ser

```

290	295	300
Asp Leu Lys Arg Ala Glu Asn Leu Leu Glu Gln Gly Glu Thr Pro Gln 305 310 315 320		
Thr Val Pro Ala Gln Ile Leu Val Gly His Lys Pro Arg Gln Gln Lys 325 330 335		
Leu Ile Ser His Cys Tyr Ile Pro Gln Ser Pro Glu Pro Asp Leu His 340 345 350		
Lys Glu Ala Leu Val Arg Ser Thr Leu Ser Phe Trp Ser Gln Ser Lys 355 360 365		
Phe Gly Gly Leu Glu Gly Leu Lys Asp Asn Gly Ser Pro Ile Phe His 370 375 380		
Gly Arg Ile Ile Pro Lys Glu Ala Gln Gln Ser Gly Ala Phe Ser Ala 385 390 395 400		
Asp Val Ser Gly Ser His Ser Pro Gly Glu Pro Val Ser Pro Ser Phe 405 410 415		
Ala Asn Val His Lys Asp Pro Asn Pro Ala His Gln Gln Val Ser His 420 425 430		
Cys Gln Cys Lys Thr His Gly Val Gly Ser Pro Gly Ser Val Arg Gln 435 440 445		
Asn Ser Arg Thr Pro Arg Ser Pro Leu Asp Cys Gly Ser Ser Pro Lys 450 455 460		
Ala Gln Phe Leu Val Glu His Glu Thr Gln Asp Ser Lys Asp Leu Ser 465 470 475 480		
Glu Ala Ala Ser His Ser Ala Leu Gln Ser Glu Leu Ser Ala Glu Ala 485 490 495		
Arg Arg Ile Leu Ala Ala Lys Ala Leu Ala Asn Leu Asn Glu Ser Val 500 505 510		
Glu Lys Glu Glu Leu Lys Arg Lys Val Glu Met Trp Gln Lys Glu Leu 515 520 525		
Asn Ser Arg Asp Gly Ala Trp Glu Arg Ile Cys Gly Glu Arg Asp Pro 530 535 540		
Phe Ile Leu Cys Ser Leu Met Trp Ser Trp Val Glu Gln Leu Lys Glu 545 550 555 560		
Pro Val Ile Thr Lys Glu Asp Val Asp Met Leu Val Asp Arg Arg Ala 565 570 575		
Asp Ala Ala Glu Ala Leu Phe Leu Leu Glu Lys Gly Gln His Gln Thr 580 585 590		
Ile Leu Cys Val Leu His Cys Ile Val Asn Leu Gln Thr Ile Pro Val 595 600 605		
Asp Val Glu Glu Ala Phe Leu Ala His Ala Ile Lys Ala Phe Thr Lys 610 615 620		

Val Asn Phe Asp Ser Glu Asn Gly Pro Thr Val Tyr Asn Thr Leu Lys
 625 630 635 640

Lys Ile Phe Lys His Thr Leu Glu Glu Lys Arg Lys Met Thr Lys Asp
 645 650 655

Gly Pro Lys Pro Gly Leu
 660

<210> 179
 <211> 25
 <212> DNA
 <213> Artificial

<220>
 <223> Synthesized Oligonucleotide.

<400> 179
 ggauaucacu acugcauugc cugga 25

<210> 180
 <211> 25
 <212> DNA
 <213> Artificial

<220>
 <223> Synthesized Oligonucleotide.

<400> 180
 uacagcagau cugugcaggc caggu 25

<210> 181
 <211> 25
 <212> DNA
 <213> Artificial

<220>
 <223> Synthesized Oligonucleotide.

<400> 181
 ugaucacaca guagcggaag augcu 25

<210> 182
 <211> 25
 <212> DNA
 <213> Artificial

<220>
 <223> Synthesized Oligonucleotide.

<400> 182
 aggaguagca gaaugguuag ccuuc 25

<210> 183
 <211> 25
 <212> DNA

<213> Artificial

<220>

<223> Synthesized Oligonucleotide.

<400> 183

ugaaagcagg cgagauucga uccga

25

<210> 184

<211> 20

<212> DNA

<213> Homo sapiens

<400> 184

actaccgcct cacacgcttc

20

<210> 185

<211> 20

<212> DNA

<213> Homo sapiens

<400> 185

cttgactcca gcagggttc

20

<210> 186

<211> 26

<212> DNA

<213> Homo sapiens

<400> 186

atcaagtgtg acccagactg cctccg

26

<210> 187

<211> 28

<212> DNA

<213> Homo sapiens

<400> 187

catatgggat ccatggccca tgagattg

28

<210> 188

<211> 30

<212> DNA

<213> Homo sapiens

<400> 188

ggtaccctcg agtcaggaga cctcaatgat

30

<210> 189

<211> 30

<212> DNA

<213> Homo sapiens

<400> 189

ggtaccctcg agtcaagtct gggtcttaat

30

<210> 190
 <211> 664
 <212> PRT
 <213> Homo sapiens

<400> 190

Met Ala His Glu Ile Gly Thr Gln Ile Val Thr Glu Arg Leu Val Ala
 1 5 10 15
 Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp Ser Arg Pro
 20 25 30
 Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile Asn Ile Asn
 35 40 45
 Cys Ser Lys Leu Met Lys Arg Arg Leu Gln Gln Asp Lys Val Leu Ile
 50 55 60
 Thr Glu Leu Ile Gln His Ser Ala Lys His Lys Val Asp Ile Asp Cys
 65 70 75 80
 Ser Gln Lys Val Val Val Tyr Asp Gln Ser Ser Gln Asp Val Ala Ser
 85 90 95
 Leu Ser Ser Asp Cys Phe Leu Thr Val Leu Leu Gly Lys Leu Glu Lys
 100 105 110
 Ser Phe Asn Ser Val His Leu Leu Ala Gly Gly Phe Ala Glu Phe Ser
 115 120 125
 Arg Cys Phe Pro Gly Leu Cys Glu Gly Lys Ser Thr Leu Val Pro Thr
 130 135 140
 Cys Ile Ser Gln Pro Cys Leu Pro Val Ala Asn Ile Gly Pro Thr Arg
 145 150 155 160
 Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp Val Leu Asn Lys
 165 170 175
 Glu Leu Met Gln Gln Asn Gly Ile Gly Tyr Val Leu Asn Ala Ser Asn
 180 185 190
 Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His Phe Leu Arg Val
 195 200 205
 Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro Trp Leu Asp Lys
 210 215 220
 Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn Gly Cys Val Leu
 225 230 235 240
 Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile Ala Ile Ala
 245 250 255
 Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu Ala Tyr Arg Phe
 260 265 270
 Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Ser Phe Asn Phe Leu Gly

275					280					285					
Gln	Leu	Leu	Asp	Tyr	Glu	Lys	Lys	Ile	Lys	Asn	Gln	Ala	Gly	Ala	Ser
290						295					300				
Gly	Pro	Lys	Ser	Lys	Leu	Lys	Leu	Leu	His	Leu	Glu	Lys	Pro	Asn	Glu
305					310					315					320
Pro	Val	Pro	Ala	Val	Ser	Glu	Gly	Gly	Gln	Lys	Ser	Glu	Thr	Pro	Leu
				325					330					335	
Ser	Pro	Pro	Cys	Ala	Asp	Ser	Ala	Thr	Ser	Glu	Ala	Ala	Gly	Gln	Arg
			340					345					350		
Pro	Val	His	Pro	Ala	Ser	Val	Pro	Ser	Val	Pro	Ser	Val	Gln	Pro	Ser
		355					360					365			
Leu	Leu	Glu	Asp	Ser	Pro	Leu	Val	Gln	Ala	Leu	Ser	Gly	Leu	His	Leu
	370					375					380				
Ser	Ala	Asp	Arg	Leu	Glu	Asp	Ser	Asn	Lys	Leu	Lys	Arg	Ser	Phe	Ser
385					390					395					400
Leu	Asp	Ile	Lys	Ser	Val	Ser	Tyr	Ser	Ala	Ser	Met	Ala	Ala	Ser	Leu
			405						410					415	
His	Gly	Phe	Ser	Ser	Ser	Glu	Asp	Ala	Leu	Glu	Tyr	Tyr	Lys	Pro	Ser
		420					425						430		
Thr	Thr	Leu	Asp	Gly	Thr	Asn	Lys	Leu	Cys	Gln	Phe	Ser	Pro	Val	Gln
		435					440					445			
Glu	Leu	Ser	Glu	Gln	Thr	Pro	Glu	Thr	Ser	Pro	Asp	Lys	Glu	Glu	Ala
	450					455					460				
Ser	Ile	Pro	Lys	Lys	Leu	Gln	Thr	Ala	Arg	Pro	Ser	Asp	Ser	Gln	Ser
465					470					475					480
Lys	Arg	Leu	His	Ser	Val	Arg	Thr	Ser	Ser	Ser	Gly	Thr	Ala	Gln	Arg
			485						490					495	
Ser	Leu	Leu	Ser	Pro	Leu	His	Arg	Ser	Gly	Ser	Val	Glu	Asp	Asn	Tyr
		500						505					510		
His	Thr	Ser	Phe	Leu	Phe	Gly	Leu	Ser	Thr	Ser	Gln	Gln	His	Leu	Thr
		515					520					525			
Lys	Ser	Ala	Gly	Leu	Gly	Leu	Lys	Gly	Trp	His	Ser	Asp	Ile	Leu	Ala
	530					535					540				
Pro	Gln	Thr	Ser	Thr	Pro	Ser	Leu	Thr	Ser	Ser	Trp	Tyr	Phe	Ala	Thr
	545					550					555				560
Glu	Ser	Ser	His	Phe	Tyr	Ser	Ala	Ser	Ala	Ile	Tyr	Gly	Gly	Ser	Ala
			565						570					575	
Ser	Tyr	Ser	Ala	Tyr	Ser	Arg	Ser	Gln	Leu	Pro	Thr	Cys	Gly	Asp	Gln
		580					585						590		
Val	Tyr	Ser	Val	Arg	Arg	Arg	Gln	Lys	Pro	Ser	Asp	Arg	Ala	Asp	Ser
		595					600					605			

Arg Arg Ser Trp His Glu Glu Ser Pro Phe Glu Lys Gln Phe Lys Arg
 610 615 620

Arg Ser Cys Gln Met Glu Phe Gly Glu Ser Ile Met Ser Glu Asn Arg
 625 630 635 640

Ser Arg Glu Glu Leu Gly Lys Val Gly Ser Gln Ser Ser Phe Ser Gly
 645 650 655

Ser Met Glu Ile Ile Glu Val Ser
 660

<210> 191

<211> 302

<212> PRT

<213> Homo sapiens

<400> 191

Met Ala His Glu Ile Val Gly Thr Gln Ile Val Thr Glu Arg Leu Val
 1 5 10 15

Ala Leu Leu Glu Ser Gly Thr Glu Lys Val Leu Leu Ile Asp Ser Arg
 20 25 30

Pro Phe Val Glu Tyr Asn Thr Ser His Ile Leu Glu Ala Ile Asn Ile
 35 40 45

Asn Cys Ser Lys Leu Met Lys Arg Arg Leu Gln Gln Asp Lys Val Leu
 50 55 60

Ile Thr Glu Leu Ile Gln His Ser Ala Lys His Lys Val Asp Ile Asp
 65 70 75 80

Cys Ser Gln Lys Val Val Val Tyr Asp Gln Ser Ser Gln Asp Val Ala
 85 90 95

Ser Leu Ser Ser Asp Cys Phe Leu Thr Val Leu Leu Gly Lys Leu Glu
 100 105 110

Lys Ser Phe Asn Ser Val His Leu Leu Ala Gly Gly Phe Ala Glu Phe
 115 120 125

Ser Arg Cys Phe Pro Gly Leu Cys Glu Gly Lys Ser Thr Leu Val Pro
 130 135 140

Thr Cys Ile Ser Gln Pro Cys Leu Pro Val Ala Asn Ile Gly Pro Thr
 145 150 155 160

Arg Ile Leu Pro Asn Leu Tyr Leu Gly Cys Gln Arg Asp Val Leu Asn
 165 170 175

Lys Glu Leu Met Gln Gln Asn Gly Ile Gly Tyr Val Leu Asn Ala Ser
 180 185 190

Asn Thr Cys Pro Lys Pro Asp Phe Ile Pro Glu Ser His Phe Leu Arg
 195 200 205

Val Pro Val Asn Asp Ser Phe Cys Glu Lys Ile Leu Pro Trp Leu Asp
 210 215 220

Lys Ser Val Asp Phe Ile Glu Lys Ala Lys Ala Ser Asn Gly Cys Val
 225 230 235 240

Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Ala Thr Ile Ala Ile
 245 250 255

Ala Tyr Ile Met Lys Arg Met Asp Met Ser Leu Asp Glu Ala Tyr Arg
 260 265 270

Phe Val Lys Glu Lys Arg Pro Thr Ile Ser Pro Ser Phe Asn Phe Leu
 275 280 285

Gly Gln Leu Leu Asp Tyr Glu Lys Lys Ile Lys Asn Gln Thr
 290 295 300

<210> 192

<211> 20

<212> PRT

<213> Homo sapiens

<400> 192

Lys Asn Gln Thr Gly Ala Ser Gly Pro Lys Ser Lys Lys Leu Lys Leu
 1 5 10 15

Leu His Leu Glu
 20

<210> 193

<211> 19

<212> PRT

<213> artificial

<220>

<223> Synthesized Oligonucleotide.

<400> 193

Cys Lys Lys Leu Gln Thr Ala Arg Pro Ser Asp Ser Gln Ser Lys Arg
 1 5 10 15

Leu His Ser

<210> 194

<211> 21

<212> DNA

<213> Homo sapiens

<400> 194

ctgcgtgttg cactgcatag t

21

<210> 195

<211> 19

<212> DNA

<213> Homo sapiens

<400> 195

tgggcaagga aagcttcct

19

<210> 196
<211> 26
<212> DNA
<213> Homo sapiens

<400> 196
aacctgcaga caattcccgt ggatgt

26

<210> 197
<211> 21
<212> DNA
<213> Homo sapiens

<400> 197
gagatgccat tgctgaaatc c

21

<210> 198
<211> 23
<212> DNA
<213> Homo sapiens

<400> 198
gactgctttc tcctgctcat agg

23

<210> 199
<211> 23
<212> DNA
<213> Homo sapiens

<400> 199
cgactacgac ccggtccat cga

23

<210> 200
<211> 23
<212> DNA
<213> Homo sapiens

<400> 200
aggagcagat ggtagacgtg ttc

23

<210> 201
<211> 20
<212> DNA
<213> Homo sapiens

<400> 201
ggctcagggt ctggatcatg

20

<210> 202
<211> 25
<212> DNA
<213> Homo sapiens

<400> 202
tgctgtgtat gcactccgga tgcac 25

<210> 203
<211> 25
<212> DNA
<213> Homo sapiens

<400> 203
cacacaccaa atgtgtaaca gttca 25

<210> 204
<211> 27
<212> DNA
<213> Homo sapiens

<400> 204
gctactgctt tcctttctta aacatgt .27

<210> 205
<211> 25
<212> DNA
<213> Homo sapiens

<400> 205
cacttccaga gtgtgggtcat gccca 25

<210> 206
<211> 321
<212> PRT
<213> Homo sapiens

<400> 206

Met Glu Met Glu Lys Glu Phe Glu Gln Ile Asp Lys Ser Gly Ser Trp
1 5 10 15

Ala Ala Ile Tyr Gln Asp Ile Arg His Glu Ala Ser Asp Phe Pro Cys
20 25 30

Arg Val Ala Lys Leu Pro Lys Asn Lys Asn Arg Asn Arg Tyr Arg Asp
35 40 45

Val Ser Pro Phe Asp His Ser Arg Ile Lys Leu His Gln Glu Asp Asn
50 55 60

Asp Tyr Ile Asn Ala Ser Leu Ile Lys Met Glu Glu Ala Gln Arg Ser
65 70 75 80

Tyr Ile Leu Thr Gln Gly Pro Leu Pro Asn Thr Cys Gly His Phe Trp
85 90 95

Glu Met Val Trp Glu Gln Lys Ser Arg Gly Val Val Met Leu Asn Arg
100 105 110

Val Met Glu Lys Gly Ser Leu Lys Cys Ala Gln Tyr Trp Pro Gln Lys
115 120 125

Glu Glu Lys Glu Met Ile Phe Glu Asp Thr Asn Leu Lys Leu Thr Leu
 130 135 140
 Ile Ser Glu Asp Ile Lys Ser Tyr Tyr Thr Val Arg Gln Leu Glu Leu
 145 150 155 160
 Glu Asn Leu Thr Thr Gln Glu Thr Arg Glu Ile Leu His Phe His Tyr
 165 170 175
 Thr Thr Trp Pro Asp Phe Gly Val Pro Glu Ser Pro Ala Ser Phe Leu
 180 185 190
 Asn Phe Leu Phe Lys Val Arg Glu Ser Gly Ser Leu Ser Pro Glu His
 195 200 205
 Gly Pro Val Val Val His Ser Ser Ala Gly Ile Gly Arg Ser Gly Thr
 210 215 220
 Phe Cys Leu Ala Asp Thr Cys Leu Leu Leu Met Asp Lys Arg Lys Asp
 225 230 235 240
 Pro Ser Ser Val Asp Ile Lys Lys Val Leu Leu Glu Met Arg Lys Phe
 245 250 255
 Arg Met Gly Leu Ile Gln Thr Ala Asp Gln Leu Arg Phe Ser Tyr Leu
 260 265 270
 Ala Val Ile Glu Gly Ala Lys Phe Ile Met Gly Asp Ser Ser Val Gln
 275 280 285
 Asp Gln Trp Lys Glu Leu Ser His Glu Asp Leu Glu Pro Pro Pro Gly
 290 295 300
 His Ile Pro Pro Pro Pro Arg Pro Pro Lys Arg Ile Leu Glu Pro His
 305 310 315 320

Asn

<210> 207
 <211> 184
 <212> PRT
 <213> Homo sapiens

<400> 207

Ser Gly Ser Phe Glu Leu Ser Val Gln Asp Leu Asn Asp Leu Leu Ser
 1 5 10 15
 Asp Gly Ser Gly Cys Tyr Ser Leu Pro Ser Gln Pro Cys Asn Glu Val
 20 25 30
 Thr Pro Arg Ile Tyr Val Gly Asn Ala Ser Val Ala Gln Asp Ile Pro
 35 40 45
 Lys Leu Gln Lys Leu Gly Ile Thr His Val Leu Asn Ala Ala Glu Gly
 50 55 60
 Arg Ser Phe Met His Val Asn Thr Asn Ala Asn Phe Tyr Lys Asp Ser
 65 70 75 80

```
<210> 208
<211> 144
<212> PRT
<213> Homo sapiens
```

Ala	Ser	Phe	Pro	Val	Glu	Ile	Leu	Pro	Phe	Leu	Tyr	Leu	Gly	Cys	Ala	
1			5					10						15		
Lys	Asp	Ser	Thr	Asn	Leu	Asp	Val	Leu	Glu	Glu	Phe	Gly	Ile	Lys	Tyr	
		20						25					30			
Ile	Leu	Asn	Val	Thr	Pro	Asn	Leu	Pro	Asn	Leu	Phe	Glu	Asn	Ala	Gly	
		35					40					45				
Glu	Phe	Lys	Tyr	Lys	Gln	Ile	Pro	Ile	Ser	Asp	His	Trp	Ser	Gln	Asn	
	50					55					60					
Leu	Ser	Gln	Phe	Phe	Pro	Glu	Ala	Ile	Ser	Phe	Ile	Asp	Glu	Ala	Arg	
65					70					75					80	
Gly	Lys	Asn	Cys	Gly	Val	Leu	Val	His	Ser	Leu	Ala	Gly	Ile	Ser	Arg	
			85						90					95		
Ser	Val	Thr	Val	Thr	Val	Ala	Tyr	Leu	Met	Gln	Lys	Leu	Asn	Leu	Ser	
		100						105					110			
Met	Asn	Asp	Ala	Tyr	Asp	Ile	Val	Lys	Met	Lys	Lys	Ser	Asn	Ile	Ser	
		115					120					125				
Pro	Asn	Phe	Asn	Phe	Met	Gly	Gln	Leu	Leu	Asp	Phe	Glu	Arg	Thr	Leu	
	130					135					140					

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057460 A3

(51) International Patent Classification: C12N 15/55,
9/16, 15/63, 5/10, C07K 16/40, C12P 21/00, A61K 38/46,
C12Q 1/68, 1/42, G06F 19/00, 17/50

(21) International Application Number: PCT/US01/50459

(22) International Filing Date:
20 December 2001 (20.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/256,868 20 December 2000 (20.12.2000) US
60/280,186 30 March 2001 (30.03.2001) US
60/287,735 1 May 2001 (01.05.2001) US
60/295,848 5 June 2001 (05.06.2001) US
60/300,465 25 June 2001 (25.06.2001) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; P.O. BOX 4000, ROUTE 206 and PROVINCE-
LINE ROAD, PRINCETON, NJ 08543-4000 (US).

(72) Inventors: JACKSON, Donald, G.; 2641 Main St. Apt. 1, Lawrenceville, NJ 08648 (US). FEDER, John; 277 Dutchtown Zion Road, Belle Mead, NJ 08502 (US). NELSON, Thomas; 12 Azalea Court, Lawrenceville, NJ 08648 (US). MINTIER, Gabe; 318 Morrison Ave., Hightstown, NJ 08520 (US). RAMANATHAN, Chandra; 41 Alison Avenue, Wallingford, CT 06492 (US). LEE, Liana; 8 Petunia Drive Apt. 1J, North Brunswick, NJ 08902 (US). SIEMERS, Nathan; 171 East Delaware Ave., Pennington, NJ 08534 (US). BOL, David; 1467 Franklin Road, Langhorne, PA 19047 (US). SCHIEVEN, Gary; 519 Bergan Street, Lawrenceville, NJ 08648 (US). FINGER, Joshua; 222 Woodland Parkway, Apt. 254, San Marcos, CA 92069 (US). TODDERUD, C, Gordon.; 56 Autumn Drive, Newtown, PA 18940 (US). BASSOLINO, Donna; 9 Hidden Hollow Dr., Hamilton, NJ 08620 (US). KRYSTEK, Stanley; 15 Back Brook Road, Ringoes, NJ 08551 (US). MCATEE, Patrick; 416 Hale Street, Pennington, NH 08534 (US). SUCHARD, Susan; 621 Foulkstone Rd., Wilmington, DE 19803 (US). BANAS, Dana; 2465 Sylvan Avenue, Hamilton, NJ 08610 (US).

[Continued on next page]

(54) Title: POLYNUCLEOTIDES ENCODING HUMAN PHOSPHATASES

EMY_HPP1_A

1 CTAGTTTACT TCTACAATTT CGGATGGAAG GATTATGGTG TAGCGTCTCT TACTACTATC 60
1 L V Y F Y N F G W K D Y G V A S L T T I 20

61 CTAGATATGG TGAAGGTGAT GACATTTGCC TTACAGGAAG GAAAAGTAGC TATCCATTGT 120
21 L D M V K V M T F A L Q E G K V A I H C 40

121 CATGCAGGGC TTGGTCGAAC AGGT 144
41 H A G L G R T G 48

EMY_HPP1_B

1 GATGTCTTCT GGGCCCTCCT GTGGAACACA GTT 33
1 D V F W A L L W N T V 11

(57) Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

WO 02/057460 A3



(74) **Agents:** D'AMICO, Stephen et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) **Date of publication of the international search report:**
10 April 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Intel  onal Application No

PCT/US 01/50459

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/55 C12N9/16 C12N15/63 C12N5/10 C07K16/40
C12P21/00 A61K38/46 C12Q1/68 C12Q1/42 G06F19/00
G06F17/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N G06F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

SEQUENCE SEARCH, EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EM NEW [Online] EMBL; 29 September 2000 (2000-09-29) ISOGAI ET AL.: "Homo sapiens cDNA FLJ12041 fis, clone HEMBB1001945" retrieved from EBI Database accession no. AK022103 XP002211553 the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 August 2002

Date of mailing of the international search report

18. 12. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

CEDER O.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/50459

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EM_HUM [Online] EMBL; 27 January 2000 (2000-01-27) DUESTERHOEFT ET AL.: "Homo sapiens mRNA, cDNA DKFZp434C035 (from clone DKFZp434C035)" retrieved from EBI, accession no. HSM802329 Database accession no. AL137633 XP002211554 the whole document</p> <p>---</p>	1
A	<p>WO 97 06245 A (MEDICAL RES COUNCIL ;DAVIES KAY ELIZABETH (GB); THEODOSIOU ASPASIA) 20 February 1997 (1997-02-20) abstract; claims; figure 3</p> <p>---</p>	1-22
A	<p>WO 92 01050 A (UNIV NEW YORK) 23 January 1992 (1992-01-23) abstract; claims</p> <p>---</p>	1-22
A	<p>MARTELL K J ET AL: "HVVH-5: A PROTEIN TYROSINE PHOSPHATASE ABUNDANT IN BRAIN THAT INACTIVATES MITOGEN-ACTIVATED PROTEIN KINASE" JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 65, no. 4, 1995, pages 1823-1833, XP000196676 ISSN: 0022-3042 abstract; figure 1</p> <p>---</p>	1-22
A	<p>WO 00 39751 A (UNIV HARVARD) 6 July 2000 (2000-07-06) abstract; claims</p> <p>---</p>	23-25
A	<p>SHAFFER R W ET AL: "Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 28, no. 1, 1 January 2000 (2000-01-01), pages 346-348, XP002202302 ISSN: 0305-1048 the whole document</p> <p>---</p>	23-25
P,X	<p>WO 01 46394 A (PLOWMAN GREGORY D ;HILL RONALD J (US); SUGEN INC (US); WHYTE DAVID) 28 June 2001 (2001-06-28) Seq Id Nos 2, 14 abstract; claims</p> <p>---</p>	1-22

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/50459

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 01 73059 A (MEYERS RACHEL A ;MILLENNIUM PHARM INC (US)) 4 October 2001 (2001-10-04) abstract; claims; figures 1A-1D ---	1-22
P,X	WO 01 77340 A (MERCK PATENT GMBH ;DUECKER KLAUS (DE)) 18 October 2001 (2001-10-18) Seq Id Nos 1, 2 abstract; claims ---	1-22
E	WO 02 10363 A (HAFALIA APRIL J A ;INCYTE GENOMICS INC (US); PATTERSON CHANDRA (US)) 7 February 2002 (2002-02-07) Seq Id Nos 7, 17 abstract; claims -----	1-22

INTERNATIONAL SEARCH REPORT

national application No.
PCT/US 01/50459

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-25 all partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 11 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-25 all partially

An isolated polynucleotide(fragment) and the polypeptide(fragment) encoded by it and their uses, where the polynucleotide and polypeptide are Seq Id Nos 41 or 108 and 42 or 109, respectively.

2. Claims: 1-25 all partially

An isolated polynucleotide(fragment) and the polypeptide(fragment) encoded by it and their uses, where the polynucleotide and polypeptide are Seq Id Nos 149 and 150, respectively.

3. Claims: 1-25 all partially

An isolated polynucleotide(fragment) and the polypeptide(fragment) encoded by it and their uses, where the polynucleotide and polypeptide are Seq Id Nos 151 and 152, respectively.

INTERNATIONAL SEARCH REPORT
information on patent family members

Intel[®] onal Application No
PCT/US 01/50459

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9706245	A	20-02-1997	AU 6664996 A WO 9706245 A1	05-03-1997 20-02-1997
WO 9201050	A	23-01-1992	AT 182624 T AU 662296 B2 AU 8412891 A CA 2087008 A1 DE 69131482 D1 DE 69131482 T2 EP 0538401 A1 JP 2002136292 A US 5604094 A US 5532123 A US 6160090 A WO 9201050 A1 US 5891700 A US 5925536 A US 5888794 A US 2002127226 A1 US 5538886 A	15-08-1999 31-08-1995 04-02-1992 12-01-1992 02-09-1999 18-11-1999 28-04-1993 14-05-2002 18-02-1997 02-07-1996 12-12-2000 23-01-1992 06-04-1999 20-07-1999 30-03-1999 12-09-2002 23-07-1996
WO 0039751	A	06-07-2000	EP 1140737 A2 JP 2002533477 T WO 0039751 A2 US 2002055536 A1	10-10-2001 08-10-2002 06-07-2000 09-05-2002
WO 0146394	A	28-06-2001	AU 2445601 A WO 0146394 A2 AU 3454401 A EP 1254214 A2 WO 0155356 A2	03-07-2001 28-06-2001 07-08-2001 06-11-2002 02-08-2001
WO 0173059	A	04-10-2001	AU 4778201 A AU 4942301 A WO 0173059 A2 WO 0173060 A2 US 2002065406 A1 US 2002034807 A1	08-10-2001 08-10-2001 04-10-2001 04-10-2001 30-05-2002 21-03-2002
WO 0177340	A	18-10-2001	WO 0177340 A1 EP 1263970 A1	18-10-2001 11-12-2002
WO 0210363	A	07-02-2002	AU 8301201 A WO 0210363 A2	13-02-2002 07-02-2002